{"3e91ee7d9cad3f0feb2ea60be831a65d42569036": [["IntroductionAcute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are common and devastating clinical disorders characterized by increased non-hydrostatic extravascular lung water, reduced pulmonary compliance, and acute hypoxemic respiratory failure [1] .", [["lung", "ANATOMY", 18, 22], ["extravascular lung", "ANATOMY", 172, 190], ["pulmonary", "ANATOMY", 206, 215], ["respiratory", "ANATOMY", 248, 259], ["IntroductionAcute lung injury", "DISEASE", 0, 29], ["ALI", "DISEASE", 31, 34], ["acute respiratory distress syndrome", "DISEASE", 40, 75], ["ARDS", "DISEASE", 77, 81], ["hypoxemic respiratory failure", "DISEASE", 238, 267], ["lung", "ORGAN", 18, 22], ["lung", "ORGAN", 186, 190], ["pulmonary", "ORGAN", 206, 215], ["IntroductionAcute lung injury (ALI)", "PROBLEM", 0, 35], ["acute respiratory distress syndrome", "PROBLEM", 40, 75], ["ARDS", "PROBLEM", 77, 81], ["devastating clinical disorders", "PROBLEM", 98, 128], ["increased non-hydrostatic extravascular lung water", "PROBLEM", 146, 196], ["reduced pulmonary compliance", "PROBLEM", 198, 226], ["acute hypoxemic respiratory failure", "PROBLEM", 232, 267], ["lung", "ANATOMY", 18, 22], ["injury", "OBSERVATION", 23, 29], ["ALI", "ANATOMY", 31, 34], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory distress", "OBSERVATION", 46, 66], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["non-hydrostatic", "OBSERVATION_MODIFIER", 156, 171], ["extravascular", "ANATOMY_MODIFIER", 172, 185], ["lung", "ANATOMY", 186, 190], ["reduced", "OBSERVATION_MODIFIER", 198, 205], ["pulmonary compliance", "OBSERVATION", 206, 226], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["hypoxemic", "OBSERVATION_MODIFIER", 238, 247], ["respiratory failure", "OBSERVATION", 248, 267]]], ["Despite substantial progress in mechanical ventilatory strategies, significant advances in the quality of care of critically ill patients, and an enhanced understanding of molecular mechanisms, the mortality rate among patients with ALI/ARDS remains unacceptably high [2, 3] .IntroductionThe pathophysiological mechanism of ALI/ARDS is believed to be associated with numerous target and effector cells [1] .", [["effector cells", "ANATOMY", 387, 401], ["critically ill", "DISEASE", 114, 128], ["ALI", "DISEASE", 233, 236], ["ARDS", "DISEASE", 237, 241], ["ALI", "DISEASE", 324, 327], ["ARDS", "DISEASE", 328, 332], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 219, 227], ["cells", "CELL", 396, 401], ["effector cells", "CELL_TYPE", 387, 401], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 219, 227], ["mechanical ventilatory strategies", "TREATMENT", 32, 65], ["the mortality rate", "TEST", 194, 212], ["ALI", "PROBLEM", 233, 236], ["ARDS", "PROBLEM", 237, 241], ["ALI", "PROBLEM", 324, 327], ["ARDS", "PROBLEM", 328, 332], ["mechanical ventilatory strategies", "OBSERVATION", 32, 65], ["ARDS", "OBSERVATION", 237, 241], ["ALI", "OBSERVATION", 324, 327], ["ARDS", "OBSERVATION", 328, 332], ["effector cells", "OBSERVATION", 387, 401]]], ["Among these cells, lung macrophages are the most important cells of the innate immune system and form the first line of defense against airborne particles and microbes [4, 5] .", [["cells", "ANATOMY", 12, 17], ["lung macrophages", "ANATOMY", 19, 35], ["cells", "ANATOMY", 59, 64], ["immune system", "ANATOMY", 79, 92], ["cells", "CELL", 12, 17], ["lung macrophages", "CELL", 19, 35], ["cells", "CELL", 59, 64], ["innate", "ANATOMICAL_SYSTEM", 72, 78], ["immune system", "ANATOMICAL_SYSTEM", 79, 92], ["lung macrophages", "CELL_TYPE", 19, 35], ["lung macrophages", "PROBLEM", 19, 35], ["lung", "ANATOMY", 19, 23], ["macrophages", "OBSERVATION", 24, 35]]], ["Macrophages recognize pathogen-associated molecular patterns and trigger innate immunity and host defenses [6] .", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "PROBLEM", 0, 11], ["pathogen", "PROBLEM", 22, 30]]], ["Macrophages also reportedly participate in the entire pathogenesis of ALI/ARDS, including modulation of inflammatory responses and repair of damaged lung tissues [4, 7, 8] .IntroductionMacrophages are highly plastic cells that display versatile functional phenotypes depending on microenvironmental stimuli [9] .", [["Macrophages", "ANATOMY", 0, 11], ["lung tissues", "ANATOMY", 149, 161], ["Macrophages", "ANATOMY", 185, 196], ["cells", "ANATOMY", 216, 221], ["ALI", "DISEASE", 70, 73], ["ARDS", "DISEASE", 74, 78], ["Macrophages", "CELL", 0, 11], ["lung tissues", "TISSUE", 149, 161], ["Macrophages", "CELL", 185, 196], ["plastic cells", "CELL", 208, 221], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "CELL_TYPE", 185, 196], ["ALI", "PROBLEM", 70, 73], ["ARDS", "PROBLEM", 74, 78], ["inflammatory responses", "PROBLEM", 104, 126], ["repair", "TREATMENT", 131, 137], ["damaged lung tissues", "PROBLEM", 141, 161], ["versatile functional phenotypes", "PROBLEM", 235, 266], ["microenvironmental stimuli", "TEST", 280, 306], ["ALI", "OBSERVATION", 70, 73], ["ARDS", "OBSERVATION", 74, 78], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116], ["damaged", "OBSERVATION", 141, 148], ["lung tissues", "ANATOMY", 149, 161], ["plastic cells", "OBSERVATION", 208, 221]]], ["Macrophages commonly exist in two distinct subsets: the classically activated (M1) macrophages or the alternatively activated (M2) macrophages [10] .", [["Macrophages", "ANATOMY", 0, 11], ["M1) macrophages", "ANATOMY", 79, 94], ["macrophages", "ANATOMY", 131, 142], ["Macrophages", "CELL", 0, 11], ["M1) macrophages", "CELL", 79, 94], ["M2", "CELL", 127, 129], ["Macrophages", "CELL_TYPE", 0, 11], ["classically activated (M1) macrophages", "CELL_TYPE", 56, 94], ["alternatively activated (M2) macrophages", "CELL_TYPE", 102, 142], ["Macrophages", "PROBLEM", 0, 11], ["two distinct", "OBSERVATION_MODIFIER", 30, 42]]], ["M1/M2 macrophages have different functions and transcriptional profiles [9] .", [["M1/M2 macrophages", "ANATOMY", 0, 17], ["M2 macrophages", "CELL", 3, 17], ["M1/M2 macrophages", "CELL_LINE", 0, 17], ["transcriptional profiles", "TEST", 47, 71], ["M2", "ANATOMY", 3, 5], ["macrophages", "OBSERVATION", 6, 17]]], ["Moreover, the balance of the M1/M2 phenotype governs the fate of an organ in inflammation or injury [11] .", [["organ", "ANATOMY", 68, 73], ["inflammation", "DISEASE", 77, 89], ["M2", "GENE_OR_GENE_PRODUCT", 32, 34], ["organ", "ORGAN", 68, 73], ["inflammation", "PROBLEM", 77, 89], ["injury", "PROBLEM", 93, 99], ["organ", "ANATOMY", 68, 73], ["inflammation", "OBSERVATION", 77, 89]]], ["In the acute exudative phase of ALI/ARDS, lung macrophages are M1 polarized.", [["lung macrophages", "ANATOMY", 42, 58], ["ALI", "DISEASE", 32, 35], ["ARDS", "DISEASE", 36, 40], ["lung macrophages", "CELL", 42, 58], ["M1", "CELL", 63, 65], ["lung macrophages", "CELL_TYPE", 42, 58], ["ALI", "PROBLEM", 32, 35], ["ARDS", "PROBLEM", 36, 40], ["lung macrophages", "PROBLEM", 42, 58], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["exudative", "OBSERVATION_MODIFIER", 13, 22], ["phase", "OBSERVATION_MODIFIER", 23, 28], ["ALI", "OBSERVATION", 32, 35], ["ARDS", "OBSERVATION", 36, 40], ["lung", "ANATOMY", 42, 46], ["macrophages", "OBSERVATION", 47, 58], ["M1", "OBSERVATION_MODIFIER", 63, 65], ["polarized", "OBSERVATION_MODIFIER", 66, 75]]], ["Continuous M1 polarization can release tumor necrosis factor \u03b1 (TNF-\u03b1), interleukin 1 (IL-1), nitric oxide (NO), and reactive oxygen species (ROS) to induce a severe inflammatory response [11] .", [["tumor", "DISEASE", 39, 44], ["necrosis", "DISEASE", 45, 53], ["nitric oxide", "CHEMICAL", 94, 106], ["NO", "CHEMICAL", 108, 110], ["oxygen", "CHEMICAL", 126, 132], ["ROS", "CHEMICAL", 142, 145], ["nitric oxide", "CHEMICAL", 94, 106], ["NO", "CHEMICAL", 108, 110], ["oxygen", "CHEMICAL", 126, 132], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 39, 62], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["interleukin 1", "GENE_OR_GENE_PRODUCT", 72, 85], ["IL-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["nitric oxide", "SIMPLE_CHEMICAL", 94, 106], ["NO", "SIMPLE_CHEMICAL", 108, 110], ["reactive oxygen species", "SIMPLE_CHEMICAL", 117, 140], ["ROS", "SIMPLE_CHEMICAL", 142, 145], ["tumor necrosis factor \u03b1", "PROTEIN", 39, 62], ["TNF", "PROTEIN", 64, 67], ["interleukin 1", "PROTEIN", 72, 85], ["Continuous M1 polarization", "TREATMENT", 0, 26], ["tumor necrosis factor", "PROBLEM", 39, 60], ["TNF", "TEST", 64, 67], ["interleukin 1 (IL", "TREATMENT", 72, 89], ["nitric oxide", "TREATMENT", 94, 106], ["reactive oxygen species", "PROBLEM", 117, 140], ["a severe inflammatory response", "PROBLEM", 157, 187], ["tumor", "OBSERVATION", 39, 44], ["reactive", "OBSERVATION_MODIFIER", 117, 125], ["oxygen species", "OBSERVATION", 126, 140], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["inflammatory", "OBSERVATION", 166, 178]]], ["In contrast, excessive M2 polarization contributes to a pathological fibroproliferative response and pulmonary fibrosis in the later fibroproliferative phase of ALI/ARDS [12, 13] .IntroductionThe findings of the present review are organized into three sections.", [["pulmonary", "ANATOMY", 101, 110], ["sections", "ANATOMY", 252, 260], ["fibrosis", "DISEASE", 111, 119], ["ALI", "DISEASE", 161, 164], ["ARDS", "DISEASE", 165, 169], ["M2", "GENE_OR_GENE_PRODUCT", 23, 25], ["pulmonary", "ORGAN", 101, 110], ["M2", "PROTEIN", 23, 25], ["excessive M2 polarization", "PROBLEM", 13, 38], ["a pathological fibroproliferative response", "PROBLEM", 54, 96], ["pulmonary fibrosis", "PROBLEM", 101, 119], ["ALI", "PROBLEM", 161, 164], ["ARDS", "PROBLEM", 165, 169], ["excessive", "OBSERVATION_MODIFIER", 13, 22], ["M2 polarization", "OBSERVATION", 23, 38], ["pathological", "OBSERVATION_MODIFIER", 56, 68], ["fibroproliferative", "OBSERVATION_MODIFIER", 69, 87], ["pulmonary", "ANATOMY", 101, 110], ["fibrosis", "OBSERVATION", 111, 119], ["fibroproliferative", "OBSERVATION_MODIFIER", 133, 151], ["phase", "OBSERVATION_MODIFIER", 152, 157], ["ALI", "OBSERVATION", 161, 164], ["ARDS", "OBSERVATION", 165, 169]]], ["First, the origin of macrophages are presented.", [["macrophages", "ANATOMY", 21, 32], ["macrophages", "CELL", 21, 32], ["macrophages", "CELL_TYPE", 21, 32], ["origin", "ANATOMY_MODIFIER", 11, 17], ["macrophages", "OBSERVATION", 21, 32]]], ["Second, the polarization phenotypes and regulation of macrophages are discussed.", [["macrophages", "ANATOMY", 54, 65], ["macrophages", "CELL", 54, 65], ["macrophages", "CELL_TYPE", 54, 65], ["the polarization phenotypes", "PROBLEM", 8, 35], ["polarization phenotypes", "OBSERVATION", 12, 35], ["macrophages", "OBSERVATION", 54, 65]]], ["Third, the role of macrophage polarization in ALI/ARDS is reviewed.", [["macrophage", "ANATOMY", 19, 29], ["ALI", "DISEASE", 46, 49], ["ARDS", "DISEASE", 50, 54], ["macrophage", "CELL", 19, 29], ["ALI", "PROBLEM", 46, 49], ["ARDS", "PROBLEM", 50, 54], ["macrophage polarization", "OBSERVATION", 19, 42], ["ALI", "ANATOMY", 46, 49], ["ARDS", "OBSERVATION", 50, 54]]], ["Notably, this review is meant to be a broad overview for researchers seeking to understand the role of macrophage polarization in the development and prognosis of ALI/ARDS.", [["macrophage", "ANATOMY", 103, 113], ["ALI", "DISEASE", 163, 166], ["ARDS", "DISEASE", 167, 171], ["macrophage", "CELL", 103, 113], ["macrophage polarization", "TREATMENT", 103, 126], ["ALI", "PROBLEM", 163, 166], ["ARDS", "PROBLEM", 167, 171], ["ALI", "OBSERVATION", 163, 166], ["ARDS", "OBSERVATION", 167, 171]]], ["The goal of the present review is to further our understanding of the physiological and pathological mechanisms that modulate macrophage polarization in ALI/ARDS.Origin of macrophagesMacrophages have long been thought to be derived from bone marrow hematopoietic stem cells (HSCs) [14, 15] .", [["macrophage", "ANATOMY", 126, 136], ["macrophages", "ANATOMY", 172, 183], ["Macrophages", "ANATOMY", 183, 194], ["bone marrow hematopoietic stem cells", "ANATOMY", 237, 273], ["HSCs", "ANATOMY", 275, 279], ["ALI", "DISEASE", 153, 156], ["ARDS", "DISEASE", 157, 161], ["macrophage", "CELL", 126, 136], ["macrophages", "CELL", 172, 183], ["Macrophages", "CELL", 183, 194], ["bone marrow hematopoietic stem cells", "CELL", 237, 273], ["HSCs", "CELL", 275, 279], ["macrophages", "CELL_TYPE", 172, 183], ["Macrophages", "CELL_TYPE", 183, 194], ["bone marrow hematopoietic stem cells", "CELL_TYPE", 237, 273], ["HSCs", "CELL_TYPE", 275, 279], ["ALI", "PROBLEM", 153, 156], ["ARDS", "PROBLEM", 157, 161], ["bone marrow hematopoietic stem cells", "PROBLEM", 237, 273], ["macrophage polarization", "OBSERVATION", 126, 149], ["ALI", "ANATOMY", 153, 156], ["ARDS", "OBSERVATION", 157, 161], ["macrophages", "OBSERVATION", 172, 183], ["thought to be", "UNCERTAINTY", 210, 223], ["bone", "ANATOMY", 237, 241], ["marrow hematopoietic stem cells", "OBSERVATION", 242, 273]]], ["In response to instructive cytokines and growth factors, bone marrow HSCs produce several discrete intermediate progenitor populations including common myeloid progenitors, granulocyte and macrophage progenitors, macrophage and dendritic cell progenitors, and common monocyte progenitors, which increasingly lose self-renewing capacity as they commit to the mononuclear phagocyte lineage [16, 17] .", [["bone marrow HSCs", "ANATOMY", 57, 73], ["progenitor populations", "ANATOMY", 112, 134], ["myeloid progenitors", "ANATOMY", 152, 171], ["granulocyte", "ANATOMY", 173, 184], ["macrophage progenitors", "ANATOMY", 189, 211], ["macrophage", "ANATOMY", 213, 223], ["dendritic cell progenitors", "ANATOMY", 228, 254], ["monocyte progenitors", "ANATOMY", 267, 287], ["mononuclear phagocyte", "ANATOMY", 358, 379], ["bone marrow HSCs", "CELL", 57, 73], ["intermediate progenitor populations", "CELL", 99, 134], ["myeloid progenitors", "CELL", 152, 171], ["granulocyte", "CELL", 173, 184], ["macrophage progenitors", "CELL", 189, 211], ["macrophage", "CELL", 213, 223], ["dendritic cell progenitors", "CELL", 228, 254], ["monocyte progenitors", "CELL", 267, 287], ["mononuclear phagocyte lineage", "CELL", 358, 387], ["cytokines", "PROTEIN", 27, 36], ["growth factors", "PROTEIN", 41, 55], ["bone marrow HSCs", "CELL_TYPE", 57, 73], ["intermediate progenitor populations", "CELL_TYPE", 99, 134], ["myeloid progenitors", "CELL_TYPE", 152, 171], ["granulocyte and macrophage progenitors", "CELL_TYPE", 173, 211], ["macrophage", "CELL_TYPE", 213, 223], ["dendritic cell progenitors", "CELL_TYPE", 228, 254], ["common monocyte progenitors", "CELL_TYPE", 260, 287], ["mononuclear phagocyte lineage", "CELL_TYPE", 358, 387], ["instructive cytokines and growth factors", "PROBLEM", 15, 55], ["bone marrow HSCs", "TEST", 57, 73], ["common myeloid progenitors", "TREATMENT", 145, 171], ["granulocyte", "TREATMENT", 173, 184], ["macrophage progenitors", "TREATMENT", 189, 211], ["macrophage", "PROBLEM", 213, 223], ["dendritic cell progenitors", "PROBLEM", 228, 254], ["common monocyte progenitors", "PROBLEM", 260, 287], ["intermediate progenitor populations", "OBSERVATION", 99, 134], ["common myeloid progenitors", "OBSERVATION", 145, 171], ["macrophage progenitors", "OBSERVATION", 189, 211], ["dendritic cell progenitors", "OBSERVATION", 228, 254], ["common monocyte progenitors", "OBSERVATION", 260, 287], ["mononuclear phagocyte", "ANATOMY", 358, 379]]], ["Mature HSC-derived monocytes then enter the blood circulation and splenic reservoir [17] .", [["HSC", "ANATOMY", 7, 10], ["monocytes", "ANATOMY", 19, 28], ["blood", "ANATOMY", 44, 49], ["splenic", "ANATOMY", 66, 73], ["HSC-derived monocytes", "CELL", 7, 28], ["blood circulation", "MULTI-TISSUE_STRUCTURE", 44, 61], ["HSC", "CELL_TYPE", 7, 10], ["monocytes", "CELL_TYPE", 19, 28], ["splenic reservoir", "TREATMENT", 66, 83], ["HSC", "ANATOMY", 7, 10], ["derived monocytes", "OBSERVATION", 11, 28], ["blood", "ANATOMY", 44, 49], ["splenic", "ANATOMY", 66, 73], ["reservoir", "ANATOMY_MODIFIER", 74, 83]]], ["When associated mobilization signaling is activated, circulating monocytes penetrate through the capillary endothelial cell layer, migrate into many different organs, and switch to tissue-resident macrophages [16] .Origin of macrophagesHowever, recent studies have shown that a significant number of tissue macrophages are maintained independent of blood monocytes and are prenatally derived from primitive macrophages existing within the yolk sac or fetal liver (e.g., brain microglia, liver Kupffer cells, cardiac macrophages, and other macrophages that reside in the lungs, spleen, bone marrow, and peritoneal cavity) [18, 19] .", [["monocytes", "ANATOMY", 65, 74], ["capillary endothelial cell layer", "ANATOMY", 97, 129], ["organs", "ANATOMY", 159, 165], ["tissue", "ANATOMY", 181, 187], ["macrophages", "ANATOMY", 197, 208], ["macrophages", "ANATOMY", 225, 236], ["tissue macrophages", "ANATOMY", 300, 318], ["blood monocytes", "ANATOMY", 349, 364], ["macrophages", "ANATOMY", 407, 418], ["yolk sac", "ANATOMY", 439, 447], ["fetal liver", "ANATOMY", 451, 462], ["brain microglia", "ANATOMY", 470, 485], ["liver Kupffer cells", "ANATOMY", 487, 506], ["cardiac macrophages", "ANATOMY", 508, 527], ["macrophages", "ANATOMY", 539, 550], ["lungs", "ANATOMY", 570, 575], ["spleen", "ANATOMY", 577, 583], ["bone marrow", "ANATOMY", 585, 596], ["peritoneal cavity", "ANATOMY", 602, 619], ["monocytes", "CELL", 65, 74], ["capillary endothelial cell layer", "TISSUE", 97, 129], ["organs", "ORGAN", 159, 165], ["tissue", "TISSUE", 181, 187], ["macrophages", "CELL", 197, 208], ["macrophages", "CELL", 225, 236], ["tissue macrophages", "CELL", 300, 318], ["blood monocytes", "CELL", 349, 364], ["macrophages", "CELL", 407, 418], ["yolk sac", "MULTI-TISSUE_STRUCTURE", 439, 447], ["fetal", "ORGAN", 451, 456], ["liver", "ORGAN", 457, 462], ["brain microglia", "CELL", 470, 485], ["liver Kupffer cells", "CELL", 487, 506], ["cardiac macrophages", "CELL", 508, 527], ["macrophages", "CELL", 539, 550], ["lungs", "ORGAN", 570, 575], ["spleen", "ORGAN", 577, 583], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 585, 596], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 602, 619], ["circulating monocytes", "CELL_TYPE", 53, 74], ["resident macrophages", "CELL_TYPE", 188, 208], ["macrophages", "CELL_TYPE", 225, 236], ["tissue macrophages", "CELL_TYPE", 300, 318], ["blood monocytes", "CELL_TYPE", 349, 364], ["primitive macrophages", "CELL_TYPE", 397, 418], ["brain microglia", "CELL_TYPE", 470, 485], ["liver Kupffer cells", "CELL_TYPE", 487, 506], ["cardiac macrophages", "CELL_TYPE", 508, 527], ["macrophages", "CELL_TYPE", 539, 550], ["the capillary endothelial cell layer", "TREATMENT", 93, 129], ["recent studies", "TEST", 245, 259], ["a significant number of tissue macrophages", "PROBLEM", 276, 318], ["blood monocytes", "TEST", 349, 364], ["primitive macrophages", "PROBLEM", 397, 418], ["cardiac macrophages", "TEST", 508, 527], ["other macrophages", "PROBLEM", 533, 550], ["capillary endothelial", "ANATOMY", 97, 118], ["cell layer", "OBSERVATION", 119, 129], ["macrophages", "OBSERVATION", 225, 236], ["significant", "OBSERVATION_MODIFIER", 278, 289], ["number", "OBSERVATION_MODIFIER", 290, 296], ["tissue macrophages", "OBSERVATION", 300, 318], ["blood monocytes", "OBSERVATION", 349, 364], ["primitive macrophages", "OBSERVATION", 397, 418], ["yolk", "ANATOMY_MODIFIER", 439, 443], ["sac", "ANATOMY_MODIFIER", 444, 447], ["fetal", "ANATOMY_MODIFIER", 451, 456], ["liver", "ANATOMY", 457, 462], ["brain microglia", "ANATOMY", 470, 485], ["liver", "ANATOMY", 487, 492], ["Kupffer cells", "OBSERVATION", 493, 506], ["cardiac", "ANATOMY", 508, 515], ["macrophages", "OBSERVATION", 516, 527], ["macrophages", "OBSERVATION", 539, 550], ["lungs", "ANATOMY", 570, 575], ["spleen", "ANATOMY", 577, 583], ["bone marrow", "ANATOMY", 585, 596], ["peritoneal cavity", "ANATOMY", 602, 619]]], ["In the steady state, these macrophages renew locally, exhibit selfmaintenance, and carry out a variety of clearance and organspecific trophic functions [14, 20, 21] .", [["macrophages", "ANATOMY", 27, 38], ["macrophages", "CELL", 27, 38], ["macrophages", "CELL_TYPE", 27, 38]]], ["Under inflammation, immune dysfunction, and pathologic conditions, the number of macrophages often increases dramatically [22] .", [["macrophages", "ANATOMY", 81, 92], ["inflammation", "DISEASE", 6, 18], ["immune dysfunction", "DISEASE", 20, 38], ["macrophages", "CELL", 81, 92], ["macrophages", "CELL_TYPE", 81, 92], ["inflammation", "PROBLEM", 6, 18], ["immune dysfunction", "PROBLEM", 20, 38], ["pathologic conditions", "PROBLEM", 44, 65], ["inflammation", "OBSERVATION", 6, 18], ["immune dysfunction", "OBSERVATION", 20, 38], ["macrophages", "OBSERVATION", 81, 92]]], ["Tissueresident macrophage homeostasis can be destroyed by local amplification of resident macrophages and the recruitment of circulating monocytes [14, 17] .", [["macrophage", "ANATOMY", 15, 25], ["macrophages", "ANATOMY", 90, 101], ["monocytes", "ANATOMY", 137, 146], ["Tissueresident macrophage", "CELL", 0, 25], ["macrophages", "CELL", 90, 101], ["monocytes", "CELL", 137, 146], ["resident macrophages", "CELL_TYPE", 81, 101], ["circulating monocytes", "CELL_TYPE", 125, 146], ["circulating monocytes", "TEST", 125, 146]]], ["Therefore, tissue-resident macrophages have a dual origin and consist of variably mixed populations of resident macrophages of embryonic origin and bone marrow-derived blood monocytes depending on the host status [19] Polarization phenotype and polarization regulationPolarization phenotypeMacrophage polarization is a process whereby macrophages phenotypically mount a specific phenotype and functional response to different pathophysiological conditions and surrounding microenvironments [10, 23] .", [["tissue", "ANATOMY", 11, 17], ["macrophages", "ANATOMY", 27, 38], ["macrophages", "ANATOMY", 112, 123], ["embryonic origin", "ANATOMY", 127, 143], ["bone marrow", "ANATOMY", 148, 159], ["blood monocytes", "ANATOMY", 168, 183], ["macrophages", "ANATOMY", 335, 346], ["tissue-resident macrophages", "CELL", 11, 38], ["macrophages", "CELL", 112, 123], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 127, 136], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 148, 159], ["-derived blood monocytes", "CELL", 159, 183], ["macrophages", "CELL", 335, 346], ["resident macrophages", "CELL_TYPE", 18, 38], ["resident macrophages", "CELL_TYPE", 103, 123], ["bone marrow-derived blood monocytes", "CELL_TYPE", 148, 183], ["macrophages", "CELL_TYPE", 335, 346], ["bone marrow", "TEST", 148, 159], ["blood monocytes", "TEST", 168, 183], ["Polarization phenotype", "TEST", 218, 240], ["polarization regulationPolarization phenotypeMacrophage polarization", "TREATMENT", 245, 313], ["macrophages phenotypically", "PROBLEM", 335, 361], ["a specific phenotype", "PROBLEM", 368, 388], ["different pathophysiological conditions", "PROBLEM", 416, 455], ["variably", "OBSERVATION_MODIFIER", 73, 81], ["mixed", "OBSERVATION_MODIFIER", 82, 87], ["embryonic origin", "OBSERVATION", 127, 143], ["bone marrow", "OBSERVATION", 148, 159]]], ["In general, two main macrophage phenotypes have been suggested: classically activated or inflammatory (M1) macrophages and alternatively activated or anti-inflammatory (M2) macrophages [10, 11] .", [["macrophage", "ANATOMY", 21, 31], ["M1) macrophages", "ANATOMY", 103, 118], ["macrophages", "ANATOMY", 173, 184], ["macrophage", "CELL", 21, 31], ["M1) macrophages", "CELL", 103, 118], ["macrophages", "CELL", 173, 184], ["inflammatory (M1) macrophages", "CELL_TYPE", 89, 118], ["anti-inflammatory (M2) macrophages", "CELL_TYPE", 150, 184], ["inflammatory (M1) macrophages", "PROBLEM", 89, 118], ["macrophage phenotypes", "OBSERVATION", 21, 42], ["inflammatory", "OBSERVATION_MODIFIER", 89, 101], ["anti-inflammatory", "OBSERVATION_MODIFIER", 150, 167]]], ["However, M1/M2 polarization does not completely reflect the phenotypic populations of macrophages.", [["macrophages", "ANATOMY", 86, 97], ["M2", "GENE_OR_GENE_PRODUCT", 12, 14], ["macrophages", "CELL", 86, 97], ["macrophages", "CELL_TYPE", 86, 97], ["M1/M2 polarization", "TEST", 9, 27], ["not completely reflect", "UNCERTAINTY", 33, 55], ["phenotypic", "OBSERVATION_MODIFIER", 60, 70], ["macrophages", "OBSERVATION", 86, 97]]], ["The origin and properties of some other macrophage subsets remain unclear, but these subsets are known to be involved as the main players in some human pathologies; these subsets include tumor-associated macrophages (TAMs), CD169 + macrophages, and T cell receptor-positive macrophages [24] .Polarization phenotypeM1 macrophages are typically polarized by Th1-related cytokines such as interferon \u03b3 (IFN-\u03b3) and TNF-\u03b1 as well as by microbicidal stimuli such as lipopolysaccharide (LPS) recognition.", [["macrophage", "ANATOMY", 40, 50], ["tumor", "ANATOMY", 187, 192], ["macrophages", "ANATOMY", 204, 215], ["TAMs", "ANATOMY", 217, 221], ["CD169 + macrophages", "ANATOMY", 224, 243], ["T cell", "ANATOMY", 249, 255], ["macrophages", "ANATOMY", 274, 285], ["phenotypeM1 macrophages", "ANATOMY", 305, 328], ["tumor", "DISEASE", 187, 192], ["lipopolysaccharide", "CHEMICAL", 460, 478], ["LPS", "CHEMICAL", 480, 483], ["macrophage", "CELL", 40, 50], ["human", "ORGANISM", 146, 151], ["tumor", "CANCER", 187, 192], ["macrophages", "CELL", 204, 215], ["TAMs", "CELL", 217, 221], ["CD169", "GENE_OR_GENE_PRODUCT", 224, 229], ["macrophages", "CELL", 232, 243], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 249, 264], ["phenotypeM1 macrophages", "CELL", 305, 328], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 386, 398], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 400, 405], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 411, 416], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 460, 478], ["LPS", "SIMPLE_CHEMICAL", 480, 483], ["macrophage subsets", "CELL_TYPE", 40, 58], ["tumor-associated macrophages", "CELL_TYPE", 187, 215], ["TAMs", "CELL_TYPE", 217, 221], ["CD169", "CELL_TYPE", 224, 229], ["macrophages", "CELL_TYPE", 232, 243], ["T cell receptor-positive macrophages", "CELL_TYPE", 249, 285], ["phenotypeM1 macrophages", "CELL_TYPE", 305, 328], ["cytokines", "PROTEIN", 368, 377], ["interferon \u03b3", "PROTEIN", 386, 398], ["IFN-\u03b3", "PROTEIN", 400, 405], ["TNF", "PROTEIN", 411, 414], ["\u03b1", "PROTEIN", 415, 416], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["some other macrophage subsets", "PROBLEM", 29, 58], ["some human pathologies", "PROBLEM", 141, 163], ["tumor-associated macrophages", "PROBLEM", 187, 215], ["CD169", "TEST", 224, 229], ["macrophages", "PROBLEM", 232, 243], ["T cell receptor", "TEST", 249, 264], ["positive macrophages", "PROBLEM", 265, 285], ["Polarization phenotypeM1 macrophages", "PROBLEM", 292, 328], ["Th1-related cytokines", "TREATMENT", 356, 377], ["interferon \u03b3 (IFN", "TREATMENT", 386, 403], ["TNF", "TREATMENT", 411, 414], ["microbicidal stimuli", "TEST", 431, 451], ["lipopolysaccharide (LPS)", "TREATMENT", 460, 484], ["origin", "ANATOMY_MODIFIER", 4, 10], ["macrophage subsets", "OBSERVATION", 40, 58], ["tumor", "OBSERVATION", 187, 192], ["macrophages", "ANATOMY", 204, 215], ["macrophages", "ANATOMY", 232, 243], ["positive macrophages", "OBSERVATION", 265, 285], ["macrophages", "OBSERVATION", 317, 328]]], ["These macrophages produce higher levels of TNF-\u03b1, IL-1, IL-6, IL-12, chemokine CCL8, IL-23, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 2 (MIP-2), ROS, and cyclooxygenase 2 (COX-2), and they strongly express inducible NO synthase (iNOS), CD16, and CD32.", [["macrophages", "ANATOMY", 6, 17], ["NO", "CHEMICAL", 246, 248], ["NO", "CHEMICAL", 246, 248], ["macrophages", "CELL", 6, 17], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 43, 48], ["IL-1", "GENE_OR_GENE_PRODUCT", 50, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["IL-12", "GENE_OR_GENE_PRODUCT", 62, 67], ["CCL8", "GENE_OR_GENE_PRODUCT", 79, 83], ["IL-23", "GENE_OR_GENE_PRODUCT", 85, 90], ["monocyte chemotactic protein 1", "GENE_OR_GENE_PRODUCT", 92, 122], ["MCP-1", "GENE_OR_GENE_PRODUCT", 124, 129], ["macrophage inflammatory protein 2", "GENE_OR_GENE_PRODUCT", 132, 165], ["MIP-2", "GENE_OR_GENE_PRODUCT", 167, 172], ["ROS", "SIMPLE_CHEMICAL", 175, 178], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 184, 200], ["COX-2", "GENE_OR_GENE_PRODUCT", 202, 207], ["NO synthase", "GENE_OR_GENE_PRODUCT", 246, 257], ["iNOS", "GENE_OR_GENE_PRODUCT", 259, 263], ["CD16", "GENE_OR_GENE_PRODUCT", 266, 270], ["CD32", "GENE_OR_GENE_PRODUCT", 276, 280], ["macrophages", "CELL_TYPE", 6, 17], ["TNF", "PROTEIN", 43, 46], ["chemokine", "PROTEIN", 69, 78], ["CCL8", "PROTEIN", 79, 83], ["IL-23", "PROTEIN", 85, 90], ["monocyte chemotactic protein 1 (MCP-1", "PROTEIN", 92, 129], ["macrophage inflammatory protein 2", "PROTEIN", 132, 165], ["cyclooxygenase 2", "PROTEIN", 184, 200], ["COX", "PROTEIN", 202, 205], ["NO synthase", "PROTEIN", 246, 257], ["iNOS", "PROTEIN", 259, 263], ["CD16", "PROTEIN", 266, 270], ["CD32", "PROTEIN", 276, 280], ["These macrophages", "TEST", 0, 17], ["TNF", "TEST", 43, 46], ["IL", "TEST", 50, 52], ["IL", "TEST", 56, 58], ["IL", "TEST", 62, 64], ["chemokine CCL8", "TEST", 69, 83], ["IL", "TEST", 85, 87], ["monocyte chemotactic protein", "TEST", 92, 120], ["MCP", "TEST", 124, 127], ["macrophage inflammatory protein", "TEST", 132, 163], ["MIP", "TEST", 167, 170], ["ROS", "TEST", 175, 178], ["cyclooxygenase", "TEST", 184, 198], ["COX", "TEST", 202, 205], ["CD16", "TEST", 266, 270], ["CD32", "TEST", 276, 280], ["macrophages", "OBSERVATION", 6, 17], ["higher", "OBSERVATION_MODIFIER", 26, 32]]], ["Functionally, this population of macrophages is mainly engaged in proinflammatory, chemotaxis, radical formation, matrix degradation, antimicrobial, and antitumoral activities [25, 26] .", [["macrophages", "ANATOMY", 33, 44], ["matrix", "ANATOMY", 114, 120], ["macrophages", "CELL", 33, 44], ["radical", "SIMPLE_CHEMICAL", 95, 102], ["matrix", "CELLULAR_COMPONENT", 114, 120], ["antitumoral", "CANCER", 153, 164], ["macrophages", "CELL_TYPE", 33, 44], ["macrophages", "PROBLEM", 33, 44], ["radical formation, matrix degradation", "TREATMENT", 95, 132], ["antimicrobial", "TREATMENT", 134, 147], ["macrophages", "OBSERVATION", 33, 44], ["proinflammatory", "OBSERVATION_MODIFIER", 66, 81], ["chemotaxis", "OBSERVATION_MODIFIER", 83, 93], ["radical formation", "OBSERVATION", 95, 112]]], ["Conversely, M2 macrophages are generated in response to Th2 cytokines such as IL-4 and IL-13 as well as anti-inflammatory cytokines such as IL-10 and transforming growth factor \u03b2 (TGF-\u03b2) [27] .", [["M2 macrophages", "ANATOMY", 12, 26], ["M2 macrophages", "CELL", 12, 26], ["IL-4", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL-13", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-10", "GENE_OR_GENE_PRODUCT", 140, 145], ["transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 150, 178], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 180, 185], ["M2 macrophages", "CELL_TYPE", 12, 26], ["Th2 cytokines", "PROTEIN", 56, 69], ["IL-13", "PROTEIN", 87, 92], ["anti-inflammatory cytokines", "PROTEIN", 104, 131], ["IL-10", "PROTEIN", 140, 145], ["TGF", "PROTEIN", 180, 183], ["Th2 cytokines", "TREATMENT", 56, 69], ["IL", "TEST", 78, 80], ["IL", "TREATMENT", 87, 89], ["anti-inflammatory cytokines", "TREATMENT", 104, 131], ["IL", "TEST", 140, 142], ["transforming growth factor", "TEST", 150, 176], ["TGF", "TEST", 180, 183], ["M2 macrophages", "OBSERVATION", 12, 26]]], ["These macrophages have an anti-inflammatory cytokine profile characterized by low production of IL-12 and high production of IL-1 receptor antagonist, chemokine CCL18, arginase 1 (Arg-1), found in inflammatory zone 1 (Fizz1), chitinase 3-like 3 (Chi313), IL-10, and TGF-\u03b2.", [["macrophages", "ANATOMY", 6, 17], ["macrophages", "CELL", 6, 17], ["IL-12", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 125, 149], ["CCL18", "GENE_OR_GENE_PRODUCT", 161, 166], ["arginase 1", "GENE_OR_GENE_PRODUCT", 168, 178], ["Arg-1", "GENE_OR_GENE_PRODUCT", 180, 185], ["inflammatory zone 1", "GENE_OR_GENE_PRODUCT", 197, 216], ["Fizz1", "GENE_OR_GENE_PRODUCT", 218, 223], ["chitinase 3-like 3", "GENE_OR_GENE_PRODUCT", 226, 244], ["Chi313", "GENE_OR_GENE_PRODUCT", 246, 252], ["IL-10", "GENE_OR_GENE_PRODUCT", 255, 260], ["TGF-\u03b2.", "GENE_OR_GENE_PRODUCT", 266, 272], ["macrophages", "CELL_TYPE", 6, 17], ["anti-inflammatory cytokine", "PROTEIN", 26, 52], ["IL-12", "PROTEIN", 96, 101], ["chemokine", "PROTEIN", 151, 160], ["CCL18", "PROTEIN", 161, 166], ["arginase 1", "PROTEIN", 168, 178], ["Arg-1", "PROTEIN", 180, 185], ["chitinase 3-like 3", "PROTEIN", 226, 244], ["TGF", "PROTEIN", 266, 269], ["an anti-inflammatory cytokine profile", "TEST", 23, 60], ["low production of IL", "PROBLEM", 78, 98], ["IL", "TEST", 125, 127], ["receptor antagonist", "TEST", 130, 149], ["chemokine CCL18", "TEST", 151, 166], ["arginase", "TEST", 168, 176], ["Arg", "TEST", 180, 183], ["inflammatory zone", "PROBLEM", 197, 214], ["chitinase", "TEST", 226, 235], ["IL", "TEST", 255, 257], ["TGF", "TEST", 266, 269], ["macrophages", "OBSERVATION", 6, 17], ["anti-inflammatory cytokine profile", "OBSERVATION", 26, 60], ["low", "OBSERVATION_MODIFIER", 78, 81], ["production", "OBSERVATION_MODIFIER", 82, 92], ["inflammatory", "OBSERVATION_MODIFIER", 197, 209]]], ["Functionally, M2 macrophages suppress effector T cells, promote tissue remodeling, and facilitate tumor development; however, they are beneficial for inflammation resolution, parasite clearance, tolerogenesis, scavenging, angiogenesis, and tissue repair [27, 28] .Polarization regulationAccumulating evidence indicates that identifying the polarized states of macrophages and switching the macrophage polarization from M1 to M2 or vice versa (repolarization or reprograming) could be novel diagnostic or therapeutic strategies for a wide variety of autoimmune and inflammatory diseases [8, 9, 11, 25, 29] .", [["M2 macrophages", "ANATOMY", 14, 28], ["effector T cells", "ANATOMY", 38, 54], ["tissue", "ANATOMY", 64, 70], ["tumor", "ANATOMY", 98, 103], ["tissue", "ANATOMY", 240, 246], ["macrophages", "ANATOMY", 360, 371], ["macrophage", "ANATOMY", 390, 400], ["tumor", "DISEASE", 98, 103], ["inflammation", "DISEASE", 150, 162], ["autoimmune and inflammatory diseases", "DISEASE", 549, 585], ["M2 macrophages", "CELL", 14, 28], ["effector T cells", "CELL", 38, 54], ["tissue", "TISSUE", 64, 70], ["tumor", "CANCER", 98, 103], ["tissue", "TISSUE", 240, 246], ["macrophages", "CELL", 360, 371], ["macrophage", "CELL", 390, 400], ["M2", "GENE_OR_GENE_PRODUCT", 425, 427], ["M2 macrophages", "CELL_TYPE", 14, 28], ["effector T cells", "CELL_TYPE", 38, 54], ["macrophages", "CELL_TYPE", 360, 371], ["tissue remodeling", "PROBLEM", 64, 81], ["inflammation resolution", "PROBLEM", 150, 173], ["parasite clearance", "TEST", 175, 193], ["tolerogenesis", "PROBLEM", 195, 208], ["angiogenesis", "PROBLEM", 222, 234], ["tissue repair", "TREATMENT", 240, 253], ["Polarization regulation", "TEST", 264, 287], ["macrophages", "PROBLEM", 360, 371], ["the macrophage polarization", "TREATMENT", 386, 413], ["therapeutic strategies", "TREATMENT", 504, 526], ["autoimmune and inflammatory diseases", "PROBLEM", 549, 585], ["tissue remodeling", "OBSERVATION_MODIFIER", 64, 81], ["tumor", "OBSERVATION", 98, 103], ["scavenging", "OBSERVATION_MODIFIER", 210, 220], ["macrophages", "OBSERVATION", 360, 371], ["autoimmune", "OBSERVATION", 549, 559], ["inflammatory", "OBSERVATION_MODIFIER", 564, 576]]], ["However, the precise regulatory mechanisms of macrophage polarization remain incompletely understood.", [["macrophage", "ANATOMY", 46, 56], ["macrophage", "CELL", 46, 56], ["macrophage polarization", "OBSERVATION", 46, 69]]], ["Macrophage polarization is a rigorously controlled process involving a set of signaling pathways and transcriptional and post-transcriptional regulatory networks [23, 30, 31] (Fig. 1) .JNK signaling pathwayThe c-Jun N-terminal kinase (JNK) signaling pathway belongs to the superfamily of mitogen-activated protein kinases (MAPKs) [29] .", [["Macrophage", "ANATOMY", 0, 10], ["N-", "CHEMICAL", 216, 218], ["Macrophage", "CELL", 0, 10], ["JNK", "GENE_OR_GENE_PRODUCT", 185, 188], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 210, 233], ["JNK", "GENE_OR_GENE_PRODUCT", 235, 238], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 288, 321], ["MAPKs", "GENE_OR_GENE_PRODUCT", 323, 328], ["JNK", "PROTEIN", 185, 188], ["Jun N-terminal kinase", "PROTEIN", 212, 233], ["JNK", "PROTEIN", 235, 238], ["mitogen-activated protein kinases", "PROTEIN", 288, 321], ["MAPKs", "PROTEIN", 323, 328], ["a rigorously controlled process", "PROBLEM", 27, 58], ["JNK signaling pathway", "TEST", 185, 206], ["The c-Jun N-terminal kinase", "TEST", 206, 233], ["mitogen", "TEST", 288, 295], ["activated protein kinases", "TEST", 296, 321], ["MAPKs", "TEST", 323, 328]]], ["Three distinct isoforms in the JNK family have been identified: JNK1, JNK2, and JNK3 [29] .", [["JNK", "GENE_OR_GENE_PRODUCT", 31, 34], ["JNK1", "GENE_OR_GENE_PRODUCT", 64, 68], ["JNK2", "GENE_OR_GENE_PRODUCT", 70, 74], ["JNK3", "GENE_OR_GENE_PRODUCT", 80, 84], ["JNK family", "PROTEIN", 31, 41], ["JNK1", "PROTEIN", 64, 68], ["JNK2", "PROTEIN", 70, 74], ["JNK3", "PROTEIN", 80, 84], ["JNK1", "TEST", 64, 68], ["JNK2", "TEST", 70, 74], ["JNK3", "TEST", 80, 84], ["distinct", "OBSERVATION_MODIFIER", 6, 14], ["isoforms", "OBSERVATION", 15, 23]]], ["JNK is reportedly required for M1-related inflammation and fibrosis, insulin resistance, macrophage infiltration, M1 macrophage polarization, and the M1-associated gene expression profile [32] [33] [34] [35] [36] .", [["macrophage", "ANATOMY", 89, 99], ["M1 macrophage", "ANATOMY", 114, 127], ["inflammation", "DISEASE", 42, 54], ["fibrosis", "DISEASE", 59, 67], ["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["insulin", "GENE_OR_GENE_PRODUCT", 69, 76], ["macrophage", "CELL", 89, 99], ["M1 macrophage", "CELL", 114, 127], ["M1", "GENE_OR_GENE_PRODUCT", 150, 152], ["[32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 188, 212], ["JNK", "PROTEIN", 0, 3], ["M1", "PROTEIN", 31, 33], ["M1", "PROTEIN", 150, 152], ["JNK", "TEST", 0, 3], ["M1-related inflammation", "PROBLEM", 31, 54], ["fibrosis", "PROBLEM", 59, 67], ["insulin resistance", "PROBLEM", 69, 87], ["macrophage infiltration", "PROBLEM", 89, 112], ["macrophage polarization", "TEST", 117, 140], ["gene expression profile", "TEST", 164, 187], ["inflammation", "OBSERVATION", 42, 54], ["fibrosis", "OBSERVATION", 59, 67], ["insulin resistance", "OBSERVATION", 69, 87], ["macrophage infiltration", "OBSERVATION", 89, 112]]], ["In previous studies, downregulation of phosphor-JNK induced macrophage polarization toward the M2 subset in rat white adipose tissue macrophages and in the murine macrophage cell line RAW264.7 [37, 38] .", [["macrophage", "ANATOMY", 60, 70], ["white adipose tissue macrophages", "ANATOMY", 112, 144], ["macrophage cell line RAW264.7", "ANATOMY", 163, 192], ["phosphor-JNK", "GENE_OR_GENE_PRODUCT", 39, 51], ["macrophage", "CELL", 60, 70], ["M2", "GENE_OR_GENE_PRODUCT", 95, 97], ["rat", "ORGANISM", 108, 111], ["adipose tissue macrophages", "CELL", 118, 144], ["murine", "ORGANISM", 156, 162], ["macrophage cell line RAW264.7", "CELL", 163, 192], ["JNK", "PROTEIN", 48, 51], ["M2 subset", "CELL_LINE", 95, 104], ["rat white adipose tissue macrophages", "CELL_TYPE", 108, 144], ["murine macrophage cell line", "CELL_LINE", 156, 183], ["RAW264.7", "CELL_LINE", 184, 192], ["rat", "SPECIES", 108, 111], ["murine", "SPECIES", 156, 162], ["rat", "SPECIES", 108, 111], ["previous studies", "TEST", 3, 19], ["phosphor", "TEST", 39, 47], ["macrophage polarization", "PROBLEM", 60, 83], ["white adipose tissue macrophages", "TEST", 112, 144], ["the murine macrophage cell line", "TEST", 152, 183], ["macrophage polarization", "OBSERVATION", 60, 83], ["M2", "ANATOMY_MODIFIER", 95, 97], ["white adipose", "ANATOMY", 112, 125], ["tissue macrophages", "OBSERVATION", 126, 144], ["murine", "ANATOMY", 156, 162], ["macrophage cell line", "OBSERVATION", 163, 183]]], ["However, in RAW264.7 modified with malignant fibrous histiocytomaamplified sequence 1 and praja ring finger 2, blockade of the JNK pathway did not influence the expression of M2 macrophage polarization biomarkers [39] .", [["RAW264.7", "ANATOMY", 12, 20], ["macrophage", "ANATOMY", 178, 188], ["RAW264.7", "CELL", 12, 20], ["praja ring finger 2", "GENE_OR_GENE_PRODUCT", 90, 109], ["JNK", "GENE_OR_GENE_PRODUCT", 127, 130], ["M2 macrophage", "GENE_OR_GENE_PRODUCT", 175, 188], ["RAW264.7", "CELL_LINE", 12, 20], ["malignant fibrous histiocytomaamplified sequence 1", "DNA", 35, 85], ["JNK", "PROTEIN", 127, 130], ["malignant fibrous histiocytomaamplified sequence", "TEST", 35, 83], ["macrophage polarization biomarkers", "TEST", 178, 212]]], ["In contrast, Hao et al. [40] reported that high expression of JNK is involved in IL-4-induced M2 macrophage polarization and that JNK increases the expression of downstream transcription c-Myc and M2 markers.", [["macrophage", "ANATOMY", 97, 107], ["JNK", "GENE_OR_GENE_PRODUCT", 62, 65], ["IL-4", "GENE_OR_GENE_PRODUCT", 81, 85], ["M2 macrophage", "CELL", 94, 107], ["JNK", "GENE_OR_GENE_PRODUCT", 130, 133], ["c-Myc", "GENE_OR_GENE_PRODUCT", 187, 192], ["M2", "GENE_OR_GENE_PRODUCT", 197, 199], ["JNK", "PROTEIN", 62, 65], ["IL-4", "PROTEIN", 81, 85], ["JNK", "PROTEIN", 130, 133], ["downstream transcription c-Myc and M2 markers", "PROTEIN", 162, 207], ["IL", "TEST", 81, 83], ["JNK", "PROBLEM", 130, 133], ["JNK", "ANATOMY", 62, 65], ["M2", "ANATOMY", 94, 96], ["macrophage polarization", "OBSERVATION", 97, 120]]], ["The regulatory effect of JNK on macrophage polarization might be mediated by the cyclic adenosine monophosphate/protein kinase A pathway [38] .PI3K/Akt signaling pathwayPhosphoinositide 3-kinases (PI3Ks), a class of lipid kinases, are constitutively expressed in various immune cells [41] .", [["macrophage", "ANATOMY", 32, 42], ["immune cells", "ANATOMY", 271, 283], ["adenosine", "CHEMICAL", 88, 97], ["cyclic adenosine monophosphate", "CHEMICAL", 81, 111], ["JNK", "GENE_OR_GENE_PRODUCT", 25, 28], ["macrophage", "CELL", 32, 42], ["cyclic adenosine monophosphate/protein kinase A", "GENE_OR_GENE_PRODUCT", 81, 128], ["PI3K", "GENE_OR_GENE_PRODUCT", 143, 147], ["Akt", "GENE_OR_GENE_PRODUCT", 148, 151], ["Phosphoinositide 3-kinases", "GENE_OR_GENE_PRODUCT", 169, 195], ["PI3Ks", "GENE_OR_GENE_PRODUCT", 197, 202], ["immune cells", "CELL", 271, 283], ["JNK", "PROTEIN", 25, 28], ["protein kinase A", "PROTEIN", 112, 128], ["PI3K", "PROTEIN", 143, 147], ["Akt", "PROTEIN", 148, 151], ["Phosphoinositide 3-kinases", "PROTEIN", 169, 195], ["PI3Ks", "PROTEIN", 197, 202], ["lipid kinases", "PROTEIN", 216, 229], ["immune cells", "CELL_TYPE", 271, 283], ["JNK on macrophage polarization", "TREATMENT", 25, 55], ["the cyclic adenosine monophosphate/protein kinase", "TREATMENT", 77, 126], ["PI3K", "TEST", 143, 147], ["Phosphoinositide", "TEST", 169, 185], ["PI3Ks", "TEST", 197, 202], ["lipid kinases", "TEST", 216, 229], ["effect", "OBSERVATION_MODIFIER", 15, 21], ["JNK", "OBSERVATION_MODIFIER", 25, 28]]], ["Members of the PI3K family are divided into four classes based on their structural features and substrate specificity: I A , I B , II, and III [42] .", [["PI3K", "GENE_OR_GENE_PRODUCT", 15, 19], ["I B", "GENE_OR_GENE_PRODUCT", 125, 128], ["PI3K family", "PROTEIN", 15, 26]]], ["Class I A PI3Ks can convert phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into the lipid second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ), which results in the activation of a downstream transduction signal [41] .", [["phosphatidylinositol 4,5-bisphosphate", "CHEMICAL", 28, 65], ["phosphatidylinositol (3,4,5)-trisphosphate", "CHEMICAL", 107, 149], ["phosphatidylinositol 4,5-bisphosphate", "CHEMICAL", 28, 65], ["PIP 2", "CHEMICAL", 67, 72], ["phosphatidylinositol (3,4,5)-trisphosphate", "CHEMICAL", 107, 149], ["PIP 3", "CHEMICAL", 151, 156], ["Class I A PI3Ks", "GENE_OR_GENE_PRODUCT", 0, 15], ["phosphatidylinositol 4,5-bisphosphate", "SIMPLE_CHEMICAL", 28, 65], ["PIP 2", "SIMPLE_CHEMICAL", 67, 72], ["phosphatidylinositol (3,4,5)-trisphosphate", "SIMPLE_CHEMICAL", 107, 149], ["PIP 3", "GENE_OR_GENE_PRODUCT", 151, 156], ["Class I A PI3Ks", "PROTEIN", 0, 15], ["phosphatidylinositol 4,5-bisphosphate", "PROTEIN", 28, 65], ["phosphatidylinositol", "TEST", 28, 48], ["bisphosphate (PIP", "TREATMENT", 53, 70], ["the lipid second messenger phosphatidylinositol", "TREATMENT", 80, 127], ["trisphosphate (PIP", "TREATMENT", 136, 154], ["a downstream transduction signal", "TEST", 195, 227]]], ["Akt (also known as protein kinase B) is a family of three serine/threonine protein kinases (Akt1, Akt2, and Akt3) and is the most prominent effector of PI3K [43] .", [["serine", "CHEMICAL", 58, 64], ["threonine", "CHEMICAL", 65, 74], ["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 19, 35], ["Akt1", "GENE_OR_GENE_PRODUCT", 92, 96], ["Akt2", "GENE_OR_GENE_PRODUCT", 98, 102], ["Akt3", "GENE_OR_GENE_PRODUCT", 108, 112], ["PI3K [43]", "GENE_OR_GENE_PRODUCT", 152, 161], ["Akt", "PROTEIN", 0, 3], ["protein kinase B", "PROTEIN", 19, 35], ["serine/threonine protein kinases", "PROTEIN", 58, 90], ["Akt1", "PROTEIN", 92, 96], ["Akt2", "PROTEIN", 98, 102], ["Akt3", "PROTEIN", 108, 112], ["PI3K", "PROTEIN", 152, 156], ["three serine/threonine protein kinases", "TREATMENT", 52, 90], ["most prominent", "OBSERVATION_MODIFIER", 125, 139]]], ["Once the conversion of PIP 2 to PIP 3 occurs, the downstream proteins PDK1 and Akt will be activated [41, 44] .", [["PIP 2", "GENE_OR_GENE_PRODUCT", 23, 28], ["PIP 3", "GENE_OR_GENE_PRODUCT", 32, 37], ["PDK1", "GENE_OR_GENE_PRODUCT", 70, 74], ["Akt", "GENE_OR_GENE_PRODUCT", 79, 82], ["PIP 2", "PROTEIN", 23, 28], ["PIP 3", "PROTEIN", 32, 37], ["downstream proteins", "PROTEIN", 50, 69], ["PDK1", "PROTEIN", 70, 74], ["Akt", "PROTEIN", 79, 82], ["PIP", "TEST", 23, 26], ["PIP", "TEST", 32, 35], ["the downstream proteins PDK1", "TEST", 46, 74], ["Akt", "TEST", 79, 82]]], ["Binding of PDK1 and Akt to PIP 3 further leads to the phosphorylation of Akt [42] .", [["PDK1", "GENE_OR_GENE_PRODUCT", 11, 15], ["Akt", "GENE_OR_GENE_PRODUCT", 20, 23], ["PIP 3", "GENE_OR_GENE_PRODUCT", 27, 32], ["Akt", "GENE_OR_GENE_PRODUCT", 73, 76], ["PDK1", "PROTEIN", 11, 15], ["Akt", "PROTEIN", 20, 23], ["PIP 3", "PROTEIN", 27, 32], ["Akt", "PROTEIN", 73, 76], ["PDK1", "TEST", 11, 15], ["Akt", "TEST", 20, 23], ["PIP", "TEST", 27, 30]]], ["Increasing numbers of studies are suggesting that the PI3K/Akt signaling pathway also plays crucial roles in macrophage activation and gene expression [29, 45] .", [["macrophage", "ANATOMY", 109, 119], ["PI3K", "GENE_OR_GENE_PRODUCT", 54, 58], ["Akt", "GENE_OR_GENE_PRODUCT", 59, 62], ["macrophage", "CELL", 109, 119], ["PI3K", "PROTEIN", 54, 58], ["Akt", "PROTEIN", 59, 62], ["studies", "TEST", 22, 29], ["the PI3K", "TEST", 50, 58]]], ["Zhang et al. [46] reported that inhibition of the PI3K/Akt pathway can depress M2 macrophage polarization.", [["M2 macrophage", "ANATOMY", 79, 92], ["PI3K", "GENE_OR_GENE_PRODUCT", 50, 54], ["Akt", "GENE_OR_GENE_PRODUCT", 55, 58], ["M2 macrophage", "CELL", 79, 92], ["PI3K", "PROTEIN", 50, 54], ["Akt", "PROTEIN", 55, 58], ["Akt pathway", "PROBLEM", 55, 66]]], ["In fact, the PI3K/Akt signaling pathway differentially contributes to macrophage polarization depending on the Akt isoform [43] .", [["macrophage", "ANATOMY", 70, 80], ["PI3K", "GENE_OR_GENE_PRODUCT", 13, 17], ["Akt", "GENE_OR_GENE_PRODUCT", 18, 21], ["macrophage", "CELL", 70, 80], ["Akt", "GENE_OR_GENE_PRODUCT", 111, 114], ["PI3K", "PROTEIN", 13, 17], ["Akt", "PROTEIN", 18, 21], ["Akt isoform", "PROTEIN", 111, 122], ["the PI3K", "TEST", 9, 17], ["macrophage polarization", "PROBLEM", 70, 93], ["macrophage polarization", "OBSERVATION", 70, 93]]], ["Studies have shown that Akt1 \u2212/\u2212 macrophages express high levels of iNOS, TNF-\u03b1, and IL-6, while Akt2 \u2212/\u2212 macrophages express high levels of Fizz1, Chi313, and IL-10 [43] .", [["Akt1 \u2212/\u2212 macrophages", "ANATOMY", 24, 44], ["Akt2 \u2212/\u2212 macrophages", "ANATOMY", 97, 117], ["Akt1", "GENE_OR_GENE_PRODUCT", 24, 28], ["iNOS", "GENE_OR_GENE_PRODUCT", 68, 72], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["Akt2", "GENE_OR_GENE_PRODUCT", 97, 101], ["Fizz1", "GENE_OR_GENE_PRODUCT", 141, 146], ["Chi313", "GENE_OR_GENE_PRODUCT", 148, 154], ["IL-10", "GENE_OR_GENE_PRODUCT", 160, 165], ["Akt1", "PROTEIN", 24, 28], ["iNOS", "PROTEIN", 68, 72], ["TNF", "PROTEIN", 74, 77], ["IL-6", "PROTEIN", 85, 89], ["Akt2", "PROTEIN", 97, 101], ["Fizz1", "PROTEIN", 141, 146], ["Chi313", "PROTEIN", 148, 154], ["IL", "PROTEIN", 160, 162], ["Studies", "TEST", 0, 7], ["Akt1", "TEST", 24, 28], ["macrophages", "PROBLEM", 33, 44], ["iNOS", "TEST", 68, 72], ["TNF", "TEST", 74, 77], ["IL", "TEST", 85, 87], ["Akt2", "TEST", 97, 101], ["macrophages", "PROBLEM", 106, 117], ["high levels of Fizz1", "PROBLEM", 126, 146], ["Chi313", "TEST", 148, 154]]], ["These data suggest that Akt1 ablation gives rise to an M1 phenotype and that Akt2 ablation results in an M2 phenotype [47] .", [["Akt1", "GENE_OR_GENE_PRODUCT", 24, 28], ["Akt2", "GENE_OR_GENE_PRODUCT", 77, 81], ["Akt1", "PROTEIN", 24, 28], ["Akt2", "PROTEIN", 77, 81], ["Akt1 ablation", "TREATMENT", 24, 37], ["an M1 phenotype", "PROBLEM", 52, 67], ["Akt2 ablation", "TREATMENT", 77, 90]]], ["Additionally, microRNA (miR)-155 and its target CAAT/enhancer-binding protein\u03b2 (C/EBP\u03b2) are critical for Akt isoform-dependent M1/M2 polarization of macrophages [43] .", [["macrophages", "ANATOMY", 149, 160], ["microRNA (miR)-155", "GENE_OR_GENE_PRODUCT", 14, 32], ["CAAT/enhancer-binding protein\u03b2", "GENE_OR_GENE_PRODUCT", 48, 78], ["C/EBP\u03b2", "GENE_OR_GENE_PRODUCT", 80, 86], ["Akt", "GENE_OR_GENE_PRODUCT", 105, 108], ["M2", "GENE_OR_GENE_PRODUCT", 130, 132], ["macrophages", "CELL", 149, 160], ["microRNA (miR)-155", "DNA", 14, 32], ["CAAT/enhancer-binding protein\u03b2", "PROTEIN", 48, 78], ["C/EBP\u03b2", "PROTEIN", 80, 86], ["Akt isoform", "PROTEIN", 105, 116], ["macrophages", "CELL_TYPE", 149, 160], ["microRNA (miR)", "TEST", 14, 28], ["its target CAAT/enhancer", "TEST", 37, 61], ["binding protein\u03b2", "TEST", 62, 78], ["C/EBP\u03b2", "TEST", 80, 86], ["Akt isoform", "PROBLEM", 105, 116], ["macrophages", "PROBLEM", 149, 160], ["dependent", "OBSERVATION_MODIFIER", 117, 126], ["M1", "OBSERVATION_MODIFIER", 127, 129], ["M2", "OBSERVATION_MODIFIER", 130, 132], ["macrophages", "OBSERVATION", 149, 160]]], ["Akt1 leads to upregulation of miR-155 and consequent inhibition of C/EBP\u03b2, which finally blunts the M1 macrophage reaction [43, 47] .", [["M1 macrophage", "ANATOMY", 100, 113], ["Akt1", "GENE_OR_GENE_PRODUCT", 0, 4], ["miR-155", "GENE_OR_GENE_PRODUCT", 30, 37], ["C/EBP\u03b2", "GENE_OR_GENE_PRODUCT", 67, 73], ["Akt1", "PROTEIN", 0, 4], ["miR-155", "PROTEIN", 30, 37], ["C/EBP\u03b2", "PROTEIN", 67, 73], ["miR", "TEST", 30, 33], ["consequent inhibition of C/EBP\u03b2", "PROBLEM", 42, 73], ["M1", "ANATOMY", 100, 102]]], ["Conversely, Akt2 promotes M1 phenotype transformation by an opposite influence on miR-155 and C/EBP\u03b2 [43] .Notch signaling pathwayThe Notch signaling pathway is an evolutionarily conserved pathway [48] .", [["Akt2", "GENE_OR_GENE_PRODUCT", 12, 16], ["miR-155", "GENE_OR_GENE_PRODUCT", 82, 89], ["C/EBP\u03b2 [43]", "GENE_OR_GENE_PRODUCT", 94, 105], ["Notch", "GENE_OR_GENE_PRODUCT", 107, 112], ["Notch", "GENE_OR_GENE_PRODUCT", 134, 139], ["Akt2", "PROTEIN", 12, 16], ["miR-155", "DNA", 82, 89], ["miR", "TEST", 82, 85], ["C/EBP\u03b2", "TEST", 94, 100]]], ["The Notch receptor family is divided into four classes: Notch1, Notch2, Notch3, and Notch4.", [["Notch", "GENE_OR_GENE_PRODUCT", 4, 9], ["Notch1", "GENE_OR_GENE_PRODUCT", 56, 62], ["Notch2", "GENE_OR_GENE_PRODUCT", 64, 70], ["Notch3", "GENE_OR_GENE_PRODUCT", 72, 78], ["Notch4", "GENE_OR_GENE_PRODUCT", 84, 90], ["Notch receptor family", "PROTEIN", 4, 25], ["Notch1", "PROTEIN", 56, 62], ["Notch2", "PROTEIN", 64, 70], ["Notch3", "PROTEIN", 72, 78], ["Notch4", "PROTEIN", 84, 90], ["Notch1", "ANATOMY", 56, 62], ["Notch2", "ANATOMY", 64, 70]]], ["These classes, especially Notch1, are widely expressed in various organs and tissues [49] .", [["organs", "ANATOMY", 66, 72], ["tissues", "ANATOMY", 77, 84], ["Notch1", "GENE_OR_GENE_PRODUCT", 26, 32], ["organs", "ORGAN", 66, 72], ["tissues", "TISSUE", 77, 84], ["Notch1", "PROTEIN", 26, 32], ["Notch1", "PROBLEM", 26, 32], ["Notch1", "OBSERVATION", 26, 32], ["widely", "OBSERVATION_MODIFIER", 38, 44], ["organs", "ANATOMY", 66, 72]]], ["Ligands of Notch receptors are divided into two families: Delta-like 1, 3, and 4 and the JAG-type ligands Jagged-1 and -2 [50] .The Notch signaling pathway plays a critical role in M1 phenotype polarization [51] .", [["Notch", "GENE_OR_GENE_PRODUCT", 11, 16], ["Delta-like 1", "GENE_OR_GENE_PRODUCT", 58, 70], ["3", "GENE_OR_GENE_PRODUCT", 72, 73], ["4", "GENE_OR_GENE_PRODUCT", 79, 80], ["JAG", "GENE_OR_GENE_PRODUCT", 89, 92], ["Jagged-1", "GENE_OR_GENE_PRODUCT", 106, 114], ["-2", "GENE_OR_GENE_PRODUCT", 119, 121], ["Notch", "GENE_OR_GENE_PRODUCT", 132, 137], ["M1", "CELL", 181, 183], ["Notch receptors", "PROTEIN", 11, 26], ["Delta", "PROTEIN", 58, 63], ["like 1, 3, and 4", "PROTEIN", 64, 80], ["JAG-type ligands", "PROTEIN", 89, 105], ["Jagged", "PROTEIN", 106, 112], ["Delta", "TEST", 58, 63], ["the JAG", "TEST", 85, 92]]], ["Activation of Notch signaling promotes macrophage polarization from M2 to M1 and increases M1 macrophage-associated gene expression.", [["macrophage", "ANATOMY", 39, 49], ["M1 macrophage", "ANATOMY", 91, 104], ["Notch", "GENE_OR_GENE_PRODUCT", 14, 19], ["macrophage", "CELL", 39, 49], ["M2", "GENE_OR_GENE_PRODUCT", 68, 70], ["M1", "CELL", 74, 76], ["M1 macrophage", "CELL", 91, 104], ["macrophage polarization", "OBSERVATION", 39, 62], ["M1", "ANATOMY", 74, 76], ["M1 macrophage", "OBSERVATION", 91, 104], ["gene expression", "OBSERVATION", 116, 131]]], ["In contrast, macrophages deficient in canonical Notch signaling typically show the M2 phenotype [51, 52] .", [["macrophages", "ANATOMY", 13, 24], ["macrophages", "CELL", 13, 24], ["Notch", "GENE_OR_GENE_PRODUCT", 48, 53], ["macrophages", "CELL_TYPE", 13, 24], ["macrophages deficient", "PROBLEM", 13, 34], ["canonical Notch signaling", "TEST", 38, 63], ["the M2 phenotype", "TEST", 79, 95], ["macrophages deficient", "OBSERVATION", 13, 34], ["canonical Notch", "OBSERVATION", 38, 53]]], ["Notch signaling can not only promote M1 macrophage differentiation, but also prevent M2 macrophage differentiation by binding with Delta-like 4, thus modulating the expression of M2-specific gene expression and apoptotic cell death [53] .", [["M1 macrophage", "ANATOMY", 37, 50], ["M2 macrophage", "ANATOMY", 85, 98], ["cell", "ANATOMY", 221, 225], ["Notch", "GENE_OR_GENE_PRODUCT", 0, 5], ["M1 macrophage", "CELL", 37, 50], ["M2 macrophage", "CELL", 85, 98], ["Delta-like 4", "GENE_OR_GENE_PRODUCT", 131, 143], ["M2", "GENE_OR_GENE_PRODUCT", 179, 181], ["cell", "CELL", 221, 225], ["Delta", "PROTEIN", 131, 136], ["M2", "PROTEIN", 179, 181], ["Notch signaling", "PROBLEM", 0, 15], ["Delta", "TEST", 131, 136], ["apoptotic cell death", "PROBLEM", 211, 231], ["apoptotic cell death", "OBSERVATION", 211, 231]]], ["Notch signaling can function through both canonical and non-canonical pathways [54] .", [["Notch", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["In Notch canonical signaling, the binding of a Notch ligand with its receptor triggers cleavage of Notch by a furin-like convertase [29] .", [["Notch", "GENE_OR_GENE_PRODUCT", 3, 8], ["Notch", "GENE_OR_GENE_PRODUCT", 47, 52], ["Notch", "GENE_OR_GENE_PRODUCT", 99, 104], ["furin", "GENE_OR_GENE_PRODUCT", 110, 115], ["Notch ligand", "PROTEIN", 47, 59], ["Notch", "PROTEIN", 99, 104], ["furin", "PROTEIN", 110, 115], ["a Notch ligand", "TREATMENT", 45, 59], ["Notch", "OBSERVATION_MODIFIER", 3, 8], ["canonical signaling", "OBSERVATION", 9, 28]]], ["Receptors release the Notch intracellular domain (NICD) by two subsequent proteolytic cuts, the first by a disintegrin and metalloproteinase domain (ADAM)-type proteinase and the second by a \u03b3-secretase, which results in the liberation and nuclear translocation of NICD [54] .", [["intracellular", "ANATOMY", 28, 41], ["nuclear", "ANATOMY", 240, 247], ["Notch", "GENE_OR_GENE_PRODUCT", 22, 27], ["NICD", "GENE_OR_GENE_PRODUCT", 50, 54], ["disintegrin and metalloproteinase domain (ADAM)-type proteinase", "GENE_OR_GENE_PRODUCT", 107, 170], ["\u03b3-secretase", "GENE_OR_GENE_PRODUCT", 191, 202], ["nuclear", "CELLULAR_COMPONENT", 240, 247], ["NICD", "GENE_OR_GENE_PRODUCT", 265, 269], ["Notch intracellular domain", "PROTEIN", 22, 48], ["NICD", "PROTEIN", 50, 54], ["disintegrin and metalloproteinase domain (ADAM)-type proteinase", "PROTEIN", 107, 170], ["\u03b3-secretase", "PROTEIN", 191, 202], ["NICD", "PROTEIN", 265, 269], ["two subsequent proteolytic cuts", "TREATMENT", 59, 90], ["a disintegrin and metalloproteinase domain", "TREATMENT", 105, 147], ["type proteinase", "PROBLEM", 155, 170]]], ["The binding of NICD to the sequence-specific DNA-binding factor recombinant binding protein for immunoglobulin region \u03baJ (RBP-J) leads to the formation of a transcriptional activator complex that induces the transcriptional expression of genes under the control of Notch [29] .", [["NICD", "GENE_OR_GENE_PRODUCT", 15, 19], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["immunoglobulin region \u03baJ", "GENE_OR_GENE_PRODUCT", 96, 120], ["RBP-J", "GENE_OR_GENE_PRODUCT", 122, 127], ["Notch", "GENE_OR_GENE_PRODUCT", 265, 270], ["NICD", "PROTEIN", 15, 19], ["DNA-binding factor recombinant binding protein", "PROTEIN", 45, 91], ["immunoglobulin region \u03baJ", "PROTEIN", 96, 120], ["RBP", "PROTEIN", 122, 125], ["J", "PROTEIN", 126, 127], ["transcriptional activator complex", "PROTEIN", 157, 190], ["the sequence", "TEST", 23, 35], ["immunoglobulin region \u03baJ", "TREATMENT", 96, 120], ["a transcriptional activator complex", "TREATMENT", 155, 190]]], ["Activated Notch1 and expression of the Notch target genes significantly modulate the expression of TNF-\u03b1, IL-6, and IL-10 through activation of nuclear transcription factor-\u03baB (NF-\u03baB) [51] .", [["Notch1", "GENE_OR_GENE_PRODUCT", 10, 16], ["Notch", "GENE_OR_GENE_PRODUCT", 39, 44], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 99, 104], ["IL-6", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-10", "GENE_OR_GENE_PRODUCT", 116, 121], ["nuclear transcription factor-\u03baB", "GENE_OR_GENE_PRODUCT", 144, 175], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 177, 182], ["Notch1", "PROTEIN", 10, 16], ["Notch target genes", "DNA", 39, 57], ["TNF", "PROTEIN", 99, 102], ["IL-10", "PROTEIN", 116, 121], ["nuclear transcription factor-\u03baB (NF-\u03baB", "PROTEIN", 144, 182], ["Activated Notch1", "PROBLEM", 0, 16], ["the Notch target genes", "PROBLEM", 35, 57], ["TNF", "TEST", 99, 102], ["IL", "TEST", 106, 108], ["IL", "TREATMENT", 116, 118], ["nuclear transcription factor", "TEST", 144, 172], ["Notch1", "OBSERVATION", 10, 16]]], ["However, in the noncanonical pathway, NICD activity is independent of both RBP-J and cleavage of the \u03b3-secretase complex [55] .JAK/STAT signaling pathwayThe Janus family kinases (JAKs), including JAK1, JAK2, JAK3, and TYK2, belong to the subgroup of non-receptor protein tyrosine kinases [56] .", [["tyrosine", "CHEMICAL", 271, 279], ["tyrosine", "CHEMICAL", 271, 279], ["NICD", "GENE_OR_GENE_PRODUCT", 38, 42], ["RBP-J", "GENE_OR_GENE_PRODUCT", 75, 80], ["\u03b3-secretase", "GENE_OR_GENE_PRODUCT", 101, 112], ["JAK", "GENE_OR_GENE_PRODUCT", 127, 130], ["STAT", "GENE_OR_GENE_PRODUCT", 131, 135], ["Janus family kinases", "GENE_OR_GENE_PRODUCT", 157, 177], ["JAKs", "GENE_OR_GENE_PRODUCT", 179, 183], ["JAK1", "GENE_OR_GENE_PRODUCT", 196, 200], ["JAK2", "GENE_OR_GENE_PRODUCT", 202, 206], ["JAK3", "GENE_OR_GENE_PRODUCT", 208, 212], ["TYK2", "GENE_OR_GENE_PRODUCT", 218, 222], ["non-receptor protein tyrosine kinases", "GENE_OR_GENE_PRODUCT", 250, 287], ["NICD", "PROTEIN", 38, 42], ["RBP", "PROTEIN", 75, 78], ["J", "PROTEIN", 79, 80], ["\u03b3-secretase complex", "PROTEIN", 101, 120], ["JAK", "PROTEIN", 127, 130], ["STAT", "PROTEIN", 131, 135], ["Janus family kinases", "PROTEIN", 157, 177], ["JAKs", "PROTEIN", 179, 183], ["JAK1", "PROTEIN", 196, 200], ["JAK2", "PROTEIN", 202, 206], ["JAK3", "PROTEIN", 208, 212], ["TYK2", "PROTEIN", 218, 222], ["non-receptor protein tyrosine kinases", "PROTEIN", 250, 287], ["JAK1", "TEST", 196, 200], ["TYK2", "PROBLEM", 218, 222], ["non-receptor protein tyrosine kinases", "TEST", 250, 287], ["NICD activity", "OBSERVATION", 38, 51], ["JAK1", "ANATOMY", 196, 200], ["JAK2", "ANATOMY", 202, 206], ["JAK3", "ANATOMY", 208, 212]]], ["JAKs exert their effect mainly through activation of cytosolic DNA-binding proteins called signal transducers and activators of transcription (STATs).JAK/STAT signaling pathwaySTATs include seven family members (STATs 1-6, including two STAT5 genes) [57] .", [["cytosolic", "ANATOMY", 53, 62], ["JAKs", "GENE_OR_GENE_PRODUCT", 0, 4], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["-binding proteins called signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 66, 141], ["STATs", "GENE_OR_GENE_PRODUCT", 143, 148], ["JAK", "GENE_OR_GENE_PRODUCT", 150, 153], ["STAT", "GENE_OR_GENE_PRODUCT", 154, 158], ["pathwaySTATs", "GENE_OR_GENE_PRODUCT", 169, 181], ["STATs 1-6", "GENE_OR_GENE_PRODUCT", 212, 221], ["STAT5", "GENE_OR_GENE_PRODUCT", 237, 242], ["JAKs", "PROTEIN", 0, 4], ["cytosolic DNA-binding proteins", "PROTEIN", 53, 83], ["signal transducers and activators of transcription", "PROTEIN", 91, 141], ["STATs", "PROTEIN", 143, 148], ["JAK", "PROTEIN", 150, 153], ["STAT signaling pathwaySTATs", "PROTEIN", 154, 181], ["STATs 1-6", "PROTEIN", 212, 221], ["STAT5 genes", "DNA", 237, 248], ["cytosolic DNA", "TEST", 53, 66]]], ["Accumulating evidence has confirmed that many cytokines regulate macrophage phenotypes and activation via the JAK/STAT signaling pathway [57] [58] [59] .", [["macrophage", "ANATOMY", 65, 75], ["macrophage", "CELL", 65, 75], ["JAK", "GENE_OR_GENE_PRODUCT", 110, 113], ["STAT", "GENE_OR_GENE_PRODUCT", 114, 118], ["cytokines", "PROTEIN", 46, 55], ["JAK", "PROTEIN", 110, 113], ["STAT", "PROTEIN", 114, 118], ["many cytokines regulate macrophage phenotypes", "PROBLEM", 41, 86], ["the JAK", "TEST", 106, 113], ["macrophage phenotypes", "OBSERVATION", 65, 86]]], ["STAT1 is the most important mediator of M1 macrophage polarization induced by IFN-\u03b3 [31] .", [["M1 macrophage", "ANATOMY", 40, 53], ["STAT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["M1 macrophage", "CELL", 40, 53], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["STAT1", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 78, 81]]], ["Binding of the IFN-\u03b3 ligand to its receptor induces JAK1/2-mediated tyrosine phosphorylation and subsequent dimerization of STAT1, which binds as a homodimer to cis elements known as IFN-\u03b3-activated sites in the promoter of target M1 signature genes [31] .", [["tyrosine", "CHEMICAL", 68, 76], ["tyrosine", "CHEMICAL", 68, 76], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 15, 20], ["JAK1", "GENE_OR_GENE_PRODUCT", 52, 56], ["2", "GENE_OR_GENE_PRODUCT", 57, 58], ["tyrosine", "AMINO_ACID", 68, 76], ["STAT1", "GENE_OR_GENE_PRODUCT", 124, 129], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 183, 189], ["M1", "GENE_OR_GENE_PRODUCT", 231, 233], ["IFN-\u03b3 ligand", "PROTEIN", 15, 27], ["JAK1/2", "PROTEIN", 52, 58], ["STAT1", "PROTEIN", 124, 129], ["cis elements", "DNA", 161, 173], ["IFN-\u03b3-activated sites", "DNA", 183, 204], ["M1 signature genes", "DNA", 231, 249], ["the IFN", "TEST", 11, 18], ["JAK1", "TEST", 52, 56], ["tyrosine phosphorylation", "TREATMENT", 68, 92], ["subsequent dimerization of STAT1", "TREATMENT", 97, 129], ["a homodimer to cis elements", "TREATMENT", 146, 173], ["IFN", "PROBLEM", 183, 186], ["activated sites", "PROBLEM", 189, 204]]], ["Hence, the IFN-\u03b3/JAK/STAT1 pathway is believed to be a key component of M1 phenotype modulatory factors [29] .", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 11, 16], ["JAK", "GENE_OR_GENE_PRODUCT", 17, 20], ["STAT1", "GENE_OR_GENE_PRODUCT", 21, 26], ["IFN", "PROTEIN", 11, 14], ["\u03b3", "PROTEIN", 15, 16], ["JAK", "PROTEIN", 17, 20], ["STAT1", "PROTEIN", 21, 26], ["M1 phenotype modulatory factors", "PROTEIN", 72, 103], ["the IFN", "TEST", 7, 14], ["STAT1 pathway", "PROBLEM", 21, 34], ["M1 phenotype modulatory factors", "PROBLEM", 72, 103]]], ["Oh et al. [60] found that asaronic acid could attenuate macrophage activation toward the M1 phenotype through inhibition of JAK/STAT1 signaling.", [["macrophage", "ANATOMY", 56, 66], ["asaronic acid", "CHEMICAL", 26, 39], ["asaronic acid", "CHEMICAL", 26, 39], ["asaronic acid", "SIMPLE_CHEMICAL", 26, 39], ["macrophage", "CELL", 56, 66], ["JAK", "GENE_OR_GENE_PRODUCT", 124, 127], ["STAT1", "GENE_OR_GENE_PRODUCT", 128, 133], ["JAK", "PROTEIN", 124, 127], ["STAT1", "PROTEIN", 128, 133], ["asaronic acid", "PROBLEM", 26, 39], ["macrophage activation", "PROBLEM", 56, 77], ["STAT1 signaling", "PROBLEM", 128, 143], ["M1", "ANATOMY", 89, 91]]], ["Liang et al. [61] reported that downregulation of suppressor of cytokine signaling 1 (SOCS1) could promote M1 macrophage polarization via the JAK1/STAT1 pathway.", [["M1 macrophage", "ANATOMY", 107, 120], ["suppressor of cytokine signaling 1", "GENE_OR_GENE_PRODUCT", 50, 84], ["SOCS1", "GENE_OR_GENE_PRODUCT", 86, 91], ["M1 macrophage", "CELL", 107, 120], ["JAK1", "GENE_OR_GENE_PRODUCT", 142, 146], ["STAT1", "GENE_OR_GENE_PRODUCT", 147, 152], ["suppressor of cytokine signaling 1", "PROTEIN", 50, 84], ["SOCS1", "PROTEIN", 86, 91], ["JAK1", "PROTEIN", 142, 146], ["STAT1", "PROTEIN", 147, 152], ["cytokine signaling", "PROBLEM", 64, 82], ["the JAK1/STAT1 pathway", "TREATMENT", 138, 160], ["M1", "ANATOMY", 107, 109]]], ["However, the role of type I IFN-mediated signaling in macrophage polarization remains unclear [29] .", [["macrophage", "ANATOMY", 54, 64], ["type I IFN", "GENE_OR_GENE_PRODUCT", 21, 31], ["macrophage", "CELL", 54, 64], ["type I IFN", "PROTEIN", 21, 31], ["type I IFN", "PROBLEM", 21, 31], ["macrophage polarization", "TEST", 54, 77], ["macrophage polarization", "OBSERVATION", 54, 77]]], ["Type I IFN can exhibit anti-inflammatory activity in certain conditions, and IFN\u03b1/\u03b2 receptor signaling inhibits resistance to Listeria monocytogenes infection by inducing macrophage apoptosis [29] .", [["macrophage", "ANATOMY", 171, 181], ["Listeria monocytogenes infection", "DISEASE", 126, 158], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 0, 10], ["IFN\u03b1/\u03b2 receptor", "GENE_OR_GENE_PRODUCT", 77, 92], ["Listeria monocytogenes", "ORGANISM", 126, 148], ["macrophage", "CELL", 171, 181], ["Type I IFN", "PROTEIN", 0, 10], ["IFN\u03b1", "PROTEIN", 77, 81], ["\u03b2 receptor", "PROTEIN", 82, 92], ["Listeria monocytogenes", "SPECIES", 126, 148], ["Listeria monocytogenes", "SPECIES", 126, 148], ["Type I IFN", "PROBLEM", 0, 10], ["anti-inflammatory activity in certain conditions", "PROBLEM", 23, 71], ["IFN", "TREATMENT", 77, 80], ["receptor signaling", "PROBLEM", 84, 102], ["Listeria monocytogenes infection", "PROBLEM", 126, 158], ["macrophage apoptosis", "PROBLEM", 171, 191], ["anti-inflammatory activity", "OBSERVATION", 23, 49]]], ["This suggests that IFN\u03b3-and IFN\u03b1/\u03b2-mediated STAT1 activation might have a different effect on macrophage polarization in vivo [31] .", [["macrophage", "ANATOMY", 94, 104], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 19, 23], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 28, 32], ["\u03b2-", "GENE_OR_GENE_PRODUCT", 33, 35], ["STAT1", "GENE_OR_GENE_PRODUCT", 44, 49], ["macrophage", "CELL", 94, 104], ["IFN\u03b3", "PROTEIN", 19, 23], ["IFN\u03b1", "PROTEIN", 28, 32], ["STAT1", "PROTEIN", 44, 49], ["IFN", "TEST", 19, 22], ["STAT1 activation", "PROBLEM", 44, 60], ["macrophage polarization", "TREATMENT", 94, 117]]], ["IFN-\u03b3 activates JAK/STAT-1 phosphorylation, which leads to M1-like macrophage polarization.", [["macrophage", "ANATOMY", 67, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["JAK", "GENE_OR_GENE_PRODUCT", 16, 19], ["STAT-1", "GENE_OR_GENE_PRODUCT", 20, 26], ["macrophage", "CELL", 67, 77], ["IFN", "PROTEIN", 0, 3], ["JAK", "PROTEIN", 16, 19], ["STAT", "PROTEIN", 20, 24], ["IFN", "TEST", 0, 3], ["M1", "ANATOMY", 59, 61], ["macrophage polarization", "OBSERVATION", 67, 90]]], ["In contrast, IFN-\u03b1/\u03b2 induces the expression of SOCS3, which inhibits STAT-1 phosphorylation.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 13, 18], ["\u03b2", "GENE_OR_GENE_PRODUCT", 19, 20], ["SOCS3", "GENE_OR_GENE_PRODUCT", 47, 52], ["STAT-1", "GENE_OR_GENE_PRODUCT", 69, 75], ["IFN-\u03b1/\u03b2", "PROTEIN", 13, 20], ["SOCS3", "PROTEIN", 47, 52], ["STAT-1", "PROTEIN", 69, 75], ["SOCS3", "PROBLEM", 47, 52], ["STAT", "TEST", 69, 73], ["SOCS3", "ANATOMY", 47, 52]]], ["Moreover, STAT3 is reportedly an important transcription factor for the activation of macrophages and augmentation of inflammation [62] .", [["macrophages", "ANATOMY", 86, 97], ["inflammation", "DISEASE", 118, 130], ["STAT3", "GENE_OR_GENE_PRODUCT", 10, 15], ["macrophages", "CELL", 86, 97], ["STAT3", "PROTEIN", 10, 15], ["transcription factor", "PROTEIN", 43, 63], ["macrophages", "CELL_TYPE", 86, 97], ["macrophages", "PROBLEM", 86, 97], ["inflammation", "PROBLEM", 118, 130], ["macrophages", "OBSERVATION", 86, 97], ["inflammation", "OBSERVATION", 118, 130]]], ["Suppressing STAT3 activity has a protective effect on LPS-induced ALI via inhibition of expression of proinflammatory genes and polarization of M1 macrophages [62] .", [["M1 macrophages", "ANATOMY", 144, 158], ["LPS", "CHEMICAL", 54, 57], ["ALI", "DISEASE", 66, 69], ["STAT3", "GENE_OR_GENE_PRODUCT", 12, 17], ["LPS", "SIMPLE_CHEMICAL", 54, 57], ["M1 macrophages", "CELL", 144, 158], ["STAT3", "PROTEIN", 12, 17], ["proinflammatory genes", "DNA", 102, 123], ["M1 macrophages", "CELL_TYPE", 144, 158], ["Suppressing STAT3 activity", "PROBLEM", 0, 26], ["LPS", "TREATMENT", 54, 57], ["ALI", "PROBLEM", 66, 69], ["proinflammatory genes", "PROBLEM", 102, 123], ["proinflammatory genes", "OBSERVATION", 102, 123], ["M1", "ANATOMY", 144, 146]]], ["STAT6 is a crucial transcription factor in the activation of M2 macrophages induced by IL-4 or IL-13 [63] .", [["M2 macrophages", "ANATOMY", 61, 75], ["STAT6", "GENE_OR_GENE_PRODUCT", 0, 5], ["M2 macrophages", "CELL", 61, 75], ["IL-4", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-13", "GENE_OR_GENE_PRODUCT", 95, 100], ["STAT6", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 19, 39], ["M2 macrophages", "CELL_TYPE", 61, 75], ["IL", "PROTEIN", 87, 89], ["a crucial transcription factor", "PROBLEM", 9, 39], ["IL", "TEST", 87, 89], ["IL", "TEST", 95, 97]]], ["IL-4 type I and II receptors activate STAT6, which in turn promotes expression of genes typical of M2 polarization [63] .", [["IL-4 type I and II receptors", "GENE_OR_GENE_PRODUCT", 0, 28], ["STAT6", "GENE_OR_GENE_PRODUCT", 38, 43], ["M2", "GENE_OR_GENE_PRODUCT", 99, 101], ["IL-4 type I and II receptors", "PROTEIN", 0, 28], ["STAT6", "PROTEIN", 38, 43], ["IL", "TREATMENT", 0, 2]]], ["SOCS proteins are described as feedback inhibitors of the JAK/STAT signaling pathway [64] .", [["SOCS", "GENE_OR_GENE_PRODUCT", 0, 4], ["JAK", "GENE_OR_GENE_PRODUCT", 58, 61], ["STAT", "GENE_OR_GENE_PRODUCT", 62, 66], ["SOCS proteins", "PROTEIN", 0, 13], ["JAK", "PROTEIN", 58, 61], ["STAT", "PROTEIN", 62, 66]]], ["In the process of macrophage polarization, JAK/STAT signaling is activated while the expression of SOCS1 and SOCS3 is upregulated [64] .", [["macrophage", "ANATOMY", 18, 28], ["macrophage", "CELL", 18, 28], ["JAK", "GENE_OR_GENE_PRODUCT", 43, 46], ["STAT", "GENE_OR_GENE_PRODUCT", 47, 51], ["SOCS1", "GENE_OR_GENE_PRODUCT", 99, 104], ["SOCS3", "GENE_OR_GENE_PRODUCT", 109, 114], ["JAK", "PROTEIN", 43, 46], ["STAT", "PROTEIN", 47, 51], ["SOCS1", "PROTEIN", 99, 104], ["SOCS3", "PROTEIN", 109, 114], ["macrophage polarization", "TREATMENT", 18, 41], ["JAK/STAT signaling", "TEST", 43, 61], ["SOCS1", "PROBLEM", 99, 104], ["macrophage polarization", "OBSERVATION", 18, 41]]], ["This upregulation of SOCS1 and SOCS3 in turn suppresses the action of STAT1 and STAT3, respectively, which can terminate innate and adaptive immune responses [64, 65] .", [["SOCS1", "GENE_OR_GENE_PRODUCT", 21, 26], ["SOCS3", "GENE_OR_GENE_PRODUCT", 31, 36], ["STAT1", "GENE_OR_GENE_PRODUCT", 70, 75], ["STAT3", "GENE_OR_GENE_PRODUCT", 80, 85], ["SOCS1", "PROTEIN", 21, 26], ["SOCS3", "PROTEIN", 31, 36], ["STAT1", "PROTEIN", 70, 75], ["STAT3", "PROTEIN", 80, 85], ["SOCS1", "PROBLEM", 21, 26], ["SOCS3", "PROBLEM", 31, 36], ["SOCS1", "OBSERVATION", 21, 26], ["SOCS3", "OBSERVATION", 31, 36]]], ["Moreover, the recognition component of the classical complement cascade C1q might also inhibit STAT1 phosphorylation with subsequent suppression of M1 macrophage polarization [29] .TLR4/NF-\u03baB signaling pathwayTLR engagement, particularly TLR4 stimulated by LPS and other microbial ligands, leads to NF-\u03baB activation and production of inflammatory mediators associated with the M1 phenotype [63] .", [["M1 macrophage", "ANATOMY", 148, 161], ["LPS", "CHEMICAL", 257, 260], ["C1q", "GENE_OR_GENE_PRODUCT", 72, 75], ["STAT1", "GENE_OR_GENE_PRODUCT", 95, 100], ["M1 macrophage", "CELL", 148, 161], ["TLR4", "GENE_OR_GENE_PRODUCT", 181, 185], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 186, 191], ["pathwayTLR", "GENE_OR_GENE_PRODUCT", 202, 212], ["TLR4", "GENE_OR_GENE_PRODUCT", 238, 242], ["LPS", "SIMPLE_CHEMICAL", 257, 260], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 299, 304], ["C1q", "PROTEIN", 72, 75], ["STAT1", "PROTEIN", 95, 100], ["TLR4", "PROTEIN", 181, 185], ["NF-\u03baB", "PROTEIN", 186, 191], ["pathwayTLR", "PROTEIN", 202, 212], ["TLR4", "PROTEIN", 238, 242], ["NF-\u03baB", "PROTEIN", 299, 304], ["inflammatory mediators", "PROTEIN", 334, 356], ["the classical complement cascade C1q", "PROBLEM", 39, 75], ["STAT1 phosphorylation", "PROBLEM", 95, 116], ["B signaling pathwayTLR engagement", "TREATMENT", 190, 223], ["NF", "TEST", 299, 301], ["inflammatory mediators", "PROBLEM", 334, 356], ["inflammatory", "OBSERVATION_MODIFIER", 334, 346]]], ["TLR4 signaling includes both the myeloid differentiation factor 88 (MyD88)-dependent and MyD88-independent pathways [4] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["myeloid differentiation factor 88", "GENE_OR_GENE_PRODUCT", 33, 66], ["MyD88", "GENE_OR_GENE_PRODUCT", 68, 73], ["MyD88", "GENE_OR_GENE_PRODUCT", 89, 94], ["TLR4", "PROTEIN", 0, 4], ["myeloid differentiation factor 88", "PROTEIN", 33, 66], ["MyD88", "PROTEIN", 68, 73], ["MyD88", "PROTEIN", 89, 94], ["TLR4 signaling", "TEST", 0, 14], ["the myeloid differentiation factor", "TEST", 29, 63], ["MyD88", "TEST", 68, 73], ["myeloid differentiation", "OBSERVATION", 33, 56]]], ["In the MyD88-independent pathway, TLR4 recruits TIR domain-containing adaptorinducing IFN-\u03b2 and TIR domain-containing adaptor molecule 2 [4] .", [["MyD88", "GENE_OR_GENE_PRODUCT", 7, 12], ["TLR4", "GENE_OR_GENE_PRODUCT", 34, 38], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 86, 91], ["TIR domain-containing adaptor molecule 2", "GENE_OR_GENE_PRODUCT", 96, 136], ["MyD88", "PROTEIN", 7, 12], ["TLR4", "PROTEIN", 34, 38], ["TIR domain", "PROTEIN", 48, 58], ["adaptorinducing IFN-\u03b2", "PROTEIN", 70, 91], ["TIR domain-containing adaptor molecule 2", "PROTEIN", 96, 136], ["TLR4 recruits TIR domain", "TREATMENT", 34, 58], ["adaptorinducing IFN", "TREATMENT", 70, 89], ["TIR domain-containing adaptor molecule", "TREATMENT", 96, 134]]], ["Activation of the MyD88-indpendent pathway leads to the activation and translocation of IFN regulatory factor 3 (IRF3) in the nucleus, thus inducing the secretion of type I IFN [4] .", [["nucleus", "ANATOMY", 126, 133], ["MyD88", "GENE_OR_GENE_PRODUCT", 18, 23], ["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 88, 111], ["IRF3", "GENE_OR_GENE_PRODUCT", 113, 117], ["nucleus", "CELLULAR_COMPONENT", 126, 133], ["type I IFN", "GENE_OR_GENE_PRODUCT", 166, 176], ["MyD88", "PROTEIN", 18, 23], ["IFN regulatory factor 3", "PROTEIN", 88, 111], ["IRF3", "PROTEIN", 113, 117], ["type I IFN", "PROTEIN", 166, 176], ["the MyD88-indpendent pathway", "TREATMENT", 14, 42], ["IFN regulatory factor", "PROBLEM", 88, 109], ["nucleus", "ANATOMY", 126, 133]]], ["IRF3 is involved in regulating M1 polarization and M1-associated gene induction [23] .", [["IRF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["M1", "CELL", 31, 33], ["M1", "GENE_OR_GENE_PRODUCT", 51, 53], ["IRF3", "PROTEIN", 0, 4], ["M1", "PROTEIN", 51, 53], ["IRF3", "PROBLEM", 0, 4], ["M1", "OBSERVATION_MODIFIER", 31, 33]]], ["IFN-stimulated genes include chemokine CXCL9 and CXCL10, which are characteristic of classical M1 macrophage activation [23] .", [["M1 macrophage", "ANATOMY", 95, 108], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["CXCL9", "GENE_OR_GENE_PRODUCT", 39, 44], ["CXCL10", "GENE_OR_GENE_PRODUCT", 49, 55], ["M1 macrophage", "CELL", 95, 108], ["IFN-stimulated genes", "DNA", 0, 20], ["chemokine", "PROTEIN", 29, 38], ["CXCL9", "PROTEIN", 39, 44], ["CXCL10", "PROTEIN", 49, 55], ["chemokine CXCL9", "TEST", 29, 44], ["CXCL10", "TEST", 49, 55]]], ["In the MyD88-dependent pathway, TLR4 recruits MyD88, MyD88 adaptor-like, IL-1 receptor-associated kinase, and TNF receptor-associated factor 6 [66] .", [["MyD88", "GENE_OR_GENE_PRODUCT", 7, 12], ["TLR4", "GENE_OR_GENE_PRODUCT", 32, 36], ["MyD88", "GENE_OR_GENE_PRODUCT", 46, 51], ["MyD88", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-1 receptor-associated kinase", "GENE_OR_GENE_PRODUCT", 73, 104], ["TNF receptor-associated factor 6", "GENE_OR_GENE_PRODUCT", 110, 142], ["MyD88", "PROTEIN", 7, 12], ["TLR4", "PROTEIN", 32, 36], ["MyD88", "PROTEIN", 46, 51], ["MyD88 adaptor-like, IL-1 receptor-associated kinase", "PROTEIN", 53, 104], ["TNF receptor-associated factor 6", "PROTEIN", 110, 142], ["MyD88 adaptor", "TEST", 53, 66], ["IL", "TEST", 73, 75], ["kinase", "TEST", 98, 104], ["TNF receptor", "TEST", 110, 122]]], ["The activation of this pathway finally induces the activation and translocation of NF-\u03baB in the nucleus [66] .", [["nucleus", "ANATOMY", 96, 103], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 83, 88], ["nucleus", "CELLULAR_COMPONENT", 96, 103], ["NF-\u03baB", "PROTEIN", 83, 88], ["NF", "TEST", 83, 85], ["nucleus", "ANATOMY", 96, 103]]], ["NF-\u03baB regulates the expression of a large number of inflammatory genes including TNF-\u03b1, IL-1\u03b2, cyclooxygenase 2, and IL-6, which are associated with macrophage M1 activation [23] .", [["macrophage", "ANATOMY", 149, 159], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 88, 93], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 95, 111], ["IL-6", "GENE_OR_GENE_PRODUCT", 117, 121], ["macrophage M1", "CELL", 149, 162], ["NF-\u03baB", "PROTEIN", 0, 5], ["inflammatory genes", "DNA", 52, 70], ["TNF", "PROTEIN", 81, 84], ["cyclooxygenase 2", "PROTEIN", 95, 111], ["IL-6", "PROTEIN", 117, 121], ["inflammatory genes", "PROBLEM", 52, 70], ["TNF", "TEST", 81, 84], ["IL", "TEST", 88, 90], ["cyclooxygenase", "TEST", 95, 109], ["large", "OBSERVATION_MODIFIER", 36, 41], ["inflammatory genes", "OBSERVATION", 52, 70], ["associated with", "UNCERTAINTY", 133, 148], ["macrophage M1", "OBSERVATION", 149, 162]]], ["However, NF-\u03baB activation also activates a genetic program essential for resolution of inflammation and M2 polarization of TAMs [63] .", [["inflammation", "DISEASE", 87, 99], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 9, 14], ["NF-\u03baB", "PROTEIN", 9, 14], ["TAMs", "CELL_TYPE", 123, 127], ["NF", "TEST", 9, 11], ["inflammation", "PROBLEM", 87, 99], ["inflammation", "OBSERVATION", 87, 99], ["M2", "OBSERVATION_MODIFIER", 104, 106]]], ["Otherwise, macrophage polarization is actually related to the expression ratio of various TLRs on macrophages [23] .", [["macrophage", "ANATOMY", 11, 21], ["macrophages", "ANATOMY", 98, 109], ["macrophage", "CELL", 11, 21], ["TLRs", "GENE_OR_GENE_PRODUCT", 90, 94], ["macrophages", "CELL", 98, 109], ["TLRs", "PROTEIN", 90, 94], ["macrophages", "CELL_TYPE", 98, 109], ["macrophage polarization", "OBSERVATION", 11, 34]]], ["The TLR4/TLR2 ratio is significantly higher in M1 than M2 macrophages [23] .TGF-\u03b2 signaling pathwayThe secretory TGF-\u03b2 protein family includes TGF-\u03b21, TGF-\u03b22, TGF-\u03b23, activins, and growth factors, which have pleiotropic effects on adaptive immunity [67] .", [["M1", "ANATOMY", 47, 49], ["M2 macrophages", "ANATOMY", 55, 69], ["TLR4", "GENE_OR_GENE_PRODUCT", 4, 8], ["TLR2", "GENE_OR_GENE_PRODUCT", 9, 13], ["M1", "CELL", 47, 49], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 113, 118], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 143, 149], ["TGF-\u03b22", "GENE_OR_GENE_PRODUCT", 151, 157], ["TGF-\u03b23", "GENE_OR_GENE_PRODUCT", 159, 165], ["activins", "GENE_OR_GENE_PRODUCT", 167, 175], ["TLR4", "PROTEIN", 4, 8], ["TLR2", "PROTEIN", 9, 13], ["M2 macrophages", "CELL_TYPE", 55, 69], ["TGF-\u03b2", "PROTEIN", 76, 81], ["secretory TGF-\u03b2 protein family", "PROTEIN", 103, 133], ["TGF-\u03b21", "PROTEIN", 143, 149], ["TGF-\u03b22", "PROTEIN", 151, 157], ["TGF-\u03b23", "PROTEIN", 159, 165], ["activins", "PROTEIN", 167, 175], ["growth factors", "PROTEIN", 181, 195], ["The TLR4/TLR2 ratio", "TEST", 0, 19], ["TGF", "TEST", 76, 79], ["The secretory TGF", "TEST", 99, 116], ["TGF", "TEST", 143, 146], ["TGF", "TEST", 151, 154], ["TGF", "TEST", 159, 162], ["TLR4", "ANATOMY_MODIFIER", 4, 8], ["significantly", "OBSERVATION_MODIFIER", 23, 36], ["higher", "OBSERVATION_MODIFIER", 37, 43]]], ["The TGF-\u03b2 receptor complex is composed of two type I TGF-\u03b2 receptors (TGF-\u03b2RI) and two type II TGF-\u03b2 receptors (TGF-\u03b2RII) [67] .", [["TGF-\u03b2 receptor", "GENE_OR_GENE_PRODUCT", 4, 18], ["type I TGF-\u03b2 receptors", "GENE_OR_GENE_PRODUCT", 46, 68], ["TGF-\u03b2RI", "GENE_OR_GENE_PRODUCT", 70, 77], ["type II TGF-\u03b2 receptors", "GENE_OR_GENE_PRODUCT", 87, 110], ["TGF-\u03b2RII", "GENE_OR_GENE_PRODUCT", 112, 120], ["TGF-\u03b2 receptor complex", "PROTEIN", 4, 26], ["type I TGF-\u03b2 receptors", "PROTEIN", 46, 68], ["TGF", "PROTEIN", 70, 73], ["\u03b2RI", "PROTEIN", 74, 77], ["type II TGF-\u03b2 receptors", "PROTEIN", 87, 110], ["TGF-\u03b2RII", "PROTEIN", 112, 120], ["The TGF", "TEST", 0, 7], ["receptors", "TEST", 59, 68], ["TGF", "TEST", 70, 73], ["RI", "TEST", 75, 77], ["type II TGF", "TEST", 87, 98], ["receptors", "TEST", 101, 110], ["TGF", "TEST", 112, 115]]], ["TGF-\u03b2 triggers signaling in cells by binding to the TGF-\u03b2 receptor complex [68] .", [["cells", "ANATOMY", 28, 33], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 28, 33], ["TGF-\u03b2 receptor", "GENE_OR_GENE_PRODUCT", 52, 66], ["TGF-\u03b2", "PROTEIN", 0, 5], ["TGF-\u03b2 receptor complex", "PROTEIN", 52, 74], ["TGF", "TEST", 0, 3], ["signaling in cells", "PROBLEM", 15, 33], ["the TGF", "TEST", 48, 55]]], ["Active TGF-\u03b2 binds to a dimer of TGF-\u03b2RII, which associates with a dimer of TGF-\u03b2RI to form a tetrameric receptor complex.", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 7, 12], ["TGF-\u03b2RII", "GENE_OR_GENE_PRODUCT", 33, 41], ["TGF-\u03b2RI", "GENE_OR_GENE_PRODUCT", 76, 83], ["TGF-\u03b2", "PROTEIN", 7, 12], ["TGF-\u03b2RII", "PROTEIN", 33, 41], ["TGF-\u03b2RI", "PROTEIN", 76, 83], ["tetrameric receptor complex", "PROTEIN", 94, 121], ["TGF", "TEST", 33, 36], ["TGF", "TEST", 76, 79], ["a tetrameric receptor complex", "TREATMENT", 92, 121], ["TGF", "OBSERVATION", 7, 10]]], ["TGF-\u03b2RII then phosphorylates the cytoplasmic domain of TGF-\u03b2RI [68] , allowing TGF-\u03b2RI to directly phosphorylate Smad2/3.", [["cytoplasmic", "ANATOMY", 33, 44], ["TGF-\u03b2RII", "GENE_OR_GENE_PRODUCT", 0, 8], ["cytoplasmic", "ORGANISM_SUBSTANCE", 33, 44], ["TGF-\u03b2RI [68]", "GENE_OR_GENE_PRODUCT", 55, 67], ["TGF-\u03b2RI", "GENE_OR_GENE_PRODUCT", 79, 86], ["Smad2", "GENE_OR_GENE_PRODUCT", 113, 118], ["3", "GENE_OR_GENE_PRODUCT", 119, 120], ["TGF-\u03b2RII", "PROTEIN", 0, 8], ["cytoplasmic domain", "PROTEIN", 33, 51], ["TGF", "PROTEIN", 55, 58], ["TGF-\u03b2RI", "PROTEIN", 79, 86], ["Smad2/3", "PROTEIN", 113, 120], ["TGF", "TEST", 0, 3], ["the cytoplasmic domain", "TEST", 29, 51], ["TGF", "TEST", 55, 58], ["RI", "TEST", 60, 62], ["TGF", "TEST", 79, 82]]], ["Once phosphorylated, Smad2/3 forms a complex with either Smad4 or TIF1\u03b3 to modulate gene expression by binding to Smad-responsive regulatory regions [67] .", [["Smad2", "GENE_OR_GENE_PRODUCT", 21, 26], ["3", "GENE_OR_GENE_PRODUCT", 27, 28], ["Smad4", "GENE_OR_GENE_PRODUCT", 57, 62], ["TIF1\u03b3", "GENE_OR_GENE_PRODUCT", 66, 71], ["Smad-", "GENE_OR_GENE_PRODUCT", 114, 119], ["Smad2/3", "PROTEIN", 21, 28], ["Smad4", "PROTEIN", 57, 62], ["TIF1\u03b3", "PROTEIN", 66, 71], ["Smad-responsive regulatory regions", "DNA", 114, 148], ["Smad4", "TREATMENT", 57, 62], ["TIF1", "TREATMENT", 66, 70]]], ["This signal transduction is called the Smad-dependent signaling pathway.", [["Smad-", "GENE_OR_GENE_PRODUCT", 39, 44]]], ["TGF-\u03b2 can also trigger non-Smad-mediated or Smad-independent signaling events (e.g., via MAPK, Rho GTPases, or PI3K) to regulate gene expression [67] .", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["non-Smad-", "GENE_OR_GENE_PRODUCT", 23, 32], ["Smad-", "GENE_OR_GENE_PRODUCT", 44, 49], ["MAPK", "GENE_OR_GENE_PRODUCT", 89, 93], ["Rho", "GENE_OR_GENE_PRODUCT", 95, 98], ["PI3K", "GENE_OR_GENE_PRODUCT", 111, 115], ["TGF-\u03b2", "PROTEIN", 0, 5], ["MAPK", "PROTEIN", 89, 93], ["Rho GTPases", "PROTEIN", 95, 106], ["PI3K", "PROTEIN", 111, 115], ["TGF", "TEST", 0, 3], ["Smad-independent signaling events", "PROBLEM", 44, 77], ["MAPK", "TEST", 89, 93], ["Rho GTPases", "TEST", 95, 106]]], ["In Smad-dependent pathways, TGF-\u03b2 upregulates the expression of M2 phenotype genes and induces macrophages to undergo M2 polarization [69] .", [["macrophages", "ANATOMY", 95, 106], ["Smad", "GENE_OR_GENE_PRODUCT", 3, 7], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 28, 33], ["M2", "GENE_OR_GENE_PRODUCT", 64, 66], ["macrophages", "CELL", 95, 106], ["Smad", "PROTEIN", 3, 7], ["TGF-\u03b2", "PROTEIN", 28, 33], ["M2 phenotype genes", "DNA", 64, 82], ["macrophages", "CELL_TYPE", 95, 106], ["TGF", "TEST", 28, 31], ["M2 phenotype genes", "PROBLEM", 64, 82]]], ["Conversely, in Smad-independent signaling pathways, TGF-\u03b2 activates MAPK pathways, JNK, p38, and NF-\u03baB by the TGF-\u03b2-activated kinase 1 protein, which can reprogram macrophages to the M1 phenotype, particularly when the Smad-dependent signaling pathway is blocked [69] .", [["macrophages", "ANATOMY", 164, 175], ["Smad-", "GENE_OR_GENE_PRODUCT", 15, 20], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 52, 57], ["MAPK", "GENE_OR_GENE_PRODUCT", 68, 72], ["JNK", "GENE_OR_GENE_PRODUCT", 83, 86], ["p38", "GENE_OR_GENE_PRODUCT", 88, 91], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 97, 102], ["TGF-\u03b2-activated kinase 1", "GENE_OR_GENE_PRODUCT", 110, 134], ["macrophages", "CELL", 164, 175], ["Smad-", "GENE_OR_GENE_PRODUCT", 219, 224], ["TGF-\u03b2", "PROTEIN", 52, 57], ["MAPK", "PROTEIN", 68, 72], ["JNK", "PROTEIN", 83, 86], ["p38", "PROTEIN", 88, 91], ["NF-\u03baB", "PROTEIN", 97, 102], ["TGF-\u03b2-activated kinase 1 protein", "PROTEIN", 110, 142], ["macrophages", "CELL_TYPE", 164, 175], ["Smad-", "PROTEIN", 219, 224], ["TGF", "TEST", 52, 55], ["MAPK pathways", "TEST", 68, 81], ["JNK", "TEST", 83, 86], ["p38", "TEST", 88, 91], ["NF", "TEST", 97, 99], ["the TGF", "TEST", 106, 113], ["M1", "ANATOMY", 183, 185]]], ["Moreover, the effect of Smad-dependent pathways on M2 polarization is under the control of Smad7.", [["Smad", "GENE_OR_GENE_PRODUCT", 24, 28], ["M2", "GENE_OR_GENE_PRODUCT", 51, 53], ["Smad7", "GENE_OR_GENE_PRODUCT", 91, 96], ["Smad", "PROTEIN", 24, 28], ["Smad7", "PROTEIN", 91, 96], ["Smad-dependent pathways", "PROBLEM", 24, 47], ["M2 polarization", "TREATMENT", 51, 66]]], ["Smad7 can bind to TGF-\u03b2RI and prevent Smad2/3/4 complex formation, thereby inhibiting the production of anti-inflammatory M2 cytokines [69] .", [["Smad7", "GENE_OR_GENE_PRODUCT", 0, 5], ["TGF-\u03b2RI", "GENE_OR_GENE_PRODUCT", 18, 25], ["Smad2", "GENE_OR_GENE_PRODUCT", 38, 43], ["3/4", "GENE_OR_GENE_PRODUCT", 44, 47], ["Smad7", "PROTEIN", 0, 5], ["TGF-\u03b2RI", "PROTEIN", 18, 25], ["Smad2", "PROTEIN", 38, 43], ["anti-inflammatory M2 cytokines", "PROTEIN", 104, 134], ["TGF", "TEST", 18, 21], ["Smad2/3/4 complex formation", "PROBLEM", 38, 65], ["anti-inflammatory M2 cytokines", "TREATMENT", 104, 134], ["prevent", "UNCERTAINTY", 30, 37], ["Smad2", "OBSERVATION", 38, 43], ["3/4 complex", "OBSERVATION_MODIFIER", 44, 55]]], ["Additionally, TGF-\u03b2 reportedly induces an M2-like phenotype via SNAIL upregulation and blockade of TGF-\u03b2/SNAIL signaling, thus restoring the production of proinflammatory cytokines [70] .HIF-\u03b1Hypoxic conditions can directly influence macrophage polarization [23] .", [["macrophage", "ANATOMY", 234, 244], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["SNAIL", "GENE_OR_GENE_PRODUCT", 64, 69], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 99, 104], ["SNAIL", "GENE_OR_GENE_PRODUCT", 105, 110], ["HIF-\u03b1", "GENE_OR_GENE_PRODUCT", 187, 192], ["macrophage", "CELL", 234, 244], ["TGF-\u03b2", "PROTEIN", 14, 19], ["SNAIL", "PROTEIN", 64, 69], ["TGF-\u03b2", "PROTEIN", 99, 104], ["SNAIL", "PROTEIN", 105, 110], ["proinflammatory cytokines", "PROTEIN", 155, 180], ["HIF", "PROTEIN", 187, 190], ["TGF", "TEST", 14, 17], ["SNAIL upregulation", "TREATMENT", 64, 82], ["blockade", "TREATMENT", 87, 95], ["TGF", "TEST", 99, 102], ["SNAIL signaling", "PROBLEM", 105, 120], ["proinflammatory cytokines", "PROBLEM", 155, 180], ["Hypoxic conditions", "PROBLEM", 192, 210]]], ["Hypoxia-inducible transcription factor (HIF) is an important regulator of hypoxia-related macrophage polarization [69] .", [["macrophage", "ANATOMY", 90, 100], ["hypoxia", "DISEASE", 74, 81], ["Hypoxia-inducible transcription factor", "GENE_OR_GENE_PRODUCT", 0, 38], ["HIF", "GENE_OR_GENE_PRODUCT", 40, 43], ["macrophage", "CELL", 90, 100], ["Hypoxia-inducible transcription factor", "PROTEIN", 0, 38], ["HIF", "PROTEIN", 40, 43], ["Hypoxia", "PROBLEM", 0, 7], ["inducible transcription factor", "PROBLEM", 8, 38], ["hypoxia", "PROBLEM", 74, 81], ["macrophage polarization", "TEST", 90, 113], ["hypoxia", "OBSERVATION", 74, 81], ["macrophage polarization", "OBSERVATION", 90, 113]]], ["HIF is composed of an HIF-\u03b2 subunit and HIF-\u03b1 subunit [69] .", [["HIF", "GENE_OR_GENE_PRODUCT", 0, 3], ["HIF-\u03b2 subunit", "GENE_OR_GENE_PRODUCT", 22, 35], ["HIF-\u03b1", "GENE_OR_GENE_PRODUCT", 40, 45], ["HIF", "PROTEIN", 0, 3], ["HIF", "PROTEIN", 22, 25], ["\u03b2 subunit", "PROTEIN", 26, 35], ["HIF", "PROTEIN", 40, 43], ["\u03b1 subunit", "PROTEIN", 44, 53], ["an HIF-\u03b2 subunit", "TREATMENT", 19, 35]]], ["HIF-\u03b2 is constitutively expressed in the cell, whereas HIF-\u03b1 is an oxygen-sensitive subunit [69] .", [["cell", "ANATOMY", 41, 45], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "CHEMICAL", 67, 73], ["HIF-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 41, 45], ["HIF-\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["HIF", "PROTEIN", 0, 3], ["\u03b2", "PROTEIN", 4, 5], ["HIF", "PROTEIN", 55, 58], ["\u03b1", "PROTEIN", 59, 60], ["an oxygen", "TEST", 64, 73]]], ["Hypoxia exerts its effect on macrophage polarization via two isoforms of HIF-\u03b1: HIF-1\u03b1 and HIF-2\u03b1 [71] .", [["macrophage", "ANATOMY", 29, 39], ["Hypoxia", "DISEASE", 0, 7], ["macrophage", "CELL", 29, 39], ["HIF-\u03b1", "GENE_OR_GENE_PRODUCT", 73, 78], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 80, 86], ["HIF-2", "GENE_OR_GENE_PRODUCT", 91, 96], ["HIF", "PROTEIN", 73, 76], ["\u03b1", "PROTEIN", 77, 78], ["HIF-1\u03b1", "PROTEIN", 80, 86], ["HIF", "PROTEIN", 91, 94], ["Hypoxia", "PROBLEM", 0, 7], ["macrophage polarization", "TREATMENT", 29, 52], ["HIF", "TEST", 73, 76], ["HIF", "TEST", 80, 83], ["HIF", "TEST", 91, 94]]], ["In a hypoxic microenvironment, the activity of the prolyl-4-hydroxylase domain enzyme decreases and HIF-\u03b1 consequently accumulates, which promotes the formation of an HIF-\u03b1/HIF-\u03b2 dimer [69] .", [["prolyl", "CHEMICAL", 51, 57], ["prolyl-4-hydroxylase", "GENE_OR_GENE_PRODUCT", 51, 71], ["HIF-\u03b1", "GENE_OR_GENE_PRODUCT", 100, 105], ["HIF-\u03b1", "GENE_OR_GENE_PRODUCT", 167, 172], ["HIF-\u03b2", "GENE_OR_GENE_PRODUCT", 173, 178], ["prolyl-4-hydroxylase domain enzyme", "PROTEIN", 51, 85], ["HIF", "PROTEIN", 100, 103], ["\u03b1", "PROTEIN", 104, 105], ["HIF", "PROTEIN", 167, 170], ["\u03b1", "PROTEIN", 171, 172], ["HIF", "PROTEIN", 173, 176], ["\u03b2 dimer", "PROTEIN", 177, 184], ["a hypoxic microenvironment", "TREATMENT", 3, 29], ["the prolyl", "TEST", 47, 57], ["hydroxylase domain enzyme decreases", "PROBLEM", 60, 95], ["an HIF", "TEST", 164, 170], ["hypoxic microenvironment", "OBSERVATION", 5, 29], ["decreases", "OBSERVATION_MODIFIER", 86, 95]]], ["Takeda et al. [72] reported that HIF-1\u03b1 and HIF-2\u03b1 might drive macrophage polarization by modulating NO homeostasis.", [["macrophage", "ANATOMY", 63, 73], ["NO", "CHEMICAL", 101, 103], ["NO", "CHEMICAL", 101, 103], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 33, 39], ["HIF-2\u03b1", "GENE_OR_GENE_PRODUCT", 44, 50], ["macrophage", "CELL", 63, 73], ["NO", "SIMPLE_CHEMICAL", 101, 103], ["HIF-1\u03b1", "PROTEIN", 33, 39], ["HIF-2\u03b1", "PROTEIN", 44, 50], ["HIF", "TEST", 33, 36], ["macrophage polarization", "TREATMENT", 63, 86], ["NO", "UNCERTAINTY", 101, 103]]], ["In fact, under hypoxia, either HIF-1\u03b1 or HIF-2\u03b1 is activated depending on the extent of the hypoxia [69] .", [["hypoxia", "DISEASE", 15, 22], ["hypoxia", "DISEASE", 92, 99], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 31, 37], ["HIF-2\u03b1", "GENE_OR_GENE_PRODUCT", 41, 47], ["HIF-1\u03b1", "PROTEIN", 31, 37], ["HIF-2\u03b1", "PROTEIN", 41, 47], ["hypoxia", "PROBLEM", 15, 22], ["the hypoxia", "PROBLEM", 88, 99], ["hypoxia", "OBSERVATION", 15, 22], ["hypoxia", "OBSERVATION", 92, 99]]], ["HIF-1\u03b1 induces iNOS synthesis and M1 phenotype formation, but HIF-2\u03b1 activates Arg-1 and induces M2 polarization [69] .IRFIRFs were originally described as regulators of type I IFN expression and signaling and are important mediators of macrophage polarization [31] .", [["macrophage", "ANATOMY", 237, 247], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 0, 6], ["iNOS", "GENE_OR_GENE_PRODUCT", 15, 19], ["HIF-2\u03b1", "GENE_OR_GENE_PRODUCT", 62, 68], ["Arg-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["M2", "GENE_OR_GENE_PRODUCT", 97, 99], ["IRFIRFs", "GENE_OR_GENE_PRODUCT", 119, 126], ["type I IFN", "GENE_OR_GENE_PRODUCT", 170, 180], ["macrophage", "CELL", 237, 247], ["HIF-1\u03b1", "PROTEIN", 0, 6], ["iNOS", "PROTEIN", 15, 19], ["HIF-2\u03b1", "PROTEIN", 62, 68], ["Arg-1", "PROTEIN", 79, 84], ["IRFIRFs", "PROTEIN", 119, 126], ["type I IFN", "PROTEIN", 170, 180], ["iNOS synthesis", "PROBLEM", 15, 29], ["M1 phenotype formation", "PROBLEM", 34, 56], ["HIF", "TEST", 62, 65], ["Arg", "TEST", 79, 82], ["IRFIRFs", "PROBLEM", 119, 126], ["type I IFN expression", "PROBLEM", 170, 191]]], ["There are nine IRFs in mammals, and several members have been reported in relation to a specific phenotype [30, 31] .", [["IRFs", "PROTEIN", 15, 19], ["nine", "OBSERVATION_MODIFIER", 10, 14], ["IRFs", "OBSERVATION", 15, 19]]], ["IRF4 was shown to regulate M2 macrophage polarization and its associated gene expression profile [73, 74] , and this process is likely associated with histone demethylase JMJD3 [75] .", [["M2 macrophage", "ANATOMY", 27, 40], ["IRF4", "GENE_OR_GENE_PRODUCT", 0, 4], ["M2 macrophage", "CELL", 27, 40], ["histone demethylase", "GENE_OR_GENE_PRODUCT", 151, 170], ["IRF4", "PROTEIN", 0, 4], ["histone demethylase", "PROTEIN", 151, 170], ["JMJD3", "PROTEIN", 171, 176], ["macrophage polarization", "TEST", 30, 53], ["histone demethylase JMJD3", "PROBLEM", 151, 176], ["M2", "OBSERVATION_MODIFIER", 27, 29], ["macrophage polarization", "OBSERVATION", 30, 53], ["likely associated with", "UNCERTAINTY", 128, 150]]], ["High expression of IRF5 was observed in M1 macrophages and was subsequently described as an important regulator in M1 macrophage polarization [30] .", [["M1 macrophages", "ANATOMY", 40, 54], ["M1 macrophage", "ANATOMY", 115, 128], ["IRF5", "GENE_OR_GENE_PRODUCT", 19, 23], ["M1 macrophages", "CELL", 40, 54], ["M1 macrophage", "CELL", 115, 128], ["IRF5", "PROTEIN", 19, 23], ["M1 macrophages", "CELL_TYPE", 40, 54], ["IRF5", "PROBLEM", 19, 23], ["IRF5", "OBSERVATION", 19, 23]]], ["IRF5 can be directly recruited to gene promoters associated with the M1 phenotype and then activate the transcription of proinflammatory genes and inhibit anti-inflammatory IL-10 expression [31, 76] .", [["IRF5", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-10", "GENE_OR_GENE_PRODUCT", 173, 178], ["IRF5", "PROTEIN", 0, 4], ["gene promoters", "DNA", 34, 48], ["proinflammatory genes", "DNA", 121, 142], ["IL", "PROTEIN", 173, 175], ["the M1 phenotype", "PROBLEM", 65, 81], ["anti-inflammatory IL", "TREATMENT", 155, 175]]], ["IRF1 can be described as an important mediator in M1 polarization via cooperation with NF-\u03baB and antagonization of IRF4 function [30] .PPAR\u03b3 and LXR\u03b1Peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3), a nuclear receptor, has been described as an important determinant of IL-4 or IL-13-induced M2 macrophage polarization [77] .", [["nuclear", "ANATOMY", 205, 212], ["macrophage", "ANATOMY", 298, 308], ["IRF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["M1", "CELL", 50, 52], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 87, 92], ["IRF4", "GENE_OR_GENE_PRODUCT", 115, 119], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 135, 140], ["LXR\u03b1", "GENE_OR_GENE_PRODUCT", 145, 149], ["Peroxisome proliferator-activated receptor \u03b3", "GENE_OR_GENE_PRODUCT", 149, 193], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 195, 200], ["IL-4", "GENE_OR_GENE_PRODUCT", 273, 277], ["IL-13", "GENE_OR_GENE_PRODUCT", 281, 286], ["M2 macrophage", "CELL", 295, 308], ["IRF1", "PROTEIN", 0, 4], ["NF-\u03baB", "PROTEIN", 87, 92], ["IRF4", "PROTEIN", 115, 119], ["PPAR\u03b3", "PROTEIN", 135, 140], ["LXR", "PROTEIN", 145, 148], ["Peroxisome proliferator-activated receptor \u03b3", "PROTEIN", 149, 193], ["PPAR\u03b3", "PROTEIN", 195, 200], ["nuclear receptor", "PROTEIN", 205, 221], ["IRF1", "PROBLEM", 0, 4], ["Peroxisome proliferator", "TEST", 149, 172], ["LXR", "ANATOMY", 145, 148]]], ["PPAR\u03b3 is constitutively expressed and is a master regulator of lipid metabolism in adipose tissue macrophages [31] .", [["adipose tissue macrophages", "ANATOMY", 83, 109], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["lipid", "SIMPLE_CHEMICAL", 63, 68], ["adipose tissue macrophages", "CELL", 83, 109], ["PPAR\u03b3", "PROTEIN", 0, 5], ["adipose tissue macrophages", "CELL_TYPE", 83, 109], ["lipid metabolism in adipose tissue macrophages", "PROBLEM", 63, 109], ["lipid metabolism", "OBSERVATION", 63, 79], ["adipose tissue", "ANATOMY", 83, 97]]], ["PPAR\u03b3 expression can also be induced by IL-4 and IL-13, indicating that M2 polarization in the context of Th2 cell responses might also involve PPAR\u03b3 [78] .", [["Th2 cell", "ANATOMY", 106, 114], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-4", "GENE_OR_GENE_PRODUCT", 40, 44], ["IL-13", "GENE_OR_GENE_PRODUCT", 49, 54], ["M2", "GENE_OR_GENE_PRODUCT", 72, 74], ["Th2 cell", "CELL", 106, 114], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 144, 149], ["PPAR\u03b3", "PROTEIN", 0, 5], ["IL", "PROTEIN", 40, 42], ["IL-13", "PROTEIN", 49, 54], ["PPAR", "PROTEIN", 144, 148], ["IL", "TEST", 40, 42], ["IL", "TEST", 49, 51], ["Th2 cell", "OBSERVATION", 106, 114]]], ["Studies have shown the role of PPAR\u03b3 in promoting M2 activation to protect mice from insulin resistance by using PPAR\u03b3-deficient macrophages [77] .", [["macrophages", "ANATOMY", 129, 140], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 31, 36], ["M2", "GENE_OR_GENE_PRODUCT", 50, 52], ["mice", "ORGANISM", 75, 79], ["insulin", "GENE_OR_GENE_PRODUCT", 85, 92], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 113, 118], ["PPAR\u03b3", "PROTEIN", 31, 36], ["M2", "PROTEIN", 50, 52], ["PPAR\u03b3", "PROTEIN", 113, 118], ["deficient macrophages", "CELL_TYPE", 119, 140], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["Studies", "TEST", 0, 7], ["insulin resistance", "TREATMENT", 85, 103], ["PPAR", "TEST", 113, 117], ["deficient macrophages", "PROBLEM", 119, 140]]], ["Researchers have proposed that obesity and/or inflammatory stress can lead to a polarized macrophage phenotypic switch from M2 to M1 in adipose tissue, leading to further inflammation and insulin resistance in the absence of PPAR\u03b3-mediated proinflammatory gene repression [31] .", [["macrophage", "ANATOMY", 90, 100], ["adipose tissue", "ANATOMY", 136, 150], ["obesity", "DISEASE", 31, 38], ["inflammation", "DISEASE", 171, 183], ["macrophage", "CELL", 90, 100], ["M2", "GENE_OR_GENE_PRODUCT", 124, 126], ["M1", "GENE_OR_GENE_PRODUCT", 130, 132], ["adipose tissue", "TISSUE", 136, 150], ["insulin", "GENE_OR_GENE_PRODUCT", 188, 195], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 225, 230], ["PPAR\u03b3", "PROTEIN", 225, 230], ["obesity", "PROBLEM", 31, 38], ["inflammatory stress", "PROBLEM", 46, 65], ["a polarized macrophage phenotypic switch", "TREATMENT", 78, 118], ["further inflammation", "PROBLEM", 163, 183], ["insulin resistance", "PROBLEM", 188, 206], ["PPAR", "PROBLEM", 225, 229], ["obesity", "OBSERVATION", 31, 38], ["macrophage phenotypic", "OBSERVATION", 90, 111], ["adipose tissue", "ANATOMY", 136, 150], ["inflammation", "OBSERVATION", 171, 183], ["insulin resistance", "OBSERVATION", 188, 206]]], ["Several studies have shown that cross talk exists between PPAR\u03b3 and the IL-4/STAT6 axis or endogenous PPAR\u03b3 ligands, which might coordinately control the M2 phenotype [31, 79] .", [["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-4", "GENE_OR_GENE_PRODUCT", 72, 76], ["STAT6", "GENE_OR_GENE_PRODUCT", 77, 82], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 102, 107], ["M2", "GENE_OR_GENE_PRODUCT", 154, 156], ["PPAR\u03b3", "PROTEIN", 58, 63], ["STAT6", "PROTEIN", 77, 82], ["endogenous PPAR\u03b3 ligands", "PROTEIN", 91, 115], ["Several studies", "TEST", 0, 15], ["PPAR", "TEST", 58, 62], ["the IL", "TEST", 68, 74]]], ["Another nuclear receptor, liver X receptor \u03b1 (LXR\u03b1), is similar to PPAR\u03b3 and plays an important role in M2 macrophage polarization.", [["nuclear", "ANATOMY", 8, 15], ["M2 macrophage", "ANATOMY", 104, 117], ["liver X receptor \u03b1", "GENE_OR_GENE_PRODUCT", 26, 44], ["LXR\u03b1", "GENE_OR_GENE_PRODUCT", 46, 50], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 67, 72], ["M2 macrophage", "CELL", 104, 117], ["nuclear receptor", "PROTEIN", 8, 24], ["liver X receptor \u03b1", "PROTEIN", 26, 44], ["LXR\u03b1", "PROTEIN", 46, 50], ["PPAR\u03b3", "PROTEIN", 67, 72], ["liver", "ANATOMY", 26, 31], ["M2 macrophage polarization", "OBSERVATION", 104, 130]]], ["LXR\u03b1 can upregulate Arg-1 expression and suppress inflammatory signaling in macrophages [30] .c-Mycc-Myc is a pleiotropic transcription factor involved in a variety of biological process, including cell proliferation, biosynthetic metabolism, and apoptosis [80] .", [["macrophages", "ANATOMY", 76, 87], ["cell", "ANATOMY", 198, 202], ["LXR\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Arg-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["Mycc-Myc", "GENE_OR_GENE_PRODUCT", 96, 104], ["cell", "CELL", 198, 202], ["LXR\u03b1", "PROTEIN", 0, 4], ["Arg-1", "PROTEIN", 20, 25], ["macrophages", "CELL_TYPE", 76, 87], ["Myc", "PROTEIN", 101, 104], ["pleiotropic transcription factor", "PROTEIN", 110, 142], ["LXR", "TEST", 0, 3], ["Arg", "TEST", 20, 23], ["inflammatory signaling in macrophages", "PROBLEM", 50, 87], ["a pleiotropic transcription factor", "PROBLEM", 108, 142], ["cell proliferation", "PROBLEM", 198, 216], ["biosynthetic metabolism", "PROBLEM", 218, 241], ["apoptosis", "PROBLEM", 247, 256], ["inflammatory", "OBSERVATION_MODIFIER", 50, 62], ["cell proliferation", "OBSERVATION", 198, 216], ["biosynthetic metabolism", "OBSERVATION", 218, 241]]], ["In the immune compartment, c-Myc is involved in the process of M2 macrophage polarization [23] .", [["immune compartment", "ANATOMY", 7, 25], ["M2 macrophage", "ANATOMY", 63, 76], ["c-Myc", "GENE_OR_GENE_PRODUCT", 27, 32], ["M2 macrophage", "CELL", 63, 76], ["c-Myc", "PROTEIN", 27, 32]]], ["The transcription factor c-Myc can be activated by IL-4 and different stimuli sustaining M2-like polarization, after which it translocates to the nucleus [80] . c-Myc not only directly promotes M2 polarization-associated gene expression, but also induces an M2-like phenotype via upregulation of STAT6 and PPAR\u03b3 [80] .KLF4 and KLF6Kr\u00fcppel-like factors (KLFs) are a subfamily of the zinc finger class of DNA-binding transcriptional regulators [81] .", [["nucleus", "ANATOMY", 146, 153], ["zinc", "CHEMICAL", 382, 386], ["c-Myc", "GENE_OR_GENE_PRODUCT", 25, 30], ["IL-4", "GENE_OR_GENE_PRODUCT", 51, 55], ["M2", "GENE_OR_GENE_PRODUCT", 89, 91], ["nucleus", "CELLULAR_COMPONENT", 146, 153], ["c-Myc", "GENE_OR_GENE_PRODUCT", 161, 166], ["M2", "GENE_OR_GENE_PRODUCT", 194, 196], ["STAT6", "GENE_OR_GENE_PRODUCT", 296, 301], ["PPAR\u03b3 [80]", "GENE_OR_GENE_PRODUCT", 306, 316], ["KLF4", "GENE_OR_GENE_PRODUCT", 318, 322], ["KLF6Kr\u00fcppel-like factors", "GENE_OR_GENE_PRODUCT", 327, 351], ["KLFs", "GENE_OR_GENE_PRODUCT", 353, 357], ["DNA", "CELLULAR_COMPONENT", 403, 406], ["transcription factor", "PROTEIN", 4, 24], ["Myc", "PROTEIN", 27, 30], ["IL-4", "PROTEIN", 51, 55], ["M2", "PROTEIN", 89, 91], ["c", "PROTEIN", 161, 162], ["Myc", "PROTEIN", 163, 166], ["STAT6", "PROTEIN", 296, 301], ["PPAR\u03b3", "PROTEIN", 306, 311], ["KLF4", "PROTEIN", 318, 322], ["KLF6Kr\u00fcppel-like factors", "PROTEIN", 327, 351], ["KLFs", "PROTEIN", 353, 357], ["zinc finger class of DNA-binding transcriptional regulators", "PROTEIN", 382, 441], ["KLF4", "TEST", 318, 322], ["KLF6Kr\u00fcppel", "TEST", 327, 338], ["M2", "OBSERVATION_MODIFIER", 89, 91], ["like polarization", "OBSERVATION_MODIFIER", 92, 109], ["nucleus", "ANATOMY", 146, 153]]], ["Among the members of this gene family, KLF4 has been identified as an essential regulator of macrophage M1/M2 polarization and attendant functions [82] .", [["macrophage", "ANATOMY", 93, 103], ["KLF4", "GENE_OR_GENE_PRODUCT", 39, 43], ["macrophage", "CELL", 93, 103], ["M2", "GENE_OR_GENE_PRODUCT", 107, 109], ["KLF4", "PROTEIN", 39, 43], ["macrophage M1", "OBSERVATION", 93, 106]]], ["In one study, KLF4 expression was robustly induced in M2 macrophages and strongly reduced in M1 macrophages [82] .", [["M2 macrophages", "ANATOMY", 54, 68], ["M1 macrophages", "ANATOMY", 93, 107], ["KLF4", "GENE_OR_GENE_PRODUCT", 14, 18], ["M2 macrophages", "CELL", 54, 68], ["M1 macrophages", "CELL", 93, 107], ["KLF4", "PROTEIN", 14, 18], ["M2 macrophages", "CELL_TYPE", 54, 68], ["M1 macrophages", "CELL_TYPE", 93, 107], ["one study", "TEST", 3, 12], ["KLF4 expression", "TEST", 14, 29], ["M2 macrophages", "OBSERVATION", 54, 68], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["M1 macrophages", "OBSERVATION", 93, 107]]], ["Using myeloid-specific transcription factor KLF4 knockout mice, Liao et al. [82] demonstrated the role of KLF4 in regulating M2 polarization of macrophages and protecting mice from obesity-induced insulin resistance.", [["myeloid", "ANATOMY", 6, 13], ["macrophages", "ANATOMY", 144, 155], ["obesity", "DISEASE", 181, 188], ["myeloid", "CELL", 6, 13], ["KLF4", "GENE_OR_GENE_PRODUCT", 44, 48], ["KLF4", "GENE_OR_GENE_PRODUCT", 106, 110], ["M2", "GENE_OR_GENE_PRODUCT", 125, 127], ["macrophages", "CELL", 144, 155], ["mice", "ORGANISM", 171, 175], ["insulin", "GENE_OR_GENE_PRODUCT", 197, 204], ["transcription factor", "PROTEIN", 23, 43], ["KLF4", "PROTEIN", 44, 48], ["KLF4", "PROTEIN", 106, 110], ["macrophages", "CELL_TYPE", 144, 155], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 171, 175], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 171, 175], ["KLF4", "TREATMENT", 106, 110], ["macrophages", "PROBLEM", 144, 155], ["obesity", "PROBLEM", 181, 188], ["insulin resistance", "PROBLEM", 197, 215], ["myeloid", "ANATOMY", 6, 13], ["KLF4", "ANATOMY", 106, 110], ["M2", "OBSERVATION_MODIFIER", 125, 127], ["macrophages", "OBSERVATION", 144, 155], ["obesity", "OBSERVATION", 181, 188], ["insulin resistance", "OBSERVATION", 197, 215]]], ["KLF4 cooperated with STAT6 to induce an M2 genetic program and inhibit M1 targets by suppressing NF-\u03baB/HIF-1\u03b1-dependent transcription [82] .", [["KLF4", "GENE_OR_GENE_PRODUCT", 0, 4], ["STAT6", "GENE_OR_GENE_PRODUCT", 21, 26], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 97, 102], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 103, 109], ["KLF4", "PROTEIN", 0, 4], ["STAT6", "PROTEIN", 21, 26], ["NF-\u03baB", "PROTEIN", 97, 102], ["HIF", "PROTEIN", 103, 106], ["1\u03b1", "PROTEIN", 107, 109]]], ["Compared with KLF4, KLF6 has an adverse effect on macrophage M1/M2 polarization [83] .", [["macrophage", "ANATOMY", 50, 60], ["KLF4", "GENE_OR_GENE_PRODUCT", 14, 18], ["KLF6", "GENE_OR_GENE_PRODUCT", 20, 24], ["macrophage", "CELL", 50, 60], ["M2", "GENE_OR_GENE_PRODUCT", 64, 66], ["KLF4", "PROTEIN", 14, 18], ["KLF6", "PROTEIN", 20, 24], ["an adverse effect", "PROBLEM", 29, 46], ["adverse", "OBSERVATION_MODIFIER", 32, 39], ["effect", "OBSERVATION_MODIFIER", 40, 46], ["macrophage M1", "OBSERVATION", 50, 63]]], ["Date et al. [83] showed that KLF6 expression was enhanced by proinflammatory M1 stimuli and suppressed by M2 stimuli in human and murine macrophages.", [["macrophages", "ANATOMY", 137, 148], ["KLF6", "GENE_OR_GENE_PRODUCT", 29, 33], ["M2", "GENE_OR_GENE_PRODUCT", 106, 108], ["human", "ORGANISM", 120, 125], ["murine", "ORGANISM", 130, 136], ["macrophages", "CELL", 137, 148], ["KLF6", "PROTEIN", 29, 33], ["human and murine macrophages", "CELL_TYPE", 120, 148], ["human", "SPECIES", 120, 125], ["murine", "SPECIES", 130, 136], ["human", "SPECIES", 120, 125], ["proinflammatory M1 stimuli", "TEST", 61, 87], ["proinflammatory M1", "OBSERVATION", 61, 79]]], ["KLF6 promoted M1 polarization via cooperation with NF-\u03baB and inhibited M2 polarization by suppressing PPAR\u03b3 expression [83] .miRs and polarizationFunctional miRs are believed to form a set of networks to modulate macrophage polarization and control the M1/M2 phenotype switch [69] .", [["macrophage", "ANATOMY", 213, 223], ["KLF6", "GENE_OR_GENE_PRODUCT", 0, 4], ["M1", "CELL", 14, 16], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 51, 56], ["M2", "GENE_OR_GENE_PRODUCT", 71, 73], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 102, 107], ["miRs", "GENE_OR_GENE_PRODUCT", 157, 161], ["macrophage", "CELL", 213, 223], ["M2", "GENE_OR_GENE_PRODUCT", 256, 258], ["KLF6", "PROTEIN", 0, 4], ["NF-\u03baB", "PROTEIN", 51, 56], ["PPAR\u03b3", "PROTEIN", 102, 107], ["miRs", "DNA", 157, 161], ["NF", "TEST", 51, 53], ["modulate macrophage polarization", "TREATMENT", 204, 236], ["M1 polarization", "OBSERVATION", 14, 29]]], ["In response to macrophage reprogramming factor (RF), a specific set of miR expression can be induced.", [["macrophage", "CELL", 15, 25], ["miR", "GENE_OR_GENE_PRODUCT", 71, 74], ["macrophage reprogramming factor", "PROTEIN", 15, 46], ["RF", "PROTEIN", 48, 50], ["miR", "DNA", 71, 74], ["macrophage reprogramming", "OBSERVATION", 15, 39]]], ["RF-M1s induce the synthesis of miR-155, miR-21, miR-29b, miR-125, miR-9, miR-146a, and miR-147, whereas RF-M2s induce the synthesis of miR-146b, miR-511, miR-187, miR-378, miR-222, miR-27a, miR-125a-3p, and miR-125a-5p [69] . miR-155 reportedly plays an important role in Akt-regulated and IL-13-induced M1/M2 polarization [23, 84] .", [["miR-155", "CHEMICAL", 226, 233], ["RF-M1s", "GENE_OR_GENE_PRODUCT", 0, 6], ["miR-155", "GENE_OR_GENE_PRODUCT", 31, 38], ["miR-21", "GENE_OR_GENE_PRODUCT", 40, 46], ["miR-29b", "GENE_OR_GENE_PRODUCT", 48, 55], ["miR-125", "GENE_OR_GENE_PRODUCT", 57, 64], ["miR-9", "GENE_OR_GENE_PRODUCT", 66, 71], ["miR-146a", "GENE_OR_GENE_PRODUCT", 73, 81], ["miR-147", "GENE_OR_GENE_PRODUCT", 87, 94], ["RF-M2s", "GENE_OR_GENE_PRODUCT", 104, 110], ["miR-146b", "GENE_OR_GENE_PRODUCT", 135, 143], ["miR-511", "GENE_OR_GENE_PRODUCT", 145, 152], ["miR-187", "GENE_OR_GENE_PRODUCT", 154, 161], ["miR-378", "GENE_OR_GENE_PRODUCT", 163, 170], ["miR-222", "GENE_OR_GENE_PRODUCT", 172, 179], ["miR-27a", "GENE_OR_GENE_PRODUCT", 181, 188], ["miR-125a-3p", "GENE_OR_GENE_PRODUCT", 190, 201], ["miR-125a", "GENE_OR_GENE_PRODUCT", 207, 215], ["miR-155", "GENE_OR_GENE_PRODUCT", 226, 233], ["Akt-", "GENE_OR_GENE_PRODUCT", 272, 276], ["IL-13", "GENE_OR_GENE_PRODUCT", 290, 295], ["M2", "GENE_OR_GENE_PRODUCT", 307, 309], ["RF", "PROTEIN", 0, 2], ["miR-21", "DNA", 40, 46], ["miR-29b", "DNA", 48, 55], ["miR-125", "DNA", 57, 64], ["miR-9", "DNA", 66, 71], ["miR-146a", "DNA", 73, 81], ["miR-147", "DNA", 87, 94], ["RF-M2s", "DNA", 104, 110], ["miR-146b", "DNA", 135, 143], ["miR-511", "DNA", 145, 152], ["miR-187", "DNA", 154, 161], ["miR", "DNA", 163, 166], ["miR-222", "DNA", 172, 179], ["miR-27a", "DNA", 181, 188], ["miR-125a-3p", "DNA", 190, 201], ["miR", "DNA", 207, 210], ["125a", "DNA", 211, 215], ["miR-155", "DNA", 226, 233], ["RF", "TEST", 0, 2], ["the synthesis", "TEST", 14, 27], ["miR", "TEST", 31, 34], ["miR", "TEST", 40, 43], ["miR", "TEST", 48, 51], ["miR", "TEST", 57, 60], ["miR", "TEST", 66, 69], ["miR", "TEST", 73, 76], ["miR", "TEST", 87, 90], ["RF", "TEST", 104, 106], ["the synthesis", "TEST", 118, 131], ["miR", "TEST", 135, 138], ["miR", "TEST", 145, 148], ["miR", "TEST", 154, 157], ["miR", "TEST", 163, 166], ["miR", "TEST", 172, 175], ["miR", "TEST", 181, 184], ["miR", "TEST", 190, 193], ["miR", "TEST", 207, 210], ["IL", "TEST", 290, 292]]], ["Overexpression or depletion of miR-155 promotes macrophages to exhibit the M1 or M2 phenotype by regulation of transcription factor C/EBP-\u03b2 [23] . miR-155 increases stability of the TNF-\u03b1 transcript, decreases synthesis of SOCS1, and decreases the effect of TGF-\u03b2 on M2 reprogramming [69] . miR-155 can also shift the M2 phenotype of TAM to M1, thereby promoting the development of anti-tumor immunity [85] .", [["macrophages", "ANATOMY", 48, 59], ["anti-tumor", "ANATOMY", 382, 392], ["miR-155", "CHEMICAL", 31, 38], ["miR-155", "CHEMICAL", 147, 154], ["miR-155", "CHEMICAL", 291, 298], ["TAM", "CHEMICAL", 334, 337], ["TAM", "CHEMICAL", 334, 337], ["miR-155", "GENE_OR_GENE_PRODUCT", 31, 38], ["macrophages", "CELL", 48, 59], ["M2", "GENE_OR_GENE_PRODUCT", 81, 83], ["C/EBP-\u03b2", "GENE_OR_GENE_PRODUCT", 132, 139], ["miR-155", "GENE_OR_GENE_PRODUCT", 147, 154], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 182, 187], ["SOCS1", "GENE_OR_GENE_PRODUCT", 223, 228], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 258, 263], ["M2", "GENE_OR_GENE_PRODUCT", 267, 269], ["miR-155", "GENE_OR_GENE_PRODUCT", 291, 298], ["TAM", "SIMPLE_CHEMICAL", 334, 337], ["M1", "CELL", 341, 343], ["anti-tumor", "CANCER", 382, 392], ["miR-155", "PROTEIN", 31, 38], ["macrophages", "CELL_TYPE", 48, 59], ["transcription factor", "PROTEIN", 111, 131], ["EBP", "PROTEIN", 134, 137], ["TNF-\u03b1 transcript", "RNA", 182, 198], ["SOCS1", "PROTEIN", 223, 228], ["TGF-\u03b2", "PROTEIN", 258, 263], ["miR", "TEST", 31, 34], ["macrophages", "PROBLEM", 48, 59], ["transcription factor C", "TEST", 111, 133], ["EBP", "TEST", 134, 137], ["miR", "TEST", 147, 150], ["the TNF", "TEST", 178, 185], ["SOCS1", "PROBLEM", 223, 228], ["TGF", "TEST", 258, 261], ["M2 reprogramming", "TREATMENT", 267, 283], ["M1", "ANATOMY", 75, 77], ["increases", "OBSERVATION_MODIFIER", 155, 164], ["stability", "OBSERVATION_MODIFIER", 165, 174], ["SOCS1", "OBSERVATION", 223, 228]]], ["Similarly, miR-29b and miR-125 promote formation of the M1 phenotype, whereas miR-146a, miR-9, miR-21, and miR-147 have a negative effect on M1 polarization [69] .", [["miR-125", "CHEMICAL", 23, 30], ["miR-29b", "GENE_OR_GENE_PRODUCT", 11, 18], ["miR-125", "GENE_OR_GENE_PRODUCT", 23, 30], ["miR-146a", "GENE_OR_GENE_PRODUCT", 78, 86], ["miR-9", "GENE_OR_GENE_PRODUCT", 88, 93], ["miR-21", "GENE_OR_GENE_PRODUCT", 95, 101], ["miR-147", "GENE_OR_GENE_PRODUCT", 107, 114], ["miR-29b", "DNA", 11, 18], ["miR-125", "DNA", 23, 30], ["miR-146a, miR-9", "DNA", 78, 93], ["miR-21", "DNA", 95, 101], ["miR-147", "DNA", 107, 114], ["miR", "TEST", 11, 14], ["miR", "TEST", 23, 26], ["miR", "TEST", 78, 81], ["miR", "TEST", 88, 91], ["miR", "TEST", 95, 98], ["miR", "TEST", 107, 110], ["M1", "ANATOMY", 56, 58]]], ["Ponomarev et al. [86] found that miR-124 regulates macrophage plasticity and deactivate macrophages in a C/EBP\u03b1-dependent manner.", [["macrophage", "ANATOMY", 51, 61], ["macrophages", "ANATOMY", 88, 99], ["miR-124", "CHEMICAL", 33, 40], ["miR-124", "GENE_OR_GENE_PRODUCT", 33, 40], ["macrophage", "CELL", 51, 61], ["macrophages", "CELL", 88, 99], ["EBP\u03b1", "GENE_OR_GENE_PRODUCT", 107, 111], ["miR-124", "DNA", 33, 40], ["macrophages", "CELL_TYPE", 88, 99], ["EBP\u03b1", "PROTEIN", 107, 111]]], ["Moreover, miR-223 can reportedly regulate macrophage polarization by targeting Pknox 1 [87] .", [["macrophage", "ANATOMY", 42, 52], ["miR-223", "CHEMICAL", 10, 17], ["miR-223", "GENE_OR_GENE_PRODUCT", 10, 17], ["macrophage", "CELL", 42, 52], ["Pknox 1", "GENE_OR_GENE_PRODUCT", 79, 86], ["miR-223", "DNA", 10, 17], ["Pknox", "TEST", 79, 84], ["macrophage polarization", "OBSERVATION", 42, 65]]], ["Both miR-124 and miR-223 are believed to be associated with the immunosuppressive macrophage phenotype [23] .", [["macrophage", "ANATOMY", 82, 92], ["miR-124", "CHEMICAL", 5, 12], ["miR-223", "CHEMICAL", 17, 24], ["miR-124", "GENE_OR_GENE_PRODUCT", 5, 12], ["miR-223", "GENE_OR_GENE_PRODUCT", 17, 24], ["macrophage", "CELL", 82, 92], ["miR-124", "DNA", 5, 12], ["miR-223", "DNA", 17, 24], ["Both miR", "TEST", 0, 8], ["the immunosuppressive macrophage phenotype", "PROBLEM", 60, 102]]], ["Banerjee et al. [88] found overexpression of miR-let-7c in M2-type macrophages and not in M1-type macrophages.", [["M2-type macrophages", "ANATOMY", 59, 78], ["M1-type macrophages", "ANATOMY", 90, 109], ["miR-let-7c", "GENE_OR_GENE_PRODUCT", 45, 55], ["M2-type macrophages", "CELL", 59, 78], ["M1-type macrophages", "CELL", 90, 109], ["miR", "PROTEIN", 45, 48], ["M2-type macrophages", "CELL_LINE", 59, 78], ["M1-type macrophages", "CELL_LINE", 90, 109], ["miR", "TEST", 45, 48], ["type macrophages", "PROBLEM", 62, 78], ["M2", "ANATOMY", 59, 61], ["type macrophages", "OBSERVATION", 62, 78], ["M1", "ANATOMY", 90, 92], ["type macrophages", "OBSERVATION", 93, 109]]], ["Upregulation of miR-let-7c promotes M2 polarization [88] .", [["miR-let-7c", "GENE_OR_GENE_PRODUCT", 16, 26], ["M2", "GENE_OR_GENE_PRODUCT", 36, 38], ["miR", "DNA", 16, 19], ["miR", "TEST", 16, 19]]], ["In contrast, miR-511 and miR-378 are negative regulators of the macrophage M2 response [69] .Role of macrophage polarization in ALI/ARDSARDS is a devastating disease with distinct pathological stages, including an exudative phase, rehabilitation phase, and fibrotic phase [8, 25] .", [["macrophage", "ANATOMY", 64, 74], ["macrophage", "ANATOMY", 101, 111], ["ALI", "DISEASE", 128, 131], ["ARDSARDS", "DISEASE", 132, 140], ["miR-511", "GENE_OR_GENE_PRODUCT", 13, 20], ["miR-378", "GENE_OR_GENE_PRODUCT", 25, 32], ["macrophage M2", "GENE_OR_GENE_PRODUCT", 64, 77], ["macrophage", "CELL", 101, 111], ["miR-378", "DNA", 25, 32], ["miR", "TEST", 13, 16], ["ALI/ARDSARDS", "PROBLEM", 128, 140], ["a devastating disease", "PROBLEM", 144, 165], ["distinct pathological stages", "PROBLEM", 171, 199], ["an exudative phase", "TEST", 211, 229], ["rehabilitation phase", "TEST", 231, 251], ["fibrotic phase", "TEST", 257, 271], ["macrophage polarization", "OBSERVATION", 101, 124], ["ALI", "ANATOMY", 128, 131], ["devastating", "OBSERVATION_MODIFIER", 146, 157], ["disease", "OBSERVATION", 158, 165], ["distinct", "OBSERVATION_MODIFIER", 171, 179], ["exudative", "OBSERVATION_MODIFIER", 214, 223], ["phase", "OBSERVATION_MODIFIER", 224, 229], ["fibrotic", "OBSERVATION_MODIFIER", 257, 265]]], ["Macrophages are highly plastic cells that play diverse roles in all three different pathological stages based on the microenvironment (Fig. 2) .", [["Macrophages", "ANATOMY", 0, 11], ["cells", "ANATOMY", 31, 36], ["Macrophages", "CELL", 0, 11], ["plastic cells", "CELL", 23, 36], ["Macrophages", "CELL_TYPE", 0, 11], ["plastic cells", "OBSERVATION", 23, 36], ["diverse", "OBSERVATION_MODIFIER", 47, 54]]], ["Two main classes of macrophages exist in the lung.", [["macrophages", "ANATOMY", 20, 31], ["lung", "ANATOMY", 45, 49], ["macrophages", "CELL", 20, 31], ["lung", "ORGAN", 45, 49], ["macrophages", "CELL_TYPE", 20, 31], ["macrophages", "PROBLEM", 20, 31], ["main", "OBSERVATION_MODIFIER", 4, 8], ["classes", "OBSERVATION_MODIFIER", 9, 16], ["macrophages", "OBSERVATION", 20, 31], ["lung", "ANATOMY", 45, 49]]], ["The first class is alveolar macrophages (AMs), which reside within the lumen of the alveolus and are the most abundant population [89] .Role of macrophage polarization in ALI/ARDSThe main function of AMs is to phagocytize foreign particles and catabolize surfactant [89, 90] .", [["alveolar macrophages", "ANATOMY", 19, 39], ["AMs", "ANATOMY", 41, 44], ["lumen", "ANATOMY", 71, 76], ["alveolus", "ANATOMY", 84, 92], ["macrophage", "ANATOMY", 144, 154], ["AMs", "ANATOMY", 200, 203], ["ALI", "DISEASE", 171, 174], ["alveolar macrophages", "CELL", 19, 39], ["AMs", "CELL", 41, 44], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 76], ["alveolus", "ORGAN", 84, 92], ["macrophage", "CELL", 144, 154], ["AMs", "CELL", 200, 203], ["alveolar macrophages", "CELL_TYPE", 19, 39], ["AMs", "CELL_TYPE", 41, 44], ["AMs", "CELL_TYPE", 200, 203], ["alveolar macrophages", "PROBLEM", 19, 39], ["macrophage polarization", "TREATMENT", 144, 167], ["ALI", "PROBLEM", 171, 174], ["catabolize surfactant", "TEST", 244, 265], ["alveolar macrophages", "OBSERVATION", 19, 39], ["lumen", "ANATOMY_MODIFIER", 71, 76], ["alveolus", "ANATOMY", 84, 92], ["most", "OBSERVATION_MODIFIER", 105, 109], ["abundant", "OBSERVATION_MODIFIER", 110, 118], ["macrophage polarization", "OBSERVATION", 144, 167]]], ["The other class is interstitial macrophages, which account for 30-40% of lung macrophages [89] .", [["interstitial macrophages", "ANATOMY", 19, 43], ["lung macrophages", "ANATOMY", 73, 89], ["interstitial macrophages", "CELL", 19, 43], ["lung macrophages", "CELL", 73, 89], ["interstitial macrophages", "CELL_TYPE", 19, 43], ["lung macrophages", "CELL_TYPE", 73, 89], ["interstitial macrophages", "PROBLEM", 19, 43], ["lung macrophages", "PROBLEM", 73, 89], ["interstitial", "ANATOMY_MODIFIER", 19, 31], ["macrophages", "OBSERVATION", 32, 43], ["lung", "ANATOMY", 73, 77], ["macrophages", "OBSERVATION", 78, 89]]], ["The function of interstitial macrophages is thought to be associated with tissue remodeling and repair, antigen presentation, and modulation of dendritic cell functions [89, 91] .", [["interstitial macrophages", "ANATOMY", 16, 40], ["tissue", "ANATOMY", 74, 80], ["dendritic cell", "ANATOMY", 144, 158], ["interstitial macrophages", "CELL", 16, 40], ["tissue", "TISSUE", 74, 80], ["dendritic cell", "CELL", 144, 158], ["interstitial macrophages", "CELL_TYPE", 16, 40], ["interstitial macrophages", "PROBLEM", 16, 40], ["tissue remodeling", "PROBLEM", 74, 91], ["repair", "TREATMENT", 96, 102], ["antigen presentation", "TEST", 104, 124], ["dendritic cell functions", "PROBLEM", 144, 168], ["interstitial", "ANATOMY_MODIFIER", 16, 28], ["macrophages", "OBSERVATION", 29, 40], ["thought to be associated with", "UNCERTAINTY", 44, 73], ["tissue", "OBSERVATION_MODIFIER", 74, 80], ["remodeling", "OBSERVATION", 81, 91], ["repair", "OBSERVATION", 96, 102], ["dendritic cell functions", "OBSERVATION", 144, 168]]], ["AMs can be further divided into two subpopulations according to their functional state and sources: longlived resident AMs and recruited AMs [8] .", [["AMs", "ANATOMY", 0, 3], ["AMs", "ANATOMY", 119, 122], ["AMs", "CELL", 0, 3], ["AMs", "CELL", 119, 122], ["AMs", "CELL", 137, 140], ["AMs", "CELL_TYPE", 0, 3], ["longlived resident AMs", "CELL_TYPE", 100, 122], ["AMs", "CELL_TYPE", 137, 140], ["AMs", "PROBLEM", 0, 3]]], ["The long-lived resident AMs act as a uniform, quiescent, and immunosuppressive population and mainly present the M2 phenotype [8, 92] .", [["AMs", "ANATOMY", 24, 27], ["AMs", "CELL", 24, 27], ["AMs", "CELL_TYPE", 24, 27], ["immunosuppressive population", "TREATMENT", 61, 89]]], ["However, peripheral blood monocytes are recruited into the alveolar lumen in response to certain stimuli [8] .", [["peripheral blood monocytes", "ANATOMY", 9, 35], ["alveolar lumen", "ANATOMY", 59, 73], ["peripheral blood monocytes", "CELL", 9, 35], ["alveolar lumen", "MULTI-TISSUE_STRUCTURE", 59, 73], ["peripheral blood monocytes", "CELL_TYPE", 9, 35], ["peripheral blood monocytes", "TEST", 9, 35], ["certain stimuli", "TEST", 89, 104], ["peripheral", "ANATOMY_MODIFIER", 9, 19], ["blood monocytes", "OBSERVATION", 20, 35], ["alveolar lumen", "OBSERVATION", 59, 73]]], ["This population of AMs are called recruited AMs and differentiate into macrophages with the M1 phenotype [93] .", [["AMs", "ANATOMY", 19, 22], ["AMs", "ANATOMY", 44, 47], ["macrophages", "ANATOMY", 71, 82], ["AMs", "CELL", 19, 22], ["AMs", "CELL", 44, 47], ["macrophages", "CELL", 71, 82], ["AMs", "CELL_TYPE", 19, 22], ["AMs", "CELL_TYPE", 44, 47], ["macrophages", "CELL_TYPE", 71, 82], ["AMs", "PROBLEM", 19, 22]]], ["Accumulating evidence suggests that macrophages, including both resident AMs and recruited AMs, are key factors in the pathogenesis of ALI/ARDS [8] .Exudative phase of ALI/ARDSIn this stage, the resident AMs immediately shift to the predominant M1 phenotype in response to infection-induced activation of TLRs or other recognition receptors [94] .", [["macrophages", "ANATOMY", 36, 47], ["AMs", "ANATOMY", 73, 76], ["AMs", "ANATOMY", 91, 94], ["AMs", "ANATOMY", 204, 207], ["ALI", "DISEASE", 135, 138], ["ARDS", "DISEASE", 139, 143], ["ALI", "DISEASE", 168, 171], ["infection", "DISEASE", 273, 282], ["macrophages", "CELL", 36, 47], ["AMs", "CELL", 73, 76], ["AMs", "CELL", 91, 94], ["AMs", "CELL", 204, 207], ["TLRs", "GENE_OR_GENE_PRODUCT", 305, 309], ["macrophages", "CELL_TYPE", 36, 47], ["AMs", "CELL_TYPE", 73, 76], ["AMs", "CELL_TYPE", 91, 94], ["resident AMs", "CELL_TYPE", 195, 207], ["TLRs", "PROTEIN", 305, 309], ["recognition receptors", "PROTEIN", 319, 340], ["macrophages", "PROBLEM", 36, 47], ["ALI", "PROBLEM", 135, 138], ["ARDS", "PROBLEM", 139, 143], ["ALI", "PROBLEM", 168, 171], ["infection", "PROBLEM", 273, 282], ["evidence suggests", "UNCERTAINTY", 13, 30], ["macrophages", "OBSERVATION", 36, 47], ["ALI", "ANATOMY", 135, 138], ["ARDS", "OBSERVATION", 139, 143], ["ALI", "OBSERVATION", 168, 171], ["predominant M1", "OBSERVATION_MODIFIER", 233, 247], ["infection", "OBSERVATION", 273, 282]]], ["Excessive production of macrophages can contribute to tissue damage.", [["macrophages", "ANATOMY", 24, 35], ["tissue", "ANATOMY", 54, 60], ["macrophages", "CELL", 24, 35], ["tissue", "TISSUE", 54, 60], ["macrophages", "CELL_TYPE", 24, 35], ["Excessive production of macrophages", "PROBLEM", 0, 35], ["tissue damage", "PROBLEM", 54, 67], ["macrophages", "OBSERVATION", 24, 35], ["tissue", "ANATOMY", 54, 60], ["damage", "OBSERVATION", 61, 67]]], ["These AMs release a variety of inflammatory cytokines such as IL-1\u03b2, IL-6, MCP-1, MIP-2, TNF-\u03b1, and ROS [95] .", [["AMs", "ANATOMY", 6, 9], ["ROS", "CHEMICAL", 100, 103], ["AMs", "CELL", 6, 9], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-6", "GENE_OR_GENE_PRODUCT", 69, 73], ["MCP-1", "GENE_OR_GENE_PRODUCT", 75, 80], ["MIP-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 89, 94], ["ROS", "SIMPLE_CHEMICAL", 100, 103], ["AMs", "CELL_TYPE", 6, 9], ["inflammatory cytokines", "PROTEIN", 31, 53], ["MCP", "PROTEIN", 75, 78], ["TNF", "PROTEIN", 89, 92], ["inflammatory cytokines", "PROBLEM", 31, 53], ["IL", "TEST", 62, 64], ["IL", "TEST", 69, 71], ["MCP", "TEST", 75, 78], ["MIP", "TEST", 82, 85], ["TNF", "TEST", 89, 92], ["inflammatory", "OBSERVATION_MODIFIER", 31, 43]]], ["The neutrophils induced by these proinflammatory factors are then recruited from the intravascular space, cross the endothelium and epithelium, and finally move into the lungs and alveolar spaces.", [["neutrophils", "ANATOMY", 4, 15], ["intravascular space", "ANATOMY", 85, 104], ["endothelium", "ANATOMY", 116, 127], ["epithelium", "ANATOMY", 132, 142], ["lungs", "ANATOMY", 170, 175], ["alveolar spaces", "ANATOMY", 180, 195], ["neutrophils", "CELL", 4, 15], ["intravascular space", "IMMATERIAL_ANATOMICAL_ENTITY", 85, 104], ["endothelium", "TISSUE", 116, 127], ["epithelium", "TISSUE", 132, 142], ["lungs", "ORGAN", 170, 175], ["alveolar", "MULTI-TISSUE_STRUCTURE", 180, 188], ["neutrophils", "CELL_TYPE", 4, 15], ["proinflammatory factors", "PROTEIN", 33, 56], ["these proinflammatory factors", "PROBLEM", 27, 56], ["neutrophils", "OBSERVATION", 4, 15], ["proinflammatory factors", "OBSERVATION", 33, 56], ["intravascular space", "ANATOMY", 85, 104], ["endothelium", "ANATOMY", 116, 127], ["epithelium", "ANATOMY_MODIFIER", 132, 142], ["lungs", "ANATOMY", 170, 175], ["alveolar", "ANATOMY_MODIFIER", 180, 188]]], ["Excessive accumulation of proinflammatory factors and neutrophils can lead to lung tissue damage [8] .", [["neutrophils", "ANATOMY", 54, 65], ["lung tissue", "ANATOMY", 78, 89], ["lung tissue damage", "DISEASE", 78, 96], ["neutrophils", "CELL", 54, 65], ["lung tissue", "TISSUE", 78, 89], ["proinflammatory factors", "PROTEIN", 26, 49], ["neutrophils", "CELL_TYPE", 54, 65], ["Excessive accumulation of proinflammatory factors", "PROBLEM", 0, 49], ["neutrophils", "PROBLEM", 54, 65], ["lung tissue damage", "PROBLEM", 78, 96], ["accumulation", "OBSERVATION_MODIFIER", 10, 22], ["proinflammatory factors", "OBSERVATION", 26, 49], ["lung", "ANATOMY", 78, 82], ["tissue", "OBSERVATION", 83, 89]]], ["Recent studies have shown that some naturally derived or synthesized materials can ameliorate the prognosis of ALI in animal models by inhibiting M1 polarization of AMs [96] [97] [98] [99] [100] .", [["ALI", "DISEASE", 111, 114], ["Recent studies", "TEST", 0, 14], ["some naturally derived or synthesized materials", "PROBLEM", 31, 78], ["ALI", "PROBLEM", 111, 114]]], ["Therefore, M1 macrophages serve as promoters in the process of lung tissue damage in ALI/ARDS.", [["M1 macrophages", "ANATOMY", 11, 25], ["lung tissue", "ANATOMY", 63, 74], ["lung tissue damage", "DISEASE", 63, 81], ["ALI", "DISEASE", 85, 88], ["ARDS", "DISEASE", 89, 93], ["M1 macrophages", "CELL", 11, 25], ["lung tissue", "TISSUE", 63, 74], ["M1 macrophages", "CELL_LINE", 11, 25], ["lung tissue damage", "PROBLEM", 63, 81], ["ALI", "PROBLEM", 85, 88], ["ARDS", "PROBLEM", 89, 93], ["lung", "ANATOMY", 63, 67], ["tissue", "ANATOMY_MODIFIER", 68, 74], ["damage", "OBSERVATION", 75, 81], ["ALI", "OBSERVATION", 85, 88], ["ARDS", "OBSERVATION", 89, 93]]], ["However, recent studies have demonstrated that M1 macrophages can protect against LPS-induced ALI and ventilator-induced lung injury via enhanced expression of amphiregulin, inhibiting the gene expression of proinflammatory cytokines and protecting the epithelial barrier [101] .Rehabilitation phase of ALI/ARDSFollowing the exudative phase, the second phase of ALI/ ARDS is the rehabilitation phase.", [["M1 macrophages", "ANATOMY", 47, 61], ["lung", "ANATOMY", 121, 125], ["epithelial barrier", "ANATOMY", 253, 271], ["LPS", "CHEMICAL", 82, 85], ["ALI", "DISEASE", 94, 97], ["lung injury", "DISEASE", 121, 132], ["ALI", "DISEASE", 303, 306], ["ALI", "DISEASE", 362, 365], ["ARDS", "DISEASE", 367, 371], ["M1 macrophages", "CELL", 47, 61], ["LPS", "SIMPLE_CHEMICAL", 82, 85], ["lung", "ORGAN", 121, 125], ["amphiregulin", "GENE_OR_GENE_PRODUCT", 160, 172], ["epithelial barrier", "TISSUE", 253, 271], ["M1 macrophages", "CELL_TYPE", 47, 61], ["amphiregulin", "PROTEIN", 160, 172], ["proinflammatory cytokines", "PROTEIN", 208, 233], ["recent studies", "TEST", 9, 23], ["M1 macrophages", "PROBLEM", 47, 61], ["LPS", "PROBLEM", 82, 85], ["ALI", "PROBLEM", 94, 97], ["ventilator", "TREATMENT", 102, 112], ["lung injury", "PROBLEM", 121, 132], ["amphiregulin", "TREATMENT", 160, 172], ["proinflammatory cytokines", "TREATMENT", 208, 233], ["the epithelial barrier", "TREATMENT", 249, 271], ["ALI", "PROBLEM", 303, 306], ["ALI", "PROBLEM", 362, 365], ["ARDS", "PROBLEM", 367, 371], ["ALI", "OBSERVATION", 94, 97], ["lung", "ANATOMY", 121, 125], ["injury", "OBSERVATION", 126, 132], ["proinflammatory cytokines", "OBSERVATION", 208, 233], ["ALI", "ANATOMY", 303, 306], ["ARDS", "OBSERVATION", 367, 371]]], ["In the rehabilitation phase of ALI/ARDS, pathogenic factors are eliminated, and resident and recruited macrophages then shift from the M1 to the M2 phenotype [8] .", [["macrophages", "ANATOMY", 103, 114], ["ALI", "DISEASE", 31, 34], ["ARDS", "DISEASE", 35, 39], ["macrophages", "CELL", 103, 114], ["macrophages", "CELL_TYPE", 103, 114], ["ALI", "PROBLEM", 31, 34], ["ARDS", "PROBLEM", 35, 39], ["pathogenic factors", "PROBLEM", 41, 59], ["ALI", "ANATOMY", 31, 34], ["ARDS", "OBSERVATION", 35, 39], ["macrophages", "OBSERVATION", 103, 114]]], ["The phagocytosis of apoptotic neutrophils by macrophages acts as one of the driving factors that promotes the M2 phenotype [102] .", [["neutrophils", "ANATOMY", 30, 41], ["macrophages", "ANATOMY", 45, 56], ["neutrophils", "CELL", 30, 41], ["macrophages", "CELL", 45, 56], ["M2", "GENE_OR_GENE_PRODUCT", 110, 112], ["apoptotic neutrophils", "CELL_TYPE", 20, 41], ["macrophages", "CELL_TYPE", 45, 56], ["phagocytosis", "OBSERVATION_MODIFIER", 4, 16], ["apoptotic neutrophils", "OBSERVATION", 20, 41]]], ["M2 macrophages can enhance the expression of IL-10, fibronectin 1, and the TGF-\u03b2-induced matrix-associated proteins BIG-H3 and insulin-like growth factor 1 and limit the levels of proinflammatory cytokines; this promotes repair of host tissues, reduces alveolar epithelial cell damage, and increases the pulmonary barrier function after inflammation [8, 103] .", [["M2 macrophages", "ANATOMY", 0, 14], ["tissues", "ANATOMY", 236, 243], ["alveolar epithelial cell", "ANATOMY", 253, 277], ["pulmonary barrier", "ANATOMY", 304, 321], ["inflammation", "DISEASE", 337, 349], ["M2 macrophages", "CELL", 0, 14], ["IL-10", "GENE_OR_GENE_PRODUCT", 45, 50], ["fibronectin 1", "GENE_OR_GENE_PRODUCT", 52, 65], ["TGF-\u03b2-", "GENE_OR_GENE_PRODUCT", 75, 81], ["matrix", "CELLULAR_COMPONENT", 89, 95], ["BIG-H3", "GENE_OR_GENE_PRODUCT", 116, 122], ["insulin-like growth factor 1", "GENE_OR_GENE_PRODUCT", 127, 155], ["tissues", "TISSUE", 236, 243], ["alveolar epithelial cell", "CELL", 253, 277], ["pulmonary barrier", "TISSUE", 304, 321], ["M2 macrophages", "CELL_LINE", 0, 14], ["IL-10", "PROTEIN", 45, 50], ["fibronectin 1", "PROTEIN", 52, 65], ["TGF-\u03b2-induced matrix-associated proteins", "PROTEIN", 75, 115], ["BIG", "PROTEIN", 116, 119], ["H3", "PROTEIN", 120, 122], ["insulin-like growth factor 1", "PROTEIN", 127, 155], ["proinflammatory cytokines", "PROTEIN", 180, 205], ["IL", "TEST", 45, 47], ["fibronectin", "TEST", 52, 63], ["the TGF", "TEST", 71, 78], ["proteins BIG", "TEST", 107, 119], ["H3", "PROBLEM", 120, 122], ["insulin", "TEST", 127, 134], ["growth factor", "TEST", 140, 153], ["proinflammatory cytokines", "PROBLEM", 180, 205], ["this promotes repair of host tissues", "TREATMENT", 207, 243], ["alveolar epithelial cell damage", "PROBLEM", 253, 284], ["inflammation", "PROBLEM", 337, 349], ["proinflammatory cytokines", "OBSERVATION", 180, 205], ["repair", "OBSERVATION", 221, 227], ["host tissues", "OBSERVATION", 231, 243], ["alveolar epithelial cell damage", "OBSERVATION", 253, 284], ["increases", "OBSERVATION_MODIFIER", 290, 299], ["pulmonary", "ANATOMY", 304, 313], ["barrier function", "OBSERVATION", 314, 330]]], ["Apart from the regulation of proinflammatory and antiinflammatory cytokines, M2 macrophages can also activate anti-inflammatory signaling, terminate proinflammatory responses, and finally promote rehabilitation of lung injury by the clearance of apoptotic neutrophils from inflammatory sites [8] .", [["M2 macrophages", "ANATOMY", 77, 91], ["lung", "ANATOMY", 214, 218], ["neutrophils", "ANATOMY", 256, 267], ["lung injury", "DISEASE", 214, 225], ["M2 macrophages", "CELL", 77, 91], ["lung", "ORGAN", 214, 218], ["neutrophils", "CELL", 256, 267], ["proinflammatory and antiinflammatory cytokines", "PROTEIN", 29, 75], ["M2 macrophages", "CELL_TYPE", 77, 91], ["apoptotic neutrophils", "CELL_TYPE", 246, 267], ["proinflammatory and antiinflammatory cytokines", "TREATMENT", 29, 75], ["anti-inflammatory signaling", "PROBLEM", 110, 137], ["lung injury", "PROBLEM", 214, 225], ["apoptotic neutrophils", "PROBLEM", 246, 267], ["inflammatory sites", "PROBLEM", 273, 291], ["proinflammatory", "OBSERVATION_MODIFIER", 29, 44], ["antiinflammatory", "OBSERVATION_MODIFIER", 49, 65], ["anti-inflammatory", "OBSERVATION_MODIFIER", 110, 127], ["lung", "ANATOMY", 214, 218], ["injury", "OBSERVATION", 219, 225], ["apoptotic neutrophils", "OBSERVATION", 246, 267], ["inflammatory", "OBSERVATION_MODIFIER", 273, 285]]], ["Phagocytosis of apoptotic neutrophils by M2 macrophages further increases the production of antiinflammatory factors such as IL-10 and TGF-\u03b2, which may be beneficial for inflammation control [103] .", [["neutrophils", "ANATOMY", 26, 37], ["M2 macrophages", "ANATOMY", 41, 55], ["inflammation", "DISEASE", 170, 182], ["neutrophils", "CELL", 26, 37], ["M2 macrophages", "CELL", 41, 55], ["IL-10", "GENE_OR_GENE_PRODUCT", 125, 130], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 135, 140], ["apoptotic neutrophils", "CELL_TYPE", 16, 37], ["M2 macrophages", "CELL_TYPE", 41, 55], ["antiinflammatory factors", "PROTEIN", 92, 116], ["IL-10", "PROTEIN", 125, 130], ["TGF-\u03b2", "PROTEIN", 135, 140], ["apoptotic neutrophils", "PROBLEM", 16, 37], ["M2 macrophages", "PROBLEM", 41, 55], ["antiinflammatory factors", "PROBLEM", 92, 116], ["IL", "TEST", 125, 127], ["TGF", "TEST", 135, 138], ["inflammation control", "PROBLEM", 170, 190], ["apoptotic neutrophils", "OBSERVATION", 16, 37], ["M2 macrophages", "OBSERVATION", 41, 55], ["antiinflammatory", "OBSERVATION_MODIFIER", 92, 108]]], ["Phagocytosis also inhibits the expression of iNOS and stimulates the expression of Arg-1, thereby preventing ROS production [102] .", [["ROS", "CHEMICAL", 109, 112], ["iNOS", "GENE_OR_GENE_PRODUCT", 45, 49], ["Arg-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["ROS", "SIMPLE_CHEMICAL", 109, 112], ["iNOS", "PROTEIN", 45, 49], ["Arg-1", "PROTEIN", 83, 88], ["Phagocytosis", "PROBLEM", 0, 12], ["Arg", "TEST", 83, 86], ["ROS production", "PROBLEM", 109, 123], ["iNOS", "OBSERVATION", 45, 49]]], ["In a Pseudomonas aeruginosa infection-induced ALI murine model, macrophages demonstrated peak expression phenotype.", [["macrophages", "ANATOMY", 64, 75], ["Pseudomonas aeruginosa infection", "DISEASE", 5, 37], ["ALI", "DISEASE", 46, 49], ["Pseudomonas aeruginosa", "ORGANISM", 5, 27], ["murine", "ORGANISM", 50, 56], ["macrophages", "CELL", 64, 75], ["macrophages", "CELL_TYPE", 64, 75], ["Pseudomonas aeruginosa", "SPECIES", 5, 27], ["murine", "SPECIES", 50, 56], ["Pseudomonas aeruginosa", "SPECIES", 5, 27], ["a Pseudomonas aeruginosa infection", "PROBLEM", 3, 37], ["ALI murine model", "TEST", 46, 62], ["peak expression phenotype", "PROBLEM", 89, 114], ["Pseudomonas aeruginosa", "OBSERVATION", 5, 27], ["peak expression phenotype", "OBSERVATION", 89, 114]]], ["Under certain stimuli, normal resident AMs shift to the M1 phenotype during the exudative phase of ALI/ARDS.", [["AMs", "ANATOMY", 39, 42], ["ALI", "DISEASE", 99, 102], ["ARDS", "DISEASE", 103, 107], ["AMs", "CELL", 39, 42], ["AMs", "CELL_TYPE", 39, 42], ["ALI", "PROBLEM", 99, 102], ["ARDS", "PROBLEM", 103, 107], ["normal", "OBSERVATION", 23, 29], ["exudative", "OBSERVATION_MODIFIER", 80, 89], ["ALI", "OBSERVATION", 99, 102], ["ARDS", "OBSERVATION", 103, 107]]], ["M1 macrophages release various proinflammatory cytokines at the site of inflammation, and neutrophils are then recruited from the circulation into the lungs and alveolar spaces.", [["M1 macrophages", "ANATOMY", 0, 14], ["neutrophils", "ANATOMY", 90, 101], ["lungs", "ANATOMY", 151, 156], ["alveolar spaces", "ANATOMY", 161, 176], ["inflammation", "DISEASE", 72, 84], ["M1 macrophages", "CELL", 0, 14], ["neutrophils", "CELL", 90, 101], ["lungs", "ORGAN", 151, 156], ["alveolar spaces", "MULTI-TISSUE_STRUCTURE", 161, 176], ["M1 macrophages", "CELL_TYPE", 0, 14], ["proinflammatory cytokines", "PROTEIN", 31, 56], ["neutrophils", "CELL_TYPE", 90, 101], ["various proinflammatory cytokines", "PROBLEM", 23, 56], ["inflammation", "PROBLEM", 72, 84], ["neutrophils", "TEST", 90, 101], ["various", "OBSERVATION_MODIFIER", 23, 30], ["proinflammatory cytokines", "OBSERVATION", 31, 56], ["inflammation", "OBSERVATION", 72, 84], ["neutrophils", "OBSERVATION", 90, 101], ["circulation", "ANATOMY_MODIFIER", 130, 141], ["lungs", "ANATOMY", 151, 156], ["alveolar", "ANATOMY_MODIFIER", 161, 169]]], ["Excessive accumulation of proinflammatory factors and neutrophils promote progression of inflammation and lung injury.", [["neutrophils", "ANATOMY", 54, 65], ["lung", "ANATOMY", 106, 110], ["inflammation", "DISEASE", 89, 101], ["lung injury", "DISEASE", 106, 117], ["neutrophils", "CELL", 54, 65], ["lung", "ORGAN", 106, 110], ["proinflammatory factors", "PROTEIN", 26, 49], ["neutrophils", "CELL_TYPE", 54, 65], ["Excessive accumulation of proinflammatory factors", "PROBLEM", 0, 49], ["neutrophils", "PROBLEM", 54, 65], ["inflammation", "PROBLEM", 89, 101], ["lung injury", "PROBLEM", 106, 117], ["accumulation", "OBSERVATION_MODIFIER", 10, 22], ["proinflammatory factors", "OBSERVATION", 26, 49], ["progression", "OBSERVATION_MODIFIER", 74, 85], ["inflammation", "OBSERVATION", 89, 101], ["lung", "ANATOMY", 106, 110], ["injury", "OBSERVATION", 111, 117]]], ["After causative factors are eliminated, macrophages shift from the M1 phenotype to the M2 phenotype, and ALI/ARDS progresses to the rehabilitation stage.", [["macrophages", "ANATOMY", 40, 51], ["ALI", "DISEASE", 105, 108], ["ARDS", "DISEASE", 109, 113], ["macrophages", "CELL", 40, 51], ["M2", "GENE_OR_GENE_PRODUCT", 87, 89], ["macrophages", "CELL_TYPE", 40, 51], ["macrophages shift", "PROBLEM", 40, 57], ["the M2 phenotype", "PROBLEM", 83, 99], ["ALI", "PROBLEM", 105, 108], ["ARDS", "PROBLEM", 109, 113], ["macrophages", "OBSERVATION", 40, 51], ["M2", "ANATOMY", 87, 89], ["ALI", "ANATOMY", 105, 108], ["ARDS", "OBSERVATION", 109, 113]]], ["M2 macrophages play an important role in inflammation resolution and lung tissue repair by limiting the levels of proinflammatory cytokines and enhancing the production of anti-inflammatory cytokines.", [["M2 macrophages", "ANATOMY", 0, 14], ["lung tissue", "ANATOMY", 69, 80], ["inflammation", "DISEASE", 41, 53], ["M2 macrophages", "CELL", 0, 14], ["lung tissue", "TISSUE", 69, 80], ["M2 macrophages", "CELL_TYPE", 0, 14], ["proinflammatory cytokines", "PROTEIN", 114, 139], ["anti-inflammatory cytokines", "PROTEIN", 172, 199], ["inflammation resolution", "PROBLEM", 41, 64], ["lung tissue repair", "TREATMENT", 69, 87], ["proinflammatory cytokines", "TREATMENT", 114, 139], ["anti-inflammatory cytokines", "TREATMENT", 172, 199], ["macrophages", "OBSERVATION", 3, 14], ["inflammation", "OBSERVATION", 41, 53], ["lung", "ANATOMY", 69, 73], ["tissue repair", "OBSERVATION", 74, 87], ["proinflammatory cytokines", "OBSERVATION", 114, 139], ["anti-inflammatory cytokines", "OBSERVATION", 172, 199]]], ["Clear-ance of apoptotic neutrophils and debris is also attributed to M2 macrophages, which are helpful for inflammation termination and lung tissue repair.", [["neutrophils", "ANATOMY", 24, 35], ["M2 macrophages", "ANATOMY", 69, 83], ["lung tissue", "ANATOMY", 136, 147], ["inflammation", "DISEASE", 107, 119], ["neutrophils", "CELL", 24, 35], ["M2 macrophages", "CELL", 69, 83], ["lung tissue", "TISSUE", 136, 147], ["apoptotic neutrophils", "CELL_TYPE", 14, 35], ["M2 macrophages", "CELL_TYPE", 69, 83], ["apoptotic neutrophils", "PROBLEM", 14, 35], ["debris", "PROBLEM", 40, 46], ["M2 macrophages", "PROBLEM", 69, 83], ["inflammation termination", "PROBLEM", 107, 131], ["lung tissue repair", "TREATMENT", 136, 154], ["apoptotic neutrophils", "OBSERVATION", 14, 35], ["debris", "OBSERVATION", 40, 46], ["also attributed to", "UNCERTAINTY", 50, 68], ["M2 macrophages", "OBSERVATION", 69, 83], ["lung", "ANATOMY", 136, 140], ["tissue repair", "OBSERVATION", 141, 154]]], ["During the later fibrotic phase of ALI/ARDS, the balance of M1/M2 macrophages determines the trend and extent of lung fibrosis.", [["M1/M2 macrophages", "ANATOMY", 60, 77], ["lung", "ANATOMY", 113, 117], ["ALI", "DISEASE", 35, 38], ["ARDS", "DISEASE", 39, 43], ["fibrosis", "DISEASE", 118, 126], ["lung", "ORGAN", 113, 117], ["M1/M2 macrophages", "CELL_TYPE", 60, 77], ["ALI", "PROBLEM", 35, 38], ["ARDS", "PROBLEM", 39, 43], ["lung fibrosis", "PROBLEM", 113, 126], ["fibrotic", "OBSERVATION_MODIFIER", 17, 25], ["ALI", "OBSERVATION", 35, 38], ["ARDS", "OBSERVATION", 39, 43], ["trend", "OBSERVATION_MODIFIER", 93, 98], ["extent", "OBSERVATION_MODIFIER", 103, 109], ["lung", "ANATOMY", 113, 117], ["fibrosis", "OBSERVATION", 118, 126]]], ["M1 macrophages release MMPs and CXCL10 to promote matrix degradation and decrease fibrosis.", [["M1 macrophages", "ANATOMY", 0, 14], ["matrix", "ANATOMY", 50, 56], ["fibrosis", "DISEASE", 82, 90], ["M1 macrophages", "CELL", 0, 14], ["MMPs", "GENE_OR_GENE_PRODUCT", 23, 27], ["CXCL10", "GENE_OR_GENE_PRODUCT", 32, 38], ["matrix", "CELLULAR_COMPONENT", 50, 56], ["M1 macrophages", "CELL_TYPE", 0, 14], ["MMPs", "PROTEIN", 23, 27], ["CXCL10", "PROTEIN", 32, 38], ["MMPs", "TEST", 23, 27], ["CXCL10", "TEST", 32, 38], ["matrix degradation", "PROBLEM", 50, 68], ["decrease fibrosis", "PROBLEM", 73, 90], ["decrease", "OBSERVATION_MODIFIER", 73, 81], ["fibrosis", "OBSERVATION", 82, 90]]], ["Persistence of M2 macrophages promotes fibroproliferation and ECM deposition by enhanced expression of TIMP, Arg-1, IL-13, and IL-4.", [["M2 macrophages", "ANATOMY", 15, 29], ["ECM", "ANATOMY", 62, 65], ["M2 macrophages", "CELL", 15, 29], ["ECM", "CELLULAR_COMPONENT", 62, 65], ["TIMP", "GENE_OR_GENE_PRODUCT", 103, 107], ["Arg-1", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-13", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL-4", "GENE_OR_GENE_PRODUCT", 127, 131], ["M2 macrophages", "CELL_TYPE", 15, 29], ["TIMP", "PROTEIN", 103, 107], ["Arg-1, IL-13", "PROTEIN", 109, 121], ["IL-4", "PROTEIN", 127, 131], ["M2 macrophages", "PROBLEM", 15, 29], ["ECM deposition", "PROBLEM", 62, 76], ["TIMP", "TEST", 103, 107], ["Arg", "TEST", 109, 112], ["IL", "TEST", 116, 118], ["IL", "TEST", 127, 129], ["M2 macrophages", "OBSERVATION", 15, 29], ["ECM deposition", "OBSERVATION", 62, 76]]], ["Balanced M1/ M2 polarization shifts lung injury toward normal lung repair.", [["lung", "ANATOMY", 36, 40], ["lung", "ANATOMY", 62, 66], ["M2", "GENE_OR_GENE_PRODUCT", 13, 15], ["lung", "ORGAN", 36, 40], ["lung", "ORGAN", 62, 66], ["lung injury", "PROBLEM", 36, 47], ["normal lung repair", "TREATMENT", 55, 73], ["M1", "OBSERVATION_MODIFIER", 9, 11], ["lung", "ANATOMY", 36, 40], ["injury", "OBSERVATION", 41, 47], ["lung", "ANATOMY", 62, 66], ["repair", "OBSERVATION", 67, 73]]], ["IL interleukin, MCP-1 monocyte chemotactic protein 1, MIP-2 macrophage inflammatory protein 2, TNF-\u03b1 tumor necrosis factor \u03b1, ROS reactive oxygen species, FN-1 fibronectin 1, TGF-\u03b2 transforming growth factor \u03b2, IGF1, insulin-like growth factor 1, Arg-1 arginase-1, TIMP tissue inhibitor of metalloproteinase, MMPS matrix metalloproteinase, ECM extracellular matrix of the M2 marker (transferrin receptor) during the resolution phases of lung injury in the alveolar space [102] .", [["extracellular matrix", "ANATOMY", 344, 364], ["lung", "ANATOMY", 437, 441], ["alveolar space", "ANATOMY", 456, 470], ["tumor", "DISEASE", 101, 106], ["oxygen", "CHEMICAL", 139, 145], ["lung injury", "DISEASE", 437, 448], ["oxygen", "CHEMICAL", 139, 145], ["IL interleukin", "GENE_OR_GENE_PRODUCT", 0, 14], ["MCP-1 monocyte chemotactic protein 1", "GENE_OR_GENE_PRODUCT", 16, 52], ["MIP-2 macrophage inflammatory protein 2", "GENE_OR_GENE_PRODUCT", 54, 93], ["TNF-\u03b1 tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 95, 124], ["ROS reactive oxygen species", "SIMPLE_CHEMICAL", 126, 153], ["FN-1 fibronectin 1", "GENE_OR_GENE_PRODUCT", 155, 173], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 175, 180], ["transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 181, 209], ["IGF1", "GENE_OR_GENE_PRODUCT", 211, 215], ["insulin-like growth factor 1", "GENE_OR_GENE_PRODUCT", 217, 245], ["Arg-1 arginase-1", "GENE_OR_GENE_PRODUCT", 247, 263], ["TIMP tissue inhibitor of metalloproteinase", "GENE_OR_GENE_PRODUCT", 265, 307], ["MMPS matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 309, 338], ["ECM", "CELLULAR_COMPONENT", 340, 343], ["extracellular matrix", "CELLULAR_COMPONENT", 344, 364], ["M2 marker", "GENE_OR_GENE_PRODUCT", 372, 381], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 383, 403], ["lung", "ORGAN", 437, 441], ["IL interleukin", "PROTEIN", 0, 14], ["MCP-1 monocyte chemotactic protein 1", "PROTEIN", 16, 52], ["MIP-2 macrophage inflammatory protein 2", "PROTEIN", 54, 93], ["TNF-\u03b1 tumor necrosis factor \u03b1", "PROTEIN", 95, 124], ["FN", "PROTEIN", 155, 157], ["fibronectin 1", "PROTEIN", 160, 173], ["TGF-\u03b2 transforming growth factor \u03b2", "PROTEIN", 175, 209], ["IGF1", "PROTEIN", 211, 215], ["insulin-like growth factor 1", "PROTEIN", 217, 245], ["Arg-1 arginase-1", "PROTEIN", 247, 263], ["TIMP tissue inhibitor of metalloproteinase", "PROTEIN", 265, 307], ["MMPS matrix metalloproteinase", "PROTEIN", 309, 338], ["M2 marker", "PROTEIN", 372, 381], ["transferrin receptor", "PROTEIN", 383, 403], ["IL interleukin", "TEST", 0, 14], ["MCP", "TEST", 16, 19], ["monocyte chemotactic protein", "TEST", 22, 50], ["MIP", "TEST", 54, 57], ["macrophage", "TEST", 60, 70], ["inflammatory protein", "TEST", 71, 91], ["TNF", "TEST", 95, 98], ["tumor necrosis factor", "PROBLEM", 101, 122], ["ROS", "TEST", 126, 129], ["oxygen species", "TEST", 139, 153], ["FN", "TEST", 155, 157], ["fibronectin", "TEST", 160, 171], ["TGF", "TEST", 175, 178], ["growth factor", "TEST", 194, 207], ["IGF1", "TEST", 211, 215], ["insulin", "TEST", 217, 224], ["growth factor", "TEST", 230, 243], ["Arg", "TEST", 247, 250], ["arginase", "TEST", 253, 261], ["TIMP tissue inhibitor", "TREATMENT", 265, 286], ["metalloproteinase, MMPS matrix metalloproteinase", "TREATMENT", 290, 338], ["ECM extracellular matrix", "TREATMENT", 340, 364], ["the M2 marker (transferrin receptor", "TREATMENT", 368, 403], ["lung injury in the alveolar space", "PROBLEM", 437, 470], ["tumor necrosis", "OBSERVATION", 101, 115], ["reactive", "OBSERVATION_MODIFIER", 130, 138], ["oxygen species", "OBSERVATION", 139, 153], ["lung", "ANATOMY", 437, 441], ["injury", "OBSERVATION", 442, 448], ["alveolar", "ANATOMY_MODIFIER", 456, 464]]], ["Moreover, Shirey et al. [104] reported that respiratory syncytial virus could induce AMs to produce IL-4 and IL-13, which contribute to M2 macrophage differentiation and disease resolution in respiratory syncytial virus-induced lung injury.", [["AMs", "ANATOMY", 85, 88], ["M2 macrophage", "ANATOMY", 136, 149], ["lung", "ANATOMY", 228, 232], ["respiratory syncytial virus", "DISEASE", 44, 71], ["respiratory syncytial virus", "DISEASE", 192, 219], ["lung injury", "DISEASE", 228, 239], ["respiratory syncytial virus", "ORGANISM", 44, 71], ["AMs", "CELL", 85, 88], ["IL-4", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL-13", "GENE_OR_GENE_PRODUCT", 109, 114], ["M2 macrophage", "CELL", 136, 149], ["respiratory syncytial virus", "ORGANISM", 192, 219], ["lung", "ORGAN", 228, 232], ["AMs", "CELL_TYPE", 85, 88], ["IL-4", "PROTEIN", 100, 104], ["IL-13", "PROTEIN", 109, 114], ["respiratory syncytial virus", "SPECIES", 44, 71], ["respiratory syncytial virus", "SPECIES", 192, 219], ["respiratory syncytial virus", "PROBLEM", 44, 71], ["AMs", "PROBLEM", 85, 88], ["IL", "TEST", 100, 102], ["IL", "TEST", 109, 111], ["M2 macrophage differentiation", "PROBLEM", 136, 165], ["disease resolution", "PROBLEM", 170, 188], ["respiratory syncytial virus", "PROBLEM", 192, 219], ["lung injury", "PROBLEM", 228, 239], ["respiratory", "ANATOMY", 44, 55], ["syncytial virus", "OBSERVATION", 56, 71], ["M2 macrophage differentiation", "OBSERVATION", 136, 165], ["respiratory syncytial virus", "OBSERVATION", 192, 219], ["lung", "ANATOMY", 228, 232], ["injury", "OBSERVATION", 233, 239]]], ["Additionally, Tu et al. [105] found that methylprednisolone could attenuate LPS-induced ALI by increasing the number of M2 macrophages and induction of M2 polarization.", [["M2 macrophages", "ANATOMY", 120, 134], ["methylprednisolone", "CHEMICAL", 41, 59], ["LPS", "CHEMICAL", 76, 79], ["ALI", "DISEASE", 88, 91], ["methylprednisolone", "CHEMICAL", 41, 59], ["methylprednisolone", "SIMPLE_CHEMICAL", 41, 59], ["LPS", "SIMPLE_CHEMICAL", 76, 79], ["M2 macrophages", "CELL", 120, 134], ["M2", "GENE_OR_GENE_PRODUCT", 152, 154], ["M2 macrophages", "CELL_TYPE", 120, 134], ["methylprednisolone", "TREATMENT", 41, 59], ["LPS", "TEST", 76, 79], ["ALI", "PROBLEM", 88, 91], ["M2 polarization", "TREATMENT", 152, 167], ["ALI", "OBSERVATION", 88, 91], ["M2 macrophages", "OBSERVATION", 120, 134], ["M2 polarization", "OBSERVATION", 152, 167]]], ["These results suggest that M2 macrophages are key orchestrators in the regulation of lung damage and tissue repair in the rehabilitation phase of ALI/ARDS.Fibrotic phase of ALI/ARDSPulmonary fibrosis, a late complication of ALI/ARDS, is characterized by fibroblast proliferation and excessive deposition of ECM [8, 106] .", [["M2 macrophages", "ANATOMY", 27, 41], ["lung", "ANATOMY", 85, 89], ["tissue", "ANATOMY", 101, 107], ["fibroblast", "ANATOMY", 254, 264], ["ECM", "ANATOMY", 307, 310], ["lung damage", "DISEASE", 85, 96], ["ALI", "DISEASE", 146, 149], ["ARDS", "DISEASE", 150, 154], ["ALI", "DISEASE", 173, 176], ["fibrosis", "DISEASE", 191, 199], ["ALI", "DISEASE", 224, 227], ["ARDS", "DISEASE", 228, 232], ["M2 macrophages", "CELL", 27, 41], ["lung", "ORGAN", 85, 89], ["tissue", "TISSUE", 101, 107], ["fibroblast", "CELL", 254, 264], ["ECM", "CELLULAR_COMPONENT", 307, 310], ["M2 macrophages", "CELL_TYPE", 27, 41], ["ECM", "PROTEIN", 307, 310], ["M2 macrophages", "PROBLEM", 27, 41], ["lung damage", "PROBLEM", 85, 96], ["tissue repair", "TREATMENT", 101, 114], ["ALI", "PROBLEM", 146, 149], ["ARDS", "PROBLEM", 150, 154], ["ALI", "PROBLEM", 173, 176], ["ARDSPulmonary fibrosis", "PROBLEM", 177, 199], ["a late complication", "PROBLEM", 201, 220], ["ALI", "PROBLEM", 224, 227], ["ARDS", "PROBLEM", 228, 232], ["fibroblast proliferation", "PROBLEM", 254, 278], ["excessive deposition of ECM", "PROBLEM", 283, 310], ["M2 macrophages", "OBSERVATION", 27, 41], ["lung", "ANATOMY", 85, 89], ["damage", "OBSERVATION", 90, 96], ["tissue repair", "OBSERVATION", 101, 114], ["ALI", "ANATOMY", 146, 149], ["ARDS", "OBSERVATION", 150, 154], ["phase", "OBSERVATION_MODIFIER", 164, 169], ["ALI", "OBSERVATION", 173, 176], ["ARDSPulmonary", "ANATOMY", 177, 190], ["fibrosis", "OBSERVATION", 191, 199], ["late", "OBSERVATION_MODIFIER", 203, 207], ["complication", "OBSERVATION_MODIFIER", 208, 220], ["ALI", "OBSERVATION", 224, 227], ["ARDS", "OBSERVATION", 228, 232], ["fibroblast proliferation", "OBSERVATION", 254, 278], ["excessive", "OBSERVATION_MODIFIER", 283, 292], ["deposition", "OBSERVATION_MODIFIER", 293, 303]]], ["The fibrotic phase of ALI/ARDS is linked to prolonged mechanical ventilation and increased mortality [106] .", [["ALI", "DISEASE", 22, 25], ["ARDS", "DISEASE", 26, 30], ["ALI", "PROBLEM", 22, 25], ["ARDS", "PROBLEM", 26, 30], ["prolonged mechanical ventilation", "TREATMENT", 44, 76], ["increased mortality", "PROBLEM", 81, 100], ["fibrotic", "OBSERVATION_MODIFIER", 4, 12], ["phase", "OBSERVATION_MODIFIER", 13, 18], ["ALI", "OBSERVATION", 22, 25], ["ARDS", "OBSERVATION", 26, 30], ["mechanical ventilation", "OBSERVATION", 54, 76]]], ["Following destruction of the basement membrane integrity, M1 and M2 macrophages are recruited into the lung tissue injury site to regulate the formation of fibrosis.", [["basement membrane", "ANATOMY", 29, 46], ["M1", "ANATOMY", 58, 60], ["M2 macrophages", "ANATOMY", 65, 79], ["lung tissue", "ANATOMY", 103, 114], ["fibrosis", "DISEASE", 156, 164], ["basement membrane", "CELLULAR_COMPONENT", 29, 46], ["M2 macrophages", "CELL", 65, 79], ["lung tissue", "TISSUE", 103, 114], ["M1 and M2 macrophages", "CELL_LINE", 58, 79], ["destruction of the basement membrane integrity", "PROBLEM", 10, 56], ["the lung tissue injury site", "PROBLEM", 99, 126], ["fibrosis", "PROBLEM", 156, 164], ["destruction", "OBSERVATION", 10, 21], ["basement", "ANATOMY_MODIFIER", 29, 37], ["membrane", "ANATOMY_MODIFIER", 38, 46], ["integrity", "OBSERVATION_MODIFIER", 47, 56], ["M1", "OBSERVATION_MODIFIER", 58, 60], ["M2", "OBSERVATION_MODIFIER", 65, 67], ["lung", "ANATOMY", 103, 107], ["tissue", "ANATOMY_MODIFIER", 108, 114], ["injury", "OBSERVATION", 115, 121], ["fibrosis", "OBSERVATION", 156, 164]]], ["M1 macrophages play an important role in matrix degradation by direct and indirect production of matrix metalloproteinases (MMPs) and a variety of antifibrotic cytokines such as CXCL10 [107, 108] .", [["M1 macrophages", "ANATOMY", 0, 14], ["matrix", "ANATOMY", 41, 47], ["M1 macrophages", "CELL", 0, 14], ["matrix", "CELLULAR_COMPONENT", 41, 47], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 97, 122], ["MMPs", "GENE_OR_GENE_PRODUCT", 124, 128], ["CXCL10", "GENE_OR_GENE_PRODUCT", 178, 184], ["M1 macrophages", "CELL_TYPE", 0, 14], ["matrix metalloproteinases", "PROTEIN", 97, 122], ["MMPs", "PROTEIN", 124, 128], ["antifibrotic cytokines", "PROTEIN", 147, 169], ["CXCL10", "PROTEIN", 178, 184], ["matrix metalloproteinases", "PROBLEM", 97, 122], ["antifibrotic cytokines", "TREATMENT", 147, 169], ["CXCL10", "TEST", 178, 184]]], ["The production of MMPs is important for remodeling of the ECM, which contributes to resolution of the pathological fibroproliferative response in the later phase of ALI/ARDS [107] .", [["ECM", "ANATOMY", 58, 61], ["ALI", "DISEASE", 165, 168], ["ARDS", "DISEASE", 169, 173], ["MMPs", "GENE_OR_GENE_PRODUCT", 18, 22], ["ECM", "CELLULAR_COMPONENT", 58, 61], ["MMPs", "PROTEIN", 18, 22], ["MMPs", "PROBLEM", 18, 22], ["the pathological fibroproliferative response", "PROBLEM", 98, 142], ["ARDS", "PROBLEM", 169, 173], ["MMPs", "OBSERVATION", 18, 22], ["pathological", "OBSERVATION_MODIFIER", 102, 114], ["fibroproliferative", "OBSERVATION_MODIFIER", 115, 133], ["response", "OBSERVATION_MODIFIER", 134, 142], ["ARDS", "OBSERVATION", 169, 173]]], ["M1 macrophages can also induce myofibroblasts to express MMP-13 and MMP-3 [107, 109] .", [["M1 macrophages", "ANATOMY", 0, 14], ["myofibroblasts", "ANATOMY", 31, 45], ["M1 macrophages", "CELL", 0, 14], ["myofibroblasts", "CELL", 31, 45], ["MMP-13", "GENE_OR_GENE_PRODUCT", 57, 63], ["MMP-3", "GENE_OR_GENE_PRODUCT", 68, 73], ["M1 macrophages", "CELL_LINE", 0, 14], ["myofibroblasts", "CELL_TYPE", 31, 45], ["MMP-13", "PROTEIN", 57, 63], ["MMP", "PROTEIN", 68, 71], ["MMP", "TEST", 57, 60], ["MMP", "TEST", 68, 71]]], ["In contrast to the expression of MMPs by M1 macrophages, M2 macrophages markedly express anti-inflammatory cytokines and tissue inhibitors of metalloproteinase, which impair remodeling of excessive ECM [107, 110] .", [["M1 macrophages", "ANATOMY", 41, 55], ["M2 macrophages", "ANATOMY", 57, 71], ["ECM", "ANATOMY", 198, 201], ["MMPs", "GENE_OR_GENE_PRODUCT", 33, 37], ["M1 macrophages", "CELL", 41, 55], ["M2 macrophages", "CELL", 57, 71], ["tissue inhibitors of metalloproteinase", "GENE_OR_GENE_PRODUCT", 121, 159], ["ECM", "CELLULAR_COMPONENT", 198, 201], ["MMPs", "PROTEIN", 33, 37], ["M1 macrophages", "CELL_TYPE", 41, 55], ["M2 macrophages", "CELL_TYPE", 57, 71], ["anti-inflammatory cytokines", "PROTEIN", 89, 116], ["tissue inhibitors of metalloproteinase", "PROTEIN", 121, 159], ["M2 macrophages", "PROBLEM", 57, 71], ["anti-inflammatory cytokines", "TREATMENT", 89, 116], ["tissue inhibitors of metalloproteinase", "PROBLEM", 121, 159], ["excessive ECM", "PROBLEM", 188, 201], ["anti-inflammatory cytokines", "OBSERVATION", 89, 116], ["excessive", "OBSERVATION_MODIFIER", 188, 197]]], ["Moreover, co-culture of M2 macrophages with myofibroblasts can induce complex ECM deposition [107] .", [["M2 macrophages", "ANATOMY", 24, 38], ["myofibroblasts", "ANATOMY", 44, 58], ["ECM", "ANATOMY", 78, 81], ["M2 macrophages", "CELL", 24, 38], ["myofibroblasts", "CELL", 44, 58], ["ECM", "CELLULAR_COMPONENT", 78, 81], ["M2 macrophages", "CELL_TYPE", 24, 38], ["myofibroblasts", "CELL_TYPE", 44, 58], ["myofibroblasts", "PROBLEM", 44, 58], ["complex ECM deposition", "PROBLEM", 70, 92]]], ["Arg-1 is an important M2 macrophage-associated molecule that can degrade L-arginine into L-proline [27, 107] .", [["macrophage", "ANATOMY", 25, 35], ["L-arginine", "CHEMICAL", 73, 83], ["L-proline", "CHEMICAL", 89, 98], ["L-arginine", "CHEMICAL", 73, 83], ["L-proline", "CHEMICAL", 89, 98], ["Arg-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["M2 macrophage", "CELL", 22, 35], ["L-arginine", "SIMPLE_CHEMICAL", 73, 83], ["L-proline", "SIMPLE_CHEMICAL", 89, 98], ["M2 macrophage-associated molecule", "PROTEIN", 22, 55], ["Arg", "TEST", 0, 3], ["important M2", "OBSERVATION_MODIFIER", 12, 24]]], ["It can be used to produce collagen by myofibroblasts [111] .", [["myofibroblasts", "ANATOMY", 38, 52], ["collagen", "GENE_OR_GENE_PRODUCT", 26, 34], ["myofibroblasts", "CELL", 38, 52], ["collagen", "PROTEIN", 26, 34], ["myofibroblasts", "CELL_TYPE", 38, 52]]], ["Prolonged effects of IL-13 and IL-4 on AMs promote the presence of M2 macrophages and, finally, excessive fibrogenesis [8] .", [["AMs", "ANATOMY", 39, 42], ["M2 macrophages", "ANATOMY", 67, 81], ["fibrogenesis", "DISEASE", 106, 118], ["IL-13", "GENE_OR_GENE_PRODUCT", 21, 26], ["IL-4", "GENE_OR_GENE_PRODUCT", 31, 35], ["AMs", "CELL", 39, 42], ["M2 macrophages", "CELL", 67, 81], ["IL-13", "PROTEIN", 21, 26], ["IL-4", "PROTEIN", 31, 35], ["AMs", "CELL_TYPE", 39, 42], ["M2 macrophages", "CELL_TYPE", 67, 81], ["IL", "TEST", 21, 23], ["IL", "TREATMENT", 31, 33], ["AMs", "TREATMENT", 39, 42], ["excessive fibrogenesis", "PROBLEM", 96, 118], ["excessive", "OBSERVATION_MODIFIER", 96, 105], ["fibrogenesis", "OBSERVATION", 106, 118]]], ["Therefore, M2 macrophages are usually believed to be more promotive of a fibroproliferative microenvironment.", [["M2 macrophages", "ANATOMY", 11, 25], ["M2 macrophages", "CELL", 11, 25], ["M2 macrophages", "CELL_TYPE", 11, 25], ["a fibroproliferative microenvironment", "PROBLEM", 71, 108], ["M2 macrophages", "OBSERVATION", 11, 25], ["fibroproliferative", "OBSERVATION_MODIFIER", 73, 91], ["microenvironment", "OBSERVATION", 92, 108]]], ["IL-4-polarized M2 macrophages can reportedly inhibit fibrosis by expressing Arg-1 and resistinlike \u03b1 genes (surface marker of the M2 phenotype) [112] .", [["M2 macrophages", "ANATOMY", 15, 29], ["surface", "ANATOMY", 108, 115], ["fibrosis", "DISEASE", 53, 61], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["M2 macrophages", "CELL", 15, 29], ["Arg-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["resistinlike \u03b1", "GENE_OR_GENE_PRODUCT", 86, 100], ["IL-4-polarized M2 macrophages", "CELL_LINE", 0, 29], ["Arg-1", "PROTEIN", 76, 81], ["resistinlike \u03b1 genes", "DNA", 86, 106], ["IL", "TEST", 0, 2], ["fibrosis", "PROBLEM", 53, 61], ["Arg", "TEST", 76, 79], ["fibrosis", "OBSERVATION", 53, 61]]], ["Wakayama et al. [113] found that dental pulp stem cells could attenuate bleomycin-induced lung fibrosis by inducing M2-like lung macrophages.", [["dental pulp stem cells", "ANATOMY", 33, 55], ["lung", "ANATOMY", 90, 94], ["M2-like lung macrophages", "ANATOMY", 116, 140], ["bleomycin", "CHEMICAL", 72, 81], ["fibrosis", "DISEASE", 95, 103], ["bleomycin", "CHEMICAL", 72, 81], ["dental pulp stem cells", "CELL", 33, 55], ["bleomycin", "SIMPLE_CHEMICAL", 72, 81], ["lung", "ORGAN", 90, 94], ["M2-like lung macrophages", "CELL", 116, 140], ["dental pulp stem cells", "CELL_TYPE", 33, 55], ["M2", "PROTEIN", 116, 118], ["lung macrophages", "CELL_TYPE", 124, 140], ["dental pulp stem cells", "PROBLEM", 33, 55], ["bleomycin", "PROBLEM", 72, 81], ["lung fibrosis", "PROBLEM", 90, 103], ["M2-like lung macrophages", "PROBLEM", 116, 140], ["dental pulp", "ANATOMY", 33, 44], ["stem cells", "OBSERVATION", 45, 55], ["bleomycin", "OBSERVATION", 72, 81], ["lung", "ANATOMY", 90, 94], ["fibrosis", "OBSERVATION", 95, 103], ["M2", "OBSERVATION_MODIFIER", 116, 118], ["lung", "ANATOMY", 124, 128], ["macrophages", "OBSERVATION", 129, 140]]], ["Therefore, macrophages are paradoxically involved in the process of lung fibrosis.", [["macrophages", "ANATOMY", 11, 22], ["lung", "ANATOMY", 68, 72], ["fibrosis", "DISEASE", 73, 81], ["macrophages", "CELL", 11, 22], ["lung", "ORGAN", 68, 72], ["macrophages", "CELL_TYPE", 11, 22], ["macrophages", "PROBLEM", 11, 22], ["lung fibrosis", "PROBLEM", 68, 81], ["macrophages", "OBSERVATION", 11, 22], ["lung", "ANATOMY", 68, 72], ["fibrosis", "OBSERVATION", 73, 81]]], ["The magnitude of myofibroblast activation and deposition of ECM and the severity of lung tissue fibrosis may be partly dependent on the balance of M1 versus M2 macrophages in the local microenvironment of lung tissue injury.Summary and perspectiveThis paper has reviewed the origin, polarization, and polarization regulation of macrophages and the role of macrophage polarization in various stages of ALI/ARDS.", [["myofibroblast", "ANATOMY", 17, 30], ["ECM", "ANATOMY", 60, 63], ["lung tissue", "ANATOMY", 84, 95], ["macrophages", "ANATOMY", 160, 171], ["lung tissue", "ANATOMY", 205, 216], ["macrophages", "ANATOMY", 328, 339], ["macrophage", "ANATOMY", 356, 366], ["fibrosis", "DISEASE", 96, 104], ["ALI", "DISEASE", 401, 404], ["ARDS", "DISEASE", 405, 409], ["myofibroblast", "CELL", 17, 30], ["ECM", "CELLULAR_COMPONENT", 60, 63], ["lung tissue", "TISSUE", 84, 95], ["M1", "CELL", 147, 149], ["M2 macrophages", "CELL", 157, 171], ["lung tissue", "TISSUE", 205, 216], ["macrophages", "CELL", 328, 339], ["macrophage", "CELL", 356, 366], ["ECM", "PROTEIN", 60, 63], ["M2 macrophages", "CELL_TYPE", 157, 171], ["macrophages", "CELL_TYPE", 328, 339], ["myofibroblast activation", "PROBLEM", 17, 41], ["deposition of ECM", "TREATMENT", 46, 63], ["lung tissue fibrosis", "PROBLEM", 84, 104], ["lung tissue injury", "PROBLEM", 205, 223], ["macrophages", "PROBLEM", 328, 339], ["macrophage polarization", "TREATMENT", 356, 379], ["ALI", "PROBLEM", 401, 404], ["ARDS", "PROBLEM", 405, 409], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["myofibroblast activation", "OBSERVATION", 17, 41], ["deposition", "OBSERVATION_MODIFIER", 46, 56], ["ECM", "OBSERVATION_MODIFIER", 60, 63], ["severity", "OBSERVATION_MODIFIER", 72, 80], ["lung", "ANATOMY", 84, 88], ["tissue", "ANATOMY_MODIFIER", 89, 95], ["fibrosis", "OBSERVATION", 96, 104], ["local microenvironment", "OBSERVATION", 179, 201], ["lung tissue", "ANATOMY", 205, 216], ["injury", "OBSERVATION", 217, 223], ["macrophages", "OBSERVATION", 328, 339], ["macrophage polarization", "OBSERVATION", 356, 379], ["ALI", "OBSERVATION", 401, 404], ["ARDS", "OBSERVATION", 405, 409]]], ["A much better understanding of the role that macrophage polarization plays in inflammatory, reparative, and fibrotic responses relevant to ALI/ARDS pathogenesis may pave the way for new therapeutic tools to effectively treat ALI/ARDS.Summary and perspectiveMacrophages are believed to have multiple origins, including HSCs, the yolk sac, and the fetal liver.", [["macrophage", "ANATOMY", 45, 55], ["Macrophages", "ANATOMY", 257, 268], ["HSCs", "ANATOMY", 318, 322], ["yolk sac", "ANATOMY", 328, 336], ["fetal liver", "ANATOMY", 346, 357], ["ALI", "DISEASE", 139, 142], ["ARDS", "DISEASE", 143, 147], ["ALI", "DISEASE", 225, 228], ["ARDS", "DISEASE", 229, 233], ["macrophage", "CELL", 45, 55], ["Macrophages", "CELL", 257, 268], ["HSCs", "CELL", 318, 322], ["yolk sac", "MULTI-TISSUE_STRUCTURE", 328, 336], ["fetal", "ORGAN", 346, 351], ["liver", "ORGAN", 352, 357], ["Macrophages", "CELL_TYPE", 257, 268], ["HSCs", "CELL_TYPE", 318, 322], ["inflammatory, reparative", "PROBLEM", 78, 102], ["fibrotic responses", "PROBLEM", 108, 126], ["ALI", "PROBLEM", 139, 142], ["ARDS pathogenesis", "PROBLEM", 143, 160], ["ALI", "PROBLEM", 225, 228], ["ARDS", "PROBLEM", 229, 233], ["the yolk sac", "TEST", 324, 336], ["inflammatory", "OBSERVATION_MODIFIER", 78, 90], ["fibrotic", "OBSERVATION", 108, 116], ["ARDS", "OBSERVATION", 143, 147], ["ARDS", "OBSERVATION", 229, 233], ["HSCs", "ANATOMY", 318, 322], ["sac", "OBSERVATION_MODIFIER", 333, 336], ["fetal", "ANATOMY_MODIFIER", 346, 351], ["liver", "ANATOMY", 352, 357]]], ["A high degree of plasticity is the fundamental characteristic of the macrophage.", [["macrophage", "ANATOMY", 69, 79], ["macrophage", "CELL", 69, 79], ["macrophage", "CELL_TYPE", 69, 79], ["A high degree of plasticity", "PROBLEM", 0, 27], ["high degree", "OBSERVATION_MODIFIER", 2, 13], ["plasticity", "OBSERVATION", 17, 27], ["fundamental characteristic", "OBSERVATION_MODIFIER", 35, 61], ["macrophage", "OBSERVATION", 69, 79]]], ["There are two main polarization states of macrophages according to their responses to environmental stimuli: the M1 and M2 phenotypes.", [["macrophages", "ANATOMY", 42, 53], ["macrophages", "CELL", 42, 53], ["M2", "GENE_OR_GENE_PRODUCT", 120, 122], ["macrophages", "CELL_TYPE", 42, 53], ["macrophages", "PROBLEM", 42, 53], ["environmental stimuli", "TEST", 86, 107], ["two", "OBSERVATION_MODIFIER", 10, 13], ["main", "OBSERVATION_MODIFIER", 14, 18], ["polarization", "OBSERVATION_MODIFIER", 19, 31], ["macrophages", "OBSERVATION", 42, 53], ["M1", "ANATOMY", 113, 115], ["M2", "ANATOMY", 120, 122]]], ["Macrophages can switch from one phenotype to another when the environmental stimuli change.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "TREATMENT", 0, 11]]], ["Generally, M1 macrophages are mainly involved in proinflammatory activity and tissue damage, whereas M2 macrophages have converse properties.", [["M1 macrophages", "ANATOMY", 11, 25], ["tissue", "ANATOMY", 78, 84], ["M2 macrophages", "ANATOMY", 101, 115], ["M1 macrophages", "CELL", 11, 25], ["tissue", "TISSUE", 78, 84], ["M2 macrophages", "CELL", 101, 115], ["M1 macrophages", "CELL_TYPE", 11, 25], ["M2 macrophages", "CELL_TYPE", 101, 115], ["tissue damage", "PROBLEM", 78, 91], ["M1 macrophages", "OBSERVATION", 11, 25], ["proinflammatory activity", "OBSERVATION", 49, 73], ["tissue", "OBSERVATION_MODIFIER", 78, 84], ["damage", "OBSERVATION", 85, 91], ["M2 macrophages", "OBSERVATION", 101, 115]]], ["The regulation of macrophage polarization involves a highly complex set of regulatory networks at both the transcriptional and post-transcriptional levels.Summary and perspectiveMacrophages are important effector cells that participate in all stages of ALI/ARDS, including the exudative phase, rehabilitation phase, and fibrotic phase.", [["macrophage", "ANATOMY", 18, 28], ["Macrophages", "ANATOMY", 178, 189], ["effector cells", "ANATOMY", 204, 218], ["ALI", "DISEASE", 253, 256], ["ARDS", "DISEASE", 257, 261], ["macrophage", "CELL", 18, 28], ["Macrophages", "CELL", 178, 189], ["cells", "CELL", 213, 218], ["regulatory networks", "PROTEIN", 75, 94], ["Macrophages", "CELL_TYPE", 178, 189], ["effector cells", "CELL_TYPE", 204, 218], ["effector cells", "PROBLEM", 204, 218], ["ALI", "PROBLEM", 253, 256], ["ARDS", "PROBLEM", 257, 261], ["the exudative phase", "TEST", 273, 292], ["rehabilitation phase", "TEST", 294, 314], ["macrophage polarization", "OBSERVATION", 18, 41], ["regulatory networks", "OBSERVATION", 75, 94], ["post-transcriptional levels", "OBSERVATION", 127, 154], ["ARDS", "OBSERVATION", 257, 261], ["fibrotic phase", "OBSERVATION", 320, 334]]], ["In the exudative phase of ALI/ARDS, lung macrophages shift into the M1 phenotype and act as potent promoters to induce severe inflammatory responses and lung tissue damage.", [["lung macrophages", "ANATOMY", 36, 52], ["lung tissue", "ANATOMY", 153, 164], ["ALI", "DISEASE", 26, 29], ["ARDS", "DISEASE", 30, 34], ["lung tissue damage", "DISEASE", 153, 171], ["lung macrophages", "CELL", 36, 52], ["lung tissue", "TISSUE", 153, 164], ["lung macrophages", "CELL_TYPE", 36, 52], ["ALI", "PROBLEM", 26, 29], ["ARDS", "PROBLEM", 30, 34], ["lung macrophages", "PROBLEM", 36, 52], ["severe inflammatory responses", "PROBLEM", 119, 148], ["lung tissue damage", "PROBLEM", 153, 171], ["exudative", "OBSERVATION_MODIFIER", 7, 16], ["phase", "OBSERVATION_MODIFIER", 17, 22], ["ALI", "ANATOMY", 26, 29], ["ARDS", "OBSERVATION", 30, 34], ["lung", "ANATOMY", 36, 40], ["macrophages", "OBSERVATION", 41, 52], ["M1", "ANATOMY", 68, 70], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["inflammatory", "OBSERVATION", 126, 138], ["lung", "ANATOMY", 153, 157], ["tissue", "OBSERVATION", 158, 164]]], ["Following entry into the rehabilitation stage, M2 macrophages are increasingly prominent in lung tissues and serve as key orchestrators in regulating lung tissue damage and repair and promoting disease resolution.", [["M2 macrophages", "ANATOMY", 47, 61], ["lung tissues", "ANATOMY", 92, 104], ["lung tissue", "ANATOMY", 150, 161], ["M2 macrophages", "CELL", 47, 61], ["lung tissues", "TISSUE", 92, 104], ["lung tissue", "TISSUE", 150, 161], ["M2 macrophages", "CELL_TYPE", 47, 61], ["M2 macrophages", "PROBLEM", 47, 61], ["regulating lung tissue damage", "PROBLEM", 139, 168], ["repair", "TREATMENT", 173, 179], ["promoting disease resolution", "PROBLEM", 184, 212], ["M2 macrophages", "OBSERVATION", 47, 61], ["increasingly", "OBSERVATION_MODIFIER", 66, 78], ["prominent", "OBSERVATION", 79, 88], ["lung", "ANATOMY", 92, 96], ["lung tissue", "ANATOMY", 150, 161], ["damage", "OBSERVATION", 162, 168], ["repair", "OBSERVATION", 173, 179], ["disease", "OBSERVATION_MODIFIER", 194, 201], ["resolution", "OBSERVATION_MODIFIER", 202, 212]]], ["Excessive M2 polarization contributes to the pathological fibroproliferative response and pulmonary fibrosis in the later fibrotic phase of ALI/ ARDS.", [["pulmonary", "ANATOMY", 90, 99], ["fibrosis", "DISEASE", 100, 108], ["ALI", "DISEASE", 140, 143], ["ARDS", "DISEASE", 145, 149], ["M2", "GENE_OR_GENE_PRODUCT", 10, 12], ["pulmonary", "ORGAN", 90, 99], ["M2", "PROTEIN", 10, 12], ["Excessive M2 polarization", "PROBLEM", 0, 25], ["the pathological fibroproliferative response", "PROBLEM", 41, 85], ["pulmonary fibrosis", "PROBLEM", 90, 108], ["ALI", "PROBLEM", 140, 143], ["ARDS", "PROBLEM", 145, 149], ["M2 polarization", "OBSERVATION", 10, 25], ["pathological", "OBSERVATION_MODIFIER", 45, 57], ["fibroproliferative", "OBSERVATION_MODIFIER", 58, 76], ["response", "OBSERVATION_MODIFIER", 77, 85], ["pulmonary", "ANATOMY", 90, 99], ["fibrosis", "OBSERVATION", 100, 108], ["fibrotic", "OBSERVATION_MODIFIER", 122, 130], ["phase", "OBSERVATION_MODIFIER", 131, 136], ["ALI", "OBSERVATION", 140, 143], ["ARDS", "OBSERVATION", 145, 149]]], ["However, the functions of different macrophage subsets are not absolutely defined in each phase of ALI/ARDS.", [["macrophage", "ANATOMY", 36, 46], ["ALI", "DISEASE", 99, 102], ["ARDS", "DISEASE", 103, 107], ["macrophage", "CELL", 36, 46], ["macrophage subsets", "CELL_TYPE", 36, 54], ["different macrophage subsets", "PROBLEM", 26, 54], ["ALI", "PROBLEM", 99, 102], ["ARDS", "PROBLEM", 103, 107], ["different", "OBSERVATION_MODIFIER", 26, 35], ["macrophage subsets", "OBSERVATION", 36, 54], ["ALI", "OBSERVATION", 99, 102], ["ARDS", "OBSERVATION", 103, 107]]], ["Some studies have shown that in the acute exudative phase of ALI/ARDS, M1 macrophages can attenuate the proinflammatory response and protect the epithelial barrier from injury.", [["M1 macrophages", "ANATOMY", 71, 85], ["epithelial barrier", "ANATOMY", 145, 163], ["ALI", "DISEASE", 61, 64], ["ARDS", "DISEASE", 65, 69], ["M1 macrophages", "CELL", 71, 85], ["epithelial barrier", "TISSUE", 145, 163], ["M1 macrophages", "CELL_TYPE", 71, 85], ["Some studies", "TEST", 0, 12], ["ALI", "PROBLEM", 61, 64], ["ARDS", "PROBLEM", 65, 69], ["M1 macrophages", "PROBLEM", 71, 85], ["the proinflammatory response", "PROBLEM", 100, 128], ["injury", "PROBLEM", 169, 175], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["exudative", "OBSERVATION_MODIFIER", 42, 51], ["ALI", "OBSERVATION", 61, 64], ["ARDS", "OBSERVATION", 65, 69], ["proinflammatory response", "OBSERVATION", 104, 128], ["epithelial barrier", "OBSERVATION", 145, 163], ["injury", "OBSERVATION", 169, 175]]], ["Similarly, the M2 phenotype is reportedly involved in the antifibrotic process in the fibrotic stage of ALI/ARDS.", [["ALI", "DISEASE", 104, 107], ["ARDS", "DISEASE", 108, 112], ["M2", "GENE_OR_GENE_PRODUCT", 15, 17], ["the M2 phenotype", "PROBLEM", 11, 27], ["the antifibrotic process", "PROBLEM", 54, 78], ["ALI", "PROBLEM", 104, 107], ["ARDS", "PROBLEM", 108, 112], ["M2 phenotype", "OBSERVATION", 15, 27], ["antifibrotic", "OBSERVATION", 58, 70], ["fibrotic", "OBSERVATION_MODIFIER", 86, 94], ["ALI", "OBSERVATION", 104, 107], ["ARDS", "OBSERVATION", 108, 112]]], ["Therefore, the properties and functions of each macrophage subpopulation are not rigorously inflexible.", [["macrophage subpopulation", "ANATOMY", 48, 72], ["macrophage", "CELL", 48, 58], ["macrophage subpopulation", "CELL_TYPE", 48, 72], ["each macrophage subpopulation", "TREATMENT", 43, 72]]], ["Macrophages are paradoxically involved in inflammation, tissue repair, and fibrosis in ALI/ARDS.", [["Macrophages", "ANATOMY", 0, 11], ["tissue", "ANATOMY", 56, 62], ["inflammation", "DISEASE", 42, 54], ["fibrosis", "DISEASE", 75, 83], ["ALI", "DISEASE", 87, 90], ["ARDS", "DISEASE", 91, 95], ["Macrophages", "CELL", 0, 11], ["tissue", "TISSUE", 56, 62], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "PROBLEM", 0, 11], ["inflammation", "PROBLEM", 42, 54], ["tissue repair", "TREATMENT", 56, 69], ["fibrosis", "PROBLEM", 75, 83], ["ALI", "PROBLEM", 87, 90], ["ARDS", "PROBLEM", 91, 95], ["inflammation", "OBSERVATION", 42, 54], ["tissue repair", "OBSERVATION", 56, 69], ["fibrosis", "OBSERVATION", 75, 83], ["ALI", "ANATOMY", 87, 90], ["ARDS", "OBSERVATION", 91, 95]]], ["Nonetheless, targeting macrophage polarization for ALI/ARDS treatment has been proven effective and promising in many preclinical studies [96-99, 105, 112] .", [["macrophage", "ANATOMY", 23, 33], ["ALI", "DISEASE", 51, 54], ["ARDS", "DISEASE", 55, 59], ["macrophage", "CELL", 23, 33], ["targeting macrophage polarization", "TREATMENT", 13, 46], ["ALI", "PROBLEM", 51, 54], ["ARDS treatment", "TREATMENT", 55, 69], ["macrophage polarization", "OBSERVATION", 23, 46], ["ARDS", "OBSERVATION", 55, 59]]], ["Limiting excessive proinflammatory responses and tissue damage and balancing excessive fibrosis and tissue repair via regulation of macrophage activation and polarization represent novel and potential therapeutic targets for ALI/ARDS.", [["tissue", "ANATOMY", 49, 55], ["tissue", "ANATOMY", 100, 106], ["macrophage", "ANATOMY", 132, 142], ["fibrosis", "DISEASE", 87, 95], ["ALI", "DISEASE", 225, 228], ["ARDS", "DISEASE", 229, 233], ["tissue", "TISSUE", 49, 55], ["tissue", "TISSUE", 100, 106], ["macrophage", "CELL", 132, 142], ["excessive proinflammatory responses", "PROBLEM", 9, 44], ["tissue damage", "PROBLEM", 49, 62], ["balancing excessive fibrosis", "PROBLEM", 67, 95], ["tissue repair", "TREATMENT", 100, 113], ["macrophage activation", "TREATMENT", 132, 153], ["ALI", "PROBLEM", 225, 228], ["ARDS", "PROBLEM", 229, 233], ["excessive", "OBSERVATION_MODIFIER", 9, 18], ["proinflammatory responses", "OBSERVATION", 19, 44], ["tissue damage", "OBSERVATION", 49, 62], ["excessive", "OBSERVATION_MODIFIER", 77, 86], ["fibrosis", "OBSERVATION", 87, 95], ["tissue repair", "OBSERVATION", 100, 113], ["macrophage activation", "OBSERVATION", 132, 153], ["ARDS", "OBSERVATION", 229, 233]]], ["However, several issues remain unresolved, such as the underlying signaling pathways of macrophage polarization and the mechanisms of cell-cell communication in the process of macrophage activation and polarization.", [["macrophage", "ANATOMY", 88, 98], ["cell", "ANATOMY", 134, 138], ["cell", "ANATOMY", 139, 143], ["macrophage", "ANATOMY", 176, 186], ["macrophage", "CELL", 88, 98], ["cell", "CELL", 134, 138], ["cell", "CELL", 139, 143], ["macrophage", "CELL", 176, 186], ["macrophage polarization", "PROBLEM", 88, 111], ["cell-cell communication", "TREATMENT", 134, 157], ["macrophage polarization", "OBSERVATION", 88, 111], ["cell", "OBSERVATION", 134, 138], ["cell communication", "OBSERVATION", 139, 157], ["macrophage activation", "OBSERVATION", 176, 197], ["polarization", "OBSERVATION_MODIFIER", 202, 214]]], ["Thus, fully elucidating how macrophage polarization can be manipulated to improve the outcome of ALI/ARDS requires further time and effort.", [["macrophage", "ANATOMY", 28, 38], ["ALI", "DISEASE", 97, 100], ["ARDS", "DISEASE", 101, 105], ["macrophage", "CELL", 28, 38], ["ALI", "PROBLEM", 97, 100], ["ARDS", "PROBLEM", 101, 105], ["ARDS", "OBSERVATION", 101, 105]]], ["Although macrophage polarizationbased therapy for lung injury is still a long way off, we hope that this review provides valuable information that may be helpful in developing novel therapies for ALI/ARDS.", [["macrophage", "ANATOMY", 9, 19], ["lung", "ANATOMY", 50, 54], ["lung injury", "DISEASE", 50, 61], ["ALI", "DISEASE", 196, 199], ["ARDS", "DISEASE", 200, 204], ["macrophage", "CELL", 9, 19], ["lung", "ORGAN", 50, 54], ["macrophage polarizationbased therapy", "TREATMENT", 9, 45], ["lung injury", "PROBLEM", 50, 61], ["novel therapies", "TREATMENT", 176, 191], ["ALI", "PROBLEM", 196, 199], ["ARDS", "PROBLEM", 200, 204], ["lung", "ANATOMY", 50, 54], ["injury", "OBSERVATION", 55, 61], ["ARDS", "OBSERVATION", 200, 204]]]], "PMC7205687": [["IntroductionDuring the current COVID-19 crisis, it is essential to adapt acute stroke care protocols to provide optimal care while protecting healthcare team members and patients.1 This extends from the stroke code initiation throughout the inpatient setting.", [["stroke", "DISEASE", 79, 85], ["stroke", "DISEASE", 203, 209], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["acute stroke care protocols", "TREATMENT", 73, 100], ["stroke", "OBSERVATION", 203, 209]]], ["The conventional stroke code process focuses on rapid stroke team mobilization.2 Standardized pathways for the use of healthcare resources, including personnel and personal protective equipment (PPE), are necessary to prevent depletion of assets and worsening of the crisis.", [["stroke", "DISEASE", 17, 23], ["stroke", "DISEASE", 54, 60], ["The conventional stroke code process", "PROBLEM", 0, 36], ["rapid stroke team mobilization", "TREATMENT", 48, 78], ["healthcare resources", "TREATMENT", 118, 138], ["personal protective equipment", "TREATMENT", 164, 193], ["the crisis", "PROBLEM", 263, 273], ["stroke", "OBSERVATION", 17, 23], ["worsening", "OBSERVATION_MODIFIER", 250, 259]]], ["This has also been seen in settings such as STEMI care in areas that have been affected by COVID-19 for longer periods of time.3 The American Stroke Association has provided emergency guidance for overall hyperacute treatment of stroke during this crisis and individual institutions must devise emergency care pathways that provide systematic guidance to all members of the stroke team.4 The purpose of this manuscript is to outline a stroke code and stroke care model developed by the University of California San Diego (UCSD) Stroke Center during the 2020 COVID-19 crisis to protect healthcare providers, preserve limited PPE, and provide rapid, comprehensive stroke care.MethodsThe UCSD Stroke Center reviewed aggregate and projected COVID-19 cases on March 12, 2020 from the Centers for Disease Control (CDC).5 All resources in our two academic, certified Comprehensive Stroke Centers (CSC) were assessed.", [["STEMI", "DISEASE", 44, 49], ["Stroke", "DISEASE", 142, 148], ["stroke", "DISEASE", 229, 235], ["stroke", "DISEASE", 374, 380], ["stroke", "DISEASE", 435, 441], ["stroke", "DISEASE", 451, 457], ["Stroke", "DISEASE", 528, 534], ["stroke", "DISEASE", 662, 668], ["Stroke", "DISEASE", 690, 696], ["Stroke", "DISEASE", 874, 880], ["STEMI care", "TREATMENT", 44, 54], ["COVID", "TEST", 91, 96], ["overall hyperacute treatment", "TREATMENT", 197, 225], ["stroke", "PROBLEM", 229, 235], ["this crisis", "PROBLEM", 243, 254], ["stroke care model", "TREATMENT", 451, 468], ["comprehensive stroke care", "TREATMENT", 648, 673], ["STEMI", "OBSERVATION", 44, 49], ["stroke", "OBSERVATION", 229, 235]]], ["Stroke Code, Acute Telestroke Transfer, Inpatient Stroke Rounding, use of Electronic Medical Record (EMR), and telehealth practices were evaluated for the ability to reduce exposure and transmission risk with the anticipation of the COVID-19 pandemic.", [["Stroke", "DISEASE", 0, 6], ["Stroke", "DISEASE", 50, 56], ["the COVID", "TEST", 229, 238], ["pandemic", "PROBLEM", 242, 250], ["Acute", "OBSERVATION_MODIFIER", 13, 18]]], ["Rapid, widely-available testing for COVID-19 was not in place at the time of protocol development.MethodsThe UCSD Stroke Center has provided telestroke services in a hub and spoke model for over 15 years.", [["Stroke", "DISEASE", 114, 120], ["COVID-19", "CHEMICAL", 36, 44], ["COVID", "TEST", 36, 41]]], ["However, the traditional in-person model of response to stroke code activation has previously and preferentially been utilized in our academic CSCs.", [["CSCs", "ANATOMY", 143, 147], ["stroke", "DISEASE", 56, 62], ["CSCs", "CELL", 143, 147], ["academic CSCs", "CELL_LINE", 134, 147], ["stroke code activation", "PROBLEM", 56, 78]]], ["The field of telemedicine has evolved rapidly since the COVID-19 pandemic.", [["the COVID", "TEST", 52, 61], ["pandemic", "PROBLEM", 65, 73]]], ["We are considering every aspect of patient care to reduce transmission and preserve PPE.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["patient care", "TREATMENT", 35, 47]]], ["Within one week of the declared crisis at UCSD, we deployed the use of internal telestroke evaluations in our CSCs.", [["CSCs", "ANATOMY", 110, 114], ["CSCs", "CELL", 110, 114], ["CSCs", "CELL_TYPE", 110, 114], ["internal telestroke evaluations", "TEST", 71, 102], ["crisis", "OBSERVATION", 32, 38]]], ["Emergency Department (ED) Nurses and staff were educated about the telemedicine system and instructed on the COVID-19 adapted stroke code model (Fig 1) via centralized education by the ED nurse management team.", [["stroke", "DISEASE", 126, 132], ["the COVID", "TREATMENT", 105, 114]]], ["Continued education was done with each stroke code activation.", [["stroke", "DISEASE", 39, 45]]], ["Each case is directed by a Stroke Provider, First Responder with Vascular Neurology faculty supervision (see role below).", [["Vascular", "ANATOMY", 65, 73], ["Stroke", "DISEASE", 27, 33], ["Vascular", "ANATOMY", 65, 73]]], ["Our long-standing telemedicine program and expertise allowed for rapid deployment of this modality in our CSC.", [["this modality", "TREATMENT", 85, 98]]], ["Hyperacute telestroke evaluations reduce exposure for clinicians and preserve the scarce supply of PPE.Stroke Code Protocol During COVID-19 Crisis ::: AimsStroke codes continue to follow current UCSD Medical Center Policy (MCP) (Fig 2).", [["Stroke", "DISEASE", 103, 109], ["PPE", "GENE_OR_GENE_PRODUCT", 99, 102], ["Hyperacute telestroke evaluations", "TEST", 0, 33], ["PPE", "PROBLEM", 99, 102], ["PPE", "OBSERVATION", 99, 102]]], ["The adapted UCSD stroke code model (Fig 1) provides for telestroke or in-person assessment if telestroke systems are not available for any reason (e.g. power outage, internet access outage, telestroke software failure, etc.).", [["stroke", "DISEASE", 17, 23], ["telestroke software failure", "PROBLEM", 190, 217]]], ["The use of telestroke allows for rapid, accurate assessment while reducing potential exposure preserving PPE.", [["accurate assessment", "TEST", 40, 59]]], ["Adapted in-person response to stroke code activation is included in the model for systems without access to telemedicine or for technical failures.", [["stroke", "DISEASE", 30, 36], ["stroke code activation", "TREATMENT", 30, 52], ["technical failures", "PROBLEM", 128, 146], ["failures", "OBSERVATION", 138, 146]]], ["For either pathway, one Provider from the UCSD Stroke Team is designated as the Stroke Provider First Responder (SPFR).", [["Stroke", "DISEASE", 47, 53], ["Stroke", "DISEASE", 80, 86]]], ["This is designated in rotation between Faculty Providers, Advanced Practice Providers (APP), Residents, and Vascular Neurology Fellows.", [["Vascular", "ANATOMY", 108, 116]]], ["Current policy restricts medical/nursing students from patient contact.Stroke Code Protocol During COVID-19 Crisis ::: AimsUpon stroke code activation, the SPFR either accesses the telemedicine system and begins the consultation or contacts the bedside provider (inpatient team or Emergency Medicine) via phone if the telemedicine system is not immediately available.", [["Stroke", "DISEASE", 71, 77], ["stroke", "DISEASE", 128, 134], ["patient", "ORGANISM", 55, 62], ["SPFR", "DNA", 156, 160], ["patient", "SPECIES", 55, 62]]], ["The SPFR obtains stroke symptoms, last seen well time, anticoagulation use, blood glucose, and pertinent co-morbidities.", [["blood", "ANATOMY", 76, 81], ["stroke", "DISEASE", 17, 23], ["glucose", "CHEMICAL", 82, 89], ["glucose", "CHEMICAL", 82, 89], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["glucose", "SIMPLE_CHEMICAL", 82, 89], ["stroke symptoms", "PROBLEM", 17, 32], ["blood glucose", "TEST", 76, 89], ["pertinent co-morbidities", "PROBLEM", 95, 119], ["stroke", "OBSERVATION", 17, 23]]], ["In parallel, other team members obtain data from EHR (electronic health record) and other remotely accessible resources.Stroke Code Protocol During COVID-19 Crisis ::: AimsBeginning March 20, 2020, all patients are screened for COVID-19 based on the CDC recommendations (Fig 1).", [["Stroke", "DISEASE", 120, 126], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["COVID", "TREATMENT", 228, 233]]], ["If there is a \u201cyes\u201d answer to any screening question, all stroke code team members are notified that the patient is COVID-19 screen positive per the stroke code paging system.", [["stroke", "DISEASE", 58, 64], ["stroke", "DISEASE", 149, 155], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["COVID", "TEST", 116, 121]]], ["PPE per guidelines (Fig 2) is used prior to any contact with the patient and is based on aerosolization risk.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72]]], ["For in-person management, the SPFR maintains a six foot distance from the patient except for necessary physical examination for acute stroke such as grip strength or sensation exam.", [["stroke", "DISEASE", 134, 140], ["foot", "ORGANISM_SUBDIVISION", 51, 55], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["the SPFR", "TEST", 26, 34], ["necessary physical examination", "TEST", 93, 123], ["acute stroke", "PROBLEM", 128, 140], ["grip strength", "TEST", 149, 162], ["sensation exam", "TEST", 166, 180], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["stroke", "OBSERVATION", 134, 140]]], ["A National Institutes of Health Stroke Scale (NIHSS) and stroke-specific physical exam is performed, as much of this exam can be reliably done from a distance.", [["Stroke", "DISEASE", 32, 38], ["stroke", "DISEASE", 57, 63], ["NIHSS", "TEST", 46, 51], ["stroke", "PROBLEM", 57, 63], ["specific physical exam", "TEST", 64, 86], ["this exam", "TEST", 112, 121]]], ["The patient is taken for brain imaging by the SPFR and bedside nurse in appropriate PPE.", [["brain", "ANATOMY", 25, 30], ["patient", "ORGANISM", 4, 11], ["brain", "ORGAN", 25, 30], ["patient", "SPECIES", 4, 11], ["brain imaging", "TEST", 25, 38]]], ["CT or MRI technicians are alerted as to the COVID- 19 status of the patient so that they may use appropriate PPE per CDC guidelines and implement the appropriate decontamination protocols once the patient leaves the scanner.", [["patient", "ORGANISM", 68, 75], ["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 68, 75], ["patient", "SPECIES", 197, 204], ["CT", "TEST", 0, 2], ["MRI technicians", "TEST", 6, 21], ["the COVID", "TEST", 40, 49], ["the appropriate decontamination protocols", "TREATMENT", 146, 187]]], ["The imaging machines, beds, and any other equipment used are currently cleaned after each patient use with disinfecting bleach wipes.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["The imaging machines", "TREATMENT", 0, 20], ["beds", "TREATMENT", 22, 26], ["any other equipment", "TREATMENT", 32, 51], ["disinfecting bleach wipes", "TREATMENT", 107, 132]]], ["After imaging, the patient returns to where the stroke code originated.", [["stroke", "DISEASE", 48, 54], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["imaging", "TEST", 6, 13], ["stroke", "OBSERVATION", 48, 54]]], ["The SPFR concurrently makes the treatment decision and proceeds per American Stroke Association and internal hospital guidelines.6 In thrombolysis cases, the Pharmacist prepares the bolus and infusion, places the medications no less than six feet away from the patient and has no physical contact with the SPFR, patient, or stroke code Nurse.", [["Stroke", "DISEASE", 77, 83], ["stroke", "DISEASE", 324, 330], ["patient", "ORGANISM", 261, 268], ["patient", "ORGANISM", 312, 319], ["patient", "SPECIES", 261, 268], ["patient", "SPECIES", 312, 319], ["the bolus", "TREATMENT", 178, 187], ["infusion", "TREATMENT", 192, 200], ["the medications", "TREATMENT", 209, 224], ["thrombolysis", "OBSERVATION", 134, 146]]], ["In endovascular treatment, the Endovascular team is informed of COVID-19 status via the stroke code paging system and PPE is used per guidelines (Fig 2).Stroke Code Protocol During COVID-19 Crisis ::: AimsIf all answers are \u201cno\u201d to the COVID-19 screen, stroke code team members are notified of a screen negative patient.", [["stroke", "DISEASE", 88, 94], ["Stroke", "DISEASE", 153, 159], ["stroke", "DISEASE", 253, 259], ["patient", "ORGANISM", 312, 319], ["COVID-19", "DNA", 236, 244], ["patient", "SPECIES", 312, 319], ["endovascular treatment", "TREATMENT", 3, 25], ["COVID", "TEST", 64, 69], ["PPE", "TREATMENT", 118, 121], ["a screen", "TEST", 294, 302], ["endovascular", "OBSERVATION", 3, 15]]], ["Appropriate guidelines are followed related to specific patient presentation and standard precautions.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["standard precautions", "TREATMENT", 81, 101]]], ["Any medications required are handled in the manner described above to avoid potential exposure.Stroke Code Protocol During COVID-19 Crisis ::: AimsAny patient who cannot undergo screening (no ability to access past medical history) is treated as screen positive.7", [["Stroke", "DISEASE", 95, 101], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["Any medications", "TREATMENT", 0, 15], ["screening", "TEST", 178, 187]]]], "PMC7213546": [], "PMC7323516": [["Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically relies on molecular testing of respiratory tract specimens, although viral RNA can be detected in other specimens (1).", [["respiratory tract specimens", "ANATOMY", 115, 142], ["specimens", "ANATOMY", 188, 197], ["acute respiratory syndrome coronavirus", "DISEASE", 20, 58], ["SARS-CoV-2", "ORGANISM", 62, 72], ["respiratory tract specimens", "CANCER", 115, 142], ["viral RNA", "RNA", 153, 162], ["severe acute respiratory syndrome coronavirus", "SPECIES", 13, 58], ["SARS-CoV-2", "SPECIES", 62, 72], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 13, 58], ["SARS-CoV", "TEST", 62, 70], ["molecular testing", "TEST", 94, 111], ["respiratory tract specimens", "PROBLEM", 115, 142], ["viral RNA", "PROBLEM", 153, 162], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46], ["respiratory tract", "ANATOMY", 115, 132]]], ["Real-time reverse transcription PCR (rRT-PCR) protocols have been described for SARS-CoV-2, but most involve testing with multiple, singleplex reactions (2\u20136).", [["SARS-CoV", "SPECIES", 80, 88], ["transcription PCR", "TEST", 18, 35], ["rRT", "TEST", 37, 40], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["multiple, singleplex reactions", "PROBLEM", 122, 152]]], ["Such algorithms use large volumes of reagents and limit laboratory testing capacity, both of which have become crucial during the ongoing coronavirus disease pandemic (7).", [["coronavirus disease pandemic", "DISEASE", 138, 166], ["large volumes of reagents", "TREATMENT", 20, 45], ["laboratory testing capacity", "TEST", 56, 83], ["the ongoing coronavirus disease pandemic", "PROBLEM", 126, 166], ["coronavirus", "OBSERVATION", 138, 149]]], ["Multiplex assays are commercially available (8,9) but require specific platforms and are more expensive than laboratory-developed methods.", [["Multiplex assays", "TEST", 0, 16]]]], "PMC2683903": [["IntroductionIn humans, alphaviruses can cause encephalitis, arthritis, or rash (Calisher, 1994, Laine et al., 2004).", [["alphaviruses", "DISEASE", 23, 35], ["encephalitis", "DISEASE", 46, 58], ["arthritis", "DISEASE", 60, 69], ["rash", "DISEASE", 74, 78], ["humans", "ORGANISM", 15, 21], ["alphaviruses", "ORGANISM", 23, 35], ["humans", "SPECIES", 15, 21], ["humans", "SPECIES", 15, 21], ["IntroductionIn humans", "TREATMENT", 0, 21], ["alphaviruses", "TREATMENT", 23, 35], ["encephalitis", "PROBLEM", 46, 58], ["arthritis", "PROBLEM", 60, 69], ["rash", "PROBLEM", 74, 78], ["encephalitis", "OBSERVATION", 46, 58], ["arthritis", "OBSERVATION", 60, 69]]], ["Sindbis virus (SINV), the prototype alphavirus, causes encephalomyelitis in mice and is a model system for study of the pathogenesis of diseases caused by alphavirus infections.", [["encephalomyelitis", "DISEASE", 55, 72], ["alphavirus infections", "DISEASE", 155, 176], ["Sindbis virus", "ORGANISM", 0, 13], ["SINV", "ORGANISM", 15, 19], ["mice", "ORGANISM", 76, 80], ["alphavirus", "ORGANISM", 155, 165], ["Sindbis virus", "SPECIES", 0, 13], ["mice", "SPECIES", 76, 80], ["Sindbis virus", "SPECIES", 0, 13], ["SINV", "SPECIES", 15, 19], ["mice", "SPECIES", 76, 80], ["Sindbis virus", "PROBLEM", 0, 13], ["the prototype alphavirus", "TREATMENT", 22, 46], ["encephalomyelitis", "PROBLEM", 55, 72], ["diseases", "PROBLEM", 136, 144], ["alphavirus infections", "PROBLEM", 155, 176], ["encephalomyelitis", "OBSERVATION", 55, 72], ["diseases", "OBSERVATION", 136, 144], ["alphavirus infections", "OBSERVATION", 155, 176]]], ["In the nervous system, SINV infection targets neurons, and neuronotropism is determined in part by the glycoproteins E1 and E2 on the virion surface (Lustig et al., 1988).", [["nervous system", "ANATOMY", 7, 21], ["neurons", "ANATOMY", 46, 53], ["virion surface", "ANATOMY", 134, 148], ["infection", "DISEASE", 28, 37], ["nervous system", "ANATOMICAL_SYSTEM", 7, 21], ["SINV", "ORGANISM", 23, 27], ["neurons", "CELL", 46, 53], ["E1", "GENE_OR_GENE_PRODUCT", 117, 119], ["E2", "GENE_OR_GENE_PRODUCT", 124, 126], ["virion surface", "CELLULAR_COMPONENT", 134, 148], ["glycoproteins E1", "PROTEIN", 103, 119], ["E2", "PROTEIN", 124, 126], ["SINV", "SPECIES", 23, 27], ["SINV infection targets neurons", "PROBLEM", 23, 53], ["neuronotropism", "TEST", 59, 73], ["nervous system", "ANATOMY", 7, 21], ["SINV", "OBSERVATION_MODIFIER", 23, 27], ["infection", "OBSERVATION", 28, 37]]], ["The outcome of infection depends on SINV neurovirulence and on host factors, including age and genetic background (Thach et al., 2000, Johnson et al., 1972).", [["infection", "DISEASE", 15, 24], ["SINV", "ORGANISM", 36, 40], ["SINV", "SPECIES", 36, 40], ["infection", "PROBLEM", 15, 24], ["SINV neurovirulence", "PROBLEM", 36, 55], ["infection", "OBSERVATION", 15, 24]]], ["Age-dependent susceptibility is a characteristic of alphavirus encephalitis and is due to intrinsic properties of neurons, not differences in the immune response (Fazakerley et al., 1993, Griffin, 1976).", [["neurons", "ANATOMY", 114, 121], ["alphavirus encephalitis", "DISEASE", 52, 75], ["alphavirus encephalitis", "ORGANISM", 52, 75], ["neurons", "CELL", 114, 121], ["Age-dependent susceptibility", "PROBLEM", 0, 28], ["alphavirus encephalitis", "PROBLEM", 52, 75], ["intrinsic properties of neurons", "PROBLEM", 90, 121], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["susceptibility", "OBSERVATION", 14, 28], ["characteristic of", "UNCERTAINTY", 34, 51], ["alphavirus", "OBSERVATION_MODIFIER", 52, 62], ["encephalitis", "OBSERVATION", 63, 75], ["neurons", "ANATOMY", 114, 121]]], ["Newborn mice develop fatal disease, while adult mice survive infection.", [["infection", "DISEASE", 61, 70], ["Newborn", "ORGANISM", 0, 7], ["mice", "ORGANISM", 8, 12], ["mice", "ORGANISM", 48, 52], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 48, 52], ["fatal disease", "PROBLEM", 21, 34], ["fatal disease", "OBSERVATION", 21, 34], ["infection", "OBSERVATION", 61, 70]]], ["Likewise, undifferentiated neurons replicate SINV to higher titer in vitro and are more susceptible to SINV-induced cell death than differentiated neurons (Vernon and Griffin, 2005, Burdeinick-Kerr and Griffin, 2005).IntroductionSINV is enveloped and has a single positive-strand RNA genome of 11.7 kb.", [["undifferentiated neurons", "ANATOMY", 10, 34], ["cell", "ANATOMY", 116, 120], ["neurons", "ANATOMY", 147, 154], ["death", "DISEASE", 121, 126], ["undifferentiated neurons", "CELL", 10, 34], ["SINV", "ORGANISM", 45, 49], ["SINV", "ORGANISM", 103, 107], ["cell", "CELL", 116, 120], ["neurons", "CELL", 147, 154], ["undifferentiated neurons", "CELL_TYPE", 10, 34], ["differentiated neurons", "CELL_TYPE", 132, 154], ["positive-strand RNA genome", "DNA", 264, 290], ["SINV", "SPECIES", 45, 49], ["SINV", "SPECIES", 103, 107], ["SINV-induced cell death", "PROBLEM", 103, 126]]], ["The 3\u2032-terminal one-third of the genome encodes structural proteins, and the 5\u2032-terminal two-thirds of the genome encodes nonstructural proteins (nsPs) as polyproteins (P123, P1234).", [["genome", "CELLULAR_COMPONENT", 33, 39], ["genome", "CELLULAR_COMPONENT", 107, 113], ["nsPs", "GENE_OR_GENE_PRODUCT", 146, 150], ["3\u2032-terminal one-third", "DNA", 4, 25], ["structural proteins", "PROTEIN", 48, 67], ["5\u2032", "PROTEIN", 77, 79], ["nonstructural proteins", "PROTEIN", 122, 144], ["nsPs", "PROTEIN", 146, 150], ["polyproteins", "PROTEIN", 155, 167], ["P123", "PROTEIN", 169, 173], ["P1234", "PROTEIN", 175, 180], ["polyproteins", "TEST", 155, 167], ["structural proteins", "OBSERVATION", 48, 67], ["nonstructural proteins", "OBSERVATION", 122, 144]]], ["The nonstructural polyproteins are processed into four nsPs that form replication complexes in which the polyproteins and individual nsPs play different roles in virus replication.", [["nsPs", "GENE_OR_GENE_PRODUCT", 55, 59], ["nsPs", "GENE_OR_GENE_PRODUCT", 133, 137], ["nonstructural polyproteins", "PROTEIN", 4, 30], ["nsPs", "PROTEIN", 55, 59], ["replication complexes", "PROTEIN", 70, 91], ["polyproteins", "PROTEIN", 105, 117], ["nsPs", "PROTEIN", 133, 137], ["The nonstructural polyproteins", "PROBLEM", 0, 30], ["replication complexes", "PROBLEM", 70, 91], ["the polyproteins", "PROBLEM", 101, 117], ["virus replication", "TREATMENT", 162, 179], ["nonstructural polyproteins", "OBSERVATION", 4, 30], ["four", "OBSERVATION_MODIFIER", 50, 54], ["nsPs", "OBSERVATION_MODIFIER", 55, 59], ["replication complexes", "OBSERVATION", 70, 91], ["virus replication", "OBSERVATION", 162, 179]]], ["The replication complexes containing polyproteins synthesize negative-strand RNA and after the polyproteins are cleaved into individual nsPs, synthesize positive-strand RNA (Strauss and Strauss, 1994). nsP1 has guanine-7-methyltransferase and guanyltransferase activities and plays a role in capping viral RNAs (Mi et al., 1989, Scheidel et al., 1987). nsP2 has protease activity and cleaves nonstructural polyproteins (Ding and Schlesinger, 1989, Hardy and Strauss, 1989), and also exhibits RNA helicase and 5\u2032 triphosphatase activities (Gomez et al., 1999, Vasiljeva et al., 2000). nsP4 is the RNA-dependent RNA polymerase (Kamer and Argos, 1984).IntroductionThe function of nsP3 is least understood. nsP3 mutants generated from random insertion and chemical mutagenesis show reduced minus strand and subgenomic RNA synthesis (LaStarza et al., 1994b, De et al., 2003). nsP3 also interacts with cellular proteins, which are presumed to participate in the formation and/or function of viral replication complexes (Cristea et al., 2006, Frolova et al., 2006, Gorchakov et al., 2008).", [["cellular", "ANATOMY", 896, 904], ["nsP1", "CHEMICAL", 202, 206], ["guanine", "CHEMICAL", 211, 218], ["nsP2", "CHEMICAL", 353, 357], ["nsP4", "CHEMICAL", 584, 588], ["nsP3", "CHEMICAL", 871, 875], ["guanine", "CHEMICAL", 211, 218], ["nsPs", "GENE_OR_GENE_PRODUCT", 136, 140], ["nsP1", "GENE_OR_GENE_PRODUCT", 202, 206], ["guanine-7-methyltransferase", "GENE_OR_GENE_PRODUCT", 211, 238], ["guanyltransferase", "GENE_OR_GENE_PRODUCT", 243, 260], ["nsP2", "GENE_OR_GENE_PRODUCT", 353, 357], ["5\u2032 triphosphatase", "GENE_OR_GENE_PRODUCT", 509, 526], ["nsP4", "GENE_OR_GENE_PRODUCT", 584, 588], ["nsP3", "GENE_OR_GENE_PRODUCT", 677, 681], ["nsP3", "GENE_OR_GENE_PRODUCT", 703, 707], ["nsP3", "GENE_OR_GENE_PRODUCT", 871, 875], ["cellular", "CELL", 896, 904], ["replication complexes", "PROTEIN", 4, 25], ["polyproteins", "PROTEIN", 37, 49], ["negative-strand RNA", "RNA", 61, 80], ["nsPs", "PROTEIN", 136, 140], ["nsP1", "PROTEIN", 202, 206], ["guanine-7-methyltransferase", "PROTEIN", 211, 238], ["guanyltransferase", "PROTEIN", 243, 260], ["nsP2", "PROTEIN", 353, 357], ["protease", "PROTEIN", 362, 370], ["RNA helicase and 5\u2032 triphosphatase", "PROTEIN", 492, 526], ["nsP4", "DNA", 584, 588], ["RNA-dependent RNA polymerase", "PROTEIN", 596, 624], ["nsP3", "PROTEIN", 677, 681], ["nsP3 mutants", "PROTEIN", 703, 715], ["subgenomic RNA", "RNA", 803, 817], ["nsP3", "PROTEIN", 871, 875], ["cellular proteins", "PROTEIN", 896, 913], ["viral replication complexes", "PROTEIN", 985, 1012], ["The replication complexes", "TREATMENT", 0, 25], ["polyproteins synthesize", "TEST", 37, 60], ["strand RNA", "PROBLEM", 70, 80], ["the polyproteins", "PROBLEM", 91, 107], ["nsP1", "TEST", 202, 206], ["guanine", "TEST", 211, 218], ["methyltransferase and guanyltransferase activities", "TREATMENT", 221, 271], ["nsP2", "PROBLEM", 353, 357], ["protease activity", "TREATMENT", 362, 379], ["RNA helicase", "TREATMENT", 492, 504], ["nsP4", "PROBLEM", 584, 588], ["the RNA", "TEST", 592, 599], ["nsP3 mutants", "PROBLEM", 703, 715], ["random insertion", "TREATMENT", 731, 747], ["chemical mutagenesis", "TEST", 752, 772], ["reduced minus strand and subgenomic RNA synthesis", "PROBLEM", 778, 827], ["nsP3", "PROBLEM", 871, 875], ["cellular proteins", "PROBLEM", 896, 913], ["negative", "OBSERVATION_MODIFIER", 61, 69], ["strand RNA", "OBSERVATION_MODIFIER", 70, 80], ["strand RNA", "OBSERVATION_MODIFIER", 162, 172], ["viral RNAs", "OBSERVATION", 300, 310], ["dependent", "OBSERVATION_MODIFIER", 600, 609], ["RNA polymerase", "OBSERVATION", 610, 624], ["reduced", "OBSERVATION_MODIFIER", 778, 785], ["minus strand", "OBSERVATION", 786, 798], ["subgenomic RNA synthesis", "OBSERVATION", 803, 827], ["cellular proteins", "OBSERVATION", 896, 913], ["presumed to", "UNCERTAINTY", 925, 936], ["viral replication", "OBSERVATION", 985, 1002]]], ["However, data supporting an essential role for nsP3 is limited and it has little homology with other nsPs of positive-strand RNA viruses (Ahlquist et al., 1985, Haseloff et al., 1984, LaStarza et al., 1994a).", [["nsP3", "GENE_OR_GENE_PRODUCT", 47, 51], ["nsPs", "GENE_OR_GENE_PRODUCT", 101, 105], ["nsP3", "PROTEIN", 47, 51], ["nsPs", "PROTEIN", 101, 105], ["nsP3", "PROBLEM", 47, 51]]], ["The C-terminal domain is highly variable even in alphaviruses and is heavily phosphorylated at serine/threonine (Li et al., 1990).", [["threonine", "CHEMICAL", 102, 111], ["serine", "CHEMICAL", 95, 101], ["threonine", "CHEMICAL", 102, 111], ["serine", "AMINO_ACID", 95, 101], ["threonine", "AMINO_ACID", 102, 111], ["C-terminal domain", "PROTEIN", 4, 21], ["The C-terminal domain", "PROBLEM", 0, 21], ["alphaviruses", "PROBLEM", 49, 61], ["highly", "OBSERVATION_MODIFIER", 25, 31], ["variable", "OBSERVATION_MODIFIER", 32, 40], ["alphaviruses", "OBSERVATION", 49, 61]]], ["The phosphorylated C-terminal region is not essential for SINV replication, but nsP3 phosphorylation may play a host cell-dependent role in SINV minus strand RNA synthesis (De et al., 2003, LaStarza et al., 1994a).IntroductionUnlike the C-terminus, the N-terminal region of nsP3 is well conserved among alphaviruses.", [["cell", "ANATOMY", 117, 121], ["C", "CHEMICAL", 19, 20], ["C", "CHEMICAL", 237, 238], ["N", "CHEMICAL", 253, 254], ["SINV", "ORGANISM", 58, 62], ["nsP3", "GENE_OR_GENE_PRODUCT", 80, 84], ["cell", "CELL", 117, 121], ["SINV", "ORGANISM", 140, 144], ["C-terminus", "GENE_OR_GENE_PRODUCT", 237, 247], ["nsP3", "GENE_OR_GENE_PRODUCT", 274, 278], ["phosphorylated C-terminal region", "DNA", 4, 36], ["nsP3", "PROTEIN", 80, 84], ["C-terminus", "PROTEIN", 237, 247], ["N-terminal region", "PROTEIN", 253, 270], ["nsP3", "PROTEIN", 274, 278], ["SINV", "SPECIES", 58, 62], ["SINV", "SPECIES", 140, 144], ["The phosphorylated C-terminal region", "PROBLEM", 0, 36], ["SINV replication", "TREATMENT", 58, 74], ["nsP3 phosphorylation", "TREATMENT", 80, 100], ["the C-terminus", "TREATMENT", 233, 247], ["the N-terminal region of nsP3", "PROBLEM", 249, 278], ["terminal", "ANATOMY_MODIFIER", 21, 29], ["not essential for", "UNCERTAINTY", 40, 57], ["SINV replication", "OBSERVATION", 58, 74], ["host cell", "OBSERVATION_MODIFIER", 112, 121], ["nsP3", "OBSERVATION", 274, 278]]], ["The N-terminal 150 amino acids of nsP3 was first recognized as a domain of unknown function (X domain) (Gorbalenya et al., 1991, Koonin et al., 1992) and later identified as a macro domain based on homology to the nonhistone region of histone macroH2A (Pehrson and Fried, 1992, Pehrson and Fuji, 1998).", [["amino acids", "CHEMICAL", 19, 30], ["amino acids", "CHEMICAL", 19, 30], ["amino acids", "AMINO_ACID", 19, 30], ["nsP3", "GENE_OR_GENE_PRODUCT", 34, 38], ["histone macroH2A", "GENE_OR_GENE_PRODUCT", 235, 251], ["N-terminal 150 amino acids", "PROTEIN", 4, 30], ["nsP3", "PROTEIN", 34, 38], ["X domain", "PROTEIN", 93, 101], ["macro domain", "PROTEIN", 176, 188], ["nonhistone region", "PROTEIN", 214, 231], ["histone macroH2A", "PROTEIN", 235, 251], ["The N-terminal 150 amino acids of nsP3", "TREATMENT", 0, 38], ["a macro domain", "PROBLEM", 174, 188], ["histone macroH2A", "OBSERVATION", 235, 251]]], ["Macro domains are ancient and widely distributed throughout all eukaryotic organisms, bacteria, and archaea, indicating a ubiquitous and important basic biological function.", [["Macro domains", "PROBLEM", 0, 13], ["bacteria", "PROBLEM", 86, 94], ["archaea", "PROBLEM", 100, 107], ["widely", "OBSERVATION_MODIFIER", 30, 36], ["eukaryotic organisms", "OBSERVATION", 64, 84], ["bacteria", "OBSERVATION_MODIFIER", 86, 94]]], ["Macro domains are also found in nsPs of several positive-strand RNA viruses, including hepatitis E virus, rubella virus and coronaviruses, as well as alphaviruses (Gorbalenya et al., 1991, Koonin et al., 1992, Liang et al., 2000).IntroductionDespite the wide distribution and evolutionary conservation of macro domains, the physiological role is not known.", [["hepatitis E", "DISEASE", 87, 98], ["rubella virus and coronaviruses", "DISEASE", 106, 137], ["hepatitis E virus", "ORGANISM", 87, 104], ["rubella virus", "ORGANISM", 106, 119], ["coronaviruses", "ORGANISM", 124, 137], ["nsPs", "PROTEIN", 32, 36], ["macro domains", "PROTEIN", 305, 318], ["hepatitis E virus", "SPECIES", 87, 104], ["rubella virus", "SPECIES", 106, 119], ["hepatitis E virus", "SPECIES", 87, 104], ["rubella virus", "SPECIES", 106, 119], ["Macro domains", "PROBLEM", 0, 13], ["strand RNA viruses", "PROBLEM", 57, 75], ["hepatitis E virus", "PROBLEM", 87, 104], ["rubella virus", "PROBLEM", 106, 119], ["coronaviruses", "PROBLEM", 124, 137], ["macro domains", "PROBLEM", 305, 318], ["several", "OBSERVATION_MODIFIER", 40, 47], ["positive", "OBSERVATION", 48, 56], ["strand RNA viruses", "OBSERVATION", 57, 75], ["rubella virus", "OBSERVATION", 106, 119], ["wide", "OBSERVATION_MODIFIER", 254, 258], ["distribution", "OBSERVATION_MODIFIER", 259, 271], ["evolutionary conservation", "OBSERVATION", 276, 301], ["macro domains", "OBSERVATION", 305, 318]]], ["MacroH2A, the protein with the best studied macro domain, is enriched in heterochromatin and is involved in regional chromatin silencing and cell-type specific regulation of transcription (Changolkar et al., 2008, Ladurner, 2003, Nusinow et al., 2007, Agelopoulos and Thanos, 2006).", [["heterochromatin", "ANATOMY", 73, 88], ["chromatin", "ANATOMY", 117, 126], ["cell", "ANATOMY", 141, 145], ["MacroH2A", "GENE_OR_GENE_PRODUCT", 0, 8], ["heterochromatin", "CELLULAR_COMPONENT", 73, 88], ["chromatin", "CELLULAR_COMPONENT", 117, 126], ["cell", "CELL", 141, 145], ["MacroH2A", "PROTEIN", 0, 8], ["macro domain", "PROTEIN", 44, 56], ["chromatin", "DNA", 117, 126], ["the protein", "TEST", 10, 21], ["heterochromatin", "OBSERVATION", 73, 88], ["chromatin silencing", "OBSERVATION", 117, 136]]], ["These properties are associated with the nonhistone macro domain which interacts with histone deacetylases and poly(ADP-ribose) polymerase (PARP) to inhibit histone acetylation and nucleosome remodeling and repress initiation of transcription (Chakravarthy et al., 2005, Agelopoulos and Thanos, 2006).", [["nucleosome", "ANATOMY", 181, 191], ["poly(ADP-ribose", "CHEMICAL", 111, 126], ["poly(ADP-ribose)", "CHEMICAL", 111, 127], ["histone deacetylases", "GENE_OR_GENE_PRODUCT", 86, 106], ["poly(ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 111, 138], ["PARP", "GENE_OR_GENE_PRODUCT", 140, 144], ["histone acetylation", "GENE_OR_GENE_PRODUCT", 157, 176], ["nucleosome", "CELLULAR_COMPONENT", 181, 191], ["nonhistone macro domain", "PROTEIN", 41, 64], ["histone deacetylases", "PROTEIN", 86, 106], ["poly(ADP-ribose) polymerase", "PROTEIN", 111, 138], ["PARP", "PROTEIN", 140, 144], ["histone", "PROTEIN", 157, 164], ["the nonhistone macro domain", "PROBLEM", 37, 64], ["histone deacetylases", "TREATMENT", 86, 106], ["poly(ADP-ribose) polymerase (PARP)", "TREATMENT", 111, 145], ["histone acetylation", "TREATMENT", 157, 176], ["nucleosome remodeling", "TREATMENT", 181, 202], ["nucleosome remodeling", "OBSERVATION", 181, 202]]], ["In addition, macro domains of yeast, severe acute respiratory syndrome (SARS) coronavirus and hepatitis E virus proteins exhibit ADP-ribose-1\u2033 phosphatase activity in vitro (Martzen et al., 1999, Saikatendu et al., 2005).", [["acute respiratory syndrome (SARS) coronavirus and hepatitis E", "DISEASE", 44, 105], ["ADP", "CHEMICAL", 129, 132], ["ADP", "CHEMICAL", 129, 132], ["ribose", "CHEMICAL", 133, 139], ["severe acute respiratory", "ORGANISM", 37, 61], ["hepatitis E virus", "ORGANISM", 94, 111], ["ADP-ribose-1\u2033 phosphatase", "GENE_OR_GENE_PRODUCT", 129, 154], ["macro domains", "PROTEIN", 13, 26], ["hepatitis E virus proteins", "PROTEIN", 94, 120], ["yeast", "SPECIES", 30, 35], ["coronavirus", "SPECIES", 78, 89], ["hepatitis E virus", "SPECIES", 94, 111], ["yeast", "SPECIES", 30, 35], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 37, 89], ["hepatitis E virus", "SPECIES", 94, 111], ["macro domains of yeast", "PROBLEM", 13, 35], ["severe acute respiratory syndrome", "PROBLEM", 37, 70], ["SARS", "PROBLEM", 72, 76], ["coronavirus", "PROBLEM", 78, 89], ["hepatitis E virus proteins", "TEST", 94, 120], ["ADP", "TEST", 129, 132], ["ribose", "TEST", 133, 139], ["yeast", "OBSERVATION", 30, 35], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["respiratory syndrome", "OBSERVATION", 50, 70]]], ["This enzymatic activity is dispensable for coronavirus replication, but appears to play a role in the pathogenesis of mouse hepatitis virus infection (Eriksson et al., 2008, Putics et al., 2005).", [["mouse hepatitis virus infection", "DISEASE", 118, 149], ["coronavirus", "ORGANISM", 43, 54], ["mouse hepatitis virus", "ORGANISM", 118, 139], ["mouse", "SPECIES", 118, 123], ["hepatitis virus", "SPECIES", 124, 139], ["coronavirus", "SPECIES", 43, 54], ["mouse hepatitis virus", "SPECIES", 118, 139], ["This enzymatic activity", "PROBLEM", 0, 23], ["coronavirus replication", "PROBLEM", 43, 66], ["mouse hepatitis virus infection", "PROBLEM", 118, 149]]], ["The role of macro domains in other proteins is less clear (Chakravarthy et al., 2005).IntroductionMany macro domains can bind various forms of ADP-ribose, such as mono ADP-ribose, poly(ADP-ribose) (PAR), poly(A) and the SirT1 metabolite O-acetyl-ADP-ribose (OAADPR) (Comstock and Denu, 2007, Egloff et al., 2006, Karras et al., 2005, Kustatscher et al., 2005).", [["ADP", "CHEMICAL", 143, 146], ["ribose", "CHEMICAL", 147, 153], ["ADP", "CHEMICAL", 168, 171], ["poly(ADP-ribose", "CHEMICAL", 180, 195], ["O-acetyl-ADP-ribose", "CHEMICAL", 237, 256], ["ADP", "CHEMICAL", 143, 146], ["ribose", "CHEMICAL", 147, 153], ["ADP", "CHEMICAL", 168, 171], ["ribose", "CHEMICAL", 172, 178], ["poly(ADP-ribose)", "CHEMICAL", 180, 196], ["PAR", "CHEMICAL", 198, 201], ["poly(A)", "CHEMICAL", 204, 211], ["O-acetyl-ADP-ribose", "CHEMICAL", 237, 256], ["OAADPR", "CHEMICAL", 258, 264], ["ADP-ribose", "SIMPLE_CHEMICAL", 143, 153], ["mono ADP-ribose", "SIMPLE_CHEMICAL", 163, 178], ["poly(ADP-ribose)", "SIMPLE_CHEMICAL", 180, 196], ["PAR", "SIMPLE_CHEMICAL", 198, 201], ["poly(A", "SIMPLE_CHEMICAL", 204, 210], ["SirT1", "GENE_OR_GENE_PRODUCT", 220, 225], ["O-acetyl-ADP-ribose", "SIMPLE_CHEMICAL", 237, 256], ["OAADPR", "SIMPLE_CHEMICAL", 258, 264], ["macro domains", "PROTEIN", 12, 25], ["macro domains in other proteins", "PROBLEM", 12, 43], ["ADP", "TEST", 143, 146], ["ribose", "TREATMENT", 147, 153], ["mono ADP", "TEST", 163, 171], ["ribose, poly(ADP-ribose)", "TREATMENT", 172, 196], ["the SirT1 metabolite O-acetyl", "TEST", 216, 245], ["ADP-ribose (OAADPR)", "TREATMENT", 246, 265], ["less", "OBSERVATION_MODIFIER", 47, 51], ["clear", "OBSERVATION", 52, 57]]], ["However, individual eukaryotic and viral protein macro domains vary in the forms of ADP-ribose bound and in the affinity of binding (Neuvonen and Ahola, 2009).", [["ADP", "CHEMICAL", 84, 87], ["ribose", "CHEMICAL", 88, 94], ["ADP", "CHEMICAL", 84, 87], ["ribose", "CHEMICAL", 88, 94], ["ADP", "SIMPLE_CHEMICAL", 84, 87], ["eukaryotic and viral protein macro domains", "PROTEIN", 20, 62], ["individual eukaryotic and viral protein macro domains", "PROBLEM", 9, 62], ["ADP", "TEST", 84, 87], ["ribose bound", "PROBLEM", 88, 100], ["viral protein", "OBSERVATION", 35, 48], ["ribose bound", "OBSERVATION", 88, 100]]], ["The macro domain of macroH2A binds OAADPR, but not PAR (Kustatscher et al., 2005, Comstock and Denu, 2007).", [["macroH2A", "GENE_OR_GENE_PRODUCT", 20, 28], ["OAADPR", "GENE_OR_GENE_PRODUCT", 35, 41], ["macro domain", "PROTEIN", 4, 16], ["macroH2A", "PROTEIN", 20, 28], ["OAADPR", "PROTEIN", 35, 41], ["PAR", "PROTEIN", 51, 54]]], ["The macro domain of Semliki Forest virus (SFV) binds PAR well, but monomeric ADP-ribose only poorly (Neuvonen and Ahola, 2009).", [["ADP-ribose", "CHEMICAL", 77, 87], ["ADP", "CHEMICAL", 77, 80], ["ribose", "CHEMICAL", 81, 87], ["Semliki Forest virus", "ORGANISM", 20, 40], ["SFV", "ORGANISM", 42, 45], ["PAR", "GENE_OR_GENE_PRODUCT", 53, 56], ["ADP-ribose", "SIMPLE_CHEMICAL", 77, 87], ["PAR", "PROTEIN", 53, 56], ["Semliki Forest virus", "SPECIES", 20, 40], ["Semliki Forest virus", "SPECIES", 20, 40], ["SFV", "SPECIES", 42, 45], ["Semliki Forest virus", "TREATMENT", 20, 40], ["Semliki Forest virus", "OBSERVATION", 20, 40]]], ["The significance of these different interactions remains unknown.IntroductionTo improve understanding of the function and importance of the nsP3 macro domain in alphavirus encephalitis, we have generated mutations in the putative ADP-ribose binding site.", [["alphavirus encephalitis", "DISEASE", 161, 184], ["ADP", "CHEMICAL", 230, 233], ["ribose", "CHEMICAL", 234, 240], ["ADP", "CHEMICAL", 230, 233], ["ribose", "CHEMICAL", 234, 240], ["nsP3", "GENE_OR_GENE_PRODUCT", 140, 144], ["alphavirus encephalitis", "ORGANISM", 161, 184], ["ADP", "SIMPLE_CHEMICAL", 230, 233], ["nsP3 macro domain", "PROTEIN", 140, 157], ["putative ADP-ribose binding site", "PROTEIN", 221, 253], ["the nsP3 macro domain", "PROBLEM", 136, 157], ["alphavirus encephalitis", "PROBLEM", 161, 184], ["generated mutations", "PROBLEM", 194, 213], ["alphavirus encephalitis", "OBSERVATION", 161, 184], ["ribose binding", "OBSERVATION", 234, 248]]], ["We characterized phenotypes of the mutants and revertants that appeared during replication.", [["the mutants and revertants", "PROBLEM", 31, 57]]], ["We also assessed the effect of mutations on SINV replication in neurons, synthesis of viral RNAs, and expression of viral proteins.", [["neurons", "ANATOMY", 64, 71], ["SINV", "ORGANISM", 44, 48], ["neurons", "CELL", 64, 71], ["neurons", "CELL_TYPE", 64, 71], ["viral RNAs", "RNA", 86, 96], ["viral proteins", "PROTEIN", 116, 130], ["SINV", "SPECIES", 44, 48], ["mutations", "PROBLEM", 31, 40], ["SINV replication", "TREATMENT", 44, 60], ["viral RNAs", "PROBLEM", 86, 96], ["viral proteins", "PROBLEM", 116, 130], ["viral RNAs", "OBSERVATION", 86, 96], ["viral proteins", "OBSERVATION", 116, 130]]], ["Finally, we determined the effect of mutations on SINV virulence in mice at different maturation stages as well as on replication in undifferentiated and differentiated neuronal cell lines.Mutations in the predicted ADP-ribose binding site in the nsP3 macro domain do not affect PAR binding, but do affect SINV replication ::: ResultsModeling of nsP3 against a macro domain protein from Archaeoglobus fulgidus (Fig. 1A) predicted that asparagines at amino acids 10 and 24 of nsP3 are at corresponding positions to the two amino acids in close contact with ADP-ribose in A. fulgidus (Fig. 1B) (10).", [["neuronal cell lines", "ANATOMY", 169, 188], ["ADP", "CHEMICAL", 216, 219], ["ribose", "CHEMICAL", 220, 226], ["asparagines", "CHEMICAL", 435, 446], ["amino acids 10 and 24 of nsP3", "CHEMICAL", 450, 479], ["amino acids", "CHEMICAL", 522, 533], ["ADP-ribose", "CHEMICAL", 556, 566], ["ADP", "CHEMICAL", 216, 219], ["ribose", "CHEMICAL", 220, 226], ["asparagines", "CHEMICAL", 435, 446], ["amino acids", "CHEMICAL", 450, 461], ["amino acids", "CHEMICAL", 522, 533], ["ADP", "CHEMICAL", 556, 559], ["ribose", "CHEMICAL", 560, 566], ["SINV", "ORGANISM", 50, 54], ["mice", "ORGANISM", 68, 72], ["neuronal cell lines", "CELL", 169, 188], ["ADP", "SIMPLE_CHEMICAL", 216, 219], ["PAR", "GENE_OR_GENE_PRODUCT", 279, 282], ["SINV", "ORGANISM", 306, 310], ["nsP3", "GENE_OR_GENE_PRODUCT", 346, 350], ["Archaeoglobus fulgidus", "ORGANISM", 387, 409], ["Fig. 1A", "ORGANISM", 411, 418], ["asparagines", "SIMPLE_CHEMICAL", 435, 446], ["amino acids", "AMINO_ACID", 450, 461], ["nsP3", "GENE_OR_GENE_PRODUCT", 475, 479], ["amino acids", "AMINO_ACID", 522, 533], ["ADP-ribose", "SIMPLE_CHEMICAL", 556, 566], ["A. fulgidus", "ORGANISM", 570, 581], ["Fig. 1B", "ORGANISM", 583, 590], ["differentiated neuronal cell lines", "CELL_LINE", 154, 188], ["ADP-ribose binding site", "DNA", 216, 239], ["nsP3 macro domain", "PROTEIN", 247, 264], ["PAR", "PROTEIN", 279, 282], ["nsP3", "PROTEIN", 346, 350], ["macro domain protein", "PROTEIN", 361, 381], ["nsP3", "PROTEIN", 475, 479], ["mice", "SPECIES", 68, 72], ["Archaeoglobus fulgidus", "SPECIES", 387, 409], ["A. fulgidus", "SPECIES", 570, 581], ["SINV", "SPECIES", 50, 54], ["mice", "SPECIES", 68, 72], ["SINV", "SPECIES", 306, 310], ["Archaeoglobus fulgidus", "SPECIES", 387, 409], ["A. fulgidus", "SPECIES", 570, 581], ["mutations", "PROBLEM", 37, 46], ["SINV virulence", "TREATMENT", 50, 64], ["Mutations", "PROBLEM", 189, 198], ["ribose binding site", "PROBLEM", 220, 239], ["nsP3", "PROBLEM", 346, 350], ["a macro domain protein", "TEST", 359, 381], ["Archaeoglobus fulgidus", "PROBLEM", 387, 409], ["amino acids", "TEST", 450, 461], ["nsP3", "PROBLEM", 475, 479], ["amino acids", "TEST", 522, 533], ["ADP", "TEST", 556, 559], ["ribose in A. fulgidus", "TEST", 560, 581], ["differentiated neuronal cell lines", "OBSERVATION", 154, 188], ["ribose binding", "OBSERVATION", 220, 234], ["Archaeoglobus fulgidus", "OBSERVATION", 387, 409]]], ["These asparagines were changed to alanines to generate SINV with a double mutation (SINV DM) or with single mutations at amino acid 10 (SINV SM10) or 24 (SINV SM24) (Fig. 1C).", [["asparagines", "CHEMICAL", 6, 17], ["amino acid", "CHEMICAL", 121, 131], ["asparagines", "CHEMICAL", 6, 17], ["alanines", "CHEMICAL", 34, 42], ["amino acid", "CHEMICAL", 121, 131], ["asparagines", "GENE_OR_GENE_PRODUCT", 6, 17], ["SINV", "ORGANISM", 55, 59], ["amino acid", "AMINO_ACID", 121, 131], ["SINV", "SPECIES", 55, 59], ["SINV", "SPECIES", 154, 158], ["These asparagines", "TREATMENT", 0, 17], ["alanines", "TREATMENT", 34, 42], ["SINV", "TREATMENT", 55, 59], ["a double mutation (SINV DM)", "TREATMENT", 65, 92], ["single mutations at amino acid", "TREATMENT", 101, 131], ["SINV SM10)", "TREATMENT", 136, 146]]], ["To assess the effect of these mutations on PAR binding, his-tagged WT and mutant proteins were tested for interaction with PAR at different concentrations (Fig. 1D).", [["PAR", "GENE_OR_GENE_PRODUCT", 43, 46], ["PAR", "GENE_OR_GENE_PRODUCT", 123, 126], ["PAR", "PROTEIN", 43, 46], ["his-tagged WT", "PROTEIN", 56, 69], ["mutant proteins", "PROTEIN", 74, 89], ["PAR", "PROTEIN", 123, 126], ["these mutations", "PROBLEM", 24, 39], ["PAR binding", "PROBLEM", 43, 54], ["mutant proteins", "PROBLEM", 74, 89]]], ["The mutations had no effect on binding of PAR.Mutations in the predicted ADP-ribose binding site in the nsP3 macro domain do not affect PAR binding, but do affect SINV replication ::: ResultsTo assess the potential importance of the amino acids at these positions for SINV replication, undifferentiated (Fig. 2A) and differentiated (Fig. 2B) CSM14.1 cells were infected with SINV WT, SM10, SM24, or DM.", [["Fig. 2B) CSM14.1 cells", "ANATOMY", 333, 355], ["ADP", "CHEMICAL", 73, 76], ["ribose", "CHEMICAL", 77, 83], ["amino acids", "CHEMICAL", 233, 244], ["ADP", "CHEMICAL", 73, 76], ["ribose", "CHEMICAL", 77, 83], ["amino acids", "CHEMICAL", 233, 244], ["PAR", "GENE_OR_GENE_PRODUCT", 42, 45], ["ADP", "SIMPLE_CHEMICAL", 73, 76], ["PAR", "GENE_OR_GENE_PRODUCT", 136, 139], ["SINV", "ORGANISM", 163, 167], ["amino acids", "AMINO_ACID", 233, 244], ["Fig. 2A", "CELL", 304, 311], ["Fig. 2B) CSM14.1 cells", "CELL", 333, 355], ["SINV", "ORGANISM", 375, 379], ["SM24", "GENE_OR_GENE_PRODUCT", 390, 394], ["PAR", "PROTEIN", 42, 45], ["ADP-ribose binding site", "DNA", 73, 96], ["nsP3 macro domain", "PROTEIN", 104, 121], ["PAR", "PROTEIN", 136, 139], ["CSM14.1 cells", "CELL_LINE", 342, 355], ["SINV", "SPECIES", 163, 167], ["SINV", "SPECIES", 268, 272], ["SINV", "SPECIES", 375, 379], ["The mutations", "PROBLEM", 0, 13], ["Mutations", "PROBLEM", 46, 55], ["ribose binding site", "PROBLEM", 77, 96], ["the amino acids", "TREATMENT", 229, 244], ["SINV replication", "TREATMENT", 268, 284], ["CSM", "TEST", 342, 345], ["SINV WT", "TEST", 375, 382], ["DM", "PROBLEM", 399, 401], ["ribose binding", "OBSERVATION", 77, 91]]], ["In differentiated CSM14.1 cells, the replication of SINV SM10 and DM was impaired at early times after infection (P< 0.01 before 24 h).", [["CSM14.1 cells", "ANATOMY", 18, 31], ["infection", "DISEASE", 103, 112], ["CSM14.1 cells", "CELL", 18, 31], ["SINV", "ORGANISM", 52, 56], ["SM10", "GENE_OR_GENE_PRODUCT", 57, 61], ["CSM14.1 cells", "CELL_LINE", 18, 31], ["SINV SM10", "PROTEIN", 52, 61], ["SINV", "SPECIES", 52, 56], ["SINV SM10", "TREATMENT", 52, 61], ["DM", "PROBLEM", 66, 68], ["infection", "PROBLEM", 103, 112], ["differentiated", "OBSERVATION_MODIFIER", 3, 17], ["CSM", "OBSERVATION_MODIFIER", 18, 21], ["14.1 cells", "OBSERVATION", 21, 31], ["SINV SM10", "OBSERVATION", 52, 61]]], ["After 24 h, replication of SINV WT plateaued, while replication of SINV SM10 and DM continued to increase to approximately the same level as SINV WT.", [["SINV WT", "ORGANISM", 27, 34], ["SINV", "ORGANISM", 67, 71], ["SM10", "ORGANISM", 72, 76], ["SINV", "ORGANISM", 141, 145], ["SINV", "SPECIES", 27, 31], ["SINV", "SPECIES", 67, 71], ["SINV", "SPECIES", 141, 145], ["SINV WT", "TREATMENT", 27, 34], ["SINV SM10", "TREATMENT", 67, 76], ["DM", "PROBLEM", 81, 83]]], ["Replication of SINV SM24 was less impaired, suggesting that the amino acid at position 10 of nsP3 is more important for SINV replication in neurons than the amino acid at position 24.", [["neurons", "ANATOMY", 140, 147], ["amino acid", "CHEMICAL", 64, 74], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "CHEMICAL", 64, 74], ["amino acid", "CHEMICAL", 157, 167], ["SINV", "ORGANISM", 15, 19], ["SM24", "GENE_OR_GENE_PRODUCT", 20, 24], ["amino acid", "AMINO_ACID", 64, 74], ["nsP3", "GENE_OR_GENE_PRODUCT", 93, 97], ["SINV", "ORGANISM", 120, 124], ["neurons", "CELL", 140, 147], ["amino acid", "AMINO_ACID", 157, 167], ["SINV SM24", "PROTEIN", 15, 24], ["nsP3", "PROTEIN", 93, 97], ["neurons", "CELL_TYPE", 140, 147], ["SINV", "SPECIES", 15, 19], ["SINV", "SPECIES", 120, 124], ["the amino acid", "TREATMENT", 60, 74], ["nsP3", "TREATMENT", 93, 97], ["SINV replication", "TREATMENT", 120, 136], ["the amino acid", "TEST", 153, 167]]], ["The results in undifferentiated CSM14.1 cells were similar.", [["CSM14.1 cells", "ANATOMY", 32, 45], ["CSM14.1 cells", "CELL", 32, 45], ["CSM14.1 cells", "CELL_LINE", 32, 45], ["14.1 cells", "OBSERVATION", 35, 45]]], ["In BHK21 cells, however, replication of SINV WT and DM was not different (Fig. 2C), suggesting that the effect of mutations on SINV replication is greatest in neurons.Revertants arise during growth of nsP3 macro domain mutants in neurons ::: ResultsSINV DM grown in BHK21 cells showed a small plaque phenotype compared to the large plaques produced by SINV WT (Fig. 3A).", [["BHK21 cells", "ANATOMY", 3, 14], ["neurons", "ANATOMY", 159, 166], ["neurons", "ANATOMY", 230, 237], ["BHK21 cells", "ANATOMY", 266, 277], ["plaque", "ANATOMY", 293, 299], ["plaques", "ANATOMY", 332, 339], ["BHK21 cells", "CELL", 3, 14], ["SINV WT", "ORGANISM", 40, 47], ["SINV", "ORGANISM", 127, 131], ["neurons", "CELL", 159, 166], ["nsP3", "GENE_OR_GENE_PRODUCT", 201, 205], ["neurons", "CELL", 230, 237], ["BHK21 cells", "CELL", 266, 277], ["plaques", "PATHOLOGICAL_FORMATION", 332, 339], ["SINV WT", "ORGANISM", 352, 359], ["BHK21 cells", "CELL_LINE", 3, 14], ["neurons", "CELL_TYPE", 159, 166], ["nsP3 macro domain mutants", "PROTEIN", 201, 226], ["BHK21 cells", "CELL_LINE", 266, 277], ["SINV", "SPECIES", 40, 44], ["SINV", "SPECIES", 127, 131], ["SINV", "SPECIES", 352, 356], ["SINV WT", "TEST", 40, 47], ["DM", "PROBLEM", 52, 54], ["mutations", "PROBLEM", 114, 123], ["SINV replication", "TREATMENT", 127, 143], ["ResultsSINV DM", "PROBLEM", 242, 256], ["BHK21 cells", "TEST", 266, 277], ["a small plaque phenotype", "PROBLEM", 285, 309], ["the large plaques", "PROBLEM", 322, 339], ["BHK21 cells", "OBSERVATION", 3, 14], ["BHK21 cells", "OBSERVATION", 266, 277], ["small", "OBSERVATION_MODIFIER", 287, 292], ["plaque", "OBSERVATION", 293, 299], ["large", "OBSERVATION_MODIFIER", 326, 331], ["plaques", "OBSERVATION", 332, 339]]], ["Viruses produced by SINV WT-infected differentiated CSM14.1 cells also formed large plaques (average diameter of 3 mm).", [["CSM14.1 cells", "ANATOMY", 52, 65], ["plaques", "ANATOMY", 84, 91], ["SINV WT", "ORGANISM", 20, 27], ["CSM14.1 cells", "CELL", 52, 65], ["plaques", "PATHOLOGICAL_FORMATION", 84, 91], ["CSM14.1 cells", "CELL_LINE", 52, 65], ["SINV", "SPECIES", 20, 24], ["Viruses", "PROBLEM", 0, 7], ["SINV WT", "TEST", 20, 27], ["large plaques", "PROBLEM", 78, 91], ["infected differentiated", "OBSERVATION_MODIFIER", 28, 51], ["14.1 cells", "OBSERVATION_MODIFIER", 55, 65], ["formed", "OBSERVATION_MODIFIER", 71, 77], ["large", "OBSERVATION_MODIFIER", 78, 83], ["plaques", "OBSERVATION", 84, 91], ["average", "OBSERVATION_MODIFIER", 93, 100], ["diameter", "OBSERVATION_MODIFIER", 101, 109], ["3 mm", "OBSERVATION_MODIFIER", 113, 117]]], ["In contrast, viruses produced by SINV DM-infected differentiated (Fig. 3A) and undifferentiated (data not shown) CSM14.1 cells were a mixture of small plaques (average diameter of 1.5 mm) and a few large plaques (Fig. 3A, arrow).", [["CSM14.1 cells", "ANATOMY", 113, 126], ["plaques", "ANATOMY", 151, 158], ["plaques", "ANATOMY", 204, 211], ["SINV DM", "ORGANISM", 33, 40], ["Fig. 3A", "CELL", 66, 73], ["CSM14.1 cells", "CELL", 113, 126], ["CSM14.1 cells", "CELL_LINE", 113, 126], ["SINV", "SPECIES", 33, 37], ["viruses", "PROBLEM", 13, 20], ["SINV DM", "PROBLEM", 33, 40], ["CSM", "TEST", 113, 116], ["small plaques", "PROBLEM", 145, 158], ["a few large plaques", "PROBLEM", 192, 211], ["viruses", "OBSERVATION", 13, 20], ["SINV DM", "OBSERVATION", 33, 40], ["small", "OBSERVATION_MODIFIER", 145, 150], ["plaques", "OBSERVATION", 151, 158], ["average", "OBSERVATION_MODIFIER", 160, 167], ["diameter", "OBSERVATION_MODIFIER", 168, 176], ["1.5 mm", "OBSERVATION_MODIFIER", 180, 186], ["few", "OBSERVATION_MODIFIER", 194, 197], ["large", "OBSERVATION_MODIFIER", 198, 203], ["plaques", "OBSERVATION", 204, 211]]], ["To determine whether these large plaques were revertants, plaques from SINV DM grown in undifferentiated or differentiated CSM14.1 cells, or BHK21 cells were isolated and sequenced.", [["plaques", "ANATOMY", 33, 40], ["plaques", "ANATOMY", 58, 65], ["CSM14.1 cells", "ANATOMY", 123, 136], ["BHK21 cells", "ANATOMY", 141, 152], ["plaques", "DISEASE", 58, 65], ["DM", "DISEASE", 76, 78], ["plaques", "PATHOLOGICAL_FORMATION", 58, 65], ["SINV", "ORGANISM", 71, 75], ["CSM14.1 cells", "CELL", 123, 136], ["BHK21 cells", "CELL", 141, 152], ["CSM14.1 cells", "CELL_LINE", 123, 136], ["BHK21 cells", "CELL_LINE", 141, 152], ["SINV", "SPECIES", 71, 75], ["these large plaques", "PROBLEM", 21, 40], ["plaques", "PROBLEM", 58, 65], ["SINV DM", "PROBLEM", 71, 78], ["BHK21 cells", "PROBLEM", 141, 152], ["large", "OBSERVATION_MODIFIER", 27, 32], ["plaques", "OBSERVATION", 33, 40], ["plaques", "OBSERVATION_MODIFIER", 58, 65], ["SINV DM", "OBSERVATION", 71, 78], ["undifferentiated", "OBSERVATION_MODIFIER", 88, 104], ["differentiated", "OBSERVATION_MODIFIER", 108, 122], ["CSM", "OBSERVATION_MODIFIER", 123, 126], ["14.1 cells", "OBSERVATION", 126, 136], ["BHK21 cells", "OBSERVATION", 141, 152]]], ["In BHK21 cells, all plaques were original SINV DM with no reversion.", [["BHK21 cells", "ANATOMY", 3, 14], ["plaques", "ANATOMY", 20, 27], ["DM", "DISEASE", 47, 49], ["BHK21 cells", "CELL", 3, 14], ["SINV", "ORGANISM", 42, 46], ["BHK21 cells", "CELL_LINE", 3, 14], ["SINV", "SPECIES", 42, 46], ["BHK21 cells", "PROBLEM", 3, 14], ["all plaques", "PROBLEM", 16, 27], ["original SINV DM", "PROBLEM", 33, 49], ["reversion", "PROBLEM", 58, 67], ["BHK21 cells", "OBSERVATION", 3, 14], ["all", "OBSERVATION_MODIFIER", 16, 19], ["plaques", "OBSERVATION", 20, 27], ["SINV DM", "OBSERVATION", 42, 49], ["no", "UNCERTAINTY", 55, 57], ["reversion", "OBSERVATION", 58, 67]]], ["In undifferentiated and differentiated CSM14.1 cells, however, small plaque viruses retained the original mutations, while large plaque viruses had reverted alanine (GCT) at amino acid 10 of nsP3 to threonine (ACT) or aspartate (GAT) (Fig. 3B).", [["CSM14.1 cells", "ANATOMY", 39, 52], ["alanine", "CHEMICAL", 157, 164], ["amino acid 10 of nsP3 to threonine", "CHEMICAL", 174, 208], ["aspartate", "CHEMICAL", 218, 227], ["alanine", "CHEMICAL", 157, 164], ["amino acid", "CHEMICAL", 174, 184], ["threonine", "CHEMICAL", 199, 208], ["aspartate", "CHEMICAL", 218, 227], ["CSM14.1 cells", "CELL", 39, 52], ["alanine", "AMINO_ACID", 157, 164], ["amino acid", "AMINO_ACID", 174, 184], ["nsP3", "AMINO_ACID", 191, 195], ["threonine", "AMINO_ACID", 199, 208], ["(ACT)", "GENE_OR_GENE_PRODUCT", 209, 214], ["aspartate", "SIMPLE_CHEMICAL", 218, 227], ["GAT", "SIMPLE_CHEMICAL", 229, 232], ["CSM14.1 cells", "CELL_LINE", 39, 52], ["nsP3", "PROTEIN", 191, 195], ["ACT", "PROTEIN", 210, 213], ["small plaque viruses", "PROBLEM", 63, 83], ["the original mutations", "PROBLEM", 93, 115], ["large plaque viruses", "PROBLEM", 123, 143], ["amino acid", "TEST", 174, 184], ["nsP3 to threonine", "TREATMENT", 191, 208], ["aspartate (GAT)", "TEST", 218, 233], ["undifferentiated", "OBSERVATION_MODIFIER", 3, 19], ["differentiated", "OBSERVATION_MODIFIER", 24, 38], ["CSM", "OBSERVATION_MODIFIER", 39, 42], ["14.1 cells", "OBSERVATION", 42, 52], ["small", "OBSERVATION_MODIFIER", 63, 68], ["plaque", "OBSERVATION", 69, 75], ["original mutations", "OBSERVATION", 97, 115], ["large", "OBSERVATION_MODIFIER", 123, 128], ["plaque", "OBSERVATION", 129, 135]]], ["These reversions required only a single nucleotide change and were detected as early as 8 h after infection of both undifferentiated and differentiated CSM14.1 cells.", [["CSM14.1 cells", "ANATOMY", 152, 165], ["infection", "DISEASE", 98, 107], ["nucleotide", "CHEMICAL", 40, 50], ["CSM14.1 cells", "CELL", 152, 165], ["CSM14.1 cells", "CELL_LINE", 152, 165], ["These reversions", "PROBLEM", 0, 16], ["a single nucleotide change", "PROBLEM", 31, 57], ["infection", "PROBLEM", 98, 107], ["14.1 cells", "OBSERVATION", 155, 165]]], ["SINV DM grown in CSM14.1 cells was also sequenced directly without plaque isolation (Fig. 3C) and showed co-existence of the original SINV DM and variants with reversions at amino acid 10.", [["CSM14.1 cells", "ANATOMY", 17, 30], ["plaque", "ANATOMY", 67, 73], ["DM", "DISEASE", 5, 7], ["DM", "DISEASE", 139, 141], ["amino acid", "CHEMICAL", 174, 184], ["amino acid", "CHEMICAL", 174, 184], ["SINV", "ORGANISM", 0, 4], ["CSM14.1 cells", "CELL", 17, 30], ["SINV", "ORGANISM", 134, 138], ["amino acid", "AMINO_ACID", 174, 184], ["CSM14.1 cells", "CELL_LINE", 17, 30], ["SINV", "SPECIES", 0, 4], ["SINV", "SPECIES", 134, 138], ["SINV DM", "PROBLEM", 0, 7], ["plaque isolation", "PROBLEM", 67, 83], ["the original SINV DM", "PROBLEM", 121, 141], ["reversions at amino acid", "TREATMENT", 160, 184], ["14.1 cells", "OBSERVATION", 20, 30], ["without", "UNCERTAINTY", 59, 66], ["plaque", "OBSERVATION", 67, 73], ["SINV DM", "OBSERVATION", 134, 141]]], ["No reversion was detected at amino acid 24, and SINV SM24 formed large plaques (data not shown).Revertants arise during growth of nsP3 macro domain mutants in neurons ::: ResultsIn addition to the reversion at amino acid 10, a second-site mutation was detected at amino acid 31.", [["plaques", "ANATOMY", 71, 78], ["neurons", "ANATOMY", 159, 166], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 210, 220], ["amino acid", "CHEMICAL", 264, 274], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 210, 220], ["amino acid", "CHEMICAL", 264, 274], ["amino acid", "AMINO_ACID", 29, 39], ["SINV", "ORGANISM", 48, 52], ["SM24", "GENE_OR_GENE_PRODUCT", 53, 57], ["plaques", "PATHOLOGICAL_FORMATION", 71, 78], ["nsP3", "GENE_OR_GENE_PRODUCT", 130, 134], ["neurons", "CELL", 159, 166], ["amino acid 10", "AMINO_ACID", 210, 223], ["amino acid 31", "AMINO_ACID", 264, 277], ["SINV SM24", "PROTEIN", 48, 57], ["nsP3 macro domain mutants", "PROTEIN", 130, 155], ["SINV", "SPECIES", 48, 52], ["reversion", "PROBLEM", 3, 12], ["amino acid", "TEST", 29, 39], ["SINV SM24 formed large plaques", "PROBLEM", 48, 78], ["amino acid", "TEST", 210, 220], ["a second-site mutation", "PROBLEM", 225, 247], ["amino acid", "TEST", 264, 274], ["reversion", "OBSERVATION", 3, 12], ["large", "OBSERVATION_MODIFIER", 65, 70], ["plaques", "OBSERVATION", 71, 78]]], ["A change from glutamate (GAA) (31E) to glycine (GGA) (31G) was present in plaques from SINV DM without the reversion at amino acid 10 (Fig. 3B).", [["plaques", "ANATOMY", 74, 81], ["glutamate", "CHEMICAL", 14, 23], ["GAA", "CHEMICAL", 25, 28], ["glycine", "CHEMICAL", 39, 46], ["DM", "DISEASE", 92, 94], ["amino acid", "CHEMICAL", 120, 130], ["glutamate", "CHEMICAL", 14, 23], ["glycine", "CHEMICAL", 39, 46], ["amino acid", "CHEMICAL", 120, 130], ["glutamate", "SIMPLE_CHEMICAL", 14, 23], ["GAA", "SIMPLE_CHEMICAL", 25, 28], ["glycine", "AMINO_ACID", 39, 46], ["GGA", "SIMPLE_CHEMICAL", 48, 51], ["plaques", "PATHOLOGICAL_FORMATION", 74, 81], ["amino acid", "AMINO_ACID", 120, 130], ["SINV", "SPECIES", 87, 91], ["A change from glutamate (GAA) (31E) to glycine (GGA)", "TREATMENT", 0, 52], ["plaques", "PROBLEM", 74, 81], ["SINV DM", "PROBLEM", 87, 94], ["the reversion at amino acid", "TREATMENT", 103, 130], ["plaques", "OBSERVATION", 74, 81], ["SINV DM", "OBSERVATION", 87, 94]]], ["This second-site mutation was detected as early as 8 h after infection of CSM14.1 cells and represented more than 50% of the total virus population (Fig. 3C).", [["CSM14.1 cells", "ANATOMY", 74, 87], ["infection", "DISEASE", 61, 70], ["CSM14.1 cells", "CELL", 74, 87], ["CSM14.1 cells", "CELL_LINE", 74, 87], ["This second-site mutation", "PROBLEM", 0, 25], ["infection of CSM14.1 cells", "PROBLEM", 61, 87], ["mutation", "OBSERVATION", 17, 25], ["14.1 cells", "OBSERVATION_MODIFIER", 77, 87]]], ["However, this change at amino acid 31 did not increase the plaque size (Fig. 3B).", [["plaque", "ANATOMY", 59, 65], ["amino acid", "CHEMICAL", 24, 34], ["amino acid", "CHEMICAL", 24, 34], ["amino acid", "AMINO_ACID", 24, 34], ["plaque", "PATHOLOGICAL_FORMATION", 59, 65], ["this change at amino acid", "TEST", 9, 34], ["the plaque size", "PROBLEM", 55, 70], ["plaque", "OBSERVATION", 59, 65], ["size", "OBSERVATION_MODIFIER", 66, 70]]], ["Although most alphaviruses contain glutamate or aspartate at the position corresponding to nsP3 31E, most other macro domain proteins contain glycine (Fig. 3D).", [["glutamate", "CHEMICAL", 35, 44], ["aspartate", "CHEMICAL", 48, 57], ["glycine", "CHEMICAL", 142, 149], ["glutamate", "CHEMICAL", 35, 44], ["aspartate", "CHEMICAL", 48, 57], ["glycine", "CHEMICAL", 142, 149], ["alphaviruses", "ORGANISM", 14, 26], ["glutamate", "SIMPLE_CHEMICAL", 35, 44], ["aspartate", "AMINO_ACID", 48, 57], ["nsP3 31E", "GENE_OR_GENE_PRODUCT", 91, 99], ["glycine", "AMINO_ACID", 142, 149], ["nsP3 31E", "PROTEIN", 91, 99], ["macro domain proteins", "PROTEIN", 112, 133], ["nsP3", "TEST", 91, 95]]], ["When C\u03b1 and side chain positions of nsP3 31E are compared to those of corresponding residues in the Af1521 macro domain protein from A. fulgidus (Karras et al., 2005), 31E has a bulky side chain that the template glycine residue does not have, and C\u03b1 positions of 31E and nearby residues (30G and 32G) are not similar to those of corresponding residues in the template (Fig. 3E).", [["C\u03b1", "CHEMICAL", 5, 7], ["31E", "CHEMICAL", 168, 171], ["glycine", "CHEMICAL", 213, 220], ["C\u03b1", "CHEMICAL", 5, 7], ["glycine", "CHEMICAL", 213, 220], ["C\u03b1", "SIMPLE_CHEMICAL", 5, 7], ["nsP3 31E", "GENE_OR_GENE_PRODUCT", 36, 44], ["A. fulgidus", "ORGANISM", 133, 144], ["glycine", "AMINO_ACID", 213, 220], ["C\u03b1", "PROTEIN", 5, 7], ["nsP3 31E", "PROTEIN", 36, 44], ["Af1521 macro domain protein", "PROTEIN", 100, 127], ["31E", "PROTEIN", 264, 267], ["A. fulgidus", "SPECIES", 133, 144], ["A. fulgidus", "SPECIES", 133, 144], ["nsP3", "PROBLEM", 36, 40], ["corresponding residues", "PROBLEM", 70, 92], ["A. fulgidus", "TEST", 133, 144], ["a bulky side chain", "TREATMENT", 176, 194], ["the template glycine residue", "PROBLEM", 200, 228], ["glycine residue", "OBSERVATION", 213, 228]]], ["In contrast, C\u03b1 and side chain positions of nsP3 amino acids 10N and 24N are highly similar to those of corresponding residues in Af1521.Mutations in the nsP3 macro domain affect formation of SINV replication complexes ::: ResultsTo understand how mutations in the nsP3 macro domain affect SINV replication, we examined the levels of nsPs that form SINV replication complexes by immunoblotting (Fig. 4).", [["C\u03b1", "CHEMICAL", 13, 15], ["amino acids", "CHEMICAL", 49, 60], ["C\u03b1", "CHEMICAL", 13, 15], ["amino acids", "CHEMICAL", 49, 60], ["C\u03b1", "SIMPLE_CHEMICAL", 13, 15], ["nsP3", "SIMPLE_CHEMICAL", 44, 48], ["amino acids", "AMINO_ACID", 49, 60], ["24N", "AMINO_ACID", 69, 72], ["nsP3", "GENE_OR_GENE_PRODUCT", 154, 158], ["SINV", "ORGANISM", 192, 196], ["nsP3", "GENE_OR_GENE_PRODUCT", 265, 269], ["SINV", "ORGANISM", 290, 294], ["nsPs", "GENE_OR_GENE_PRODUCT", 334, 338], ["SINV", "ORGANISM", 349, 353], ["C\u03b1", "PROTEIN", 13, 15], ["nsP3 amino acids 10N and 24N", "PROTEIN", 44, 72], ["nsP3 macro domain", "PROTEIN", 154, 171], ["SINV replication complexes", "PROTEIN", 192, 218], ["nsP3 macro domain", "PROTEIN", 265, 282], ["nsPs", "PROTEIN", 334, 338], ["SINV replication complexes", "PROTEIN", 349, 375], ["SINV", "SPECIES", 192, 196], ["SINV", "SPECIES", 290, 294], ["SINV", "SPECIES", 349, 353], ["nsP3 amino acids", "TEST", 44, 60], ["corresponding residues in Af", "PROBLEM", 104, 132], ["Mutations in the nsP3 macro domain affect", "PROBLEM", 137, 178], ["SINV replication", "TREATMENT", 290, 306], ["nsPs", "PROBLEM", 334, 338], ["SINV replication complexes", "TREATMENT", 349, 375], ["SINV replication", "OBSERVATION", 192, 208]]], ["In undifferentiated (Fig. 4A) and differentiated (Fig. 4B) CSM14.1 cells infected with SINV DM or SM10, less nsP3 was present at all times examined.", [["Fig. 4B) CSM14.1 cells", "ANATOMY", 50, 72], ["Fig. 4A", "CELL", 21, 28], ["Fig. 4B) CSM14.1 cells", "CELL", 50, 72], ["SINV", "ORGANISM", 87, 91], ["nsP3", "GENE_OR_GENE_PRODUCT", 109, 113], ["CSM14.1 cells", "CELL_LINE", 59, 72], ["nsP3", "DNA", 109, 113], ["SINV", "SPECIES", 87, 91], ["Fig", "TEST", 50, 53], ["CSM", "TEST", 59, 62], ["SINV DM", "PROBLEM", 87, 94], ["less nsP3", "PROBLEM", 104, 113], ["SINV DM", "OBSERVATION_MODIFIER", 87, 94], ["less", "OBSERVATION_MODIFIER", 104, 108], ["nsP3", "OBSERVATION", 109, 113]]], ["In differentiated CSM cells, levels of nsP2 were also slightly lower, although nsP2 itself is not mutated.", [["CSM cells", "ANATOMY", 18, 27], ["CSM cells", "CELL", 18, 27], ["nsP2", "GENE_OR_GENE_PRODUCT", 39, 43], ["nsP2", "GENE_OR_GENE_PRODUCT", 79, 83], ["CSM cells", "CELL_LINE", 18, 27], ["nsP2", "PROTEIN", 39, 43], ["nsP2", "PROTEIN", 79, 83], ["levels of nsP2", "TEST", 29, 43], ["slightly lower", "PROBLEM", 54, 68], ["nsP2", "PROBLEM", 79, 83], ["differentiated", "OBSERVATION_MODIFIER", 3, 17], ["CSM cells", "OBSERVATION", 18, 27], ["nsP2", "OBSERVATION", 39, 43], ["slightly", "OBSERVATION_MODIFIER", 54, 62], ["lower", "OBSERVATION_MODIFIER", 63, 68]]], ["SINV SM24 showed minimal defects in the level of nsPs consistent with the less pronounced defects in viral replication.", [["SINV", "ORGANISM", 0, 4], ["SM24", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsPs", "GENE_OR_GENE_PRODUCT", 49, 53], ["SINV SM24", "PROTEIN", 0, 9], ["nsPs", "PROTEIN", 49, 53], ["SINV", "SPECIES", 0, 4], ["minimal defects in the level of nsPs", "PROBLEM", 17, 53], ["the less pronounced defects in viral replication", "PROBLEM", 70, 118], ["minimal", "OBSERVATION_MODIFIER", 17, 24], ["defects", "OBSERVATION", 25, 32], ["consistent with", "UNCERTAINTY", 54, 69], ["less", "OBSERVATION_MODIFIER", 74, 78], ["pronounced", "OBSERVATION_MODIFIER", 79, 89], ["defects", "OBSERVATION", 90, 97], ["viral replication", "OBSERVATION", 101, 118]]], ["To examine the synthesis and stability of nsPs, differentiated CSM14.1 cells were labeled with tran35S at 20 h post-infection and chased for 45, 90, and 120 min, and levels of nsP2, nsP3, and nsP23 were analyzed by immunoprecipitation (Fig. 4C).", [["CSM14.1 cells", "ANATOMY", 63, 76], ["tran35S", "CHEMICAL", 95, 102], ["infection", "DISEASE", 116, 125], ["nsPs", "SIMPLE_CHEMICAL", 42, 46], ["CSM14.1 cells", "CELL", 63, 76], ["nsP2", "GENE_OR_GENE_PRODUCT", 176, 180], ["nsP3", "GENE_OR_GENE_PRODUCT", 182, 186], ["nsP23", "GENE_OR_GENE_PRODUCT", 192, 197], ["nsPs", "PROTEIN", 42, 46], ["CSM14.1 cells", "CELL_LINE", 63, 76], ["nsP2", "PROTEIN", 176, 180], ["nsP3", "PROTEIN", 182, 186], ["nsP23", "PROTEIN", 192, 197], ["the synthesis", "TEST", 11, 24], ["nsPs", "TEST", 42, 46], ["differentiated CSM14.1 cells", "PROBLEM", 48, 76], ["tran35S", "TREATMENT", 95, 102], ["infection", "PROBLEM", 116, 125], ["levels", "TEST", 166, 172], ["nsP2", "TEST", 176, 180], ["nsP3", "TEST", 182, 186], ["nsP23", "TEST", 192, 197], ["immunoprecipitation", "TEST", 215, 234], ["14.1 cells", "OBSERVATION", 66, 76], ["infection", "OBSERVATION", 116, 125]]], ["Similar amounts of nsP3 were synthesized in SINV WT- and DM-infected cells, but nsP3 was rapidly degraded in SINV DM-infected cells.", [["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 126, 131], ["SINV DM-infected", "DISEASE", 109, 125], ["nsP3", "GENE_OR_GENE_PRODUCT", 19, 23], ["SINV WT", "ORGANISM", 44, 51], ["DM", "CELL", 57, 59], ["cells", "CELL", 69, 74], ["nsP3", "GENE_OR_GENE_PRODUCT", 80, 84], ["SINV", "ORGANISM", 109, 113], ["cells", "CELL", 126, 131], ["nsP3", "PROTEIN", 19, 23], ["nsP3", "PROTEIN", 80, 84], ["SINV DM-infected cells", "CELL_LINE", 109, 131], ["SINV", "SPECIES", 44, 48], ["SINV", "SPECIES", 109, 113], ["nsP3", "PROBLEM", 19, 23], ["SINV WT", "TEST", 44, 51], ["DM", "PROBLEM", 57, 59], ["infected cells", "PROBLEM", 60, 74], ["nsP3", "PROBLEM", 80, 84], ["SINV DM", "PROBLEM", 109, 116], ["infected cells", "PROBLEM", 117, 131], ["amounts", "OBSERVATION_MODIFIER", 8, 15], ["nsP3", "OBSERVATION", 19, 23], ["infected cells", "OBSERVATION", 60, 74], ["SINV DM", "OBSERVATION", 109, 116], ["infected cells", "OBSERVATION", 117, 131]]], ["Instability of mutant nsP3 was not a result of proteasome-mediated degradation because treatment with a proteasome inhibitor MG132 decreased, rather than increased, the amount of detectable nsP3 (data not shown).", [["MG132", "CHEMICAL", 125, 130], ["MG132", "CHEMICAL", 125, 130], ["nsP3", "GENE_OR_GENE_PRODUCT", 22, 26], ["MG132", "SIMPLE_CHEMICAL", 125, 130], ["nsP3", "GENE_OR_GENE_PRODUCT", 190, 194], ["mutant nsP3", "PROTEIN", 15, 26], ["proteasome", "PROTEIN", 47, 57], ["proteasome", "PROTEIN", 104, 114], ["nsP3", "PROTEIN", 190, 194], ["Instability of mutant nsP3", "PROBLEM", 0, 26], ["proteasome-mediated degradation", "TREATMENT", 47, 78], ["a proteasome inhibitor MG132", "TREATMENT", 102, 130], ["detectable nsP3", "PROBLEM", 179, 194], ["mutant nsP3", "OBSERVATION", 15, 26]]], ["Furthermore, mutations in the nsP3 macro domain did not affect nsP3 stability in BHK21 cells (Fig. 4D), indicating that the folding of mutant nsP3 is intact.", [["BHK21 cells", "ANATOMY", 81, 92], ["nsP3", "GENE_OR_GENE_PRODUCT", 63, 67], ["BHK21 cells", "CELL", 81, 92], ["nsP3", "GENE_OR_GENE_PRODUCT", 142, 146], ["nsP3 macro domain", "PROTEIN", 30, 47], ["nsP3", "PROTEIN", 63, 67], ["BHK21 cells", "CELL_LINE", 81, 92], ["mutant nsP3", "PROTEIN", 135, 146], ["mutations in the nsP3 macro domain", "PROBLEM", 13, 47], ["nsP3 stability in BHK21 cells", "PROBLEM", 63, 92], ["the folding of mutant nsP3", "PROBLEM", 120, 146], ["nsP3 stability", "OBSERVATION", 63, 77], ["BHK21 cells", "OBSERVATION", 81, 92], ["mutant nsP3", "OBSERVATION", 135, 146], ["intact", "OBSERVATION", 150, 156]]], ["The synthesis and stability of nsP2 and nsP23 were not significantly affected, suggesting that the mutations did not affect cleavage of P23 (Fig. 4C).Mutations in the nsP3 macro domain affect formation of SINV replication complexes ::: ResultsThe effect of mutations in the nsP3 macro domain on the synthesis and stability of structural proteins (E1, E2, and capsid) was also assessed in differentiated CSM14.1 cells (Fig. 4E).", [["CSM14.1 cells", "ANATOMY", 403, 416], ["nsP23", "CHEMICAL", 40, 45], ["nsP2", "GENE_OR_GENE_PRODUCT", 31, 35], ["nsP23", "GENE_OR_GENE_PRODUCT", 40, 45], ["nsP3", "GENE_OR_GENE_PRODUCT", 167, 171], ["SINV", "ORGANISM", 205, 209], ["E1", "GENE_OR_GENE_PRODUCT", 347, 349], ["E2", "GENE_OR_GENE_PRODUCT", 351, 353], ["CSM14.1 cells", "CELL", 403, 416], ["Fig. 4E", "CELL", 418, 425], ["nsP2", "PROTEIN", 31, 35], ["nsP23", "PROTEIN", 40, 45], ["P23", "PROTEIN", 136, 139], ["nsP3 macro domain", "PROTEIN", 167, 184], ["SINV replication complexes", "PROTEIN", 205, 231], ["nsP3 macro domain", "PROTEIN", 274, 291], ["structural proteins", "PROTEIN", 326, 345], ["E1", "PROTEIN", 347, 349], ["E2", "PROTEIN", 351, 353], ["capsid", "PROTEIN", 359, 365], ["CSM14.1 cells", "CELL_LINE", 403, 416], ["SINV", "SPECIES", 205, 209], ["The synthesis", "TEST", 0, 13], ["nsP2", "TEST", 31, 35], ["nsP23", "TEST", 40, 45], ["the mutations", "PROBLEM", 95, 108], ["Mutations in the nsP3 macro domain affect", "PROBLEM", 150, 191], ["mutations in the nsP3 macro domain", "PROBLEM", 257, 291], ["the synthesis", "TEST", 295, 308], ["structural proteins (E1, E2, and capsid)", "PROBLEM", 326, 366], ["stability", "OBSERVATION_MODIFIER", 18, 27], ["SINV replication", "OBSERVATION", 205, 221], ["stability", "OBSERVATION_MODIFIER", 313, 322], ["14.1 cells", "OBSERVATION", 406, 416]]], ["Lower amounts of both capsid and E1/E2 were present at 24 h after infection with SINV DM, but comparable amounts of structural proteins were detected by 48 h.", [["E2", "CHEMICAL", 36, 38], ["infection", "DISEASE", 66, 75], ["E1", "GENE_OR_GENE_PRODUCT", 33, 35], ["E2", "GENE_OR_GENE_PRODUCT", 36, 38], ["SINV", "ORGANISM", 81, 85], ["E1", "PROTEIN", 33, 35], ["E2", "PROTEIN", 36, 38], ["structural proteins", "PROTEIN", 116, 135], ["SINV", "SPECIES", 81, 85], ["E1/E2", "TREATMENT", 33, 38], ["infection", "PROBLEM", 66, 75], ["SINV DM", "PROBLEM", 81, 88], ["structural proteins", "PROBLEM", 116, 135], ["both", "OBSERVATION_MODIFIER", 17, 21], ["capsid", "OBSERVATION", 22, 28], ["SINV DM", "OBSERVATION", 81, 88]]], ["In general, the differences in the amounts of structural proteins between SINV DM and WT were less apparent than the differences in the amounts of nonstructural proteins, suggesting that the impairment in the replication of SINV DM results from defects in nsPs.", [["DM", "DISEASE", 229, 231], ["SINV DM", "ORGANISM", 74, 81], ["SINV DM", "ORGANISM", 224, 231], ["nsPs", "GENE_OR_GENE_PRODUCT", 256, 260], ["structural proteins", "PROTEIN", 46, 65], ["nonstructural proteins", "PROTEIN", 147, 169], ["nsPs", "PROTEIN", 256, 260], ["SINV", "SPECIES", 74, 78], ["SINV", "SPECIES", 224, 228], ["SINV DM", "PROBLEM", 74, 81], ["WT", "TEST", 86, 88], ["nonstructural proteins", "PROBLEM", 147, 169], ["the impairment", "PROBLEM", 187, 201], ["SINV DM", "PROBLEM", 224, 231], ["defects in nsPs", "PROBLEM", 245, 260], ["SINV DM", "OBSERVATION", 74, 81], ["less apparent", "OBSERVATION_MODIFIER", 94, 107], ["defects", "OBSERVATION", 245, 252], ["nsPs", "OBSERVATION_MODIFIER", 256, 260]]], ["In addition, the stability of the structural proteins was not affected (Fig. 4C).Mutations in the nsP3 macro domain affect the synthesis of SINV RNAs ::: ResultsTo understand which step of virus replication is affected by mutations in the nsP3 macro domain, we compared the synthesis of viral genomic and subgenomic RNAs as well as plus and minus strand RNAs (Fig. 5).", [["nsP3", "GENE_OR_GENE_PRODUCT", 98, 102], ["SINV", "ORGANISM", 140, 144], ["structural proteins", "PROTEIN", 34, 53], ["nsP3 macro domain", "PROTEIN", 98, 115], ["SINV RNAs", "RNA", 140, 149], ["nsP3 macro domain", "PROTEIN", 239, 256], ["viral genomic and subgenomic RNAs", "RNA", 287, 320], ["plus and minus strand RNAs", "RNA", 332, 358], ["SINV", "SPECIES", 140, 144], ["the structural proteins", "PROBLEM", 30, 53], ["Mutations in the nsP3 macro domain", "PROBLEM", 81, 115], ["virus replication", "PROBLEM", 189, 206], ["viral genomic and subgenomic RNAs", "PROBLEM", 287, 320], ["minus strand RNAs", "PROBLEM", 341, 358], ["stability", "OBSERVATION_MODIFIER", 17, 26], ["viral genomic", "OBSERVATION", 287, 300], ["subgenomic RNAs", "OBSERVATION", 305, 320], ["strand RNAs", "OBSERVATION", 347, 358]]], ["In differentiated CSM14.1 cells infected with SINV WT or DM, newly synthesized viral RNAs were labeled with 3H-uridine for 2 h, and genomic and subgenomic RNAs were analyzed on an agarose gel.", [["CSM14.1 cells", "ANATOMY", 18, 31], ["3H-uridine", "CHEMICAL", 108, 118], ["3H-uridine", "CHEMICAL", 108, 118], ["CSM14.1 cells", "CELL", 18, 31], ["SINV WT", "ORGANISM", 46, 53], ["3H-uridine", "SIMPLE_CHEMICAL", 108, 118], ["agarose", "SIMPLE_CHEMICAL", 180, 187], ["CSM14.1 cells", "CELL_LINE", 18, 31], ["viral RNAs", "RNA", 79, 89], ["subgenomic RNAs", "RNA", 144, 159], ["SINV", "SPECIES", 46, 50], ["SINV WT", "PROBLEM", 46, 53], ["DM", "PROBLEM", 57, 59], ["newly synthesized viral RNAs", "PROBLEM", 61, 89], ["3H-uridine", "TREATMENT", 108, 118], ["genomic and subgenomic RNAs", "TREATMENT", 132, 159], ["an agarose gel", "TREATMENT", 177, 191], ["differentiated", "OBSERVATION_MODIFIER", 3, 17], ["CSM", "OBSERVATION_MODIFIER", 18, 21], ["14.1 cells", "OBSERVATION_MODIFIER", 21, 31], ["viral RNAs", "OBSERVATION", 79, 89], ["subgenomic RNAs", "OBSERVATION", 144, 159]]], ["Initial RNA synthesis was similar between SINV WT and DM, but the later amplification of RNA synthesis observed in SINV WT infection did not occur in SINV DM infection (Fig. 5A).", [["infection", "DISEASE", 123, 132], ["SINV DM infection", "DISEASE", 150, 167], ["SINV WT", "ORGANISM", 42, 49], ["SINV WT", "ORGANISM", 115, 122], ["SINV DM", "ORGANISM", 150, 157], ["SINV", "SPECIES", 42, 46], ["SINV", "SPECIES", 115, 119], ["SINV", "SPECIES", 150, 154], ["Initial RNA synthesis", "PROBLEM", 0, 21], ["DM", "PROBLEM", 54, 56], ["RNA synthesis", "PROBLEM", 89, 102], ["SINV WT infection", "PROBLEM", 115, 132], ["SINV DM infection", "PROBLEM", 150, 167], ["infection", "OBSERVATION", 123, 132]]], ["The ratios of genomic to subgenomic RNAs were comparable, and similar to those observed in previous studies of SINV in differentiated CSM14.1 cells (Burdeinick-Kerr and Griffin, 2005).Mutations in the nsP3 macro domain affect the synthesis of SINV RNAs ::: ResultsTo compare the synthesis of plus and minus strand viral RNAs, RNAs were purified from differentiated CSM14.1 cells infected with SINV WT or DM, and real time RT-PCR was performed using primers specifically recognizing plus or minus strand SINV RNA.", [["CSM14.1 cells", "ANATOMY", 134, 147], ["CSM14.1 cells", "ANATOMY", 365, 378], ["SINV", "ORGANISM", 111, 115], ["CSM14.1 cells", "CELL", 134, 147], ["nsP3", "GENE_OR_GENE_PRODUCT", 201, 205], ["SINV", "ORGANISM", 243, 247], ["CSM14.1 cells", "CELL", 365, 378], ["SINV", "ORGANISM", 393, 397], ["WT", "ORGANISM", 398, 400], ["subgenomic RNAs", "RNA", 25, 40], ["CSM14.1 cells", "CELL_LINE", 134, 147], ["nsP3 macro domain", "PROTEIN", 201, 218], ["SINV RNAs", "RNA", 243, 252], ["plus and minus strand viral RNAs", "RNA", 292, 324], ["RNAs", "RNA", 326, 330], ["CSM14.1 cells", "CELL_LINE", 365, 378], ["plus or minus strand SINV RNA", "RNA", 482, 511], ["SINV", "SPECIES", 111, 115], ["SINV", "SPECIES", 243, 247], ["SINV", "SPECIES", 393, 397], ["SINV", "SPECIES", 503, 507], ["The ratios", "TEST", 0, 10], ["genomic to subgenomic RNAs", "PROBLEM", 14, 40], ["previous studies", "TEST", 91, 107], ["SINV", "PROBLEM", 111, 115], ["Mutations in the nsP3 macro domain", "PROBLEM", 184, 218], ["the synthesis", "TEST", 275, 288], ["minus strand viral RNAs", "PROBLEM", 301, 324], ["SINV WT", "PROBLEM", 393, 400], ["DM", "PROBLEM", 404, 406], ["real time RT-PCR", "TEST", 412, 428], ["primers", "TEST", 449, 456], ["minus strand SINV RNA", "PROBLEM", 490, 511], ["subgenomic RNAs", "OBSERVATION", 25, 40], ["14.1 cells", "OBSERVATION", 137, 147], ["viral RNAs", "OBSERVATION", 314, 324], ["14.1 cells", "OBSERVATION_MODIFIER", 368, 378], ["SINV RNA", "OBSERVATION", 503, 511]]], ["Synthesis of both plus (Fig. 5B) and minus (Fig. 5C) strand RNAs was affected by mutations in the nsP3 macro domain at 16, 24, and 30 h post-infection.Mutations in the nsP3 macro domain reduce SINV-induced death of mature neurons ::: ResultsNext, we assessed the effect of mutations on SINV-induced neuronal death.", [["neurons", "ANATOMY", 222, 229], ["neuronal", "ANATOMY", 299, 307], ["death", "DISEASE", 206, 211], ["neuronal death", "DISEASE", 299, 313], ["nsP3", "GENE_OR_GENE_PRODUCT", 168, 172], ["SINV", "ORGANISM", 193, 197], ["neurons", "CELL", 222, 229], ["SINV", "ORGANISM", 286, 290], ["neuronal", "CELL", 299, 307], ["plus (Fig. 5B) and minus (Fig. 5C) strand RNAs", "RNA", 18, 64], ["nsP3 macro domain", "PROTEIN", 98, 115], ["nsP3 macro domain", "PROTEIN", 168, 185], ["mature neurons", "CELL_TYPE", 215, 229], ["SINV", "SPECIES", 286, 290], ["Synthesis of both plus (Fig. 5B)", "TEST", 0, 32], ["minus (Fig. 5C", "TREATMENT", 37, 51], ["strand RNAs", "PROBLEM", 53, 64], ["Mutations", "PROBLEM", 151, 160], ["mutations", "PROBLEM", 273, 282], ["SINV", "PROBLEM", 286, 290], ["induced neuronal death", "PROBLEM", 291, 313], ["neuronal death", "OBSERVATION", 299, 313]]], ["In undifferentiated CSM14.1 cells, no differences in SINV-induced death were observed between SINV WT and mutants (Fig. 6A).", [["CSM14.1 cells", "ANATOMY", 20, 33], ["death", "DISEASE", 66, 71], ["CSM14.1 cells", "CELL", 20, 33], ["SINV", "ORGANISM", 53, 57], ["SINV WT", "ORGANISM", 94, 101], ["CSM14.1 cells", "CELL_LINE", 20, 33], ["SINV", "SPECIES", 53, 57], ["SINV", "SPECIES", 94, 98], ["SINV", "PROBLEM", 53, 57], ["induced death", "PROBLEM", 58, 71], ["SINV WT", "TEST", 94, 101], ["undifferentiated", "OBSERVATION_MODIFIER", 3, 19], ["CSM", "OBSERVATION_MODIFIER", 20, 23], ["14.1 cells", "OBSERVATION", 23, 33]]], ["In differentiated CSM14.1 cells, however, SINV SM10 and DM caused less death than SINV WT (P< 0.01, 3 days after infection; P< 0.05, 4 days after infection) (Fig. 6B).", [["CSM14.1 cells", "ANATOMY", 18, 31], ["DM", "DISEASE", 56, 58], ["death", "DISEASE", 71, 76], ["infection", "DISEASE", 113, 122], ["infection", "DISEASE", 146, 155], ["CSM14.1 cells", "CELL", 18, 31], ["SINV", "ORGANISM", 42, 46], ["SM10", "GENE_OR_GENE_PRODUCT", 47, 51], ["SINV", "ORGANISM", 82, 86], ["CSM14.1 cells", "CELL_LINE", 18, 31], ["SINV SM10", "PROTEIN", 42, 51], ["SINV", "SPECIES", 42, 46], ["SINV", "SPECIES", 82, 86], ["SINV SM10", "TEST", 42, 51], ["DM", "PROBLEM", 56, 58], ["less death", "PROBLEM", 66, 76], ["SINV WT", "TEST", 82, 89], ["infection", "PROBLEM", 113, 122], ["P", "TEST", 124, 125], ["infection", "PROBLEM", 146, 155], ["differentiated", "OBSERVATION_MODIFIER", 3, 17], ["CSM", "OBSERVATION_MODIFIER", 18, 21], ["14.1 cells", "OBSERVATION", 21, 31]]], ["Survival of SINV SM24-infected neurons was modestly improved from that of SINV WT-infected neurons.Mutations in the nsP3 macro domain reduce SINV virulence in mice ::: ResultsTo assess the importance of the nsP3 macro domain for induction of encephalomyelitis in vivo, mice were infected with SINV WT or mutants, and morbidity, mortality and virus replication in brain were assessed (Fig. 7).", [["neurons", "ANATOMY", 31, 38], ["neurons", "ANATOMY", 91, 98], ["brain", "ANATOMY", 363, 368], ["encephalomyelitis", "DISEASE", 242, 259], ["SINV", "ORGANISM", 12, 16], ["SM24", "GENE_OR_GENE_PRODUCT", 17, 21], ["neurons", "CELL", 31, 38], ["SINV WT", "ORGANISM", 74, 81], ["neurons", "CELL", 91, 98], ["nsP3", "GENE_OR_GENE_PRODUCT", 116, 120], ["SINV", "ORGANISM", 141, 145], ["mice", "ORGANISM", 159, 163], ["nsP3", "GENE_OR_GENE_PRODUCT", 207, 211], ["mice", "ORGANISM", 269, 273], ["SINV WT", "ORGANISM", 293, 300], ["brain", "ORGAN", 363, 368], ["SINV SM24-infected neurons", "CELL_LINE", 12, 38], ["infected neurons", "CELL_TYPE", 82, 98], ["nsP3 macro domain", "PROTEIN", 116, 133], ["nsP3 macro domain", "PROTEIN", 207, 224], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 269, 273], ["SINV", "SPECIES", 12, 16], ["SINV", "SPECIES", 74, 78], ["SINV", "SPECIES", 141, 145], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 269, 273], ["SINV", "SPECIES", 293, 297], ["SINV SM24", "TEST", 12, 21], ["infected neurons", "PROBLEM", 22, 38], ["SINV WT", "TEST", 74, 81], ["infected neurons", "PROBLEM", 82, 98], ["Mutations", "PROBLEM", 99, 108], ["the nsP3 macro domain", "TREATMENT", 203, 224], ["encephalomyelitis", "PROBLEM", 242, 259], ["SINV WT", "TREATMENT", 293, 300], ["morbidity", "PROBLEM", 317, 326], ["virus replication in brain", "PROBLEM", 342, 368], ["improved", "OBSERVATION_MODIFIER", 52, 60], ["infected", "OBSERVATION", 82, 90], ["encephalomyelitis", "OBSERVATION", 242, 259], ["brain", "ANATOMY", 363, 368]]], ["Because mutations in the nsP3 macro domain affected SINV-induced neuronal death only in differentiated neurons (Fig. 6), we explored the possibility that the effect of mutations on SINV virulence in mice also depends on age.", [["neuronal", "ANATOMY", 65, 73], ["neurons", "ANATOMY", 103, 110], ["neuronal death", "DISEASE", 65, 79], ["nsP3", "GENE_OR_GENE_PRODUCT", 25, 29], ["SINV", "ORGANISM", 52, 56], ["neuronal", "CELL", 65, 73], ["neurons", "CELL", 103, 110], ["SINV", "ORGANISM", 181, 185], ["mice", "ORGANISM", 199, 203], ["nsP3 macro domain", "PROTEIN", 25, 42], ["differentiated neurons", "CELL_TYPE", 88, 110], ["mice", "SPECIES", 199, 203], ["SINV", "SPECIES", 181, 185], ["mice", "SPECIES", 199, 203], ["mutations", "PROBLEM", 8, 17], ["neuronal death", "PROBLEM", 65, 79], ["mutations on SINV virulence", "PROBLEM", 168, 195], ["neuronal death", "OBSERVATION", 65, 79]]], ["Two week-old or 5 day-old mice were infected with SINV WT, SM10, SM24, or DM, or mock infected with PBS.", [["mice", "ORGANISM", 26, 30], ["SINV", "ORGANISM", 50, 54], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["SINV", "SPECIES", 50, 54], ["SINV WT", "TEST", 50, 57], ["DM", "PROBLEM", 74, 76], ["mock infected with PBS", "PROBLEM", 81, 103]]], ["In 5 day-old mice, SINV WT infection resulted in severe paralysis and death 1.5 days earlier than SINV DM infection (median survival: WT, 4 days; DM, 5.5 days; P< 0.0001) (Figs.", [["infection", "DISEASE", 27, 36], ["paralysis", "DISEASE", 56, 65], ["death", "DISEASE", 70, 75], ["SINV DM infection", "DISEASE", 98, 115], ["mice", "ORGANISM", 13, 17], ["SINV", "ORGANISM", 19, 23], ["WT", "ORGANISM", 24, 26], ["SINV", "ORGANISM", 98, 102], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["SINV", "SPECIES", 19, 23], ["SINV", "SPECIES", 98, 102], ["SINV WT infection", "PROBLEM", 19, 36], ["severe paralysis", "PROBLEM", 49, 65], ["death", "PROBLEM", 70, 75], ["SINV DM infection", "PROBLEM", 98, 115], ["DM", "PROBLEM", 146, 148], ["infection", "OBSERVATION", 27, 36], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["paralysis", "OBSERVATION", 56, 65], ["infection", "OBSERVATION", 106, 115]]], ["However, survival curves for WT- and DM-infected mice were not significantly different (P= 0.2059, Log-rank test), and all of the mice infected with WT or mutant viruses died by day 6 after infection.", [["infection", "DISEASE", 190, 199], ["DM", "ORGANISM", 37, 39], ["mice", "ORGANISM", 49, 53], ["mice", "ORGANISM", 130, 134], ["mutant viruses", "ORGANISM", 155, 169], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 130, 134], ["survival curves", "TEST", 9, 24], ["WT", "TEST", 29, 31], ["DM", "PROBLEM", 37, 39], ["infected mice", "PROBLEM", 40, 53], ["P", "TEST", 88, 89], ["Log-rank test", "TEST", 99, 112], ["mutant viruses", "PROBLEM", 155, 169], ["infection", "PROBLEM", 190, 199], ["infection", "OBSERVATION", 190, 199]]], ["Viral replication in brain was not different between SINV WT and mutants (Fig. 7E).", [["brain", "ANATOMY", 21, 26], ["Viral", "ORGANISM", 0, 5], ["brain", "ORGAN", 21, 26], ["SINV WT", "ORGANISM", 53, 60], ["SINV", "SPECIES", 53, 57], ["Viral replication in brain", "PROBLEM", 0, 26], ["replication", "OBSERVATION", 6, 17], ["brain", "ANATOMY", 21, 26]]], ["In contrast, in 2 week-old mice, SINV WT infection caused 90% mortality, while DM-infected mice remained well (P< 0.0001, Log-rank test) (Figs.", [["infection", "DISEASE", 41, 50], ["DM-infected", "DISEASE", 79, 90], ["mice", "ORGANISM", 27, 31], ["SINV WT", "ORGANISM", 33, 40], ["mice", "ORGANISM", 91, 95], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 27, 31], ["SINV", "SPECIES", 33, 37], ["mice", "SPECIES", 91, 95], ["SINV WT infection", "PROBLEM", 33, 50], ["DM", "PROBLEM", 79, 81], ["Log-rank test", "TEST", 122, 135], ["infection", "OBSERVATION", 41, 50]]], ["7B and D).", [["D", "SIMPLE_CHEMICAL", 7, 8]]], ["SINV SM10 and SM24 were less attenuated than SINV DM with 40% mortality (P= 0.0228, SM10; P= 0.0170, SM24).", [["DM", "DISEASE", 50, 52], ["SINV", "ORGANISM", 0, 4], ["SM24", "GENE_OR_GENE_PRODUCT", 14, 18], ["SINV", "ORGANISM", 45, 49], ["SINV", "SPECIES", 0, 4], ["SINV", "SPECIES", 45, 49], ["SINV DM", "PROBLEM", 45, 52], ["P", "TEST", 73, 74], ["P", "TEST", 90, 91]]], ["SINV WT, and all mutants replicated to high titers in the brains of 2 week-old mice, but only mutated viruses showed evidence of clearance 7 days after infection (Fig. 7F).Mutations in the nsP3 macro domain reduce SINV virulence in mice ::: ResultsVirus produced from the brains of SINV-DM-infected mice was sequenced and the same reversions at nsP3 amino acids 10 and 31 that occurred during replication in CSM14.1 cells were detected (Figs.", [["brains", "ANATOMY", 58, 64], ["brains", "ANATOMY", 272, 278], ["CSM14.1 cells", "ANATOMY", 408, 421], ["infection", "DISEASE", 152, 161], ["amino acids", "CHEMICAL", 350, 361], ["amino acids", "CHEMICAL", 350, 361], ["SINV WT", "ORGANISM", 0, 7], ["mice", "ORGANISM", 79, 83], ["nsP3", "GENE_OR_GENE_PRODUCT", 189, 193], ["SINV", "ORGANISM", 214, 218], ["mice", "ORGANISM", 232, 236], ["ResultsVirus", "GENE_OR_GENE_PRODUCT", 241, 253], ["brains", "ORGAN", 272, 278], ["SINV-DM", "ORGANISM", 282, 289], ["mice", "ORGANISM", 299, 303], ["nsP3", "SIMPLE_CHEMICAL", 345, 349], ["amino acids", "AMINO_ACID", 350, 361], ["CSM14.1 cells", "CELL", 408, 421], ["nsP3 macro domain", "PROTEIN", 189, 206], ["ResultsVirus", "PROTEIN", 241, 253], ["nsP3 amino acids 10 and 31", "PROTEIN", 345, 371], ["CSM14.1 cells", "CELL_LINE", 408, 421], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 232, 236], ["mice", "SPECIES", 299, 303], ["SINV", "SPECIES", 0, 4], ["mice", "SPECIES", 79, 83], ["SINV", "SPECIES", 214, 218], ["mice", "SPECIES", 232, 236], ["SINV", "SPECIES", 282, 286], ["mice", "SPECIES", 299, 303], ["SINV WT", "TEST", 0, 7], ["mutated viruses", "PROBLEM", 94, 109], ["infection", "PROBLEM", 152, 161], ["Mutations", "PROBLEM", 172, 181], ["SINV", "PROBLEM", 282, 286], ["DM", "PROBLEM", 287, 289], ["infected mice", "PROBLEM", 290, 303], ["nsP3 amino acids", "TEST", 345, 361], ["14.1 cells", "OBSERVATION", 411, 421]]], ["3B and C).DiscussionWhile the roles of nsP1, nsP2, and nsP4 are well characterized in SINV replication, the function of nsP3 has been elusive.", [["nsP1", "GENE_OR_GENE_PRODUCT", 39, 43], ["nsP2", "GENE_OR_GENE_PRODUCT", 45, 49], ["nsP4", "GENE_OR_GENE_PRODUCT", 55, 59], ["SINV", "ORGANISM", 86, 90], ["nsP3", "GENE_OR_GENE_PRODUCT", 120, 124], ["nsP1", "PROTEIN", 39, 43], ["nsP2", "PROTEIN", 45, 49], ["nsP4", "PROTEIN", 55, 59], ["nsP3", "PROTEIN", 120, 124], ["SINV", "SPECIES", 86, 90], ["nsP1", "TEST", 39, 43], ["nsP2", "PROBLEM", 45, 49], ["nsP4", "PROBLEM", 55, 59], ["SINV replication", "TREATMENT", 86, 102], ["nsP3", "PROBLEM", 120, 124]]], ["Previous studies using SINV variants generated by random insertion or chemical mutagenesis of nsP3 have reported small reductions in virus replication and in minus strand or subgenomic RNA synthesis, but have not focused on the macro domain and have not examined the in vivo effects of these mutations (De et al., 2003, LaStarza et al., 1994a, LaStarza et al., 1994b).", [["SINV", "ORGANISM", 23, 27], ["nsP3", "GENE_OR_GENE_PRODUCT", 94, 98], ["nsP3", "DNA", 94, 98], ["subgenomic RNA", "RNA", 174, 188], ["macro domain", "PROTEIN", 228, 240], ["SINV", "SPECIES", 23, 27], ["Previous studies", "TEST", 0, 16], ["SINV variants", "TREATMENT", 23, 36], ["random insertion", "TREATMENT", 50, 66], ["chemical mutagenesis of nsP3", "TREATMENT", 70, 98], ["small reductions in virus replication", "PROBLEM", 113, 150], ["minus strand or subgenomic RNA synthesis", "PROBLEM", 158, 198], ["these mutations", "PROBLEM", 286, 301], ["small", "OBSERVATION_MODIFIER", 113, 118], ["reductions", "OBSERVATION_MODIFIER", 119, 129], ["virus replication", "OBSERVATION", 133, 150], ["subgenomic RNA synthesis", "OBSERVATION", 174, 198]]], ["In this study we targeted the ADP-ribose binding site in the macro domain for mutational analysis and showed that the nsP3 macro domain plays an important role in SINV replication although the mutations did not affect PAR binding.", [["ADP", "CHEMICAL", 30, 33], ["ribose", "CHEMICAL", 34, 40], ["ADP", "CHEMICAL", 30, 33], ["ribose", "CHEMICAL", 34, 40], ["ADP", "SIMPLE_CHEMICAL", 30, 33], ["nsP3", "GENE_OR_GENE_PRODUCT", 118, 122], ["SINV", "ORGANISM", 163, 167], ["PAR", "GENE_OR_GENE_PRODUCT", 218, 221], ["ADP-ribose binding site", "DNA", 30, 53], ["nsP3 macro domain", "PROTEIN", 118, 135], ["PAR", "PROTEIN", 218, 221], ["SINV", "SPECIES", 163, 167], ["this study", "TEST", 3, 13], ["the ADP-ribose binding site", "PROBLEM", 26, 53], ["mutational analysis", "TEST", 78, 97], ["the nsP3 macro domain", "PROBLEM", 114, 135], ["SINV replication", "TREATMENT", 163, 179], ["the mutations", "PROBLEM", 189, 202], ["SINV replication", "OBSERVATION", 163, 179]]], ["Mutations at nsP3 amino acids 10 and 24 in the macro domain impaired virus replication and viral RNA amplification, and caused nsP3 instability in neurons.", [["neurons", "ANATOMY", 147, 154], ["amino acids", "CHEMICAL", 18, 29], ["amino acids", "CHEMICAL", 18, 29], ["nsP3", "AMINO_ACID", 13, 17], ["amino acids", "AMINO_ACID", 18, 29], ["nsP3", "GENE_OR_GENE_PRODUCT", 127, 131], ["neurons", "CELL", 147, 154], ["nsP3 amino acids 10 and 24", "PROTEIN", 13, 39], ["macro domain", "PROTEIN", 47, 59], ["viral RNA", "RNA", 91, 100], ["nsP3", "PROTEIN", 127, 131], ["neurons", "CELL_TYPE", 147, 154], ["Mutations at nsP3 amino acids", "TEST", 0, 29], ["impaired virus replication", "TREATMENT", 60, 86], ["viral RNA amplification", "TREATMENT", 91, 114], ["nsP3 instability in neurons", "PROBLEM", 127, 154], ["virus replication", "OBSERVATION", 69, 86], ["viral RNA", "OBSERVATION", 91, 100], ["nsP3 instability", "OBSERVATION", 127, 143], ["neurons", "ANATOMY", 147, 154]]], ["The greatest effects were detected when amino acid 10 was mutated.", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["amino acid 10", "AMINO_ACID", 40, 53], ["amino acid", "TEST", 40, 50], ["greatest", "OBSERVATION_MODIFIER", 4, 12]]], ["Mutated viruses formed small plaques in BHK21 cells, and virus variants with a reversion at amino acid 10 or with a second-site mutation at amino acid 31, also in the macro domain, were rapidly selected during replication of SINV in cultured neurons and mouse brains.", [["plaques", "ANATOMY", 29, 36], ["BHK21 cells", "ANATOMY", 40, 51], ["neurons", "ANATOMY", 242, 249], ["brains", "ANATOMY", 260, 266], ["amino acid", "CHEMICAL", 92, 102], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 92, 102], ["amino acid", "CHEMICAL", 140, 150], ["BHK21 cells", "CELL", 40, 51], ["amino acid 10", "AMINO_ACID", 92, 105], ["amino acid 31", "AMINO_ACID", 140, 153], ["SINV", "ORGANISM", 225, 229], ["neurons", "CELL", 242, 249], ["mouse", "ORGANISM", 254, 259], ["brains", "ORGAN", 260, 266], ["BHK21 cells", "CELL_LINE", 40, 51], ["macro domain", "PROTEIN", 167, 179], ["cultured neurons", "CELL_LINE", 233, 249], ["mouse", "SPECIES", 254, 259], ["SINV", "SPECIES", 225, 229], ["mouse", "SPECIES", 254, 259], ["Mutated viruses formed small plaques in BHK21 cells", "PROBLEM", 0, 51], ["virus variants", "PROBLEM", 57, 71], ["a reversion at amino acid", "TREATMENT", 77, 102], ["amino acid", "TEST", 140, 150], ["SINV in cultured neurons", "TREATMENT", 225, 249], ["viruses", "OBSERVATION", 8, 15], ["small", "OBSERVATION_MODIFIER", 23, 28], ["plaques", "OBSERVATION", 29, 36], ["BHK21 cells", "OBSERVATION", 40, 51], ["virus variants", "OBSERVATION", 57, 71], ["brains", "ANATOMY", 260, 266]]], ["This study also showed that the mutations in the nsP3 macro domain impaired virulence for 2 week-old mice and mature cultured neurons.DiscussionPrevious studies support a role for the macro domain in SINV replication.", [["neurons", "ANATOMY", 126, 133], ["nsP3", "GENE_OR_GENE_PRODUCT", 49, 53], ["mice", "ORGANISM", 101, 105], ["neurons", "CELL", 126, 133], ["SINV", "ORGANISM", 200, 204], ["nsP3 macro domain", "PROTEIN", 49, 66], ["mature cultured neurons", "CELL_TYPE", 110, 133], ["macro domain", "PROTEIN", 184, 196], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["SINV", "SPECIES", 200, 204], ["This study", "TEST", 0, 10], ["the mutations", "PROBLEM", 28, 41], ["the nsP3 macro domain impaired virulence", "PROBLEM", 45, 85], ["old mice and mature cultured neurons", "PROBLEM", 97, 133], ["the macro domain", "TREATMENT", 180, 196], ["SINV replication", "TREATMENT", 200, 216], ["SINV replication", "OBSERVATION", 200, 216]]], ["SINV mutants generated by random insertion of linker sequences into the nsP3 macro domain show smaller plaque phenotypes, a decrease in plaque formation, and a defect in RNA synthesis (LaStarza et al., 1994b).", [["plaque", "ANATOMY", 103, 109], ["plaque", "ANATOMY", 136, 142], ["plaque", "DISEASE", 136, 142], ["SINV", "ORGANISM", 0, 4], ["plaque", "PATHOLOGICAL_FORMATION", 103, 109], ["plaque", "PATHOLOGICAL_FORMATION", 136, 142], ["nsP3 macro domain", "PROTEIN", 72, 89], ["SINV", "SPECIES", 0, 4], ["SINV mutants", "TREATMENT", 0, 12], ["random insertion of linker sequences", "TREATMENT", 26, 62], ["the nsP3 macro domain", "TEST", 68, 89], ["smaller plaque phenotypes", "PROBLEM", 95, 120], ["a decrease in plaque formation", "PROBLEM", 122, 152], ["a defect in RNA synthesis", "PROBLEM", 158, 183], ["smaller", "OBSERVATION_MODIFIER", 95, 102], ["plaque", "OBSERVATION", 103, 109], ["decrease", "OBSERVATION_MODIFIER", 124, 132], ["plaque", "OBSERVATION", 136, 142], ["defect", "OBSERVATION", 160, 166], ["RNA synthesis", "OBSERVATION", 170, 183]]], ["The mutation present in SINV mutant ts138 (alanine to glycine at residue 68 of nsP3) is associated with decreased C-terminal nsP3 phosphorylation and decreased minus strand synthesis (De et al., 2003).DiscussionThe importance of the nsP3 macro domain is underscored by reversions that occurred during SINV DM replication in cultured neurons or the brains of infected mice.", [["neurons", "ANATOMY", 333, 340], ["brains", "ANATOMY", 348, 354], ["alanine", "CHEMICAL", 43, 50], ["glycine", "CHEMICAL", 54, 61], ["alanine", "CHEMICAL", 43, 50], ["glycine", "CHEMICAL", 54, 61], ["C", "CHEMICAL", 114, 115], ["SINV mutant ts138", "ORGANISM", 24, 41], ["alanine", "AMINO_ACID", 43, 50], ["glycine", "AMINO_ACID", 54, 61], ["residue 68", "AMINO_ACID", 65, 75], ["nsP3", "GENE_OR_GENE_PRODUCT", 79, 83], ["nsP3", "GENE_OR_GENE_PRODUCT", 125, 129], ["nsP3", "GENE_OR_GENE_PRODUCT", 233, 237], ["SINV DM", "ORGANISM", 301, 308], ["neurons", "CELL", 333, 340], ["brains", "ORGAN", 348, 354], ["mice", "ORGANISM", 367, 371], ["nsP3", "PROTEIN", 79, 83], ["nsP3", "PROTEIN", 125, 129], ["nsP3 macro domain", "PROTEIN", 233, 250], ["cultured neurons", "CELL_LINE", 324, 340], ["mice", "SPECIES", 367, 371], ["SINV", "SPECIES", 301, 305], ["mice", "SPECIES", 367, 371], ["The mutation", "PROBLEM", 0, 12], ["SINV mutant ts", "TEST", 24, 38], ["alanine to glycine at residue", "TREATMENT", 43, 72], ["decreased C-terminal nsP3 phosphorylation", "PROBLEM", 104, 145], ["decreased minus strand synthesis", "PROBLEM", 150, 182], ["the nsP3 macro domain", "PROBLEM", 229, 250], ["SINV DM replication", "TREATMENT", 301, 320], ["nsP3 phosphorylation", "OBSERVATION", 125, 145], ["decreased", "OBSERVATION_MODIFIER", 150, 159], ["minus strand", "OBSERVATION", 160, 172], ["infected mice", "OBSERVATION", 358, 371]]], ["Virus variants with a reversion at nsP3 amino acid 10 to threonine or aspartate (the amino acid present in many macro domains at this position; Neuvonen and Ahola, 2009) emerged shortly after infection, indicating selective pressure.", [["amino acid", "CHEMICAL", 40, 50], ["threonine", "CHEMICAL", 57, 66], ["aspartate", "CHEMICAL", 70, 79], ["amino acid", "CHEMICAL", 85, 95], ["infection", "DISEASE", 192, 201], ["amino acid", "CHEMICAL", 40, 50], ["threonine", "CHEMICAL", 57, 66], ["aspartate", "CHEMICAL", 70, 79], ["amino acid", "CHEMICAL", 85, 95], ["Virus", "ORGANISM", 0, 5], ["amino acid 10", "AMINO_ACID", 40, 53], ["threonine", "AMINO_ACID", 57, 66], ["aspartate", "AMINO_ACID", 70, 79], ["amino acid", "AMINO_ACID", 85, 95], ["Virus variants", "PROBLEM", 0, 14], ["a reversion", "TREATMENT", 20, 31], ["nsP3 amino acid", "TEST", 35, 50], ["aspartate", "TEST", 70, 79], ["the amino acid", "TEST", 81, 95], ["infection", "PROBLEM", 192, 201], ["selective", "OBSERVATION_MODIFIER", 214, 223], ["pressure", "OBSERVATION_MODIFIER", 224, 232]]], ["Furthermore, viruses with a second-site change at nsP3 amino acid 31 (glutamate to glycine) were selected and thus became more homologous in amino acid sequence and structure to other macro domains, in which this is a highly conserved amino acid (Neuvonen and Ahola, 2009, Till and Ladurner, 2009).", [["amino acid", "CHEMICAL", 55, 65], ["glutamate", "CHEMICAL", 70, 79], ["glycine", "CHEMICAL", 83, 90], ["amino acid", "CHEMICAL", 141, 151], ["amino acid", "CHEMICAL", 235, 245], ["amino acid", "CHEMICAL", 55, 65], ["glutamate", "CHEMICAL", 70, 79], ["glycine", "CHEMICAL", 83, 90], ["amino acid", "CHEMICAL", 141, 151], ["amino acid", "CHEMICAL", 235, 245], ["nsP3", "SIMPLE_CHEMICAL", 50, 54], ["amino acid 31", "AMINO_ACID", 55, 68], ["glutamate", "AMINO_ACID", 70, 79], ["glycine", "AMINO_ACID", 83, 90], ["amino acid", "AMINO_ACID", 141, 151], ["amino acid", "AMINO_ACID", 235, 245], ["nsP3 amino acid 31", "PROTEIN", 50, 68], ["amino acid sequence", "PROTEIN", 141, 160], ["macro domains", "PROTEIN", 184, 197], ["viruses", "PROBLEM", 13, 20], ["a second-site change", "PROBLEM", 26, 46], ["nsP3 amino acid", "TEST", 50, 65], ["more homologous in amino acid sequence", "PROBLEM", 122, 160], ["viruses", "OBSERVATION", 13, 20], ["amino acid", "OBSERVATION", 235, 245]]], ["Viruses with reversions at amino acid 10 of nsP3 did not have the change at amino acid 31, and the population of viruses with amino acid 10 reversion increased as the infection progressed, while the population of viruses with amino acid 31 reversion decreased (data not shown), suggesting that virus variants with these amino acid changes are different populations or are selected at different times after infection.", [["amino acid", "CHEMICAL", 27, 37], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 126, 136], ["infection", "DISEASE", 167, 176], ["amino acid", "CHEMICAL", 226, 236], ["amino acid", "CHEMICAL", 320, 330], ["infection", "DISEASE", 406, 415], ["amino acid", "CHEMICAL", 27, 37], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 226, 236], ["amino acid", "CHEMICAL", 320, 330], ["amino acid", "AMINO_ACID", 27, 37], ["nsP3", "GENE_OR_GENE_PRODUCT", 44, 48], ["amino acid 31", "AMINO_ACID", 76, 89], ["amino acid 10", "AMINO_ACID", 126, 139], ["amino acid", "AMINO_ACID", 226, 236], ["amino acid", "AMINO_ACID", 320, 330], ["nsP3", "PROTEIN", 44, 48], ["Viruses", "PROBLEM", 0, 7], ["amino acid", "TEST", 27, 37], ["nsP3", "PROBLEM", 44, 48], ["amino acid", "TEST", 76, 86], ["amino acid", "TEST", 126, 136], ["the infection", "PROBLEM", 163, 176], ["amino acid", "TEST", 226, 236], ["virus variants", "PROBLEM", 294, 308], ["these amino acid changes", "PROBLEM", 314, 338], ["infection", "PROBLEM", 406, 415], ["viruses", "OBSERVATION", 113, 120], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["infection", "OBSERVATION", 167, 176], ["virus variants", "OBSERVATION", 294, 308], ["amino acid", "OBSERVATION", 320, 330], ["infection", "OBSERVATION", 406, 415]]], ["The reciprocal relationship between these amino acid reversions suggests cooperativity and that a change at residue 31 is not required once the mutation at amino acid 10 is reverted.DiscussionSeveral positive-strand RNA viruses have conserved macro domains in their nonstructural proteins, suggesting an evolutionarily preserved role (Koonin et al., 1992, Gorbalenya et al., 1991).", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 156, 166], ["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 156, 166], ["amino acid", "AMINO_ACID", 42, 52], ["amino acid", "AMINO_ACID", 156, 166], ["nonstructural proteins", "PROTEIN", 266, 288], ["these amino acid reversions", "TREATMENT", 36, 63], ["a change at residue", "PROBLEM", 96, 115], ["the mutation at amino acid", "TEST", 140, 166], ["strand RNA viruses", "PROBLEM", 209, 227], ["acid reversions", "OBSERVATION", 48, 63], ["strand RNA viruses", "OBSERVATION", 209, 227], ["nonstructural proteins", "OBSERVATION", 266, 288]]], ["Viral macro domains are often closely associated with papain-like protease domains, but no functional link between the macro domain and protease activity has been reported (Liang et al., 2000, Putics et al., 2005, Gorbalenya et al., 1991).", [["papain-like protease", "GENE_OR_GENE_PRODUCT", 54, 74], ["Viral macro domains", "PROTEIN", 0, 19], ["papain-like protease domains", "PROTEIN", 54, 82], ["macro domain", "PROTEIN", 119, 131], ["protease", "PROTEIN", 136, 144], ["Viral macro domains", "PROBLEM", 0, 19], ["papain", "TREATMENT", 54, 60], ["protease domains", "PROBLEM", 66, 82]]], ["Some macro domains can hydrolyze ADP-ribose-1\u2033 phosphate (ADPR-1\u2033P), a product of tRNA splicing, to yield ADP-ribose.", [["ADP-ribose-1\u2033 phosphate", "CHEMICAL", 33, 56], ["ADPR-1\u2033P", "CHEMICAL", 58, 66], ["ADP-ribose", "CHEMICAL", 106, 116], ["ADP-ribose-1\u2033 phosphate", "CHEMICAL", 33, 56], ["ADPR-1\u2033P", "CHEMICAL", 58, 66], ["ADP", "CHEMICAL", 106, 109], ["ribose", "CHEMICAL", 110, 116], ["ADP-ribose-1\u2033 phosphate", "SIMPLE_CHEMICAL", 33, 56], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 58, 66], ["ADP-ribose", "SIMPLE_CHEMICAL", 106, 116], ["Some macro domains", "PROBLEM", 0, 18], ["hydrolyze ADP", "TEST", 23, 36], ["ribose", "TEST", 37, 43], ["phosphate (ADPR", "TREATMENT", 47, 62], ["a product of tRNA splicing", "TREATMENT", 69, 95], ["ADP-ribose", "TREATMENT", 106, 116]]], ["ADPR-1\u2033P phosphatase activity is detected in the macro domain of hepatitis E virus and coronaviruses (Neuvonen and Ahola, 2009, Saikatendu et al., 2005), but this enzymatic activity is dispensable for replication of human coronavirus 229E in vitro (Putics et al., 2005).", [["hepatitis E", "DISEASE", 65, 76], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["hepatitis E virus", "ORGANISM", 65, 82], ["coronaviruses", "ORGANISM", 87, 100], ["human", "ORGANISM", 216, 221], ["coronavirus 229E", "ORGANISM", 222, 238], ["ADPR-1\u2033P phosphatase", "PROTEIN", 0, 20], ["hepatitis E virus", "SPECIES", 65, 82], ["human", "SPECIES", 216, 221], ["coronavirus", "SPECIES", 222, 233], ["hepatitis E virus", "SPECIES", 65, 82], ["human coronavirus", "SPECIES", 216, 233], ["ADPR", "TEST", 0, 4], ["P phosphatase activity", "TEST", 7, 29], ["hepatitis E virus", "PROBLEM", 65, 82], ["coronaviruses", "PROBLEM", 87, 100], ["human coronavirus", "PROBLEM", 216, 233], ["hepatitis", "OBSERVATION", 65, 74]]], ["However, mutation of a residue important for this enzymatic activity in the coronavirus mouse hepatitis virus A59 results in altered liver pathology in infected mice associated with decreased induction of IL-6, decreased hepatic necrosis and improved virus clearance, but little change in peak virus replication.DiscussionThe macro domains of alphaviruses have little ADPR-1\u2033P phosphatase activity.", [["liver", "ANATOMY", 133, 138], ["hepatic", "ANATOMY", 221, 228], ["hepatitis", "DISEASE", 94, 103], ["liver pathology", "DISEASE", 133, 148], ["hepatic necrosis", "DISEASE", 221, 237], ["coronavirus", "ORGANISM", 76, 87], ["mouse hepatitis virus A59", "ORGANISM", 88, 113], ["liver", "ORGAN", 133, 138], ["mice", "ORGANISM", 161, 165], ["IL-6", "GENE_OR_GENE_PRODUCT", 205, 209], ["hepatic", "ORGAN", 221, 228], ["alphaviruses", "ORGANISM", 343, 355], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 368, 374], ["IL-6", "PROTEIN", 205, 209], ["ADPR", "PROTEIN", 368, 372], ["1\u2033P phosphatase", "PROTEIN", 373, 388], ["coronavirus", "SPECIES", 76, 87], ["mouse", "SPECIES", 88, 93], ["hepatitis virus", "SPECIES", 94, 109], ["mice", "SPECIES", 161, 165], ["mouse hepatitis virus", "SPECIES", 88, 109], ["mice", "SPECIES", 161, 165], ["a residue", "PROBLEM", 21, 30], ["this enzymatic activity", "PROBLEM", 45, 68], ["the coronavirus mouse hepatitis virus A59", "TEST", 72, 113], ["altered liver pathology", "PROBLEM", 125, 148], ["decreased induction of IL", "TREATMENT", 182, 207], ["decreased hepatic necrosis", "PROBLEM", 211, 237], ["improved virus clearance", "PROBLEM", 242, 266], ["little change in peak virus replication", "PROBLEM", 272, 311], ["alphaviruses", "PROBLEM", 343, 355], ["ADPR", "TEST", 368, 372], ["liver", "ANATOMY", 133, 138], ["pathology", "OBSERVATION", 139, 148], ["infected mice", "OBSERVATION", 152, 165], ["decreased", "OBSERVATION_MODIFIER", 182, 191], ["decreased", "OBSERVATION_MODIFIER", 211, 220], ["hepatic", "ANATOMY", 221, 228], ["necrosis", "OBSERVATION", 229, 237], ["improved", "OBSERVATION_MODIFIER", 242, 250], ["virus", "OBSERVATION", 251, 256], ["little", "OBSERVATION_MODIFIER", 272, 278], ["change", "OBSERVATION_MODIFIER", 279, 285], ["peak virus replication", "OBSERVATION", 289, 311]]], ["Residue 24 of SINV nsP3 is in the APPR-1\u2033P catalytic site, and mutation of this site in SFV, along with amino acid 21, eliminates the small amount of enzymatic activity present in the WT protein (Neuvonen and Ahola, 2009).", [["amino acid", "CHEMICAL", 104, 114], ["amino acid", "CHEMICAL", 104, 114], ["SINV", "ORGANISM", 14, 18], ["nsP3", "GENE_OR_GENE_PRODUCT", 19, 23], ["APPR-1", "GENE_OR_GENE_PRODUCT", 34, 40], ["SFV", "ORGANISM", 88, 91], ["amino acid 21", "AMINO_ACID", 104, 117], ["SINV nsP3", "PROTEIN", 14, 23], ["APPR-1\u2033P catalytic site", "DNA", 34, 57], ["WT protein", "PROTEIN", 184, 194], ["SINV", "SPECIES", 14, 18], ["SINV nsP3", "PROBLEM", 14, 23], ["the APPR", "TEST", 30, 38], ["mutation of this site in SFV", "PROBLEM", 63, 91], ["amino acid", "TEST", 104, 114], ["enzymatic activity", "PROBLEM", 150, 168], ["SINV nsP3", "OBSERVATION", 14, 23], ["SFV", "ANATOMY", 88, 91], ["small", "OBSERVATION_MODIFIER", 134, 139], ["amount", "OBSERVATION_MODIFIER", 140, 146], ["enzymatic activity", "OBSERVATION", 150, 168]]], ["SINV SM24 was least impaired of the mutated SINVs studied, suggesting that the ADPR-1\u2033P phosphatase activity of nsP3 is not crucial for SINV replication.", [["SINV", "ORGANISM", 0, 4], ["SM24", "GENE_OR_GENE_PRODUCT", 5, 9], ["SINVs", "CANCER", 44, 49], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 79, 85], ["nsP3", "GENE_OR_GENE_PRODUCT", 112, 116], ["SINV", "ORGANISM", 136, 140], ["mutated SINVs", "PROTEIN", 36, 49], ["ADPR", "DNA", 79, 83], ["P phosphatase", "PROTEIN", 86, 99], ["nsP3", "PROTEIN", 112, 116], ["SINV", "SPECIES", 0, 4], ["SINV", "SPECIES", 136, 140], ["P phosphatase activity", "TEST", 86, 108], ["nsP3", "PROBLEM", 112, 116], ["SINV replication", "TREATMENT", 136, 152]]], ["In differentiated neurons, SM24 nsP3 was stable, virus replication and induction of neuronal death were similar to that observed with WT virus, and revertants were not detected during replication.", [["neurons", "ANATOMY", 18, 25], ["neuronal", "ANATOMY", 84, 92], ["neuronal death", "DISEASE", 84, 98], ["neurons", "CELL", 18, 25], ["SM24 nsP3", "GENE_OR_GENE_PRODUCT", 27, 36], ["neuronal", "CELL", 84, 92], ["WT virus", "ORGANISM", 134, 142], ["differentiated neurons", "CELL_TYPE", 3, 25], ["SM24 nsP3", "PROTEIN", 27, 36], ["SM24 nsP3", "PROBLEM", 27, 36], ["virus replication", "TREATMENT", 49, 66], ["neuronal death", "PROBLEM", 84, 98], ["WT virus", "PROBLEM", 134, 142], ["neurons", "ANATOMY", 18, 25], ["stable", "OBSERVATION_MODIFIER", 41, 47]]], ["However, in 2 week-old mice virulence was attenuated and clearance was facilitated compared to WT virus, suggesting a potential role in the pathogenesis of encephalitis.DiscussionMany viral macro domains have the ability to interact with ADP-ribose in some form.", [["encephalitis", "DISEASE", 156, 168], ["ADP-ribose", "CHEMICAL", 238, 248], ["ADP", "CHEMICAL", 238, 241], ["ribose", "CHEMICAL", 242, 248], ["mice", "ORGANISM", 23, 27], ["WT virus", "ORGANISM", 95, 103], ["ADP-ribose", "SIMPLE_CHEMICAL", 238, 248], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["old mice virulence", "PROBLEM", 19, 37], ["WT virus", "PROBLEM", 95, 103], ["encephalitis", "PROBLEM", 156, 168], ["ADP-ribose", "TREATMENT", 238, 248], ["encephalitis", "OBSERVATION", 156, 168]]], ["The ability of macro domains to bind monomeric ADP-ribose appears unrelated to the ability to bind PAR.", [["ADP-ribose", "CHEMICAL", 47, 57], ["ADP", "CHEMICAL", 47, 50], ["ribose", "CHEMICAL", 51, 57], ["ADP-ribose", "SIMPLE_CHEMICAL", 47, 57], ["PAR", "GENE_OR_GENE_PRODUCT", 99, 102], ["macro domains", "PROTEIN", 15, 28], ["PAR", "PROTEIN", 99, 102], ["macro domains", "TREATMENT", 15, 28], ["bind monomeric ADP-ribose", "TREATMENT", 32, 57]]], ["The macro domain of SFV binds PAR well, but does not efficiently bind monomeric ADP-ribose (Neuvonen and Ahola, 2009).", [["ADP-ribose", "CHEMICAL", 80, 90], ["ADP", "CHEMICAL", 80, 83], ["ribose", "CHEMICAL", 84, 90], ["SFV", "ORGANISM", 20, 23], ["PAR", "GENE_OR_GENE_PRODUCT", 30, 33], ["ADP-ribose", "SIMPLE_CHEMICAL", 80, 90], ["Neuvonen", "SIMPLE_CHEMICAL", 92, 100], ["macro domain", "PROTEIN", 4, 16], ["PAR", "PROTEIN", 30, 33], ["SFV", "SPECIES", 20, 23], ["SFV", "OBSERVATION", 20, 23]]], ["Likewise, mutations at nsP3 amino acids 10 and 31 in the SFV macro domain that affect coronavirus binding of monomeric ADP-ribose (Karras et al., 2005) did not affect binding of PAR (Neuvonen and Ahola, 2009).", [["amino acids", "CHEMICAL", 28, 39], ["ADP-ribose", "CHEMICAL", 119, 129], ["amino acids", "CHEMICAL", 28, 39], ["ADP", "CHEMICAL", 119, 122], ["ribose", "CHEMICAL", 123, 129], ["nsP3", "AMINO_ACID", 23, 27], ["amino acids", "AMINO_ACID", 28, 39], ["SFV", "ORGANISM", 57, 60], ["coronavirus", "ORGANISM", 86, 97], ["ADP-ribose", "SIMPLE_CHEMICAL", 119, 129], ["PAR", "GENE_OR_GENE_PRODUCT", 178, 181], ["nsP3 amino acids 10 and 31", "PROTEIN", 23, 49], ["SFV macro domain", "PROTEIN", 57, 73], ["PAR", "PROTEIN", 178, 181], ["mutations at nsP3 amino acids", "TEST", 10, 39]]], ["Our studies confirm the lack of effect of mutation at residues 10 and 24 for binding PAR and suggest that additional macro domain residues are important for this binding.", [["PAR", "GENE_OR_GENE_PRODUCT", 85, 88], ["PAR", "PROTEIN", 85, 88], ["Our studies", "TEST", 0, 11], ["mutation at residues", "PROBLEM", 42, 62], ["additional macro domain residues", "TREATMENT", 106, 138], ["this binding", "PROBLEM", 157, 169]]], ["Residues 10 and 24 may be involved in binding another NAD metabolite that has not yet been examined.DiscussionThe significance of the interaction between PAR and the nsP3 macro domain is unclear.", [["NAD", "CHEMICAL", 54, 57], ["NAD", "CHEMICAL", 54, 57], ["NAD", "SIMPLE_CHEMICAL", 54, 57], ["PAR", "GENE_OR_GENE_PRODUCT", 154, 157], ["nsP3", "GENE_OR_GENE_PRODUCT", 166, 170], ["PAR", "PROTEIN", 154, 157], ["nsP3 macro domain", "PROTEIN", 166, 183], ["the nsP3 macro domain", "TEST", 162, 183]]], ["It is possible that some cellular proteins modified with PAR are recruited by nsP3 into replication complexes.", [["cellular", "ANATOMY", 25, 33], ["cellular", "CELL", 25, 33], ["PAR", "GENE_OR_GENE_PRODUCT", 57, 60], ["nsP3", "GENE_OR_GENE_PRODUCT", 78, 82], ["cellular proteins", "PROTEIN", 25, 42], ["PAR", "PROTEIN", 57, 60], ["nsP3", "PROTEIN", 78, 82], ["replication complexes", "PROTEIN", 88, 109], ["some cellular proteins", "PROBLEM", 20, 42]]], ["However, there is no evidence that a deficiency in PAR binding is important for the phenotypes of the mutants we have studied because all retained the ability to bind PAR.DiscussionIn vivo studies of nsP3 macro domain mutants are few.", [["PAR", "GENE_OR_GENE_PRODUCT", 51, 54], ["PAR", "GENE_OR_GENE_PRODUCT", 167, 170], ["nsP3", "GENE_OR_GENE_PRODUCT", 200, 204], ["PAR", "PROTEIN", 51, 54], ["PAR", "PROTEIN", 167, 170], ["nsP3 macro domain mutants", "PROTEIN", 200, 225], ["a deficiency in PAR binding", "PROBLEM", 35, 62], ["nsP3 macro domain mutants", "PROBLEM", 200, 225], ["no evidence", "UNCERTAINTY", 18, 29], ["deficiency", "OBSERVATION", 37, 47], ["few", "OBSERVATION_MODIFIER", 230, 233]]], ["Studies of SFV have shown that mutation of the opal termination codon between nsP3 and nsP4 to encode arginine increases neurovirulence (Tuittila and Hinkkanen, 2003, Tuittila et al., 2000).", [["arginine", "CHEMICAL", 102, 110], ["arginine", "CHEMICAL", 102, 110], ["SFV", "ORGANISM", 11, 14], ["nsP3", "GENE_OR_GENE_PRODUCT", 78, 82], ["nsP4", "GENE_OR_GENE_PRODUCT", 87, 91], ["arginine", "AMINO_ACID", 102, 110], ["opal termination codon", "DNA", 47, 69], ["nsP3", "DNA", 78, 82], ["nsP4", "DNA", 87, 91], ["SFV", "SPECIES", 11, 14], ["Studies of SFV", "TEST", 0, 14], ["mutation of the opal termination codon", "PROBLEM", 31, 69], ["nsP3", "PROBLEM", 78, 82], ["nsP4", "PROBLEM", 87, 91], ["SFV", "ANATOMY", 11, 14], ["increases", "OBSERVATION_MODIFIER", 111, 120], ["neurovirulence", "OBSERVATION_MODIFIER", 121, 135]]], ["In addition, mutations in the macro domain at nsP3 amino acid 11 (valine to isoleucine), 48 (alanine to glutamate) and 70 (glycine to alanine) collectively contribute to increased neurovirulence, but the mechanisms are not known (Tuittila and Hinkkanen, 2003).", [["amino acid", "CHEMICAL", 51, 61], ["valine", "CHEMICAL", 66, 72], ["isoleucine", "CHEMICAL", 76, 86], ["alanine", "CHEMICAL", 93, 100], ["glutamate", "CHEMICAL", 104, 113], ["glycine", "CHEMICAL", 123, 130], ["alanine", "CHEMICAL", 134, 141], ["amino acid", "CHEMICAL", 51, 61], ["valine", "CHEMICAL", 66, 72], ["isoleucine", "CHEMICAL", 76, 86], ["alanine", "CHEMICAL", 93, 100], ["glutamate", "CHEMICAL", 104, 113], ["glycine", "CHEMICAL", 123, 130], ["alanine", "CHEMICAL", 134, 141], ["nsP3", "AMINO_ACID", 46, 50], ["amino acid", "AMINO_ACID", 51, 61], ["11", "AMINO_ACID", 62, 64], ["valine", "AMINO_ACID", 66, 72], ["isoleucine", "AMINO_ACID", 76, 86], ["alanine", "AMINO_ACID", 93, 100], ["glutamate", "AMINO_ACID", 104, 113], ["glycine", "AMINO_ACID", 123, 130], ["alanine", "AMINO_ACID", 134, 141], ["macro domain", "PROTEIN", 30, 42], ["mutations in the macro domain", "PROBLEM", 13, 42], ["nsP3 amino acid", "TEST", 46, 61], ["isoleucine", "TEST", 76, 86], ["increased neurovirulence", "PROBLEM", 170, 194], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["neurovirulence", "OBSERVATION", 180, 194]]], ["We have shown that mutations in the nsP3 macro domain significantly reduced SINV virulence in 2 week-old mice and impaired the ability of the virus to induce death in mature neurons.", [["neurons", "ANATOMY", 174, 181], ["death", "DISEASE", 158, 163], ["nsP3", "GENE_OR_GENE_PRODUCT", 36, 40], ["SINV", "ORGANISM", 76, 80], ["mice", "ORGANISM", 105, 109], ["neurons", "CELL", 174, 181], ["nsP3 macro domain", "PROTEIN", 36, 53], ["mature neurons", "CELL_TYPE", 167, 181], ["mice", "SPECIES", 105, 109], ["SINV", "SPECIES", 76, 80], ["mice", "SPECIES", 105, 109], ["mutations in the nsP3 macro domain", "PROBLEM", 19, 53], ["the virus", "PROBLEM", 138, 147], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["SINV virulence", "OBSERVATION", 76, 90]]], ["Although replication of SINV WT and mutants was similar in mice as indicated by titers at 24 h after infection, the mutations facilitated virus clearance from the nervous system, a process dependent on the responses of infected cells to immune effectors such as interferon-\u03b3 and antibody (Burdeinick-Kerr and Griffin, 2005, Levine et al., 1991).", [["nervous system", "ANATOMY", 163, 177], ["cells", "ANATOMY", 228, 233], ["infection", "DISEASE", 101, 110], ["SINV WT", "ORGANISM", 24, 31], ["mice", "ORGANISM", 59, 63], ["nervous system", "ANATOMICAL_SYSTEM", 163, 177], ["cells", "CELL", 228, 233], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 262, 274], ["infected cells", "CELL_TYPE", 219, 233], ["immune effectors", "PROTEIN", 237, 253], ["interferon", "PROTEIN", 262, 272], ["\u03b3", "PROTEIN", 273, 274], ["mice", "SPECIES", 59, 63], ["SINV", "SPECIES", 24, 28], ["mice", "SPECIES", 59, 63], ["SINV WT", "TREATMENT", 24, 31], ["infection", "PROBLEM", 101, 110], ["the mutations facilitated virus clearance", "PROBLEM", 112, 153], ["infected cells", "PROBLEM", 219, 233], ["immune effectors", "TREATMENT", 237, 253], ["interferon", "TREATMENT", 262, 272], ["nervous system", "ANATOMY", 163, 177], ["infected cells", "OBSERVATION", 219, 233]]], ["A similar effect on virus clearance was observed in the studies of MHV A59 with a single amino acid change in the macro domain (Eriksson et al., 2008).", [["amino acid", "CHEMICAL", 89, 99], ["amino acid", "CHEMICAL", 89, 99], ["MHV A59", "ORGANISM", 67, 74], ["amino acid", "AMINO_ACID", 89, 99], ["MHV A59", "PROTEIN", 67, 74], ["macro domain", "PROTEIN", 114, 126], ["MHV", "SPECIES", 67, 70], ["A similar effect on virus clearance", "PROBLEM", 0, 35], ["the studies", "TEST", 52, 63], ["a single amino acid change", "PROBLEM", 80, 106], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["effect", "OBSERVATION_MODIFIER", 10, 16], ["virus", "OBSERVATION", 20, 25]]], ["These data further suggest that nsP3 interaction with host factors is affected by the macro domain amino acid sequence.Cell culture ::: Materials and methodsThe rat neuronal CSM14.1 cell line was derived from nigral-striatal neurons immortalized with a temperature-sensitive simian virus 40 T antigen and was a gift from Dale E. Bredesen (Buck Institute for Age Research) (Durand et al., 1990, Zhong et al., 1993).", [["Cell", "ANATOMY", 119, 123], ["neuronal CSM14.1 cell line", "ANATOMY", 165, 191], ["nigral-striatal neurons", "ANATOMY", 209, 232], ["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 99, 109], ["nsP3", "GENE_OR_GENE_PRODUCT", 32, 36], ["amino acid", "AMINO_ACID", 99, 109], ["Cell", "CELL", 119, 123], ["rat", "ORGANISM", 161, 164], ["neuronal CSM14.1 cell line", "CELL", 165, 191], ["nigral-striatal neurons", "CELL", 209, 232], ["simian", "ORGANISM", 275, 281], ["nsP3", "PROTEIN", 32, 36], ["host factors", "PROTEIN", 54, 66], ["macro domain amino acid sequence", "PROTEIN", 86, 118], ["rat neuronal CSM14.1 cell line", "CELL_LINE", 161, 191], ["nigral-striatal neurons", "CELL_TYPE", 209, 232], ["simian virus 40 T antigen", "PROTEIN", 275, 300], ["rat", "SPECIES", 161, 164], ["simian virus", "SPECIES", 275, 287], ["rat", "SPECIES", 161, 164], ["simian virus", "SPECIES", 275, 287], ["nsP3 interaction", "PROBLEM", 32, 48], ["the macro domain amino acid sequence", "TEST", 82, 118], ["Cell culture", "TEST", 119, 131], ["The rat neuronal CSM", "TEST", 157, 177], ["cell line", "TEST", 182, 191], ["a temperature", "TEST", 251, 264], ["14.1 cell line", "OBSERVATION", 177, 191]]], ["CSM14.1 cells were grown at the permissive temperature (31 \u00b0C) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), l-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 \u03bcg/ml) (Gibco BRL) in a 5% CO2 incubator.", [["CSM14.1 cells", "ANATOMY", 0, 13], ["fetal bovine serum", "ANATOMY", 147, 165], ["FBS", "ANATOMY", 167, 170], ["l-glutamine", "CHEMICAL", 173, 184], ["penicillin", "CHEMICAL", 193, 203], ["streptomycin", "CHEMICAL", 220, 232], ["BRL", "CHEMICAL", 252, 255], ["CO2", "CHEMICAL", 265, 268], ["l-glutamine", "CHEMICAL", 173, 184], ["penicillin", "CHEMICAL", 193, 203], ["streptomycin", "CHEMICAL", 220, 232], ["CO2", "CHEMICAL", 265, 268], ["CSM14.1 cells", "CELL", 0, 13], ["bovine", "ORGANISM", 153, 159], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["FBS", "ORGANISM_SUBSTANCE", 167, 170], ["l-glutamine", "SIMPLE_CHEMICAL", 173, 184], ["penicillin", "SIMPLE_CHEMICAL", 193, 203], ["streptomycin", "SIMPLE_CHEMICAL", 220, 232], ["CO2", "SIMPLE_CHEMICAL", 265, 268], ["CSM14.1 cells", "CELL_LINE", 0, 13], ["bovine", "SPECIES", 153, 159], ["bovine", "SPECIES", 153, 159], ["CSM", "TEST", 0, 3], ["the permissive temperature", "TEST", 28, 54], ["Dulbecco's modified Eagle's medium (DMEM", "TREATMENT", 66, 106], ["fetal bovine serum (FBS", "TREATMENT", 147, 170], ["l-glutamine (2 mM)", "TREATMENT", 173, 191], ["penicillin", "TREATMENT", 193, 203], ["streptomycin", "TREATMENT", 220, 232], ["a 5% CO2 incubator", "TREATMENT", 260, 278], ["14.1 cells", "OBSERVATION_MODIFIER", 3, 13]]], ["For differentiation, CSM14.1 cells were grown under permissive conditions until they were 95% confluent and then switched to the restrictive temperature (39 \u00b0C) and DMEM-1% FBS supplemented as above.", [["CSM14.1 cells", "ANATOMY", 21, 34], ["FBS", "ANATOMY", 173, 176], ["CSM14.1 cells", "CELL", 21, 34], ["FBS", "ORGANISM_SUBSTANCE", 173, 176], ["CSM14.1 cells", "CELL_LINE", 21, 34], ["CSM", "TEST", 21, 24], ["the restrictive temperature", "TEST", 125, 152], ["DMEM", "TEST", 165, 169], ["FBS", "TEST", 173, 176]]], ["Baby hamster kidney 21 (BHK21) cells were grown at 37 \u00b0C in DMEM-10% FBS supplemented as above.", [["kidney 21 (BHK21) cells", "ANATOMY", 13, 36], ["FBS", "ANATOMY", 69, 72], ["hamster kidney 21", "CELL", 5, 22], ["BHK21) cells", "CELL", 24, 36], ["FBS", "ORGANISM_SUBSTANCE", 69, 72], ["Baby hamster kidney 21 (BHK21) cells", "CELL_LINE", 0, 36], ["hamster", "SPECIES", 5, 12], ["hamster", "SPECIES", 5, 12], ["BHK21) cells", "TEST", 24, 36], ["DMEM", "TEST", 60, 64], ["FBS", "TEST", 69, 72], ["kidney", "ANATOMY", 13, 19]]], ["BHK21 cells were used to grow virus stocks and to quantitate virus by plaque assay.Homology modeling ::: Materials and methodsThe full-length amino acid sequence of nsP3 was run with GENO3D (http://geno3d-pbil.ibcp.fr).", [["BHK21 cells", "ANATOMY", 0, 11], ["plaque", "ANATOMY", 70, 76], ["amino acid", "CHEMICAL", 142, 152], ["amino acid", "CHEMICAL", 142, 152], ["BHK21 cells", "CELL", 0, 11], ["amino acid", "AMINO_ACID", 142, 152], ["nsP3", "GENE_OR_GENE_PRODUCT", 165, 169], ["BHK21 cells", "CELL_LINE", 0, 11], ["nsP3", "PROTEIN", 165, 169], ["GENO3D", "PROTEIN", 183, 189], ["BHK21 cells", "PROBLEM", 0, 11], ["virus stocks", "TREATMENT", 30, 42], ["The full-length amino acid sequence", "TEST", 126, 161], ["nsP3", "PROBLEM", 165, 169]]], ["A macro domain protein Af1521 (Protein Data Bank ID: 2bfq), which has an expectation value of 1.0e\u2212 32 when compared with amino acid 3\u2013158 of SINV nsP3, was chosen for a template structure, and the structure of the nsP3 macro domain was predicted by homology modeling.Viruses, mutagenesis and sequencing ::: Materials and methodsTE, a recombinant strain of SINV, was previously constructed by replacing restriction fragments of the Toto1101 cDNA clone of SINV with the E2 fragment from neuroadapted SINV and the E1 fragment from the original SINV isolate AR339 (Lustig et al., 1988).", [["amino acid", "CHEMICAL", 122, 132], ["E2", "CHEMICAL", 469, 471], ["amino acid", "CHEMICAL", 122, 132], ["SINV", "ORGANISM", 142, 146], ["nsP3", "GENE_OR_GENE_PRODUCT", 147, 151], ["nsP3", "GENE_OR_GENE_PRODUCT", 215, 219], ["methodsTE", "GENE_OR_GENE_PRODUCT", 322, 331], ["SINV", "ORGANISM", 357, 361], ["SINV", "ORGANISM", 455, 459], ["neuroadapted SINV", "ORGANISM", 486, 503], ["SINV", "ORGANISM", 542, 546], ["macro domain protein", "PROTEIN", 2, 22], ["Af1521", "PROTEIN", 23, 29], ["Protein Data Bank ID: 2bfq", "PROTEIN", 31, 57], ["amino acid 3\u2013158", "PROTEIN", 122, 138], ["SINV nsP3", "PROTEIN", 142, 151], ["nsP3 macro domain", "PROTEIN", 215, 232], ["methodsTE", "DNA", 322, 331], ["restriction fragments", "DNA", 403, 424], ["Toto1101 cDNA clone", "DNA", 432, 451], ["E2 fragment", "DNA", 469, 480], ["E1 fragment", "DNA", 512, 523], ["SINV", "SPECIES", 357, 361], ["SINV", "SPECIES", 455, 459], ["SINV", "SPECIES", 499, 503], ["SINV", "SPECIES", 542, 546], ["A macro domain protein Af", "TEST", 0, 25], ["Protein Data", "TEST", 31, 43], ["amino acid", "TEST", 122, 132], ["SINV nsP3", "TREATMENT", 142, 151], ["a template structure", "PROBLEM", 168, 188], ["the nsP3 macro domain", "PROBLEM", 211, 232], ["methodsTE", "TREATMENT", 322, 331], ["a recombinant strain of SINV", "TREATMENT", 333, 361], ["replacing restriction fragments", "TREATMENT", 393, 424], ["SINV", "PROBLEM", 455, 459], ["the E2 fragment", "TREATMENT", 465, 480], ["neuroadapted SINV", "TREATMENT", 486, 503], ["the E1 fragment", "PROBLEM", 508, 523], ["SINV nsP3", "OBSERVATION", 142, 151], ["E2 fragment", "OBSERVATION", 469, 480], ["E1 fragment", "OBSERVATION", 512, 523]]], ["At amino acid positions 10 and 24 of nsP3, asparagines were changed to alanines in the TE plasmid using the Quick Change\u00ae Site-Directed Mutagenesis Kit (Stratagene) to create viruses with single mutations (SM10 and SM24) and double mutations (DM).", [["amino acid", "CHEMICAL", 3, 13], ["asparagines", "CHEMICAL", 43, 54], ["DM", "DISEASE", 243, 245], ["amino acid", "CHEMICAL", 3, 13], ["asparagines", "CHEMICAL", 43, 54], ["alanines", "CHEMICAL", 71, 79], ["amino acid", "AMINO_ACID", 3, 13], ["nsP3", "GENE_OR_GENE_PRODUCT", 37, 41], ["asparagines", "SIMPLE_CHEMICAL", 43, 54], ["nsP3", "PROTEIN", 37, 41], ["TE plasmid", "DNA", 87, 97], ["amino acid positions", "TEST", 3, 23], ["nsP3", "TREATMENT", 37, 41], ["asparagines", "TREATMENT", 43, 54], ["alanines", "TREATMENT", 71, 79], ["the TE plasmid", "TREATMENT", 83, 97], ["the Quick Change\u00ae Site", "TREATMENT", 104, 126], ["Directed Mutagenesis Kit (Stratagene)", "TREATMENT", 127, 164], ["single mutations", "TREATMENT", 188, 204], ["double mutations (DM", "PROBLEM", 225, 245], ["viruses", "OBSERVATION", 175, 182]]], ["Viral RNAs were transcribed using mMESSAGE mMACHINE\u00ae High Yield Capped RNA Transcription Kit (Ambion) and then transfected into BHK21 cells using Lipofectamine 2000 (Invitrogen).", [["BHK21 cells", "ANATOMY", 128, 139], ["Kit", "GENE_OR_GENE_PRODUCT", 89, 92], ["BHK21 cells", "CELL", 128, 139], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 166, 176], ["Viral RNAs", "RNA", 0, 10], ["mMESSAGE mMACHINE\u00ae", "DNA", 34, 52], ["BHK21 cells", "CELL_LINE", 128, 139], ["Viral RNAs", "PROBLEM", 0, 10], ["High Yield Capped RNA Transcription Kit (Ambion)", "TREATMENT", 53, 101], ["Lipofectamine", "TREATMENT", 146, 159]]], ["Virus titers were assessed by plaque formation in BHK21 cells.", [["plaque", "ANATOMY", 30, 36], ["BHK21 cells", "ANATOMY", 50, 61], ["Virus", "ORGANISM", 0, 5], ["plaque", "PATHOLOGICAL_FORMATION", 30, 36], ["BHK21 cells", "CELL", 50, 61], ["BHK21 cells", "CELL_LINE", 50, 61], ["Virus titers", "TEST", 0, 12], ["plaque", "OBSERVATION", 30, 36], ["BHK21 cells", "OBSERVATION", 50, 61]]], ["For sequencing, viral RNAs were purified from virus released into cell culture media using the QIAamp\u00ae Viral RNA Mini kit (Qiagen), or from mouse brains using RNease\u00ae Mini Kit (Qiagen), and were amplified by RT-PCR using primers TE 3958(+) (5\u2032 GACCAGATTGTGTCTCAAGC 3\u2032) and TE 4352(\u2212) (5\u2032 CAATTTCAAGGCTTCTGCTTC 3\u2032).", [["cell", "ANATOMY", 66, 70], ["brains", "ANATOMY", 146, 152], ["cell", "CELL", 66, 70], ["Qiagen", "GENE_OR_GENE_PRODUCT", 123, 129], ["mouse", "ORGANISM", 140, 145], ["brains", "ORGAN", 146, 152], ["Kit", "GENE_OR_GENE_PRODUCT", 172, 175], ["viral RNAs", "RNA", 16, 26], ["Viral RNA", "RNA", 103, 112], ["TE 4352", "DNA", 273, 280], ["mouse", "SPECIES", 140, 145], ["mouse", "SPECIES", 140, 145], ["sequencing", "TEST", 4, 14], ["viral RNAs", "PROBLEM", 16, 26], ["virus", "PROBLEM", 46, 51], ["RNease\u00ae Mini Kit (Qiagen)", "TREATMENT", 159, 184], ["PCR", "TEST", 211, 214], ["primers TE", "TEST", 221, 231], ["GACCAGATTGTGTCTCAAGC", "TEST", 244, 264], ["TE", "TEST", 273, 275], ["CAATTTCAAGGCTTCTGCTTC", "TEST", 288, 309]]], ["RT-PCR products were sequenced using the primer TE 3958(+).Viruses, mutagenesis and sequencing ::: Materials and methodsFor analysis of replication, virus was diluted in DMEM-1% FBS, and cells were infected at a multiplicity of infection (MOI) of 10 for 1 h at 31 \u00b0C (undifferentiated CSM14.1 cells), 39 \u00b0C (differentiated CSM14.1 cells), or 37 \u00b0C (BHK21 cells).", [["FBS", "ANATOMY", 178, 181], ["cells", "ANATOMY", 187, 192], ["CSM14.1 cells", "ANATOMY", 285, 298], ["CSM14.1 cells", "ANATOMY", 323, 336], ["BHK21 cells", "ANATOMY", 349, 360], ["infection", "DISEASE", 228, 237], ["FBS", "ORGANISM_SUBSTANCE", 178, 181], ["cells", "CELL", 187, 192], ["CSM14.1 cells", "CELL", 285, 298], ["CSM14.1 cells", "CELL", 323, 336], ["BHK21 cells", "CELL", 349, 360], ["RT-PCR products", "DNA", 0, 15], ["primer TE 3958", "DNA", 41, 55], ["differentiated CSM14.1 cells", "CELL_LINE", 308, 336], ["BHK21 cells", "CELL_LINE", 349, 360], ["RT-PCR products", "TREATMENT", 0, 15], ["the primer TE", "TEST", 37, 50], ["analysis", "TEST", 124, 132], ["replication", "PROBLEM", 136, 147], ["virus", "PROBLEM", 149, 154], ["DMEM", "TEST", 170, 174], ["FBS", "TEST", 178, 181], ["cells", "PROBLEM", 187, 192], ["infection", "PROBLEM", 228, 237], ["cells", "TEST", 293, 298], ["\u00b0C", "TEST", 304, 306], ["CSM", "TEST", 323, 326], ["cells", "TEST", 331, 336], ["infection", "OBSERVATION", 228, 237]]], ["Cells were then washed with medium 3 times, and the medium was replaced.Viruses, mutagenesis and sequencing ::: Materials and methodsTo assess viability, cells were washed with PBS, trypsinized, resuspended, and incubated with 0.4% trypan blue.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 154, 159], ["trypan blue", "CHEMICAL", 232, 243], ["trypan blue", "CHEMICAL", 232, 243], ["Cells", "CELL", 0, 5], ["cells", "CELL", 154, 159], ["trypan blue", "SIMPLE_CHEMICAL", 232, 243], ["PBS", "TREATMENT", 177, 180]]], ["Unstained live cells were counted, and cell viability was calculated by dividing the number of live cells by the number of live cells at the time of infection.Poly(ADP-ribose) (PAR) binding assay ::: Materials and methodsThe nsP3 macro domains from WT, SM10, SM24 and DM were amplified by PCR and inserted into pRSET (Invitrogen) to express hexahistidine (his)-tagged proteins.", [["cells", "ANATOMY", 15, 20], ["cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 100, 105], ["cells", "ANATOMY", 128, 133], ["infection", "DISEASE", 149, 158], ["Poly(ADP-ribose", "CHEMICAL", 159, 174], ["Poly(ADP-ribose)", "CHEMICAL", 159, 175], ["PAR", "CHEMICAL", 177, 180], ["cells", "CELL", 15, 20], ["cell", "CELL", 39, 43], ["cells", "CELL", 100, 105], ["cells", "CELL", 128, 133], ["Poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 159, 175], ["PAR", "SIMPLE_CHEMICAL", 177, 180], ["nsP3", "GENE_OR_GENE_PRODUCT", 225, 229], ["SM10", "GENE_OR_GENE_PRODUCT", 253, 257], ["SM24", "GENE_OR_GENE_PRODUCT", 259, 263], ["DM", "GENE_OR_GENE_PRODUCT", 268, 270], ["pRSET", "GENE_OR_GENE_PRODUCT", 311, 316], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 318, 328], ["hexahistidine", "GENE_OR_GENE_PRODUCT", 341, 354], ["live cells", "CELL_TYPE", 95, 105], ["live cells", "CELL_TYPE", 123, 133], ["nsP3 macro domains", "PROTEIN", 225, 243], ["SM10", "PROTEIN", 253, 257], ["SM24", "PROTEIN", 259, 263], ["pRSET", "PROTEIN", 311, 316], ["hexahistidine (his)-tagged proteins", "PROTEIN", 341, 376], ["Unstained live cells", "PROBLEM", 0, 20], ["cell viability", "TEST", 39, 53], ["infection", "PROBLEM", 149, 158], ["Poly(ADP-ribose)", "TREATMENT", 159, 175], ["The nsP3 macro domains", "TEST", 221, 243], ["WT", "TEST", 249, 251], ["SM10", "TEST", 253, 257], ["DM", "PROBLEM", 268, 270], ["PCR", "TEST", 289, 292], ["hexahistidine", "TEST", 341, 354], ["tagged proteins", "PROBLEM", 361, 376], ["cell viability", "OBSERVATION", 39, 53], ["infection", "OBSERVATION", 149, 158]]], ["The macro domain proteins were purified over a nickel column using ProBond\u2122 Purification System (Invitrogen) and were dot-blotted, along with lysozyme (Sigma), onto a nitrocellulose membrane.", [["membrane", "ANATOMY", 182, 190], ["nickel", "CHEMICAL", 47, 53], ["nickel", "CHEMICAL", 47, 53], ["nitrocellulose", "CHEMICAL", 167, 181], ["lysozyme", "GENE_OR_GENE_PRODUCT", 142, 150], ["membrane", "CELLULAR_COMPONENT", 182, 190], ["macro domain proteins", "PROTEIN", 4, 25], ["lysozyme", "PROTEIN", 142, 150], ["The macro domain proteins", "TEST", 0, 25], ["a nickel column", "TREATMENT", 45, 60], ["ProBond\u2122 Purification System", "TREATMENT", 67, 95], ["a nitrocellulose membrane", "TREATMENT", 165, 190]]], ["The membrane was blocked for 1 h at RT in TBS-T buffer (10 mM Tris, pH7.4, 150 mM NaCl, 0.04% Tween 20) containing 5% nonfat dry milk and incubated with PAR (1 \u03bcg/ml, Trevigen) in blocking buffer for 1 h at RT.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 129, 133], ["NaCl", "CHEMICAL", 82, 86], ["Tris", "CHEMICAL", 62, 66], ["NaCl", "CHEMICAL", 82, 86], ["Tween 20", "CHEMICAL", 94, 102], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 129, 133], ["Trevigen", "SIMPLE_CHEMICAL", 167, 175], ["150 mM NaCl", "TREATMENT", 75, 86], ["PAR", "TREATMENT", 153, 156]]], ["The membrane was then washed with TBS-T, blocked and incubated with antibody to PAR (1:1000, Trevigen) overnight at 4 \u00b0C. Membrane was incubated with HRP-conjugated secondary antibody (Amersham), and ECL (Amersham) was used to visualize signals.Morbidity, mortality and virus production in mice ::: Materials and methodsFive day or 2 week-old CD-1 mice (Charles River Laboratories) were infected intracerebrally with 1000 plaque forming units (PFU) of virus in 10 \u03bcl phosphate-buffered saline (PBS) under isoflurane anesthesia.", [["membrane", "ANATOMY", 4, 12], ["Membrane", "ANATOMY", 122, 130], ["phosphate", "CHEMICAL", 467, 476], ["isoflurane", "CHEMICAL", 505, 515], ["phosphate", "CHEMICAL", 467, 476], ["isoflurane", "CHEMICAL", 505, 515], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["PAR", "GENE_OR_GENE_PRODUCT", 80, 83], ["Membrane", "CELLULAR_COMPONENT", 122, 130], ["HRP", "SIMPLE_CHEMICAL", 150, 153], ["mice", "ORGANISM", 290, 294], ["mice", "ORGANISM", 348, 352], ["Charles River Laboratories", "ORGANISM", 354, 380], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 467, 492], ["isoflurane", "SIMPLE_CHEMICAL", 505, 515], ["PAR", "PROTEIN", 80, 83], ["HRP", "PROTEIN", 150, 153], ["secondary antibody", "PROTEIN", 165, 183], ["mice", "SPECIES", 290, 294], ["mice", "SPECIES", 348, 352], ["mice", "SPECIES", 290, 294], ["mice", "SPECIES", 348, 352], ["antibody to PAR", "TREATMENT", 68, 83], ["HRP", "TEST", 150, 153], ["Morbidity", "PROBLEM", 245, 254], ["virus", "TREATMENT", 452, 457], ["buffered saline (PBS", "TREATMENT", 477, 497], ["isoflurane anesthesia", "TREATMENT", 505, 526]]], ["To determine morbidity and mortality, groups of 10 infected animals were monitored daily and clinically scored.", [["animals", "ORGANISM", 60, 67], ["morbidity", "PROBLEM", 13, 22]]], ["To assess virus replication, brains were collected and homogenized in PBS using FastPrep\u00ae (MP Biomedicals), and assayed for PFU on BHK21 cells.Analysis of viral RNA synthesis ::: Materials and methodsTo assess viral genomic and subgenomic RNA synthesis, differentiated CSM14.1 cells were incubated with culture medium containing [5,6-3H] uridine (20 \u03bcCi/ml) (PerkinElmer) and dactinomycin (1 \u03bcg/ml) (Calbiochem) at 39 \u00b0C for 2 h.", [["brains", "ANATOMY", 29, 35], ["BHK21 cells", "ANATOMY", 131, 142], ["CSM14.1 cells", "ANATOMY", 269, 282], ["[5,6-3H] uridine", "CHEMICAL", 329, 345], ["dactinomycin", "CHEMICAL", 376, 388], ["[5,6-3H] uridine", "CHEMICAL", 329, 345], ["dactinomycin", "CHEMICAL", 376, 388], ["brains", "ORGANISM", 29, 35], ["FastPrep\u00ae", "SIMPLE_CHEMICAL", 80, 89], ["BHK21 cells", "CELL", 131, 142], ["CSM14.1 cells", "CELL", 269, 282], ["[5,6-3H] uridine", "SIMPLE_CHEMICAL", 329, 345], ["dactinomycin", "SIMPLE_CHEMICAL", 376, 388], ["Calbiochem", "SIMPLE_CHEMICAL", 400, 410], ["BHK21 cells", "CELL_LINE", 131, 142], ["viral RNA", "RNA", 155, 164], ["subgenomic RNA", "RNA", 228, 242], ["CSM14.1 cells", "CELL_LINE", 269, 282], ["virus replication", "TREATMENT", 10, 27], ["FastPrep\u00ae (MP Biomedicals", "TREATMENT", 80, 105], ["BHK21 cells", "TREATMENT", 131, 142], ["viral genomic and subgenomic RNA synthesis", "PROBLEM", 210, 252], ["culture", "TEST", 303, 310], ["uridine", "TREATMENT", 338, 345], ["dactinomycin", "TREATMENT", 376, 388], ["BHK21 cells", "OBSERVATION", 131, 142], ["viral RNA synthesis", "OBSERVATION", 155, 174], ["viral genomic", "OBSERVATION", 210, 223], ["subgenomic RNA synthesis", "OBSERVATION", 228, 252]]], ["Cells were then washed with PBS and lysed with RNA STAT-60 (Tel-Test).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["STAT-60", "GENE_OR_GENE_PRODUCT", 51, 58], ["STAT", "PROTEIN", 51, 55], ["PBS", "TREATMENT", 28, 31], ["RNA STAT", "TEST", 47, 55]]], ["RNAs were purified by chloroform extraction and isopropanol precipitation, and were separated at 120 volt-hours on a 1% agarose gel.", [["isopropanol", "CHEMICAL", 48, 59], ["chloroform", "CHEMICAL", 22, 32], ["isopropanol", "CHEMICAL", 48, 59], ["chloroform", "SIMPLE_CHEMICAL", 22, 32], ["isopropanol", "SIMPLE_CHEMICAL", 48, 59], ["agarose", "SIMPLE_CHEMICAL", 120, 127], ["RNAs", "RNA", 0, 4], ["chloroform extraction", "TREATMENT", 22, 43], ["isopropanol precipitation", "TREATMENT", 48, 73], ["a 1% agarose gel", "TREATMENT", 115, 131]]], ["For fluorography, the gel was fixed with methanol at RT for 30 min, impregnated with 2.5% 2,5-diphenyloxazole in methanol overnight, and then washed with water.", [["methanol", "CHEMICAL", 41, 49], ["2,5-diphenyloxazole", "CHEMICAL", 90, 109], ["methanol", "CHEMICAL", 41, 49], ["2,5-diphenyloxazole", "CHEMICAL", 90, 109], ["methanol", "CHEMICAL", 113, 121], ["methanol", "SIMPLE_CHEMICAL", 41, 49], ["2,5-diphenyloxazole", "SIMPLE_CHEMICAL", 90, 109], ["methanol", "SIMPLE_CHEMICAL", 113, 121], ["fluorography", "TEST", 4, 16], ["the gel", "TREATMENT", 18, 25], ["methanol", "TREATMENT", 41, 49], ["diphenyloxazole", "TREATMENT", 94, 109], ["methanol", "TREATMENT", 113, 121]]], ["The gel was then dried with a vacuum dryer at 50 \u00b0C for 1 h and exposed to Kodak BioMax MS film at \u2212 80 \u00b0C until signals were detected.Analysis of viral RNA synthesis ::: Materials and methodsTo quantitate viral plus and minus strand RNA, SINV-infected differentiated CSM14.1 cells were lysed, and total RNAs were purified using the RNease\u00ae Mini Kit (Qiagen).", [["CSM14.1 cells", "ANATOMY", 268, 281], ["SINV", "ORGANISM", 239, 243], ["CSM14.1 cells", "CELL", 268, 281], ["viral RNA", "RNA", 147, 156], ["viral plus and minus strand RNA", "RNA", 206, 237], ["CSM14.1 cells", "CELL_LINE", 268, 281], ["SINV", "SPECIES", 239, 243], ["The gel", "TREATMENT", 0, 7], ["a vacuum dryer", "TREATMENT", 28, 42], ["MS film", "TEST", 88, 95], ["viral plus", "TEST", 206, 216], ["minus strand RNA", "PROBLEM", 221, 237], ["SINV", "TEST", 239, 243], ["total RNAs", "TEST", 298, 308], ["the RNease\u00ae Mini Kit", "TREATMENT", 329, 349], ["viral RNA synthesis", "OBSERVATION", 147, 166], ["viral", "OBSERVATION", 206, 211], ["strand RNA", "OBSERVATION", 227, 237], ["infected differentiated", "OBSERVATION_MODIFIER", 244, 267], ["CSM", "OBSERVATION_MODIFIER", 268, 271], ["14.1 cells", "OBSERVATION", 271, 281]]], ["Each cDNA was synthesized from RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science) with a SINV-specific primer (SINV8456F 5\u2032 CACGGCAATGTGTTTGCT 3\u2032 for the cDNA synthesis of minus strand RNA; SINV9899R 5\u2032 AGCATTGGCCGACCTAACGCAGCAC 3\u2032 for the cDNA synthesis of plus strand RNA).", [["cDNA", "DNA", 5, 9], ["SINV-specific primer", "DNA", 121, 141], ["minus strand RNA", "RNA", 204, 220], ["plus strand RNA", "RNA", 290, 305], ["SINV", "SPECIES", 121, 125], ["the Transcriptor First Strand cDNA Synthesis Kit", "TREATMENT", 41, 89], ["minus strand RNA", "PROBLEM", 204, 220], ["AGCATTGGCCGACCTAACGCAGCAC", "TEST", 235, 260], ["the cDNA synthesis", "TEST", 268, 286], ["strand RNA", "PROBLEM", 295, 305]]], ["Real time PCR was performed with the synthesized cDNA, primers SVE2F 5\u2032 TGGGACGAAGCGGACGATAA 3\u2032 and SVE2R 5\u2032 CTGCTCCGCTTTGGTCGTAT 3\u2032, and Taqman probe 5\u2032 [FAM] CGCATACAGACTTCCGCCCAGT [TAMRA] 3\u2032 (Applied Biosystems) using TaqMan\u2122 PCR Core Reagent Kit (Applied Biosystems).", [["[FAM] CGCATACAGACTTCCGCCCAGT", "CHEMICAL", 154, 182], ["TAMRA", "CHEMICAL", 184, 189], ["synthesized cDNA", "DNA", 37, 53], ["primers SVE2F 5", "DNA", 55, 70], ["Real time PCR", "TEST", 0, 13], ["the synthesized cDNA", "TEST", 33, 53], ["primers SVE2F", "TEST", 55, 68], ["TGGGACGAAGCGGACGATAA", "TEST", 72, 92], ["CTGCTCCGCTTTGGTCGTAT", "TEST", 109, 129], ["TaqMan\u2122 PCR Core Reagent Kit (Applied Biosystems", "TREATMENT", 221, 269]]], ["Real time PCR was run and analyzed with the 7500 Real Time PCR System (Applied Biosystems).Analysis of viral protein synthesis ::: Materials and methodsFor immunoblots, cells were lysed using radioimmune precipitation assay (RIPA) buffer (1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 0.1% sodium deoxycholate, 10 mM Tris\u2013Cl, 150 mM NaCl, 1 mM EDTA, pH 7.5) containing a protease inhibitor cocktail (Sigma) and Halt\u2122 phosphatase inhibitor cocktail (Pierce).", [["cells", "ANATOMY", 169, 174], ["Nonidet P-40", "CHEMICAL", 242, 254], ["sodium dodecyl sulfate", "CHEMICAL", 261, 283], ["sodium deoxycholate", "CHEMICAL", 296, 315], ["Tris\u2013Cl", "CHEMICAL", 323, 330], ["NaCl", "CHEMICAL", 339, 343], ["sodium dodecyl sulfate", "CHEMICAL", 261, 283], ["SDS", "CHEMICAL", 285, 288], ["sodium deoxycholate", "CHEMICAL", 296, 315], ["Tris\u2013Cl", "CHEMICAL", 323, 330], ["NaCl", "CHEMICAL", 339, 343], ["EDTA", "CHEMICAL", 350, 354], ["cells", "CELL", 169, 174], ["Nonidet P-40", "SIMPLE_CHEMICAL", 242, 254], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 261, 283], ["SDS", "SIMPLE_CHEMICAL", 285, 288], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 296, 315], ["Tris\u2013Cl", "SIMPLE_CHEMICAL", 323, 330], ["EDTA", "SIMPLE_CHEMICAL", 350, 354], ["Sigma", "SIMPLE_CHEMICAL", 406, 411], ["Halt\u2122", "SIMPLE_CHEMICAL", 417, 422], ["Real time PCR", "TEST", 0, 13], ["viral protein synthesis", "TEST", 103, 126], ["immunoblots, cells", "TREATMENT", 156, 174], ["radioimmune precipitation assay (RIPA) buffer", "TREATMENT", 192, 237], ["0.1% sodium dodecyl sulfate", "TREATMENT", 256, 283], ["SDS", "TEST", 285, 288], ["sodium deoxycholate", "TREATMENT", 296, 315], ["NaCl", "TREATMENT", 339, 343], ["1 mM EDTA", "TREATMENT", 345, 354], ["pH", "TEST", 356, 358], ["a protease inhibitor cocktail", "TREATMENT", 375, 404], ["Halt\u2122 phosphatase inhibitor cocktail", "TREATMENT", 417, 453], ["viral protein", "OBSERVATION", 103, 116]]], ["Cell lysates were centrifuged at 13,000 rpm for 30 min to remove cell debris and used for immunoblot.", [["Cell lysates", "ANATOMY", 0, 12], ["cell", "ANATOMY", 65, 69], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["cell", "CELL", 65, 69], ["Cell lysates", "TEST", 0, 12], ["cell debris", "PROBLEM", 65, 76], ["immunoblot", "TEST", 90, 100], ["cell debris", "OBSERVATION", 65, 76]]], ["Antibodies used for immunoblotting were against actin (Chemicon), nsP2 (polyclonal rabbit antibody raised against amino acid 113\u2013130 of nsP2, Quality Controlled Biochemicals (QCB)), nsP3 (polyclonal rabbit antibody raised against amino acid 212\u2013230 of nsP3, QCB), and polyclonal rabbit antibody to SINV structural proteins (Jackson et al., 1988).Analysis of viral protein synthesis ::: Materials and methodsTo label newly synthesized proteins, differentiated CSM14.1 cells at 19 h post-infection or BHK21 cells at 6 h post-infection were incubated with Met/Cys-free DMEM (MP Biomedicals) for 1 h, followed by incubation with Met/Cys-free DMEM containing Tran35S (100 \u03bcCi/ml) (MP Biomedicals) at 39 \u00b0C for 2 h (CSM14.1 cells) or 1 h (BHK21 cells).", [["CSM14.1 cells", "ANATOMY", 459, 472], ["BHK21 cells", "ANATOMY", 499, 510], ["cells", "ANATOMY", 718, 723], ["BHK21 cells", "ANATOMY", 733, 744], ["amino acid", "CHEMICAL", 114, 124], ["amino acid 212\u2013230", "CHEMICAL", 230, 248], ["infection", "DISEASE", 486, 495], ["Met/Cys", "CHEMICAL", 553, 560], ["Met", "CHEMICAL", 625, 628], ["Cys", "CHEMICAL", 629, 632], ["Tran35S", "CHEMICAL", 654, 661], ["amino acid", "CHEMICAL", 114, 124], ["amino acid", "CHEMICAL", 230, 240], ["Met", "CHEMICAL", 553, 556], ["Cys", "CHEMICAL", 557, 560], ["Met", "CHEMICAL", 625, 628], ["Cys", "CHEMICAL", 629, 632], ["Tran35S", "CHEMICAL", 654, 661], ["actin", "GENE_OR_GENE_PRODUCT", 48, 53], ["Chemicon", "GENE_OR_GENE_PRODUCT", 55, 63], ["nsP2", "GENE_OR_GENE_PRODUCT", 66, 70], ["amino acid", "AMINO_ACID", 114, 124], ["nsP3", "GENE_OR_GENE_PRODUCT", 182, 186], ["rabbit", "ORGANISM", 199, 205], ["amino acid", "AMINO_ACID", 230, 240], ["nsP3", "GENE_OR_GENE_PRODUCT", 252, 256], ["QCB", "GENE_OR_GENE_PRODUCT", 258, 261], ["SINV", "ORGANISM", 298, 302], ["CSM14.1 cells", "CELL", 459, 472], ["BHK21 cells", "CELL", 499, 510], ["Met", "GENE_OR_GENE_PRODUCT", 553, 556], ["Met", "GENE_OR_GENE_PRODUCT", 625, 628], ["Tran35S", "SIMPLE_CHEMICAL", 654, 661], ["cells", "CELL", 718, 723], ["BHK21 cells", "CELL", 733, 744], ["actin", "PROTEIN", 48, 53], ["Chemicon", "PROTEIN", 55, 63], ["nsP2", "PROTEIN", 66, 70], ["polyclonal rabbit antibody", "PROTEIN", 72, 98], ["nsP2", "PROTEIN", 136, 140], ["nsP3", "PROTEIN", 182, 186], ["polyclonal rabbit antibody", "PROTEIN", 188, 214], ["nsP3", "PROTEIN", 252, 256], ["QCB", "PROTEIN", 258, 261], ["polyclonal rabbit antibody", "PROTEIN", 268, 294], ["SINV structural proteins", "PROTEIN", 298, 322], ["CSM14.1 cells", "CELL_LINE", 459, 472], ["BHK21 cells", "CELL_LINE", 499, 510], ["BHK21 cells", "CELL_LINE", 733, 744], ["rabbit", "SPECIES", 83, 89], ["rabbit", "SPECIES", 199, 205], ["rabbit", "SPECIES", 279, 285], ["rabbit", "SPECIES", 83, 89], ["rabbit", "SPECIES", 199, 205], ["rabbit", "SPECIES", 279, 285], ["SINV", "SPECIES", 298, 302], ["Antibodies", "TEST", 0, 10], ["immunoblotting", "TEST", 20, 34], ["actin (Chemicon)", "TEST", 48, 64], ["nsP2", "TEST", 66, 70], ["polyclonal rabbit antibody", "TEST", 72, 98], ["amino acid", "TEST", 114, 124], ["nsP2", "TEST", 136, 140], ["nsP3 (polyclonal rabbit antibody", "TEST", 182, 214], ["amino acid", "TEST", 230, 240], ["nsP3", "TEST", 252, 256], ["QCB", "TEST", 258, 261], ["polyclonal rabbit antibody", "TEST", 268, 294], ["viral protein synthesis", "TEST", 358, 381], ["infection", "PROBLEM", 486, 495], ["BHK21 cells", "PROBLEM", 499, 510], ["infection", "PROBLEM", 523, 532], ["Cys", "TEST", 557, 560], ["free DMEM", "TREATMENT", 633, 642], ["Tran35S", "TREATMENT", 654, 661], ["CSM", "TEST", 710, 713], ["BHK21 cells", "TEST", 733, 744], ["viral protein", "OBSERVATION", 358, 371], ["14.1 cells", "OBSERVATION_MODIFIER", 462, 472], ["infection", "OBSERVATION", 486, 495], ["BHK21 cells", "OBSERVATION", 499, 510]]], ["To chase labeled proteins, cells were washed, incubated with cold media containing 15 mg/l of L-Met, and lysed with RIPA buffer.", [["cells", "ANATOMY", 27, 32], ["L-Met", "CHEMICAL", 94, 99], ["L-Met", "CHEMICAL", 94, 99], ["cells", "CELL", 27, 32], ["L-Met", "SIMPLE_CHEMICAL", 94, 99], ["chase labeled proteins", "PROTEIN", 3, 25], ["cold media", "TREATMENT", 61, 71], ["RIPA buffer", "TREATMENT", 116, 127]]], ["To inhibit proteasome activity, MG132 (1 \u03bcM, Biomol) was added to the medium after infection.", [["MG132", "CHEMICAL", 32, 37], ["Biomol", "CHEMICAL", 45, 51], ["infection", "DISEASE", 83, 92], ["MG132", "CHEMICAL", 32, 37], ["Biomol", "CHEMICAL", 45, 51], ["MG132", "SIMPLE_CHEMICAL", 32, 37], ["Biomol", "SIMPLE_CHEMICAL", 45, 51], ["proteasome", "PROTEIN", 11, 21], ["proteasome activity", "TREATMENT", 11, 30], ["MG132", "TREATMENT", 32, 37], ["Biomol)", "TREATMENT", 45, 52], ["infection", "PROBLEM", 83, 92], ["infection", "OBSERVATION", 83, 92]]], ["For immunoprecipitation, cell lysates were incubated with antibody to nsP3, nsP2, or SINV structural proteins (10 \u03bcg) in RIPA buffer overnight with gentle rocking at 4 \u00b0C. ImmunoPure\u00ae Immobilized Protein A/G (10 \u03bcl of settled gel) (Pierce) was added to the mixture of cell lysate and antibody, followed by overnight incubation with gentle rocking at 4 \u00b0C. The gel was washed with RIPA buffer 3 times, and bound proteins were eluted by boiling at 90 \u00b0C with 2\u00d7 SDS sample buffer for 5 min.", [["cell lysates", "ANATOMY", 25, 37], ["cell lysate", "ANATOMY", 268, 279], ["cell lysates", "CELL", 25, 37], ["nsP3", "GENE_OR_GENE_PRODUCT", 70, 74], ["nsP2", "GENE_OR_GENE_PRODUCT", 76, 80], ["SINV", "ORGANISM", 85, 89], ["cell lysate", "ORGANISM_SUBSTANCE", 268, 279], ["nsP3", "PROTEIN", 70, 74], ["nsP2", "PROTEIN", 76, 80], ["SINV structural proteins", "PROTEIN", 85, 109], ["SINV", "SPECIES", 85, 89], ["immunoprecipitation", "TEST", 4, 23], ["cell lysates", "TEST", 25, 37], ["antibody", "TEST", 58, 66], ["nsP3", "TEST", 70, 74], ["nsP2", "TEST", 76, 80], ["SINV structural proteins", "PROBLEM", 85, 109], ["RIPA buffer", "TREATMENT", 121, 132], ["gentle rocking", "TREATMENT", 148, 162], ["ImmunoPure", "TEST", 172, 182], ["Immobilized Protein A/G", "TREATMENT", 184, 207], ["settled gel) (Pierce)", "TREATMENT", 218, 239], ["cell lysate", "TREATMENT", 268, 279], ["antibody", "TREATMENT", 284, 292], ["gentle rocking at 4 \u00b0C", "TREATMENT", 332, 354], ["The gel", "TREATMENT", 356, 363], ["RIPA buffer", "TREATMENT", 380, 391], ["bound proteins", "TREATMENT", 405, 419]]], ["Eluted proteins were analyzed by PAGE.", [["Eluted proteins", "TEST", 0, 15]]], ["Then, the gel was fixed in 50% methanol and 10% glacial acetic acid (in water) at RT for 30 min, incubated in 10% glycerol (in water) for 5 min to prevent cracking, dried using a vacuum dryer at 80 \u00b0C for 1 h, and exposed to Kodak BioMax MS film at RT until signals were detected.Statistical analysis ::: Materials and methodsStatistical analyses were performed using Student's unpaired t-test or Kaplan\u2013Meyer survival analysis and log rank test using GraphPad QuickCalcs software.", [["methanol", "CHEMICAL", 31, 39], ["glacial acetic acid", "CHEMICAL", 48, 67], ["glycerol", "CHEMICAL", 114, 122], ["methanol", "CHEMICAL", 31, 39], ["acetic acid", "CHEMICAL", 56, 67], ["glycerol", "CHEMICAL", 114, 122], ["methanol", "SIMPLE_CHEMICAL", 31, 39], ["acetic acid", "SIMPLE_CHEMICAL", 56, 67], ["glycerol", "SIMPLE_CHEMICAL", 114, 122], ["the gel", "TREATMENT", 6, 13], ["50% methanol", "TREATMENT", 27, 39], ["10% glacial acetic acid", "TREATMENT", 44, 67], ["cracking", "PROBLEM", 155, 163], ["a vacuum dryer", "TREATMENT", 177, 191], ["MS film", "TEST", 238, 245], ["Statistical analyses", "TEST", 326, 346], ["log rank test", "TEST", 432, 445], ["cracking", "OBSERVATION", 155, 163]]]], "PMC7094113": [["IntroductionFirst confirmed on 20 May 2015, the latest outbreak of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infections in Korea accounted for 186 laboratory-confirmed cases, including 36 deaths, 138 recovered individuals discharged from hospitals, and 12 remaining in hospitals up to 28 July 2015, a de facto end date of the outbreak (Ministry of Health and Welfare , MoH).", [["Middle East Respiratory Syndrome coronavirus", "DISEASE", 67, 111], ["MERS-CoV) infections", "DISEASE", 113, 133], ["deaths", "DISEASE", 202, 208], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 67, 111], ["MERS-CoV", "ORGANISM", 113, 121], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 67, 111], ["MERS-CoV", "SPECIES", 113, 121], ["Middle East Respiratory Syndrome coronavirus", "PROBLEM", 67, 111], ["infections", "PROBLEM", 123, 133], ["Middle", "ANATOMY_MODIFIER", 67, 73], ["Respiratory Syndrome", "OBSERVATION", 79, 99]]], ["It spread remarkably fast in hospitals, which has caused the largest MERS outbreak outside the Middle East.", [["spread", "OBSERVATION_MODIFIER", 3, 9], ["remarkably", "OBSERVATION_MODIFIER", 10, 20], ["fast", "OBSERVATION_MODIFIER", 21, 25], ["largest", "OBSERVATION_MODIFIER", 61, 68], ["MERS", "OBSERVATION", 69, 73], ["Middle", "ANATOMY_MODIFIER", 95, 101]]], ["The case fatality rate of 19.4% is, however, much lower than the reported rate of 37.7% prior to the outbreak in Korea, according to the World Health Organization (WHO).", [["The case fatality rate", "TEST", 0, 22]]], ["The MERS-CoV is a novel betacoronavirus which was first identified from the sputum of a 60-year-old man in fall 2012 (Zaki et al., 2012).", [["sputum", "ANATOMY", 76, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["betacoronavirus", "CANCER", 24, 39], ["man", "ORGANISM", 100, 103], ["man", "SPECIES", 100, 103], ["MERS-CoV", "SPECIES", 4, 12], ["a novel betacoronavirus", "PROBLEM", 16, 39]]], ["Clinical features of MERS range from mild illness to fatal conditions such as acute respiratory distress syndrome and multi-organ failure resulting in death, especially in patients with underlying comorbidities (Zumla et al., 2015).", [["respiratory", "ANATOMY", 84, 95], ["multi-organ", "ANATOMY", 118, 129], ["MERS", "DISEASE", 21, 25], ["illness", "DISEASE", 42, 49], ["acute respiratory distress syndrome", "DISEASE", 78, 113], ["multi-organ failure", "DISEASE", 118, 137], ["death", "DISEASE", 151, 156], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["MERS range", "PROBLEM", 21, 31], ["mild illness", "PROBLEM", 37, 49], ["fatal conditions", "PROBLEM", 53, 69], ["acute respiratory distress syndrome", "PROBLEM", 78, 113], ["multi-organ failure", "PROBLEM", 118, 137], ["death", "PROBLEM", 151, 156], ["underlying comorbidities", "PROBLEM", 186, 210], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["illness", "OBSERVATION", 42, 49], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory distress", "OBSERVATION", 84, 104], ["multi-organ", "ANATOMY", 118, 129], ["failure", "OBSERVATION", 130, 137]]], ["Although it is initially known as a zoonotic disease, human-to-human transmission occurs in health care settings and now is linked with significant morbidity (Oboho et al., 2015).", [["zoonotic disease", "DISEASE", 36, 52], ["human-to-human transmission", "DISEASE", 54, 81], ["human", "ORGANISM", 54, 59], ["human", "ORGANISM", 63, 68], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 63, 68], ["a zoonotic disease", "PROBLEM", 34, 52], ["zoonotic", "OBSERVATION_MODIFIER", 36, 44]]], ["This outbreak of the MERS-CoV infection, including the index cases roommates, their caregiver, and even the healthcare workers, in what is called as a super-spreading event (Kupferschmidt, 2015), raised several important issues for global public health surveillance and raised several issues regarding infection control policies, including the control of nosocomial transmission to avoid a repeated outbreak (Keeling and Rohani, 2008).IntroductionIn this study, we carry out an epidemiological assessment of the MERS-CoV outbreak in Korea in order to provide a mathematical framework for understanding the complex dynamics of the pathogen spread and establishing efficient guidelines for implementing quarantine and isolation strategies.", [["MERS-CoV infection", "DISEASE", 21, 39], ["infection", "DISEASE", 302, 311], ["MERS-CoV", "ORGANISM", 21, 29], ["MERS-CoV", "SPECIES", 21, 29], ["MERS-CoV", "SPECIES", 512, 520], ["CoV infection", "PROBLEM", 26, 39], ["infection control policies", "TREATMENT", 302, 328], ["nosocomial transmission", "TREATMENT", 355, 378], ["a repeated outbreak", "PROBLEM", 388, 407], ["this study", "TEST", 450, 460], ["an epidemiological assessment", "TEST", 475, 504], ["implementing quarantine", "TREATMENT", 688, 711], ["isolation strategies", "TREATMENT", 716, 736], ["CoV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39]]], ["More specifically, we propose a class of nonlinear susceptible-infectious-quarantined (SIQ) models for analyzing and controlling the MERS outbreak in Korea.", [["infectious", "OBSERVATION", 63, 73]]], ["The proposed SIQ model is innovative, in that the MERS transmission probability is time-dependent, monotone decreasing, and squashing-type.", [["innovative", "OBSERVATION_MODIFIER", 26, 36], ["decreasing", "OBSERVATION_MODIFIER", 108, 118]]], ["More specifically, it is initially almost flat, then decreasing rapidly, and finally gradually reaching a saturation point, which is reasonable because this can reflect the change in individuals\u2019 hygienic behaviour with time.", [["the change in individuals", "PROBLEM", 169, 194], ["almost", "OBSERVATION_MODIFIER", 35, 41], ["flat", "OBSERVATION_MODIFIER", 42, 46], ["decreasing", "OBSERVATION_MODIFIER", 53, 63], ["rapidly", "OBSERVATION_MODIFIER", 64, 71]]], ["Recently, there has been much interest in investigating some aspects of the time-dependent nature of the disease transmission probability.", [["the disease transmission probability", "PROBLEM", 101, 137], ["disease", "OBSERVATION", 105, 112]]], ["In particular, several methods have been considered to model the time-dependence due to the impact of media coverage (Cui, Sun, Zhu, 2008, Liu, Wu, Zhu, 2007, Sun, Yang, Arino, Khan, 2011, Xiao, Tang, Wu, 2015).", [["media coverage", "TREATMENT", 102, 116]]], ["However, these studies have mostly focused on only a single factor under consideration.", [["these studies", "TEST", 9, 22]]], ["In this paper, we consider all relevant factors that can affect the MERS transmission probability (e.g., media coverage, increased awareness, etc.) collectively, and try to model the resultant time-dependent transmission probability using a sigmoidal function.", [["the MERS transmission probability", "PROBLEM", 64, 97], ["media coverage", "TREATMENT", 105, 119]]], ["Note that the sigmoidal functions are quite popular in the field of machine learning when one needs to address monotone and squashing-type phenomena.", [["monotone and squashing-type phenomena", "PROBLEM", 111, 148], ["sigmoidal", "ANATOMY_MODIFIER", 14, 23], ["popular", "OBSERVATION", 44, 51], ["type phenomena", "OBSERVATION", 134, 148]]], ["For the proposed SIQ model, we perform the task of parameter estimation, and apply optimal control theory to the controlled SIQ model, with the goal of minimizing the infectious compartment population and the cost of implementing the quarantine and isolation strategies.", [["parameter estimation", "TEST", 51, 71], ["the infectious compartment population", "TREATMENT", 163, 200], ["the quarantine", "TREATMENT", 230, 244], ["isolation strategies", "TREATMENT", 249, 269]]], ["Simulation results show that the proposed SIQ model can explain the observed data for the confirmed cases and the quarantined cases in the MERS outbreak very well, and the number of the MERS cases can be controlled reasonably well via the optimal control approach.", [["SIQ", "DNA", 42, 45]]], ["Finally in the last two sections of this paper, discussion and concluding remarks are given along with brief descriptions of data treatment.The SIQ model for the MERS analysis ::: Methods and resultsIn this section, we will propose a nonlinear susceptible-infectious-quarantined (SIQ) model for analyzing the MERS outbreak in Korea.", [["data treatment", "TREATMENT", 125, 139], ["infectious", "OBSERVATION", 256, 266]]], ["The SIQ model is a generalization of an epidemiological population model involving susceptible, infectious, and quarantined compartments (Hethcote, Zhien, Shengbing, 2002, Keeling, Rohani, 2008, Lenhart, Workman, 2007, Xiao, Tang, Wu, 2015).", [["susceptible, infectious, and quarantined compartments", "PROBLEM", 83, 136], ["susceptible", "OBSERVATION_MODIFIER", 83, 94], ["infectious", "OBSERVATION", 96, 106]]], ["In the SIQ model, the four compartment populations are used as the model\u2019s state variables: S(t), the number of individuals that are susceptible to the MERS disease at time t; I(t), the number of individuals that are actively infectious at time t; Sq(t), the number of quarantined susceptible individuals at time t; and Cq(t), the number of confirmed cases at time t.", [["the MERS disease", "PROBLEM", 148, 164], ["infectious", "OBSERVATION", 226, 236]]], ["Also, note that Cq(t) is a collective sink-type compartment, which includes the number of the MERS patients under treatment, the recovered cases, and the dead cases altogether at time t.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["treatment", "TREATMENT", 114, 123]]], ["As shown in Fig. 1, the SIQ model considers two kinds of non-pharmaceutical interventions: quarantine of the susceptible and infected individuals, and isolation of the infectious individuals following contact tracing.", [["non-pharmaceutical interventions", "TREATMENT", 57, 89], ["quarantine", "TREATMENT", 91, 101], ["the susceptible and infected individuals", "PROBLEM", 105, 145], ["the infectious individuals", "PROBLEM", 164, 190], ["contact tracing", "TEST", 201, 216], ["infected", "OBSERVATION", 125, 133], ["infectious", "OBSERVATION", 168, 178]]], ["As a result of a contact tracing, a proportion, q, of individuals who are contacted in connection with a MERS patient is quarantined.", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["a contact tracing", "TEST", 15, 32]]], ["The quarantined individuals can move to compartments Cq or Sq, depending on whether they are exposed to the MERS coronavirus or not.", [["compartments", "ANATOMY", 40, 52], ["individuals", "ORGANISM", 16, 27], ["Sq", "GENE_OR_GENE_PRODUCT", 59, 61], ["MERS coronavirus", "ORGANISM", 108, 124], ["MERS coronavirus", "SPECIES", 108, 124], ["Sq", "TREATMENT", 59, 61], ["the MERS coronavirus", "PROBLEM", 104, 124]]], ["Note that in the SIQ model, the MERS transmission probability, \u03b2(t), is time-dependent, monotone decreasing, and squashing-type.", [["decreasing", "OBSERVATION_MODIFIER", 97, 107]]], ["As shown in Fig. 1, if infected, the quarantined individuals move to the compartment Cq at a rate of c\u03b2(t)q.", [["infected", "PROBLEM", 23, 31], ["infected", "OBSERVATION", 23, 31], ["compartment", "ANATOMY", 73, 84]]], ["Also, the remaining proportion (i.e., the proportion missed from the contact tracing), 1\u2212q, can move to compartment I or stay in compartment S, depending on whether they are exposed to the MERS coronavirus or not.", [["MERS coronavirus", "ORGANISM", 189, 205], ["MERS coronavirus", "SPECIES", 189, 205], ["the contact tracing", "TEST", 65, 84], ["the MERS coronavirus", "PROBLEM", 185, 205]]], ["The transmission dynamics of the SIQ model is illustrated in Fig. 1, and its state equations are as follows:(1)S\u02d9(t)=\u2212c(1\u2212\u03b2(t))qS(t)I(t)\u2212c\u03b2(t)qS(t)I(t)\u2212c\u03b2(t)(1\u2212q)S(t)I(t)+\u03bbSq(t)I\u02d9(t)=c\u03b2(t)(1\u2212q)S(t)I(t)\u2212\u03b8I(t)S\u02d9q(t)=c(1\u2212\u03b2(t))qS(t)I(t)\u2212\u03bbSq(t)I\u02d9q(t)=c\u03b2(t)qS(t)I(t)+\u03b8I(t)The first equation of (1) describes the rate of change of the susceptible compartment population, with four terms on its right-hand side.", [["right-hand", "ANATOMY", 387, 397], ["c\u03b2(t)(1\u2212q)S(t)I(t)\u2212\u03b8I(t)S\u02d9q", "CHEMICAL", 183, 210], ["SIQ", "DNA", 33, 36], ["its state equations", "TEST", 73, 92], ["S\u02d9", "TEST", 111, 113], ["\u2212c", "TEST", 117, 119], ["t", "TEST", 134, 135], ["\u2212c", "TEST", 136, 138], ["\u03b2", "TEST", 138, 139], ["t", "TEST", 140, 141], ["t", "TEST", 145, 146], ["t", "TEST", 149, 150], ["\u2212c", "TEST", 151, 153], ["\u03b2", "TEST", 153, 154], ["t", "TEST", 155, 156], ["t", "TEST", 168, 169], ["Sq", "TEST", 172, 174], ["t", "TEST", 175, 176], ["I\u02d9", "TEST", 177, 179], ["t", "TEST", 180, 181], ["c\u03b2", "TEST", 183, 185], ["t", "TEST", 186, 187], ["S", "TEST", 193, 194], ["t", "TEST", 195, 196], ["I(", "TEST", 197, 199], ["t", "TEST", 199, 200], ["\u2212", "TEST", 201, 202], ["\u03b8", "TEST", 202, 203], ["t", "TEST", 205, 206], ["S\u02d9q", "TEST", 207, 210], ["t", "TEST", 211, 212], ["c", "TEST", 214, 215], ["t", "TEST", 230, 231], ["\u2212\u03bb", "TEST", 232, 234], ["Sq", "TEST", 234, 236], ["t", "TEST", 237, 238], ["I\u02d9q", "TEST", 239, 242], ["t", "TEST", 243, 244], ["c\u03b2", "TEST", 246, 248], ["t", "TEST", 249, 250], ["t", "TEST", 258, 259], ["t", "TEST", 264, 265], ["The first equation", "TEST", 266, 284], ["the susceptible compartment population", "PROBLEM", 324, 362], ["susceptible", "OBSERVATION_MODIFIER", 328, 339], ["compartment population", "OBSERVATION", 340, 362], ["right", "ANATOMY_MODIFIER", 387, 392], ["hand", "ANATOMY", 393, 397]]], ["Its first term concerns the transition from S to Sq due to quarantine of susceptible individuals.", [["Sq", "DISEASE", 49, 51], ["Sq", "TREATMENT", 49, 51], ["susceptible individuals", "PROBLEM", 73, 96]]], ["The second and third terms model the transition from S to Cq and the transition from S to I, respectively.", [["transition", "OBSERVATION_MODIFIER", 37, 47]]], ["The fourth term represents the transition from Sq to S, and this transition means the release from quarantine into the wider community.", [["fourth term", "OBSERVATION_MODIFIER", 4, 15]]], ["In the second equation of (1), the rate of change of the infectious compartment population is described by two terms.", [["the infectious compartment population", "PROBLEM", 53, 90], ["infectious", "OBSERVATION_MODIFIER", 57, 67], ["compartment population", "OBSERVATION", 68, 90]]], ["The first represents the transition from the susceptible state to the infectious state, and the second term denotes the transition from I to Cq due to detection and isolation of the infectious patients.", [["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["detection", "TEST", 151, 160], ["infectious", "OBSERVATION", 70, 80], ["infectious", "OBSERVATION", 182, 192]]], ["The remaining equations of (1) describe the rates of change of Sq and Cq in the super-compartment Q, respectively, and the exact meaning of their terms can be explained similarly.", [["Sq", "GENE_OR_GENE_PRODUCT", 63, 65], ["Sq", "PROTEIN", 63, 65]]], ["The natural birth and death rates are not considered in the SIQ model, and this omission allows us to focus on the core theme of the paper.", [["death", "DISEASE", 22, 27]]], ["For example, if the natural birth rate of a susceptible population, \u039b, and the natural death rate, d, are considered, the resultant reduced SIQ system1with a constant transmission probability, \u03b20, would have the disease-free equilibrium point E0=(\u039b/d,0,0), which is locally asymptotically stable if the basic reproduction number R0 < 1, where R0=\u039bc\u03b20(1\u2212q)/(d(d+\u03b8)).The SIQ model for the MERS analysis ::: Methods and resultsAs previously mentioned, the MERS transmission probability, \u03b2(t), of our SIQ model, is time-dependent, monotone decreasing, and squashing-type.", [["death", "DISEASE", 87, 92], ["SIQ", "PROTEIN", 140, 143], ["a susceptible population", "PROBLEM", 42, 66], ["the resultant reduced SIQ", "PROBLEM", 118, 143], ["a constant transmission probability", "PROBLEM", 156, 191], ["the disease", "PROBLEM", 208, 219], ["R0", "TEST", 343, 345], ["\u039bc\u03b2", "TEST", 346, 349], ["reduced", "OBSERVATION_MODIFIER", 132, 139], ["decreasing", "OBSERVATION_MODIFIER", 536, 546]]], ["Since many factors (e.g., media coverage, increased awareness, etc.) can alter individuals\u2019 hygienic behavior, we employ the squashing-type function of Fig. 2for \u03b2(t).2More specifically, we utilize(2)\u03b2(t)=\u03b20\u2212\u0394\u03b2\u03c3(s\u03b2(t\u2212t\u03b2))),where \u03c3(\u00b7) is the logistic sigmoidal function (Bishop, 2006) defined as \u03c3(x)=1/(1+exp(\u2212x)); t\u03b2 is the inflection point of \u03b2(t); s\u03b2 is the parameter determining the slope of \u03b2(t) at its inflection point.", [["\u03b2(t)", "PROTEIN", 162, 166], ["\u0394\u03b2\u03c3", "PROTEIN", 208, 211], ["t\u2212t\u03b2", "PROTEIN", 215, 219], ["\u00b7", "PROTEIN", 231, 232], ["t\u03b2", "PROTEIN", 315, 317], ["\u03b2(t)", "PROTEIN", 345, 349], ["s\u03b2", "PROTEIN", 351, 353], ["\u03b2(t)", "PROTEIN", 396, 400], ["media coverage", "TREATMENT", 26, 40], ["Bishop", "TEST", 270, 276], ["t\u03b2", "TEST", 315, 317], ["s\u03b2", "TEST", 351, 353], ["the parameter", "TEST", 357, 370], ["slope", "OBSERVATION_MODIFIER", 387, 392]]], ["Note that the use of logistic sigmoidal functions is quite popular in the field of machine learning(Bishop, 2006) when one needs to represent monotone and squashing-type phenomena.", [["logistic sigmoidal functions", "TREATMENT", 21, 49], ["monotone and squashing-type phenomena", "PROBLEM", 142, 179], ["type phenomena", "OBSERVATION", 165, 179]]], ["Also, note that using the logistic sigmoidal function of (2) lead to the following simplification when we compute its derivative:(3)\u03b2\u02d9(t)=\u2212\u0394\u03b2s\u03b2\u03c3(s\u03b2(t\u2212t\u03b2))(1\u2212\u03c3(s\u03b2(t\u2212t\u03b2)).This property can be utilized effectively in further studies on the qualitative properties of the SIQ model (e.g., study of the global stability of the disease-free and endemic equilibrium points of the SIQ model).", [["\u0394\u03b2s\u03b2\u03c3", "PROTEIN", 139, 144], ["\u03b2", "PROTEIN", 146, 147], ["t\u2212t\u03b2", "PROTEIN", 148, 152], ["1\u2212\u03c3", "PROTEIN", 155, 158], ["s\u03b2", "PROTEIN", 159, 161], ["further studies", "TEST", 214, 229], ["the disease", "PROBLEM", 317, 328]]], ["An explanation of the SIQ parameters is given in Table 1.The SIQ model for the MERS analysis ::: Methods and resultsBy fitting the SIQ model to the reported data for the confirmed cases and the quarantined cases, we obtain the following parameters:3(4)S0=1.6\u00d710+04,c=7.2\u00d710\u221203,\u03b20=6.5\u00d710\u221203,\u0394\u03b2=3.3\u00d710\u221203,s\u03b2=0.78,t\u03b2=2.18\u00d710+01,q=2.3\u00d710\u221201,\u03bb=5.46\u00d710\u221202,\u03b8=3.8\u00d710\u221201.We performed simulations based on the estimated parameters.", [["SIQ", "DNA", 22, 25], ["the SIQ parameters", "TEST", 18, 36], ["c=", "TEST", 265, 267], ["simulations", "TEST", 375, 386]]], ["Our parameter estimation results show that the MERS transmission probability, \u03b2(t), is initially almost flat, then decreasing rapidly, and finally gradually reaching a saturation point (see the solid line of Fig. 5).", [["Our parameter estimation", "TEST", 0, 24], ["the MERS transmission probability", "PROBLEM", 43, 76], ["almost", "OBSERVATION_MODIFIER", 97, 103], ["flat", "OBSERVATION_MODIFIER", 104, 108], ["decreasing", "OBSERVATION_MODIFIER", 115, 125], ["rapidly", "OBSERVATION_MODIFIER", 126, 133]]], ["This has a natural interpretation, in that as information on the MERS outbreak becomes more widely known with the passage of time, health authorities\u2019 and individuals\u2019 efforts against the epidemic intensify accordingly, which results in the MERS transmission probability decreasing in the squashing-type fashion, as in Fig. 5.", [["the MERS transmission probability", "PROBLEM", 237, 270], ["decreasing", "OBSERVATION_MODIFIER", 271, 281]]], ["In retrospect, if the initial effort to reduce the MERS transmission probability were more effective, the magnitude of \u03b20 could be decreased further.", [["\u03b20", "GENE_OR_GENE_PRODUCT", 119, 121], ["\u03b20", "DNA", 119, 121], ["the MERS transmission probability", "PROBLEM", 47, 80], ["decreased", "OBSERVATION", 131, 140]]], ["Fig. 6shows that the infectious population could be reduced significantly if the aforementioned effort were successful.", [["the infectious population", "PROBLEM", 17, 42], ["infectious", "OBSERVATION_MODIFIER", 21, 31]]], ["4 and 7 shows the superiority of using the time-dependent \u03b2.The controlled SIQ (C-SIQ) model and optimal control ::: Methods and resultsSince quarantine and isolation strategies are the most important and effective measures against the outbreaks of disease when one does not have valid medicines and vaccine (see e.g., Castillo-Chavez, Castillo-Garsow, Yakubu, 2003, Day, Park, Madras, Gumel, Wu, 2006, Yan, Zou, 2009, Yan, Zou, Li, 2007), one can view the efforts of implementing quarantine and isolation strategies as the actions that control the entire model.", [["The controlled SIQ (C-SIQ) model", "TREATMENT", 60, 92], ["Methods", "TEST", 117, 124], ["quarantine and isolation strategies", "TREATMENT", 142, 177], ["disease", "PROBLEM", 249, 256], ["valid medicines", "TREATMENT", 280, 295], ["vaccine", "TREATMENT", 300, 307], ["implementing quarantine", "TREATMENT", 468, 491], ["isolation strategies", "TREATMENT", 496, 516]]], ["Note that recent applications of optimal control theory are increasingly used in communities of biological systems (e.g. (Buonomo, Messina, 2012, Joshi, Lenhart, Li, Wang, 2006, Jung, Lenhart, Feng, 2002, Kirschner, Lenhart, Serbin, 1997, de Pillis, Gu, Fister, Head, Maples, Murugan, Neal, Yoshida, 2007)), and in particular, they have been widely used and discussed in the control of epidemics (e.g.Caetano, Yoneyama, 2001, Feng, Yang, Xu, Zhang, McCauley, Glasser, 2009, Gupta, Rink, 1973, Joshi, Lenhart, Li, Wang, 2006, Lenhart, Workman, 2007).", [["Li", "ANATOMY", 162, 164], ["Kirschner", "ANATOMY", 205, 214], ["Head", "ANATOMY", 262, 266], ["Li", "ANATOMY", 509, 511]]], ["By incorporating the control inputs, q(t) into our SIQ model (1), one can obtain the following state equations for the controlled model:(5)S\u02d9(t)=\u2212c{(1\u2212\u03b2(t))q(t))S(t)I(t)\u2212\u03b8(t)S(t)I(t)\u2212\u03bbSq(t)I\u02d9q(t)=c\u03b2(t)q(t)I(t)Note that for the optimal control of (5), it is enough to consider the first three variables only.", [["\u2212c", "TEST", 145, 147], ["S(t", "TEST", 161, 164], ["t", "TEST", 167, 168], ["\u03b8", "TEST", 170, 171], ["t", "TEST", 180, 181], ["Sq", "TEST", 184, 186], ["t", "TEST", 187, 188], ["t", "TEST", 193, 194], ["the optimal control", "TEST", 223, 242]]], ["Hence, we consider the following controlled SIQ (C-SIQ) model:(6)S\u02d9(t)=\u2212c{(1\u2212\u03b2(t))q(t))S(t)I(t)\u2212\u03b8(t)S(t)I(t)\u2212\u03bbSq(t)From the data fitting based on the SIQ model, we have already obtained the estimation results for the quarantine probability, q, and the isolation rate, \u03b8.", [["SIQ", "TEST", 44, 47], ["\u2212c", "TEST", 71, 73], ["t", "TEST", 106, 107], ["the data fitting", "TEST", 120, 136], ["the SIQ model", "TEST", 146, 159], ["the quarantine probability", "TEST", 213, 239], ["the isolation rate", "TEST", 248, 266]]], ["In retrospect, however, control-theoretic investigation is desirable for the purpose of improving our response to the outbreak.", [["theoretic investigation", "TEST", 32, 55]]], ["In the following, we consider the problem of improving the quarantine probability and isolation rate further with additional efforts (\u0394q(t)) by minimizing an objective function in the form of J=\u222b0tfg(I(t),\u0394q(t))dt.", [["isolation rate", "TREATMENT", 86, 100], ["an objective function", "TEST", 155, 176], ["dt", "PROBLEM", 211, 213]]], ["Note that in this problem, the quarantine probability and isolation rate at time t are represented by(7)q(t)\u03b8(t),and the control inputs to be determined via optimal control theory are the additional efforts described by \u0394q(t).", [["the control inputs", "TREATMENT", 117, 135]]], ["Here g( \u00b7 ) should be reasonably chosen to reflect the relative importance of the quarantine and isolation efforts over the infection.", [["infection", "DISEASE", 124, 133], ["the quarantine", "TREATMENT", 78, 92], ["isolation efforts", "TREATMENT", 97, 114], ["the infection", "PROBLEM", 120, 133], ["infection", "OBSERVATION", 124, 133]]], ["More precisely, in order to minimize an objective function comprising the infection cost (i.e., the infectious compartment population) and the cost of implementing quarantine and isolation strategies, we consider the following optimal control problem:(8)minu(\u00b7)\u222b0tf[I(t)+cq(\u0394q(t))2]dtsubject to the C-SIQ state equations (6).The controlled SIQ (C-SIQ) model and optimal control ::: Methods and resultsIn the cost rate of this problem, cq and c\u03b8 are the trade-off constants defining the relative importance of the implementation costs over the infection cost.", [["infection", "DISEASE", 74, 83], ["infection", "DISEASE", 543, 552], ["I(t)+cq(\u0394q(t))2", "CHEMICAL", 266, 281], ["cq", "GENE_OR_GENE_PRODUCT", 435, 437], ["the infection cost", "PROBLEM", 70, 88], ["implementing quarantine", "TREATMENT", 151, 174], ["isolation strategies", "TREATMENT", 179, 199], ["The controlled SIQ (C-SIQ) model", "TREATMENT", 325, 357], ["cq", "PROBLEM", 435, 437], ["the infection cost", "PROBLEM", 539, 557], ["infection", "OBSERVATION", 74, 83], ["infectious", "OBSERVATION_MODIFIER", 100, 110], ["infection", "OBSERVATION", 543, 552]]], ["Note that the cost rate considers quadratic cost terms for the control inputs, which is a commonly used strategy in related control problems dealing with epidemic-model-based systems (e.g., Lenhart and Workman, 2007).", [["quadratic cost terms", "TREATMENT", 34, 54], ["the control inputs", "TREATMENT", 59, 77]]], ["Also, note that the existence of an optimal control and corresponding optimal state trajectory comes from the convexity of the integrand of the objective function with respect to the control and the Lipschitz property of the state system with respect to the state variables (see, e.g., Fleming and Rishel, 1975), and based on the existence, we can now rely on the Pontryagin maximum principle (PMP) (Pontryagin et al., 1987) for an optimal solution.", [["an optimal solution", "TREATMENT", 429, 448], ["convexity", "OBSERVATION_MODIFIER", 110, 119]]], ["For this, the Hamiltonian H of the optimal control problem (8) is defined as(9)H(S(t),I(t),Sq(t),p1(t),p2(t),p3(t),\u0394q(t))=I(t)+cq(\u0394q(t))2+p1(\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))S(t)I(t)\u2212(\u03b8+\u0394\u03b8(t))S(t)I(t)\u2212\u03bbSq(t)).and its costate equations can be obtained via(10)p\u02d91=\u2212\u2202H\u2202S,p\u02d92=\u2212\u2202H\u2202I,p\u02d93=\u2212\u2202H\u2202Sq,p1(tf)=p2(tf)=p3(tf)=0.From the optimality conditions, \u2202H\u2202\u0394q=0, we can also obtain the following condition for optimal control:(11)\u0394q(t)=p2(t)2c\u03b8I(t).Also, if upper bounds for the nonnegative control inputs are forced, then by confining the control input to be nonnegative and subject to a positive upper bound \u0394qmax and \u0394\u03b8max, the optimal control of (8) can be written in the following form:(12)\u0394q(t)=max(0,min(p2(t)2c\u03b8I(t),\u0394\u03b8max)).From the above steps, we can conclude that any solution to the optimal control problem (8) must satisfy the following:(13)S\u02d9(t)=\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))S(t)I(t)\u2212(\u03b8+\u0394\u03b8(t))S(t)I(t)\u2212\u03bbSq(t),p\u02d91(t)=\u2212p1(t)(\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))I(t))\u2212p3(t)(c(1\u2212\u03b2(t))(q+\u0394q(t))+\u03b2(t)})S(t)\u2212p2(t)(c\u03b2(t)(1\u2212(q+\u0394q(t)))\u2212p3(t)(c(1\u2212\u03b2(t))(q+\u0394q(t)=max(0,min(c{p1(t)(1\u2212\u03b2(t))+p2(t)\u03b2(t)\u2212p3(t)(1\u2212\u03b2(t))}2cqS(t)I(t),\u0394qmax)),\u0394\u03b8(t) and \u0394\u03b8*(t).", [["H", "CHEMICAL", 26, 27], ["(9)H", "CHEMICAL", 76, 80], ["H", "CHEMICAL", 252, 253], ["S", "CHEMICAL", 254, 255], ["H", "CHEMICAL", 262, 263], ["\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))S(t)I(t)\u2212(\u03b8+\u0394\u03b8(t))S(t)I(t)\u2212\u03bbSq(t)", "CHEMICAL", 838, 892], ["\u2212p1(t)(\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))I(t))\u2212p3(t)(c(1\u2212\u03b2(t))(q+\u0394q(t))+\u03b2(t)})S(t)\u2212p2", "CHEMICAL", 900, 972], ["\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)", "SIMPLE_CHEMICAL", 141, 160], ["\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))S(t)I(t)", "SIMPLE_CHEMICAL", 838, 867], ["p\u02d91(t)=\u2212p1(t)", "SIMPLE_CHEMICAL", 893, 906], ["\u2212c{(1\u2212\u03b2(t))(q+\u0394q(t)))I(t", "SIMPLE_CHEMICAL", 907, 931], ["t", "TEST", 168, 169], ["S", "TEST", 254, 255], ["H", "TEST", 262, 263], ["I", "TEST", 264, 265], ["p\u02d9", "TEST", 266, 268], ["Sq", "TEST", 274, 276], ["tf", "TEST", 280, 282], ["tf)", "TEST", 287, 290], ["tf", "TEST", 294, 296], ["upper bounds", "PROBLEM", 436, 448], ["a positive upper bound \u0394qmax", "TREATMENT", 565, 593], ["\u0394\u03b8max", "TREATMENT", 598, 603], ["any solution", "TREATMENT", 753, 765], ["\u2212c", "TEST", 838, 840], ["S(", "TEST", 859, 861], ["t", "TEST", 861, 862], ["t", "TEST", 865, 866], ["\u2212", "TEST", 867, 868], ["\u0394\u03b8", "TEST", 871, 873], ["S", "TEST", 877, 878], ["t", "TEST", 883, 884], ["Sq", "TEST", 887, 889], ["p\u02d9", "TEST", 893, 895], ["\u2212c", "TEST", 907, 909], ["t", "TEST", 930, 931], ["\u2212", "TEST", 933, 934], ["c", "TEST", 940, 941], ["\u03b2", "TEST", 944, 945], ["t", "TEST", 967, 968], ["c\u03b2", "TEST", 976, 978], ["\u2212", "TEST", 994, 995], ["c", "TEST", 1001, 1002], ["\u03b2", "TEST", 1005, 1006], ["t", "TEST", 1007, 1008], ["q+\u0394q", "TEST", 1011, 1015], ["max", "TEST", 1019, 1022], ["c", "TEST", 1029, 1030], ["1\u2212", "TEST", 1037, 1039], ["\u03b2", "TEST", 1039, 1040], ["\u03b2", "TEST", 1050, 1051], ["S", "TEST", 1072, 1073], ["t", "TEST", 1078, 1079], ["\u0394qmax", "TEST", 1081, 1086]]], ["For the trade-off constants of (8), we used c\u03b8=10,000,cq=1.", [["c\u03b8", "TEST", 44, 46]]], ["The initial conditions for the simulations were also taken from the estimation results, i.e., S0=16,000,I0=1, and Sq0=0.", [["the simulations", "TEST", 27, 42], ["S0", "TEST", 94, 96]]], ["With the goal of keeping the infection level low with reasonable control efforts, we solved the boundary value ODE problem (13) using bvp4c, the MATLAB function to solve boundary value problems for ordinary differential equations).Fig.", [["infection", "DISEASE", 29, 38], ["bvp4c", "PROTEIN", 134, 139], ["the infection level low", "PROBLEM", 25, 48], ["bvp4c", "TREATMENT", 134, 139], ["boundary value problems", "PROBLEM", 170, 193], ["infection", "OBSERVATION", 29, 38]]], ["8, Fig. 9, Fig. 10show the simulation results for the first scenario.The controlled SIQ (C-SIQ) model and optimal control ::: Methods and results", [["The controlled SIQ (C-SIQ) model", "TREATMENT", 69, 101]]]], "b06ab59bc8867c6b47c22e3fb5bc377f66a262d0": [["IntroductionThe current outbreak of SARS-CoV-2 and the huge associated number of cases of COVID-19 is leading to increasing pressure on hospitals in general and intensive care units (ICUs) in particular around the globe.", [["SARS", "DISEASE", 36, 40], ["COVID-19", "CHEMICAL", 90, 98], ["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["CoV", "TEST", 41, 44], ["COVID", "TEST", 90, 95], ["increasing pressure", "PROBLEM", 113, 132], ["increasing", "OBSERVATION_MODIFIER", 113, 123], ["pressure", "OBSERVATION_MODIFIER", 124, 132], ["globe", "ANATOMY", 214, 219]]], ["About one-tenth of patients with COVID-19 will require some form of ventilatory support (invasive and non-invasive) on ICUs that are already (almost) full under normal circumstances.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["COVID", "TREATMENT", 33, 38], ["ventilatory support", "TREATMENT", 68, 87]]], ["The lesions of COVID-19 are potentially reversible, so that efforts to support patients must be sustained.", [["lesions", "ANATOMY", 4, 11], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["COVID", "TEST", 15, 20], ["lesions", "OBSERVATION", 4, 11], ["reversible", "OBSERVATION_MODIFIER", 40, 50]]], ["But the acute course of the disease can last many days and even weeks, so that bed occupancy is often prolonged, resulting in a critical shortage of ICU bed availability and ventilators.IntroductionThe acute shortages of ICU beds, facilities and staff raise multiple ethical dilemmas related to how best to share the available resources to ensure the best possible outcomes for as many as possible.", [["the disease", "PROBLEM", 24, 35], ["ventilators", "TREATMENT", 174, 185], ["acute", "OBSERVATION_MODIFIER", 8, 13], ["disease", "OBSERVATION", 28, 35], ["acute", "OBSERVATION_MODIFIER", 202, 207]]], ["Here we will consider some of the difficult ethical decisions we are all facing.The basic principlesIn principle, ICUs should be reserved for patients who treating clinicians believe can be expected to recover with a good quality of life.", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150]]], ["Admitting patients who are going to die, regardless of any medical effort, is not acceptable (Figure 1 ).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Similarly, patients who are not very severely ill and do not really require 'intensive care' should not be admitted.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["very severely ill", "PROBLEM", 32, 49]]], ["Discharge from the ICU earlier than usual may also be encouraged, especially when some form of respiratory support can be continued outside the ICU.", [["respiratory", "ANATOMY", 95, 106], ["respiratory support", "TREATMENT", 95, 114]]], ["Intensive care admission can thus be denied or discharge advanced for some patients who are most likely to die and also for patients who are likely to do well.", [["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 124, 132]]], ["In a crisis situation, as at present, these two extreme ends of the spectrum will expand, thus effectively increasing the numbers of available ICU beds (Figure 1 ).The basic principlesWhen the situation becomes really critical, the key ethical principle of distributive justice may apply and can help guide appropriate allocation of the limited healthcare resources.", [["crisis", "OBSERVATION", 5, 11]]], ["The principle of distributive justice in this context relates to the fair and equal distribution of healthcare resources to all who need them, taking into account society as a whole and not individual patients.", [["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["distributive", "OBSERVATION_MODIFIER", 17, 29], ["justice", "OBSERVATION", 30, 37]]], ["When resources are scarce, distributive justice supports their distribution to those most likely to benefit.", [["distributive justice", "OBSERVATION", 27, 47]]], ["Very importantly, this does not mean the patients who are most likely to survive, as many of those could be managed outside the ICU.Catastrophes and epidemics are not the sameThe same rule of reserving ICU beds for the most likely to benefit also applies in other conditions of disaster medicine.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Catastrophes", "PROBLEM", 132, 144], ["epidemics", "PROBLEM", 149, 158], ["reserving ICU beds", "TREATMENT", 192, 210], ["disaster medicine", "TREATMENT", 278, 295], ["most likely", "UNCERTAINTY", 58, 69]]], ["However, although the pandemic situation is similar in many aspects to disaster medicine, there are five important differences between a single catastrophe (for example, an explosion in a factory, a train crash, a collapsed building) and an epidemic:Catastrophes and epidemics are not the same1.", [["Catastrophes", "DISEASE", 250, 262], ["the pandemic situation", "PROBLEM", 18, 40], ["a single catastrophe", "PROBLEM", 135, 155], ["Catastrophes", "PROBLEM", 250, 262], ["epidemics", "PROBLEM", 267, 276], ["catastrophe", "OBSERVATION", 144, 155], ["Catastrophes", "OBSERVATION", 250, 262]]], ["In a catastrophe, the number of patients is generally known and fixed at a relatively early stage although of course some patients may deteriorate later.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 122, 130], ["a catastrophe", "PROBLEM", 3, 16], ["catastrophe", "OBSERVATION", 5, 16]]], ["In epidemics, it is difficult to predict how many patients will become infected and need ICU admission.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["infected", "OBSERVATION", 71, 79]]], ["In a catastrophe, there is a one-off trigger event and the acute situation is limited in time.", [["catastrophe", "DISEASE", 5, 16], ["the acute situation", "PROBLEM", 55, 74], ["catastrophe", "OBSERVATION", 5, 16], ["acute", "OBSERVATION_MODIFIER", 59, 64]]], ["Some patients may deteriorate over subsequent days, but these are usually limited in number, and this is not generally a major challenge.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["deteriorate", "OBSERVATION_MODIFIER", 18, 29]]], ["The amplitude of the problem is quickly appreciated.", [["amplitude", "OBSERVATION_MODIFIER", 4, 13]]], ["In epidemics, patients continue to be infected over a prolonged, and generally difficult to predict, period of time, with initially small numbers of cases increasing often rapidly over a period of days, weeks or even months.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["infected", "PROBLEM", 38, 46], ["infected", "OBSERVATION", 38, 46], ["small", "OBSERVATION_MODIFIER", 132, 137], ["numbers", "OBSERVATION_MODIFIER", 138, 145], ["increasing", "OBSERVATION_MODIFIER", 155, 165]]], ["In a catastrophe, healthcare staff are generally not affected and there are many who can be called in to help.", [["catastrophe", "OBSERVATION", 5, 16]]], ["In a catastrophe, patient transfer is usually possible from one centre (often the hospital or clinic closest to the catastrophe) to other more specialized centres.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["catastrophe", "OBSERVATION", 5, 16]]], ["In epidemics, this is particularly difficult because of the extra hygiene measures necessary to protect staff and other patients and the fact that most, if not all, hospitals will be under similar pressure with shortages of staff, beds and equipment.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["the extra hygiene measures", "TREATMENT", 56, 82]]], ["In a catastrophe, most hospitals have established disaster plans in place, which are periodically enacted and can be activated immediately.", [["catastrophe", "OBSERVATION", 5, 16]]], ["They can also learn from the approaches implemented by other affected countries.Increasing ICU capabilitiesFortunately, crises such as the current pandemic remain relatively rare, but this also means that the chances of expansion are limited.", [["Increasing ICU capabilities", "PROBLEM", 80, 107], ["crises", "PROBLEM", 120, 126], ["expansion", "OBSERVATION", 220, 229]]], ["The numbers of ICU beds within each hospital are usually relatively small and they are generally well occupied.", [["numbers", "OBSERVATION_MODIFIER", 4, 11], ["small", "OBSERVATION", 68, 73]]], ["The obvious solution to lack of ICU bed availability is to somehow increase the number of beds available for critically ill patients (Table 1 ).", [["critically ill", "DISEASE", 109, 123], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132]]], ["This could be achieved by transforming less sophisticated units, such as recovery rooms, coronary care units or stroke units, into ICUs.", [["coronary", "ANATOMY", 89, 97], ["stroke", "DISEASE", 112, 118], ["coronary care units", "TREATMENT", 89, 108], ["stroke units", "TREATMENT", 112, 124], ["coronary", "ANATOMY", 89, 97]]], ["This raises potential problems, however, related to obtaining sufficient numbers of trained staff for the extra beds.", [["potential problems", "PROBLEM", 12, 30], ["the extra beds", "TREATMENT", 102, 116]]], ["A second option is to perform some interventions normally reserved for the ICU on general wards.", [["some interventions", "TREATMENT", 30, 48]]], ["There are three types of ICU treatment that cannot be provided elsewhere: mechanical ventilation for acute respiratory failure, renal replacement therapy for acute renal failure and cardiovascular support for acute circulatory failure (shock).", [["respiratory", "ANATOMY", 107, 118], ["renal", "ANATOMY", 128, 133], ["renal", "ANATOMY", 164, 169], ["cardiovascular", "ANATOMY", 182, 196], ["circulatory", "ANATOMY", 215, 226], ["acute respiratory failure", "DISEASE", 101, 126], ["acute renal failure", "DISEASE", 158, 177], ["acute circulatory failure", "DISEASE", 209, 234], ["shock", "DISEASE", 236, 241], ["renal", "ORGAN", 128, 133], ["renal", "ORGAN", 164, 169], ["ICU treatment", "TREATMENT", 25, 38], ["mechanical ventilation", "TREATMENT", 74, 96], ["acute respiratory failure", "PROBLEM", 101, 126], ["renal replacement therapy", "TREATMENT", 128, 153], ["acute renal failure", "PROBLEM", 158, 177], ["cardiovascular support", "TREATMENT", 182, 204], ["acute circulatory failure", "PROBLEM", 209, 234], ["mechanical ventilation", "OBSERVATION", 74, 96], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory failure", "OBSERVATION", 107, 126], ["renal", "ANATOMY", 128, 133], ["replacement", "OBSERVATION", 134, 145], ["renal", "ANATOMY", 164, 169], ["failure", "OBSERVATION", 170, 177], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["circulatory failure", "OBSERVATION", 215, 234]]], ["In the case of COVID-19, one could consider using some forms of respiratory support, such as high flow oxygen therapy, continuous positive airway pressure or non-invasive respiratory support, outside the ICU, even though there is a risk if staff are not familiar with these techniques or trained to use them.Triaging ICU admissions and treatmentsTriaging is already used in most ICUs worldwide to limit unnecessary ICU admissions, but in times of acute bed shortages has an even greater role to play.", [["respiratory", "ANATOMY", 64, 75], ["airway", "ANATOMY", 139, 145], ["respiratory", "ANATOMY", 171, 182], ["oxygen", "CHEMICAL", 103, 109], ["COVID-19", "CHEMICAL", 15, 23], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["airway", "MULTI-TISSUE_STRUCTURE", 139, 145], ["COVID", "TEST", 15, 20], ["respiratory support", "TREATMENT", 64, 83], ["high flow oxygen therapy", "TREATMENT", 93, 117], ["continuous positive airway pressure", "TREATMENT", 119, 154], ["non-invasive respiratory support", "TREATMENT", 158, 190], ["treatments", "TREATMENT", 336, 346], ["acute bed shortages", "PROBLEM", 447, 466], ["respiratory support", "OBSERVATION", 64, 83], ["oxygen therapy", "OBSERVATION", 103, 117], ["airway pressure", "OBSERVATION", 139, 154], ["respiratory support", "OBSERVATION", 171, 190]]], ["However, triaging must be appropriate and follow carefully defined and documented rules.Triaging ICU admissions and treatmentsThe priority is not the patients who are most likely to survive.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["treatments", "TREATMENT", 116, 126], ["most likely", "UNCERTAINTY", 167, 178]]], ["Patients who are most likely to survive may not even need ICU admission and could be cared for effectively on general wards.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["most likely", "UNCERTAINTY", 17, 28]]], ["Criteria for ICU admission that need to be considered include the severity of the acute disease, the presence of comorbidities, the degree of chronic organ failure and the potential for recovering a reasonable quality of life.", [["organ", "ANATOMY", 150, 155], ["chronic organ failure", "DISEASE", 142, 163], ["organ", "ORGAN", 150, 155], ["the acute disease", "PROBLEM", 78, 95], ["comorbidities", "PROBLEM", 113, 126], ["chronic organ failure", "PROBLEM", 142, 163], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["disease", "OBSERVATION", 88, 95], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["organ", "ANATOMY", 150, 155], ["failure", "OBSERVATION", 156, 163]]], ["The triage decision process must therefore take a number of factors into account:Triaging ICU admissions and treatments1.", [["treatments", "TREATMENT", 109, 119]]], ["Of course, the age of the patient is an important element, but it is clearly not the only one that should be considered.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33]]], ["An elderly patient who is independent and active, with no previous medical conditions, may take precedence over a younger individual with advanced cancer, severe heart failure or alcoholic cirrhosis.", [["cancer", "ANATOMY", 147, 153], ["heart", "ANATOMY", 162, 167], ["cancer", "DISEASE", 147, 153], ["heart failure", "DISEASE", 162, 175], ["alcoholic cirrhosis", "DISEASE", 179, 198], ["patient", "ORGANISM", 11, 18], ["cancer", "CANCER", 147, 153], ["heart", "ORGAN", 162, 167], ["patient", "SPECIES", 11, 18], ["previous medical conditions", "PROBLEM", 58, 85], ["advanced cancer", "PROBLEM", 138, 153], ["severe heart failure", "PROBLEM", 155, 175], ["alcoholic cirrhosis", "PROBLEM", 179, 198], ["cancer", "OBSERVATION", 147, 153], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["heart", "ANATOMY", 162, 167], ["failure", "OBSERVATION", 168, 175], ["alcoholic cirrhosis", "OBSERVATION", 179, 198]]], ["Indeed, life expectancy is perhaps more important than age: excluding patients with a predicted life expectancy <1 year could be considered.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Frailty is an important element.", [["Frailty", "DISEASE", 0, 7], ["important element", "OBSERVATION", 14, 31]]], ["Past history and comorbidities, including the degree of chronic organ failure, must be taken into account.", [["organ", "ANATOMY", 64, 69], ["chronic organ failure", "DISEASE", 56, 77], ["organ", "ORGAN", 64, 69], ["comorbidities", "PROBLEM", 17, 30], ["chronic organ failure", "PROBLEM", 56, 77], ["comorbidities", "OBSERVATION", 17, 30], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["organ", "ANATOMY", 64, 69], ["failure", "OBSERVATION", 70, 77]]], ["Other patients than those with COVID-19 may also need intensive care.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["COVID", "TREATMENT", 31, 36], ["intensive care", "TREATMENT", 54, 68]]], ["It is important not to become so focused on COVID-19 that the treatment of patients who also need ICU care but do not have the disease is compromised.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["ICU care", "TREATMENT", 98, 106], ["the disease", "PROBLEM", 123, 134], ["important not to", "UNCERTAINTY", 6, 22], ["disease", "OBSERVATION", 127, 134]]], ["There is a real risk of 'forgetting' patients who are not directly affected by the ongoing epidemic, but whose survival may be reduced by the interruption of planned elective surgical interventions, outpatient clinics and reduced availability of ICU resources.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["planned elective surgical interventions", "TREATMENT", 158, 197], ["ICU resources", "TREATMENT", 246, 259]]], ["The same rules for admission and discharge must apply to all patients ( Table 2 ).Triaging ICU admissions and treatmentsThe concept of first come, first served should not apply.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["treatments", "TREATMENT", 110, 120]]], ["This approach may result in intensive care being withheld from a new patient because the bed is occupied by another patient who is predicted not to survive with a meaningful quality of life even with maximum treatment.", [["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 116, 123], ["maximum treatment", "TREATMENT", 200, 217]]], ["1 The appropriateness of life-sustaining treatments should be re-evaluated on a daily basis, taking into account all patient-related factors, including the clinical course, complications and response to treatment.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["sustaining treatments", "TREATMENT", 30, 51], ["complications", "PROBLEM", 173, 186], ["treatment", "TREATMENT", 203, 212]]], ["Patients, their families and staff members must all be clearly informed of this strategy.Triaging ICU admissions and treatmentsThe decision to remove a patient from a ventilator or to discharge them from the ICU to free the bed to provide for others who could benefit more is justifiable 2 and patients and their families should be made aware of this possibility at the time of admission.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 152, 159], ["patients", "ORGANISM", 294, 302], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 152, 159], ["patients", "SPECIES", 294, 302], ["treatments", "TREATMENT", 117, 127], ["a ventilator", "TREATMENT", 165, 177]]], ["Withdrawing ventilator support from a patient in order to use the equipment to try and save someone with a better prognosis can be extremely difficult for healthcare staff involved in the patient's care and distressing for their families.", [["patient", "ORGANISM", 38, 45], ["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 38, 45], ["patient", "SPECIES", 188, 195], ["ventilator support", "TREATMENT", 12, 30], ["the equipment", "TREATMENT", 62, 75]]], ["However, in such situations, this should not be considered as an act of killing and does not require patient consent; such decisions are ethically permissible.", [["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108]]], ["3 Careful triage from the very start of such an epidemic, with allocation of beds and ventilators taking into consideration the need to maximize benefits for all, could help reduce the later need for withdrawal.Triaging ICU admissions and treatmentsSome have suggested that, in cases of comparable medical urgency, selection based on 'random' criteria or lottery may be the fairest, but we would avoid this option as much as possible, because good clinical appraisal should generally prevail over chance.", [["Careful triage", "TEST", 2, 16], ["allocation of beds", "TREATMENT", 63, 81], ["ventilators", "TREATMENT", 86, 97], ["withdrawal", "PROBLEM", 200, 210], ["treatments", "TREATMENT", 239, 249], ["comparable medical urgency", "PROBLEM", 287, 313]]], ["Nevertheless, relying on clinical judgment alone when making such decisions may not be adequate 3 and to increase objectivity, the use of scoring systems has been suggested.", [["scoring systems", "TEST", 138, 153]]], ["The Sequential Organ Failure Assessment Score was proposed as a triage tool in previous epidemics, with patients with very low or very high scores given low priority for ICU admission, 4 and is being used by some institutions in the current pandemic.", [["Organ", "ANATOMY", 15, 20], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["The Sequential Organ Failure", "PROBLEM", 0, 28], ["very low or very high scores", "PROBLEM", 118, 146], ["Organ", "ANATOMY", 15, 20], ["Failure", "OBSERVATION", 21, 28]]], ["A Clinical Frailty Score 5 could also be calculated, as has been recommended by the National Institute for Health and Care Excellence in the UK.", [["A Clinical Frailty Score", "TEST", 0, 24]]], ["6 These scores, combined with other factors including clinical evaluation, age and comorbid conditions, could potentially be used to create a priority score to guide limited resource allocation.", [["clinical evaluation", "TEST", 54, 73], ["comorbid conditions", "PROBLEM", 83, 102]]], ["7 Working closely with other medical disciplines, including geriatric medicine, can help in these complex decisions.Triaging ICU admissions and treatmentsThe same discussions apply to the use of extracorporeal membrane oxygenation (ECMO), when the ICU staff trained to use it and/or the number of machines is restricted.", [["extracorporeal membrane", "ANATOMY", 195, 218], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 195, 218], ["geriatric medicine", "TREATMENT", 60, 78], ["treatments", "TREATMENT", 144, 154], ["extracorporeal membrane oxygenation", "TREATMENT", 195, 230]]], ["ECMO can save lives in some of the most seriously ill COVID-19 patients, but is the most resource-consuming treatment that we can offer in the ICU.", [["COVID", "DISEASE", 54, 59], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["ECMO", "TREATMENT", 0, 4], ["treatment", "TREATMENT", 108, 117]]], ["As such, it should be reserved for very carefully selected patients, and ideally only be available in high-volume referral centres.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["Importantly, there may be a conflict between the provision of such very advanced care to a very limited number of patients versus the need to provide less advanced care to more patients.", [["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 177, 185], ["such very advanced care", "TREATMENT", 62, 85], ["less advanced care", "TREATMENT", 150, 168], ["may be", "UNCERTAINTY", 19, 25], ["conflict", "OBSERVATION", 28, 36]]], ["This is a difficult ethical balance.Triaging ICU admissions and treatmentsRole of the ICU leader in triage.", [["treatments", "TREATMENT", 64, 74]]], ["Triage decisions during epidemics are difficult and can be emotionally draining.", [["epidemics", "PROBLEM", 24, 33]]], ["ICU staff are not familiar with or well prepared for the need to triage patients according to likely or expected benefit.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["The ICU team, already faced with new hurdles related to complex additional hygiene and protection measures, must also learn how to deal with the very difficult ethical decisions associated with insufficient availability of ICU beds and equipment.", [["protection measures", "TREATMENT", 87, 106], ["ICU beds", "TREATMENT", 223, 231]]], ["Hospital staff are often even less prepared for such decision making and all healthcare staff must be supported when having to make such difficult decisions.Triaging ICU admissions and treatmentsTriage rules must therefore be based on a clear set of rules that are as explicit as possible and are developed according to local circumstances and resources.", [["treatments", "TREATMENT", 185, 195]]], ["Even with carefully developed protocols, however, uncertainties will remain.", [["protocols", "TREATMENT", 30, 39]]], ["At the peak of such epidemics with large numbers of patients needing admission on a continuous basis, there is also no time to have prolonged discussions about these decisions.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["large", "OBSERVATION_MODIFIER", 35, 40], ["numbers", "OBSERVATION_MODIFIER", 41, 48]]], ["As such, it is important that an ICU leader (usually the Head of the ICU or a senior staff physician) who is available 24 hours a day (perhaps on a separate pager just for this purpose) is identified as the ultimate person responsible for triage decisions.", [["person", "SPECIES", 216, 222]]], ["8 The triage leader or committee will be in charge of ICU admission and resource allocation.Triaging ICU admissions and treatmentsNot having explicit rules -or, even worse, not respecting them -can result in a feeling of injustice (with sometimes 'VIP medicine'), waste of time spent on discussions, disagreement and even conflict.", [["treatments", "TREATMENT", 120, 130]]], ["The person in charge of triage must treat everybody in all fairness keeping in mind the fundamental principles presented in Table 2 .", [["person", "SPECIES", 4, 10]]], ["Triage decisions cannot be influenced by the VIP status of a patient, family links to staff members, patient wealth or place in society.Triaging ICU admissions and treatmentsICU admission policies should be discussed within the department (colleagues and nurses) and outside the ICU (hospital management), so that stakeholders can understand and share the principles and everyone is in agreement to adhere to the decisions.", [["patient", "ORGANISM", 61, 68], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 61, 68], ["patient", "SPECIES", 101, 108], ["treatmentsICU admission policies", "TREATMENT", 164, 196]]], ["Different stages of triage may be considered as the epidemic progresses (Table 1 ) and movement from one stage to the next must be clearly communicated to each member of the ICU team.", [["triage", "TEST", 20, 26], ["may be considered", "UNCERTAINTY", 27, 44]]], ["A list of triage decisions should be kept for transparency and later evaluation.After the crisisOnce the crisis is over, full debriefing is necessary to support and stabilize the teams and to rebuild morale.", [["later evaluation", "TEST", 63, 79]]], ["Psychological support should be offered to all who need it, perhaps particularly those who were involved in triage decisions.", [["Psychological support", "TREATMENT", 0, 21]]], ["One should share gestures of support and thanks received from the patients and/or their relatives throughout the epidemic, and again once the crisis is over when there is more time to discuss and absorb these aspects.After the crisisLater in the post-crisis process, lessons learned (both good and bad) from the epidemic about ICU management must be used to put structures in place to improve the situation for the next catastrophe.ConclusionFortunately, the occurrence of crises such as the current pandemic remains relatively rare, but this makes the decisions associated with allocation of scarce resources even more of a challenge as for many it is unknown territory.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["ICU management", "TREATMENT", 327, 341], ["the next catastrophe", "PROBLEM", 411, 431], ["crises", "PROBLEM", 473, 479], ["crises", "OBSERVATION", 473, 479]]], ["This is a very unusual situation, but we have no choice but to rapidly, but carefully, develop rules for triage to ensure ICU beds and life-saving equipment are reserved for those who will be most likely to benefit and survive with a good quality of life.", [["ICU beds", "TREATMENT", 122, 130], ["life-saving equipment", "TREATMENT", 135, 156]]], ["We must be transparent about such decisions among ourselves, but also with patients and their families.ConclusionNetworking among healthcare professionals is essential during and after epidemics such as this, in order to share experience and expertise.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]], ["This can also allow the early detection of burnout symptoms or psychological distress among the healthcare staff.", [["burnout", "DISEASE", 43, 50], ["psychological distress", "DISEASE", 63, 85], ["burnout symptoms", "PROBLEM", 43, 59], ["psychological distress", "PROBLEM", 63, 85]]], ["Effective post-crisis debriefing and psychologic support are crucial.", [["psychologic support", "TREATMENT", 37, 56]]]], "4fcb95cc0c4ea6d1fa4137a4a087715ed6b68cea": [["IntroductionImprovements in neonatal intensive care have resulted in decreased mortality rates of preterm infants.", [["infants", "ORGANISM", 106, 113], ["infants", "SPECIES", 106, 113], ["decreased mortality rates of preterm infants", "PROBLEM", 69, 113], ["decreased", "OBSERVATION_MODIFIER", 69, 78], ["mortality", "OBSERVATION", 79, 88]]], ["The development of intraventricular haemorrhage (IVH), however, can result in long-term adverse outcomes.", [["intraventricular haemorrhage", "DISEASE", 19, 47], ["IVH", "DISEASE", 49, 52], ["intraventricular haemorrhage", "PROBLEM", 19, 47], ["IVH", "PROBLEM", 49, 52], ["long-term adverse outcomes", "PROBLEM", 78, 104], ["intraventricular", "ANATOMY_MODIFIER", 19, 35], ["haemorrhage", "OBSERVATION", 36, 47], ["IVH", "OBSERVATION", 49, 52], ["long-term", "OBSERVATION_MODIFIER", 78, 87]]], ["Several studies of preterm infants have demonstrated that abnormal levels of carbon dioxide (CO 2 ) within the first few days post-delivery are associated with the development of IVH [1, 2] .", [["carbon dioxide", "CHEMICAL", 77, 91], ["IVH", "DISEASE", 179, 182], ["carbon dioxide", "CHEMICAL", 77, 91], ["CO 2", "CHEMICAL", 93, 97], ["infants", "ORGANISM", 27, 34], ["carbon dioxide", "SIMPLE_CHEMICAL", 77, 91], ["infants", "SPECIES", 27, 34], ["Several studies", "TEST", 0, 15], ["abnormal levels of carbon dioxide", "PROBLEM", 58, 91], ["delivery", "TREATMENT", 131, 139], ["IVH", "PROBLEM", 179, 182], ["IVH", "OBSERVATION", 179, 182]]], ["We recently reported that preterm infants who developed an IVH had higher endtidal CO 2 (EtCO 2 ) levels in the delivery suite during resuscitation [3] .", [["IVH", "DISEASE", 59, 62], ["CO 2", "CHEMICAL", 83, 87], ["EtCO 2", "CHEMICAL", 89, 95], ["infants", "ORGANISM", 34, 41], ["CO 2", "GENE_OR_GENE_PRODUCT", 83, 87], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 89, 95], ["infants", "SPECIES", 34, 41], ["an IVH", "PROBLEM", 56, 62], ["higher endtidal CO", "PROBLEM", 67, 85], ["EtCO", "TEST", 89, 93], ["IVH", "OBSERVATION", 59, 62]]], ["It has not, however, been determined whether abnormal EtCO 2 levels during resuscitation of preterm infants translate into abnormal CO 2 levels over the subsequent 72 h after birth, and hence, whether it is a prolonged rather than an early insult which results in the development of IVH.", [["IVH", "DISEASE", 283, 286], ["EtCO 2", "CHEMICAL", 54, 60], ["CO 2", "CHEMICAL", 132, 136], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 54, 60], ["infants", "ORGANISM", 100, 107], ["CO 2", "GENE_OR_GENE_PRODUCT", 132, 136], ["EtCO 2", "PROTEIN", 54, 60], ["infants", "SPECIES", 100, 107], ["abnormal EtCO 2 levels", "PROBLEM", 45, 67], ["resuscitation of preterm infants", "TREATMENT", 75, 107], ["abnormal CO 2 levels", "PROBLEM", 123, 143], ["an early insult", "PROBLEM", 231, 246], ["IVH", "PROBLEM", 283, 286], ["IVH", "OBSERVATION", 283, 286]]], ["Our aim then was to study EtCO 2 levels in the delivery suite during resuscitation of preterm infants and their relationship to the subsequent CO 2 levels within the first 3 days after birth and the development of IVH.IntroductionIn one study of very low birth weight infants, not only high but also low partial pressures of carbon dioxide (pCO 2 ) were associated with severe IVH development, as was a greater degree of fluctuation in pCO 2 levels within the first 4 days after birth [2] .", [["IVH", "DISEASE", 214, 217], ["carbon dioxide", "CHEMICAL", 325, 339], ["pCO 2", "CHEMICAL", 341, 346], ["IVH", "DISEASE", 377, 380], ["EtCO 2", "CHEMICAL", 26, 32], ["CO 2", "CHEMICAL", 143, 147], ["carbon dioxide", "CHEMICAL", 325, 339], ["pCO 2", "CHEMICAL", 341, 346], ["pCO 2", "CHEMICAL", 436, 441], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 26, 32], ["infants", "ORGANISM", 94, 101], ["CO 2", "GENE_OR_GENE_PRODUCT", 143, 147], ["infants", "ORGANISM", 268, 275], ["carbon dioxide", "SIMPLE_CHEMICAL", 325, 339], ["pCO 2", "GENE_OR_GENE_PRODUCT", 436, 441], ["EtCO 2", "PROTEIN", 26, 32], ["infants", "SPECIES", 94, 101], ["infants", "SPECIES", 268, 275], ["EtCO 2 levels", "TEST", 26, 39], ["resuscitation of preterm infants", "TREATMENT", 69, 101], ["the subsequent CO 2 levels", "TEST", 128, 154], ["IVH", "PROBLEM", 214, 217], ["one study", "TEST", 233, 242], ["carbon dioxide", "TREATMENT", 325, 339], ["severe IVH development", "PROBLEM", 370, 392], ["fluctuation in pCO 2 levels", "PROBLEM", 421, 448], ["IVH", "OBSERVATION", 214, 217], ["pressures", "OBSERVATION_MODIFIER", 312, 321], ["carbon dioxide", "OBSERVATION", 325, 339], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["IVH", "OBSERVATION", 377, 380], ["greater degree", "OBSERVATION_MODIFIER", 403, 417], ["fluctuation", "OBSERVATION_MODIFIER", 421, 432]]], ["In term infants, undergoing therapeutic hypothermia for hypoxic ischaemic encephalopathy, adverse neurodevelopmental outcomes were also associated with a greater degree of pCO 2 variability [4] .", [["hypothermia", "DISEASE", 40, 51], ["hypoxic ischaemic encephalopathy", "DISEASE", 56, 88], ["pCO 2", "CHEMICAL", 172, 177], ["infants", "ORGANISM", 8, 15], ["pCO 2", "GENE_OR_GENE_PRODUCT", 172, 177], ["infants", "SPECIES", 8, 15], ["therapeutic hypothermia", "TREATMENT", 28, 51], ["hypoxic ischaemic encephalopathy", "PROBLEM", 56, 88], ["adverse neurodevelopmental outcomes", "PROBLEM", 90, 125], ["pCO 2 variability", "PROBLEM", 172, 189], ["hypoxic", "OBSERVATION_MODIFIER", 56, 63], ["ischaemic", "OBSERVATION_MODIFIER", 64, 73], ["encephalopathy", "OBSERVATION", 74, 88], ["pCO", "OBSERVATION", 172, 175]]], ["Preterm and unstable infants are more susceptible to changes in cerebral blood flow and display pressure passivity [5] .", [["cerebral", "ANATOMY", 64, 72], ["blood", "ANATOMY", 73, 78], ["infants", "ORGANISM", 21, 28], ["cerebral", "MULTI-TISSUE_STRUCTURE", 64, 72], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["infants", "SPECIES", 21, 28], ["Preterm and unstable infants", "PROBLEM", 0, 28], ["cerebral blood flow", "TEST", 64, 83], ["pressure passivity", "TEST", 96, 114], ["unstable", "OBSERVATION_MODIFIER", 12, 20], ["cerebral blood", "ANATOMY", 64, 78], ["pressure passivity", "OBSERVATION", 96, 114]]], ["Furthermore, fluctuations of pCO 2 can adversely affect cerebral oxygenation and perfusion and the electrical activity of the brain [6] ; such fluctuation is predictive of adverse neurodevelopmental outcomes [7] .", [["cerebral", "ANATOMY", 56, 64], ["brain", "ANATOMY", 126, 131], ["pCO 2", "CHEMICAL", 29, 34], ["pCO 2", "GENE_OR_GENE_PRODUCT", 29, 34], ["cerebral", "ORGAN", 56, 64], ["brain", "ORGAN", 126, 131], ["pCO 2", "PROTEIN", 29, 34], ["cerebral oxygenation", "TEST", 56, 76], ["perfusion", "TEST", 81, 90], ["such fluctuation", "TEST", 138, 154], ["adverse neurodevelopmental outcomes", "PROBLEM", 172, 207], ["brain", "ANATOMY", 126, 131]]], ["We have demonstrated that not only high EtCO 2 levels during resuscitation in the delivery suite were associated with IVH development but also inflations resulting in larger tidal volumes and lower EtCO 2 levels [3] .", [["IVH", "DISEASE", 118, 121], ["EtCO 2", "CHEMICAL", 40, 46], ["EtCO 2", "CHEMICAL", 198, 204], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 40, 46], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 198, 204], ["EtCO 2", "PROTEIN", 40, 46], ["resuscitation", "TREATMENT", 61, 74], ["IVH development", "PROBLEM", 118, 133], ["larger tidal volumes", "TEST", 167, 187], ["lower EtCO 2 levels", "PROBLEM", 192, 211], ["IVH", "OBSERVATION", 118, 121], ["larger", "OBSERVATION_MODIFIER", 167, 173], ["tidal volumes", "OBSERVATION", 174, 187]]], ["Those findings were subsequently confirmed by Mian and colleagues who found that tidal volumes in excess of 6 ml/kg were associated with cerebral damage in the neonatal period [8] .", [["cerebral", "ANATOMY", 137, 145], ["cerebral damage", "DISEASE", 137, 152], ["cerebral", "ORGAN", 137, 145], ["tidal volumes", "TEST", 81, 94], ["cerebral damage", "PROBLEM", 137, 152], ["cerebral", "ANATOMY", 137, 145], ["damage", "OBSERVATION", 146, 152]]], ["A further aim, therefore, of this study then was to test the hypothesis that infants exposed to the largest fluctuations in EtCO 2 levels during resuscitation in the delivery suite would be at greatest risk of developing an IVH.MethodsWe reviewed the records of infants born at less than or equal to 33 weeks of gestational age who required resuscitation in the delivery suite between March 2010 and March 2014.", [["IVH", "DISEASE", 224, 227], ["EtCO 2", "CHEMICAL", 124, 130], ["infants", "ORGANISM", 77, 84], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 124, 130], ["infants", "ORGANISM", 262, 269], ["infants", "SPECIES", 77, 84], ["infants", "SPECIES", 262, 269], ["this study", "TEST", 29, 39], ["EtCO 2 levels", "TEST", 124, 137], ["resuscitation", "TREATMENT", 145, 158], ["an IVH", "PROBLEM", 221, 227], ["Methods", "TREATMENT", 228, 235], ["resuscitation", "TREATMENT", 341, 354], ["largest", "OBSERVATION_MODIFIER", 100, 107], ["fluctuations", "OBSERVATION_MODIFIER", 108, 120], ["IVH", "OBSERVATION", 224, 227]]], ["Ethical approval was given by the Outer London Ethics Committee for the data collection.", [["Ethical approval", "TREATMENT", 0, 16], ["the data collection", "TEST", 68, 87]]], ["The committee required parental consent only for analysis of the data, which was obtained once the mother was transferred to the postnatal ward.", [["analysis of the data", "TEST", 49, 69]]], ["This study was approved by the King's College Hospital NHS Foundation Trust Research and Audit Department.Resuscitation protocolThe resuscitation protocol, together with the monitoring methodology, has previously been described [3] .", [["This study", "TEST", 0, 10], ["Resuscitation protocol", "TREATMENT", 106, 128], ["The resuscitation protocol", "TREATMENT", 128, 154], ["the monitoring methodology", "TEST", 170, 196]]], ["The clinicians attending the resuscitations had all been trained in newborn life support and had received the Resuscitation Council (UK) Newborn Life Support provider certificate.", [["newborn life support", "TREATMENT", 68, 88]]], ["They had also been trained to operate the respiratory function monitor.", [["respiratory", "ANATOMY", 42, 53], ["the respiratory function monitor", "TEST", 38, 70]]], ["During the resuscitation, the respiratory function monitor was set to display tidal volume, flow, inflation pressure and EtCO 2 levels.Resuscitation monitoringThe resuscitation recordings were analysed to determine the duration of resuscitation, the number of inflations, the inflation pressure, the positive end expiratory pressure (PEEP), inflation time (Ti), mean airway pressure (MAP), expiratory tidal volume (V TE ) of each inflation and the breath-by-breath minute ventilation.", [["respiratory", "ANATOMY", 30, 41], ["airway", "ANATOMY", 367, 373], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 121, 127], ["airway", "MULTI-TISSUE_STRUCTURE", 367, 373], ["the resuscitation", "TREATMENT", 7, 24], ["the respiratory function monitor", "TEST", 26, 58], ["tidal volume", "TEST", 78, 90], ["inflation pressure", "TEST", 98, 116], ["EtCO 2 levels", "TEST", 121, 134], ["Resuscitation monitoring", "TEST", 135, 159], ["The resuscitation recordings", "TEST", 159, 187], ["resuscitation", "TREATMENT", 231, 244], ["the inflation pressure", "TEST", 272, 294], ["the positive end expiratory pressure", "TEST", 296, 332], ["PEEP", "TREATMENT", 334, 338], ["inflation time", "TEST", 341, 355], ["mean airway pressure", "TEST", 362, 382], ["MAP", "TEST", 384, 387], ["expiratory tidal volume", "TEST", 390, 413], ["each inflation", "TREATMENT", 425, 439], ["the breath", "TEST", 444, 454], ["breath minute ventilation", "TREATMENT", 458, 483], ["tidal volume", "OBSERVATION", 78, 90], ["inflations", "OBSERVATION", 260, 270], ["inflation", "OBSERVATION_MODIFIER", 276, 285], ["pressure", "OBSERVATION_MODIFIER", 286, 294], ["positive", "OBSERVATION_MODIFIER", 300, 308], ["end", "OBSERVATION_MODIFIER", 309, 312], ["expiratory pressure", "OBSERVATION", 313, 332], ["airway pressure", "OBSERVATION", 367, 382]]], ["The highest EtCO 2 was recorded as were the number of inflations with tidal volumes more than 6 mls/kg (high tidal volumes) or end-tidal CO 2 levels of less than 4.5 kPa (low EtCO 2 levels) and the number of inflations with both high tidal volumes and low EtCO 2 levels as previously described [3] .", [["CO 2", "CHEMICAL", 137, 141], ["EtCO 2", "CHEMICAL", 175, 181], ["EtCO 2", "CHEMICAL", 256, 262], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 256, 262], ["EtCO 2", "PROTEIN", 12, 18], ["EtCO 2", "PROTEIN", 256, 262], ["The highest EtCO", "TEST", 0, 16], ["tidal volumes", "TEST", 70, 83], ["high tidal volumes", "TEST", 104, 122], ["end-tidal CO", "TEST", 127, 139], ["kPa", "TEST", 166, 169], ["inflations", "TEST", 208, 218], ["both high tidal volumes", "PROBLEM", 224, 247], ["low EtCO 2 levels", "PROBLEM", 252, 269], ["inflations", "OBSERVATION", 54, 64], ["inflations", "OBSERVATION_MODIFIER", 208, 218], ["both", "OBSERVATION_MODIFIER", 224, 228], ["high", "OBSERVATION_MODIFIER", 229, 233], ["tidal volumes", "OBSERVATION", 234, 247], ["low EtCO", "OBSERVATION", 252, 260]]], ["The degree of fluctuation of EtCO 2 (delta EtCO 2 ) during resuscitation was determined by calculating the difference between the highest and lowest EtCO 2 value during resuscitation in delivery suite.NICU monitoringThe unit's routine policy was to insert arterial lines for blood gas sampling, and in the absence of such, access capillary sampling was undertaken.", [["arterial lines", "ANATOMY", 256, 270], ["blood", "ANATOMY", 275, 280], ["capillary", "ANATOMY", 330, 339], ["EtCO 2", "CHEMICAL", 29, 35], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 29, 35], ["arterial lines", "CELL", 256, 270], ["blood", "ORGANISM_SUBSTANCE", 275, 280], ["capillary", "TISSUE", 330, 339], ["EtCO 2", "PROTEIN", 29, 35], ["EtCO", "TEST", 29, 33], ["delta EtCO", "TEST", 37, 47], ["resuscitation", "TREATMENT", 59, 72], ["resuscitation in delivery suite", "TREATMENT", 169, 200], ["NICU monitoring", "TEST", 201, 216], ["arterial lines", "TREATMENT", 256, 270], ["blood gas sampling", "TEST", 275, 293], ["access capillary sampling", "TEST", 323, 348], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["fluctuation", "OBSERVATION_MODIFIER", 14, 25], ["arterial", "ANATOMY", 256, 264]]], ["Blood gases were recorded on the intensive care observation charts every 4 to 6 h depending on the clinical status of the infant, and the hourly ventilator settings were collected at the time as each arterial gas result.", [["Blood", "ANATOMY", 0, 5], ["arterial", "ANATOMY", 200, 208], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["infant", "ORGANISM", 122, 128], ["arterial", "MULTI-TISSUE_STRUCTURE", 200, 208], ["Blood gases", "TEST", 0, 11], ["the hourly ventilator settings", "TREATMENT", 134, 164], ["each arterial gas result", "TEST", 195, 219]]], ["Venous blood gases were not analysed in this study.", [["Venous blood", "ANATOMY", 0, 12], ["Venous", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["Venous blood gases", "TEST", 0, 18], ["this study", "TEST", 40, 50]]], ["Data on the maximum, minimum and average pCO 2 value on each of the first, second and third days after birth were collected.", [["average pCO", "TEST", 33, 44]]], ["The degree of fluctuation of CO 2 (delta CO 2 ) during each of the first 3 postnatal days was determined by calculating the difference between the highest and lowest CO 2 value on each day.", [["CO 2", "CHEMICAL", 29, 33], ["CO 2", "CHEMICAL", 41, 45], ["CO 2", "CHEMICAL", 166, 170], ["CO 2", "GENE_OR_GENE_PRODUCT", 29, 33], ["delta CO 2", "GENE_OR_GENE_PRODUCT", 35, 45], ["fluctuation of CO", "PROBLEM", 14, 31], ["delta CO", "TEST", 35, 43], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["fluctuation", "OBSERVATION_MODIFIER", 14, 25]]], ["Volume targeted ventilation was not used on the NICU during the study period.NICU monitoringThe medical records were examined to determine whether the infants developed an IVH which was diagnosed from cranial ultrasounds.", [["cranial", "ANATOMY", 201, 208], ["IVH", "DISEASE", 172, 175], ["infants", "ORGANISM", 151, 158], ["cranial", "ORGAN", 201, 208], ["infants", "SPECIES", 151, 158], ["Volume targeted ventilation", "TREATMENT", 0, 27], ["the study", "TEST", 60, 69], ["NICU monitoring", "TEST", 77, 92], ["an IVH", "PROBLEM", 169, 175], ["cranial ultrasounds", "TEST", 201, 220], ["ventilation", "OBSERVATION", 16, 27], ["IVH", "OBSERVATION", 172, 175]]], ["As per unit policy, cranial ultrasounds were performed on admission to the unit for all infants born below 34 weeks of gestation.", [["cranial", "ANATOMY", 20, 27], ["infants", "ORGANISM", 88, 95], ["infants", "SPECIES", 88, 95], ["cranial ultrasounds", "TEST", 20, 39], ["cranial", "ANATOMY", 20, 27]]], ["Cranial ultrasounds were repeated on day 3, between days 7 and 10, days 14 and 21 and days 28 and 30.", [["Cranial", "ANATOMY", 0, 7], ["Cranial ultrasounds", "TEST", 0, 19]]], ["All cranial ultrasounds were reported by a neonatal consultant.", [["cranial", "ANATOMY", 4, 11], ["All cranial ultrasounds", "TEST", 0, 23], ["cranial", "ANATOMY", 4, 11]]], ["The IVHs were reported as grades I to IV using the Papile classification [9] .", [["IVHs", "CANCER", 4, 8]]], ["Severe IVH was diagnosed as a grade III or IV IVH.", [["IVH", "DISEASE", 7, 10], ["IVH", "DISEASE", 46, 49], ["Severe IVH", "PROBLEM", 0, 10], ["a grade III or IV IVH", "PROBLEM", 28, 49], ["IVH", "OBSERVATION", 7, 10], ["grade III", "OBSERVATION_MODIFIER", 30, 39], ["IVH", "OBSERVATION", 46, 49]]], ["Other data extracted from the medical records included the infant's gestational age, birth weight and Apgar score at 5 min, and whether the mother had received corticosteroids antenatally or had chorioamnionitis.Statistical analysisThe data were tested for normality using the Kolmogorov-Smirnov test and found to be non-normally distributed; hence, differences were assessed for statistical significance using the Mann-Whitney U test or the chi-square test as appropriate.", [["chorioamnionitis", "DISEASE", 195, 211], ["corticosteroids", "CHEMICAL", 160, 175], ["infant", "SPECIES", 59, 65], ["Apgar score", "TEST", 102, 113], ["corticosteroids", "TREATMENT", 160, 175], ["chorioamnionitis", "PROBLEM", 195, 211], ["Statistical analysis", "TEST", 212, 232], ["The data", "TEST", 232, 240], ["the Kolmogorov-Smirnov test", "TEST", 273, 300], ["the chi-square test", "TEST", 438, 457], ["chorioamnionitis", "OBSERVATION", 195, 211]]], ["As infants who develop IVH tend to be more immature, regression analyses were performed to determine if the results remained statistically significant after correcting for differences in gestational age.", [["IVH", "DISEASE", 23, 26], ["infants", "ORGANISM", 3, 10], ["infants", "SPECIES", 3, 10], ["IVH", "PROBLEM", 23, 26], ["regression analyses", "TEST", 53, 72], ["IVH", "OBSERVATION", 23, 26]]], ["The strength of any relationships of EtCO 2 values during resuscitation with CO 2 levels during the first 3 days after birth were assessed by calculating Spearman correlation coefficients.", [["EtCO 2", "CHEMICAL", 37, 43], ["CO 2", "CHEMICAL", 77, 81], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 37, 43], ["CO 2", "GENE_OR_GENE_PRODUCT", 77, 81], ["EtCO 2", "PROTEIN", 37, 43], ["EtCO", "TEST", 37, 41], ["resuscitation", "TREATMENT", 58, 71], ["CO 2 levels", "TEST", 77, 88]]], ["The performance of factors identified as significantly related to IVH development from the regression analysis were assessed by receiver operator characteristic curve analysis and estimation of the corresponding area under the curve (AUC).", [["IVH", "DISEASE", 66, 69], ["IVH development", "PROBLEM", 66, 81], ["the regression analysis", "TEST", 87, 110], ["receiver operator characteristic curve analysis", "TEST", 128, 175], ["IVH", "OBSERVATION", 66, 69]]], ["Statistical analyses were performed using JMP statistical software (JMP 13.0.0, SAS Institute Inc., NC, USA) and SPSS software 25.0 (SPSS Inc., Chicago IL, USA).ResultsThree hundred and seventy infants were born at less than or equal to 33 weeks of gestation within the study period.", [["infants", "ORGANISM", 194, 201], ["infants", "SPECIES", 194, 201], ["Statistical analyses", "TEST", 0, 20], ["JMP", "TEST", 68, 71], ["SPSS software", "TEST", 113, 126]]], ["There were 150 infant recordings available for analysis, but 56 had recordings of tidal volume or EtCO 2 traces which were unsuitable for analysis, a further 24 were excluded due to a large leak throughout and 12 excluded due to missing neonatal unit observation charts.", [["infant", "SPECIES", 15, 21], ["infant recordings", "TEST", 15, 32], ["analysis", "TEST", 47, 55], ["tidal volume", "TEST", 82, 94], ["analysis", "TEST", 138, 146], ["a large leak", "PROBLEM", 182, 194], ["large", "OBSERVATION_MODIFIER", 184, 189], ["leak", "OBSERVATION", 190, 194]]], ["The remaining 58 infants were included in this study and had a median gestational age of 27.3 (interquartile range (IQR) 24.9-29.0) weeks and a birth weight of 0.90 (0.72-1.21) kg.", [["infants", "ORGANISM", 17, 24], ["infants", "SPECIES", 17, 24], ["this study", "TEST", 42, 52], ["IQR", "TEST", 116, 119], ["a birth weight", "TEST", 142, 156]]], ["The infants who were and were not included in this study did not differ significantly with regard to birth weight (p = 0.893) or gestational age (p = 0.785).", [["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["this study", "TEST", 46, 56], ["birth weight", "TEST", 101, 113]]], ["Fifty-three of the 58 infants were ventilated on day 1 after birth.", [["infants", "ORGANISM", 22, 29], ["infants", "SPECIES", 22, 29], ["ventilated", "OBSERVATION", 35, 45]]], ["Thirty infants developed no IVH with 28 infants developing an IVH.", [["IVH", "DISEASE", 28, 31], ["IVH", "DISEASE", 62, 65], ["infants", "ORGANISM", 7, 14], ["infants", "ORGANISM", 40, 47], ["infants", "SPECIES", 7, 14], ["infants", "SPECIES", 40, 47], ["IVH", "PROBLEM", 28, 31], ["an IVH", "PROBLEM", 59, 65], ["no", "UNCERTAINTY", 25, 27], ["IVH", "OBSERVATION", 28, 31], ["IVH", "OBSERVATION", 62, 65]]], ["Seven infants developed a grade 1, eight infants grade 2, five infants grade 3 and the remaining eight infants a grade 4 IVH, that is 13 infants developed a severe IVH.", [["IVH", "DISEASE", 121, 124], ["IVH", "DISEASE", 164, 167], ["infants", "ORGANISM", 6, 13], ["infants", "ORGANISM", 103, 110], ["infants", "ORGANISM", 137, 144], ["infants", "SPECIES", 6, 13], ["infants", "SPECIES", 41, 48], ["infants", "SPECIES", 63, 70], ["infants", "SPECIES", 103, 110], ["infants", "SPECIES", 137, 144], ["a grade 4 IVH", "PROBLEM", 111, 124], ["a severe IVH", "PROBLEM", 155, 167], ["IVH", "OBSERVATION", 121, 124], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["IVH", "OBSERVATION", 164, 167]]], ["All infants who developed an IVH did so in the first 3 days after birth.", [["IVH", "DISEASE", 29, 32], ["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["an IVH", "PROBLEM", 26, 32], ["IVH", "OBSERVATION", 29, 32]]], ["Eleven infants developed an IVH on day 1 (9 grade 1-2), nine on day 2 (5 grade 1-2) and eight on day 3 (1 grade 1-2).", [["IVH", "DISEASE", 28, 31], ["infants", "ORGANISM", 7, 14], ["infants", "SPECIES", 7, 14], ["an IVH", "PROBLEM", 25, 31], ["IVH", "OBSERVATION", 28, 31]]], ["There were no significant differences in CO 2 levels on the NICU and IVH development.ResultsThe highest EtCO 2 during resuscitation in the no-IVH group was 8.0 (7.1-8.4) kPa and 10.0 (8.9-11.2) kPa in the IVH group; the difference remained statistically significant after adjusting for differences in gestational age between the two groups (p = 0.0002).", [["no-IVH", "ANATOMY", 139, 145], ["IVH", "DISEASE", 69, 72], ["IVH", "DISEASE", 205, 208], ["CO 2", "CHEMICAL", 41, 45], ["CO 2", "GENE_OR_GENE_PRODUCT", 41, 45], ["no-IVH", "CANCER", 139, 145], ["significant differences in CO 2 levels", "PROBLEM", 14, 52], ["IVH development", "PROBLEM", 69, 84], ["The highest EtCO", "TEST", 92, 108], ["resuscitation", "TREATMENT", 118, 131], ["kPa", "TEST", 170, 173], ["kPa", "TEST", 194, 197], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["IVH", "OBSERVATION", 69, 72], ["IVH", "OBSERVATION", 205, 208], ["significant", "OBSERVATION_MODIFIER", 254, 265]]], ["The highest EtCO 2 during resuscitation in the no/non-severe group IVH was 8.2 (7.4-9.9) kPa and 10.2 (8.6-11.1) kPa in the severe IVH group; the difference remained statistically significant after adjusting for differences in gestational age between the two groups (p = 0.037).", [["IVH", "DISEASE", 67, 70], ["IVH", "DISEASE", 131, 134], ["EtCO 2", "PROTEIN", 12, 18], ["The highest EtCO", "TEST", 0, 16], ["resuscitation", "TREATMENT", 26, 39], ["non-severe group IVH", "PROBLEM", 50, 70], ["kPa", "TEST", 89, 92], ["kPa", "TEST", 113, 116], ["the severe IVH group", "PROBLEM", 120, 140], ["no", "UNCERTAINTY", 47, 49], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["IVH", "OBSERVATION", 131, 134], ["significant", "OBSERVATION_MODIFIER", 180, 191]]], ["There was no significant difference in the mean tidal volume during resuscitation between infants in the no/non severe IVH group and the severe IVH group (p = 0.621).ResultsThe lowest EtCO 2 during resuscitation in the no-IVH group was 4.2 (3.2-5.2) kPa and 3.5 (3.0-4.5) kPa in the IVH group, but this was not statistically significant after adjusting for the difference in gestational age between the two groups (p = 0.11).", [["IVH", "DISEASE", 119, 122], ["IVH", "DISEASE", 144, 147], ["IVH", "DISEASE", 283, 286], ["EtCO 2", "CHEMICAL", 184, 190], ["tidal", "ORGANISM_SUBDIVISION", 48, 53], ["infants", "ORGANISM", 90, 97], ["no-IVH", "CANCER", 219, 225], ["infants", "SPECIES", 90, 97], ["significant difference", "PROBLEM", 13, 35], ["the mean tidal volume", "TEST", 39, 60], ["resuscitation", "TREATMENT", 68, 81], ["non severe IVH group", "PROBLEM", 108, 128], ["the severe IVH group", "PROBLEM", 133, 153], ["The lowest EtCO", "TEST", 173, 188], ["resuscitation", "TREATMENT", 198, 211], ["kPa", "TEST", 250, 253], ["kPa", "TEST", 272, 275], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["mean", "OBSERVATION", 43, 47], ["tidal volume", "OBSERVATION", 48, 60], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["IVH", "OBSERVATION", 119, 122], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["IVH", "OBSERVATION", 144, 147], ["IVH", "OBSERVATION", 283, 286]]], ["The lowest EtCO 2 during resuscitation in the no/non-severe IVH group was 4.0 (3.2-5.1) kPa and 3.1 (2.7-3.5) kPa in the severe IVH group; the difference remained significant after adjusting for the difference in gestational age between the two groups (p = 0.041).ResultsThere were weak correlations between the highest end-tidal CO 2 on delivery suite and the highest pCO 2 on the neonatal unit on days 2 (r = 0.274, p = 0.047) and 3 (r = 0.383, p = 0.005).ResultsThe delta EtCO 2 during resuscitation was significantly different between the no/non-severe IVH (4.3 (3.1-5.6) kPa) and severe IVH groups (7.2 (5.9-7.6) kPa) (p = 0.003) and between infants with any IVH (6.2 (5.4-7.5) kPa) or no IVH (3.8 (2.7-4.3) kPa) (p < 0.001) after adjusting for differences in gestational age.", [["IVH", "DISEASE", 60, 63], ["IVH", "DISEASE", 128, 131], ["IVH", "DISEASE", 557, 560], ["IVH", "DISEASE", 592, 595], ["IVH", "DISEASE", 664, 667], ["IVH", "DISEASE", 694, 697], ["CO 2", "CHEMICAL", 330, 334], ["delta EtCO 2", "GENE_OR_GENE_PRODUCT", 469, 481], ["infants", "ORGANISM", 647, 654], ["EtCO 2", "PROTEIN", 11, 17], ["infants", "SPECIES", 647, 654], ["The lowest EtCO", "TEST", 0, 15], ["resuscitation", "TREATMENT", 25, 38], ["non-severe IVH group", "PROBLEM", 49, 69], ["kPa", "TEST", 88, 91], ["kPa", "TEST", 110, 113], ["the severe IVH group", "PROBLEM", 117, 137], ["the highest pCO", "TEST", 357, 372], ["p", "TEST", 418, 419], ["p", "TEST", 447, 448], ["The delta EtCO", "TEST", 465, 479], ["resuscitation", "TREATMENT", 489, 502], ["non-severe IVH", "PROBLEM", 546, 560], ["kPa", "TEST", 576, 579], ["severe IVH groups", "PROBLEM", 585, 602], ["kPa", "TEST", 618, 621], ["p", "TEST", 624, 625], ["any IVH", "PROBLEM", 660, 667], ["kPa", "TEST", 683, 686], ["IVH", "PROBLEM", 694, 697], ["kPa", "TEST", 713, 716], ["no", "UNCERTAINTY", 46, 48], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["IVH", "OBSERVATION", 128, 131], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["non-severe", "OBSERVATION_MODIFIER", 546, 556], ["IVH", "OBSERVATION", 557, 560], ["severe", "OBSERVATION_MODIFIER", 585, 591], ["IVH", "OBSERVATION", 592, 595], ["IVH", "OBSERVATION", 664, 667], ["no", "UNCERTAINTY", 691, 693], ["IVH", "OBSERVATION", 694, 697]]], ["The delta CO 2 level during resuscitation weakly correlated with the delta CO 2 level on the neonatal unit on days 2 (r = 0.385, p = 0.004) and 3 (r = 0.423, p = 0.002).ResultsThe receiver operator characteristic curve analysis demonstrated that in predicting any IVH, the maximum level of EtCO 2 on the delivery suite had an AUC of 0.856 and the delta CO 2 during resuscitation had an AUC of 0.940.", [["IVH", "DISEASE", 264, 267], ["CO 2", "CHEMICAL", 10, 14], ["CO 2", "CHEMICAL", 75, 79], ["CO 2", "CHEMICAL", 353, 357], ["delta CO 2", "GENE_OR_GENE_PRODUCT", 4, 14], ["delta CO 2", "GENE_OR_GENE_PRODUCT", 69, 79], ["delta CO 2", "PROTEIN", 69, 79], ["The delta CO", "TEST", 0, 12], ["the delta CO", "TEST", 65, 77], ["p", "TEST", 129, 130], ["p", "TEST", 158, 159], ["The receiver operator characteristic curve analysis", "TEST", 176, 227], ["any IVH", "PROBLEM", 260, 267], ["EtCO", "TEST", 290, 294], ["an AUC", "TEST", 323, 329], ["the delta CO", "TEST", 343, 355], ["resuscitation", "TREATMENT", 365, 378], ["an AUC", "TEST", 383, 389], ["IVH", "OBSERVATION", 264, 267], ["maximum", "OBSERVATION_MODIFIER", 273, 280]]], ["A delta EtCO 2 equal or greater than 4.9 kPa predicted any IVH development with 96.4% sensitivity and 83.3% specificity.DiscussionWe have demonstrated that preterm infants who developed an IVH had a higher maximum level of EtCO 2 and greater degree of fluctuation of EtCO 2 levels during resuscitation.", [["IVH", "DISEASE", 59, 62], ["IVH", "DISEASE", 189, 192], ["EtCO 2", "CHEMICAL", 267, 273], ["infants", "ORGANISM", 164, 171], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 223, 229], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 267, 273], ["infants", "SPECIES", 164, 171], ["A delta EtCO", "TEST", 0, 12], ["IVH development", "PROBLEM", 59, 74], ["sensitivity", "TEST", 86, 97], ["an IVH", "PROBLEM", 186, 192], ["EtCO", "TEST", 223, 227], ["EtCO", "TEST", 267, 271], ["resuscitation", "TREATMENT", 288, 301], ["IVH", "OBSERVATION", 59, 62], ["IVH", "OBSERVATION", 189, 192]]], ["In addition, we highlight that the delta EtCO 2 level in the delivery suite had both a high sensitivity and specificity in predicting IVH development.", [["IVH", "DISEASE", 134, 137], ["delta EtCO 2", "GENE_OR_GENE_PRODUCT", 35, 47], ["delta EtCO 2", "PROTEIN", 35, 47], ["the delta EtCO", "TEST", 31, 45], ["a high sensitivity", "PROBLEM", 85, 103], ["IVH development", "PROBLEM", 134, 149], ["IVH", "OBSERVATION", 134, 137]]], ["Importantly, we have shown that abnormal EtCO 2 levels during resuscitation did not necessarily translate into abnormal levels on the neonatal unit.", [["EtCO 2", "CHEMICAL", 41, 47], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 41, 47], ["EtCO 2", "PROTEIN", 41, 47], ["abnormal EtCO 2 levels", "PROBLEM", 32, 54], ["resuscitation", "TREATMENT", 62, 75], ["abnormal levels", "PROBLEM", 111, 126]]], ["Our findings, then suggest that it is early abnormal carbon dioxide levels in preterm infants that are important in IVH development.", [["carbon dioxide", "CHEMICAL", 53, 67], ["IVH", "DISEASE", 116, 119], ["carbon dioxide", "CHEMICAL", 53, 67], ["carbon dioxide", "SIMPLE_CHEMICAL", 53, 67], ["infants", "ORGANISM", 86, 93], ["infants", "SPECIES", 86, 93], ["early abnormal carbon dioxide levels in preterm infants", "PROBLEM", 38, 93], ["IVH development", "PROBLEM", 116, 131], ["early", "OBSERVATION_MODIFIER", 38, 43], ["abnormal", "OBSERVATION_MODIFIER", 44, 52], ["carbon dioxide", "OBSERVATION", 53, 67]]], ["Previously, initial post-delivery levels of pCO 2 were found to be significantly higher in infants with cerebral haemorrhage than those without, but by 8 h after birth, those differences were no longer significant [10] , which are consistent with our findings of the significant association of abnormal CO 2 levels in the delivery suite, but not the neonatal unit, with IVH development.", [["cerebral", "ANATOMY", 104, 112], ["cerebral haemorrhage", "DISEASE", 104, 124], ["IVH", "DISEASE", 370, 373], ["pCO 2", "CHEMICAL", 44, 49], ["CO 2", "CHEMICAL", 303, 307], ["pCO 2", "GENE_OR_GENE_PRODUCT", 44, 49], ["infants", "ORGANISM", 91, 98], ["cerebral", "ORGAN", 104, 112], ["CO 2", "GENE_OR_GENE_PRODUCT", 303, 307], ["infants", "SPECIES", 91, 98], ["pCO", "TEST", 44, 47], ["cerebral haemorrhage", "PROBLEM", 104, 124], ["abnormal CO 2 levels", "PROBLEM", 294, 314], ["IVH development", "PROBLEM", 370, 385], ["significantly", "OBSERVATION_MODIFIER", 67, 80], ["higher", "OBSERVATION_MODIFIER", 81, 87], ["cerebral", "ANATOMY", 104, 112], ["haemorrhage", "OBSERVATION", 113, 124], ["no longer", "UNCERTAINTY", 192, 201], ["consistent with", "UNCERTAINTY", 231, 246], ["significant", "OBSERVATION_MODIFIER", 267, 278], ["abnormal", "OBSERVATION", 294, 302], ["IVH", "OBSERVATION", 370, 373]]], ["Some studies have suggested that sicker infants undergo more blood gas analysis than more stable infants, hence, allowing detection of a greater degree of fluctuation in levels of carbon dioxide [2] .", [["blood", "ANATOMY", 61, 66], ["carbon dioxide", "CHEMICAL", 180, 194], ["carbon dioxide", "CHEMICAL", 180, 194], ["infants", "ORGANISM", 40, 47], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["infants", "ORGANISM", 97, 104], ["carbon dioxide", "SIMPLE_CHEMICAL", 180, 194], ["infants", "SPECIES", 40, 47], ["infants", "SPECIES", 97, 104], ["Some studies", "TEST", 0, 12], ["blood gas analysis", "TEST", 61, 79], ["fluctuation in levels of carbon dioxide", "PROBLEM", 155, 194], ["greater degree", "OBSERVATION_MODIFIER", 137, 151]]], ["We continuously monitored EtCO 2 during resuscitation in all infants included in our cohort, and therefore, the outcomes relating to fluctuation of carbon dioxide are not influenced by the infant's degree of sickness.", [["carbon dioxide", "CHEMICAL", 148, 162], ["sickness", "DISEASE", 208, 216], ["EtCO 2", "CHEMICAL", 26, 32], ["carbon dioxide", "CHEMICAL", 148, 162], ["infants", "ORGANISM", 61, 68], ["carbon dioxide", "SIMPLE_CHEMICAL", 148, 162], ["infants", "SPECIES", 61, 68], ["EtCO", "TEST", 26, 30], ["resuscitation", "TREATMENT", 40, 53], ["carbon dioxide", "TREATMENT", 148, 162], ["sickness", "PROBLEM", 208, 216], ["sickness", "OBSERVATION", 208, 216]]], ["We speculate that by the time infants are admitted to the neonatal unit, clinicians have greater access to routine monitoring and would readily re-check abnormal levels of pCO 2 by blood gas analysis, hence, limiting the degree of fluctuation between extremes of values and thereby achieving tighter control.", [["blood", "ANATOMY", 181, 186], ["pCO 2", "CHEMICAL", 172, 177], ["infants", "ORGANISM", 30, 37], ["pCO 2", "GENE_OR_GENE_PRODUCT", 172, 177], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["infants", "SPECIES", 30, 37], ["routine monitoring", "TEST", 107, 125], ["abnormal levels of pCO", "PROBLEM", 153, 175], ["blood gas analysis", "TEST", 181, 199], ["fluctuation between extremes of values", "PROBLEM", 231, 269]]], ["This would explain our findings that it is the delivery suite levels of CO 2 that are more influential regarding IVH development and why the extreme levels of carbon dioxide seen during resuscitation do not translate to neonatal unit levels of CO 2 during the subsequent 72 h.", [["IVH", "DISEASE", 113, 116], ["carbon dioxide", "CHEMICAL", 159, 173], ["CO 2", "CHEMICAL", 72, 76], ["carbon dioxide", "CHEMICAL", 159, 173], ["CO 2", "CHEMICAL", 244, 248], ["CO 2", "GENE_OR_GENE_PRODUCT", 72, 76], ["carbon dioxide", "SIMPLE_CHEMICAL", 159, 173], ["CO 2", "GENE_OR_GENE_PRODUCT", 244, 248], ["IVH development", "PROBLEM", 113, 128], ["carbon dioxide", "TREATMENT", 159, 173], ["resuscitation", "TREATMENT", 186, 199]]], ["We did not use volume targeted ventilation during the study period and this would have likely reduced fluctuations in CO 2 levels on the NICU.DiscussionAs previously mentioned [3] , we did find low EtCO 2 levels that were associated with IVH development, but this was no longer significant after adjustment for gestational age.", [["IVH", "DISEASE", 238, 241], ["CO 2", "CHEMICAL", 118, 122], ["EtCO 2", "CHEMICAL", 198, 204], ["CO 2", "GENE_OR_GENE_PRODUCT", 118, 122], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 198, 204], ["EtCO 2", "PROTEIN", 198, 204], ["volume targeted ventilation", "TREATMENT", 15, 42], ["the study", "TEST", 50, 59], ["reduced fluctuations in CO 2 levels", "PROBLEM", 94, 129], ["low EtCO 2 levels", "PROBLEM", 194, 211], ["IVH development", "PROBLEM", 238, 253], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["fluctuations", "OBSERVATION_MODIFIER", 102, 114], ["IVH", "OBSERVATION", 238, 241], ["no longer", "UNCERTAINTY", 268, 277]]], ["Nevertheless, we highlight fluctuations in EtCO 2 that are highly predictive of IVH development.", [["IVH", "DISEASE", 80, 83], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 43, 49], ["IVH", "PATHOLOGICAL_FORMATION", 80, 83], ["EtCO 2", "PROTEIN", 43, 49], ["EtCO", "TEST", 43, 47], ["IVH development", "PROBLEM", 80, 95], ["IVH", "OBSERVATION", 80, 83]]], ["Hence, it is important to avoid both high and low levels of EtCO 2 during resuscitation.", [["EtCO 2", "CHEMICAL", 60, 66], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 60, 66], ["resuscitation", "TREATMENT", 74, 87]]], ["Our results emphasize that respiratory function monitoring should be helpful in the labour suite.", [["respiratory", "ANATOMY", 27, 38], ["respiratory function monitoring", "TEST", 27, 58]]], ["It has been previously shown that resuscitators were unable to accurately assess chest wall movement [11, 12] , and use of respiratory function monitoring (RFM) can result in less mask leak and a lower rate of excessive tidal volumes [13] .", [["chest wall", "ANATOMY", 81, 91], ["respiratory", "ANATOMY", 123, 134], ["chest wall", "MULTI-TISSUE_STRUCTURE", 81, 91], ["chest wall movement", "TEST", 81, 100], ["respiratory function monitoring", "TEST", 123, 154], ["less mask leak", "PROBLEM", 175, 189], ["excessive tidal volumes", "PROBLEM", 210, 233], ["less", "OBSERVATION_MODIFIER", 175, 179], ["mask leak", "OBSERVATION", 180, 189]]], ["We have, however, previously emphasized that resuscitators must have appropriate training so they can accurately interpret the results of such monitoring in real time [14] .", [["such monitoring", "TEST", 138, 153]]], ["Eye tracking technology has demonstrated that providers spend more time looking at the exhaled tidal volume waveform data than any other RFM parameter to guide positive pressure ventilation [15] suggesting further training is required on the importance of EtCO 2 levels during resuscitation.DiscussionOur study has strengths and some limitations.", [["EtCO 2", "CHEMICAL", 256, 262], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 256, 262], ["the exhaled tidal volume waveform data", "TEST", 83, 121], ["positive pressure ventilation", "TREATMENT", 160, 189], ["further training", "TREATMENT", 206, 222], ["EtCO", "TEST", 256, 260], ["resuscitation", "TREATMENT", 277, 290], ["DiscussionOur study", "TEST", 291, 310]]], ["This is the first study to evaluate EtCO 2 levels and fluctuation of EtCO 2 levels during resuscitation and how they correlated with both carbon dioxide levels in the first 3 days after birth and IVH development.", [["carbon dioxide", "CHEMICAL", 138, 152], ["IVH", "DISEASE", 196, 199], ["EtCO 2", "CHEMICAL", 36, 42], ["EtCO 2", "CHEMICAL", 69, 75], ["carbon dioxide", "CHEMICAL", 138, 152], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 36, 42], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 69, 75], ["carbon dioxide", "SIMPLE_CHEMICAL", 138, 152], ["EtCO 2", "PROTEIN", 36, 42], ["EtCO 2", "PROTEIN", 69, 75], ["the first study", "TEST", 8, 23], ["EtCO 2 levels", "TEST", 36, 49], ["fluctuation of EtCO 2 levels", "TEST", 54, 82], ["resuscitation", "TREATMENT", 90, 103], ["both carbon dioxide levels", "TEST", 133, 159], ["IVH development", "PROBLEM", 196, 211], ["IVH", "OBSERVATION", 196, 199]]], ["We monitored EtCO 2 levels during resuscitation, yet on the neonatal unit, we have analysed levels of CO 2 from blood gas measurements.", [["blood", "ANATOMY", 112, 117], ["EtCO 2", "CHEMICAL", 13, 19], ["CO 2", "CHEMICAL", 102, 106], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 13, 19], ["CO 2", "GENE_OR_GENE_PRODUCT", 102, 106], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["EtCO 2", "PROTEIN", 13, 19], ["EtCO", "TEST", 13, 17], ["resuscitation", "TREATMENT", 34, 47], ["CO", "TEST", 102, 104], ["blood gas measurements", "TEST", 112, 134]]], ["Previous studies, however, have found EtCO 2 to be as accurate as arterial monitoring when trending carbon dioxide levels [16] .", [["arterial", "ANATOMY", 66, 74], ["carbon dioxide", "CHEMICAL", 100, 114], ["EtCO 2", "CHEMICAL", 38, 44], ["carbon dioxide", "CHEMICAL", 100, 114], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 38, 44], ["arterial", "MULTI-TISSUE_STRUCTURE", 66, 74], ["carbon dioxide", "SIMPLE_CHEMICAL", 100, 114], ["Previous studies", "TEST", 0, 16], ["EtCO", "TEST", 38, 42], ["arterial monitoring", "TEST", 66, 85], ["trending carbon dioxide levels", "TEST", 91, 121]]], ["We did not, however, measure cerebral blood flow in our cohort and hence, cannot speculate on the mechanisms behind our findings.DiscussionIn conclusion, a greater degree of fluctuation of EtCO 2 levels in the delivery suite was associated with a significantly increased risk in the development of IVH.", [["cerebral", "ANATOMY", 29, 37], ["blood", "ANATOMY", 38, 43], ["IVH", "DISEASE", 298, 301], ["EtCO 2", "CHEMICAL", 189, 195], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 29, 43], ["EtCO 2", "GENE_OR_GENE_PRODUCT", 189, 195], ["EtCO 2", "PROTEIN", 189, 195], ["cerebral blood flow", "TEST", 29, 48], ["EtCO 2 levels", "TEST", 189, 202], ["a significantly increased risk", "PROBLEM", 245, 275], ["IVH", "PROBLEM", 298, 301], ["IVH", "OBSERVATION", 298, 301]]], ["Those results emphasise the need for EtCO 2 monitoring during resuscitation in the delivery suite.Compliance with ethical standardsConflict of interest The authors declare that they have no conflicts of interest.Compliance with ethical standardsEthical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Statement of informed consent Parents gave informed written consent.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["EtCO 2", "CHEMICAL", 37, 43], ["human", "ORGANISM", 308, 313], ["human", "SPECIES", 308, 313], ["participants", "SPECIES", 314, 326], ["human", "SPECIES", 308, 313], ["EtCO 2 monitoring", "TEST", 37, 54], ["resuscitation", "TREATMENT", 62, 75], ["ethical standards", "TREATMENT", 114, 131], ["ethical standards", "TREATMENT", 228, 245], ["Ethical approval", "TREATMENT", 245, 261], ["All procedures", "TREATMENT", 262, 276], ["Open Access", "TREATMENT", 593, 604]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "f3233453648f7a0384c2ddc70ea4001eae7432b9": [["What Are CoronavirusesCoronaviruses (CoVs) are a group of highly enveloped viruses that are diversely found in humans and wildlife.", [["CoronavirusesCoronaviruses", "GENE_OR_GENE_PRODUCT", 9, 35], ["CoVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["humans", "ORGANISM", 111, 117], ["humans", "SPECIES", 111, 117], ["humans", "SPECIES", 111, 117], ["enveloped", "OBSERVATION_MODIFIER", 65, 74], ["viruses", "OBSERVATION", 75, 82]]], ["With their high mutation rate and infectivity, CoVs are important zoonotic pathogens that can infect animals [1, 2] and humans, leading to 5-10% of acute respiratory syndromes [3] .", [["respiratory", "ANATOMY", 154, 165], ["acute respiratory syndromes", "DISEASE", 148, 175], ["CoVs", "GENE_OR_GENE_PRODUCT", 47, 51], ["humans", "ORGANISM", 120, 126], ["humans", "SPECIES", 120, 126], ["CoVs", "SPECIES", 47, 51], ["humans", "SPECIES", 120, 126], ["their high mutation rate", "PROBLEM", 5, 29], ["infectivity", "PROBLEM", 34, 45], ["CoVs", "PROBLEM", 47, 51], ["zoonotic pathogens", "PROBLEM", 66, 84], ["acute respiratory syndromes", "PROBLEM", 148, 175], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["respiratory syndromes", "OBSERVATION", 154, 175]]], ["Apart from infecting a variety of economically important vertebrates (such as pigs and chickens), six species have been identified to cause disease in humans [4] .", [["pigs", "ORGANISM", 78, 82], ["chickens", "ORGANISM", 87, 95], ["humans", "ORGANISM", 151, 157], ["pigs", "SPECIES", 78, 82], ["chickens", "SPECIES", 87, 95], ["humans", "SPECIES", 151, 157], ["pigs", "SPECIES", 78, 82], ["chickens", "SPECIES", 87, 95], ["humans", "SPECIES", 151, 157], ["pigs and chickens)", "TREATMENT", 78, 96], ["disease in humans", "PROBLEM", 140, 157], ["infecting", "OBSERVATION", 11, 20], ["variety", "OBSERVATION_MODIFIER", 23, 30], ["economically", "OBSERVATION_MODIFIER", 34, 46]]], ["They are known to infect respiratory, gastrointestinal, hepatic and neurologic systems with a wide range of clinical features from asymptomatic course to severe disease that require hospitalization in the intensive care unit [4, 5] .", [["respiratory", "ANATOMY", 25, 36], ["gastrointestinal", "ANATOMY", 38, 54], ["hepatic", "ANATOMY", 56, 63], ["neurologic", "ANATOMY", 68, 78], ["respiratory, gastrointestinal, hepatic and neurologic systems", "DISEASE", 25, 86], ["gastrointestinal", "ANATOMICAL_SYSTEM", 38, 54], ["hepatic", "MULTI-TISSUE_STRUCTURE", 56, 63], ["infect respiratory, gastrointestinal, hepatic and neurologic systems", "PROBLEM", 18, 86], ["severe disease", "PROBLEM", 154, 168], ["gastrointestinal", "ANATOMY", 38, 54], ["hepatic", "ANATOMY", 56, 63], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["disease", "OBSERVATION", 161, 168]]], ["The first human coronaviruses (HCoVs), HCoV-229E and OC43, shown to be significant respiratory pathogens, were identified in the 1960s [6, 7] .", [["respiratory pathogens", "DISEASE", 83, 104], ["human", "ORGANISM", 10, 15], ["coronaviruses", "ORGANISM", 16, 29], ["HCoVs", "GENE_OR_GENE_PRODUCT", 31, 36], ["HCoV-229E", "CELL", 39, 48], ["OC43", "CELL", 53, 57], ["human", "SPECIES", 10, 15], ["human coronaviruses", "SPECIES", 10, 29], ["HCoVs", "SPECIES", 31, 36], ["HCoV-229E", "SPECIES", 39, 48], ["The first human coronaviruses", "TEST", 0, 29], ["HCoV", "TEST", 39, 43], ["OC43", "PROBLEM", 53, 57], ["significant respiratory pathogens", "PROBLEM", 71, 104], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["respiratory pathogens", "OBSERVATION", 83, 104]]], ["However, it is assumed that the first recorded coronavirus-related disease was feline infectious peritonitis (FIP) in 1912 [8] .", [["coronavirus", "DISEASE", 47, 58], ["feline infectious peritonitis", "DISEASE", 79, 108], ["FIP", "DISEASE", 110, 113], ["coronavirus", "ORGANISM", 47, 58], ["feline", "ORGANISM", 79, 85], ["feline", "SPECIES", 79, 85], ["the first recorded coronavirus-related disease", "PROBLEM", 28, 74], ["feline infectious peritonitis", "PROBLEM", 79, 108], ["coronavirus", "OBSERVATION", 47, 58], ["infectious", "OBSERVATION_MODIFIER", 86, 96], ["peritonitis", "OBSERVATION", 97, 108]]], ["The \"corona\"-like or crown-like morphology of these viruses leads to choose the name \"coronavirus,\" in 1968 [6] .What Are CoronavirusesCoronaviruses were not considered as highly pathogenic for humans before the beginning of the 21st century.", [["humans", "ORGANISM", 194, 200], ["humans", "SPECIES", 194, 200], ["humans", "SPECIES", 194, 200], ["CoronavirusesCoronaviruses", "PROBLEM", 122, 148], ["corona", "OBSERVATION_MODIFIER", 5, 11], ["viruses", "OBSERVATION", 52, 59]]], ["Afterward, two highly pathogenic HCoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), emerging from animal reservoirs, have led to global epidemics of deadly pneumonia in humans with high morbidity and mortality [9, 10] .", [["HCoVs", "DISEASE", 33, 38], ["acute respiratory syndrome coronavirus", "DISEASE", 57, 95], ["SARS-CoV)", "DISEASE", 97, 106], ["Middle East respiratory syndrome coronavirus", "DISEASE", 111, 155], ["pneumonia", "DISEASE", 240, 249], ["HCoVs", "CANCER", 33, 38], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 50, 95], ["SARS-CoV", "ORGANISM", 97, 105], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 111, 155], ["MERS-CoV", "ORGANISM", 157, 165], ["humans", "ORGANISM", 253, 259], ["coronavirus", "SPECIES", 144, 155], ["humans", "SPECIES", 253, 259], ["severe acute respiratory syndrome coronavirus", "SPECIES", 50, 95], ["SARS-CoV", "SPECIES", 97, 105], ["Middle East respiratory syndrome coronavirus", "SPECIES", 111, 155], ["MERS-CoV", "SPECIES", 157, 165], ["humans", "SPECIES", 253, 259], ["two highly pathogenic HCoVs", "PROBLEM", 11, 38], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 50, 95], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 111, 155], ["deadly pneumonia", "PROBLEM", 233, 249], ["high morbidity", "PROBLEM", 265, 279], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["pathogenic HCoVs", "OBSERVATION", 22, 38], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome coronavirus", "OBSERVATION", 63, 95], ["Middle", "ANATOMY_MODIFIER", 111, 117], ["respiratory syndrome", "OBSERVATION", 123, 143], ["deadly", "OBSERVATION_MODIFIER", 233, 239], ["pneumonia", "OBSERVATION", 240, 249]]], ["In December 2019, seven years after MERS outbreak, the third pathogenic HCoV emerged in Wuhan, the capital city of Hubei province in China, causing severe pneumonia [11, 12] .", [["pneumonia", "DISEASE", 155, 164], ["HCoV", "CANCER", 72, 76], ["HCoV", "SPECIES", 72, 76], ["MERS outbreak", "PROBLEM", 36, 49], ["severe pneumonia", "PROBLEM", 148, 164], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["pneumonia", "OBSERVATION", 155, 164]]], ["Considered as agents that are a great public health threat, an epidemiological alert was placed by the World Health Organization (WHO) and this new coronavirus was named SARS-CoV-2 and the related respiratory disease COVID-19 (https://www.who.int).", [["coronavirus", "DISEASE", 148, 159], ["respiratory disease", "DISEASE", 197, 216], ["coronavirus", "ORGANISM", 148, 159], ["coronavirus", "SPECIES", 148, 159], ["SARS-CoV", "SPECIES", 170, 178], ["this new coronavirus", "PROBLEM", 139, 159], ["CoV", "TEST", 175, 178], ["the related respiratory disease COVID", "PROBLEM", 185, 222], ["respiratory disease", "OBSERVATION", 197, 216]]], ["Compared with SARS-CoV, SARS-CoV-2 appears to be more readily transmitted from human-to-human, spreading to multiple continents and the outbreak of SARS-CoV-2 was declared on January 30, 2020 [13] (https://www.who.int).", [["SARS", "DISEASE", 14, 18], ["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 148, 152], ["SARS-CoV", "ORGANISM", 14, 22], ["SARS-CoV-2", "ORGANISM", 24, 34], ["human", "ORGANISM", 79, 84], ["human", "ORGANISM", 88, 93], ["SARS-CoV-2", "ORGANISM", 148, 158], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 88, 93], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 24, 32], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 88, 93], ["SARS-CoV", "SPECIES", 148, 156], ["SARS", "TEST", 14, 18], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 153, 156], ["multiple", "OBSERVATION_MODIFIER", 108, 116]]], ["In this review, we will introduce the current knowledge on the origin and evolution of SARS-CoV-2, emphasizing its characteristics and its genetic diversity from previous coronaviruses, with a brief comment on its epidemiology and pathogenesis.", [["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV", "SPECIES", 87, 95], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["previous coronaviruses", "PROBLEM", 162, 184], ["pathogenesis", "PROBLEM", 231, 243]]], ["Knowledge about this novel coronavirus is rapidly evolving, and efforts must be implemented in order to protect the populations by reducing transmission and controlling the spread of this fatal disease.Origin, Family Member, Diversity and Taxonomy of CoronavirusesAccording to the International Committee on Taxonomy of Viruses, CoVs are classified under the order of Nidovirales, a family of Coronaviridae and subfamily of Coronavirinae [14] .", [["coronavirus", "DISEASE", 27, 38], ["coronavirus", "ORGANISM", 27, 38], ["CoVs", "GENE_OR_GENE_PRODUCT", 329, 333], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 368, 379], ["this novel coronavirus", "PROBLEM", 16, 38], ["this fatal disease", "PROBLEM", 183, 201], ["Nidovirales", "TREATMENT", 368, 379], ["Coronaviridae", "TREATMENT", 393, 406]]], ["Based on previous serologic and recent genomic evidences, the family of Coronaviridae encompasses two subfamilies: subfamily Orthocoronavirinae and subfamily Torovirinae ( Figure 1) [7, 15] .", [["previous serologic", "TEST", 9, 27], ["subfamily Torovirinae ( Figure", "TREATMENT", 148, 178]]], ["The subfamily of Orthocoronavirinae consists of four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus [7, 16, 17] .", [["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 17, 35], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 61, 77], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 79, 94], ["Alphacoronavirus", "TREATMENT", 61, 77], ["Betacoronavirus", "TREATMENT", 79, 94], ["Gammacoronavirus", "TREATMENT", 96, 112], ["Deltacoronavirus", "TREATMENT", 117, 133]]], ["CoVs can be isolated from different animal species, including birds, livestock and mammals such as camels, bats, masked palm civets, mice, dogs and cats [18, 19] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["camels", "ORGANISM_SUBDIVISION", 99, 105], ["palm", "ORGANISM_SUBDIVISION", 120, 124], ["mice", "ORGANISM", 133, 137], ["dogs", "ORGANISM", 139, 143], ["cats", "ORGANISM", 148, 152], ["CoVs", "PROTEIN", 0, 4], ["mice", "SPECIES", 133, 137], ["dogs", "SPECIES", 139, 143], ["cats", "SPECIES", 148, 152], ["mice", "SPECIES", 133, 137], ["CoVs", "PROBLEM", 0, 4]]], ["Animal CoVs are known to cause acute diseases in several animals and could be responsible for economic losses in domestic animals or birds [20, 21] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 7, 11], ["Animal CoVs", "PROBLEM", 0, 11], ["acute diseases", "PROBLEM", 31, 45], ["economic losses in domestic animals", "PROBLEM", 94, 129], ["CoVs", "OBSERVATION", 7, 11], ["known to cause", "UNCERTAINTY", 16, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["diseases", "OBSERVATION", 37, 45], ["could be responsible for", "UNCERTAINTY", 69, 93]]], ["Domestic animals may play an important role as intermediate hosts that enable virus transmission from one species to humans [17] .", [["humans", "ORGANISM", 117, 123], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 117, 123]]], ["The genera Gamma-and Deltacoronavirus infect birds, but some of them can also infect mammals [16] .", [["Gamma-", "GENE_OR_GENE_PRODUCT", 11, 17], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 21, 37], ["birds", "ORGANISM", 45, 50], ["Deltacoronavirus infect birds", "PROBLEM", 21, 50], ["genera Gamma-", "OBSERVATION_MODIFIER", 4, 17]]], ["These animal CoVs include transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), avian infectious bronchitis virus (IBV)-and more recently-swine acute diarrhea syndrome coronavirus (SADS-CoV).", [["transmissible gastroenteritis", "DISEASE", 26, 55], ["porcine epidemic diarrhea virus", "DISEASE", 70, 101], ["avian infectious bronchitis virus", "DISEASE", 110, 143], ["acute diarrhea syndrome coronavirus", "DISEASE", 174, 209], ["CoVs", "GENE_OR_GENE_PRODUCT", 13, 17], ["transmissible gastroenteritis virus", "ORGANISM", 26, 61], ["TGEV", "ORGANISM", 63, 67], ["porcine epidemic diarrhea virus", "ORGANISM", 70, 101], ["avian infectious bronchitis virus", "ORGANISM", 110, 143], ["IBV", "ORGANISM", 145, 148], ["transmissible gastroenteritis virus", "SPECIES", 26, 61], ["porcine epidemic diarrhea virus", "SPECIES", 70, 101], ["avian infectious bronchitis virus", "SPECIES", 110, 143], ["swine", "SPECIES", 168, 173], ["coronavirus", "SPECIES", 198, 209], ["transmissible gastroenteritis virus", "SPECIES", 26, 61], ["TGEV", "SPECIES", 63, 67], ["porcine epidemic diarrhea virus", "SPECIES", 70, 101], ["PEDV", "SPECIES", 103, 107], ["infectious bronchitis virus", "SPECIES", 116, 143], ["IBV", "SPECIES", 145, 148], ["swine acute diarrhea syndrome coronavirus", "SPECIES", 168, 209], ["SADS-CoV", "SPECIES", 211, 219], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 26, 67], ["porcine epidemic diarrhea virus (PEDV", "PROBLEM", 70, 107], ["avian infectious bronchitis virus", "PROBLEM", 110, 143], ["swine acute diarrhea syndrome coronavirus", "PROBLEM", 168, 209], ["transmissible", "OBSERVATION_MODIFIER", 26, 39], ["gastroenteritis", "OBSERVATION", 40, 55], ["infectious", "OBSERVATION_MODIFIER", 116, 126], ["bronchitis", "OBSERVATION", 127, 137], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["diarrhea", "OBSERVATION", 180, 188]]], ["However, animal CoVs can also infect humans that can spread the infection through human-tohuman transmission [17, 22] .", [["CoVs", "CHEMICAL", 16, 20], ["infection", "DISEASE", 64, 73], ["CoVs", "GENE_OR_GENE_PRODUCT", 16, 20], ["humans", "ORGANISM", 37, 43], ["human", "ORGANISM", 82, 87], ["humans", "SPECIES", 37, 43], ["human", "SPECIES", 82, 87], ["humans", "SPECIES", 37, 43], ["human", "SPECIES", 82, 87], ["animal CoVs", "PROBLEM", 9, 20], ["the infection", "PROBLEM", 60, 73], ["infection", "OBSERVATION", 64, 73]]], ["On the other hand, Alpha-and Betacoronavirus infect only mammals and usually cause respiratory illness in humans; among these, strains 229E, OC43, HKU1 and NL63 are the most widespread infecting young children, infants as well as elderly individuals [23] [24] [25] .", [["respiratory", "ANATOMY", 83, 94], ["respiratory illness", "DISEASE", 83, 102], ["Alpha-", "GENE_OR_GENE_PRODUCT", 19, 25], ["humans", "ORGANISM", 106, 112], ["strains 229E", "ORGANISM", 127, 139], ["OC43", "GENE_OR_GENE_PRODUCT", 141, 145], ["HKU1", "GENE_OR_GENE_PRODUCT", 147, 151], ["NL63", "GENE_OR_GENE_PRODUCT", 156, 160], ["children", "ORGANISM", 201, 209], ["infants", "ORGANISM", 211, 218], ["humans", "SPECIES", 106, 112], ["children", "SPECIES", 201, 209], ["infants", "SPECIES", 211, 218], ["humans", "SPECIES", 106, 112], ["Alpha-and Betacoronavirus infect", "PROBLEM", 19, 51], ["respiratory illness in humans", "PROBLEM", 83, 112], ["OC43", "TEST", 141, 145], ["HKU1", "TEST", 147, 151]]], ["The high rates of mutation characterizing all RNA viruses [23, 26] , the evolving nature of CoVs and the simplicity of transmission from one species to another are the most relevant features learned from SARS-CoV and MERS-CoV previous outbreaks [15, 23, 25] .", [["SARS", "DISEASE", 204, 208], ["CoVs", "GENE_OR_GENE_PRODUCT", 92, 96], ["SARS-CoV", "ORGANISM", 204, 212], ["MERS-CoV", "ORGANISM", 217, 225], ["SARS-CoV", "SPECIES", 204, 212], ["MERS-CoV", "SPECIES", 217, 225], ["The high rates of mutation", "PROBLEM", 0, 26], ["all RNA viruses", "PROBLEM", 42, 57], ["CoVs", "PROBLEM", 92, 96], ["SARS", "PROBLEM", 204, 208], ["RNA viruses", "OBSERVATION", 46, 57], ["CoVs", "OBSERVATION", 92, 96]]], ["Importantly, most of Alpha-and Betacoronavirus were found only in bats, and many genetically diverse coronaviruses phylogenetically related to SARS-CoV and MERS-CoV have been discovered in diverse bat species worldwide [17] .", [["SARS", "DISEASE", 143, 147], ["Alpha-", "GENE_OR_GENE_PRODUCT", 21, 27], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 31, 46], ["coronaviruses", "ORGANISM", 101, 114], ["SARS-CoV", "ORGANISM", 143, 151], ["MERS-CoV", "ORGANISM", 156, 164], ["MERS-CoV", "SPECIES", 156, 164], ["SARS-CoV", "SPECIES", 143, 151], ["MERS-CoV", "SPECIES", 156, 164], ["Alpha-", "TEST", 21, 27], ["Betacoronavirus", "TREATMENT", 31, 46], ["many genetically diverse coronaviruses", "PROBLEM", 76, 114], ["SARS", "PROBLEM", 143, 147], ["CoV", "PROBLEM", 148, 151], ["MERS", "PROBLEM", 156, 160], ["CoV", "PROBLEM", 161, 164], ["diverse coronaviruses", "OBSERVATION", 93, 114]]], ["Therefore, HCoVs such as SARS-and MERS-CoVs seem to have originated in bats by sequential mutations and recombination, including those occurring in the intermediate hosts, civets and raccoon dogs for SARS-CoV and camels in the case of MERS-CoV, finally acquiring the ability to infect humans [15, 17] .", [["SARS", "DISEASE", 25, 29], ["SARS", "DISEASE", 200, 204], ["HCoVs", "GENE_OR_GENE_PRODUCT", 11, 16], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 34, 43], ["raccoon dogs", "ORGANISM", 183, 195], ["SARS-CoV", "ORGANISM", 200, 208], ["camels", "ORGANISM", 213, 219], ["MERS-CoV", "ORGANISM", 235, 243], ["humans", "ORGANISM", 285, 291], ["HCoVs", "PROTEIN", 11, 16], ["SARS-and MERS-CoVs", "DNA", 25, 43], ["dogs", "SPECIES", 191, 195], ["humans", "SPECIES", 285, 291], ["SARS-CoV", "SPECIES", 200, 208], ["MERS-CoV", "SPECIES", 235, 243], ["humans", "SPECIES", 285, 291], ["SARS", "PROBLEM", 25, 29], ["CoVs", "PROBLEM", 39, 43], ["SARS", "PROBLEM", 200, 204], ["CoV", "PROBLEM", 240, 243]]], ["Comparative genome studies published in recent papers strongly support the hypothesis that SARS-CoV-2 originated in bats and that pangolins (Manis javanica) acted as intermediate mammalian hosts [11, 27] (Figure 2) .", [["SARS", "DISEASE", 91, 95], ["SARS-CoV-2", "ORGANISM", 91, 101], ["bats", "ORGANISM", 116, 120], ["pangolins", "GENE_OR_GENE_PRODUCT", 130, 139], ["Manis javanica", "ORGANISM", 141, 155], ["Manis javanica", "SPECIES", 141, 155], ["Manis javanica", "SPECIES", 141, 155], ["Comparative genome studies", "TEST", 0, 26], ["the hypothesis", "PROBLEM", 71, 85], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99]]], ["Indeed, the genetic sequence of the SARS-CoV-2 showed more than 79% nucleotide identity with the sequence of SARS-CoV and 50% with MERS-CoV [17, 19] .", [["SARS", "DISEASE", 36, 40], ["nucleotide", "CHEMICAL", 68, 78], ["SARS-CoV", "DISEASE", 109, 117], ["nucleotide", "CHEMICAL", 68, 78], ["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV", "ORGANISM", 109, 117], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 131, 139], ["SARS-CoV-2", "DNA", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 109, 117], ["MERS-CoV", "SPECIES", 131, 139], ["the SARS", "TEST", 32, 40], ["CoV", "TEST", 41, 44], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117]]], ["The high degree of homology of the angiotensin-converting enzyme 2 (ACE2) receptor in several animal species can be considered as an additional evidence to support that SARS-CoV-2 originated from bats [28] .", [["angiotensin", "CHEMICAL", 35, 46], ["SARS", "DISEASE", 169, 173], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 35, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["SARS-CoV-2", "ORGANISM", 169, 179], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 35, 82], ["the angiotensin", "TREATMENT", 31, 46], ["converting enzyme", "TEST", 47, 64], ["ACE2) receptor", "TREATMENT", 68, 82], ["SARS", "PROBLEM", 169, 173], ["CoV", "TEST", 174, 177], ["high degree", "OBSERVATION_MODIFIER", 4, 15]]], ["Based on findings from molecular studies, the ACE2 proteins of non-human primates, pigs, cats and ferrets closely resemble the human ACE2 receptor.", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["non-human primates", "ORGANISM", 63, 81], ["pigs", "ORGANISM", 83, 87], ["cats", "ORGANISM", 89, 93], ["ferrets", "ORGANISM", 98, 105], ["human", "ORGANISM", 127, 132], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 133, 146], ["ACE2 proteins", "PROTEIN", 46, 59], ["human ACE2 receptor", "PROTEIN", 127, 146], ["pigs", "SPECIES", 83, 87], ["cats", "SPECIES", 89, 93], ["ferrets", "SPECIES", 98, 105], ["human", "SPECIES", 127, 132], ["pigs", "SPECIES", 83, 87], ["human", "SPECIES", 127, 132], ["molecular studies", "TEST", 23, 40], ["the ACE2 proteins", "TEST", 42, 59], ["pigs, cats", "TREATMENT", 83, 93], ["ferrets", "TREATMENT", 98, 105], ["the human ACE2 receptor", "TREATMENT", 123, 146]]], ["Therefore, these species CoVs can be isolated from different animal species, including birds, livestock and mammals such as camels, bats, masked palm civets, mice, dogs and cats [18, 19] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["camels", "ORGANISM_SUBDIVISION", 124, 130], ["palm", "ORGANISM_SUBDIVISION", 145, 149], ["mice", "ORGANISM", 158, 162], ["dogs", "ORGANISM", 164, 168], ["cats", "ORGANISM", 173, 177], ["mice", "SPECIES", 158, 162], ["dogs", "SPECIES", 164, 168], ["cats", "SPECIES", 173, 177], ["mice", "SPECIES", 158, 162], ["these species CoVs", "PROBLEM", 11, 29], ["species CoVs", "OBSERVATION", 17, 29]]], ["Animal CoVs are known to cause acute diseases in several animals and could be responsible for economic losses in domestic animals or birds [20, 21] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 7, 11], ["Animal CoVs", "PROBLEM", 0, 11], ["acute diseases", "PROBLEM", 31, 45], ["economic losses in domestic animals", "PROBLEM", 94, 129], ["CoVs", "OBSERVATION", 7, 11], ["known to cause", "UNCERTAINTY", 16, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["diseases", "OBSERVATION", 37, 45], ["could be responsible for", "UNCERTAINTY", 69, 93]]], ["Domestic animals may play an important role as intermediate hosts that enable virus transmission from one species to humans [17] .", [["humans", "ORGANISM", 117, 123], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 117, 123]]], ["The genera Gammaand Deltacoronavirus infect birds, but some of them can also infect mammals [16] .", [["Gammaand Deltacoronavirus", "ORGANISM", 11, 36], ["birds", "ORGANISM", 44, 49]]], ["These animal CoVs include transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), avian infectious bronchitis virus (IBV)-and more recently-swine acute diarrhea syndrome coronavirus (SADS-CoV).", [["transmissible gastroenteritis", "DISEASE", 26, 55], ["porcine epidemic diarrhea virus", "DISEASE", 70, 101], ["avian infectious bronchitis virus", "DISEASE", 110, 143], ["acute diarrhea syndrome coronavirus", "DISEASE", 174, 209], ["CoVs", "GENE_OR_GENE_PRODUCT", 13, 17], ["transmissible gastroenteritis virus", "ORGANISM", 26, 61], ["TGEV", "ORGANISM", 63, 67], ["porcine epidemic diarrhea virus", "ORGANISM", 70, 101], ["avian infectious bronchitis virus", "ORGANISM", 110, 143], ["IBV", "ORGANISM", 145, 148], ["transmissible gastroenteritis virus", "SPECIES", 26, 61], ["porcine epidemic diarrhea virus", "SPECIES", 70, 101], ["avian infectious bronchitis virus", "SPECIES", 110, 143], ["swine", "SPECIES", 168, 173], ["coronavirus", "SPECIES", 198, 209], ["transmissible gastroenteritis virus", "SPECIES", 26, 61], ["TGEV", "SPECIES", 63, 67], ["porcine epidemic diarrhea virus", "SPECIES", 70, 101], ["PEDV", "SPECIES", 103, 107], ["infectious bronchitis virus", "SPECIES", 116, 143], ["IBV", "SPECIES", 145, 148], ["swine acute diarrhea syndrome coronavirus", "SPECIES", 168, 209], ["SADS-CoV", "SPECIES", 211, 219], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 26, 67], ["porcine epidemic diarrhea virus (PEDV", "PROBLEM", 70, 107], ["avian infectious bronchitis virus", "PROBLEM", 110, 143], ["swine acute diarrhea syndrome coronavirus", "PROBLEM", 168, 209], ["transmissible", "OBSERVATION_MODIFIER", 26, 39], ["gastroenteritis", "OBSERVATION", 40, 55], ["infectious", "OBSERVATION_MODIFIER", 116, 126], ["bronchitis", "OBSERVATION", 127, 137], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["diarrhea", "OBSERVATION", 180, 188]]], ["However, animal CoVs can also infect humans that can spread the infection through human-to-human transmission [17, 22] .", [["CoVs", "CHEMICAL", 16, 20], ["infection", "DISEASE", 64, 73], ["CoVs", "GENE_OR_GENE_PRODUCT", 16, 20], ["humans", "ORGANISM", 37, 43], ["human", "ORGANISM", 82, 87], ["human", "ORGANISM", 91, 96], ["humans", "SPECIES", 37, 43], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 91, 96], ["humans", "SPECIES", 37, 43], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 91, 96], ["animal CoVs", "PROBLEM", 9, 20], ["the infection", "PROBLEM", 60, 73], ["infection", "OBSERVATION", 64, 73]]], ["On the other hand, Alphaand Betacoronavirus infect only mammals and usually cause respiratory illness in humans; among these, strains 229E, OC43, HKU1 and NL63 are the most widespread infecting young children, infants as well as elderly individuals [23] [24] [25] .", [["respiratory", "ANATOMY", 82, 93], ["respiratory illness", "DISEASE", 82, 101], ["Alphaand Betacoronavirus", "ORGANISM", 19, 43], ["humans", "ORGANISM", 105, 111], ["strains 229E", "ORGANISM", 126, 138], ["OC43", "GENE_OR_GENE_PRODUCT", 140, 144], ["HKU1", "GENE_OR_GENE_PRODUCT", 146, 150], ["NL63", "GENE_OR_GENE_PRODUCT", 155, 159], ["children", "ORGANISM", 200, 208], ["infants", "ORGANISM", 210, 217], ["humans", "SPECIES", 105, 111], ["children", "SPECIES", 200, 208], ["infants", "SPECIES", 210, 217], ["humans", "SPECIES", 105, 111], ["Alphaand Betacoronavirus infect", "PROBLEM", 19, 50], ["respiratory illness in humans", "PROBLEM", 82, 111], ["OC43", "TEST", 140, 144], ["HKU1", "TEST", 146, 150]]], ["The high rates of mutation characterizing all RNA viruses [23, 26] , the evolving nature of CoVs and the simplicity of transmission from one species to another are the most relevant features learned from SARS-CoV and MERS-CoV previous outbreaks [15, 23, 25] .", [["SARS", "DISEASE", 204, 208], ["CoVs", "GENE_OR_GENE_PRODUCT", 92, 96], ["SARS-CoV", "ORGANISM", 204, 212], ["MERS-CoV", "ORGANISM", 217, 225], ["SARS-CoV", "SPECIES", 204, 212], ["MERS-CoV", "SPECIES", 217, 225], ["The high rates of mutation", "PROBLEM", 0, 26], ["all RNA viruses", "PROBLEM", 42, 57], ["CoVs", "PROBLEM", 92, 96], ["SARS", "PROBLEM", 204, 208], ["RNA viruses", "OBSERVATION", 46, 57], ["CoVs", "OBSERVATION", 92, 96]]], ["Importantly, most of Alphaand Betacoronavirus were found only in bats, and many genetically diverse coronaviruses phylogenetically related to SARS-CoV and MERS-CoV have been discovered in diverse bat species worldwide [17] .", [["SARS", "DISEASE", 142, 146], ["Alphaand Betacoronavirus", "ORGANISM", 21, 45], ["coronaviruses", "ORGANISM", 100, 113], ["SARS-CoV", "ORGANISM", 142, 150], ["MERS-CoV", "ORGANISM", 155, 163], ["MERS-CoV", "SPECIES", 155, 163], ["SARS-CoV", "SPECIES", 142, 150], ["MERS-CoV", "SPECIES", 155, 163], ["Alphaand Betacoronavirus", "TREATMENT", 21, 45], ["many genetically diverse coronaviruses", "PROBLEM", 75, 113], ["SARS", "PROBLEM", 142, 146], ["CoV", "PROBLEM", 147, 150], ["MERS", "PROBLEM", 155, 159], ["CoV", "PROBLEM", 160, 163], ["coronaviruses", "OBSERVATION", 100, 113]]], ["Therefore, HCoVs such as SARS-and MERS-CoVs seem to have originated in bats by sequential mutations and recombination, including those occurring in the intermediate hosts, civets and raccoon dogs for SARS-CoV and camels in the case of MERS-CoV, finally acquiring the ability to infect humans [15, 17] .", [["SARS", "DISEASE", 25, 29], ["SARS", "DISEASE", 200, 204], ["HCoVs", "GENE_OR_GENE_PRODUCT", 11, 16], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 34, 43], ["raccoon dogs", "ORGANISM", 183, 195], ["SARS-CoV", "ORGANISM", 200, 208], ["camels", "ORGANISM", 213, 219], ["MERS-CoV", "ORGANISM", 235, 243], ["humans", "ORGANISM", 285, 291], ["HCoVs", "PROTEIN", 11, 16], ["SARS-and MERS-CoVs", "DNA", 25, 43], ["dogs", "SPECIES", 191, 195], ["humans", "SPECIES", 285, 291], ["SARS-CoV", "SPECIES", 200, 208], ["MERS-CoV", "SPECIES", 235, 243], ["humans", "SPECIES", 285, 291], ["SARS", "PROBLEM", 25, 29], ["CoVs", "PROBLEM", 39, 43], ["SARS", "PROBLEM", 200, 204], ["CoV", "PROBLEM", 240, 243]]], ["Comparative genome studies published in recent papers strongly support the hypothesis that SARS-CoV-2 originated in bats and that pangolins (Manis javanica) acted as intermediate mammalian hosts [11, 27] (Figure 2) .", [["SARS", "DISEASE", 91, 95], ["SARS-CoV-2", "ORGANISM", 91, 101], ["bats", "ORGANISM", 116, 120], ["pangolins", "GENE_OR_GENE_PRODUCT", 130, 139], ["Manis javanica", "ORGANISM", 141, 155], ["Manis javanica", "SPECIES", 141, 155], ["Manis javanica", "SPECIES", 141, 155], ["Comparative genome studies", "TEST", 0, 26], ["the hypothesis", "PROBLEM", 71, 85], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99]]], ["Indeed, the genetic sequence of the SARS-CoV-2 showed more than 79% nucleotide identity with the sequence of SARS-CoV and 50% with MERS-CoV [17, 19] .", [["SARS", "DISEASE", 36, 40], ["nucleotide", "CHEMICAL", 68, 78], ["SARS-CoV", "DISEASE", 109, 117], ["nucleotide", "CHEMICAL", 68, 78], ["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV", "ORGANISM", 109, 117], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 131, 139], ["SARS-CoV-2", "DNA", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 109, 117], ["MERS-CoV", "SPECIES", 131, 139], ["the SARS", "TEST", 32, 40], ["CoV", "TEST", 41, 44], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117]]], ["The high degree of homology of the angiotensin-converting enzyme 2 (ACE2) receptor in several animal species can be considered as an additional evidence to support that SARS-CoV-2 originated from bats [28] .", [["angiotensin", "CHEMICAL", 35, 46], ["SARS", "DISEASE", 169, 173], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 35, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["SARS-CoV-2", "ORGANISM", 169, 179], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 35, 82], ["the angiotensin", "TREATMENT", 31, 46], ["converting enzyme", "TEST", 47, 64], ["ACE2) receptor", "TREATMENT", 68, 82], ["SARS", "PROBLEM", 169, 173], ["CoV", "TEST", 174, 177], ["high degree", "OBSERVATION_MODIFIER", 4, 15]]], ["Based on findings from molecular studies, the ACE2 proteins of non-human primates, pigs, cats and ferrets closely resemble the human ACE2 receptor.", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["non-human primates", "ORGANISM", 63, 81], ["pigs", "ORGANISM", 83, 87], ["cats", "ORGANISM", 89, 93], ["ferrets", "ORGANISM", 98, 105], ["human", "ORGANISM", 127, 132], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 133, 146], ["ACE2 proteins", "PROTEIN", 46, 59], ["human ACE2 receptor", "PROTEIN", 127, 146], ["pigs", "SPECIES", 83, 87], ["cats", "SPECIES", 89, 93], ["ferrets", "SPECIES", 98, 105], ["human", "SPECIES", 127, 132], ["pigs", "SPECIES", 83, 87], ["human", "SPECIES", 127, 132], ["molecular studies", "TEST", 23, 40], ["the ACE2 proteins", "TEST", 42, 59], ["pigs, cats", "TREATMENT", 83, 93], ["ferrets", "TREATMENT", 98, 105], ["the human ACE2 receptor", "TREATMENT", 123, 146]]], ["Therefore, these species may be susceptible to SARS-CoV-2 infection, as has been shown for SARS-CoV.", [["SARS-CoV-2 infection", "DISEASE", 47, 67], ["SARS-CoV-2", "ORGANISM", 47, 57], ["SARS-CoV", "ORGANISM", 91, 99], ["SARS-CoV-2", "SPECIES", 47, 57], ["SARS-CoV", "SPECIES", 91, 99], ["these species", "PROBLEM", 11, 24], ["SARS", "PROBLEM", 47, 51], ["CoV-2 infection", "PROBLEM", 52, 67], ["SARS", "PROBLEM", 91, 95], ["infection", "OBSERVATION", 58, 67]]], ["Although a recent study showed that neither pigs nor chickens are susceptible to SARS-CoV-2 by intranasal or oculo-oronasal infections, more evidences are needed to exclude pigs as intermediate host of SARS-CoV-2 [29] .", [["SARS", "DISEASE", 81, 85], ["oculo-oronasal infections", "DISEASE", 109, 134], ["SARS", "DISEASE", 202, 206], ["pigs", "ORGANISM", 44, 48], ["chickens", "ORGANISM", 53, 61], ["SARS-CoV-2", "ORGANISM", 81, 91], ["pigs", "ORGANISM", 173, 177], ["SARS-CoV-2", "ORGANISM", 202, 212], ["pigs", "SPECIES", 44, 48], ["chickens", "SPECIES", 53, 61], ["pigs", "SPECIES", 173, 177], ["pigs", "SPECIES", 44, 48], ["chickens", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 81, 89], ["pigs", "SPECIES", 173, 177], ["SARS-CoV", "SPECIES", 202, 210], ["a recent study", "TEST", 9, 23], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89], ["intranasal", "PROBLEM", 95, 105], ["oculo-oronasal infections", "PROBLEM", 109, 134], ["CoV", "TEST", 207, 210], ["oronasal", "ANATOMY", 115, 123], ["infections", "OBSERVATION", 124, 134]]], ["[15] .Origin, Family Member, Diversity and Taxonomy of CoronavirusesBased on the genetic sequence identity and the phylogenetic reports, SARS-CoV-2 is sufficiently different from SARS-CoV; thus, WHO has classified it as a new Betacoronavirus that infects humans [30] .Morphology and Genomic Structure of HCoVsThe genome of HCoVs is a single-stranded positive-sense RNA (+ssRNA) (~26-32 kb) with 5\u2032cap structure and 3\u2032-poly A tail, which is among the largest known RNA genomes [31] [32] [33] .", [["SARS", "DISEASE", 137, 141], ["SARS", "DISEASE", 179, 183], ["SARS-CoV-2", "ORGANISM", 137, 147], ["SARS-CoV", "ORGANISM", 179, 187], ["Betacoronavirus", "CANCER", 226, 241], ["humans", "ORGANISM", 255, 261], ["HCoVs", "GENE_OR_GENE_PRODUCT", 304, 309], ["HCoVs", "GENE_OR_GENE_PRODUCT", 323, 328], ["HCoVs", "DNA", 304, 309], ["HCoVs", "DNA", 323, 328], ["RNA genomes", "DNA", 464, 475], ["humans", "SPECIES", 255, 261], ["SARS-CoV", "SPECIES", 137, 145], ["SARS-CoV", "SPECIES", 179, 187], ["humans", "SPECIES", 255, 261], ["Coronaviruses", "PROBLEM", 55, 68], ["SARS-CoV", "TEST", 137, 145], ["a single-stranded positive-sense RNA", "PROBLEM", 332, 368], ["ssRNA", "TEST", 371, 376], ["5\u2032cap structure", "TEST", 395, 410], ["Genomic Structure", "OBSERVATION", 283, 300], ["tail", "ANATOMY", 425, 429], ["largest", "OBSERVATION_MODIFIER", 450, 457], ["RNA genomes", "OBSERVATION", 464, 475]]], ["The typical HCoVs gene order is 5\u2032-replicase-S-E-M-N-3\u2032, with numerous (6 to 11) open reading frames (ORFs) encoding accessory proteins scattered among the structural genes [34, 35] .", [["HCoVs", "CANCER", 12, 17], ["N-3", "GENE_OR_GENE_PRODUCT", 51, 54], ["HCoVs gene", "DNA", 12, 22], ["5\u2032", "DNA", 32, 34], ["E", "DNA", 47, 48], ["N-3\u2032", "DNA", 51, 55], ["open reading frames", "DNA", 81, 100], ["ORFs", "DNA", 102, 106], ["accessory proteins", "PROTEIN", 117, 135], ["structural genes", "DNA", 156, 172], ["open reading frames", "TEST", 81, 100], ["encoding accessory proteins", "PROBLEM", 108, 135], ["scattered", "OBSERVATION_MODIFIER", 136, 145]]], ["The first ORFs (ORF1a and 1b) comprise two-thirds (approximately 67%) of the genome length and encode 16 nonstructural polyproteins (nsps [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and are directly translated from the genomic RNA [17] .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 16, 21], ["nsps [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 133, 208], ["ORFs", "DNA", 10, 14], ["ORF1a", "DNA", 16, 21], ["1b", "DNA", 26, 28], ["The first ORFs", "TEST", 0, 14], ["ORF1a", "TEST", 16, 21], ["the genome length", "TEST", 73, 90], ["encode", "TEST", 95, 101], ["nonstructural polyproteins (nsps [1] [2] [3] [4] [5]", "TEST", 105, 157]]], ["There is a \u22121 ribosomal frameshift between ORF1a and ORF1b, leading to the production of two large replicase polypeptides (pp): pp1a and pp1ab.", [["ribosomal", "ANATOMY", 14, 23], ["ORF1a", "GENE_OR_GENE_PRODUCT", 43, 48], ["ORF1b", "GENE_OR_GENE_PRODUCT", 53, 58], ["pp1a", "GENE_OR_GENE_PRODUCT", 128, 132], ["pp1ab", "GENE_OR_GENE_PRODUCT", 137, 142], ["\u22121 ribosomal frameshift", "DNA", 11, 34], ["ORF1a", "DNA", 43, 48], ["ORF1b", "DNA", 53, 58], ["replicase polypeptides", "PROTEIN", 99, 121], ["pp", "PROTEIN", 123, 125], ["pp1a", "PROTEIN", 128, 132], ["pp1ab", "PROTEIN", 137, 142], ["a \u22121 ribosomal frameshift", "PROBLEM", 9, 34], ["ORF1a", "TREATMENT", 43, 48], ["ORF1b", "TREATMENT", 53, 58], ["ribosomal frameshift", "OBSERVATION", 14, 34], ["large", "OBSERVATION_MODIFIER", 93, 98], ["replicase polypeptides", "OBSERVATION", 99, 121]]], ["These polypeptides are further processed by two virally encoded cysteine proteases, the papain-like protease (PLpro) and a 3-chymotrypsin-like protease (3CLpro) into 16 nsps [3, 33, 36] .", [["cysteine", "CHEMICAL", 64, 72], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 88, 108], ["PLpro", "GENE_OR_GENE_PRODUCT", 110, 115], ["3-chymotrypsin", "GENE_OR_GENE_PRODUCT", 123, 137], ["virally encoded cysteine proteases", "PROTEIN", 48, 82], ["papain-like protease", "PROTEIN", 88, 108], ["PLpro", "PROTEIN", 110, 115], ["chymotrypsin", "PROTEIN", 125, 137], ["protease", "PROTEIN", 143, 151], ["3CLpro", "PROTEIN", 153, 159], ["These polypeptides", "PROBLEM", 0, 18], ["two virally encoded cysteine proteases", "PROBLEM", 44, 82], ["the papain", "TREATMENT", 84, 94], ["protease (PLpro)", "TREATMENT", 100, 116], ["a 3-chymotrypsin-like protease (3CLpro)", "TREATMENT", 121, 160], ["cysteine proteases", "OBSERVATION", 64, 82]]], ["There are at least four structural proteins encoded by the coronaviral genome: a spike glycoprotein (S), an envelope protein (E), a membrane protein (M) and nucleocapsid protein (N) with short untranslated regions at both termini, required to produce a structurally complete viral particle [37] .", [["membrane", "ANATOMY", 132, 140], ["E", "GENE_OR_GENE_PRODUCT", 126, 127], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 157, 181], ["structural proteins", "PROTEIN", 24, 43], ["coronaviral genome", "DNA", 59, 77], ["spike glycoprotein", "PROTEIN", 81, 99], ["S", "PROTEIN", 101, 102], ["envelope protein", "PROTEIN", 108, 124], ["E", "PROTEIN", 126, 127], ["membrane protein", "PROTEIN", 132, 148], ["M", "PROTEIN", 150, 151], ["nucleocapsid protein", "PROTEIN", 157, 177], ["N", "PROTEIN", 179, 180], ["short untranslated regions", "DNA", 187, 213], ["an envelope protein", "TEST", 105, 124], ["a membrane protein", "TEST", 130, 148], ["nucleocapsid protein", "TEST", 157, 177], ["short untranslated regions", "PROBLEM", 187, 213], ["proteins", "OBSERVATION", 35, 43], ["coronaviral genome", "OBSERVATION", 59, 77]]], ["The typical coronavirus virion structure and proteins are shown in Figure 3 .", [["coronavirus", "ORGANISM", 12, 23], ["coronavirus virion structure", "PROTEIN", 12, 40], ["coronavirus", "SPECIES", 12, 23], ["The typical coronavirus virion structure", "PROBLEM", 0, 40], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["coronavirus virion structure", "OBSERVATION", 12, 40]]], ["The M protein is in higher quantities in comparison to any other proteins in the virus particle; with its three transmembrane domains, it shapes virions, promotes membrane curvature and binds to the nucleocapsid [38, 39] .", [["transmembrane", "ANATOMY", 112, 125], ["virions", "ANATOMY", 145, 152], ["membrane", "ANATOMY", 163, 171], ["M protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["membrane", "CELLULAR_COMPONENT", 163, 171], ["M protein", "PROTEIN", 4, 13], ["transmembrane domains", "PROTEIN", 112, 133], ["The M protein", "TEST", 0, 13], ["any other proteins in the virus particle", "PROBLEM", 55, 95], ["higher quantities", "OBSERVATION_MODIFIER", 20, 37], ["virus", "OBSERVATION", 81, 86], ["shapes virions", "OBSERVATION", 138, 152], ["membrane curvature", "OBSERVATION", 163, 181]]], ["The N protein contains two domains, both of which can bind to nsp3 protein to help tether the genome to replication-transcription complex (RTC) and package viral RNA into the viral particle during viral assembly [39, 40] .", [["nsp3", "GENE_OR_GENE_PRODUCT", 62, 66], ["genome", "CELLULAR_COMPONENT", 94, 100], ["RTC", "GENE_OR_GENE_PRODUCT", 139, 142], ["N protein", "PROTEIN", 4, 13], ["nsp3 protein", "PROTEIN", 62, 74], ["replication-transcription complex", "PROTEIN", 104, 137], ["RTC", "PROTEIN", 139, 142], ["viral RNA", "RNA", 156, 165], ["The N protein", "TREATMENT", 0, 13], ["nsp3 protein", "TREATMENT", 62, 74], ["transcription complex (RTC)", "TREATMENT", 116, 143], ["package viral RNA", "TREATMENT", 148, 165], ["two domains", "OBSERVATION_MODIFIER", 23, 34], ["viral particle", "OBSERVATION", 175, 189]]], ["The E protein is involved in virus assembly and virion release from host cells, while the S protein plays a vital role in attachment to host receptors, viral entry and determines host tropism [41, 42] .", [["cells", "ANATOMY", 73, 78], ["E", "GENE_OR_GENE_PRODUCT", 4, 5], ["virion", "CELLULAR_COMPONENT", 48, 54], ["host cells", "CELL", 68, 78], ["E protein", "PROTEIN", 4, 13], ["host cells", "CELL_TYPE", 68, 78], ["S protein", "PROTEIN", 90, 99], ["host receptors", "PROTEIN", 136, 150], ["The E protein", "TEST", 0, 13], ["virus assembly", "TREATMENT", 29, 43], ["virion release", "TREATMENT", 48, 62], ["host cells", "OBSERVATION", 68, 78]]], ["Additionally, some coronaviruses, such as HCoV-OC43 and HCoV-HKU1, have a hemagglutinin-esterase (HE) gene between ORF1b and S [43] [44] [45] [46] .", [["coronaviruses", "ORGANISM", 19, 32], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 42, 51], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 56, 65], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 74, 96], ["ORF1b", "SIMPLE_CHEMICAL", 115, 120], ["HCoV", "DNA", 42, 46], ["OC43", "DNA", 47, 51], ["HCoV", "DNA", 56, 60], ["HKU1", "DNA", 61, 65], ["hemagglutinin-esterase (HE) gene", "DNA", 74, 106], ["HCoV-OC43", "SPECIES", 42, 51], ["some coronaviruses", "PROBLEM", 14, 32], ["HCoV", "TEST", 42, 46], ["OC43", "TEST", 47, 51], ["HCoV", "TEST", 56, 60], ["HKU1", "TEST", 61, 65], ["a hemagglutinin-esterase", "TEST", 72, 96], ["ORF1b and S", "TEST", 115, 126], ["coronaviruses", "OBSERVATION", 19, 32]]], ["This Based on the genetic sequence identity and the phylogenetic reports, SARS-CoV-2 is sufficiently different from SARS-CoV; thus, WHO has classified it as a new Betacoronavirus that infects humans [30] .Morphology and Genomic Structure of HCoVsThe genome of HCoVs is a single-stranded positive-sense RNA (+ssRNA) (~26-32 kb) with 5 -cap structure and 3 -poly A tail, which is among the largest known RNA genomes [31] [32] [33] .", [["SARS", "DISEASE", 74, 78], ["SARS", "DISEASE", 116, 120], ["SARS-CoV-2", "ORGANISM", 74, 84], ["SARS-CoV", "ORGANISM", 116, 124], ["Betacoronavirus", "CANCER", 163, 178], ["humans", "ORGANISM", 192, 198], ["HCoVs", "GENE_OR_GENE_PRODUCT", 241, 246], ["HCoVs", "GENE_OR_GENE_PRODUCT", 260, 265], ["HCoVs", "DNA", 241, 246], ["HCoVs", "DNA", 260, 265], ["RNA genomes", "DNA", 402, 413], ["humans", "SPECIES", 192, 198], ["SARS-CoV", "SPECIES", 74, 82], ["SARS-CoV", "SPECIES", 116, 124], ["humans", "SPECIES", 192, 198], ["SARS-CoV", "TEST", 74, 82], ["a single-stranded positive-sense RNA", "PROBLEM", 269, 305], ["ssRNA", "TEST", 308, 313], ["Genomic Structure", "OBSERVATION", 220, 237], ["tail", "OBSERVATION_MODIFIER", 363, 367], ["largest", "OBSERVATION_MODIFIER", 388, 395], ["RNA genomes", "OBSERVATION", 402, 413]]], ["The typical HCoVs gene order is 5 -replicase-S-E-M-N-3 , with numerous (6 to 11) open reading frames (ORFs) encoding accessory proteins scattered among the structural genes [34, 35] .", [["HCoVs", "CANCER", 12, 17], ["N-3", "GENE_OR_GENE_PRODUCT", 51, 54], ["HCoVs gene", "DNA", 12, 22], ["E", "DNA", 47, 48], ["N-3", "DNA", 51, 54], ["open reading frames", "DNA", 81, 100], ["ORFs", "DNA", 102, 106], ["accessory proteins", "PROTEIN", 117, 135], ["structural genes", "DNA", 156, 172], ["open reading frames", "TEST", 81, 100], ["encoding accessory proteins", "PROBLEM", 108, 135], ["scattered", "OBSERVATION_MODIFIER", 136, 145]]], ["The first ORFs (ORF1a and 1b) comprise two-thirds (approximately 67%) of the genome length and encode 16 nonstructural polyproteins (nsps 1-16) and are directly translated from the genomic RNA [17] .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 16, 21], ["nsps 1-16", "GENE_OR_GENE_PRODUCT", 133, 142], ["ORFs", "DNA", 10, 14], ["ORF1a", "DNA", 16, 21], ["1b", "DNA", 26, 28], ["nonstructural polyproteins", "PROTEIN", 105, 131], ["nsps 1-16", "DNA", 133, 142], ["The first ORFs", "TEST", 0, 14], ["ORF1a", "TEST", 16, 21], ["encode 16 nonstructural polyproteins", "PROBLEM", 95, 131], ["nsps", "TEST", 133, 137], ["nonstructural polyproteins", "OBSERVATION", 105, 131], ["genomic RNA", "OBSERVATION", 181, 192]]], ["There is a \u22121 ribosomal frameshift between ORF1a and ORF1b, leading to the production of two large replicase polypeptides (pp): pp1a and pp1ab.", [["ribosomal", "ANATOMY", 14, 23], ["ORF1a", "GENE_OR_GENE_PRODUCT", 43, 48], ["ORF1b", "GENE_OR_GENE_PRODUCT", 53, 58], ["pp1a", "GENE_OR_GENE_PRODUCT", 128, 132], ["pp1ab", "GENE_OR_GENE_PRODUCT", 137, 142], ["\u22121 ribosomal frameshift", "DNA", 11, 34], ["ORF1a", "DNA", 43, 48], ["ORF1b", "DNA", 53, 58], ["replicase polypeptides", "PROTEIN", 99, 121], ["pp", "PROTEIN", 123, 125], ["pp1a", "PROTEIN", 128, 132], ["pp1ab", "PROTEIN", 137, 142], ["a \u22121 ribosomal frameshift", "PROBLEM", 9, 34], ["ORF1a", "TREATMENT", 43, 48], ["ORF1b", "TREATMENT", 53, 58], ["ribosomal frameshift", "OBSERVATION", 14, 34], ["large", "OBSERVATION_MODIFIER", 93, 98], ["replicase polypeptides", "OBSERVATION", 99, 121]]], ["These polypeptides are further processed by two virally encoded cysteine proteases, the papain-like protease (PLpro) and a 3-chymotrypsin-like protease (3CLpro) into 16 nsps [3, 33, 36] .", [["cysteine", "CHEMICAL", 64, 72], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 88, 108], ["PLpro", "GENE_OR_GENE_PRODUCT", 110, 115], ["3-chymotrypsin", "GENE_OR_GENE_PRODUCT", 123, 137], ["virally encoded cysteine proteases", "PROTEIN", 48, 82], ["papain-like protease", "PROTEIN", 88, 108], ["PLpro", "PROTEIN", 110, 115], ["chymotrypsin", "PROTEIN", 125, 137], ["protease", "PROTEIN", 143, 151], ["3CLpro", "PROTEIN", 153, 159], ["These polypeptides", "PROBLEM", 0, 18], ["two virally encoded cysteine proteases", "PROBLEM", 44, 82], ["the papain", "TREATMENT", 84, 94], ["protease (PLpro)", "TREATMENT", 100, 116], ["a 3-chymotrypsin-like protease (3CLpro)", "TREATMENT", 121, 160], ["cysteine proteases", "OBSERVATION", 64, 82]]], ["There are at least four structural proteins encoded by the coronaviral genome: a spike glycoprotein (S), an envelope protein (E), a membrane protein (M) and nucleocapsid protein (N) with short untranslated regions at both termini, required to produce a structurally complete viral particle [37] .", [["membrane", "ANATOMY", 132, 140], ["E", "GENE_OR_GENE_PRODUCT", 126, 127], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 157, 181], ["structural proteins", "PROTEIN", 24, 43], ["coronaviral genome", "DNA", 59, 77], ["spike glycoprotein", "PROTEIN", 81, 99], ["S", "PROTEIN", 101, 102], ["envelope protein", "PROTEIN", 108, 124], ["E", "PROTEIN", 126, 127], ["membrane protein", "PROTEIN", 132, 148], ["M", "PROTEIN", 150, 151], ["nucleocapsid protein", "PROTEIN", 157, 177], ["N", "PROTEIN", 179, 180], ["short untranslated regions", "DNA", 187, 213], ["an envelope protein", "TEST", 105, 124], ["a membrane protein", "TEST", 130, 148], ["nucleocapsid protein", "TEST", 157, 177], ["short untranslated regions", "PROBLEM", 187, 213], ["proteins", "OBSERVATION", 35, 43], ["coronaviral genome", "OBSERVATION", 59, 77]]], ["The typical coronavirus virion structure and proteins are shown in Figure 3 .", [["coronavirus", "ORGANISM", 12, 23], ["coronavirus virion structure", "PROTEIN", 12, 40], ["coronavirus", "SPECIES", 12, 23], ["The typical coronavirus virion structure", "PROBLEM", 0, 40], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["coronavirus virion structure", "OBSERVATION", 12, 40]]], ["The M protein is in higher quantities in comparison to any other proteins in the virus particle; with its three transmembrane domains, it shapes virions, promotes membrane curvature and binds to the nucleocapsid [38, 39] .", [["transmembrane", "ANATOMY", 112, 125], ["virions", "ANATOMY", 145, 152], ["membrane", "ANATOMY", 163, 171], ["M protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["membrane", "CELLULAR_COMPONENT", 163, 171], ["M protein", "PROTEIN", 4, 13], ["transmembrane domains", "PROTEIN", 112, 133], ["The M protein", "TEST", 0, 13], ["any other proteins in the virus particle", "PROBLEM", 55, 95], ["higher quantities", "OBSERVATION_MODIFIER", 20, 37], ["virus", "OBSERVATION", 81, 86], ["shapes virions", "OBSERVATION", 138, 152], ["membrane curvature", "OBSERVATION", 163, 181]]], ["The N protein contains two domains, both of which can bind to nsp3 protein to help tether the genome to replication-transcription complex (RTC) and package viral RNA into the viral particle during viral assembly [39, 40] .", [["nsp3", "GENE_OR_GENE_PRODUCT", 62, 66], ["genome", "CELLULAR_COMPONENT", 94, 100], ["RTC", "GENE_OR_GENE_PRODUCT", 139, 142], ["N protein", "PROTEIN", 4, 13], ["nsp3 protein", "PROTEIN", 62, 74], ["replication-transcription complex", "PROTEIN", 104, 137], ["RTC", "PROTEIN", 139, 142], ["viral RNA", "RNA", 156, 165], ["The N protein", "TREATMENT", 0, 13], ["nsp3 protein", "TREATMENT", 62, 74], ["transcription complex (RTC)", "TREATMENT", 116, 143], ["package viral RNA", "TREATMENT", 148, 165], ["two domains", "OBSERVATION_MODIFIER", 23, 34], ["viral particle", "OBSERVATION", 175, 189]]], ["The E protein is involved in virus assembly and virion release from host cells, while the S protein plays a vital role in attachment to host receptors, viral entry and determines host tropism [41, 42] .", [["cells", "ANATOMY", 73, 78], ["E", "GENE_OR_GENE_PRODUCT", 4, 5], ["virion", "CELLULAR_COMPONENT", 48, 54], ["host cells", "CELL", 68, 78], ["E protein", "PROTEIN", 4, 13], ["host cells", "CELL_TYPE", 68, 78], ["S protein", "PROTEIN", 90, 99], ["host receptors", "PROTEIN", 136, 150], ["The E protein", "TEST", 0, 13], ["virus assembly", "TREATMENT", 29, 43], ["virion release", "TREATMENT", 48, 62], ["host cells", "OBSERVATION", 68, 78]]], ["Additionally, some coronaviruses, such as HCoV-OC43 and HCoV-HKU1, have a hemagglutinin-esterase (HE) gene between ORF1b and S [43] [44] [45] [46] .", [["coronaviruses", "ORGANISM", 19, 32], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 42, 51], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 56, 65], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 74, 96], ["ORF1b", "SIMPLE_CHEMICAL", 115, 120], ["HCoV", "DNA", 42, 46], ["OC43", "DNA", 47, 51], ["HCoV", "DNA", 56, 60], ["HKU1", "DNA", 61, 65], ["hemagglutinin-esterase (HE) gene", "DNA", 74, 106], ["HCoV-OC43", "SPECIES", 42, 51], ["some coronaviruses", "PROBLEM", 14, 32], ["HCoV", "TEST", 42, 46], ["OC43", "TEST", 47, 51], ["HCoV", "TEST", 56, 60], ["HKU1", "TEST", 61, 65], ["a hemagglutinin-esterase", "TEST", 72, 96], ["ORF1b and S", "TEST", 115, 126], ["coronaviruses", "OBSERVATION", 19, 32]]], ["This hemagglutinin, like the influenza homolog enzyme, binds to sialic acid on host cell-surface glycoproteins and possesses acetyl-esterase activity [47] .", [["cell", "ANATOMY", 84, 88], ["surface", "ANATOMY", 89, 96], ["sialic acid", "CHEMICAL", 64, 75], ["acetyl", "CHEMICAL", 125, 131], ["sialic acid", "CHEMICAL", 64, 75], ["acetyl", "CHEMICAL", 125, 131], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 5, 18], ["sialic acid", "SIMPLE_CHEMICAL", 64, 75], ["cell", "CELL", 84, 88], ["acetyl-esterase", "GENE_OR_GENE_PRODUCT", 125, 140], ["hemagglutinin", "PROTEIN", 5, 18], ["influenza homolog enzyme", "PROTEIN", 29, 53], ["host cell-surface glycoproteins", "PROTEIN", 79, 110], ["acetyl-esterase", "PROTEIN", 125, 140], ["This hemagglutinin", "TREATMENT", 0, 18], ["the influenza homolog enzyme", "TEST", 25, 53], ["sialic acid", "TEST", 64, 75], ["host cell", "TEST", 79, 88], ["surface glycoproteins", "TREATMENT", 89, 110], ["possesses acetyl", "TREATMENT", 115, 131]]], ["Besides coronavirus-conserved genes, the SARS-CoV, SARS-CoV-2 and MERS-CoV genomes contain several specific accessory genes including ORF3a/b, 4a/b, ORF5, ORF6, ORF7a/b, ORF8a/b and 9b ( Figure 4) [4, 48, 49] .", [["coronavirus", "ORGANISM", 8, 19], ["SARS-CoV", "ORGANISM", 41, 49], ["SARS-CoV-2", "ORGANISM", 51, 61], ["MERS-CoV", "ORGANISM", 66, 74], ["ORF3a", "GENE_OR_GENE_PRODUCT", 134, 139], ["b", "GENE_OR_GENE_PRODUCT", 140, 141], ["4a", "GENE_OR_GENE_PRODUCT", 143, 145], ["b", "GENE_OR_GENE_PRODUCT", 146, 147], ["ORF5", "GENE_OR_GENE_PRODUCT", 149, 153], ["ORF6", "GENE_OR_GENE_PRODUCT", 155, 159], ["ORF7a", "GENE_OR_GENE_PRODUCT", 161, 166], ["b", "GENE_OR_GENE_PRODUCT", 167, 168], ["ORF8a", "GENE_OR_GENE_PRODUCT", 170, 175], ["coronavirus-conserved genes", "DNA", 8, 35], ["SARS-CoV, SARS-CoV-2 and MERS-CoV genomes", "DNA", 41, 82], ["accessory genes", "DNA", 108, 123], ["ORF3a", "DNA", 134, 139], ["ORF5", "DNA", 149, 153], ["ORF6", "DNA", 155, 159], ["ORF7a", "DNA", 161, 166], ["b", "DNA", 167, 168], ["ORF8a", "DNA", 170, 175], ["b", "DNA", 176, 177], ["9b", "DNA", 182, 184], ["SARS-CoV", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 66, 74], ["coronavirus", "PROBLEM", 8, 19], ["the SARS", "TEST", 37, 45], ["CoV", "TEST", 46, 49], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["MERS", "PROBLEM", 66, 70], ["ORF6", "TEST", 155, 159], ["ORF7a", "TEST", 161, 166], ["ORF8a", "TEST", 170, 175], ["Figure", "TEST", 187, 193], ["coronavirus", "OBSERVATION", 8, 19]]], ["All the structural and accessory proteins are translated from subgenomic RNAs (sgRNAs) generated during genome transcription/replication of CoVs [4] .Morphology and Genomic Structure of HCoVshemagglutinin, like the influenza homolog enzyme, binds to sialic acid on host cell-surface glycoproteins and possesses acetyl-esterase activity [47] .", [["cell", "ANATOMY", 270, 274], ["surface", "ANATOMY", 275, 282], ["HCoVshemagglutinin", "CHEMICAL", 186, 204], ["sialic acid", "CHEMICAL", 250, 261], ["acetyl", "CHEMICAL", 311, 317], ["sialic acid", "CHEMICAL", 250, 261], ["acetyl", "CHEMICAL", 311, 317], ["sgRNAs", "GENE_OR_GENE_PRODUCT", 79, 85], ["HCoVshemagglutinin", "GENE_OR_GENE_PRODUCT", 186, 204], ["sialic acid", "SIMPLE_CHEMICAL", 250, 261], ["cell", "CELL", 270, 274], ["acetyl-esterase", "GENE_OR_GENE_PRODUCT", 311, 326], ["accessory proteins", "PROTEIN", 23, 41], ["subgenomic RNAs", "RNA", 62, 77], ["sgRNAs", "DNA", 79, 85], ["HCoVshemagglutinin", "PROTEIN", 186, 204], ["influenza homolog enzyme", "PROTEIN", 215, 239], ["host cell-surface glycoproteins", "PROTEIN", 265, 296], ["acetyl-esterase", "PROTEIN", 311, 326], ["subgenomic RNAs (sgRNAs)", "PROBLEM", 62, 86], ["genome transcription", "TREATMENT", 104, 124], ["CoVs", "PROBLEM", 140, 144], ["Genomic Structure of HCoVshemagglutinin", "PROBLEM", 165, 204], ["the influenza homolog enzyme", "TEST", 211, 239], ["sialic acid", "TEST", 250, 261], ["host cell", "TEST", 265, 274], ["surface glycoproteins", "TREATMENT", 275, 296], ["possesses acetyl", "TREATMENT", 301, 317], ["accessory proteins", "OBSERVATION", 23, 41], ["subgenomic RNAs", "OBSERVATION", 62, 77], ["Genomic Structure", "OBSERVATION", 165, 182]]], ["Besides coronavirus-conserved genes, the SARS-CoV, SARS-CoV-2 and MERS-CoV genomes contain several specific accessory genes including ORF3a/b, 4a/b, ORF5, ORF6, ORF7a/b, ORF8a/b and 9b ( Figure 4) [4, 48, 49] .", [["coronavirus", "ORGANISM", 8, 19], ["SARS-CoV", "ORGANISM", 41, 49], ["SARS-CoV-2", "ORGANISM", 51, 61], ["MERS-CoV", "ORGANISM", 66, 74], ["ORF3a", "GENE_OR_GENE_PRODUCT", 134, 139], ["b", "GENE_OR_GENE_PRODUCT", 140, 141], ["4a", "GENE_OR_GENE_PRODUCT", 143, 145], ["b", "GENE_OR_GENE_PRODUCT", 146, 147], ["ORF5", "GENE_OR_GENE_PRODUCT", 149, 153], ["ORF6", "GENE_OR_GENE_PRODUCT", 155, 159], ["ORF7a", "GENE_OR_GENE_PRODUCT", 161, 166], ["b", "GENE_OR_GENE_PRODUCT", 167, 168], ["ORF8a", "GENE_OR_GENE_PRODUCT", 170, 175], ["coronavirus-conserved genes", "DNA", 8, 35], ["SARS-CoV, SARS-CoV-2 and MERS-CoV genomes", "DNA", 41, 82], ["accessory genes", "DNA", 108, 123], ["ORF3a", "DNA", 134, 139], ["ORF5", "DNA", 149, 153], ["ORF6", "DNA", 155, 159], ["ORF7a", "DNA", 161, 166], ["b", "DNA", 167, 168], ["ORF8a", "DNA", 170, 175], ["b", "DNA", 176, 177], ["9b", "DNA", 182, 184], ["SARS-CoV", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 66, 74], ["coronavirus", "PROBLEM", 8, 19], ["the SARS", "TEST", 37, 45], ["CoV", "TEST", 46, 49], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["MERS", "PROBLEM", 66, 70], ["ORF6", "TEST", 155, 159], ["ORF7a", "TEST", 161, 166], ["ORF8a", "TEST", 170, 175], ["Figure", "TEST", 187, 193], ["coronavirus", "OBSERVATION", 8, 19]]], ["All the structural and accessory proteins are translated from subgenomic RNAs (sgRNAs) generated during genome transcription/replication of CoVs [4] .Attachment, Entry and Life Cycle of HCoVsAttachment, cell entry, translation of viral replicase, genome replication, translation of structural proteins and virion assembly and release are the phases of coronavirus replication cycle [4, 50] .", [["cell", "ANATOMY", 203, 207], ["sgRNAs", "GENE_OR_GENE_PRODUCT", 79, 85], ["cell", "CELL", 203, 207], ["virion", "CELLULAR_COMPONENT", 306, 312], ["coronavirus", "ORGANISM", 352, 363], ["accessory proteins", "PROTEIN", 23, 41], ["subgenomic RNAs", "RNA", 62, 77], ["sgRNAs", "DNA", 79, 85], ["viral replicase", "PROTEIN", 230, 245], ["structural proteins", "PROTEIN", 282, 301], ["subgenomic RNAs (sgRNAs)", "PROBLEM", 62, 86], ["genome transcription", "TREATMENT", 104, 124], ["CoVs", "PROBLEM", 140, 144], ["HCoVsAttachment", "TREATMENT", 186, 201], ["cell entry", "TREATMENT", 203, 213], ["viral replicase", "TREATMENT", 230, 245], ["genome replication", "TREATMENT", 247, 265], ["structural proteins", "PROBLEM", 282, 301], ["virion assembly", "TREATMENT", 306, 321], ["coronavirus replication cycle", "TREATMENT", 352, 381], ["accessory proteins", "OBSERVATION", 23, 41], ["subgenomic RNAs", "OBSERVATION", 62, 77], ["viral replicase", "OBSERVATION", 230, 245]]], ["SARS-CoV, MERS-CoV and SARS-CoV-2 bind to different host receptors to gain entry into host cells [4, 51, 52] .", [["cells", "ANATOMY", 91, 96], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 10, 18], ["SARS-CoV-2", "ORGANISM", 23, 33], ["cells", "CELL", 91, 96], ["MERS-CoV and SARS-CoV-2", "DNA", 10, 33], ["host cells", "CELL_TYPE", 86, 96], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 0, 4], ["SARS", "PROBLEM", 23, 27], ["CoV-2 bind", "TREATMENT", 28, 38], ["different host receptors", "TREATMENT", 42, 66]]], ["Viral entry is mediated by the transmembrane S glycoprotein that comprises two functional subunits (S1 and S2 subunits) responsible for receptor recognition and viral-host cell membranes fusion, respectively [53, 54] .", [["transmembrane", "ANATOMY", 31, 44], ["cell membranes", "ANATOMY", 172, 186], ["transmembrane", "CELLULAR_COMPONENT", 31, 44], ["S1", "GENE_OR_GENE_PRODUCT", 100, 102], ["S2", "GENE_OR_GENE_PRODUCT", 107, 109], ["cell membranes", "CELLULAR_COMPONENT", 172, 186], ["transmembrane S glycoprotein", "PROTEIN", 31, 59], ["S1", "PROTEIN", 100, 102], ["S2 subunits", "PROTEIN", 107, 118], ["Viral entry", "PROBLEM", 0, 11], ["the transmembrane S glycoprotein", "TREATMENT", 27, 59], ["S1 and S2 subunits", "TREATMENT", 100, 118], ["receptor recognition", "TEST", 136, 156], ["viral-host cell membranes fusion", "TREATMENT", 161, 193], ["viral", "OBSERVATION_MODIFIER", 161, 166], ["host cell membranes fusion", "OBSERVATION", 167, 193]]], ["S1 receptor-binding domain (RBD) mediates binding to the cognate host cell receptor; however, the S2 domain mediates the fusion events, between viral envelope and host cell membrane [52, 55, 56] .", [["cell", "ANATOMY", 70, 74], ["cell membrane", "ANATOMY", 168, 181], ["S1 receptor-binding domain", "GENE_OR_GENE_PRODUCT", 0, 26], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 65, 83], ["S2", "GENE_OR_GENE_PRODUCT", 98, 100], ["host cell membrane", "CELLULAR_COMPONENT", 163, 181], ["S1 receptor-binding domain", "PROTEIN", 0, 26], ["RBD", "PROTEIN", 28, 31], ["cognate host cell receptor", "PROTEIN", 57, 83], ["S2 domain", "PROTEIN", 98, 107], ["S1 receptor-binding domain (RBD) mediates binding", "PROBLEM", 0, 49], ["the S2 domain mediates the fusion events", "PROBLEM", 94, 134], ["viral envelope", "PROBLEM", 144, 158], ["host cell membrane", "TEST", 163, 181], ["binding domain", "OBSERVATION", 12, 26], ["fusion", "OBSERVATION", 121, 127], ["host cell membrane", "OBSERVATION", 163, 181]]], ["As recently found, SARS-CoV-2 uses the same ACE2 receptor [57] , as SARS-CoV, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4, also known as CD26) receptor (Table 1 ) [58] .", [["SARS-CoV-2", "ORGANISM", 19, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["SARS-CoV", "ORGANISM", 68, 76], ["MERS-CoV", "ORGANISM", 86, 94], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 100, 122], ["DPP4", "GENE_OR_GENE_PRODUCT", 124, 128], ["CD26", "GENE_OR_GENE_PRODUCT", 144, 148], ["ACE2 receptor", "PROTEIN", 44, 57], ["MERS-CoV", "PROTEIN", 86, 94], ["dipeptidyl peptidase 4", "PROTEIN", 100, 122], ["DPP4", "PROTEIN", 124, 128], ["CD26", "PROTEIN", 144, 148], ["SARS-CoV", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 86, 94], ["SARS", "PROBLEM", 19, 23], ["CoV", "TEST", 24, 27], ["the same ACE2 receptor", "TEST", 35, 57], ["SARS", "TEST", 68, 72], ["dipeptidyl peptidase", "TREATMENT", 100, 120]]], ["The fusion of the S protein to the plasma membrane of host cell generates a double membrane vesicle in the host cell, thereby allowing release of the nucleocapsid into the cytoplasm, followed by genome transcription [53, 54] .", [["plasma membrane", "ANATOMY", 35, 50], ["cell", "ANATOMY", 59, 63], ["membrane vesicle", "ANATOMY", 83, 99], ["cell", "ANATOMY", 112, 116], ["cytoplasm", "ANATOMY", 172, 181], ["plasma membrane", "CELLULAR_COMPONENT", 35, 50], ["host cell", "CELL", 54, 63], ["membrane vesicle", "CELLULAR_COMPONENT", 83, 99], ["host cell", "CELL", 107, 116], ["nucleocapsid", "CELLULAR_COMPONENT", 150, 162], ["cytoplasm", "ORGANISM_SUBSTANCE", 172, 181], ["S protein", "PROTEIN", 18, 27], ["host cell", "CELL_TYPE", 54, 63], ["host cell", "CELL_TYPE", 107, 116], ["The fusion", "TREATMENT", 0, 10], ["the S protein", "TEST", 14, 27], ["host cell", "PROBLEM", 54, 63], ["a double membrane vesicle", "PROBLEM", 74, 99], ["fusion", "OBSERVATION", 4, 10], ["host cell", "OBSERVATION", 54, 63], ["double membrane vesicle", "OBSERVATION", 76, 99], ["host cell", "OBSERVATION", 107, 116]]], ["Upon entry into the cell, virus-specific RNA and proteins are synthesized, probably entirely in the cytoplasm.", [["cell", "ANATOMY", 20, 24], ["cytoplasm", "ANATOMY", 100, 109], ["cell", "CELL", 20, 24], ["cytoplasm", "ORGANISM_SUBSTANCE", 100, 109], ["cell", "ANATOMY", 20, 24], ["probably entirely", "UNCERTAINTY", 75, 92], ["cytoplasm", "OBSERVATION", 100, 109]]], ["Translation starts with the expression of two polyproteins, pp1a and pp1ab, which undergo co-translational proteolytic processing into the proteins that form the replicase complex.", [["pp1a", "GENE_OR_GENE_PRODUCT", 60, 64], ["pp1ab", "GENE_OR_GENE_PRODUCT", 69, 74], ["polyproteins", "PROTEIN", 46, 58], ["pp1a", "PROTEIN", 60, 64], ["pp1ab", "PROTEIN", 69, 74], ["replicase complex", "PROTEIN", 162, 179], ["pp1ab", "TREATMENT", 69, 74], ["co-translational proteolytic processing", "TREATMENT", 90, 129]]], ["This complex is used to transcribe a 3\u2032-coterminal set of nested subgenomic mRNAs, as well as genomic RNA that have a common 5\u2032 \"leader\" sequence derived from the 5\u2032 end of the genome.", [["genome", "CELLULAR_COMPONENT", 177, 183], ["nested subgenomic mRNAs", "RNA", 58, 81], ["genomic RNA", "RNA", 94, 105], ["5\u2032 \"leader\" sequence", "DNA", 125, 145], ["5\u2032 end", "DNA", 163, 169], ["nested subgenomic mRNAs", "PROBLEM", 58, 81], ["subgenomic mRNAs", "OBSERVATION", 65, 81], ["genome", "OBSERVATION", 177, 183]]], ["New virions are assembled by budding into intracellular membranes of the pre-Golgi compartment and released through the cell secretory mechanisms [4, 42, 48, 50] .Attachment, Entry and Life Cycle of HCoVsAttachment, cell entry, translation of viral replicase, genome replication, translation of structural proteins and virion assembly and release are the phases of coronavirus replication cycle [4, 50] .", [["virions", "ANATOMY", 4, 11], ["intracellular membranes", "ANATOMY", 42, 65], ["pre-Golgi compartment", "ANATOMY", 73, 94], ["cell", "ANATOMY", 120, 124], ["cell", "ANATOMY", 216, 220], ["intracellular membranes", "CELLULAR_COMPONENT", 42, 65], ["pre-Golgi compartment", "CELLULAR_COMPONENT", 73, 94], ["cell", "CELL", 120, 124], ["cell", "CELL", 216, 220], ["virion", "CELLULAR_COMPONENT", 319, 325], ["coronavirus", "ORGANISM", 365, 376], ["viral replicase", "PROTEIN", 243, 258], ["structural proteins", "PROTEIN", 295, 314], ["New virions", "PROBLEM", 0, 11], ["HCoVsAttachment", "TREATMENT", 199, 214], ["cell entry", "TREATMENT", 216, 226], ["viral replicase", "TREATMENT", 243, 258], ["genome replication", "TREATMENT", 260, 278], ["structural proteins", "PROBLEM", 295, 314], ["virion assembly", "TREATMENT", 319, 334], ["coronavirus replication cycle", "TREATMENT", 365, 394], ["virions", "OBSERVATION", 4, 11], ["intracellular membranes", "OBSERVATION", 42, 65], ["viral replicase", "OBSERVATION", 243, 258]]], ["SARS-CoV, MERS-CoV and SARS-CoV-2 bind to different host receptors to gain entry into host cells [4, 51, 52] .", [["cells", "ANATOMY", 91, 96], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 10, 18], ["SARS-CoV-2", "ORGANISM", 23, 33], ["cells", "CELL", 91, 96], ["MERS-CoV and SARS-CoV-2", "DNA", 10, 33], ["host cells", "CELL_TYPE", 86, 96], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 0, 4], ["SARS", "PROBLEM", 23, 27], ["CoV-2 bind", "TREATMENT", 28, 38], ["different host receptors", "TREATMENT", 42, 66]]], ["Viral entry is mediated by the transmembrane S glycoprotein that comprises two functional subunits (S1 and S2 subunits) responsible for receptor recognition and viral-host cell membranes fusion, respectively [53, 54] .", [["transmembrane", "ANATOMY", 31, 44], ["cell membranes", "ANATOMY", 172, 186], ["transmembrane", "CELLULAR_COMPONENT", 31, 44], ["S1", "GENE_OR_GENE_PRODUCT", 100, 102], ["S2", "GENE_OR_GENE_PRODUCT", 107, 109], ["cell membranes", "CELLULAR_COMPONENT", 172, 186], ["transmembrane S glycoprotein", "PROTEIN", 31, 59], ["S1", "PROTEIN", 100, 102], ["S2 subunits", "PROTEIN", 107, 118], ["Viral entry", "PROBLEM", 0, 11], ["the transmembrane S glycoprotein", "TREATMENT", 27, 59], ["S1 and S2 subunits", "TREATMENT", 100, 118], ["receptor recognition", "TEST", 136, 156], ["viral-host cell membranes fusion", "TREATMENT", 161, 193], ["viral", "OBSERVATION_MODIFIER", 161, 166], ["host cell membranes fusion", "OBSERVATION", 167, 193]]], ["S1 receptor-binding domain (RBD) mediates binding to the cognate host cell receptor; however, the S2 domain mediates the fusion events, between viral envelope and host cell membrane [52, 55, 56] .", [["cell", "ANATOMY", 70, 74], ["cell membrane", "ANATOMY", 168, 181], ["S1 receptor-binding domain", "GENE_OR_GENE_PRODUCT", 0, 26], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 65, 83], ["S2", "GENE_OR_GENE_PRODUCT", 98, 100], ["host cell membrane", "CELLULAR_COMPONENT", 163, 181], ["S1 receptor-binding domain", "PROTEIN", 0, 26], ["RBD", "PROTEIN", 28, 31], ["cognate host cell receptor", "PROTEIN", 57, 83], ["S2 domain", "PROTEIN", 98, 107], ["S1 receptor-binding domain (RBD) mediates binding", "PROBLEM", 0, 49], ["the S2 domain mediates the fusion events", "PROBLEM", 94, 134], ["viral envelope", "PROBLEM", 144, 158], ["host cell membrane", "TEST", 163, 181], ["binding domain", "OBSERVATION", 12, 26], ["fusion", "OBSERVATION", 121, 127], ["host cell membrane", "OBSERVATION", 163, 181]]], ["As recently found, SARS-CoV-2 uses the same ACE2 receptor [57] , as SARS-CoV, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4, also known as CD26) receptor (Table 1 ) [58] .", [["SARS-CoV-2", "ORGANISM", 19, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["SARS-CoV", "ORGANISM", 68, 76], ["MERS-CoV", "ORGANISM", 86, 94], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 100, 122], ["DPP4", "GENE_OR_GENE_PRODUCT", 124, 128], ["CD26", "GENE_OR_GENE_PRODUCT", 144, 148], ["ACE2 receptor", "PROTEIN", 44, 57], ["MERS-CoV", "PROTEIN", 86, 94], ["dipeptidyl peptidase 4", "PROTEIN", 100, 122], ["DPP4", "PROTEIN", 124, 128], ["CD26", "PROTEIN", 144, 148], ["SARS-CoV", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 86, 94], ["SARS", "PROBLEM", 19, 23], ["CoV", "TEST", 24, 27], ["the same ACE2 receptor", "TEST", 35, 57], ["SARS", "TEST", 68, 72], ["dipeptidyl peptidase", "TREATMENT", 100, 120]]], ["The fusion of the S protein to the plasma membrane of host cell generates a double membrane vesicle in the host cell, thereby allowing release of the nucleocapsid into the cytoplasm, followed by genome transcription [53, 54] .", [["plasma membrane", "ANATOMY", 35, 50], ["cell", "ANATOMY", 59, 63], ["membrane vesicle", "ANATOMY", 83, 99], ["cell", "ANATOMY", 112, 116], ["cytoplasm", "ANATOMY", 172, 181], ["plasma membrane", "CELLULAR_COMPONENT", 35, 50], ["host cell", "CELL", 54, 63], ["membrane vesicle", "CELLULAR_COMPONENT", 83, 99], ["host cell", "CELL", 107, 116], ["nucleocapsid", "CELLULAR_COMPONENT", 150, 162], ["cytoplasm", "ORGANISM_SUBSTANCE", 172, 181], ["S protein", "PROTEIN", 18, 27], ["host cell", "CELL_TYPE", 54, 63], ["host cell", "CELL_TYPE", 107, 116], ["The fusion", "TREATMENT", 0, 10], ["the S protein", "TEST", 14, 27], ["host cell", "PROBLEM", 54, 63], ["a double membrane vesicle", "PROBLEM", 74, 99], ["fusion", "OBSERVATION", 4, 10], ["host cell", "OBSERVATION", 54, 63], ["double membrane vesicle", "OBSERVATION", 76, 99], ["host cell", "OBSERVATION", 107, 116]]], ["Upon entry into the cell, virus-specific RNA and proteins are synthesized, probably entirely in the cytoplasm.", [["cell", "ANATOMY", 20, 24], ["cytoplasm", "ANATOMY", 100, 109], ["cell", "CELL", 20, 24], ["cytoplasm", "ORGANISM_SUBSTANCE", 100, 109], ["cell", "ANATOMY", 20, 24], ["probably entirely", "UNCERTAINTY", 75, 92], ["cytoplasm", "OBSERVATION", 100, 109]]], ["Translation starts with the expression of two polyproteins, pp1a and pp1ab, which undergo co-translational proteolytic processing into the proteins that form the replicase complex.", [["pp1a", "GENE_OR_GENE_PRODUCT", 60, 64], ["pp1ab", "GENE_OR_GENE_PRODUCT", 69, 74], ["polyproteins", "PROTEIN", 46, 58], ["pp1a", "PROTEIN", 60, 64], ["pp1ab", "PROTEIN", 69, 74], ["replicase complex", "PROTEIN", 162, 179], ["pp1ab", "TREATMENT", 69, 74], ["co-translational proteolytic processing", "TREATMENT", 90, 129]]], ["This complex is used to transcribe a 3 -coterminal set of nested subgenomic mRNAs, as well as genomic RNA that have a common 5 \"leader\" sequence derived from the 5 end of the genome.", [["genome", "CELLULAR_COMPONENT", 175, 181], ["nested subgenomic mRNAs", "RNA", 58, 81], ["genomic RNA", "RNA", 94, 105], ["5 \"leader\" sequence", "DNA", 125, 144], ["5 end", "DNA", 162, 167], ["nested subgenomic mRNAs", "PROBLEM", 58, 81], ["subgenomic mRNAs", "OBSERVATION", 65, 81]]], ["New virions are assembled by budding into intracellular membranes of the pre-Golgi compartment and released through the cell secretory mechanisms [4, 42, 48, 50] . , the 3\u2032-terminus of the SARS-CoV-2 and SARS-CoV genomes contain eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and orf14 and 3a, 3b, p6, 7a, 7b, 8a, 8b and 9b, respectively) while MERS-CoV genome contains only five (3, 4a, 4b, 5 and 8b).", [["virions", "ANATOMY", 4, 11], ["intracellular membranes", "ANATOMY", 42, 65], ["pre-Golgi compartment", "ANATOMY", 73, 94], ["cell", "ANATOMY", 120, 124], ["intracellular membranes", "CELLULAR_COMPONENT", 42, 65], ["pre-Golgi compartment", "CELLULAR_COMPONENT", 73, 94], ["cell", "CELL", 120, 124], ["SARS-CoV-2", "ORGANISM", 189, 199], ["SARS-CoV", "ORGANISM", 204, 212], ["3", "GENE_OR_GENE_PRODUCT", 259, 260], ["b", "GENE_OR_GENE_PRODUCT", 260, 261], ["p6", "GENE_OR_GENE_PRODUCT", 263, 265], ["7a", "GENE_OR_GENE_PRODUCT", 267, 269], ["7b", "GENE_OR_GENE_PRODUCT", 271, 273], ["b", "GENE_OR_GENE_PRODUCT", 276, 277], ["b", "GENE_OR_GENE_PRODUCT", 280, 281], ["orf14", "GENE_OR_GENE_PRODUCT", 286, 291], ["3a", "GENE_OR_GENE_PRODUCT", 296, 298], ["3", "GENE_OR_GENE_PRODUCT", 300, 301], ["b", "GENE_OR_GENE_PRODUCT", 301, 302], ["p6", "GENE_OR_GENE_PRODUCT", 304, 306], ["7a", "GENE_OR_GENE_PRODUCT", 308, 310], ["7b", "GENE_OR_GENE_PRODUCT", 312, 314], ["8a", "GENE_OR_GENE_PRODUCT", 316, 318], ["b", "GENE_OR_GENE_PRODUCT", 321, 322], ["9b", "GENE_OR_GENE_PRODUCT", 327, 329], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 351, 359], ["3\u2032-terminus", "PROTEIN", 170, 181], ["SARS-CoV-2 and SARS-CoV genomes", "DNA", 189, 220], ["3a, 3b, p6, 7a, 7b, 8b, 9b and orf14 and 3a, 3b, p6, 7a, 7b, 8a, 8b and 9b", "PROTEIN", 255, 329], ["MERS-CoV genome", "DNA", 351, 366], ["SARS-CoV", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 204, 212], ["MERS-CoV", "SPECIES", 351, 359], ["New virions", "PROBLEM", 0, 11], ["the SARS", "TEST", 185, 193], ["CoV", "TEST", 194, 197], ["SARS", "PROBLEM", 204, 208], ["CoV genomes", "TEST", 209, 220], ["eight accessory proteins", "TEST", 229, 253], ["p6", "TEST", 263, 265], ["7b", "TEST", 271, 273], ["orf", "TEST", 286, 289], ["3a", "TEST", 296, 298], ["p6", "TEST", 304, 306], ["7a", "TEST", 308, 310], ["7b", "TEST", 312, 314], ["9b", "TEST", 327, 329], ["MERS", "TEST", 351, 355], ["CoV genome", "TEST", 356, 366], ["virions", "OBSERVATION", 4, 11], ["intracellular membranes", "OBSERVATION", 42, 65], ["SARS", "OBSERVATION", 189, 193], ["eight", "OBSERVATION_MODIFIER", 229, 234], ["accessory proteins", "OBSERVATION", 235, 253], ["CoV genome", "OBSERVATION", 356, 366]]], ["The genes encoding accessory proteins are unique in different coronaviruses in terms of number, genomic organization, sequence and functions (data extracted from [35, 49, 57] The coronavirus genomes encode two replicase polypeptides pp1a and pp1ab translated from ORF1a and ORF1b; four structural genes encoding for four structural proteins including (S) spike, (M) membrane, (E) envelope and (N) nucleocapsid proteins.", [["coronavirus", "ORGANISM", 179, 190], ["pp1a", "GENE_OR_GENE_PRODUCT", 233, 237], ["pp1ab", "GENE_OR_GENE_PRODUCT", 242, 247], ["ORF1a", "GENE_OR_GENE_PRODUCT", 264, 269], ["ORF1b", "GENE_OR_GENE_PRODUCT", 274, 279], ["accessory proteins", "PROTEIN", 19, 37], ["coronavirus genomes", "DNA", 179, 198], ["replicase polypeptides", "PROTEIN", 210, 232], ["pp1a", "PROTEIN", 233, 237], ["pp1ab", "PROTEIN", 242, 247], ["ORF1a", "PROTEIN", 264, 269], ["ORF1b", "PROTEIN", 274, 279], ["structural proteins", "PROTEIN", 321, 340], ["(S) spike, (M) membrane, (E) envelope and (N) nucleocapsid proteins", "PROTEIN", 351, 418], ["coronavirus", "SPECIES", 179, 190], ["The genes encoding accessory proteins", "PROBLEM", 0, 37], ["The coronavirus genomes", "PROBLEM", 175, 198], ["replicase polypeptides pp1a", "TEST", 210, 237], ["pp1ab", "TEST", 242, 247], ["ORF1a", "TEST", 264, 269], ["ORF1b", "TREATMENT", 274, 279], ["four structural proteins", "PROBLEM", 316, 340], ["spike", "PROBLEM", 355, 360], ["envelope and (N) nucleocapsid proteins", "PROBLEM", 380, 418], ["accessory proteins", "OBSERVATION", 19, 37], ["different", "OBSERVATION_MODIFIER", 52, 61], ["coronaviruses", "OBSERVATION", 62, 75], ["genomic organization", "OBSERVATION", 96, 116], ["coronavirus genomes", "OBSERVATION", 179, 198]]], ["The single-stranded RNA genomes of SARS-CoV-2 (~29.8 kb), SARS-CoV (~29.7 kb) and MERS-CoV (~30.1 kb) harbor two large genes, the ORF1a (red) and 1b (blue) genes encoding accessory genes (nsps 1-16, shades of red and blue).", [["SARS-CoV-2", "ORGANISM", 35, 45], ["SARS-CoV", "ORGANISM", 58, 66], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["ORF1a (red)", "GENE_OR_GENE_PRODUCT", 130, 141], ["1b (blue)", "GENE_OR_GENE_PRODUCT", 146, 155], ["nsps 1-16", "GENE_OR_GENE_PRODUCT", 188, 197], ["single-stranded RNA genomes", "DNA", 4, 31], ["SARS-CoV-2", "DNA", 35, 45], ["SARS-CoV", "DNA", 58, 66], ["MERS-CoV", "DNA", 82, 90], ["ORF1a (red) and 1b (blue) genes", "DNA", 130, 161], ["accessory genes", "DNA", 171, 186], ["nsps 1-16", "DNA", 188, 197], ["red and blue", "DNA", 209, 221], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV-2", "SPECIES", 35, 45], ["SARS-CoV", "SPECIES", 58, 66], ["MERS-CoV", "SPECIES", 82, 90], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["kb", "TEST", 53, 55], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["kb", "TEST", 74, 76], ["MERS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["the ORF1a", "TEST", 126, 135], ["accessory genes", "TEST", 171, 186], ["nsps", "TEST", 188, 192], ["large", "OBSERVATION_MODIFIER", 113, 118], ["genes", "OBSERVATION", 119, 124], ["accessory genes", "OBSERVATION", 171, 186]]], ["Encoded nonstructural proteins: 16 nsps (nsp1-nsp16) in SARS-CoV-2, SARS-CoV and MERS-CoV.", [["nsps", "GENE_OR_GENE_PRODUCT", 35, 39], ["nsp1-nsp16", "GENE_OR_GENE_PRODUCT", 41, 51], ["SARS-CoV-2", "ORGANISM", 56, 66], ["SARS-CoV", "ORGANISM", 68, 76], ["MERS-CoV", "ORGANISM", 81, 89], ["Encoded nonstructural proteins", "PROTEIN", 0, 30], ["nsps", "PROTEIN", 35, 39], ["nsp1", "PROTEIN", 41, 45], ["nsp16", "PROTEIN", 46, 51], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 81, 89], ["Encoded nonstructural proteins", "TEST", 0, 30], ["nsps", "TEST", 35, 39], ["nsp1", "TEST", 41, 45], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["SARS", "PROBLEM", 68, 72], ["nonstructural proteins", "OBSERVATION", 8, 30]]], ["Along with structural proteins (S, E, M and N), the 3 -terminus of the SARS-CoV-2 and SARS-CoV genomes contain eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and orf14 and 3a, 3b, p6, 7a, 7b, 8a, 8b and 9b, respectively) while MERS-CoV genome contains only five (3, 4a, 4b, 5 and 8b).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 71, 81], ["SARS-CoV", "ORGANISM", 86, 94], ["3", "GENE_OR_GENE_PRODUCT", 141, 142], ["p6", "GENE_OR_GENE_PRODUCT", 145, 147], ["7a", "GENE_OR_GENE_PRODUCT", 149, 151], ["7b", "GENE_OR_GENE_PRODUCT", 153, 155], ["b", "GENE_OR_GENE_PRODUCT", 158, 159], ["b", "GENE_OR_GENE_PRODUCT", 162, 163], ["orf14", "GENE_OR_GENE_PRODUCT", 168, 173], ["3a", "GENE_OR_GENE_PRODUCT", 178, 180], ["3", "GENE_OR_GENE_PRODUCT", 182, 183], ["p6", "GENE_OR_GENE_PRODUCT", 186, 188], ["7a", "GENE_OR_GENE_PRODUCT", 190, 192], ["7b", "GENE_OR_GENE_PRODUCT", 194, 196], ["8a", "GENE_OR_GENE_PRODUCT", 198, 200], ["b", "GENE_OR_GENE_PRODUCT", 203, 204], ["9b", "GENE_OR_GENE_PRODUCT", 209, 211], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 233, 241], ["structural proteins", "PROTEIN", 11, 30], ["S", "PROTEIN", 32, 33], ["E", "PROTEIN", 35, 36], ["N", "PROTEIN", 44, 45], ["3 -terminus", "PROTEIN", 52, 63], ["SARS-CoV-2 and SARS-CoV genomes", "DNA", 71, 102], ["3a, 3b, p6, 7a, 7b, 8b, 9b and orf14 and 3a, 3b, p6, 7a, 7b, 8a, 8b and 9b", "PROTEIN", 137, 211], ["MERS-CoV genome", "DNA", 233, 248], ["SARS-CoV", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 86, 94], ["MERS-CoV", "SPECIES", 233, 241], ["structural proteins", "TEST", 11, 30], ["the SARS", "TEST", 67, 75], ["CoV", "TEST", 76, 79], ["SARS", "PROBLEM", 86, 90], ["CoV genomes", "TEST", 91, 102], ["eight accessory proteins", "TEST", 111, 135], ["p6", "TEST", 145, 147], ["7b", "TEST", 153, 155], ["orf", "TEST", 168, 171], ["3a", "TEST", 178, 180], ["p6", "TEST", 186, 188], ["7a", "TEST", 190, 192], ["7b", "TEST", 194, 196], ["9b", "TEST", 209, 211], ["MERS", "TEST", 233, 237], ["CoV genome", "TEST", 238, 248], ["4b", "TEST", 276, 278], ["accessory proteins", "OBSERVATION", 117, 135], ["CoV genome", "OBSERVATION", 238, 248]]], ["The genes encoding accessory proteins are unique in different coronaviruses in terms of number, genomic organization, sequence and functions (data extracted from [35, 49, 57]Pathogenesis and Mode of TransmissionVirologic as well as genetic studies have demonstrated that bats are reservoir hosts of both SARS-CoV and MERS-CoV, but also that they can use other species as intermediate hosts before spreading to humans [59, 60] .", [["SARS", "DISEASE", 304, 308], ["bats", "ORGANISM", 271, 275], ["SARS-CoV", "ORGANISM", 304, 312], ["MERS-CoV", "ORGANISM", 317, 325], ["humans", "ORGANISM", 410, 416], ["accessory proteins", "PROTEIN", 19, 37], ["humans", "SPECIES", 410, 416], ["SARS-CoV", "SPECIES", 304, 312], ["MERS-CoV", "SPECIES", 317, 325], ["humans", "SPECIES", 410, 416], ["The genes encoding accessory proteins", "PROBLEM", 0, 37], ["genetic studies", "TEST", 232, 247], ["accessory proteins", "OBSERVATION", 19, 37], ["different", "OBSERVATION_MODIFIER", 52, 61], ["coronaviruses", "OBSERVATION", 62, 75], ["genomic organization", "OBSERVATION", 96, 116]]], ["The detection of two genomes distinct from known swine in ill piglets were reported by two independent groups [61, 62] .", [["swine", "ORGANISM", 49, 54], ["piglets", "ORGANISM", 62, 69], ["swine", "SPECIES", 49, 54], ["piglets", "SPECIES", 62, 69], ["swine", "SPECIES", 49, 54], ["two genomes distinct", "PROBLEM", 17, 37], ["known swine in ill piglets", "PROBLEM", 43, 69], ["distinct", "OBSERVATION_MODIFIER", 29, 37], ["swine", "OBSERVATION_MODIFIER", 49, 54]]], ["The phylogenetic analyses showed that these novel swine enteric Alphacoronaviruses (SeACoVs) were strongly related to the Rhinolophus bat coronavirus HKU2 isolated in Guangdong Province, in southern China [61, 62] .", [["swine enteric Alphacoronaviruses", "ORGANISM", 50, 82], ["SeACoVs", "GENE_OR_GENE_PRODUCT", 84, 91], ["Rhinolophus bat coronavirus", "ORGANISM", 122, 149], ["HKU2", "ORGANISM", 150, 154], ["swine", "SPECIES", 50, 55], ["Rhinolophus bat coronavirus", "SPECIES", 122, 149], ["swine", "SPECIES", 50, 55], ["Rhinolophus bat coronavirus", "SPECIES", 122, 149], ["The phylogenetic analyses", "TEST", 0, 25], ["these novel swine enteric Alphacoronaviruses (SeACoVs)", "PROBLEM", 38, 92]]], ["This suggests that coronaviruses of bat origin may have 'jumped' the barrier of the species to infect pigs as intermediate hosts.", [["coronaviruses", "ORGANISM", 19, 32], ["bat", "ORGANISM", 36, 39], ["pigs", "ORGANISM", 102, 106], ["pigs", "SPECIES", 102, 106], ["pigs", "SPECIES", 102, 106], ["coronaviruses", "PROBLEM", 19, 32], ["coronaviruses", "OBSERVATION", 19, 32]]], ["The CD26 receptor sequence alignment between humans and pigs demonstrates a 94.5% overlap, which is sufficient for the possible cross-species transmission [63] .", [["CD26", "GENE_OR_GENE_PRODUCT", 4, 8], ["humans", "ORGANISM", 45, 51], ["pigs", "ORGANISM", 56, 60], ["CD26", "PROTEIN", 4, 8], ["humans", "SPECIES", 45, 51], ["pigs", "SPECIES", 56, 60], ["humans", "SPECIES", 45, 51], ["The CD26 receptor sequence alignment", "TEST", 0, 36]]], ["It has also been documented that pigs are susceptible to human SARS-CoV [64] and MERS-CoV infections [65] .", [["SARS", "DISEASE", 63, 67], ["MERS-CoV infections", "DISEASE", 81, 100], ["pigs", "ORGANISM", 33, 37], ["human", "ORGANISM", 57, 62], ["SARS-CoV", "ORGANISM", 63, 71], ["MERS-CoV", "ORGANISM", 81, 89], ["pigs", "SPECIES", 33, 37], ["human", "SPECIES", 57, 62], ["pigs", "SPECIES", 33, 37], ["human SARS-CoV", "SPECIES", 57, 71], ["MERS-CoV", "SPECIES", 81, 89], ["human SARS", "TEST", 57, 67], ["CoV infections", "PROBLEM", 86, 100]]], ["The large number of mutations within the RBD enabled viruses to infect new hosts, representing a potential threat for both animal and human health.", [["RBD", "GENE_OR_GENE_PRODUCT", 41, 44], ["human", "ORGANISM", 134, 139], ["RBD", "PROTEIN", 41, 44], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["mutations", "PROBLEM", 20, 29], ["the RBD", "PROBLEM", 37, 44], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["mutations", "OBSERVATION", 20, 29]]], ["In southern China, the unique climate, the high density of domestic as well as wild pigs, along with the extensive bat distribution and carriage of tremendous quantities of recombinant novel coronaviruses may result in the appearance of more novel coronaviruses in the future [66] .", [["pigs", "ORGANISM", 84, 88], ["coronaviruses", "ORGANISM", 191, 204], ["pigs", "SPECIES", 84, 88], ["recombinant novel coronaviruses", "PROBLEM", 173, 204], ["high density", "OBSERVATION_MODIFIER", 43, 55], ["extensive", "OBSERVATION_MODIFIER", 105, 114], ["bat", "OBSERVATION_MODIFIER", 115, 118], ["distribution", "OBSERVATION_MODIFIER", 119, 131]]], ["It is generally acknowledged that numerous viruses have existed and were restricted to their natural reservoirs for lengthy times [17] .", [["numerous viruses", "PROBLEM", 34, 50], ["numerous", "OBSERVATION_MODIFIER", 34, 42], ["viruses", "OBSERVATION", 43, 50]]], ["The consistent spillover of viruses from natural hosts to humans and other species is essentially related to human activities, including urbanization and modern agricultural practices, leading to the constant human exposure to the ever-changing mutant CoVs from their reservoirs [15, 17] .", [["humans", "ORGANISM", 58, 64], ["human", "ORGANISM", 109, 114], ["human", "ORGANISM", 209, 214], ["CoVs", "GENE_OR_GENE_PRODUCT", 252, 256], ["mutant CoVs", "PROTEIN", 245, 256], ["humans", "SPECIES", 58, 64], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 209, 214], ["humans", "SPECIES", 58, 64], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 209, 214], ["The consistent spillover of viruses", "PROBLEM", 0, 35], ["modern agricultural practices", "TREATMENT", 154, 183], ["spillover of viruses", "OBSERVATION", 15, 35]]], ["The close contact between humans and animals and the practice of eating raw meat are both risk factors for causing a new human CoV outbreak [15] .", [["meat", "ANATOMY", 76, 80], ["humans", "ORGANISM", 26, 32], ["meat", "ORGANISM_SUBDIVISION", 76, 80], ["human", "ORGANISM", 121, 126], ["humans", "SPECIES", 26, 32], ["human", "SPECIES", 121, 126], ["humans", "SPECIES", 26, 32], ["human CoV", "SPECIES", 121, 130], ["a new human CoV outbreak", "PROBLEM", 115, 139]]], ["Hence, COVID-19 should be considered as a zoonotic disease that spread from animals to humans.Pathogenesis and Mode of TransmissionFollowing the first SARS-CoV-2 outbreak in seafood and wildlife market in Wuhan, secondary cases started to be identified after ten days.", [["COVID-19", "CHEMICAL", 7, 15], ["zoonotic disease", "DISEASE", 42, 58], ["humans", "ORGANISM", 87, 93], ["humans", "SPECIES", 87, 93], ["humans", "SPECIES", 87, 93], ["COVID", "TEST", 7, 12], ["a zoonotic disease", "PROBLEM", 40, 58], ["zoonotic", "OBSERVATION_MODIFIER", 42, 50], ["disease", "OBSERVATION", 51, 58]]], ["Although these new patients did not have any contact with the market, they had a history of contact with people who attended the market [60] .", [["patients", "ORGANISM", 19, 27], ["people", "ORGANISM", 105, 111], ["patients", "SPECIES", 19, 27], ["people", "SPECIES", 105, 111], ["new", "OBSERVATION_MODIFIER", 15, 18]]], ["Therefore, similarly to SARS-CoV and unlikely to MERS-CoV, human-to-human transmission for SARS-CoV-2 has been reported and is currently considered as the main type of transmission worldwide [5, 19] .", [["SARS-CoV", "DISEASE", 24, 32], ["SARS", "DISEASE", 91, 95], ["SARS-CoV", "ORGANISM", 24, 32], ["MERS-CoV", "ORGANISM", 49, 57], ["human", "ORGANISM", 59, 64], ["human", "ORGANISM", 68, 73], ["SARS-CoV-2", "ORGANISM", 91, 101], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 68, 73], ["SARS-CoV", "SPECIES", 24, 32], ["MERS-CoV", "SPECIES", 49, 57], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 68, 73], ["SARS-CoV", "SPECIES", 91, 99], ["SARS", "TEST", 24, 28], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99]]], ["On January 13, 2020, Thailand announced the first non-Chinese case of infection that spread from the Chinese provinces, to the Asian continent [60] .", [["infection", "DISEASE", 70, 79], ["infection", "PROBLEM", 70, 79], ["infection", "OBSERVATION", 70, 79]]], ["More recently, Forster et al., by using phylogenetic analysis based on nucleotide mutations of 160 complete human SARS-CoV-2 genomes found that three variants of SARS-CoV-2 (A as the ancestral type, plus B and C) represent the bat outgroup coronaviruses.", [["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["human", "ORGANISM", 108, 113], ["SARS-CoV-2", "ORGANISM", 114, 124], ["SARS-CoV-2", "ORGANISM", 162, 172], ["A", "GENE_OR_GENE_PRODUCT", 174, 175], ["coronaviruses", "ORGANISM", 240, 253], ["160 complete human SARS-CoV-2 genomes", "DNA", 95, 132], ["SARS-CoV-2", "DNA", 162, 172], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["SARS-CoV", "SPECIES", 162, 170], ["phylogenetic analysis", "TEST", 40, 61], ["nucleotide mutations", "TEST", 71, 91], ["complete human SARS", "TEST", 99, 118], ["CoV", "TEST", 119, 122], ["SARS", "TEST", 162, 166], ["CoV", "TEST", 167, 170], ["the bat outgroup coronaviruses", "PROBLEM", 223, 253], ["outgroup coronaviruses", "OBSERVATION", 231, 253]]], ["In particular, the A and C types were found mostly in European-American patients, whereas the B type was common in East Asia suggesting that this kind of analysis could help in following the evolution of SARS-CoV-2 [67] .Human-to-Human Transmission and Viral ReservoirIt was demonstrated that SARS-CoVs have adapted themselves to bind to human ACE2 receptor and infect human cells effectively [68] .", [["cells", "ANATOMY", 375, 380], ["SARS", "DISEASE", 204, 208], ["A", "GENE_OR_GENE_PRODUCT", 19, 20], ["C", "GENE_OR_GENE_PRODUCT", 25, 26], ["patients", "ORGANISM", 72, 80], ["B type", "CELL", 94, 100], ["SARS-CoV-2", "ORGANISM", 204, 214], ["Human", "ORGANISM", 221, 226], ["Human", "ORGANISM", 230, 235], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 293, 302], ["human", "ORGANISM", 338, 343], ["ACE2", "GENE_OR_GENE_PRODUCT", 344, 348], ["human", "ORGANISM", 369, 374], ["cells", "CELL", 375, 380], ["human ACE2 receptor", "PROTEIN", 338, 357], ["human cells", "CELL_TYPE", 369, 380], ["patients", "SPECIES", 72, 80], ["Human", "SPECIES", 221, 226], ["Human", "SPECIES", 230, 235], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 369, 374], ["SARS-CoV", "SPECIES", 204, 212], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 369, 374], ["SARS", "PROBLEM", 204, 208], ["CoV", "TEST", 209, 212], ["Viral ReservoirIt", "TREATMENT", 253, 270], ["SARS", "PROBLEM", 293, 297], ["human ACE2 receptor", "TREATMENT", 338, 357]]], ["This form of adaptation required a series of amino acid changes in the RBD within the S protein of SARS viruses that circulated in bats [56, 68] .", [["amino acid", "CHEMICAL", 45, 55], ["SARS", "DISEASE", 99, 103], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 45, 55], ["SARS viruses", "ORGANISM", 99, 111], ["RBD", "PROTEIN", 71, 74], ["S protein", "PROTEIN", 86, 95], ["SARS viruses", "SPECIES", 99, 111], ["amino acid changes", "TREATMENT", 45, 63], ["the RBD", "PROBLEM", 67, 74], ["SARS viruses", "PROBLEM", 99, 111]]], ["Therefore, the human-to-human transmission that was seen in the course of the SARS-CoV outbreaks is directly attributable to the ability of SARS-CoVs to adapt their S protein to efficiently bind to human ACE2, thus infecting ciliated bronchial epithelial cells and type II pneumocytes [15, 69] .", [["ciliated bronchial epithelial cells", "ANATOMY", 225, 260], ["type II pneumocytes", "ANATOMY", 265, 284], ["SARS", "DISEASE", 78, 82], ["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 24, 29], ["SARS-CoV", "ORGANISM", 78, 86], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 140, 149], ["human", "ORGANISM", 198, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["ciliated bronchial epithelial cells", "CELL", 225, 260], ["type II pneumocytes", "CELL", 265, 284], ["S protein", "PROTEIN", 165, 174], ["human ACE2", "PROTEIN", 198, 208], ["ciliated bronchial epithelial cells", "CELL_TYPE", 225, 260], ["type II pneumocytes", "CELL_TYPE", 265, 284], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 24, 29], ["SARS-CoV", "SPECIES", 78, 86], ["human", "SPECIES", 198, 203], ["the SARS", "PROBLEM", 74, 82], ["CoV outbreaks", "PROBLEM", 83, 96], ["SARS", "PROBLEM", 140, 144], ["CoVs", "PROBLEM", 145, 149], ["their S protein", "TREATMENT", 159, 174], ["human ACE2", "TEST", 198, 208], ["infecting ciliated bronchial epithelial cells", "PROBLEM", 215, 260], ["type II pneumocytes", "PROBLEM", 265, 284], ["bronchial epithelial cells", "OBSERVATION", 234, 260]]], ["Similar to SARS-CoV, ACE2 is also used by SARS-CoV-2 as the entry receptor in the ACE2-expressing cells, suggesting that SARS-CoV-2 has a life cycle similar to SARS-CoV [56, 68] .", [["cells", "ANATOMY", 98, 103], ["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 160, 164], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 11, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["cells", "CELL", 98, 103], ["SARS-CoV-2", "ORGANISM", 121, 131], ["SARS-CoV", "ORGANISM", 160, 168], ["ACE2", "PROTEIN", 21, 25], ["ACE2", "PROTEIN", 82, 86], ["expressing cells", "CELL_TYPE", 87, 103], ["SARS-CoV", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 160, 168], ["ACE2", "TEST", 21, 25], ["CoV", "TEST", 47, 50], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["SARS", "OBSERVATION", 11, 15]]], ["As outlined before, SARS-CoV S protein regulates the receptor binding and membrane fusion activities determining host tropism and transmission capacity.", [["membrane", "ANATOMY", 74, 82], ["SARS-CoV S protein", "GENE_OR_GENE_PRODUCT", 20, 38], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["SARS-CoV S protein", "PROTEIN", 20, 38], ["SARS-CoV", "SPECIES", 20, 28], ["SARS-CoV S protein regulates", "TREATMENT", 20, 48], ["the receptor binding", "TREATMENT", 49, 69], ["membrane fusion activities", "TREATMENT", 74, 100], ["transmission capacity", "TEST", 130, 151], ["membrane fusion", "OBSERVATION", 74, 89]]], ["Several evidences highlighted a higher binding affinity of SARS-CoV-2 RBD to the ACE2 receptor.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 81, 94], ["SARS-CoV-2 RBD", "PROTEIN", 59, 73], ["ACE2 receptor", "PROTEIN", 81, 94], ["a higher binding affinity of SARS", "PROBLEM", 30, 63], ["CoV", "TEST", 64, 67]]], ["In particular, molecular and in silico analyses demonstrated that SARS-CoV-2 RBD conformation and amino acid composition enhance the bonding between the S protein and ACE2 receptor [51, 70, 71] .", [["amino acid", "CHEMICAL", 98, 108], ["amino acid", "CHEMICAL", 98, 108], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 66, 76], ["amino acid", "AMINO_ACID", 98, 108], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 167, 180], ["RBD", "PROTEIN", 77, 80], ["S protein", "PROTEIN", 153, 162], ["ACE2 receptor", "PROTEIN", 167, 180], ["silico analyses", "TEST", 32, 47], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["amino acid composition", "TREATMENT", 98, 120], ["the S protein", "TEST", 149, 162], ["ACE2 receptor", "TEST", 167, 180]]], ["A recent biophysical and structural analysis of the SARS-CoV-2 S protein showed that it binds to ACE2 receptor with about 10-to 20-fold higher affinity than the S protein of SARS-CoV [52, 72] .", [["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 52, 64], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 97, 110], ["SARS-CoV", "ORGANISM", 174, 182], ["SARS-CoV-2 S protein", "PROTEIN", 52, 72], ["ACE2 receptor", "PROTEIN", 97, 110], ["S protein", "PROTEIN", 161, 170], ["SARS-CoV", "SPECIES", 174, 182], ["structural analysis", "TEST", 25, 44], ["the SARS", "TEST", 48, 56], ["CoV-2 S protein", "TEST", 57, 72], ["ACE2 receptor", "TEST", 97, 110], ["the S protein", "TEST", 157, 170], ["CoV", "TEST", 179, 182]]], ["This high affinity could account for its extreme infectivity among human populations.", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["This high affinity", "PROBLEM", 0, 18], ["its extreme infectivity", "PROBLEM", 37, 60]]], ["Another feature of the powerful infectivity of SARS-CoV-2 is that the shedding pattern of viral particles in SARS-CoV-2 diagnosed patients is similar to that of influenza patients in which viral loads at the time of symptom onset are higher and gradually decrease within days; interestingly, this pattern seems to be different from that reported for SARS-CoV patients where the highest shedding is reported 10 days after the onset of symptoms [20, 73, 74] .", [["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 109, 113], ["influenza", "DISEASE", 161, 170], ["SARS-CoV", "DISEASE", 350, 358], ["SARS-CoV-2", "ORGANISM", 47, 57], ["SARS-CoV-2", "ORGANISM", 109, 119], ["patients", "ORGANISM", 130, 138], ["influenza", "ORGANISM", 161, 170], ["patients", "ORGANISM", 171, 179], ["SARS-CoV", "ORGANISM", 350, 358], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 171, 179], ["patients", "SPECIES", 359, 367], ["SARS-CoV", "SPECIES", 47, 55], ["SARS-CoV", "SPECIES", 109, 117], ["SARS-CoV", "SPECIES", 350, 358], ["SARS", "PROBLEM", 47, 51], ["viral particles", "PROBLEM", 90, 105], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["influenza", "PROBLEM", 161, 170], ["viral loads", "PROBLEM", 189, 200], ["symptom", "PROBLEM", 216, 223], ["SARS", "PROBLEM", 350, 354], ["symptoms", "PROBLEM", 434, 442], ["powerful", "OBSERVATION_MODIFIER", 23, 31], ["infectivity", "OBSERVATION", 32, 43], ["viral particles", "OBSERVATION", 90, 105], ["higher", "OBSERVATION_MODIFIER", 234, 240], ["gradually", "OBSERVATION_MODIFIER", 245, 254], ["decrease", "OBSERVATION_MODIFIER", 255, 263]]], ["These results indicate that SARS-CoV-2 can spread more easily than SARS-CoV in the community even in the absence of symptoms or when only initial mild symptoms are present [75] .Human-to-Human Transmission and Viral ReservoirThe human-to-human transmission of SARS-CoV-2 mainly occurs by inhalation of respiratory droplets spread by coughing or sneezing from an infected individual, but also by direct contact of contaminated surfaces and then touching the nose, mouth and eyes [24, [76] [77] [78] .", [["respiratory droplets", "ANATOMY", 302, 322], ["nose", "ANATOMY", 457, 461], ["mouth", "ANATOMY", 463, 468], ["eyes", "ANATOMY", 473, 477], ["SARS", "DISEASE", 67, 71], ["SARS", "DISEASE", 260, 264], ["coughing", "DISEASE", 333, 341], ["SARS-CoV-2", "ORGANISM", 28, 38], ["SARS-CoV", "ORGANISM", 67, 75], ["Human", "ORGANISM", 178, 183], ["Human", "ORGANISM", 187, 192], ["human", "ORGANISM", 229, 234], ["human", "ORGANISM", 238, 243], ["SARS-CoV-2", "ORGANISM", 260, 270], ["nose", "ORGANISM_SUBDIVISION", 457, 461], ["mouth", "ORGANISM_SUBDIVISION", 463, 468], ["eyes", "ORGAN", 473, 477], ["Human", "SPECIES", 178, 183], ["Human", "SPECIES", 187, 192], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 238, 243], ["SARS-CoV", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 67, 75], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 238, 243], ["SARS-CoV", "SPECIES", 260, 268], ["SARS", "PROBLEM", 28, 32], ["symptoms", "PROBLEM", 116, 124], ["initial mild symptoms", "PROBLEM", 138, 159], ["Viral Reservoir", "TREATMENT", 210, 225], ["SARS", "PROBLEM", 260, 264], ["respiratory droplets", "PROBLEM", 302, 322], ["coughing", "PROBLEM", 333, 341], ["sneezing", "PROBLEM", 345, 353], ["an infected individual", "PROBLEM", 359, 381], ["respiratory droplets", "OBSERVATION", 302, 322], ["infected", "OBSERVATION", 362, 370], ["nose", "ANATOMY", 457, 461], ["mouth", "ANATOMY", 463, 468], ["eyes", "ANATOMY", 473, 477]]], ["The virus was shown to remain stable in favorable atmospheric conditions on different surfaces for days [79] .", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["stable", "OBSERVATION_MODIFIER", 30, 36], ["favorable", "OBSERVATION_MODIFIER", 40, 49], ["atmospheric conditions", "OBSERVATION", 50, 72]]], ["Additionally, transmission in an unventilated environment or closed spaces due to high aerosol concentrations has been suggested [76, 77] .", [["closed spaces", "PROBLEM", 61, 74], ["high aerosol concentrations", "PROBLEM", 82, 109]]], ["In agreement, the presence of SARS-CoV-2 in the surfaces of the houses of confirmed patients was reported, further strengthening this mode of contact transmission.", [["SARS", "DISEASE", 30, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38]]], ["Moreover, live viruses were also found in the stool of COVID-19 patients, as previously found for both SARS-CoV and MERS-CoV [77] .", [["stool", "ANATOMY", 46, 51], ["stool", "ORGANISM_SUBSTANCE", 46, 51], ["patients", "ORGANISM", 64, 72], ["SARS-CoV", "ORGANISM", 103, 111], ["MERS-CoV", "ORGANISM", 116, 124], ["patients", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 103, 111], ["MERS-CoV", "SPECIES", 116, 124], ["live viruses", "PROBLEM", 10, 22], ["COVID", "TEST", 55, 60]]], ["Given its capacity for survival in feces and the expression of ACE2 within intestine, it was demonstrated that SARS-CoV-2 can infect these tissues and can be released in feces; therefore, water supply contamination and fecal-oral route transmission is also hypothesized [24, 80] .", [["feces", "ANATOMY", 35, 40], ["intestine", "ANATOMY", 75, 84], ["tissues", "ANATOMY", 139, 146], ["feces", "ANATOMY", 170, 175], ["oral", "ANATOMY", 225, 229], ["feces", "ORGANISM_SUBDIVISION", 35, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["intestine", "ORGAN", 75, 84], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["tissues", "TISSUE", 139, 146], ["feces", "ORGANISM_SUBDIVISION", 170, 175], ["fecal", "ORGANISM_SUBDIVISION", 219, 224], ["oral", "ORGANISM_SUBDIVISION", 225, 229], ["ACE2", "PROTEIN", 63, 67], ["its capacity", "PROBLEM", 6, 18], ["survival in feces", "PROBLEM", 23, 40], ["SARS", "PROBLEM", 111, 115], ["water supply contamination", "TREATMENT", 188, 214], ["fecal-oral route transmission", "TREATMENT", 219, 248], ["capacity", "OBSERVATION_MODIFIER", 10, 18], ["intestine", "ANATOMY", 75, 84], ["fecal", "ANATOMY", 219, 224]]], ["However, at present, there have not been reported cases of fecal-oral transmission of the virus.", [["oral", "ANATOMY", 65, 69], ["fecal", "ORGANISM_SUBDIVISION", 59, 64], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["fecal-oral transmission of the virus", "PROBLEM", 59, 95]]], ["Studies have also indicated that SARS-CoV-2 transmission via ocular surfaces should not be overlooked, as contaminated droplets and body fluids could easily infect the human conjunctival epithelium [81] .", [["ocular surfaces", "ANATOMY", 61, 76], ["droplets", "ANATOMY", 119, 127], ["body fluids", "ANATOMY", 132, 143], ["conjunctival epithelium", "ANATOMY", 174, 197], ["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["body fluids", "ORGANISM_SUBSTANCE", 132, 143], ["human", "ORGANISM", 168, 173], ["conjunctival epithelium", "TISSUE", 174, 197], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["Studies", "TEST", 0, 7], ["SARS", "TEST", 33, 37], ["CoV", "TEST", 38, 41], ["ocular surfaces", "TREATMENT", 61, 76], ["body fluids", "TREATMENT", 132, 143]]], ["SARS-CoV-2 is also responsible for cluster transmission, in particular within family clusters [77] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10]]], ["In some cities, 50% to 80% of all reported cases of COVID-19 accounted for cluster transmission [82] .", [["COVID-19", "CHEMICAL", 52, 60], ["COVID-19", "DNA", 52, 60], ["COVID", "TEST", 52, 57], ["some", "OBSERVATION_MODIFIER", 3, 7], ["cities", "OBSERVATION_MODIFIER", 8, 14]]], ["Based on the current information, there is no evidence for transplacental transmission from infected pregnant women to their fetus, who underwent caesarean section [24, 78] .", [["fetus", "ANATOMY", 125, 130], ["women", "ORGANISM", 110, 115], ["fetus", "ORGAN", 125, 130], ["women", "SPECIES", 110, 115], ["transplacental transmission", "PROBLEM", 59, 86], ["caesarean section", "TREATMENT", 146, 163], ["no evidence for", "UNCERTAINTY", 43, 58], ["infected", "OBSERVATION", 92, 100]]], ["Therefore, whether transmission during vaginal birth can occur remains to be established, neonatal COVID-19 disease as postnatal transmission was documented [83] .", [["vaginal", "ANATOMY", 39, 46], ["vaginal", "ORGANISM_SUBDIVISION", 39, 46], ["transmission during vaginal birth", "PROBLEM", 19, 52], ["neonatal COVID-19 disease", "PROBLEM", 90, 115], ["postnatal transmission", "TEST", 119, 141]]], ["Although, SARS-CoV-2 may definitely infect infants, it has been reported that neonates, infants and children develop significantly milder forms of the disease than their adult counterparts [24, 84] .EpidemiologyCoronaviruses are responsible for 5-10% of acute respiratory illness while it has been estimated that 2% of the population is deemed as an asymptomatic carrier of these viruses.", [["respiratory", "ANATOMY", 260, 271], ["Coronaviruses", "DISEASE", 211, 224], ["respiratory illness", "DISEASE", 260, 279], ["SARS-CoV-2", "ORGANISM", 10, 20], ["infants", "ORGANISM", 43, 50], ["neonates", "ORGANISM", 78, 86], ["infants", "ORGANISM", 88, 95], ["children", "ORGANISM", 100, 108], ["infants", "SPECIES", 43, 50], ["infants", "SPECIES", 88, 95], ["children", "SPECIES", 100, 108], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "PROBLEM", 10, 14], ["the disease", "PROBLEM", 147, 158], ["EpidemiologyCoronaviruses", "PROBLEM", 199, 224], ["acute respiratory illness", "PROBLEM", 254, 279], ["these viruses", "PROBLEM", 374, 387], ["acute", "OBSERVATION_MODIFIER", 254, 259], ["respiratory illness", "OBSERVATION", 260, 279], ["viruses", "OBSERVATION", 380, 387]]], ["The first discovered HCoV was IBV that causes respiratory disease in human whereas, HCoV-229E and HCoV-OC43, which cause the common cold in humans [15, 26, 85] .", [["respiratory", "ANATOMY", 46, 57], ["respiratory disease", "DISEASE", 46, 65], ["HCoV", "GENE_OR_GENE_PRODUCT", 21, 25], ["IBV", "ORGANISM", 30, 33], ["human", "ORGANISM", 69, 74], ["HCoV-229E", "ORGANISM", 84, 93], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 98, 107], ["humans", "ORGANISM", 140, 146], ["HCoV", "DNA", 21, 25], ["human", "SPECIES", 69, 74], ["humans", "SPECIES", 140, 146], ["HCoV", "SPECIES", 21, 25], ["IBV", "SPECIES", 30, 33], ["human", "SPECIES", 69, 74], ["HCoV-229E", "SPECIES", 84, 93], ["humans", "SPECIES", 140, 146], ["IBV", "PROBLEM", 30, 33], ["respiratory disease in human whereas", "PROBLEM", 46, 82], ["HCoV", "TEST", 84, 88], ["HCoV", "TEST", 98, 102], ["respiratory disease", "OBSERVATION", 46, 65]]], ["They were not considered to be highly pathogenic for humans until the outbreak of SARS in Guangdong state of China in 2002 and 2003.", [["SARS", "DISEASE", 82, 86], ["humans", "ORGANISM", 53, 59], ["humans", "SPECIES", 53, 59], ["humans", "SPECIES", 53, 59], ["SARS", "PROBLEM", 82, 86], ["pathogenic", "OBSERVATION", 38, 48]]], ["SARS-CoV infected more than 8000 people worldwide and caused 916 deaths (Table 2) , representing a mortality rate by around 10% [86] .", [["SARS-CoV infected", "DISEASE", 0, 17], ["deaths", "DISEASE", 65, 71], ["SARS-CoV", "ORGANISM", 0, 8], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["a mortality rate", "TEST", 97, 113]]], ["Ten years later in 2012, MERS-CoV emerged in Saudi Arabia and infected over 2494 people with 858 deaths, accounting for a mortality rate approximately of 35% [9, 24, 87] .", [["deaths", "DISEASE", 97, 103], ["MERS-CoV", "ORGANISM", 25, 33], ["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["MERS-CoV", "SPECIES", 25, 33], ["a mortality rate", "TEST", 120, 136]]], ["Starting in China in December 2019, there were reports of patients presenting severe viral pneumonia [15, 88, 89] .", [["viral pneumonia", "DISEASE", 85, 100], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["severe viral pneumonia", "PROBLEM", 78, 100], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["pneumonia", "OBSERVATION", 91, 100]]], ["This public health concern resulted in many unknown pneumonia cases who were admitted to local hospitals [22, 78] (https://www.who.int).", [["pneumonia", "DISEASE", 52, 61], ["pneumonia", "OBSERVATION", 52, 61]]], ["Primary etiologic investigations performed in those patients showed that they were epidemiologically linked to a Huanan wholesale seafood market that also traded live animals and wildlife [17, 24, 90] .", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Primary etiologic investigations", "TEST", 0, 32]]], ["By January 7th, 2020 Chinese authorities announced that a new type of coronavirus was isolated [60, 91] .", [["coronavirus", "DISEASE", 70, 81], ["coronavirus", "ORGANISM", 70, 81], ["coronavirus", "PROBLEM", 70, 81]]], ["The epicenter of infection was probably linked to a zoonotic pathogen being present in the seafood and exotic animal wholesale market [60, 91] .", [["infection", "DISEASE", 17, 26], ["infection", "PROBLEM", 17, 26], ["a zoonotic pathogen", "PROBLEM", 50, 69], ["epicenter", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 17, 26], ["probably linked to", "UNCERTAINTY", 31, 49], ["zoonotic", "OBSERVATION_MODIFIER", 52, 60], ["pathogen", "OBSERVATION", 61, 69], ["exotic", "OBSERVATION_MODIFIER", 103, 109]]], ["The rapid increasing numbers and rate of fatalities indicated a second mode of transmission, from human-to-human, that allowed viral spreading primarily in other Asian countries such as South Korea and Iran followed by many countries such as Italy, Spain, Germany, France, Brazil and USA [24, 60] .", [["human", "ORGANISM", 98, 103], ["human", "ORGANISM", 107, 112], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 107, 112], ["The rapid increasing numbers", "PROBLEM", 0, 28], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["increasing", "OBSERVATION_MODIFIER", 10, 20], ["numbers", "OBSERVATION_MODIFIER", 21, 28]]], ["It is very intriguing to note that the SARS epidemic in southern China in 2002 and the current outbreak of COVID-19 had peaked in mid-February due to exposure to live animals sold in markets.", [["SARS", "DISEASE", 39, 43], ["COVID-19", "CHEMICAL", 107, 115], ["the SARS epidemic", "PROBLEM", 35, 52], ["COVID", "TEST", 107, 112]]], ["Furthermore, similar to the SARS outbreak, this epidemic has occurred during the Spring Festival in China, as the most famous traditional countrywide festival in China, gathering nearly three billion people from different areas.", [["SARS", "DISEASE", 28, 32], ["people", "ORGANISM", 200, 206], ["people", "SPECIES", 200, 206], ["the SARS outbreak", "PROBLEM", 24, 41], ["different", "OBSERVATION_MODIFIER", 212, 221], ["areas", "OBSERVATION_MODIFIER", 222, 227]]], ["These favorable conditions caused the wide transmission of this fatal pneumonia and severe difficulties for disease control and prevention of the epidemic [92] .", [["pneumonia", "DISEASE", 70, 79], ["These favorable conditions", "PROBLEM", 0, 26], ["this fatal pneumonia", "PROBLEM", 59, 79], ["severe difficulties", "PROBLEM", 84, 103], ["disease control", "TREATMENT", 108, 123], ["wide", "OBSERVATION_MODIFIER", 38, 42], ["fatal", "OBSERVATION_MODIFIER", 64, 69], ["pneumonia", "OBSERVATION", 70, 79], ["severe", "OBSERVATION_MODIFIER", 84, 90]]], ["Based on clinical data of diagnosed patients during the SARS-CoV-2 outbreak, the basic reproduction number (R0) is estimated to range between 2 and 6.47 in various modeling studies [76, 93] .", [["SARS", "DISEASE", 56, 60], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 56, 64], ["the SARS", "TEST", 52, 60], ["various modeling studies", "TEST", 156, 180]]], ["The SARS-CoV-2 R0 is in line with the one estimated for SARS-CoVs and MERS-CoVs (from 2 to 5) [94, 95] .", [["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 56, 60], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 56, 65], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 70, 79], ["SARS-CoV-2 R0", "DNA", 4, 17], ["SARS-CoVs", "DNA", 56, 65], ["MERS-CoVs", "DNA", 70, 79], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["SARS", "PROBLEM", 56, 60]]], ["Currently, increasing countries are experiencing clusters of cases and community transmission following SARS-CoV-2 pandemic.", [["SARS-CoV-2 pandemic", "DISEASE", 104, 123], ["SARS-CoV-2", "ORGANISM", 104, 114], ["SARS", "PROBLEM", 104, 108], ["pandemic", "PROBLEM", 115, 123]]], ["Since its emergence, the COVID-19 has drawn well-deserved attention from authorities in order to protect their community and stop or slow down transmission of this disease.", [["COVID-19", "DNA", 25, 33], ["the COVID", "TEST", 21, 30], ["this disease", "PROBLEM", 159, 171], ["disease", "OBSERVATION", 164, 171]]], ["At the time of this review, according to the daily report of the World Health Organization, SARS-CoV-2 has affected over 17,889,134 people with around 228,611 daily new cases and killed more than 686,145 people all over the world, by August 3rd, 2020 (the up to date fatality rate is reported from https://covid19.who.int).", [["SARS", "DISEASE", 92, 96], ["people", "ORGANISM", 132, 138], ["people", "ORGANISM", 204, 210], ["people", "SPECIES", 132, 138], ["people", "SPECIES", 204, 210], ["SARS-CoV", "SPECIES", 92, 100]]], ["We must take into consideration that these data are relative to laboratories and clinically confirmed cases while the actual number including asymptomatic cases, infected undiagnosed and death patients would be much higher than reported cases.The Possible Effects of Weather Conditions on the Transmission of SARS-CoV-2The transmission of seasonal respiratory coronaviruses can be affected by several climate parameters such as temperature and humidity [96] .", [["death", "DISEASE", 187, 192], ["SARS", "DISEASE", 309, 313], ["respiratory coronaviruses", "DISEASE", 348, 373], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 309, 317], ["asymptomatic cases", "PROBLEM", 142, 160], ["infected undiagnosed and death", "PROBLEM", 162, 192], ["SARS", "PROBLEM", 309, 313], ["CoV", "TEST", 314, 317], ["seasonal respiratory coronaviruses", "PROBLEM", 339, 373], ["Possible", "UNCERTAINTY", 247, 255], ["respiratory coronaviruses", "OBSERVATION", 348, 373]]], ["Therefore, understanding the relationship between weather and transmission of COVID-19 is the key to forecast the intensity and end time of this pandemic.", [["COVID", "TEST", 78, 83], ["this pandemic", "PROBLEM", 140, 153]]], ["To this regard, emerging evidence suggests that whether climate conditions may influence the transmission of the SARS-CoV-2 by boosting the spread (much of the data have not been peer-reviewed yet).", [["SARS", "DISEASE", 113, 117], ["SARS-CoV-2", "ORGANISM", 113, 123], ["SARS-CoV", "SPECIES", 113, 121], ["climate conditions", "PROBLEM", 56, 74], ["the SARS", "PROBLEM", 109, 117], ["CoV", "TEST", 118, 121]]], ["To date, COVID-19 has had a significant expansion in the Northern Hemisphere (NH) belt, given that it covers cities and populated areas; conversely, in the belt of the Southern Hemisphere (SH), which covers very low population and landless areas, COVID-19 has not been reported yet.The Possible Effects of Weather Conditions on the Transmission of SARS-CoV-2Based on climate and ERA-interim reanalysis dataset in NH belt from November 2019 to March 2020, we compared the average rate of humidity and temperature between five cities in European Countries with significant community transmission of COVID-19 versus five cities of North Africa which are expected to be less exposed to COVID-19.", [["COVID-19", "CHEMICAL", 9, 17], ["COVID-19", "CHEMICAL", 247, 255], ["SARS", "DISEASE", 348, 352], ["COVID-19", "CHEMICAL", 682, 690], ["COVID-19", "CELL", 9, 17], ["COVID-19", "DNA", 247, 255], ["SARS-CoV", "SPECIES", 348, 356], ["COVID", "TEST", 9, 14], ["a significant expansion", "PROBLEM", 26, 49], ["very low population and landless areas", "PROBLEM", 207, 245], ["COVID", "TEST", 247, 252], ["SARS", "PROBLEM", 348, 352], ["CoV", "TEST", 353, 356], ["COVID", "TEST", 597, 602], ["COVID", "TEST", 682, 687], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["expansion", "OBSERVATION", 40, 49], ["Northern Hemisphere", "ANATOMY", 57, 76], ["populated", "OBSERVATION_MODIFIER", 120, 129], ["areas", "OBSERVATION_MODIFIER", 130, 135], ["Southern Hemisphere", "ANATOMY", 168, 187], ["very", "OBSERVATION_MODIFIER", 207, 211], ["low population", "OBSERVATION_MODIFIER", 212, 226], ["Possible", "UNCERTAINTY", 286, 294]]], ["The information recorded by the meteorological stations has been used, since these are more accurate than satellite data [97] .", [["satellite data", "TEST", 106, 120]]], ["As shown in Table 3 , the average amount of humidity is very close between European and African selected sites.", [["African selected sites", "TREATMENT", 88, 110], ["average", "OBSERVATION_MODIFIER", 26, 33], ["amount", "OBSERVATION_MODIFIER", 34, 40]]], ["The main reason is the proximity of these cities to the Mediterranean Sea coastline.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["Mediterranean Sea coastline", "OBSERVATION", 56, 83]]], ["In addition, the north wind, which blows from northern Europe to European cities (ECs), increases the humidity of these cities.", [["ECs", "ANATOMY", 82, 85], ["ECs", "CELL", 82, 85], ["ECs", "CELL_TYPE", 82, 85]]], ["Conversely, there are temperature differences between considered ECs and North African cities (Table 3) .", [["ECs", "ANATOMY", 65, 68], ["ECs", "CELL", 65, 68], ["ECs", "CELL_TYPE", 65, 68], ["temperature differences", "PROBLEM", 22, 45]]], ["Thus, temperature and humidity should be considered parameters involved in the transmission of COVID-19.", [["COVID-19", "CHEMICAL", 95, 103], ["COVID-19", "CHEMICAL", 95, 103], ["humidity", "TREATMENT", 22, 30], ["COVID", "TEST", 95, 100]]], ["Up to know, few studies have investigated the association of temperature and humidity with COVID-19 incidence and death rates.", [["death", "DISEASE", 114, 119], ["COVID", "TREATMENT", 91, 96], ["death rates", "TEST", 114, 125]]], ["The first meteorological study was done in 100 different Chinese cities each having more than 40 cases of COVID-19 in a 3-day period during the end of January [98] .", [["The first meteorological study", "TEST", 0, 30], ["COVID", "TREATMENT", 106, 111]]], ["This group showed that high temperature and humidity significantly reduces the transmission of COVID-19.", [["COVID-19", "CHEMICAL", 95, 103], ["high temperature and humidity", "PROBLEM", 23, 52], ["COVID", "TEST", 95, 100], ["high temperature", "OBSERVATION_MODIFIER", 23, 39]]], ["Their results indicate that the increases of 1 \u2022 C in temperature and 1% in relative humidity lower R by 0.0225 and 0.0158, respectively [98] .", [["temperature", "TEST", 54, 65], ["relative humidity", "TEST", 76, 93], ["increases", "OBSERVATION_MODIFIER", 32, 41]]], ["A preprint study on confirmed COVID-19 cases collected from 429 cities showed that every 1 \u2022 C increase in the minimum temperature of higher-temperature cities reduced the disease incidence and death rates by 0.86 [99] .", [["death", "DISEASE", 194, 199], ["A preprint study", "TEST", 0, 16], ["COVID", "TEST", 30, 35], ["the minimum temperature", "TEST", 107, 130], ["the disease incidence", "PROBLEM", 168, 189], ["death rates", "TEST", 194, 205]]], ["Another preprint study suggested that the average increase of 1 \u2022 C in temperature correlates negatively with the predicted number of cases worldwide [100] .", [["Another preprint study", "TEST", 0, 22]]], ["These results are in accordance with Wu Y et al. who showed that among all confirmed COVID-19 new cases and new deaths from 166 countries (excluding China), a 1 \u2022 C increase in temperature is associated with a 3.08% reduction in daily new cases and a 1.19% reduction in daily new deaths, whereas a 1% increase in relative humidity was associated with a 0.85% reduction in daily new cases and a 0.51% reduction in daily new deaths [101] .", [["deaths", "DISEASE", 112, 118], ["deaths", "DISEASE", 280, 286], ["deaths", "DISEASE", 423, 429], ["COVID", "TEST", 85, 90], ["a 3.08% reduction", "TREATMENT", 208, 225], ["a 1.19% reduction", "TREATMENT", 249, 266], ["relative humidity", "PROBLEM", 313, 330], ["a 0.85% reduction", "TREATMENT", 351, 368], ["a 0.51% reduction", "TREATMENT", 392, 409]]], ["A recent study conducted in Italy showed a positive correlation of SARS-CoV-2 spreading and weather conditions including temperatures ranging 4-12 \u2022 C and relative humidity of 60-80% [102] .", [["SARS", "DISEASE", 67, 71], ["A recent study", "TEST", 0, 14], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["temperatures", "TEST", 121, 133], ["relative humidity", "TEST", 155, 172]]], ["In a geographic and population modeling study conducted in five largest cities in Colombia, the transmission of SARS-CoV-2 seems to be comodulated by temperature and humidity.", [["SARS", "DISEASE", 112, 116], ["SARS-CoV-2", "ORGANISM", 112, 122], ["SARS-CoV", "SPECIES", 112, 120], ["population modeling study", "TEST", 20, 45], ["SARS", "PROBLEM", 112, 116], ["largest", "OBSERVATION_MODIFIER", 64, 71]]], ["Their observation revealed a strong reduction of transmission in climates with temperatures above 30 \u2022 C and relative humidity below 78% which may comodulate the infectivity of SARS-CoV-2 within respiratory droplets [103] .", [["SARS", "DISEASE", 177, 181], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 177, 187], ["SARS-CoV", "SPECIES", 177, 185], ["Their observation", "TEST", 0, 17], ["temperatures", "TEST", 79, 91], ["relative humidity", "TEST", 109, 126], ["the infectivity of SARS", "PROBLEM", 158, 181], ["CoV", "TEST", 182, 185], ["respiratory droplets", "TEST", 195, 215], ["strong", "OBSERVATION_MODIFIER", 29, 35], ["reduction", "OBSERVATION_MODIFIER", 36, 45]]], ["The first five cities represent significant communities where transmission of COVID-19 was reported, whereas the second 5 cities are expected to be less exposed to COVID-19 due to different weather conditions.CityAverage Humidity (%) Temperature ( \u2022 C) Rome 71 65 66 63 63 15 1 11 13 14 Paris 78 76 79 74 66 9 8 8 9 9 Madrid 70 67 68 63 61 10 10 9 13 12 Milan 77 74 69 58 62 11 8 7 11 11 Lisbon 75 74 77 76 71 15 14 12 15 15 Rabat 72 71 69 72 74 16 17 14 17 16 Algiers 64 62 61 61 66 16 17 15 18 16 Tunis 61 66 72 65 70 17 16 14 15 15 Tripoli 80 83 73 75 71 15 10 8 9 11 Cairo 45 52 55 53 46 25 18 16 18 22 Overall, these meteorological analyses support that the combination of temperature and humidity could represent a direct influence on the transmission of the COVID-19.", [["COVID", "TEST", 78, 83], ["COVID", "TEST", 164, 169], ["CityAverage Humidity", "TEST", 209, 229], ["Temperature", "TEST", 234, 245], ["Rabat", "TEST", 425, 430], ["Algiers", "TEST", 461, 468], ["Tripoli", "TEST", 535, 542], ["Cairo", "TEST", 571, 576], ["these meteorological analyses", "TEST", 616, 645], ["the COVID", "TEST", 761, 770], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["communities", "OBSERVATION", 44, 55]]], ["It can be assumed that the arrival of summer and rainy season in the NH can effectively reduce the transmission of the COVID-19.", [["COVID-19", "DNA", 119, 127], ["the COVID", "TEST", 115, 124]]], ["The distribution of COVID-19 across different longitudes and latitudes with a range of temperatures and humidity may help to predict the prevalence of this disease in terms of environmental characteristics.", [["COVID-19", "DNA", 20, 28], ["COVID", "TEST", 20, 25], ["this disease", "PROBLEM", 151, 163], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["disease", "OBSERVATION", 156, 163]]], ["This could lead to a better understanding of how the virus spreads around the world ( Figure 5 ).", [["the virus", "PROBLEM", 49, 58]]], ["It should be noted that apart from the capability of SARS-CoV-2 to persist on environmental surfaces under favorable atmospheric conditions, the duration of its persistence may be affected by temperature and humidity.", [["SARS", "PROBLEM", 53, 57], ["favorable", "OBSERVATION_MODIFIER", 107, 116], ["atmospheric conditions", "OBSERVATION", 117, 139]]], ["Although warmer climates may slow the spread of SARS-CoV-2, relying on weather changes alone to slow the transmission of COVID-19 are unlikely to be enough.", [["SARS", "DISEASE", 48, 52], ["COVID-19", "CHEMICAL", 121, 129], ["COVID-19", "DNA", 121, 129], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["COVID", "TEST", 121, 126]]], ["However, using this type of dataset and climate analysis modeling is possible to identify areas that are most likely to be at risk of significant COVID-19 cases in the future and serve as an alarm signal to various government departments and agencies to adopt the necessary measures to prevent virus spread [104] .", [["climate analysis modeling", "TEST", 40, 65], ["significant COVID-19 cases", "PROBLEM", 134, 160], ["the necessary measures", "TREATMENT", 260, 282], ["virus spread", "PROBLEM", 294, 306], ["most likely", "UNCERTAINTY", 105, 116]]], ["Moreover, more data are gathering around the world due to the change of the season and all authors agree that the association between temperature/humidity and SARS-CoV-2 is an appreciable hypothesis, but not a certainty yet.", [["SARS", "DISEASE", 159, 163], ["SARS-CoV", "SPECIES", 159, 167], ["temperature/humidity", "TEST", 134, 154], ["SARS", "PROBLEM", 159, 163], ["an appreciable hypothesis", "PROBLEM", 173, 198], ["appreciable", "OBSERVATION_MODIFIER", 176, 187], ["hypothesis", "OBSERVATION", 188, 198]]], ["19 cases in the future and serve as an alarm signal to various government departments and agencies to adopt the necessary measures to prevent virus spread [104] .", [["the necessary measures", "TREATMENT", 108, 130], ["virus spread", "PROBLEM", 142, 154]]], ["Moreover, more data are gathering around the world due to the change of the season and all authors agree that the association between temperature/humidity and SARS-CoV-2 is an appreciable hypothesis, but not a certainty yet.Clinical PresentationsThe most common symptoms of patients at onset of COVID-19 disease are defined as fever, dry cough, fatigue and less often, symptoms of sputum production, headache, sore throat, myalgia; hemoptysis, dyspnea, diarrhea and lymphopenia were also observed [15, 24, 28] (Figure 6 ).", [["sputum", "ANATOMY", 381, 387], ["SARS", "DISEASE", 159, 163], ["fever", "DISEASE", 327, 332], ["dry cough", "DISEASE", 334, 343], ["fatigue", "DISEASE", 345, 352], ["sputum production", "DISEASE", 381, 398], ["headache", "DISEASE", 400, 408], ["sore throat", "DISEASE", 410, 421], ["myalgia", "DISEASE", 423, 430], ["hemoptysis", "DISEASE", 432, 442], ["dyspnea", "DISEASE", 444, 451], ["diarrhea", "DISEASE", 453, 461], ["lymphopenia", "DISEASE", 466, 477], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 274, 282], ["SARS-CoV", "SPECIES", 159, 167], ["temperature/humidity", "TEST", 134, 154], ["SARS", "PROBLEM", 159, 163], ["an appreciable hypothesis", "PROBLEM", 173, 198], ["COVID-19 disease", "PROBLEM", 295, 311], ["fever", "PROBLEM", 327, 332], ["dry cough", "PROBLEM", 334, 343], ["fatigue", "PROBLEM", 345, 352], ["symptoms", "PROBLEM", 369, 377], ["sputum production", "PROBLEM", 381, 398], ["headache", "PROBLEM", 400, 408], ["sore throat", "PROBLEM", 410, 421], ["myalgia", "PROBLEM", 423, 430], ["hemoptysis", "PROBLEM", 432, 442], ["dyspnea", "PROBLEM", 444, 451], ["diarrhea", "PROBLEM", 453, 461], ["lymphopenia", "PROBLEM", 466, 477], ["appreciable", "OBSERVATION_MODIFIER", 176, 187], ["hypothesis", "OBSERVATION", 188, 198], ["sore throat", "ANATOMY", 410, 421], ["myalgia", "OBSERVATION", 423, 430], ["hemoptysis", "OBSERVATION", 432, 442], ["diarrhea", "OBSERVATION", 453, 461], ["lymphopenia", "OBSERVATION", 466, 477]]], ["The spectrum of clinical features of COVID-19 has been found ranging from an asymptomatic state to severe respiratory failure and multiorgan dysfunction [24, 76] .", [["respiratory", "ANATOMY", 106, 117], ["multiorgan", "ANATOMY", 130, 140], ["COVID-19", "CHEMICAL", 37, 45], ["respiratory failure", "DISEASE", 106, 125], ["multiorgan dysfunction", "DISEASE", 130, 152], ["COVID-19", "CHEMICAL", 37, 45], ["COVID-19", "GENE_OR_GENE_PRODUCT", 37, 45], ["COVID", "TEST", 37, 42], ["an asymptomatic state", "PROBLEM", 74, 95], ["severe respiratory failure", "PROBLEM", 99, 125], ["multiorgan dysfunction", "PROBLEM", 130, 152], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["respiratory failure", "OBSERVATION", 106, 125], ["multiorgan dysfunction", "OBSERVATION", 130, 152]]], ["Symptomatic people are considered to be more contagious, similar to most viral-related respiratory diseases.", [["respiratory", "ANATOMY", 87, 98], ["respiratory diseases", "DISEASE", 87, 107], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["Symptomatic people", "PROBLEM", 0, 18], ["respiratory diseases", "PROBLEM", 87, 107], ["respiratory diseases", "OBSERVATION", 87, 107]]], ["However, individuals who remain asymptomatic may also transmit the virus and cases infected by an asymptomatic individual in the prodrome period of COVID-19 have also been reported [76] .", [["individuals", "ORGANISM", 9, 20], ["asymptomatic", "PROBLEM", 32, 44], ["the virus", "PROBLEM", 63, 72], ["COVID", "TEST", 148, 153]]], ["Asymptomatic infections can occur because of weakened immune responses and subclinical manifestations or also because theClinical PresentationsThe most common symptoms of patients at onset of COVID-19 disease are defined as fever, dry cough, fatigue and less often, symptoms of sputum production, headache, sore throat, myalgia; hemoptysis, dyspnea, diarrhea and lymphopenia were also observed [15, 24, 28] (Figure 6 ).", [["sputum", "ANATOMY", 278, 284], ["infections", "DISEASE", 13, 23], ["fever", "DISEASE", 224, 229], ["dry cough", "DISEASE", 231, 240], ["fatigue", "DISEASE", 242, 249], ["sputum production", "DISEASE", 278, 295], ["headache", "DISEASE", 297, 305], ["sore throat", "DISEASE", 307, 318], ["myalgia", "DISEASE", 320, 327], ["hemoptysis", "DISEASE", 329, 339], ["dyspnea", "DISEASE", 341, 348], ["diarrhea", "DISEASE", 350, 358], ["lymphopenia", "DISEASE", 363, 374], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["Asymptomatic infections", "PROBLEM", 0, 23], ["weakened immune responses", "PROBLEM", 45, 70], ["subclinical manifestations", "PROBLEM", 75, 101], ["COVID-19 disease", "PROBLEM", 192, 208], ["fever", "PROBLEM", 224, 229], ["dry cough", "PROBLEM", 231, 240], ["fatigue", "PROBLEM", 242, 249], ["symptoms", "PROBLEM", 266, 274], ["sputum production", "PROBLEM", 278, 295], ["headache", "PROBLEM", 297, 305], ["sore throat", "PROBLEM", 307, 318], ["myalgia", "PROBLEM", 320, 327], ["hemoptysis", "PROBLEM", 329, 339], ["dyspnea", "PROBLEM", 341, 348], ["diarrhea", "PROBLEM", 350, 358], ["lymphopenia", "PROBLEM", 363, 374], ["infections", "OBSERVATION", 13, 23], ["sore throat", "ANATOMY", 307, 318], ["myalgia", "OBSERVATION", 320, 327], ["hemoptysis", "OBSERVATION", 329, 339], ["diarrhea", "OBSERVATION", 350, 358], ["lymphopenia", "OBSERVATION", 363, 374]]], ["The spectrum of clinical features of COVID-19 has been found ranging from an asymptomatic state to severe respiratory failure and multiorgan dysfunction [24, 76] .", [["respiratory", "ANATOMY", 106, 117], ["multiorgan", "ANATOMY", 130, 140], ["COVID-19", "CHEMICAL", 37, 45], ["respiratory failure", "DISEASE", 106, 125], ["multiorgan dysfunction", "DISEASE", 130, 152], ["COVID-19", "CHEMICAL", 37, 45], ["COVID-19", "GENE_OR_GENE_PRODUCT", 37, 45], ["COVID", "TEST", 37, 42], ["an asymptomatic state", "PROBLEM", 74, 95], ["severe respiratory failure", "PROBLEM", 99, 125], ["multiorgan dysfunction", "PROBLEM", 130, 152], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["respiratory failure", "OBSERVATION", 106, 125], ["multiorgan dysfunction", "OBSERVATION", 130, 152]]], ["Symptomatic people are considered to be more contagious, similar to most viral-related respiratory diseases.", [["respiratory", "ANATOMY", 87, 98], ["respiratory diseases", "DISEASE", 87, 107], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["Symptomatic people", "PROBLEM", 0, 18], ["respiratory diseases", "PROBLEM", 87, 107], ["respiratory diseases", "OBSERVATION", 87, 107]]], ["However, individuals who remain asymptomatic may also transmit the virus and cases infected by an asymptomatic individual in the prodrome period of COVID-19 have also been reported [76] .", [["individuals", "ORGANISM", 9, 20], ["asymptomatic", "PROBLEM", 32, 44], ["the virus", "PROBLEM", 63, 72], ["COVID", "TEST", 148, 153]]], ["Asymptomatic infections can occur because of weakened immune responses and subclinical manifestations or also because the virus is waiting for opportunities to invade and reproduce.", [["infections", "DISEASE", 13, 23], ["Asymptomatic infections", "PROBLEM", 0, 23], ["weakened immune responses", "PROBLEM", 45, 70], ["subclinical manifestations", "PROBLEM", 75, 101], ["the virus", "PROBLEM", 118, 127], ["infections", "OBSERVATION", 13, 23]]], ["A recent study has shown that a viral load detected in an asymptomatic patient was just like to the one observed in symptomatic patients, indicating the capability of transmission in asymptomatic patients [74] .", [["patient", "ORGANISM", 71, 78], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 196, 204], ["patient", "SPECIES", 71, 78], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 196, 204], ["A recent study", "TEST", 0, 14], ["a viral load", "PROBLEM", 30, 42], ["viral load", "OBSERVATION", 32, 42]]], ["According to disease presentation, COVID-19 can be classified as mild, moderate, severe and critical ( virus is waiting for opportunities to invade and reproduce.", [["COVID-19", "DNA", 35, 43], ["COVID", "TEST", 35, 40], ["mild, moderate, severe and critical ( virus", "PROBLEM", 65, 108], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["moderate", "OBSERVATION_MODIFIER", 71, 79], ["severe", "OBSERVATION_MODIFIER", 81, 87]]], ["A recent study has shown that a viral load detected in an asymptomatic patient was just like to the one observed in symptomatic patients, indicating the capability of transmission in asymptomatic patients [74] .", [["patient", "ORGANISM", 71, 78], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 196, 204], ["patient", "SPECIES", 71, 78], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 196, 204], ["A recent study", "TEST", 0, 14], ["a viral load", "PROBLEM", 30, 42], ["viral load", "OBSERVATION", 32, 42]]], ["According to disease presentation, COVID-19 can be classified as mild, moderate, severe and critical (Table 4 ) [57, 76, 105] .MildIn 81% of all confirmed COVID-19 cases.", [["COVID-19", "DNA", 35, 43], ["COVID", "TEST", 35, 40], ["mild, moderate, severe", "PROBLEM", 65, 87], ["MildIn", "TEST", 127, 133], ["COVID", "TEST", 155, 160], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["moderate", "OBSERVATION_MODIFIER", 71, 79], ["severe", "OBSERVATION_MODIFIER", 81, 87]]], ["Dry cough, mild fever, sore throat, nasal congestion, muscle pain, headache and malaise.", [["nasal", "ANATOMY", 36, 41], ["muscle", "ANATOMY", 54, 60], ["Dry cough", "DISEASE", 0, 9], ["fever", "DISEASE", 16, 21], ["sore throat", "DISEASE", 23, 34], ["nasal congestion", "DISEASE", 36, 52], ["muscle pain", "DISEASE", 54, 65], ["headache", "DISEASE", 67, 75], ["nasal", "ORGANISM_SUBDIVISION", 36, 41], ["muscle", "ORGAN", 54, 60], ["Dry cough", "PROBLEM", 0, 9], ["mild fever", "PROBLEM", 11, 21], ["sore throat", "PROBLEM", 23, 34], ["nasal congestion", "PROBLEM", 36, 52], ["muscle pain", "PROBLEM", 54, 65], ["headache", "PROBLEM", 67, 75], ["malaise", "PROBLEM", 80, 87], ["cough", "OBSERVATION", 4, 9], ["mild", "OBSERVATION_MODIFIER", 11, 15], ["fever", "OBSERVATION", 16, 21], ["sore throat", "ANATOMY", 23, 34], ["nasal", "ANATOMY", 36, 41], ["congestion", "OBSERVATION", 42, 52], ["muscle", "ANATOMY", 54, 60], ["pain", "OBSERVATION", 61, 65], ["headache", "OBSERVATION", 67, 75], ["malaise", "OBSERVATION", 80, 87]]], ["Absence of serious symptoms like dyspnea, also the absence of radiograph features.", [["dyspnea", "DISEASE", 33, 40], ["serious symptoms", "PROBLEM", 11, 27], ["dyspnea", "PROBLEM", 33, 40], ["radiograph features", "TEST", 62, 81], ["serious", "OBSERVATION_MODIFIER", 11, 18], ["dyspnea", "OBSERVATION", 33, 40]]], ["It may rapidly deteriorate into severe or critical cases, non-pneumonia or mild pneumonia.ModerateDry cough, tachypnea and shortness of breath.SevereAcute respiratory distress syndrome (ARDS), severe pneumonia, severe dyspnea, sepsis or septic shock, tachypnea (respiratory frequency) \u2265 30/min, blood oxygen saturation (SpO2) \u2264 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) < 300, and/or lung infiltrates > 50% within 24 to 48 h.", [["respiratory", "ANATOMY", 262, 273], ["blood", "ANATOMY", 295, 300], ["arterial", "ANATOMY", 353, 361], ["lung", "ANATOMY", 432, 436], ["non-pneumonia", "DISEASE", 58, 71], ["pneumonia", "DISEASE", 80, 89], ["cough", "DISEASE", 102, 107], ["tachypnea", "DISEASE", 109, 118], ["shortness of breath", "DISEASE", 123, 142], ["SevereAcute respiratory distress syndrome", "DISEASE", 143, 184], ["ARDS", "DISEASE", 186, 190], ["pneumonia", "DISEASE", 200, 209], ["dyspnea", "DISEASE", 218, 225], ["sepsis", "DISEASE", 227, 233], ["septic shock", "DISEASE", 237, 249], ["tachypnea", "DISEASE", 251, 260], ["oxygen", "CHEMICAL", 301, 307], ["oxygen", "CHEMICAL", 362, 368], ["oxygen", "CHEMICAL", 393, 399], ["oxygen", "CHEMICAL", 301, 307], ["oxygen", "CHEMICAL", 362, 368], ["oxygen", "CHEMICAL", 393, 399], ["blood", "ORGANISM_SUBSTANCE", 295, 300], ["oxygen", "SIMPLE_CHEMICAL", 301, 307], ["arterial", "MULTI-TISSUE_STRUCTURE", 353, 361], ["oxygen", "SIMPLE_CHEMICAL", 362, 368], ["oxygen", "SIMPLE_CHEMICAL", 393, 399], ["lung", "ORGAN", 432, 436], ["non-pneumonia", "PROBLEM", 58, 71], ["mild pneumonia", "PROBLEM", 75, 89], ["ModerateDry cough", "PROBLEM", 90, 107], ["tachypnea", "PROBLEM", 109, 118], ["shortness of breath", "PROBLEM", 123, 142], ["SevereAcute respiratory distress syndrome", "PROBLEM", 143, 184], ["ARDS)", "PROBLEM", 186, 191], ["severe pneumonia", "PROBLEM", 193, 209], ["severe dyspnea", "PROBLEM", 211, 225], ["sepsis", "PROBLEM", 227, 233], ["septic shock", "PROBLEM", 237, 249], ["tachypnea", "PROBLEM", 251, 260], ["respiratory frequency)", "PROBLEM", 262, 284], ["blood oxygen saturation", "TEST", 295, 318], ["SpO2", "TEST", 320, 324], ["partial pressure of arterial oxygen", "TREATMENT", 333, 368], ["inspired oxygen ratio", "TEST", 384, 405], ["PaO2/FiO2", "TEST", 407, 416], ["lung infiltrates", "PROBLEM", 432, 448], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["critical", "OBSERVATION_MODIFIER", 42, 50], ["cases", "OBSERVATION", 51, 56], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["pneumonia", "OBSERVATION", 80, 89], ["cough", "OBSERVATION", 102, 107], ["tachypnea", "OBSERVATION", 109, 118], ["respiratory distress", "OBSERVATION", 155, 175], ["ARDS", "OBSERVATION", 186, 190], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["pneumonia", "OBSERVATION", 200, 209], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["dyspnea", "OBSERVATION", 218, 225], ["sepsis", "OBSERVATION", 227, 233], ["septic shock", "OBSERVATION", 237, 249], ["arterial", "ANATOMY", 353, 361], ["oxygen ratio", "OBSERVATION", 393, 405], ["lung", "ANATOMY", 432, 436], ["infiltrates", "OBSERVATION", 437, 448]]], ["Fever can be absent or moderate.CriticalIn 5% of all confirmed COVID-19 cases.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["CriticalIn", "TREATMENT", 32, 42], ["COVID", "TEST", 63, 68], ["moderate", "OBSERVATION_MODIFIER", 23, 31]]], ["Respiratory failure, septic shock, RNAemia, cardiac injury and/or multiple organ dysfunction or failure.", [["Respiratory", "ANATOMY", 0, 11], ["cardiac", "ANATOMY", 44, 51], ["organ", "ANATOMY", 75, 80], ["Respiratory failure", "DISEASE", 0, 19], ["septic shock", "DISEASE", 21, 33], ["RNAemia", "DISEASE", 35, 42], ["cardiac injury", "DISEASE", 44, 58], ["organ dysfunction", "DISEASE", 75, 92], ["cardiac", "ORGAN", 44, 51], ["organ", "ORGAN", 75, 80], ["Respiratory failure", "PROBLEM", 0, 19], ["septic shock", "PROBLEM", 21, 33], ["RNAemia", "PROBLEM", 35, 42], ["cardiac injury", "PROBLEM", 44, 58], ["multiple organ dysfunction", "PROBLEM", 66, 92], ["failure", "PROBLEM", 96, 103], ["failure", "OBSERVATION", 12, 19], ["septic shock", "OBSERVATION", 21, 33], ["cardiac", "ANATOMY", 44, 51], ["injury", "OBSERVATION", 52, 58], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["organ", "ANATOMY", 75, 80], ["dysfunction", "OBSERVATION", 81, 92], ["failure", "OBSERVATION", 96, 103]]], ["Case fatality rate is 49% (higher case fatality rate for patients with preexisting co-morbidities and lower-case fatality rate (0.9%) for patients without co-morbidities).", [["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 138, 146], ["Case fatality rate", "TEST", 0, 18], ["preexisting co-morbidities", "PROBLEM", 71, 97], ["fatality rate", "TEST", 113, 126], ["co-morbidities", "PROBLEM", 155, 169]]], ["Cardiovascular disease (10.5%), diabetes (7.3%), respiratory disease (6.5%), hypertension (6%) and oncological complications (5.6%).MildIn 81% of all confirmed COVID-19 cases.", [["Cardiovascular", "ANATOMY", 0, 14], ["respiratory", "ANATOMY", 49, 60], ["Cardiovascular disease", "DISEASE", 0, 22], ["diabetes", "DISEASE", 32, 40], ["respiratory disease", "DISEASE", 49, 68], ["hypertension", "DISEASE", 77, 89], ["Cardiovascular", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Cardiovascular disease", "PROBLEM", 0, 22], ["diabetes", "PROBLEM", 32, 40], ["respiratory disease", "PROBLEM", 49, 68], ["hypertension", "PROBLEM", 77, 89], ["oncological complications", "PROBLEM", 99, 124], ["MildIn", "TEST", 132, 138], ["COVID", "TEST", 160, 165], ["disease", "OBSERVATION", 15, 22], ["respiratory", "ANATOMY", 49, 60], ["disease", "OBSERVATION", 61, 68], ["hypertension", "OBSERVATION", 77, 89]]], ["Dry cough, mild fever, sore throat, nasal congestion, muscle pain, headache and malaise.", [["nasal", "ANATOMY", 36, 41], ["muscle", "ANATOMY", 54, 60], ["Dry cough", "DISEASE", 0, 9], ["fever", "DISEASE", 16, 21], ["sore throat", "DISEASE", 23, 34], ["nasal congestion", "DISEASE", 36, 52], ["muscle pain", "DISEASE", 54, 65], ["headache", "DISEASE", 67, 75], ["nasal", "ORGANISM_SUBDIVISION", 36, 41], ["muscle", "ORGAN", 54, 60], ["Dry cough", "PROBLEM", 0, 9], ["mild fever", "PROBLEM", 11, 21], ["sore throat", "PROBLEM", 23, 34], ["nasal congestion", "PROBLEM", 36, 52], ["muscle pain", "PROBLEM", 54, 65], ["headache", "PROBLEM", 67, 75], ["malaise", "PROBLEM", 80, 87], ["cough", "OBSERVATION", 4, 9], ["mild", "OBSERVATION_MODIFIER", 11, 15], ["fever", "OBSERVATION", 16, 21], ["sore throat", "ANATOMY", 23, 34], ["nasal", "ANATOMY", 36, 41], ["congestion", "OBSERVATION", 42, 52], ["muscle", "ANATOMY", 54, 60], ["pain", "OBSERVATION", 61, 65], ["headache", "OBSERVATION", 67, 75], ["malaise", "OBSERVATION", 80, 87]]], ["Absence of serious symptoms like dyspnea, also the absence of radiograph features.", [["dyspnea", "DISEASE", 33, 40], ["serious symptoms", "PROBLEM", 11, 27], ["dyspnea", "PROBLEM", 33, 40], ["radiograph features", "TEST", 62, 81], ["serious", "OBSERVATION_MODIFIER", 11, 18], ["dyspnea", "OBSERVATION", 33, 40]]], ["It may rapidly deteriorate into severe or critical cases, non-pneumonia or mild pneumonia.ModerateDry cough, tachypnea and shortness of breath.SevereAcute respiratory distress syndrome (ARDS), severe pneumonia, severe dyspnea, sepsis or septic shock, tachypnea (respiratory frequency) \u2265 30/min, blood oxygen saturation (SpO 2 ) \u2264 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO 2 /FiO 2 ) < 300, and/or lung infiltrates > 50% within 24 to 48 h.", [["respiratory", "ANATOMY", 262, 273], ["blood", "ANATOMY", 295, 300], ["arterial", "ANATOMY", 355, 363], ["lung", "ANATOMY", 438, 442], ["non-pneumonia", "DISEASE", 58, 71], ["pneumonia", "DISEASE", 80, 89], ["cough", "DISEASE", 102, 107], ["tachypnea", "DISEASE", 109, 118], ["shortness of breath", "DISEASE", 123, 142], ["SevereAcute respiratory distress syndrome", "DISEASE", 143, 184], ["ARDS", "DISEASE", 186, 190], ["pneumonia", "DISEASE", 200, 209], ["dyspnea", "DISEASE", 218, 225], ["sepsis", "DISEASE", 227, 233], ["septic shock", "DISEASE", 237, 249], ["tachypnea", "DISEASE", 251, 260], ["oxygen", "CHEMICAL", 301, 307], ["oxygen", "CHEMICAL", 364, 370], ["oxygen", "CHEMICAL", 395, 401], ["oxygen", "CHEMICAL", 301, 307], ["oxygen", "CHEMICAL", 364, 370], ["oxygen", "CHEMICAL", 395, 401], ["blood", "ORGANISM_SUBSTANCE", 295, 300], ["oxygen", "SIMPLE_CHEMICAL", 301, 307], ["arterial", "MULTI-TISSUE_STRUCTURE", 355, 363], ["oxygen", "SIMPLE_CHEMICAL", 364, 370], ["oxygen", "SIMPLE_CHEMICAL", 395, 401], ["lung", "ORGAN", 438, 442], ["non-pneumonia", "PROBLEM", 58, 71], ["mild pneumonia", "PROBLEM", 75, 89], ["ModerateDry cough", "PROBLEM", 90, 107], ["tachypnea", "PROBLEM", 109, 118], ["shortness of breath", "PROBLEM", 123, 142], ["SevereAcute respiratory distress syndrome", "PROBLEM", 143, 184], ["ARDS)", "PROBLEM", 186, 191], ["severe pneumonia", "PROBLEM", 193, 209], ["severe dyspnea", "PROBLEM", 211, 225], ["sepsis", "PROBLEM", 227, 233], ["septic shock", "PROBLEM", 237, 249], ["tachypnea", "PROBLEM", 251, 260], ["respiratory frequency)", "PROBLEM", 262, 284], ["blood oxygen saturation", "TEST", 295, 318], ["SpO", "TEST", 320, 323], ["partial pressure of arterial oxygen", "TREATMENT", 335, 370], ["inspired oxygen ratio", "TEST", 386, 407], ["PaO", "TEST", 409, 412], ["FiO", "TEST", 416, 419], ["lung infiltrates", "PROBLEM", 438, 454], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["critical", "OBSERVATION_MODIFIER", 42, 50], ["cases", "OBSERVATION", 51, 56], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["pneumonia", "OBSERVATION", 80, 89], ["cough", "OBSERVATION", 102, 107], ["tachypnea", "OBSERVATION", 109, 118], ["respiratory distress", "OBSERVATION", 155, 175], ["ARDS", "OBSERVATION", 186, 190], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["pneumonia", "OBSERVATION", 200, 209], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["dyspnea", "OBSERVATION", 218, 225], ["sepsis", "OBSERVATION", 227, 233], ["septic shock", "OBSERVATION", 237, 249], ["arterial", "ANATOMY", 355, 363], ["lung", "ANATOMY", 438, 442], ["infiltrates", "OBSERVATION", 443, 454]]], ["Fever can be absent or moderate.CriticalIn 5% of all confirmed COVID-19 cases.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["CriticalIn", "TREATMENT", 32, 42], ["COVID", "TEST", 63, 68], ["moderate", "OBSERVATION_MODIFIER", 23, 31]]], ["Respiratory failure, septic shock, RNAemia, cardiac injury and/or multiple organ dysfunction or failure.", [["Respiratory", "ANATOMY", 0, 11], ["cardiac", "ANATOMY", 44, 51], ["organ", "ANATOMY", 75, 80], ["Respiratory failure", "DISEASE", 0, 19], ["septic shock", "DISEASE", 21, 33], ["RNAemia", "DISEASE", 35, 42], ["cardiac injury", "DISEASE", 44, 58], ["organ dysfunction", "DISEASE", 75, 92], ["cardiac", "ORGAN", 44, 51], ["organ", "ORGAN", 75, 80], ["Respiratory failure", "PROBLEM", 0, 19], ["septic shock", "PROBLEM", 21, 33], ["RNAemia", "PROBLEM", 35, 42], ["cardiac injury", "PROBLEM", 44, 58], ["multiple organ dysfunction", "PROBLEM", 66, 92], ["failure", "PROBLEM", 96, 103], ["failure", "OBSERVATION", 12, 19], ["septic shock", "OBSERVATION", 21, 33], ["cardiac", "ANATOMY", 44, 51], ["injury", "OBSERVATION", 52, 58], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["organ", "ANATOMY", 75, 80], ["dysfunction", "OBSERVATION", 81, 92], ["failure", "OBSERVATION", 96, 103]]], ["Case fatality rate is 49% (higher case fatality rate for patients with preexisting co-morbidities and lower-case fatality rate (0.9%) for patients without co-morbidities).", [["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 138, 146], ["Case fatality rate", "TEST", 0, 18], ["preexisting co-morbidities", "PROBLEM", 71, 97], ["fatality rate", "TEST", 113, 126], ["co-morbidities", "PROBLEM", 155, 169]]], ["Cardiovascular disease (10.5%), diabetes (7.3%), respiratory disease (6.5%), hypertension (6%) and oncological complications (5.6%).The symptoms of SARS-CoV-2 infection appear after an incubation period of 1 to 14 days, similar to those of SARS-and MERS-CoV infections (median approximately 5.2 days in different studies)and 95% of patients are likely to experience symptoms within 12.5 days from contact [24, [106] [107] [108] .", [["Cardiovascular", "ANATOMY", 0, 14], ["respiratory", "ANATOMY", 49, 60], ["Cardiovascular disease", "DISEASE", 0, 22], ["diabetes", "DISEASE", 32, 40], ["respiratory disease", "DISEASE", 49, 68], ["hypertension", "DISEASE", 77, 89], ["SARS-CoV-2 infection", "DISEASE", 148, 168], ["SARS", "DISEASE", 240, 244], ["infections", "DISEASE", 258, 268], ["Cardiovascular", "MULTI-TISSUE_STRUCTURE", 0, 14], ["SARS-CoV-2", "ORGANISM", 148, 158], ["MERS-CoV", "ORGANISM", 249, 257], ["patients", "ORGANISM", 332, 340], ["CoV-2", "SPECIES", 153, 158], ["patients", "SPECIES", 332, 340], ["SARS-CoV-2", "SPECIES", 148, 158], ["MERS-CoV", "SPECIES", 249, 257], ["Cardiovascular disease", "PROBLEM", 0, 22], ["diabetes", "PROBLEM", 32, 40], ["respiratory disease", "PROBLEM", 49, 68], ["hypertension", "PROBLEM", 77, 89], ["oncological complications", "PROBLEM", 99, 124], ["The symptoms", "PROBLEM", 132, 144], ["SARS", "PROBLEM", 148, 152], ["CoV-2 infection", "PROBLEM", 153, 168], ["SARS", "PROBLEM", 240, 244], ["MERS", "PROBLEM", 249, 253], ["CoV infections", "PROBLEM", 254, 268], ["different studies", "TEST", 303, 320], ["symptoms", "PROBLEM", 366, 374], ["disease", "OBSERVATION", 15, 22], ["respiratory", "ANATOMY", 49, 60], ["disease", "OBSERVATION", 61, 68], ["hypertension", "OBSERVATION", 77, 89], ["SARS", "OBSERVATION", 148, 152], ["infection", "OBSERVATION", 159, 168]]], ["The median time between onset of symptoms and dyspnea is 5 days, 7 days for hospitalization and 8 days for acute respiratory distress syndrome (ARDS) (Figure 7 ) [24] (https://www.epicentro.iss.it/coronavirus/sars-cov-2).", [["respiratory", "ANATOMY", 113, 124], ["dyspnea", "DISEASE", 46, 53], ["acute respiratory distress syndrome", "DISEASE", 107, 142], ["ARDS", "DISEASE", 144, 148], ["symptoms", "PROBLEM", 33, 41], ["dyspnea", "PROBLEM", 46, 53], ["acute respiratory distress syndrome", "PROBLEM", 107, 142], ["ARDS", "PROBLEM", 144, 148], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory", "ANATOMY", 113, 124], ["distress", "OBSERVATION", 125, 133]]], ["Patients at this stage in intensive care unit (ICU) with quarantine facilities may require mechanical ventilation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["quarantine facilities", "TREATMENT", 57, 78], ["mechanical ventilation", "TREATMENT", 91, 113], ["mechanical ventilation", "OBSERVATION", 91, 113]]], ["Moreover, bacterial infections can cause a secondary pneumonia [108] .", [["bacterial infections", "DISEASE", 10, 30], ["pneumonia", "DISEASE", 53, 62], ["bacterial infections", "PROBLEM", 10, 30], ["a secondary pneumonia", "PROBLEM", 41, 62], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30], ["secondary", "OBSERVATION_MODIFIER", 43, 52], ["pneumonia", "OBSERVATION", 53, 62]]], ["In addition, the period from the beginning of COVID-19 symptoms to death varied between 6 and 41 days with an average of 14 days [110] .", [["death", "DISEASE", 67, 72], ["COVID", "TEST", 46, 51], ["symptoms", "PROBLEM", 55, 63], ["death", "PROBLEM", 67, 72]]], ["This period depends on immune system status and the patient's age, being shorter in 70-year-old subjects compared with those younger [78, 110] .", [["immune system", "ANATOMY", 23, 36], ["patient", "ORGANISM", 52, 59], ["subjects", "ORGANISM", 96, 104], ["patient", "SPECIES", 52, 59]]], ["In people with compromised immune systems and in elderly patients with underlying health problems, SARS-CoV-2 is able to infect the lower respiratory tract leading to severe pneumonia [111] .", [["lower respiratory tract", "ANATOMY", 132, 155], ["SARS", "DISEASE", 99, 103], ["lower respiratory tract", "DISEASE", 132, 155], ["pneumonia", "DISEASE", 174, 183], ["people", "ORGANISM", 3, 9], ["patients", "ORGANISM", 57, 65], ["SARS-CoV-2", "ORGANISM", 99, 109], ["lower", "ORGANISM_SUBDIVISION", 132, 137], ["respiratory tract", "ORGANISM_SUBDIVISION", 138, 155], ["people", "SPECIES", 3, 9], ["patients", "SPECIES", 57, 65], ["SARS-CoV", "SPECIES", 99, 107], ["compromised immune systems", "PROBLEM", 15, 41], ["underlying health problems", "PROBLEM", 71, 97], ["SARS", "PROBLEM", 99, 103], ["severe pneumonia", "PROBLEM", 167, 183], ["lower", "ANATOMY_MODIFIER", 132, 137], ["respiratory tract", "ANATOMY", 138, 155], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["pneumonia", "OBSERVATION", 174, 183]]], ["In 25-30% of patients presenting acute lung injury, shock, ARDS and acute kidney injury, ICU admission was absolutely required [24] .", [["lung", "ANATOMY", 39, 43], ["kidney", "ANATOMY", 74, 80], ["acute lung injury", "DISEASE", 33, 50], ["shock", "DISEASE", 52, 57], ["ARDS", "DISEASE", 59, 63], ["acute kidney injury", "DISEASE", 68, 87], ["patients", "ORGANISM", 13, 21], ["lung", "ORGAN", 39, 43], ["kidney", "ORGAN", 74, 80], ["patients", "SPECIES", 13, 21], ["acute lung injury", "PROBLEM", 33, 50], ["shock", "PROBLEM", 52, 57], ["ARDS", "PROBLEM", 59, 63], ["acute kidney injury", "PROBLEM", 68, 87], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["lung", "ANATOMY", 39, 43], ["injury", "OBSERVATION", 44, 50], ["shock", "OBSERVATION", 52, 57], ["ARDS", "OBSERVATION", 59, 63], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["kidney", "ANATOMY", 74, 80], ["injury", "OBSERVATION", 81, 87]]], ["The virus appears to be more fatal in individuals with underlying co-morbidities (50-75% of fatal cases) [24, 111] .", [["The virus", "PROBLEM", 0, 9], ["underlying co-morbidities", "PROBLEM", 55, 80], ["virus", "OBSERVATION", 4, 9], ["appears to be", "UNCERTAINTY", 10, 23], ["more", "OBSERVATION_MODIFIER", 24, 28], ["fatal", "OBSERVATION_MODIFIER", 29, 34], ["co-morbidities", "OBSERVATION", 66, 80]]], ["Available dataset was obtained from Italian Istituto Superiore di Sanit\u00e0 (ISS) on 34,026 patients dying in-hospitals ( Figure 7) .", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["The mean number of diseases was 3.3 (median 3, SD 1.9).", [["diseases", "PROBLEM", 19, 27], ["SD", "TEST", 47, 49], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["diseases", "OBSERVATION", 19, 27]]], ["Overall, 4.0% of the reported cases has no co-morbidities, 14.0% with a single comorbidity, 20.6% with 2 and 61.4% with 3 or more (https://www.epicentro.iss.it/coronavirus/sars-cov-2).The symptoms of SARS-CoV-2 infection appear after an incubation period of 1 to 14 days, similar to those of SARS-and MERS-CoV infections (median approximately 5.2 days in different studies)SARS-CoV-2 infections revealed some unique clinical characteristics that include targeting the lower airway which is evident by symptoms of upper respiratory tract including rhinorrhoea, sneezing and sore throat [78] .", [["lower airway", "ANATOMY", 468, 480], ["upper respiratory tract", "ANATOMY", 513, 536], ["SARS-CoV-2 infection", "DISEASE", 200, 220], ["SARS", "DISEASE", 292, 296], ["infections", "DISEASE", 310, 320], ["SARS", "DISEASE", 373, 377], ["infections", "DISEASE", 384, 394], ["rhinorrhoea", "DISEASE", 547, 558], ["sneezing", "DISEASE", 560, 568], ["sore throat", "DISEASE", 573, 584], ["SARS-CoV-2", "ORGANISM", 200, 210], ["MERS-CoV", "ORGANISM", 301, 309], ["SARS-CoV-2", "ORGANISM", 373, 383], ["lower airway", "ORGANISM_SUBDIVISION", 468, 480], ["upper respiratory", "ORGANISM_SUBDIVISION", 513, 530], ["tract", "ORGANISM_SUBDIVISION", 531, 536], ["CoV-2", "SPECIES", 205, 210], ["SARS-CoV", "SPECIES", 200, 208], ["MERS-CoV", "SPECIES", 301, 309], ["co-morbidities", "PROBLEM", 43, 57], ["a single comorbidity", "TEST", 70, 90], ["The symptoms", "PROBLEM", 184, 196], ["SARS", "PROBLEM", 200, 204], ["CoV-2 infection", "PROBLEM", 205, 220], ["SARS", "PROBLEM", 292, 296], ["MERS", "PROBLEM", 301, 305], ["CoV infections", "PROBLEM", 306, 320], ["different studies", "TEST", 355, 372], ["SARS", "PROBLEM", 373, 377], ["CoV-2 infections", "PROBLEM", 378, 394], ["the lower airway", "PROBLEM", 464, 480], ["symptoms", "PROBLEM", 501, 509], ["upper respiratory tract", "PROBLEM", 513, 536], ["rhinorrhoea", "PROBLEM", 547, 558], ["sneezing", "PROBLEM", 560, 568], ["sore throat", "PROBLEM", 573, 584], ["no", "UNCERTAINTY", 40, 42], ["infection", "OBSERVATION", 211, 220], ["lower", "ANATOMY_MODIFIER", 468, 473], ["airway", "ANATOMY", 474, 480], ["upper", "ANATOMY_MODIFIER", 513, 518], ["respiratory tract", "ANATOMY", 519, 536], ["rhinorrhoea", "OBSERVATION", 547, 558]]], ["Chest computed tomography (CT) scans revealed pneumonia in most SARS-CoV-2 infected patients and several cases showed an infiltrate in the upper lung lobe, which is related to increasing dyspnea with hypoxemia [28, 78, 112] .", [["upper lung lobe", "ANATOMY", 139, 154], ["pneumonia", "DISEASE", 46, 55], ["SARS-CoV-2 infected", "DISEASE", 64, 83], ["dyspnea", "DISEASE", 187, 194], ["hypoxemia", "DISEASE", 200, 209], ["SARS-CoV-2", "ORGANISM", 64, 74], ["patients", "ORGANISM", 84, 92], ["upper lung lobe", "MULTI-TISSUE_STRUCTURE", 139, 154], ["patients", "SPECIES", 84, 92], ["Chest computed tomography (CT) scans", "TEST", 0, 36], ["pneumonia", "PROBLEM", 46, 55], ["most SARS", "PROBLEM", 59, 68], ["CoV", "TEST", 69, 72], ["several cases", "TEST", 97, 110], ["an infiltrate in the upper lung lobe", "PROBLEM", 118, 154], ["increasing dyspnea", "PROBLEM", 176, 194], ["hypoxemia", "PROBLEM", 200, 209], ["pneumonia", "OBSERVATION", 46, 55], ["infiltrate", "OBSERVATION", 121, 131], ["upper lung", "ANATOMY", 139, 149], ["lobe", "ANATOMY", 150, 154], ["increasing", "OBSERVATION_MODIFIER", 176, 186], ["dyspnea", "OBSERVATION", 187, 194], ["hypoxemia", "OBSERVATION", 200, 209]]], ["Atypical symptoms include RNAemia, acute cardiac injury, ARDS and grand-glass opacities that lead to death [113] .", [["cardiac", "ANATOMY", 41, 48], ["RNAemia", "DISEASE", 26, 33], ["cardiac injury", "DISEASE", 41, 55], ["ARDS", "DISEASE", 57, 61], ["opacities", "DISEASE", 78, 87], ["death", "DISEASE", 101, 106], ["cardiac", "ORGAN", 41, 48], ["Atypical symptoms", "PROBLEM", 0, 17], ["RNAemia", "PROBLEM", 26, 33], ["acute cardiac injury", "PROBLEM", 35, 55], ["ARDS", "PROBLEM", 57, 61], ["grand-glass opacities", "PROBLEM", 66, 87], ["death", "PROBLEM", 101, 106], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["cardiac", "ANATOMY", 41, 48], ["injury", "OBSERVATION", 49, 55], ["ARDS", "OBSERVATION", 57, 61], ["glass opacities", "OBSERVATION", 72, 87]]], ["It should be noted that COVID-19 manifestations such as fever, dyspnea, dry cough and bilateral ground-glass opacities in chest CT scans are similar to the previous Betacoronavirus-related diseases [113, 114] .", [["fever", "DISEASE", 56, 61], ["dyspnea", "DISEASE", 63, 70], ["dry cough", "DISEASE", 72, 81], ["Betacoronavirus", "CHEMICAL", 165, 180], ["COVID", "TEST", 24, 29], ["fever", "PROBLEM", 56, 61], ["dyspnea", "PROBLEM", 63, 70], ["dry cough", "PROBLEM", 72, 81], ["bilateral ground-glass opacities", "PROBLEM", 86, 118], ["chest CT scans", "TEST", 122, 136], ["related diseases", "PROBLEM", 181, 197], ["dry", "OBSERVATION_MODIFIER", 72, 75], ["cough", "OBSERVATION", 76, 81], ["bilateral", "ANATOMY_MODIFIER", 86, 95], ["ground", "OBSERVATION_MODIFIER", 96, 102], ["glass opacities", "OBSERVATION", 103, 118], ["chest", "ANATOMY", 122, 127]]], ["Although gastrointestinal symptoms such as diarrhea were reported in SARS-CoV-2 infected patients, the similar gastrointestinal distress occurred in only a small percentage of MERS-CoV or SARS-CoV patients ( Figure 6 ) [78] .", [["gastrointestinal", "ANATOMY", 9, 25], ["gastrointestinal", "ANATOMY", 111, 127], ["gastrointestinal symptoms", "DISEASE", 9, 34], ["diarrhea", "DISEASE", 43, 51], ["SARS-CoV-2 infected", "DISEASE", 69, 88], ["gastrointestinal distress", "DISEASE", 111, 136], ["SARS-CoV", "DISEASE", 188, 196], ["gastrointestinal", "ORGAN", 9, 25], ["SARS-CoV-2", "ORGANISM", 69, 79], ["patients", "ORGANISM", 89, 97], ["gastrointestinal", "ORGAN", 111, 127], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 176, 184], ["SARS-CoV", "ORGANISM", 188, 196], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 197, 205], ["SARS-CoV", "SPECIES", 69, 77], ["MERS-CoV", "SPECIES", 176, 184], ["SARS-CoV", "SPECIES", 188, 196], ["gastrointestinal symptoms", "PROBLEM", 9, 34], ["diarrhea", "PROBLEM", 43, 51], ["SARS", "PROBLEM", 69, 73], ["the similar gastrointestinal distress", "PROBLEM", 99, 136], ["SARS", "PROBLEM", 188, 192], ["gastrointestinal", "ANATOMY", 9, 25], ["gastrointestinal", "ANATOMY", 111, 127], ["distress", "OBSERVATION", 128, 136], ["small", "OBSERVATION_MODIFIER", 156, 161]]], ["It was shown that severe cases were characterized by an increased inflammation due to both systemic and localized immune response activation [78, 115] .", [["inflammation", "DISEASE", 66, 78], ["severe cases", "PROBLEM", 18, 30], ["an increased inflammation", "PROBLEM", 53, 78], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["inflammation", "OBSERVATION", 66, 78], ["immune response", "OBSERVATION", 114, 129]]], ["Higher leukocyte numbers, significantly high blood concentrations of cytokines and chemokines were noted in these cases [28, 78] .", [["leukocyte", "ANATOMY", 7, 16], ["blood", "ANATOMY", 45, 50], ["leukocyte", "CELL", 7, 16], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["cytokines", "PROTEIN", 69, 78], ["chemokines", "PROTEIN", 83, 93], ["Higher leukocyte numbers", "TEST", 0, 24], ["significantly high blood concentrations of cytokines", "PROBLEM", 26, 78], ["chemokines", "TEST", 83, 93], ["these cases", "TEST", 108, 119], ["significantly", "OBSERVATION_MODIFIER", 26, 39], ["high", "OBSERVATION_MODIFIER", 40, 44]]], ["Hence, it is now accepted that high levels of proinflammatory cytokines could worsen the prognosis [28, 113] .Int.", [["proinflammatory cytokines", "PROTEIN", 46, 71], ["proinflammatory cytokines", "PROBLEM", 46, 71]]], ["Res. Public Health 2020, 17, x FOR PEER REVIEW 14 of 35The symptoms of SARS-CoV-2 infection appear after an incubation period of 1 to 14 days, similar to those of SARS-and MERS-CoV infections (median approximately 5.2 days in different studies) and 95% of patients are likely to experience symptoms within 12.5 days from contact [24, [106] [107] [108] .", [["SARS-CoV-2 infection", "DISEASE", 71, 91], ["SARS", "DISEASE", 163, 167], ["infections", "DISEASE", 181, 191], ["SARS-CoV-2", "ORGANISM", 71, 81], ["MERS-CoV", "ORGANISM", 172, 180], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 256, 264], ["SARS-CoV-2", "SPECIES", 71, 81], ["MERS-CoV", "SPECIES", 172, 180], ["PEER REVIEW", "TEST", 35, 46], ["The symptoms", "PROBLEM", 55, 67], ["SARS", "PROBLEM", 71, 75], ["CoV-2 infection", "PROBLEM", 76, 91], ["SARS", "PROBLEM", 163, 167], ["MERS", "PROBLEM", 172, 176], ["CoV infections", "PROBLEM", 177, 191], ["different studies", "TEST", 226, 243], ["symptoms", "PROBLEM", 290, 298], ["infection", "OBSERVATION", 82, 91]]], ["The median time between onset of symptoms and dyspnea is 5 days, 7 days for hospitalization and 8 days for acute respiratory distress syndrome (ARDS) (Figure 7 ) [24] (https://www.epicentro.iss.it/coronavirus/sars-cov-2).", [["respiratory", "ANATOMY", 113, 124], ["dyspnea", "DISEASE", 46, 53], ["acute respiratory distress syndrome", "DISEASE", 107, 142], ["ARDS", "DISEASE", 144, 148], ["symptoms", "PROBLEM", 33, 41], ["dyspnea", "PROBLEM", 46, 53], ["acute respiratory distress syndrome", "PROBLEM", 107, 142], ["ARDS", "PROBLEM", 144, 148], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory", "ANATOMY", 113, 124], ["distress", "OBSERVATION", 125, 133]]], ["Patients at this stage in intensive care unit (ICU) with quarantine facilities may require mechanical ventilation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["quarantine facilities", "TREATMENT", 57, 78], ["mechanical ventilation", "TREATMENT", 91, 113], ["mechanical ventilation", "OBSERVATION", 91, 113]]], ["Moreover, bacterial infections can cause a secondary pneumonia [108] .", [["bacterial infections", "DISEASE", 10, 30], ["pneumonia", "DISEASE", 53, 62], ["bacterial infections", "PROBLEM", 10, 30], ["a secondary pneumonia", "PROBLEM", 41, 62], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30], ["secondary", "OBSERVATION_MODIFIER", 43, 52], ["pneumonia", "OBSERVATION", 53, 62]]], ["In addition, the period from the beginning of COVID-19 symptoms to death varied between 6 and 41 days with an average of 14 days [110] .", [["death", "DISEASE", 67, 72], ["COVID", "TEST", 46, 51], ["symptoms", "PROBLEM", 55, 63], ["death", "PROBLEM", 67, 72]]], ["This period depends on immune system status and the patient's age, being shorter in 70-year-old subjects compared with those younger [78, 110] .", [["immune system", "ANATOMY", 23, 36], ["patient", "ORGANISM", 52, 59], ["subjects", "ORGANISM", 96, 104], ["patient", "SPECIES", 52, 59]]], ["In people with compromised immune systems and in elderly patients with underlying health problems, SARS-CoV-2 is able to infect the lower respiratory tract leading to severe pneumonia [111] .", [["lower respiratory tract", "ANATOMY", 132, 155], ["SARS", "DISEASE", 99, 103], ["lower respiratory tract", "DISEASE", 132, 155], ["pneumonia", "DISEASE", 174, 183], ["people", "ORGANISM", 3, 9], ["patients", "ORGANISM", 57, 65], ["SARS-CoV-2", "ORGANISM", 99, 109], ["lower", "ORGANISM_SUBDIVISION", 132, 137], ["respiratory tract", "ORGANISM_SUBDIVISION", 138, 155], ["people", "SPECIES", 3, 9], ["patients", "SPECIES", 57, 65], ["SARS-CoV", "SPECIES", 99, 107], ["compromised immune systems", "PROBLEM", 15, 41], ["underlying health problems", "PROBLEM", 71, 97], ["SARS", "PROBLEM", 99, 103], ["severe pneumonia", "PROBLEM", 167, 183], ["lower", "ANATOMY_MODIFIER", 132, 137], ["respiratory tract", "ANATOMY", 138, 155], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["pneumonia", "OBSERVATION", 174, 183]]], ["In 25%-30% of patients presenting acute lung injury, shock, ARDS and acute kidney injury, ICU admission was absolutely required [24] .", [["lung", "ANATOMY", 40, 44], ["kidney", "ANATOMY", 75, 81], ["acute lung injury", "DISEASE", 34, 51], ["shock", "DISEASE", 53, 58], ["ARDS", "DISEASE", 60, 64], ["acute kidney injury", "DISEASE", 69, 88], ["patients", "ORGANISM", 14, 22], ["lung", "ORGAN", 40, 44], ["kidney", "ORGAN", 75, 81], ["patients", "SPECIES", 14, 22], ["acute lung injury", "PROBLEM", 34, 51], ["shock", "PROBLEM", 53, 58], ["ARDS", "PROBLEM", 60, 64], ["acute kidney injury", "PROBLEM", 69, 88], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["lung", "ANATOMY", 40, 44], ["injury", "OBSERVATION", 45, 51], ["shock", "OBSERVATION", 53, 58], ["ARDS", "OBSERVATION", 60, 64], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["kidney", "ANATOMY", 75, 81], ["injury", "OBSERVATION", 82, 88]]], ["The virus appears to be more fatal in individuals with underlying co-morbidities (50%-75% of fatal cases) [24, 111] .", [["The virus", "PROBLEM", 0, 9], ["underlying co-morbidities", "PROBLEM", 55, 80], ["virus", "OBSERVATION", 4, 9], ["appears to be", "UNCERTAINTY", 10, 23], ["more", "OBSERVATION_MODIFIER", 24, 28], ["fatal", "OBSERVATION_MODIFIER", 29, 34], ["co-morbidities", "OBSERVATION", 66, 80]]], ["Available dataset was obtained from Italian Istituto Superiore di Sanit\u00e0 (ISS) on 34,026 patients dying inhospitals ( Figure 7) .", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["The mean number of diseases was 3.3 (median 3, SD 1.9).", [["diseases", "PROBLEM", 19, 27], ["SD", "TEST", 47, 49], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["diseases", "OBSERVATION", 19, 27]]], ["Overall, 4.0% of the reported cases has no co-morbidities, 14.0% with a single comorbidity, 20.6% with 2 and 61.4% with 3 or more (https://www.epicentro.iss.it/coronavirus/sars-cov-2).", [["co-morbidities", "PROBLEM", 43, 57], ["a single comorbidity", "TEST", 70, 90], ["no", "UNCERTAINTY", 40, 42]]], ["Median times, in days, from the onset of symptoms to death, to hospitalization, from hospitalization to death with and without intensive care unit (ICU)-admittance (Report based on available data on July 9th, 2020 collected from Istituto Superiore di Sanit\u00e0, ISS).", [["death", "DISEASE", 53, 58], ["death", "DISEASE", 104, 109], ["symptoms", "PROBLEM", 41, 49]]], ["SARS-CoV-2 infections revealed some unique clinical characteristics that include targeting the lower airway which is evident by symptoms of upper respiratory tract including rhinorrhoea, sneezing and sore throat [78] .", [["lower airway", "ANATOMY", 95, 107], ["upper respiratory tract", "ANATOMY", 140, 163], ["SARS", "DISEASE", 0, 4], ["infections", "DISEASE", 11, 21], ["rhinorrhoea", "DISEASE", 174, 185], ["sneezing", "DISEASE", 187, 195], ["sore throat", "DISEASE", 200, 211], ["SARS-CoV-2", "ORGANISM", 0, 10], ["lower airway", "ORGANISM_SUBDIVISION", 95, 107], ["upper", "ORGANISM_SUBDIVISION", 140, 145], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["SARS", "PROBLEM", 0, 4], ["CoV-2 infections", "PROBLEM", 5, 21], ["the lower airway", "PROBLEM", 91, 107], ["symptoms", "PROBLEM", 128, 136], ["upper respiratory tract", "PROBLEM", 140, 163], ["rhinorrhoea", "PROBLEM", 174, 185], ["sneezing", "PROBLEM", 187, 195], ["sore throat", "PROBLEM", 200, 211], ["lower", "ANATOMY_MODIFIER", 95, 100], ["airway", "ANATOMY", 101, 107], ["upper", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163], ["rhinorrhoea", "OBSERVATION", 174, 185]]], ["Chest computed tomography (CT) scans revealed pneumonia in most SARS-CoV-2 infected patients and several cases showed an infiltrate in the upper lung lobe, which is related to increasing dyspnea with hypoxemia [28, 78, 112] .", [["upper lung lobe", "ANATOMY", 139, 154], ["pneumonia", "DISEASE", 46, 55], ["SARS-CoV-2 infected", "DISEASE", 64, 83], ["dyspnea", "DISEASE", 187, 194], ["hypoxemia", "DISEASE", 200, 209], ["SARS-CoV-2", "ORGANISM", 64, 74], ["patients", "ORGANISM", 84, 92], ["upper lung lobe", "MULTI-TISSUE_STRUCTURE", 139, 154], ["patients", "SPECIES", 84, 92], ["Chest computed tomography (CT) scans", "TEST", 0, 36], ["pneumonia", "PROBLEM", 46, 55], ["most SARS", "PROBLEM", 59, 68], ["CoV", "TEST", 69, 72], ["several cases", "TEST", 97, 110], ["an infiltrate in the upper lung lobe", "PROBLEM", 118, 154], ["increasing dyspnea", "PROBLEM", 176, 194], ["hypoxemia", "PROBLEM", 200, 209], ["pneumonia", "OBSERVATION", 46, 55], ["infiltrate", "OBSERVATION", 121, 131], ["upper lung", "ANATOMY", 139, 149], ["lobe", "ANATOMY", 150, 154], ["increasing", "OBSERVATION_MODIFIER", 176, 186], ["dyspnea", "OBSERVATION", 187, 194], ["hypoxemia", "OBSERVATION", 200, 209]]], ["Atypical symptoms include RNAemia, acute cardiac injury, ARDS and grand-glass opacities that lead to death [113] .", [["cardiac", "ANATOMY", 41, 48], ["RNAemia", "DISEASE", 26, 33], ["cardiac injury", "DISEASE", 41, 55], ["ARDS", "DISEASE", 57, 61], ["opacities", "DISEASE", 78, 87], ["death", "DISEASE", 101, 106], ["cardiac", "ORGAN", 41, 48], ["Atypical symptoms", "PROBLEM", 0, 17], ["RNAemia", "PROBLEM", 26, 33], ["acute cardiac injury", "PROBLEM", 35, 55], ["ARDS", "PROBLEM", 57, 61], ["grand-glass opacities", "PROBLEM", 66, 87], ["death", "PROBLEM", 101, 106], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["cardiac", "ANATOMY", 41, 48], ["injury", "OBSERVATION", 49, 55], ["ARDS", "OBSERVATION", 57, 61], ["glass opacities", "OBSERVATION", 72, 87]]], ["It should be noted that COVID-19 manifestations Figure 7 .", [["COVID", "TEST", 24, 29]]], ["Median times, in days, from the onset of symptoms to death, to hospitalization, from hospitalization to death with and without intensive care unit (ICU)-admittance (Report based on available data on July 9th, 2020 collected from Istituto Superiore di Sanit\u00e0, ISS).DiagnosisCOVID-19 clinical evaluation is focused mainly on epidemiological data, clinical symptoms and clinical and laboratory tests.", [["death", "DISEASE", 53, 58], ["death", "DISEASE", 104, 109], ["symptoms", "PROBLEM", 41, 49], ["DiagnosisCOVID", "TEST", 264, 278], ["clinical evaluation", "TEST", 282, 301], ["epidemiological data", "TEST", 323, 343], ["clinical symptoms", "PROBLEM", 345, 362], ["clinical and laboratory tests", "TEST", 367, 396]]], ["Although the scenario is continually changing, several approaches were selected as standard laboratory methods for COVID-19 diagnosis.", [["COVID", "TEST", 115, 120]]], ["Lab tests, differently from clinical-based analyses, immediately reveal SARS-CoV-2 infected patients.", [["SARS-CoV-2 infected", "DISEASE", 72, 91], ["SARS-CoV-2", "ORGANISM", 72, 82], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Lab tests", "TEST", 0, 9], ["clinical-based analyses", "TEST", 28, 51], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["SARS", "OBSERVATION", 72, 76]]], ["This was particularly important for diagnosis due to the difficulties in detecting specific clinical signs and symptoms in COVID-19 patients.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["the difficulties", "PROBLEM", 53, 69], ["symptoms", "PROBLEM", 111, 119], ["COVID", "TEST", 123, 128]]], ["Moreover, atypical manifestations revealed by pulmonary imaging [116] and the huge number of different clinical signs and symptoms forced the development of molecular-based laboratory tests [117, 118] .", [["pulmonary", "ANATOMY", 46, 55], ["pulmonary", "ORGAN", 46, 55], ["atypical manifestations", "PROBLEM", 10, 33], ["pulmonary imaging", "TEST", 46, 63], ["different clinical signs", "PROBLEM", 93, 117], ["symptoms", "PROBLEM", 122, 130], ["pulmonary", "ANATOMY", 46, 55], ["huge", "OBSERVATION_MODIFIER", 78, 82], ["number", "OBSERVATION_MODIFIER", 83, 89]]], ["Lastly, the analysis of personal history of each patient played a fundamental role in COVID-19 diagnosis and up to now is considered one of the key information for detecting infected patients also in the early phases of infection.", [["infection", "DISEASE", 220, 229], ["patient", "ORGANISM", 49, 56], ["patients", "ORGANISM", 183, 191], ["patient", "SPECIES", 49, 56], ["patients", "SPECIES", 183, 191], ["infection", "PROBLEM", 220, 229], ["infected", "OBSERVATION", 174, 182], ["early phases", "OBSERVATION_MODIFIER", 204, 216], ["infection", "OBSERVATION", 220, 229]]], ["Therefore, the epidemiological history together with clinical and laboratory tests are all required for the diagnosis of COVID-19.", [["laboratory tests", "TEST", 66, 82], ["COVID", "TEST", 121, 126]]], ["A detailed description focused on clinical diagnostic methods was reviewed by Taisheng Li [119] .", [["Taisheng Li", "CHEMICAL", 78, 89]]], ["Herein, we present an updated overview of the principal techniques used for COVID-19 diagnosis.Nucleic Acid Detection TechnologyHigh-throughput sequencing and real time quantitative polymerase chain reaction (RT-qPCR) are the best nucleic acid detection techniques for SARS-CoV-2.", [["SARS-CoV", "SPECIES", 269, 277], ["High-throughput sequencing", "PROBLEM", 128, 154], ["real time quantitative polymerase chain reaction", "PROBLEM", 159, 207], ["RT-qPCR", "TEST", 209, 216], ["SARS", "TEST", 269, 273], ["CoV", "TEST", 274, 277]]], ["Moreover, to speed up the development of standardized analytic kits for diagnostic application, the quantification of viral load was not considered.", [["diagnostic application", "TREATMENT", 72, 94], ["viral load", "PROBLEM", 118, 128], ["viral load", "OBSERVATION", 118, 128]]], ["Therefore, the RT-PCR method was chosen as the gold standard for the detection of SARS-CoV-2 infections from the commonly used samples such as naso-and oropharyngeal swabs [106, 107, 121, 122] .", [["samples", "ANATOMY", 127, 134], ["oropharyngeal swabs", "ANATOMY", 152, 171], ["SARS", "DISEASE", 82, 86], ["infections", "DISEASE", 93, 103], ["SARS-CoV-2", "ORGANISM", 82, 92], ["SARS-CoV-2", "SPECIES", 82, 92], ["the RT-PCR method", "TEST", 11, 28], ["the detection", "TEST", 65, 78], ["SARS", "PROBLEM", 82, 86], ["CoV", "PROBLEM", 87, 90], ["2 infections", "PROBLEM", 91, 103], ["naso", "TEST", 143, 147], ["oropharyngeal swabs", "TEST", 152, 171], ["oropharyngeal swabs", "ANATOMY", 152, 171]]], ["This molecular method relies on the amplification of up to three SARS-CoV-2 specific targets including the RNA-dependent RNA polymerase (RdRp), E and N genes [121] .", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 107, 135], ["E", "GENE_OR_GENE_PRODUCT", 144, 145], ["SARS-CoV-2 specific targets", "DNA", 65, 92], ["RNA-dependent RNA polymerase (RdRp), E and N genes", "DNA", 107, 157], ["the amplification", "TEST", 32, 49], ["CoV", "TEST", 70, 73], ["the RNA", "TEST", 103, 110]]], ["The WHO has released numerous RT-PCR protocols for the detection of SARS-CoV-2 RNA at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance (Accessed March 15, 2020).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["SARS-CoV", "SPECIES", 68, 76], ["numerous RT-PCR protocols", "TREATMENT", 21, 46], ["the detection", "TEST", 51, 64], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76]]], ["Three of those protocols are mentioned below.", [["those protocols", "TREATMENT", 9, 24]]], ["The US centers for disease control and prevention (CDC) developed an RT-PCR that includes three sets of oligonucleotide primers and probes recognizing three regions of the virus N gene (named N1, N2 and N3) and an additional primer/probe set to detect the human RNase P gene (RP) representing an internal control for RNA extraction and retro-transcription.", [["human", "ORGANISM", 256, 261], ["RNase P", "GENE_OR_GENE_PRODUCT", 262, 269], ["oligonucleotide primers", "DNA", 104, 127], ["virus N gene", "DNA", 172, 184], ["N1", "DNA", 192, 194], ["N2", "DNA", 196, 198], ["N3", "DNA", 203, 205], ["human RNase P gene", "DNA", 256, 274], ["RP", "DNA", 276, 278], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["The US", "TEST", 0, 6], ["disease control", "TREATMENT", 19, 34], ["an RT-PCR", "TEST", 66, 75], ["oligonucleotide primers", "TREATMENT", 104, 127], ["N2 and N3", "TREATMENT", 196, 205], ["an additional primer/probe", "TREATMENT", 211, 237], ["an internal control", "TREATMENT", 293, 312], ["RNA extraction", "TREATMENT", 317, 331], ["retro-transcription", "TREATMENT", 336, 355], ["oligonucleotide primers", "OBSERVATION", 104, 127]]], ["Moreover, the positive control consisting in retro-transcribed viral RNA is also available at CDC.", [["retro-transcribed viral RNA", "RNA", 45, 72], ["the positive control", "TREATMENT", 10, 30], ["retro-transcribed viral RNA", "TREATMENT", 45, 72], ["viral RNA", "OBSERVATION", 63, 72]]], ["To report the positivity for SARS-CoV-2 two out of three N regions must be positive.", [["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "SPECIES", 29, 37], ["the positivity", "TEST", 10, 24], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["positive", "OBSERVATION", 75, 83]]], ["The Chinese Center for Disease Control and Prevention (China CDC) recommends the use of specific primers and probes targeting the ORF1ab and N gene regions for SARS-CoV-2 detection by RT-PCR [123] .", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 130, 136], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 160, 170], ["ORF1ab and N gene regions", "DNA", 130, 155], ["SARS-CoV", "SPECIES", 160, 168], ["Disease Control", "TREATMENT", 23, 38], ["specific primers", "TREATMENT", 88, 104], ["the ORF1ab and N gene regions", "TREATMENT", 126, 155], ["SARS", "PROBLEM", 160, 164], ["CoV", "TEST", 165, 168], ["RT-PCR", "TEST", 184, 190]]], ["Available online: http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html (accessed on 21 January 2020).Nucleic Acid Detection TechnologyOverall, the WHO summarized all the primer pairs and probes that can be used to detect SARS-CoV-2 in clinical specimens with the description of RT-PCR settings and the specificity.", [["specimens", "ANATOMY", 249, 258], ["CoV-2", "ORGANISM", 231, 236], ["specimens", "CANCER", 249, 258], ["primer pairs", "DNA", 175, 187], ["SARS-CoV", "SPECIES", 226, 234], ["SARS", "PROBLEM", 226, 230], ["CoV", "TEST", 231, 234], ["RT-PCR settings", "TEST", 283, 298]]], ["Apart from the possibility to perform the RT-PCR in house using the selected primer pairs and probes, several ready to use kits were developed for RT-PCR performing.", [["primer pairs", "DNA", 77, 89], ["the RT-PCR", "TEST", 38, 48], ["kits", "TREATMENT", 123, 127], ["RT-PCR", "TEST", 147, 153]]], ["Another example is represented by the BGI's real-time fluorescent RT-PCR Kit for detecting SARS-CoV-2 that includes one SARS-CoV-2 specific target and an internal control of the reaction (BGI, Cambridge, MA, USA).", [["SARS-CoV-2 specific target", "DNA", 120, 146], ["SARS-CoV", "SPECIES", 91, 99], ["the BGI", "TEST", 34, 41], ["fluorescent RT", "TEST", 54, 68], ["PCR Kit", "TEST", 69, 76], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["one SARS", "TEST", 116, 124], ["CoV", "TEST", 125, 128], ["the reaction", "PROBLEM", 174, 186]]], ["Both companies declared a sensibility of 100-150 viral copies per mL and a high specificity that excludes most respiratory tract viral and bacterial pathogens.", [["respiratory tract", "ANATOMY", 111, 128], ["most respiratory tract viral and bacterial pathogens", "PROBLEM", 106, 158], ["respiratory tract", "ANATOMY", 111, 128], ["bacterial pathogens", "OBSERVATION", 139, 158]]], ["The recommended samples for both in-house and ready-to-use RT-PCR kits include upper and lower respiratory specimens such as throat, nasal nasopharyngeal (NP) and/or oropharyngeal (OP) swabs, lower respiratory tract aspirates, sputum, bronchoalveolar lavage (BAL) fluid and nasopharyngeal wash/aspirate or nasal aspirate.", [["samples", "ANATOMY", 16, 23], ["lower respiratory specimens", "ANATOMY", 89, 116], ["throat", "ANATOMY", 125, 131], ["nasal nasopharyngeal", "ANATOMY", 133, 153], ["NP", "ANATOMY", 155, 157], ["oropharyngeal", "ANATOMY", 166, 179], ["OP", "ANATOMY", 181, 183], ["swabs", "ANATOMY", 185, 190], ["lower respiratory tract aspirates", "ANATOMY", 192, 225], ["sputum", "ANATOMY", 227, 233], ["bronchoalveolar lavage (BAL) fluid", "ANATOMY", 235, 269], ["nasopharyngeal", "ANATOMY", 274, 288], ["aspirate", "ANATOMY", 294, 302], ["nasal aspirate", "ANATOMY", 306, 320], ["upper", "ORGANISM_SUBDIVISION", 79, 84], ["throat", "ORGANISM_SUBDIVISION", 125, 131], ["nasal nasopharyngeal", "CANCER", 133, 153], ["oropharyngeal", "ORGANISM_SUBDIVISION", 166, 179], ["tract", "ORGANISM_SUBDIVISION", 210, 215], ["aspirates", "MULTI-TISSUE_STRUCTURE", 216, 225], ["sputum", "ORGANISM_SUBSTANCE", 227, 233], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 235, 257], ["fluid", "ORGANISM_SUBSTANCE", 264, 269], ["nasopharyngeal", "ORGAN", 274, 288], ["nasal aspirate", "MULTI-TISSUE_STRUCTURE", 306, 320], ["RT-PCR kits", "TEST", 59, 70], ["upper and lower respiratory specimens", "PROBLEM", 79, 116], ["nasal nasopharyngeal (NP)", "TREATMENT", 133, 158], ["oropharyngeal (OP)", "TREATMENT", 166, 184], ["lower respiratory tract aspirates", "PROBLEM", 192, 225], ["sputum", "TEST", 227, 233], ["bronchoalveolar lavage (BAL) fluid", "TEST", 235, 269], ["nasopharyngeal wash/aspirate", "TEST", 274, 302], ["nasal aspirate", "PROBLEM", 306, 320], ["upper", "ANATOMY_MODIFIER", 79, 84], ["lower", "ANATOMY_MODIFIER", 89, 94], ["respiratory", "ANATOMY", 95, 106], ["throat", "ANATOMY", 125, 131], ["nasal nasopharyngeal", "ANATOMY", 133, 153], ["oropharyngeal", "ANATOMY", 166, 179], ["respiratory tract", "ANATOMY", 198, 215], ["bronchoalveolar lavage", "OBSERVATION", 235, 257], ["nasopharyngeal", "ANATOMY", 274, 288], ["nasal", "ANATOMY", 306, 311], ["aspirate", "OBSERVATION", 312, 320]]], ["It was observed that samples of the lower respiratory tract provide the higher viral loads [74] .", [["samples", "ANATOMY", 21, 28], ["lower respiratory tract", "ANATOMY", 36, 59], ["lower", "ORGANISM_SUBDIVISION", 36, 41], ["respiratory tract", "ORGANISM_SUBDIVISION", 42, 59], ["the lower respiratory tract", "PROBLEM", 32, 59], ["the higher viral loads", "PROBLEM", 68, 90], ["lower", "ANATOMY_MODIFIER", 36, 41], ["respiratory tract", "ANATOMY", 42, 59]]], ["On the other hand, it was shown that in the early stage of infection, the positive rate of RT-PCR was reported to be about 60% for throat swab samples [125] .", [["throat swab samples", "ANATOMY", 131, 150], ["infection", "DISEASE", 59, 68], ["infection", "PROBLEM", 59, 68], ["PCR", "TEST", 94, 97], ["throat swab samples", "TEST", 131, 150], ["infection", "OBSERVATION", 59, 68]]], ["Indeed, although being the gold standard, the RT-PCR presents some drawbacks.", [["the RT-PCR", "TREATMENT", 42, 52]]], ["One of the most important is related to the sensibility because it was extensively reported that in the presence of low viral load this technique fails in detecting viral genome leading to false negative results [126] .", [["viral genome", "DNA", 165, 177], ["low viral load", "PROBLEM", 116, 130], ["viral genome", "PROBLEM", 165, 177], ["most important", "OBSERVATION_MODIFIER", 11, 25], ["low", "OBSERVATION_MODIFIER", 116, 119], ["viral load", "OBSERVATION", 120, 130], ["viral genome", "OBSERVATION", 165, 177]]], ["Due to this problem, clinical governance as well as kit troubleshooting indicate to retest all the samples showing only single positive target along with patient resampling.", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["this problem", "PROBLEM", 7, 19], ["kit troubleshooting", "TEST", 52, 71], ["the samples", "TEST", 95, 106], ["single positive target", "PROBLEM", 120, 142], ["patient resampling", "TREATMENT", 154, 172]]], ["To this respect, it should be underlined that operator skills or sampling sources can profoundly affect RT-PCR testing results [22] .", [["PCR testing", "TEST", 107, 118]]], ["Finally, during this pandemic several microbiologic labs worldwide are experiencing scarce availability of RNA extraction as well as ready-to-use RT-PCR kits increasing the timing of diagnosis confirmation through molecular approaches.", [["RNA extraction", "TREATMENT", 107, 121], ["RT-PCR kits", "TREATMENT", 146, 157]]], ["Very recently, it was reported that the Allplex 2019-nCoV and the RealStar SARS-CoV-2 RT-PCR kits can amplify the target genes bypassing the RNA extraction step for a faster diagnosis [127] .CT scans and Serology MethodsAlthough RT-PCR is specific for the diagnosis of COVID-19, its false-negative rate cannot be overlooked due to the severe consequences of missed diagnosis.", [["Allplex 2019-nCoV and the RealStar SARS-CoV-2 RT-PCR kits", "DNA", 40, 97], ["target genes", "DNA", 114, 126], ["the Allplex", "TEST", 36, 47], ["the RealStar SARS", "TEST", 62, 79], ["CoV", "TEST", 80, 83], ["RT-PCR kits", "TREATMENT", 86, 97], [".CT scans", "TEST", 190, 199], ["Serology", "TEST", 204, 212], ["PCR", "TEST", 232, 235], ["COVID", "TEST", 269, 274]]], ["Clinicians have demonstrated the usefulness of CT and chest radiography for the diagnosis of COVID-19 associated pneumonia [128] .", [["COVID-19", "CHEMICAL", 93, 101], ["pneumonia", "DISEASE", 113, 122], ["COVID-19", "CHEMICAL", 93, 101], ["CT", "TEST", 47, 49], ["chest radiography", "TEST", 54, 71], ["COVID-19 associated pneumonia", "PROBLEM", 93, 122], ["chest", "ANATOMY", 54, 59], ["pneumonia", "OBSERVATION", 113, 122]]], ["Moreover, the ability of radiologists to diagnose COVID-19 pneumonia from chest CT evaluations has been reported to be very high [129] .", [["COVID", "DISEASE", 50, 55], ["pneumonia", "DISEASE", 59, 68], ["chest", "ORGAN", 74, 79], ["COVID", "TEST", 50, 55], ["pneumonia", "PROBLEM", 59, 68], ["chest CT evaluations", "TEST", 74, 94], ["pneumonia", "OBSERVATION", 59, 68], ["chest", "ANATOMY", 74, 79]]], ["Then a combination between RT-PCR and CT imaging represents the best approach for the correct COVID-19 diagnosis.", [["RT-PCR", "TEST", 27, 33], ["CT imaging", "TEST", 38, 48], ["the correct COVID", "TEST", 82, 99]]], ["In particular, for early detection and assessment of disease severity, the high-resolution CT (HRCT) of the chest is considered necessary [130, 131] .", [["chest", "ANATOMY", 108, 113], ["chest", "ORGAN", 108, 113], ["early detection", "TEST", 19, 34], ["disease severity", "PROBLEM", 53, 69], ["the high-resolution CT (HRCT) of the chest", "TEST", 71, 113], ["chest", "ANATOMY", 108, 113]]], ["One study analyzed the consistency and diagnostic value of RT-PCR test compared with chest CT in 1014 patients with suspected SARS-CoV-2 infection.", [["chest", "ANATOMY", 85, 90], ["SARS-CoV-2 infection", "DISEASE", 126, 146], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["SARS-CoV-2", "SPECIES", 126, 136], ["One study", "TEST", 0, 9], ["diagnostic value", "TEST", 39, 55], ["RT-PCR test", "TEST", 59, 70], ["chest CT", "TEST", 85, 93], ["SARS", "PROBLEM", 126, 130], ["CoV-2 infection", "PROBLEM", 131, 146], ["chest", "ANATOMY", 85, 90], ["SARS", "OBSERVATION", 126, 130], ["infection", "OBSERVATION", 137, 146]]], ["Findings indicated that the chest CT sensitivity in suspected patients was 75% based on negative RT-PCR results and 97% based on positive RT-PCR results [132] .", [["chest", "ANATOMY", 28, 33], ["chest", "ORGAN", 28, 33], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["the chest CT sensitivity", "TEST", 24, 48], ["PCR", "TEST", 100, 103], ["positive RT", "TEST", 129, 140], ["chest", "ANATOMY", 28, 33]]], ["Moreover, Salehi et al. confirmed the higher sensibility of pulmonary imaging with respect to RT-PCR for COVID-19 diagnosis and showed a positive correlation between specific CT findings with the different stages of the disease and its severity [116] .", [["pulmonary", "ANATOMY", 60, 69], ["pulmonary", "ORGAN", 60, 69], ["pulmonary imaging", "TEST", 60, 77], ["RT-PCR", "TEST", 94, 100], ["COVID", "TEST", 105, 110], ["specific CT findings", "TEST", 166, 186], ["the disease", "PROBLEM", 216, 227], ["pulmonary", "ANATOMY", 60, 69], ["disease", "OBSERVATION", 220, 227]]], ["The collection of numerous CT images has opened the possibility to build a database of pulmonary images from COVID-19 patients.", [["pulmonary", "ANATOMY", 87, 96], ["pulmonary", "ORGAN", 87, 96], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["numerous CT images", "TEST", 18, 36], ["pulmonary images", "TEST", 87, 103], ["COVID", "TEST", 109, 114], ["pulmonary", "ANATOMY", 87, 96]]], ["Interestingly, the recent progress in integrating artificial intelligence (AI) with computer-aided design (CAD) software for diagnostic imaging revealed that AI could be used to support disease diagnosis [133, 134] .", [["diagnostic imaging", "TEST", 125, 143], ["AI", "PROBLEM", 158, 160]]], ["Ito et al. reviewed the literature on the use of AI for lung diagnostic imaging of COVID-19 patients.", [["lung", "ANATOMY", 56, 60], ["lung", "ORGAN", 56, 60], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["AI", "TREATMENT", 49, 51], ["lung diagnostic imaging", "TEST", 56, 79], ["COVID", "TEST", 83, 88], ["lung", "ANATOMY", 56, 60]]], ["Among the 15 selected studies, 11 used AI for CT and 4 used AI for chest radiography.", [["chest", "ANATOMY", 67, 72], ["selected studies", "TEST", 13, 29], ["CT", "TEST", 46, 48], ["chest radiography", "TEST", 67, 84], ["chest", "ANATOMY", 67, 72]]], ["The number of datasets ranged from 106 to 5941, with sensitivities ranging from 67-100% and specificities ranging from 81-100% for prediction of COVID-19 pneumonia.", [["pneumonia", "DISEASE", 154, 163], ["COVID-19", "SPECIES", 145, 153], ["datasets", "TEST", 14, 22], ["sensitivities", "TEST", 53, 66], ["specificities", "TEST", 92, 105], ["COVID", "TEST", 145, 150], ["pneumonia", "PROBLEM", 154, 163], ["pneumonia", "OBSERVATION", 154, 163]]], ["This study revealed the usefulness of AI approach to support the diagnosis of COVID-19, but also for future emerging diseases [134] .", [["This study", "TEST", 0, 10], ["AI approach", "TREATMENT", 38, 49], ["COVID", "TEST", 78, 83], ["future emerging diseases", "PROBLEM", 101, 125]]], ["All the collected knowledge on lung lesions revealed some characteristic CT findings of COVID-19 pneumonia: the pulmonary ground-glass opacities in a peripheral distribution and the consolidation referring to an increase in pulmonary parenchymal density [135] [136] [137] .", [["lung lesions", "ANATOMY", 31, 43], ["pulmonary", "ANATOMY", 112, 121], ["pulmonary parenchymal", "ANATOMY", 224, 245], ["pneumonia", "DISEASE", 97, 106], ["lung lesions", "CANCER", 31, 43], ["pulmonary parenchymal", "MULTI-TISSUE_STRUCTURE", 224, 245], ["lung lesions", "PROBLEM", 31, 43], ["COVID", "TEST", 88, 93], ["pneumonia", "PROBLEM", 97, 106], ["the pulmonary ground-glass opacities", "PROBLEM", 108, 144], ["the consolidation", "PROBLEM", 178, 195], ["an increase in pulmonary parenchymal density", "PROBLEM", 209, 253], ["lung", "ANATOMY", 31, 35], ["lesions", "OBSERVATION", 36, 43], ["pneumonia", "OBSERVATION", 97, 106], ["pulmonary", "ANATOMY", 112, 121], ["ground-glass opacities", "OBSERVATION", 122, 144], ["peripheral", "ANATOMY_MODIFIER", 150, 160], ["distribution", "OBSERVATION_MODIFIER", 161, 173], ["consolidation", "OBSERVATION", 182, 195], ["increase", "OBSERVATION_MODIFIER", 212, 220], ["pulmonary", "ANATOMY", 224, 233], ["parenchymal", "ANATOMY_MODIFIER", 234, 245], ["density", "OBSERVATION", 246, 253]]], ["However, chest CT manifestations can vary in different patients and stages of infection, highlighting certain shortcomings of this approach.", [["chest", "ANATOMY", 9, 14], ["infection", "DISEASE", 78, 87], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["chest CT manifestations", "TEST", 9, 32], ["infection", "PROBLEM", 78, 87], ["this approach", "TREATMENT", 126, 139], ["chest", "ANATOMY", 9, 14], ["infection", "OBSERVATION", 78, 87]]], ["Apart from atypical manifestation that cannot be recognized by radiologists, several lung images are common in viral pneumonia leading to misdiagnosis [138] .", [["lung", "ANATOMY", 85, 89], ["pneumonia", "DISEASE", 117, 126], ["misdiagnosis", "DISEASE", 138, 150], ["lung", "ORGAN", 85, 89], ["atypical manifestation", "PROBLEM", 11, 33], ["several lung images", "TEST", 77, 96], ["viral pneumonia", "PROBLEM", 111, 126], ["misdiagnosis", "PROBLEM", 138, 150], ["atypical", "OBSERVATION_MODIFIER", 11, 19], ["manifestation", "OBSERVATION", 20, 33], ["cannot be recognized", "UNCERTAINTY", 39, 59], ["lung", "ANATOMY", 85, 89], ["viral", "OBSERVATION_MODIFIER", 111, 116], ["pneumonia", "OBSERVATION", 117, 126]]], ["Soon after the beginning of SARS-CoV-2 spreading, infected patients underwent antibody research for both basic research and clinical applications.", [["SARS", "DISEASE", 28, 32], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36], ["antibody research", "TEST", 78, 95], ["clinical applications", "TREATMENT", 124, 145]]], ["One of the first studies reported the seroconversion of 100% of infected patients (n = 285) within 19 days after symptom onset.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["the seroconversion", "TEST", 34, 52], ["symptom onset", "PROBLEM", 113, 126]]], ["Seroconversion for IgM and IgG occurred simultaneously or sequentially and both immunoglobulins titers plateaued within 6 days after seroconversion.", [["IgM", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 27, 30], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 80, 95], ["IgM", "PROTEIN", 19, 22], ["IgG", "PROTEIN", 27, 30], ["immunoglobulins", "PROTEIN", 80, 95], ["Seroconversion", "TREATMENT", 0, 14], ["IgM", "PROBLEM", 19, 22], ["IgG", "PROBLEM", 27, 30], ["both immunoglobulins titers", "TEST", 75, 102], ["seroconversion", "PROBLEM", 133, 147]]], ["Importantly, the application of serology testing in surveillance in a cluster of 164 close contacts of COVID-19 patients identified 4.6% of positive patients showing negative RT-PCR results [139] .", [["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 149, 157], ["serology testing", "TEST", 32, 48], ["surveillance", "TEST", 52, 64], ["COVID", "TEST", 103, 108]]], ["Hence, several studies underlined the recommended usage of serology to promote the detection of SARS-CoV-2 infections where NP swab specimens were improperly collected, molecular assays were unsatisfactorily carried out and for determining asymptomatic infections [122] .", [["swab specimens", "ANATOMY", 127, 141], ["SARS", "DISEASE", 96, 100], ["infections", "DISEASE", 107, 117], ["infections", "DISEASE", 253, 263], ["SARS-CoV-2", "ORGANISM", 96, 106], ["NP swab specimens", "CANCER", 124, 141], ["SARS-CoV", "SPECIES", 96, 104], ["several studies", "TEST", 7, 22], ["serology", "TEST", 59, 67], ["the detection", "TEST", 79, 92], ["SARS", "PROBLEM", 96, 100], ["CoV", "PROBLEM", 101, 104], ["2 infections", "PROBLEM", 105, 117], ["NP swab specimens", "TEST", 124, 141], ["molecular assays", "TEST", 169, 185], ["asymptomatic infections", "PROBLEM", 240, 263]]], ["Based on these data, several companies developed kits for IgM/IgG testing showing a high detection rate of infected patients.", [["IgM", "GENE_OR_GENE_PRODUCT", 58, 61], ["IgG", "GENE_OR_GENE_PRODUCT", 62, 65], ["patients", "ORGANISM", 116, 124], ["IgM", "PROTEIN", 58, 61], ["IgG", "PROTEIN", 62, 65], ["patients", "SPECIES", 116, 124], ["these data", "TEST", 9, 19], ["kits", "TEST", 49, 53], ["IgM/IgG testing", "TEST", 58, 73], ["infected", "OBSERVATION", 107, 115]]], ["Basically, there are two different testing methods: the rapid IgG-IgM test and the classical enzyme-linked immunosorbent assay (ELISA)-based test.", [["IgG", "PROTEIN", 62, 65], ["IgM", "PROTEIN", 66, 69], ["the rapid IgG", "TEST", 52, 65], ["IgM test", "TEST", 66, 74], ["the classical enzyme", "TEST", 79, 99], ["immunosorbent assay", "TEST", 107, 126], ["ELISA", "TEST", 128, 133], ["based test", "TEST", 135, 145]]], ["The rapid test consists in a lateral flow qualitative immunoassay on a strip to detect the presence of both anti-SARS-CoV-2-IgM and anti-SARS-CoV-2-IgG in human specimens such as whole blood, serum and plasma.", [["specimens", "ANATOMY", 161, 170], ["whole blood", "ANATOMY", 179, 190], ["serum", "ANATOMY", 192, 197], ["plasma", "ANATOMY", 202, 208], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 123], ["IgM", "GENE_OR_GENE_PRODUCT", 124, 127], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 132, 147], ["IgG", "GENE_OR_GENE_PRODUCT", 148, 151], ["human", "ORGANISM", 155, 160], ["specimens", "CANCER", 161, 170], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["plasma", "ORGANISM_SUBSTANCE", 202, 208], ["anti-SARS", "PROTEIN", 108, 117], ["CoV", "PROTEIN", 118, 121], ["IgM", "PROTEIN", 124, 127], ["anti-SARS", "PROTEIN", 132, 141], ["CoV", "PROTEIN", 142, 145], ["IgG", "PROTEIN", 148, 151], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["The rapid test", "TEST", 0, 14], ["a lateral flow qualitative immunoassay", "TEST", 27, 65], ["a strip", "TEST", 69, 76], ["anti-SARS", "TEST", 108, 117], ["CoV", "TEST", 118, 121], ["IgM", "TEST", 124, 127], ["anti-SARS", "TEST", 132, 141], ["CoV", "TEST", 142, 145], ["IgG in human specimens", "TEST", 148, 170], ["whole blood", "TEST", 179, 190], ["serum", "TEST", 192, 197], ["plasma", "TEST", 202, 208]]], ["This IgG-and IgM-combined antibody test kit has a sensitivity of 88.66% and specificity of 90.63%.", [["IgG", "GENE_OR_GENE_PRODUCT", 5, 8], ["IgM", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgG", "PROTEIN", 5, 8], ["IgM", "PROTEIN", 13, 16], ["This IgG", "TEST", 0, 8], ["IgM", "TEST", 13, 16], ["combined antibody test kit", "TEST", 17, 43], ["a sensitivity", "TEST", 48, 61], ["specificity", "TEST", 76, 87]]], ["Results are obtained in 15 min leading to its useful application as point-of-care testing and in supporting RT-PCR-based diagnostic [140] .", [["care testing", "TEST", 77, 89], ["PCR", "TEST", 111, 114]]], ["On the other hand, several ELISA-based kits are now commercially available, and their sensitivity and specificity were compared showing an overall high specificity, but a variable sensibility [141] .", [["several ELISA", "TEST", 19, 32], ["their sensitivity", "TEST", 80, 97]]], ["Differently from the rapid tests, the ELISA-based test should be performed on serum or plasma samples collected from venous sampling.", [["serum", "ANATOMY", 78, 83], ["plasma samples", "ANATOMY", 87, 101], ["venous", "ANATOMY", 117, 123], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["plasma samples", "ORGANISM_SUBSTANCE", 87, 101], ["venous", "MULTI-TISSUE_STRUCTURE", 117, 123], ["the rapid tests", "TEST", 17, 32], ["the ELISA-based test", "TEST", 34, 54], ["serum", "TEST", 78, 83], ["plasma samples", "TEST", 87, 101], ["venous sampling", "TEST", 117, 132], ["venous", "ANATOMY", 117, 123]]], ["Interestingly, the authors showed the neutralizing capacity of SARS-CoV-2 specific antibodies on Caco-2 cells directly incubating the sera from patients with the cell monolayers [141] .", [["Caco-2 cells", "ANATOMY", 97, 109], ["sera", "ANATOMY", 134, 138], ["cell monolayers", "ANATOMY", 162, 177], ["Caco-2 cells", "CELL", 97, 109], ["sera", "ORGANISM_SUBSTANCE", 134, 138], ["patients", "ORGANISM", 144, 152], ["cell monolayers", "CELL", 162, 177], ["SARS-CoV-2 specific antibodies", "PROTEIN", 63, 93], ["Caco-2 cells", "CELL_LINE", 97, 109], ["patients", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 63, 71], ["the neutralizing capacity of SARS", "PROBLEM", 34, 67], ["CoV", "TEST", 68, 71], ["Caco", "TEST", 97, 101], ["the sera", "TEST", 130, 138], ["the cell monolayers", "TEST", 158, 177]]], ["This assay is extremely important for the plasma-based therapies that are successfully used to treat seriously ill patients (see below).", [["plasma", "ANATOMY", 42, 48], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["This assay", "TEST", 0, 10], ["the plasma-based therapies", "TREATMENT", 38, 64]]], ["Finally, recently published papers described the seroconversion of COVID-19 patients including the evaluation of IgA that seems high in the early stages of infection (about 4 days' post symptom development) [142, 143] .", [["infection", "DISEASE", 156, 165], ["patients", "ORGANISM", 76, 84], ["IgA", "GENE_OR_GENE_PRODUCT", 113, 116], ["IgA", "PROTEIN", 113, 116], ["patients", "SPECIES", 76, 84], ["the evaluation", "TEST", 95, 109], ["IgA", "PROBLEM", 113, 116], ["infection", "PROBLEM", 156, 165], ["high", "OBSERVATION_MODIFIER", 128, 132], ["early stages", "OBSERVATION_MODIFIER", 140, 152], ["infection", "OBSERVATION", 156, 165]]], ["Another interesting application of antibody detection is represented by the fluorescence immuno-chromatographic assay for the detection of SARS-CoV-2 nucleocapsid protein in human specimens such as NP swab [144] .", [["specimens", "ANATOMY", 180, 189], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 139, 149], ["human", "ORGANISM", 174, 179], ["specimens", "CANCER", 180, 189], ["SARS-CoV-2 nucleocapsid protein", "PROTEIN", 139, 170], ["human", "SPECIES", 174, 179], ["SARS-CoV", "SPECIES", 139, 147], ["human", "SPECIES", 174, 179], ["antibody detection", "TEST", 35, 53], ["the detection", "TEST", 122, 135], ["SARS", "PROBLEM", 139, 143], ["CoV", "TEST", 144, 147], ["2 nucleocapsid protein in human specimens", "PROBLEM", 148, 189], ["NP swab", "TEST", 198, 205]]], ["It shows the fastness of rapid tests (results in 10 min), the possibility to use the same type of sample that is commonly used for RT-PCR-based diagnosis and high sensibility (detection of the nucleoprotein in all positive samples tested).", [["sample", "ANATOMY", 98, 104], ["samples", "ANATOMY", 223, 230], ["rapid tests", "TEST", 25, 36], ["RT-PCR", "TEST", 131, 137], ["the nucleoprotein", "PROBLEM", 189, 206], ["high sensibility", "OBSERVATION_MODIFIER", 158, 174]]], ["Although these methods were suggested for COVID-19 diagnosis, the extent of antibodies production by infected patients is greatly variable.", [["patients", "ORGANISM", 110, 118], ["antibodies", "PROTEIN", 76, 86], ["patients", "SPECIES", 110, 118], ["these methods", "TEST", 9, 22], ["COVID", "TEST", 42, 47], ["antibodies production", "PROBLEM", 76, 97]]], ["Moreover, the delay of antibodies production with respect to the onset of symptoms affects the use of this approach for diagnosis.", [["antibodies", "PROTEIN", 23, 33], ["the delay of antibodies production", "PROBLEM", 10, 44], ["symptoms", "PROBLEM", 74, 82], ["this approach", "TREATMENT", 102, 115]]], ["Vice versa, it is reported that several governments, included Italy, are using serologic test for population screening to assess the proportion of people that have developed an immunological response against SARS-CoV-2 (http://www.salute.gov.it/portale/nuovocoronavirus).", [["people", "ORGANISM", 147, 153], ["SARS-CoV-2", "ORGANISM", 208, 218], ["people", "SPECIES", 147, 153], ["serologic test", "TEST", 79, 93], ["population screening", "TEST", 98, 118], ["SARS-CoV", "PROBLEM", 208, 216]]], ["This screening will help also to detect asymptomatic and/or paucisymptomatic subjects.SARS-CoV-2 Therapeutics StrategiesThe rapid spread of SARS-CoV-2 raises an urgent requirement for effective therapeutic strategies against COVID-19.", [["SARS", "DISEASE", 86, 90], ["SARS", "DISEASE", 140, 144], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV", "SPECIES", 140, 148], ["This screening", "TEST", 0, 14], ["asymptomatic and/or paucisymptomatic subjects", "PROBLEM", 40, 85], ["SARS", "TEST", 86, 90], ["SARS", "PROBLEM", 140, 144], ["an urgent requirement", "PROBLEM", 158, 179], ["COVID", "TEST", 225, 230]]], ["Although many efforts have been intended to develop vaccines against HCoVs infections in recent years, there is no official and effective treatment against SARS-CoV-2.", [["HCoVs infections", "DISEASE", 69, 85], ["SARS", "DISEASE", 156, 160], ["SARS-CoV-2", "ORGANISM", 156, 166], ["HCoVs", "SPECIES", 69, 74], ["SARS-CoV", "SPECIES", 156, 164], ["vaccines", "TREATMENT", 52, 60], ["HCoVs infections", "PROBLEM", 69, 85], ["SARS", "PROBLEM", 156, 160], ["CoV", "TEST", 161, 164], ["no", "UNCERTAINTY", 112, 114]]], ["However, different considerable options have been applied for possible vaccine validity, efficacy and safety along with speeding up other ongoing searches to discover valuable modalities for dealing with the emerging COVID-19 [12, [145] [146] [147] [148] .SARS-CoV-2 Therapeutics StrategiesMost of the drugs that are being used to cope with COVID-19 epidemic are directed towards specific viral molecular targets and biologic processes through which the virus spreads damaging the host.", [["SARS", "DISEASE", 256, 260], ["COVID-19", "CHEMICAL", 217, 225], ["vaccine validity", "TREATMENT", 71, 87], ["the emerging COVID", "TEST", 204, 222], ["SARS", "PROBLEM", 256, 260], ["Therapeutics Strategies", "TREATMENT", 267, 290], ["the drugs", "TREATMENT", 298, 307], ["COVID", "TREATMENT", 341, 346], ["the virus", "PROBLEM", 450, 459]]], ["In line, all available experimental therapies for COVID-19 management are based on previous experiences in treating SARS-CoV and MERS-CoV infections, such as inhibitors of SARS-CoV-2 fusion/entry/replication, anti-viral agents against main viral proteases, regulators of SARS-CoV-2 induced host inflammatory response and direct administration of human monoclonal antibodies (mAbs) (Figure 8 ) [149] .", [["SARS", "DISEASE", 116, 120], ["infections", "DISEASE", 138, 148], ["SARS-CoV", "ORGANISM", 116, 124], ["MERS-CoV", "ORGANISM", 129, 137], ["SARS-CoV-2", "ORGANISM", 172, 182], ["SARS-CoV-2", "ORGANISM", 271, 281], ["human", "ORGANISM", 346, 351], ["viral proteases", "PROTEIN", 240, 255], ["human monoclonal antibodies", "PROTEIN", 346, 373], ["mAbs", "PROTEIN", 375, 379], ["human", "SPECIES", 346, 351], ["SARS-CoV", "SPECIES", 116, 124], ["MERS-CoV", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 271, 279], ["human", "SPECIES", 346, 351], ["experimental therapies", "TREATMENT", 23, 45], ["COVID-19 management", "TREATMENT", 50, 69], ["SARS", "PROBLEM", 116, 120], ["CoV", "PROBLEM", 121, 124], ["MERS", "PROBLEM", 129, 133], ["CoV infections", "PROBLEM", 134, 148], ["SARS", "PROBLEM", 172, 176], ["CoV-2 fusion", "TREATMENT", 177, 189], ["entry/replication", "TREATMENT", 190, 207], ["anti-viral agents", "TREATMENT", 209, 226], ["main viral proteases", "PROBLEM", 235, 255], ["SARS", "PROBLEM", 271, 275], ["CoV", "TEST", 276, 279], ["host inflammatory response", "PROBLEM", 290, 316], ["direct administration", "TREATMENT", 321, 342], ["human monoclonal antibodies", "TREATMENT", 346, 373], ["inflammatory", "OBSERVATION_MODIFIER", 295, 307]]], ["Apart from all these possible therapeutic approaches, it has been reported that the Chinese medicine products, as Lianhuaqingwen and ShuFeng JieDu capsules may be helpful for SARS-CoV-2 treatment [12, 150] .", [["SARS", "DISEASE", 175, 179], ["Lianhuaqingwen", "SIMPLE_CHEMICAL", 114, 128], ["CoV-2", "ORGANISM", 180, 185], ["the Chinese medicine products", "TREATMENT", 80, 109], ["Lianhuaqingwen and ShuFeng JieDu capsules", "TREATMENT", 114, 155], ["SARS", "PROBLEM", 175, 179]]], ["Indeed, this product is mainly used to treat upper respiratory tract infections such as the flu, swelling and pain in the throat, mumps and strep throat [151, 152] .", [["upper respiratory tract", "ANATOMY", 45, 68], ["throat", "ANATOMY", 122, 128], ["respiratory tract infections", "DISEASE", 51, 79], ["flu", "DISEASE", 92, 95], ["swelling", "DISEASE", 97, 105], ["pain", "DISEASE", 110, 114], ["mumps", "DISEASE", 130, 135], ["strep throat", "DISEASE", 140, 152], ["upper", "ORGANISM_SUBDIVISION", 45, 50], ["respiratory tract", "ORGANISM_SUBDIVISION", 51, 68], ["throat", "ORGANISM_SUBDIVISION", 122, 128], ["upper respiratory tract infections", "PROBLEM", 45, 79], ["the flu", "PROBLEM", 88, 95], ["swelling", "PROBLEM", 97, 105], ["pain in the throat", "PROBLEM", 110, 128], ["mumps", "PROBLEM", 130, 135], ["strep throat", "PROBLEM", 140, 152], ["upper", "ANATOMY_MODIFIER", 45, 50], ["respiratory tract", "ANATOMY", 51, 68], ["infections", "OBSERVATION", 69, 79], ["flu", "OBSERVATION", 92, 95], ["swelling", "OBSERVATION", 97, 105], ["throat", "ANATOMY", 122, 128]]], ["Moreover, four COVID-19 cases have been described to gain improvement after taking combined Chinese and Western medicine [153] .", [["four COVID", "TEST", 10, 20]]], ["Notably, encouraging progress in deciphering SARS-CoV-2 genome will lead to new potential therapeutic targets.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["SARS-CoV-2 genome", "DNA", 45, 62], ["SARS-CoV", "SPECIES", 45, 53]]], ["Likewise, more prospective, rigorous population studies are urgently required to confirm the therapeutic effect as well as the safety of new potential therapeutic strategies in order to further implement robust preventive and control measures against SARS-CoV-2 spread.Inhibitors of SARS-CoV-2 Fusion/EntryAs outlined above, multiple strategies are aimed at developing CoVs vaccines, most of which are headed for the surface-exposed spike (S protein) glycoprotein as the major virus-host cell membrane interactor.", [["surface", "ANATOMY", 417, 424], ["cell membrane", "ANATOMY", 488, 501], ["SARS", "DISEASE", 251, 255], ["CoV-2", "ORGANISM", 256, 261], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 283, 293], ["EntryAs", "GENE_OR_GENE_PRODUCT", 301, 308], ["CoVs", "GENE_OR_GENE_PRODUCT", 369, 373], ["cell membrane", "CELLULAR_COMPONENT", 488, 501], ["SARS-CoV-2 Fusion/EntryAs", "PROTEIN", 283, 308], ["surface-exposed spike (S protein) glycoprotein", "PROTEIN", 417, 463], ["major virus-host cell membrane interactor", "PROTEIN", 471, 512], ["SARS-CoV", "SPECIES", 251, 259], ["rigorous population studies", "TEST", 28, 55], ["therapeutic strategies", "TREATMENT", 151, 173], ["robust preventive and control measures", "TREATMENT", 204, 242], ["SARS", "PROBLEM", 251, 255], ["CoV", "PROBLEM", 256, 259], ["Inhibitors", "TREATMENT", 269, 279], ["SARS", "TEST", 283, 287], ["CoV-2 Fusion/EntryAs", "TREATMENT", 288, 308], ["multiple strategies", "TREATMENT", 325, 344], ["CoVs vaccines", "TREATMENT", 369, 382], ["the surface", "TEST", 413, 424], ["glycoprotein", "TREATMENT", 451, 463], ["host cell membrane interactor", "OBSERVATION", 483, 512]]], ["To this aim, vaccines under study are based on full-length S protein, S1-RBD, expression of virus-like particles (VLP), DNA or viral vectors [42, [154] [155] [156] [157] [158] .", [["S1-RBD", "GENE_OR_GENE_PRODUCT", 70, 76], ["virus-like particles", "ORGANISM", 92, 112], ["VLP", "ORGANISM", 114, 117], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["full-length S protein", "PROTEIN", 47, 68], ["S1", "PROTEIN", 70, 72], ["RBD", "PROTEIN", 73, 76], ["vaccines under study", "TEST", 13, 33], ["length S protein", "TEST", 52, 68], ["RBD", "PROBLEM", 73, 76], ["virus", "PROBLEM", 92, 97], ["DNA", "PROBLEM", 120, 123], ["viral vectors", "TEST", 127, 140], ["virus", "OBSERVATION", 92, 97]]], ["As outlined above, the S1 includes the RBD that interacts with its host cell receptor, ACE2, whereas the S2 mediates fusion between the virus and host cell membranes promoting the entry and subsequent replication of the viral RNA into the cytoplasm [158] .", [["cell", "ANATOMY", 72, 76], ["cell membranes", "ANATOMY", 151, 165], ["cytoplasm", "ANATOMY", 239, 248], ["RBD", "GENE_OR_GENE_PRODUCT", 39, 42], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 67, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["S2", "GENE_OR_GENE_PRODUCT", 105, 107], ["cell membranes", "CELLULAR_COMPONENT", 151, 165], ["cytoplasm", "ORGANISM_SUBSTANCE", 239, 248], ["S1", "PROTEIN", 23, 25], ["RBD", "PROTEIN", 39, 42], ["host cell receptor", "PROTEIN", 67, 85], ["ACE2", "PROTEIN", 87, 91], ["S2", "PROTEIN", 105, 107], ["viral RNA", "RNA", 220, 229], ["the RBD", "PROBLEM", 35, 42], ["ACE2", "TEST", 87, 91], ["the S2 mediates fusion", "TREATMENT", 101, 123], ["the virus", "PROBLEM", 132, 141], ["host cell membranes", "TREATMENT", 146, 165], ["RBD", "OBSERVATION", 39, 42], ["host cell", "OBSERVATION", 67, 76], ["fusion", "OBSERVATION", 117, 123], ["virus", "OBSERVATION", 136, 141], ["host cell membranes", "OBSERVATION", 146, 165], ["viral RNA", "OBSERVATION", 220, 229]]], ["The ACE2 receptor, as a specific biologic target for vaccine development, is under study in a controlled pilot clinical trial to investigate the effect of recombinant human ACE2 (rhACE2; GSK2586881) in patients with severe COVID-19 (NCT04287686) ( Figure 8I ) [159, 160] .", [["GSK2586881", "CHEMICAL", 187, 197], ["GSK2586881", "CHEMICAL", 187, 197], ["COVID-19", "CHEMICAL", 223, 231], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 4, 17], ["human", "ORGANISM", 167, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["rhACE2", "GENE_OR_GENE_PRODUCT", 179, 185], ["GSK2586881", "GENE_OR_GENE_PRODUCT", 187, 197], ["patients", "ORGANISM", 202, 210], ["ACE2 receptor", "PROTEIN", 4, 17], ["recombinant human ACE2", "PROTEIN", 155, 177], ["rhACE2", "PROTEIN", 179, 185], ["human", "SPECIES", 167, 172], ["patients", "SPECIES", 202, 210], ["human", "SPECIES", 167, 172], ["The ACE2 receptor", "TREATMENT", 0, 17], ["a controlled pilot clinical trial", "TREATMENT", 92, 125], ["recombinant human ACE2 (rhACE2", "TREATMENT", 155, 185], ["severe COVID", "PROBLEM", 216, 228]]], ["Vice versa, both recombinant proteins containing RBD and the recombinant vectors encoding RBD can be used to generate the effective SARS-CoV vaccines given the capability of this domain to induce neutralizing antibody [156] .", [["SARS", "DISEASE", 132, 136], ["RBD", "GENE_OR_GENE_PRODUCT", 49, 52], ["RBD", "GENE_OR_GENE_PRODUCT", 90, 93], ["SARS-CoV", "ORGANISM", 132, 140], ["recombinant proteins", "PROTEIN", 17, 37], ["RBD", "PROTEIN", 49, 52], ["RBD", "PROTEIN", 90, 93], ["SARS-CoV", "SPECIES", 132, 140], ["both recombinant proteins", "TREATMENT", 12, 37], ["RBD", "PROBLEM", 49, 52], ["the recombinant vectors", "TREATMENT", 57, 80], ["CoV vaccines", "TREATMENT", 137, 149], ["neutralizing antibody", "TEST", 196, 217]]], ["Indeed, the first available SARS-CoV-specific human monoclonal antibody with neutralizing activity against SARS-CoV, named CR3022, was found to bind potently to SARS-CoV-2 RBD, in agreement with the high homology shared by this domain with SARS-CoV homolog [161] .", [["CR3022", "CHEMICAL", 123, 129], ["SARS-CoV", "ORGANISM", 28, 36], ["human", "ORGANISM", 46, 51], ["SARS-CoV", "ORGANISM", 107, 115], ["CR3022", "GENE_OR_GENE_PRODUCT", 123, 129], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 240, 248], ["SARS-CoV-specific human monoclonal antibody", "PROTEIN", 28, 71], ["RBD", "PROTEIN", 172, 175], ["human", "SPECIES", 46, 51], ["SARS-CoV", "SPECIES", 28, 36], ["human", "SPECIES", 46, 51], ["SARS-CoV", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 240, 248], ["CoV", "TEST", 33, 36], ["specific human monoclonal antibody", "TEST", 37, 71], ["SARS", "PROBLEM", 107, 111], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169]]], ["However, it must be taken into account that more than 85% of the RBD antibody epitopes in SARS-CoV-2 show implicit noticeable changes, indicating the necessity to develop more specific monoclonal antibodies for SARS-CoV-2 [162] .Inhibitors of SARS-CoV-2 Fusion/EntryAngiotensin receptor blockers (ARBs), such as losartan, valsartan, telmisartan, usually assumed for treating high blood pressure, heart and kidney failure in people with diabetes, have been recently proposed as a novel therapeutic approach to block SARS-CoV-2 RBD binding to ACE2-expressing cells binding, similarly to ACE inhibitors [163] .Inhibitors of SARS-CoV-2 Fusion/EntryAdditional targetable epitopes that should be considered are the heptad repeat 1 (HR1) and heptad repeat 2 (HR2) in SARS-CoV-2 S protein.", [["blood", "ANATOMY", 380, 385], ["heart", "ANATOMY", 396, 401], ["kidney", "ANATOMY", 406, 412], ["cells", "ANATOMY", 557, 562], ["losartan", "CHEMICAL", 312, 320], ["valsartan", "CHEMICAL", 322, 331], ["telmisartan", "CHEMICAL", 333, 344], ["high blood pressure", "DISEASE", 375, 394], ["heart and kidney failure", "DISEASE", 396, 420], ["diabetes", "DISEASE", 436, 444], ["losartan", "CHEMICAL", 312, 320], ["valsartan", "CHEMICAL", 322, 331], ["telmisartan", "CHEMICAL", 333, 344], ["SARS-CoV-2", "ORGANISM", 90, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 243, 253], ["EntryAngiotensin receptor blockers", "SIMPLE_CHEMICAL", 261, 295], ["ARBs", "SIMPLE_CHEMICAL", 297, 301], ["losartan", "SIMPLE_CHEMICAL", 312, 320], ["valsartan", "SIMPLE_CHEMICAL", 322, 331], ["telmisartan", "SIMPLE_CHEMICAL", 333, 344], ["blood", "ORGANISM_SUBSTANCE", 380, 385], ["heart", "ORGAN", 396, 401], ["kidney", "ORGAN", 406, 412], ["people", "ORGANISM", 424, 430], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 515, 525], ["ACE2", "GENE_OR_GENE_PRODUCT", 541, 545], ["cells", "CELL", 557, 562], ["ACE", "GENE_OR_GENE_PRODUCT", 585, 588], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 621, 631], ["heptad repeat 1", "GENE_OR_GENE_PRODUCT", 709, 724], ["HR1", "GENE_OR_GENE_PRODUCT", 726, 729], ["heptad repeat 2", "GENE_OR_GENE_PRODUCT", 735, 750], ["HR2", "GENE_OR_GENE_PRODUCT", 752, 755], ["SARS-CoV-2 S protein", "GENE_OR_GENE_PRODUCT", 760, 780], ["RBD antibody epitopes", "PROTEIN", 65, 86], ["monoclonal antibodies", "PROTEIN", 185, 206], ["RBD", "PROTEIN", 526, 529], ["ACE2", "PROTEIN", 541, 545], ["SARS-CoV-2 Fusion/EntryAdditional targetable epitopes", "PROTEIN", 621, 674], ["heptad repeat 1", "PROTEIN", 709, 724], ["HR1", "PROTEIN", 726, 729], ["heptad repeat 2", "DNA", 735, 750], ["HR2", "DNA", 752, 755], ["SARS-CoV-2 S protein", "PROTEIN", 760, 780], ["people", "SPECIES", 424, 430], ["SARS-CoV", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 211, 219], ["the RBD antibody epitopes", "TEST", 61, 86], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98], ["monoclonal antibodies", "TEST", 185, 206], ["SARS", "TEST", 211, 215], ["CoV", "TEST", 216, 219], ["Inhibitors", "TREATMENT", 229, 239], ["SARS", "TEST", 243, 247], ["CoV-2 Fusion", "TREATMENT", 248, 260], ["EntryAngiotensin receptor blockers", "TREATMENT", 261, 295], ["ARBs", "TREATMENT", 297, 301], ["losartan", "TREATMENT", 312, 320], ["valsartan", "TREATMENT", 322, 331], ["telmisartan", "TREATMENT", 333, 344], ["high blood pressure", "PROBLEM", 375, 394], ["heart and kidney failure", "PROBLEM", 396, 420], ["diabetes", "PROBLEM", 436, 444], ["a novel therapeutic approach", "TREATMENT", 477, 505], ["block SARS", "PROBLEM", 509, 519], ["CoV", "TEST", 520, 523], ["RBD binding", "PROBLEM", 526, 537], ["ACE2", "TEST", 541, 545], ["expressing cells binding", "PROBLEM", 546, 570], ["ACE inhibitors", "TREATMENT", 585, 599], ["Inhibitors", "TREATMENT", 607, 617], ["SARS", "TEST", 621, 625], ["CoV-2 Fusion", "TREATMENT", 626, 638], ["EntryAdditional targetable epitopes", "TREATMENT", 639, 674], ["the heptad repeat", "TEST", 705, 722], ["heptad repeat", "TEST", 735, 748], ["HR2", "TEST", 752, 755], ["SARS", "TEST", 760, 764], ["CoV", "TEST", 765, 768], ["heart", "ANATOMY", 396, 401], ["kidney", "ANATOMY", 406, 412], ["failure", "OBSERVATION", 413, 420]]], ["In fact, the HR2-derived peptides (HR2P) and EK1 (a modified OC43-HR2P peptide), exhibit effective fusion inhibitory activity towards SARS-CoV-2, suggesting a promising strategy in treating SARS-CoV-2 infection, although further studies are required to strengthen these hypotheses ( Figure 8I ) [164, 165] .Inhibitors of SARS-CoV-2 Fusion/EntryLately, immuno-informatics have been employed to identify significant cytotoxic T lymphocyte (CTL) and B-cell epitopes in SARS-CoV-2 S protein, such as the nucleocapsid (N) protein as well as the potential B cell epitopes of the E protein of MERS-CoV as likely immunoprotective targets [166, 167] .Inhibitors of SARS-CoV-2 Fusion/EntryReverse genetic strategies have been successfully used in live-attenuated vaccines to inactivate the exonuclease effects of non-structural protein 14 (nsp14) or to wipe out the envelope protein in SARS [154] .", [["cytotoxic T lymphocyte", "ANATOMY", 414, 436], ["CTL", "ANATOMY", 438, 441], ["B-cell", "ANATOMY", 447, 453], ["B cell", "ANATOMY", 550, 556], ["SARS-CoV-2 infection", "DISEASE", 190, 210], ["SARS", "DISEASE", 876, 880], ["HR2-derived peptides", "GENE_OR_GENE_PRODUCT", 13, 33], ["HR2P", "GENE_OR_GENE_PRODUCT", 35, 39], ["EK1", "GENE_OR_GENE_PRODUCT", 45, 48], ["OC43", "GENE_OR_GENE_PRODUCT", 61, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 134, 144], ["SARS-CoV-2", "ORGANISM", 190, 200], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 321, 331], ["cytotoxic T lymphocyte", "CELL", 414, 436], ["CTL", "CELL", 438, 441], ["B-cell", "CELL", 447, 453], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 466, 478], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 500, 516], ["B cell", "CELL", 550, 556], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 586, 594], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 656, 666], ["non-structural protein 14", "GENE_OR_GENE_PRODUCT", 803, 828], ["nsp14", "GENE_OR_GENE_PRODUCT", 830, 835], ["HR2", "PROTEIN", 13, 16], ["OC43", "PROTEIN", 61, 65], ["cytotoxic T lymphocyte", "CELL_TYPE", 414, 436], ["CTL", "CELL_TYPE", 438, 441], ["B-cell epitopes", "PROTEIN", 447, 462], ["SARS-CoV-2 S protein", "PROTEIN", 466, 486], ["nucleocapsid (N) protein", "PROTEIN", 500, 524], ["B cell epitopes", "PROTEIN", 550, 565], ["E protein", "PROTEIN", 573, 582], ["MERS-CoV", "PROTEIN", 586, 594], ["exonuclease", "PROTEIN", 780, 791], ["non-structural protein 14", "PROTEIN", 803, 828], ["nsp14", "PROTEIN", 830, 835], ["envelope protein", "PROTEIN", 856, 872], ["SARS-CoV", "SPECIES", 134, 142], ["SARS-CoV-2", "SPECIES", 190, 200], ["SARS-CoV", "SPECIES", 466, 474], ["MERS-CoV", "SPECIES", 586, 594], ["the HR2", "TEST", 9, 16], ["EK1", "TEST", 45, 48], ["a modified OC43-HR2P peptide", "TREATMENT", 50, 78], ["effective fusion inhibitory activity", "PROBLEM", 89, 125], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142], ["SARS", "PROBLEM", 190, 194], ["CoV", "PROBLEM", 195, 198], ["2 infection", "PROBLEM", 199, 210], ["further studies", "TEST", 221, 236], ["Inhibitors", "TREATMENT", 307, 317], ["SARS", "TEST", 321, 325], ["CoV-2 Fusion", "TREATMENT", 326, 338], ["significant cytotoxic T lymphocyte (CTL", "PROBLEM", 402, 441], ["B-cell epitopes", "TEST", 447, 462], ["SARS", "TEST", 466, 470], ["CoV", "TEST", 471, 474], ["S protein", "TEST", 477, 486], ["the nucleocapsid (N) protein", "TEST", 496, 524], ["CoV", "PROBLEM", 591, 594], ["Inhibitors", "TREATMENT", 642, 652], ["SARS", "TEST", 656, 660], ["CoV-2 Fusion", "TREATMENT", 661, 673], ["EntryReverse genetic strategies", "TREATMENT", 674, 705], ["live-attenuated vaccines", "TREATMENT", 737, 761], ["non-structural protein", "TEST", 803, 825], ["infection", "OBSERVATION", 201, 210], ["cell epitopes", "OBSERVATION", 552, 565]]], ["A recent study also revealed that the invasion process requires the priming of the S protein which is facilitated by the host cell produced serine protease TMPRSS211.", [["cell", "ANATOMY", 126, 130], ["serine", "CHEMICAL", 140, 146], ["cell", "CELL", 126, 130], ["TMPRSS211", "GENE_OR_GENE_PRODUCT", 156, 165], ["S protein", "PROTEIN", 83, 92], ["host cell produced serine protease", "PROTEIN", 121, 155], ["TMPRSS211", "PROTEIN", 156, 165], ["A recent study", "TEST", 0, 14], ["the invasion process", "PROBLEM", 34, 54], ["the S protein", "TEST", 79, 92], ["serine protease TMPRSS211", "TREATMENT", 140, 165], ["invasion", "OBSERVATION", 38, 46], ["host cell", "OBSERVATION", 121, 130]]], ["The clinically demonstrated serine protease TMPRSS2 inhibitor Camostat mesylate, which partially blocks SARS-CoV-2 entry into host cells, was shown to be a good target to significantly reduce pulmonary infection in COVID-19 affected individuals ( Figure 8I ) [168] Moreover, it has been suggested that coronavirus entry also involves pH and receptor-dependent endocytosis [169, 170] ; thus, targeting endocytosis may be another assessable option for fighting SARS-CoV-2 ( Figure 8I ).", [["cells", "ANATOMY", 131, 136], ["pulmonary", "ANATOMY", 192, 201], ["Camostat mesylate", "CHEMICAL", 62, 79], ["pulmonary infection", "DISEASE", 192, 211], ["SARS", "DISEASE", 459, 463], ["serine", "CHEMICAL", 28, 34], ["Camostat mesylate", "CHEMICAL", 62, 79], ["serine", "AMINO_ACID", 28, 34], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 44, 51], ["Camostat mesylate", "SIMPLE_CHEMICAL", 62, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["host cells", "CELL", 126, 136], ["pulmonary", "ORGAN", 192, 201], ["coronavirus", "ORGANISM", 302, 313], ["CoV-2", "ORGANISM", 464, 469], ["host cells", "CELL_TYPE", 126, 136], ["SARS-CoV", "SPECIES", 459, 467], ["serine protease TMPRSS2 inhibitor Camostat mesylate", "TREATMENT", 28, 79], ["pulmonary infection", "PROBLEM", 192, 211], ["COVID", "TEST", 215, 220], ["coronavirus entry", "PROBLEM", 302, 319], ["pH", "TEST", 334, 336], ["receptor-dependent endocytosis", "PROBLEM", 341, 371], ["fighting SARS", "PROBLEM", 450, 463], ["CoV", "TEST", 464, 467], ["pulmonary", "ANATOMY", 192, 201], ["infection", "OBSERVATION", 202, 211]]], ["In this view, throughout AI technology, a group of approved drugs, such as the Janus kinase (JAK) inhibitor baricitinib [171] targeting the AP-2-associated protein kinase 1 (AAK1) regulating clathrin-mediated endocytosis, has been developed ( Figure 8I ) [172] .", [["baricitinib", "CHEMICAL", 108, 119], ["baricitinib", "CHEMICAL", 108, 119], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 79, 91], ["JAK", "GENE_OR_GENE_PRODUCT", 93, 96], ["baricitinib", "SIMPLE_CHEMICAL", 108, 119], ["AP-2-associated protein kinase 1", "GENE_OR_GENE_PRODUCT", 140, 172], ["AAK1", "GENE_OR_GENE_PRODUCT", 174, 178], ["clathrin", "GENE_OR_GENE_PRODUCT", 191, 199], ["Janus kinase", "PROTEIN", 79, 91], ["JAK", "PROTEIN", 93, 96], ["AP-2-associated protein kinase 1", "PROTEIN", 140, 172], ["AAK1", "PROTEIN", 174, 178], ["clathrin", "PROTEIN", 191, 199], ["approved drugs", "TREATMENT", 51, 65], ["the Janus kinase (JAK) inhibitor baricitinib", "TREATMENT", 75, 119], ["the AP", "TEST", 136, 142], ["protein kinase", "TEST", 156, 170]]], ["Furthermore, other drugs such as arbidol (ChiCTR2000029621), a haemagglutinin inhibitor and chloroquine phosphate, a traditional antimalarial drug, have been added to the National Health Commission of the People's Republic of China (NHC) guidelines for COVID-19 treatment ( Figure 8I ) (http://www.nhc.gov.cn).", [["arbidol", "CHEMICAL", 33, 40], ["ChiCTR2000029621", "CHEMICAL", 42, 58], ["chloroquine phosphate", "CHEMICAL", 92, 113], ["COVID-19", "CHEMICAL", 253, 261], ["arbidol", "CHEMICAL", 33, 40], ["ChiCTR2000029621", "CHEMICAL", 42, 58], ["chloroquine phosphate", "CHEMICAL", 92, 113], ["arbidol", "SIMPLE_CHEMICAL", 33, 40], ["ChiCTR2000029621", "SIMPLE_CHEMICAL", 42, 58], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 92, 113], ["other drugs", "TREATMENT", 13, 24], ["arbidol (ChiCTR2000029621)", "TREATMENT", 33, 59], ["a haemagglutinin inhibitor", "TREATMENT", 61, 87], ["chloroquine phosphate", "TREATMENT", 92, 113], ["a traditional antimalarial drug", "TREATMENT", 115, 146], ["China (NHC)", "TREATMENT", 226, 237], ["COVID-19 treatment", "TREATMENT", 253, 271]]], ["In particular, in vitro studies have demonstrated that chloroquine as well as hydroxychloroquine could impair the endosome-mediated viral entry or later stages of viral replication [173] .", [["endosome", "ANATOMY", 114, 122], ["chloroquine", "CHEMICAL", 55, 66], ["hydroxychloroquine", "CHEMICAL", 78, 96], ["chloroquine", "CHEMICAL", 55, 66], ["hydroxychloroquine", "CHEMICAL", 78, 96], ["chloroquine", "SIMPLE_CHEMICAL", 55, 66], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 78, 96], ["endosome", "CELLULAR_COMPONENT", 114, 122], ["vitro studies", "TEST", 18, 31], ["chloroquine", "TREATMENT", 55, 66], ["hydroxychloroquine", "TREATMENT", 78, 96], ["viral replication", "PROBLEM", 163, 180], ["viral replication", "OBSERVATION", 163, 180]]], ["Combination of hydroxychloroquine and azithromycin has also been suggested as a valid approach since it showed more rapid resolution of infection than hydroxychloroquine alone [174] ; however, the combined use of azithromycin and hydroxychloroquine seems to be associated with at increased risk of arrhythmias.", [["hydroxychloroquine", "CHEMICAL", 15, 33], ["azithromycin", "CHEMICAL", 38, 50], ["infection", "DISEASE", 136, 145], ["hydroxychloroquine", "CHEMICAL", 151, 169], ["azithromycin", "CHEMICAL", 213, 225], ["hydroxychloroquine", "CHEMICAL", 230, 248], ["arrhythmias", "DISEASE", 298, 309], ["hydroxychloroquine", "CHEMICAL", 15, 33], ["azithromycin", "CHEMICAL", 38, 50], ["hydroxychloroquine", "CHEMICAL", 151, 169], ["azithromycin", "CHEMICAL", 213, 225], ["hydroxychloroquine", "CHEMICAL", 230, 248], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 15, 33], ["azithromycin", "SIMPLE_CHEMICAL", 38, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 151, 169], ["azithromycin", "SIMPLE_CHEMICAL", 213, 225], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 230, 248], ["hydroxychloroquine", "TREATMENT", 15, 33], ["azithromycin", "TREATMENT", 38, 50], ["a valid approach", "TREATMENT", 78, 94], ["infection", "PROBLEM", 136, 145], ["hydroxychloroquine", "TREATMENT", 151, 169], ["azithromycin", "TREATMENT", 213, 225], ["hydroxychloroquine", "TREATMENT", 230, 248], ["arrhythmias", "PROBLEM", 298, 309], ["infection", "OBSERVATION", 136, 145], ["arrhythmias", "OBSERVATION", 298, 309]]], ["Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-riskdue-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 (accessed on 29 March 2020).Inhibitors of SARS-CoV-2 Main EnzymesTo date, several attempts have also been made in targeting viral main enzymes; in fact, many inhibitory drugs targeting the coronavirus main proteinase 3C-like protease (3CLpro) have been validated in clinical trials (e.g., Lopinavir/Ritonavir; ChiCTR2000029387, ChiCTR2000029468, ChiCTR2000029539) ( Figure 8II ) [175] .", [["Lopinavir", "CHEMICAL", 463, 472], ["Ritonavir", "CHEMICAL", 473, 482], ["ChiCTR2000029387", "CHEMICAL", 484, 500], ["ChiCTR2000029468", "CHEMICAL", 502, 518], ["ChiCTR2000029539", "CHEMICAL", 520, 536], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 216, 226], ["proteinase 3C-like protease", "GENE_OR_GENE_PRODUCT", 380, 407], ["SARS-CoV-2 Main Enzymes", "PROTEIN", 216, 239], ["viral main enzymes", "PROTEIN", 298, 316], ["coronavirus main proteinase 3C-like protease", "PROTEIN", 363, 407], ["3CLpro", "PROTEIN", 409, 415], ["coronavirus", "SPECIES", 363, 374], ["SARS", "TEST", 216, 220], ["CoV", "TEST", 221, 224], ["Main Enzymes", "TEST", 227, 239], ["viral main enzymes", "TEST", 298, 316], ["many inhibitory drugs", "TREATMENT", 327, 348], ["the coronavirus main proteinase 3C", "TREATMENT", 359, 393], ["protease (3CLpro)", "TREATMENT", 399, 416], ["Lopinavir", "TREATMENT", 463, 472], ["Ritonavir", "TREATMENT", 473, 482]]], ["Moreover, four additional molecules including prulifloxacin, tegobuvir, bictegravir and nelfinavir, detected by high-throughput screening, showed reasonable binding conformations with the viral main protease [176] .", [["prulifloxacin", "CHEMICAL", 46, 59], ["tegobuvir", "CHEMICAL", 61, 70], ["bictegravir", "CHEMICAL", 72, 83], ["nelfinavir", "CHEMICAL", 88, 98], ["prulifloxacin", "CHEMICAL", 46, 59], ["tegobuvir", "CHEMICAL", 61, 70], ["bictegravir", "CHEMICAL", 72, 83], ["nelfinavir", "CHEMICAL", 88, 98], ["prulifloxacin", "SIMPLE_CHEMICAL", 46, 59], ["tegobuvir", "SIMPLE_CHEMICAL", 61, 70], ["bictegravir", "SIMPLE_CHEMICAL", 72, 83], ["nelfinavir", "SIMPLE_CHEMICAL", 88, 98], ["prulifloxacin", "TREATMENT", 46, 59], ["tegobuvir", "TREATMENT", 61, 70], ["bictegravir", "TREATMENT", 72, 83], ["nelfinavir", "TREATMENT", 88, 98], ["reasonable binding conformations", "PROBLEM", 146, 178]]], ["Moreover, a recent study by performing a virtual screening using a three-dimensional model of the SARS-CoV-2 3C-like protease (3CL), identified 16 biologic candidates that deserve further consideration.", [["SARS", "DISEASE", 98, 102], ["SARS-CoV-2 3C", "GENE_OR_GENE_PRODUCT", 98, 111], ["SARS-CoV-2 3C-like protease", "PROTEIN", 98, 125], ["3CL", "PROTEIN", 127, 130], ["SARS-CoV", "SPECIES", 98, 106], ["a recent study", "TEST", 10, 24], ["a virtual screening", "TEST", 39, 58], ["the SARS", "TEST", 94, 102], ["CoV", "TEST", 103, 106], ["3C-like protease", "TREATMENT", 109, 125]]], ["Among these, the antivirals Ledipasvir or Velpatasvir proved to be particularly attracting as therapeutics to combat the new coronavirus showing optimal anti-viral activity and minimal side effects, such as fatigue and headache; also, Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) are promising antivirals, not only for their effective and synergic inhibitory activities against two viral enzymes, but also for their minimized possibilities to develop resistance [177] .Inhibitors of SARS-CoV-2 ReplicationA certain number of clinical trials on antiviral drugs aimed to arrest SARS-CoV-2 replication are currently in progress, such as Remdesivir (NCT04252664, NCT04257656) Favipiravir (ChiCTR2000029600, ChiCTR2000029544) and ASC09 (ChiCTR2000029603) ( Figure 8III ).", [["Ledipasvir", "CHEMICAL", 28, 38], ["Velpatasvir", "CHEMICAL", 42, 53], ["coronavirus", "DISEASE", 125, 136], ["fatigue", "DISEASE", 207, 214], ["headache", "DISEASE", 219, 227], ["Epclusa", "CHEMICAL", 235, 242], ["velpatasvir", "CHEMICAL", 244, 255], ["sofosbuvir", "CHEMICAL", 256, 266], ["Harvoni", "CHEMICAL", 272, 279], ["ledipasvir", "CHEMICAL", 281, 291], ["sofosbuvir", "CHEMICAL", 292, 302], ["SARS", "DISEASE", 600, 604], ["Favipiravir", "CHEMICAL", 696, 707], ["ASC09", "CHEMICAL", 749, 754], ["Ledipasvir", "CHEMICAL", 28, 38], ["Velpatasvir", "CHEMICAL", 42, 53], ["velpatasvir", "CHEMICAL", 244, 255], ["sofosbuvir", "CHEMICAL", 256, 266], ["ledipasvir", "CHEMICAL", 281, 291], ["sofosbuvir", "CHEMICAL", 292, 302], ["Remdesivir", "CHEMICAL", 658, 668], ["NCT04252664", "CHEMICAL", 670, 681], ["Favipiravir", "CHEMICAL", 696, 707], ["ChiCTR2000029600", "CHEMICAL", 709, 725], ["ChiCTR2000029544", "CHEMICAL", 727, 743], ["ASC09", "CHEMICAL", 749, 754], ["ChiCTR2000029603", "CHEMICAL", 756, 772], ["Ledipasvir", "SIMPLE_CHEMICAL", 28, 38], ["Velpatasvir", "SIMPLE_CHEMICAL", 42, 53], ["coronavirus", "ORGANISM", 125, 136], ["Epclusa", "SIMPLE_CHEMICAL", 235, 242], ["velpatasvir", "SIMPLE_CHEMICAL", 244, 255], ["sofosbuvir", "SIMPLE_CHEMICAL", 256, 266], ["Harvoni", "SIMPLE_CHEMICAL", 272, 279], ["ledipasvir", "SIMPLE_CHEMICAL", 281, 291], ["sofosbuvir", "SIMPLE_CHEMICAL", 292, 302], ["CoV-2", "ORGANISM", 605, 610], ["viral enzymes", "PROTEIN", 406, 419], ["the antivirals Ledipasvir", "TREATMENT", 13, 38], ["Velpatasvir", "TREATMENT", 42, 53], ["the new coronavirus", "PROBLEM", 117, 136], ["minimal side effects", "PROBLEM", 177, 197], ["fatigue", "PROBLEM", 207, 214], ["headache", "PROBLEM", 219, 227], ["Epclusa", "TREATMENT", 235, 242], ["velpatasvir", "TREATMENT", 244, 255], ["sofosbuvir", "TREATMENT", 256, 266], ["Harvoni (ledipasvir", "TREATMENT", 272, 291], ["sofosbuvir", "TREATMENT", 292, 302], ["antivirals", "TREATMENT", 318, 328], ["synergic inhibitory activities", "TREATMENT", 363, 393], ["two viral enzymes", "TEST", 402, 419], ["Inhibitors", "TREATMENT", 493, 503], ["SARS", "PROBLEM", 507, 511], ["CoV", "TEST", 512, 515], ["clinical trials", "TREATMENT", 549, 564], ["antiviral drugs", "TREATMENT", 568, 583], ["arrest SARS", "PROBLEM", 593, 604], ["CoV-2 replication", "TREATMENT", 605, 622], ["anti-viral activity", "OBSERVATION", 153, 172]]], ["Among these, Remdesivir was recently approved for medical use in America and European Union and seems to be the most promising antiviral for fighting SARS-CoV-2 [178] (http://www.who.int), as in vitro studies demonstrated that this molecule, a mono-phosphoramidate prodrug of an adenosine, effectively inhibited SARS-CoV-2 RNA synthesis [179] .", [["Remdesivir", "CHEMICAL", 13, 23], ["SARS", "DISEASE", 150, 154], ["mono-phosphoramidate", "CHEMICAL", 244, 264], ["adenosine", "CHEMICAL", 279, 288], ["Remdesivir", "CHEMICAL", 13, 23], ["mono-phosphoramidate", "CHEMICAL", 244, 264], ["adenosine", "CHEMICAL", 279, 288], ["Remdesivir", "SIMPLE_CHEMICAL", 13, 23], ["mono-phosphoramidate", "SIMPLE_CHEMICAL", 244, 264], ["adenosine", "SIMPLE_CHEMICAL", 279, 288], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 312, 322], ["fighting SARS", "PROBLEM", 141, 154], ["CoV", "TEST", 155, 158], ["vitro studies", "TEST", 195, 208], ["a mono-phosphoramidate prodrug", "TREATMENT", 242, 272], ["an adenosine", "TREATMENT", 276, 288], ["CoV", "TEST", 317, 320]]], ["Targeting the SARS-CoV-2 RNA genome could, therefore, be another potential strategy.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV-2 RNA genome", "DNA", 14, 35], ["SARS-CoV", "SPECIES", 14, 22], ["the SARS", "TEST", 10, 18], ["CoV", "TEST", 19, 22], ["SARS", "OBSERVATION", 14, 18]]], ["In fact, a CRISPR/Cas13d technology, which is an RNA-guided RNA-targeting CRISPR system, has been employed to specifically chew up SARS-CoV-2 RNA genome.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 131, 141], ["CRISPR", "DNA", 11, 17], ["Cas13d", "DNA", 18, 24], ["SARS-CoV-2 RNA genome", "DNA", 131, 152], ["CoV", "TEST", 136, 139]]], ["In this system, a Cas13d protein and guide RNAs-containing spacer sequences are used to specifically complement the virus RNA genome ( Figure 8IV ).", [["Cas13d", "GENE_OR_GENE_PRODUCT", 18, 24], ["Cas13d protein", "PROTEIN", 18, 32], ["guide RNAs", "RNA", 37, 47], ["spacer sequences", "DNA", 59, 75], ["virus RNA genome", "DNA", 116, 132], ["a Cas13d protein and guide RNAs-containing spacer sequences", "TREATMENT", 16, 75]]], ["Furthermore, RNA genome can be packaged into one adeno-associated virus (AAV) vector, making the CRISPR/Cas13d system more efficient for virus elimination and resistance prevention, taking into account that AAV has serotypes highly specific to the lung, the main organ infected by SARS-CoV-2 [180] .Modulators of SARS-CoV-2 Induced Inflammatory ResponseIn addition to antiviral therapy, a new treatment strategy having a significant impact on clinical outcomes is utmost required.", [["lung", "ANATOMY", 248, 252], ["organ", "ANATOMY", 263, 268], ["adeno-associated virus", "ORGANISM", 49, 71], ["AAV", "ORGANISM", 73, 76], ["Cas13d", "GENE_OR_GENE_PRODUCT", 104, 110], ["AAV", "ORGANISM", 207, 210], ["lung", "ORGAN", 248, 252], ["organ", "ORGAN", 263, 268], ["SARS-CoV-2", "ORGANISM", 281, 291], ["RNA genome", "DNA", 13, 23], ["CRISPR", "DNA", 97, 103], ["AAV", "SPECIES", 73, 76], ["AAV", "SPECIES", 207, 210], ["SARS-CoV", "SPECIES", 281, 289], ["RNA genome", "PROBLEM", 13, 23], ["adeno-associated virus (AAV) vector", "TREATMENT", 49, 84], ["the CRISPR/Cas13d system", "TREATMENT", 93, 117], ["virus elimination", "TREATMENT", 137, 154], ["resistance prevention", "TREATMENT", 159, 180], ["serotypes", "PROBLEM", 215, 224], ["CoV", "TEST", 286, 289], ["SARS", "PROBLEM", 313, 317], ["CoV", "PROBLEM", 318, 321], ["antiviral therapy", "TREATMENT", 368, 385], ["a new treatment strategy", "TREATMENT", 387, 411], ["lung", "ANATOMY", 248, 252], ["main organ", "ANATOMY", 258, 268], ["infected", "OBSERVATION", 269, 277], ["SARS", "OBSERVATION", 313, 317], ["Inflammatory", "OBSERVATION_MODIFIER", 332, 344], ["antiviral therapy", "OBSERVATION", 368, 385]]], ["Immunomodulatory therapy to downregulate the cytokine storm may provide great benefit to the treatment of COVID-19.", [["cytokine", "PROTEIN", 45, 53], ["Immunomodulatory therapy", "TREATMENT", 0, 24], ["the cytokine storm", "TREATMENT", 41, 59], ["COVID", "TEST", 106, 111]]], ["Recently, researchers focused on targeting specific molecular markers involved in inflammatory cytokines-receptors interactions, their correlation in health and disease and drugs in use that can activate or block their actions.", [["inflammatory cytokines", "PROTEIN", 82, 104], ["inflammatory cytokines", "PROBLEM", 82, 104], ["drugs", "TREATMENT", 173, 178], ["inflammatory", "OBSERVATION_MODIFIER", 82, 94]]], ["A higher concentration of cytokines has been found in the plasma from COVID-19 patients in ICU compared with the ones from non-ICU COVID-19 patients, suggesting that the cytokine storm could be linked to the severity of the disease [113] .", [["plasma", "ANATOMY", 58, 64], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 140, 148], ["cytokines", "PROTEIN", 26, 35], ["cytokine", "PROTEIN", 170, 178], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 140, 148], ["A higher concentration of cytokines", "PROBLEM", 0, 35], ["the cytokine storm", "PROBLEM", 166, 184], ["the disease", "PROBLEM", 220, 231], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["cytokines", "OBSERVATION", 26, 35], ["disease", "OBSERVATION", 224, 231]]], ["Corticosteroids are among the most commonly used drugs for immunomodulatory therapy of infectious diseases.", [["infectious diseases", "DISEASE", 87, 106], ["Corticosteroids", "TREATMENT", 0, 15], ["drugs", "TREATMENT", 49, 54], ["immunomodulatory therapy", "TREATMENT", 59, 83], ["infectious diseases", "PROBLEM", 87, 106], ["infectious", "OBSERVATION", 87, 97]]], ["However, the use of corticosteroids in the treatment of COVID-19 can cause host immune suppression and delay of viral clearance.", [["corticosteroids", "CHEMICAL", 20, 35], ["COVID-19", "CHEMICAL", 56, 64], ["corticosteroids", "CHEMICAL", 20, 35], ["COVID-19", "CHEMICAL", 56, 64], ["COVID-19", "ORGANISM", 56, 64], ["corticosteroids", "TREATMENT", 20, 35], ["COVID", "TREATMENT", 56, 61], ["host immune suppression", "PROBLEM", 75, 98], ["viral clearance", "PROBLEM", 112, 127], ["viral clearance", "OBSERVATION", 112, 127]]], ["A recent study on 201 patients with ARDS showed that treatment with methylprednisolone decreased the risk of death (hazard ratio 0.38, 95% confidence interval 0.20-0.72).", [["ARDS", "DISEASE", 36, 40], ["methylprednisolone", "CHEMICAL", 68, 86], ["death", "DISEASE", 109, 114], ["methylprednisolone", "CHEMICAL", 68, 86], ["patients", "ORGANISM", 22, 30], ["methylprednisolone", "SIMPLE_CHEMICAL", 68, 86], ["patients", "SPECIES", 22, 30], ["A recent study", "TEST", 0, 14], ["ARDS", "PROBLEM", 36, 40], ["methylprednisolone", "TREATMENT", 68, 86], ["death", "PROBLEM", 109, 114], ["hazard ratio", "TEST", 116, 128]]], ["These findings indicate that using corticosteroids does not influence viral clearance time, length of hospital stays or duration of symptoms in patients with mild COVID-19 [181] .", [["corticosteroids", "CHEMICAL", 35, 50], ["corticosteroids", "CHEMICAL", 35, 50], ["COVID-19", "CHEMICAL", 163, 171], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["corticosteroids", "TREATMENT", 35, 50], ["symptoms", "PROBLEM", 132, 140], ["mild COVID", "PROBLEM", 158, 168]]], ["Thus, the use of corticosteroids is considered beneficial in severe cases of COVID-19 (especially in patients with ARDS), but not in mild cases.", [["corticosteroids", "CHEMICAL", 17, 32], ["ARDS", "DISEASE", 115, 119], ["corticosteroids", "CHEMICAL", 17, 32], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["corticosteroids", "TREATMENT", 17, 32], ["COVID", "TEST", 77, 82], ["ARDS", "PROBLEM", 115, 119], ["ARDS", "OBSERVATION", 115, 119], ["mild", "OBSERVATION_MODIFIER", 133, 137], ["cases", "OBSERVATION", 138, 143]]], ["Accordingly, a recent retrospective study showed the potential benefits from low-dose corticosteroids treatment in a subset of critically SARS-CoV-2 patients [182] ; these data are in contrast with NHC guidelines that highlight that systematic use of corticosteroids is not recommended for these cases, due to their immunosuppressive effects.", [["corticosteroids", "CHEMICAL", 86, 101], ["SARS", "DISEASE", 138, 142], ["corticosteroids", "CHEMICAL", 86, 101], ["corticosteroids", "CHEMICAL", 251, 266], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["a recent retrospective study", "TEST", 13, 41], ["low-dose corticosteroids treatment", "TREATMENT", 77, 111], ["critically SARS", "PROBLEM", 127, 142], ["these data", "TEST", 166, 176], ["NHC guidelines", "TREATMENT", 198, 212], ["corticosteroids", "TREATMENT", 251, 266], ["their immunosuppressive effects", "PROBLEM", 310, 341]]], ["However, administration of corticosteroids has been indicated for specific reasons such as exacerbation of asthma or chronic obstructive pulmonary disease (COPD), septic shock or severe acute respiratory distress syndrome (ARDS).", [["pulmonary", "ANATOMY", 137, 146], ["respiratory", "ANATOMY", 192, 203], ["corticosteroids", "CHEMICAL", 27, 42], ["asthma", "DISEASE", 107, 113], ["chronic obstructive pulmonary disease", "DISEASE", 117, 154], ["COPD", "DISEASE", 156, 160], ["septic shock", "DISEASE", 163, 175], ["acute respiratory distress syndrome", "DISEASE", 186, 221], ["ARDS", "DISEASE", 223, 227], ["corticosteroids", "CHEMICAL", 27, 42], ["pulmonary", "ORGAN", 137, 146], ["corticosteroids", "TREATMENT", 27, 42], ["asthma", "PROBLEM", 107, 113], ["chronic obstructive pulmonary disease", "PROBLEM", 117, 154], ["COPD)", "PROBLEM", 156, 161], ["septic shock", "PROBLEM", 163, 175], ["severe acute respiratory distress syndrome", "PROBLEM", 179, 221], ["ARDS", "PROBLEM", 223, 227], ["asthma", "OBSERVATION", 107, 113], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["obstructive", "OBSERVATION_MODIFIER", 125, 136], ["pulmonary", "ANATOMY", 137, 146], ["disease", "OBSERVATION", 147, 154], ["COPD", "OBSERVATION", 156, 160], ["septic shock", "OBSERVATION", 163, 175], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["respiratory distress syndrome", "OBSERVATION", 192, 221]]], ["Further studies are required to find out how and when it is appropriate the use of corticosteroids for COVID-19, as there are no available data on the benefits of corticosteroid treatment in SARS-CoV or MERS infection [183] .Modulators of SARS-CoV-2 Induced Inflammatory ResponseApart from corticosteroids, IL-6 pathway inhibitors such as sarilumab, siltuximab and tocilizumab have been proposed as experimental approach considering the increased IL-6 levels that have been observed in patients with severe COVID-19 [184] .", [["SARS-CoV or MERS infection", "DISEASE", 191, 217], ["sarilumab", "CHEMICAL", 339, 348], ["siltuximab", "CHEMICAL", 350, 360], ["tocilizumab", "CHEMICAL", 365, 376], ["corticosteroids", "CHEMICAL", 83, 98], ["COVID-19", "CHEMICAL", 103, 111], ["corticosteroids", "CHEMICAL", 290, 305], ["sarilumab", "CHEMICAL", 339, 348], ["siltuximab", "CHEMICAL", 350, 360], ["COVID-19", "CHEMICAL", 507, 515], ["corticosteroid", "SIMPLE_CHEMICAL", 163, 177], ["SARS-CoV", "ORGANISM", 191, 199], ["IL-6", "GENE_OR_GENE_PRODUCT", 307, 311], ["sarilumab", "SIMPLE_CHEMICAL", 339, 348], ["siltuximab", "SIMPLE_CHEMICAL", 350, 360], ["tocilizumab", "SIMPLE_CHEMICAL", 365, 376], ["IL-6", "GENE_OR_GENE_PRODUCT", 447, 451], ["patients", "ORGANISM", 486, 494], ["IL-6", "PROTEIN", 447, 451], ["patients", "SPECIES", 486, 494], ["SARS-CoV", "SPECIES", 191, 199], ["Further studies", "TEST", 0, 15], ["corticosteroids", "TREATMENT", 83, 98], ["COVID", "TREATMENT", 103, 108], ["corticosteroid treatment", "TREATMENT", 163, 187], ["SARS", "PROBLEM", 191, 195], ["CoV", "PROBLEM", 196, 199], ["MERS infection", "PROBLEM", 203, 217], ["SARS", "PROBLEM", 239, 243], ["CoV", "PROBLEM", 244, 247], ["Inflammatory ResponseApart", "PROBLEM", 258, 284], ["corticosteroids", "TREATMENT", 290, 305], ["IL", "TREATMENT", 307, 309], ["pathway inhibitors", "TREATMENT", 312, 330], ["sarilumab", "TREATMENT", 339, 348], ["siltuximab", "TREATMENT", 350, 360], ["tocilizumab", "TREATMENT", 365, 376], ["experimental approach", "TREATMENT", 399, 420], ["the increased IL", "TREATMENT", 433, 449], ["severe COVID", "PROBLEM", 500, 512], ["SARS", "OBSERVATION", 239, 243], ["Inflammatory", "OBSERVATION_MODIFIER", 258, 270]]], ["Tocilizumab is a recombinant, humanized monoclonal antibody commonly used for treating patients with rheumatoid arthritis, lupus and psoriasis that binds to IL-6 receptors blocking FcR activation; in COVID-19 patients, Tocilizumab could reduce SARS-CoV-2-induced inflammatory responses [185] .", [["Tocilizumab", "CHEMICAL", 0, 11], ["rheumatoid arthritis", "DISEASE", 101, 121], ["lupus", "DISEASE", 123, 128], ["psoriasis", "DISEASE", 133, 142], ["Tocilizumab", "CHEMICAL", 219, 230], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "CHEMICAL", 219, 230], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 87, 95], ["lupus", "CANCER", 123, 128], ["IL-6 receptors", "GENE_OR_GENE_PRODUCT", 157, 171], ["FcR", "GENE_OR_GENE_PRODUCT", 181, 184], ["patients", "ORGANISM", 209, 217], ["Tocilizumab", "SIMPLE_CHEMICAL", 219, 230], ["CoV-2", "GENE_OR_GENE_PRODUCT", 249, 254], ["recombinant, humanized monoclonal antibody", "PROTEIN", 17, 59], ["IL-6 receptors", "PROTEIN", 157, 171], ["FcR", "PROTEIN", 181, 184], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 209, 217], ["Tocilizumab", "TREATMENT", 0, 11], ["a recombinant", "TREATMENT", 15, 28], ["humanized monoclonal antibody", "TREATMENT", 30, 59], ["rheumatoid arthritis", "PROBLEM", 101, 121], ["lupus", "PROBLEM", 123, 128], ["psoriasis", "PROBLEM", 133, 142], ["IL", "TREATMENT", 157, 159], ["Tocilizumab", "TREATMENT", 219, 230], ["SARS", "PROBLEM", 244, 248], ["CoV", "TEST", 249, 252], ["inflammatory responses", "PROBLEM", 263, 285], ["rheumatoid arthritis", "OBSERVATION", 101, 121], ["lupus", "OBSERVATION", 123, 128]]], ["Accordingly, several case reports have referred positive outcomes regarding Tocilizumab [113, [186] [187] [188] [189] [190] , but clinical impact of Tocilizumab on COVID-19 patients as an approved clinical approach has not been evaluated yet.", [["Tocilizumab", "CHEMICAL", 76, 87], ["Tocilizumab", "CHEMICAL", 149, 160], ["Tocilizumab", "CHEMICAL", 76, 87], ["Tocilizumab", "CHEMICAL", 149, 160], ["Tocilizumab", "SIMPLE_CHEMICAL", 76, 87], ["[186] [187] [188", "SIMPLE_CHEMICAL", 94, 110], ["Tocilizumab", "SIMPLE_CHEMICAL", 149, 160], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["Tocilizumab", "TEST", 76, 87], ["Tocilizumab on COVID", "TREATMENT", 149, 169]]], ["In line, to further investigate the efficacy and safety of Tocilizumab in patients with COVID-19, a controlled clinical trial is now under way (ChiCTR2000029765) ( Figure 8V ).", [["Tocilizumab", "CHEMICAL", 59, 70], ["COVID-19", "CHEMICAL", 88, 96], ["Tocilizumab", "CHEMICAL", 59, 70], ["ChiCTR2000029765", "CHEMICAL", 144, 160], ["Tocilizumab", "SIMPLE_CHEMICAL", 59, 70], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Tocilizumab", "TREATMENT", 59, 70], ["COVID", "TEST", 88, 93]]], ["Overall, the combination of an immunomodulatory agent to reduce the cytokine storm with an antiviral agent may give physicians more time to provide supportive treatment for patients with COVID-19.Passive ImmunizationAt the time of writing this review, due to the lack of a specific available therapy, plasma from convalescent patients containing specific antibodies has been proposed as a principal treatment [190, 191] , for patients in rapid disease progression, severe or critical conditions ( Figure 8VI ).", [["plasma", "ANATOMY", 301, 307], ["patients", "ORGANISM", 173, 181], ["plasma", "ORGANISM_SUBSTANCE", 301, 307], ["patients", "ORGANISM", 326, 334], ["patients", "ORGANISM", 426, 434], ["cytokine", "PROTEIN", 68, 76], ["specific antibodies", "PROTEIN", 346, 365], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 326, 334], ["patients", "SPECIES", 426, 434], ["an immunomodulatory agent", "TREATMENT", 28, 53], ["the cytokine storm", "TREATMENT", 64, 82], ["an antiviral agent", "TREATMENT", 88, 106], ["supportive treatment", "TREATMENT", 148, 168], ["COVID", "TEST", 187, 192], ["a specific available therapy", "TREATMENT", 271, 299], ["specific antibodies", "TEST", 346, 365], ["rapid disease progression", "PROBLEM", 438, 463], ["severe or critical conditions", "PROBLEM", 465, 494], ["cytokine storm", "OBSERVATION", 68, 82], ["rapid", "OBSERVATION_MODIFIER", 438, 443], ["disease", "OBSERVATION", 444, 451], ["severe", "OBSERVATION_MODIFIER", 465, 471]]], ["In a recent retrospective study, one dose (200 mL) of convalescent plasma (CP) collected from 10 severe adult cases has been reported to be tolerated; thus, increasing or maintaining high level of neutralizing antibodies broke down the viral load in seven days, improve clinical symptoms and paraclinical criteria within three days and lung lesions were found to be differently absorbed on radiological examination within seven days [192] .", [["plasma", "ANATOMY", 67, 73], ["lung lesions", "ANATOMY", 336, 348], ["convalescent", "ORGANISM", 54, 66], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["lung lesions", "CANCER", 336, 348], ["neutralizing antibodies", "PROTEIN", 197, 220], ["a recent retrospective study", "TEST", 3, 31], ["convalescent plasma (CP)", "TREATMENT", 54, 78], ["neutralizing antibodies", "PROBLEM", 197, 220], ["clinical symptoms", "PROBLEM", 270, 287], ["paraclinical criteria", "TEST", 292, 313], ["lung lesions", "PROBLEM", 336, 348], ["radiological examination", "TEST", 390, 414], ["viral load", "OBSERVATION", 236, 246], ["lung", "ANATOMY", 336, 340], ["lesions", "OBSERVATION", 341, 348]]], ["Therefore, being CP a promising rescue option for severe COVID-19, several clinical trials (ChiCTR2000030010, ChiCTR2000030179, and ChiCTR2000030381) are in progress to investigate the efficacy and safeness of CP direct infusion in COVID-19 patients [191] .", [["CP", "CHEMICAL", 210, 212], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["severe COVID", "PROBLEM", 50, 62], ["CP direct infusion", "TREATMENT", 210, 228]]], ["In addition, combined therapy with mAbs and Remdesivir seems to be an ideal therapeutic option for COVID-19 [193] .", [["Remdesivir", "CHEMICAL", 44, 54], ["Remdesivir", "CHEMICAL", 44, 54], ["Remdesivir", "SIMPLE_CHEMICAL", 44, 54], ["mAbs", "PROTEIN", 35, 39], ["combined therapy", "TREATMENT", 13, 29], ["mAbs", "TREATMENT", 35, 39], ["Remdesivir", "TREATMENT", 44, 54], ["COVID", "TEST", 99, 104]]], ["Pharmaceuticals companies are now focused on searching for specific and effective mAbs against COVID-19.", [["mAbs", "PROTEIN", 82, 86], ["COVID", "TEST", 95, 100]]], ["Taking into account that technologies capable of making fully human antibodies such as human single-chain antibody variable fragments (Hu-scFvs) or humanized-nanobodies (single-domain antibodies, sdAb) able to overpass virus-infected cell membranes (trans bodies) and to interact or interpose with biologic processes required for virus replication are already available [194] .Cell-Based TherapiesA large number of clinical trials regarding cell-based therapies have been started in China during COVID-19 outbreak.", [["cell membranes", "ANATOMY", 234, 248], ["bodies", "ANATOMY", 256, 262], ["Cell", "ANATOMY", 377, 381], ["cell", "ANATOMY", 441, 445], ["human", "ORGANISM", 62, 67], ["human", "ORGANISM", 87, 92], ["Hu-scFvs", "GENE_OR_GENE_PRODUCT", 135, 143], ["sdAb", "GENE_OR_GENE_PRODUCT", 196, 200], ["cell membranes", "CELLULAR_COMPONENT", 234, 248], ["trans bodies", "CELLULAR_COMPONENT", 250, 262], ["Cell", "CELL", 377, 381], ["cell", "CELL", 441, 445], ["human antibodies", "PROTEIN", 62, 78], ["human single-chain antibody variable fragments", "PROTEIN", 87, 133], ["Hu-scFvs", "PROTEIN", 135, 143], ["humanized-nanobodies", "PROTEIN", 148, 168], ["single-domain antibodies", "PROTEIN", 170, 194], ["sdAb", "PROTEIN", 196, 200], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 87, 92], ["fully human antibodies", "PROBLEM", 56, 78], ["human single-chain antibody variable fragments", "TREATMENT", 87, 133], ["Hu-scFvs", "TREATMENT", 135, 143], ["humanized-nanobodies", "TREATMENT", 148, 168], ["single-domain antibodies", "TREATMENT", 170, 194], ["sdAb", "TREATMENT", 196, 200], ["infected cell membranes", "PROBLEM", 225, 248], ["biologic processes", "TREATMENT", 298, 316], ["virus replication", "TREATMENT", 330, 347], ["Cell", "TEST", 377, 381], ["clinical trials", "TREATMENT", 415, 430], ["cell-based therapies", "TREATMENT", 441, 461], ["COVID", "TEST", 496, 501], ["infected cell membranes", "OBSERVATION", 225, 248], ["large", "OBSERVATION_MODIFIER", 399, 404], ["number", "OBSERVATION_MODIFIER", 405, 411]]], ["Among these, mesenchymal stromal cells (MSCs)-based therapy displayed strong safety profile and possible efficacy in patients with ARDS, according to COVID-19-related clinical studies listed on the WHO's International Clinical Trials Registry Platform (WHO ICTRP) and National Institutes of Health's clinical trials.gov databases [195] .", [["mesenchymal stromal cells", "ANATOMY", 13, 38], ["MSCs", "ANATOMY", 40, 44], ["ARDS", "DISEASE", 131, 135], ["mesenchymal stromal cells", "CELL", 13, 38], ["MSCs", "CELL", 40, 44], ["patients", "ORGANISM", 117, 125], ["mesenchymal stromal cells", "CELL_TYPE", 13, 38], ["MSCs", "CELL_TYPE", 40, 44], ["patients", "SPECIES", 117, 125], ["mesenchymal stromal cells (MSCs)", "TREATMENT", 13, 45], ["based therapy", "TREATMENT", 46, 59], ["ARDS", "PROBLEM", 131, 135], ["mesenchymal stromal cells", "OBSERVATION", 13, 38], ["ARDS", "OBSERVATION", 131, 135]]], ["Nevertheless, further investigations are required to better understand if these therapies could be effective in treating respiratory virus-induced complications.", [["respiratory virus", "DISEASE", 121, 138], ["further investigations", "TEST", 14, 36], ["these therapies", "TREATMENT", 74, 89], ["respiratory virus", "PROBLEM", 121, 138], ["induced complications", "PROBLEM", 139, 160]]], ["MSCs have been largely employed in basic research and clinical trials [196] [197] [198] , and their safeness and effectiveness have been extensively documented especially in immune-mediated inflammatory disorders, such as graft-versus-host disease (GVHD) [199] and systemic lupus erythematosus (SLE) [200] .", [["MSCs", "ANATOMY", 0, 4], ["graft", "ANATOMY", 222, 227], ["inflammatory disorders", "DISEASE", 190, 212], ["graft-versus-host disease", "DISEASE", 222, 247], ["GVHD", "DISEASE", 249, 253], ["systemic lupus erythematosus", "DISEASE", 265, 293], ["SLE", "DISEASE", 295, 298], ["MSCs", "CELL", 0, 4], ["graft-versus-host", "CANCER", 222, 239], ["MSCs", "CELL_TYPE", 0, 4], ["MSCs", "PROBLEM", 0, 4], ["immune-mediated inflammatory disorders", "PROBLEM", 174, 212], ["host disease", "PROBLEM", 235, 247], ["GVHD)", "PROBLEM", 249, 254], ["systemic lupus erythematosus", "PROBLEM", 265, 293], ["inflammatory", "OBSERVATION", 190, 202], ["graft", "OBSERVATION", 222, 227], ["host disease", "OBSERVATION", 235, 247], ["systemic", "OBSERVATION_MODIFIER", 265, 273], ["lupus erythematosus", "OBSERVATION", 274, 293]]], ["MSCs immunomodulatory and differentiation abilities [201] as well as their competency to produce several cytokine types or to directly interact with immune cells have been already described [202] .", [["MSCs", "ANATOMY", 0, 4], ["immune cells", "ANATOMY", 149, 161], ["MSCs", "CELL", 0, 4], ["immune cells", "CELL", 149, 161], ["MSCs", "CELL_TYPE", 0, 4], ["cytokine types", "PROTEIN", 105, 119], ["immune cells", "CELL_TYPE", 149, 161], ["MSCs immunomodulatory", "TREATMENT", 0, 21]]], ["Indeed, they are activated by pathogen-associated molecules (PAMPs) such as single or double-stranded RNAs [203, 204] , priming the immune response during infections.", [["infections", "DISEASE", 155, 165], ["pathogen-associated molecules", "GENE_OR_GENE_PRODUCT", 30, 59], ["PAMPs", "GENE_OR_GENE_PRODUCT", 61, 66], ["pathogen-associated molecules", "PROTEIN", 30, 59], ["PAMPs", "PROTEIN", 61, 66], ["infections", "PROBLEM", 155, 165], ["infections", "OBSERVATION", 155, 165]]], ["Two clinical investigations of systemic MSC administration in patients with either COVID-19 or avian influenza A (H7N9) have been recently published [205, 206] .", [["MSC", "ANATOMY", 40, 43], ["COVID-19", "CHEMICAL", 83, 91], ["influenza A", "DISEASE", 101, 112], ["MSC", "CELL", 40, 43], ["patients", "ORGANISM", 62, 70], ["COVID-19", "ORGANISM", 83, 91], ["avian influenza A", "ORGANISM", 95, 112], ["H7N9", "CANCER", 114, 118], ["patients", "SPECIES", 62, 70], ["avian influenza A", "SPECIES", 95, 112], ["H7N9", "SPECIES", 114, 118], ["systemic MSC administration", "TREATMENT", 31, 58], ["COVID", "TEST", 83, 88], ["avian influenza A", "PROBLEM", 95, 112], ["systemic MSC", "OBSERVATION", 31, 43]]], ["The first one, a single-center MSC transplantation pilot study, was aimed at exploring MSCs therapeutic potentiality in patients with COVID-19 pneumonia and conducted at the You'an Hospital in Beijing, China, from 23 Jan 2020 to 16 Feb 2020 (ChiCTR2000029990).", [["MSC", "ANATOMY", 31, 34], ["MSCs", "ANATOMY", 87, 91], ["pneumonia", "DISEASE", 143, 152], ["MSC", "CELL", 31, 34], ["MSCs", "CELL", 87, 91], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["center MSC transplantation pilot study", "TEST", 24, 62], ["COVID", "TEST", 134, 139], ["pneumonia", "PROBLEM", 143, 152], ["pneumonia", "OBSERVATION", 143, 152]]], ["Seven patients with COVID-19 pneumonia, SARS-CoV-2 RNA positive, with different degrees of severity, including one critically ill requiring ICU care were enrolled and monitored for 14 days after MSC injection.", [["MSC", "ANATOMY", 195, 198], ["pneumonia", "DISEASE", 29, 38], ["SARS", "DISEASE", 40, 44], ["critically ill", "DISEASE", 115, 129], ["patients", "ORGANISM", 6, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["MSC", "CELL", 195, 198], ["patients", "SPECIES", 6, 14], ["COVID", "TEST", 20, 25], ["pneumonia", "PROBLEM", 29, 38], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["2 RNA positive", "PROBLEM", 49, 63], ["different degrees of severity", "PROBLEM", 70, 99], ["ICU care", "TREATMENT", 140, 148], ["MSC injection", "TREATMENT", 195, 208], ["pneumonia", "OBSERVATION", 29, 38], ["different degrees", "OBSERVATION_MODIFIER", 70, 87]]], ["A significant improvement of pulmonary function and symptoms were observed two days after MSC transplantation characterized by an increase of peripheral lymphocytes and of the anti-inflammatory IL-10 levels and a decrease of the C-reactive protein and TNF-\u03b1 amounts [205] .", [["pulmonary", "ANATOMY", 29, 38], ["MSC", "ANATOMY", 90, 93], ["peripheral lymphocytes", "ANATOMY", 142, 164], ["pulmonary", "ORGAN", 29, 38], ["MSC", "CELL", 90, 93], ["peripheral lymphocytes", "CELL", 142, 164], ["IL-10", "GENE_OR_GENE_PRODUCT", 194, 199], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 229, 247], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 252, 257], ["peripheral lymphocytes", "CELL_TYPE", 142, 164], ["C-reactive protein", "PROTEIN", 229, 247], ["TNF", "PROTEIN", 252, 255], ["pulmonary function", "PROBLEM", 29, 47], ["symptoms", "PROBLEM", 52, 60], ["MSC transplantation", "TREATMENT", 90, 109], ["an increase of peripheral lymphocytes", "PROBLEM", 127, 164], ["the anti-inflammatory IL", "TREATMENT", 172, 196], ["the C-reactive protein", "TEST", 225, 247], ["TNF", "TEST", 252, 255], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["improvement", "OBSERVATION_MODIFIER", 14, 25], ["pulmonary", "ANATOMY", 29, 38], ["increase", "OBSERVATION_MODIFIER", 130, 138], ["peripheral lymphocytes", "OBSERVATION", 142, 164], ["decrease", "OBSERVATION_MODIFIER", 213, 221]]], ["Moreover, an increment of the CD14 + CD11c + CD11b mid regulatory dendritic cell (DC) population and a decrease of cytokine-secreting immune cells such as CXCR3 + CD4 + T cells, CXCR3 + CD8 + T cells, and CXCR3 + NK were detected within 3-6 days in the treated patients compared to the placebo control group [205] .", [["CD14 + CD11c + CD11b mid regulatory dendritic cell", "ANATOMY", 30, 80], ["DC", "ANATOMY", 82, 84], ["immune cells", "ANATOMY", 134, 146], ["CXCR3 + CD4 + T cells", "ANATOMY", 155, 176], ["CXCR3 + CD8 + T cells", "ANATOMY", 178, 199], ["CXCR3 + NK", "ANATOMY", 205, 215], ["CD14", "GENE_OR_GENE_PRODUCT", 30, 34], ["CD11c", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD11b", "GENE_OR_GENE_PRODUCT", 45, 50], ["dendritic cell", "CELL", 66, 80], ["DC", "CELL", 82, 84], ["immune cells", "CELL", 134, 146], ["CXCR3", "GENE_OR_GENE_PRODUCT", 155, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 163, 166], ["CXCR3", "GENE_OR_GENE_PRODUCT", 178, 183], ["CD8", "GENE_OR_GENE_PRODUCT", 186, 189], ["CXCR3", "GENE_OR_GENE_PRODUCT", 205, 210], ["patients", "ORGANISM", 261, 269], ["CD14", "PROTEIN", 30, 34], ["CD11c", "PROTEIN", 37, 42], ["CD11b mid regulatory dendritic cell (DC) population", "CELL_TYPE", 45, 96], ["cytokine", "PROTEIN", 115, 123], ["immune cells", "CELL_TYPE", 134, 146], ["CXCR3", "PROTEIN", 155, 160], ["CD4", "PROTEIN", 163, 166], ["T cells", "CELL_TYPE", 169, 176], ["CXCR3", "PROTEIN", 178, 183], ["CD8", "PROTEIN", 186, 189], ["T cells", "CELL_TYPE", 192, 199], ["CXCR3", "PROTEIN", 205, 210], ["patients", "SPECIES", 261, 269], ["the CD14", "TEST", 26, 34], ["CD11c", "TEST", 37, 42], ["CD11b mid regulatory dendritic cell (DC) population", "PROBLEM", 45, 96], ["a decrease of cytokine-secreting immune cells", "PROBLEM", 101, 146], ["CXCR3", "TEST", 155, 160], ["CD4", "TEST", 163, 166], ["T cells", "TEST", 169, 176], ["CXCR3", "TEST", 178, 183], ["CD8", "TEST", 186, 189], ["T cells", "TEST", 192, 199], ["CXCR3", "TEST", 205, 210], ["NK", "TEST", 213, 215], ["the placebo control group", "TREATMENT", 282, 307], ["CD11c", "ANATOMY", 37, 42], ["CD11b", "ANATOMY", 45, 50], ["mid", "ANATOMY_MODIFIER", 51, 54], ["dendritic cell", "OBSERVATION", 66, 80], ["decrease", "OBSERVATION_MODIFIER", 103, 111], ["NK", "ANATOMY", 213, 215]]], ["MSCs play a role in attenuating cytokine storm, most importantly, because these cells do not express ACE2 and TMPRSS2 viral receptors are insusceptible of SARS-CoV-2 infection.", [["MSCs", "ANATOMY", 0, 4], ["cells", "ANATOMY", 80, 85], ["infection", "DISEASE", 166, 175], ["MSCs", "CELL", 0, 4], ["cells", "CELL", 80, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 110, 117], ["SARS-CoV-2", "ORGANISM", 155, 165], ["MSCs", "CELL_TYPE", 0, 4], ["cytokine", "PROTEIN", 32, 40], ["ACE2", "PROTEIN", 101, 105], ["TMPRSS2 viral receptors", "PROTEIN", 110, 133], ["SARS-CoV-2", "SPECIES", 155, 165], ["MSCs", "PROBLEM", 0, 4], ["these cells", "PROBLEM", 74, 85], ["ACE2", "TEST", 101, 105], ["TMPRSS2 viral receptors", "TEST", 110, 133], ["SARS", "PROBLEM", 155, 159], ["CoV-2 infection", "PROBLEM", 160, 175], ["infection", "OBSERVATION", 166, 175]]], ["These observations are in agreement with the knowledge that MSCs induce the maturation of dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population [207] , shifting the Th1/Th2 balance towards Th2.", [["MSCs", "ANATOMY", 60, 64], ["dendritic cells", "ANATOMY", 90, 105], ["dendritic cell", "ANATOMY", 149, 163], ["MSCs", "CELL", 60, 64], ["dendritic cells", "CELL", 90, 105], ["Jagged-2", "GENE_OR_GENE_PRODUCT", 119, 127], ["dendritic cell", "CELL", 149, 163], ["Th1", "GENE_OR_GENE_PRODUCT", 196, 199], ["Th2", "GENE_OR_GENE_PRODUCT", 200, 203], ["Th2", "GENE_OR_GENE_PRODUCT", 220, 223], ["MSCs", "CELL_TYPE", 60, 64], ["dendritic cells", "CELL_TYPE", 90, 105], ["Jagged-2", "PROTEIN", 119, 127], ["Th2", "CELL_LINE", 220, 223], ["dendritic cells", "PROBLEM", 90, 105], ["dependent regulatory dendritic cell population", "PROBLEM", 128, 174], ["dendritic cells", "OBSERVATION", 90, 105], ["dendritic cell", "OBSERVATION", 149, 163], ["Th2 balance", "OBSERVATION", 200, 211]]], ["Thus, from these preliminary results, it seems evident that MSCs intravenous transplantation could represent a secure and effective treatment in patients with COVID-19 pneumonia, especially those critical.", [["MSCs", "ANATOMY", 60, 64], ["pneumonia", "DISEASE", 168, 177], ["MSCs", "CELL", 60, 64], ["patients", "ORGANISM", 145, 153], ["MSCs", "CELL_TYPE", 60, 64], ["patients", "SPECIES", 145, 153], ["MSCs intravenous transplantation", "TREATMENT", 60, 92], ["a secure and effective treatment", "TREATMENT", 109, 141], ["COVID", "TEST", 159, 164], ["pneumonia", "PROBLEM", 168, 177], ["pneumonia", "OBSERVATION", 168, 177]]], ["Indeed, it inhibits the over activation of the immune system and promotes endogenous repair by preventing pulmonary fibrosis and improving both pulmonary microenvironment and lung function [205] .VaccinesMore than 15 potential vaccine candidates for COVID-19 are under development around the world, including inactivated, recombinant subunits, nucleic-acid-based, adenoviral vector, and recombinant influenza viral vector vaccines [208] .", [["immune system", "ANATOMY", 47, 60], ["pulmonary", "ANATOMY", 106, 115], ["pulmonary", "ANATOMY", 144, 153], ["lung", "ANATOMY", 175, 179], ["fibrosis", "DISEASE", 116, 124], ["COVID-19", "CHEMICAL", 250, 258], ["nucleic-acid", "CHEMICAL", 344, 356], ["pulmonary", "ORGAN", 106, 115], ["pulmonary", "ORGAN", 144, 153], ["lung", "ORGAN", 175, 179], ["nucleic-acid", "SIMPLE_CHEMICAL", 344, 356], ["adenoviral", "ORGANISM", 364, 374], ["recombinant subunits", "PROTEIN", 322, 342], ["the immune system", "TREATMENT", 43, 60], ["endogenous repair", "TREATMENT", 74, 91], ["pulmonary fibrosis", "PROBLEM", 106, 124], ["Vaccines", "TREATMENT", 196, 204], ["COVID", "TEST", 250, 255], ["recombinant subunits", "TREATMENT", 322, 342], ["nucleic", "TEST", 344, 351], ["adenoviral vector", "TREATMENT", 364, 381], ["recombinant influenza viral vector vaccines", "TREATMENT", 387, 430], ["endogenous repair", "OBSERVATION", 74, 91], ["preventing", "UNCERTAINTY", 95, 105], ["pulmonary", "ANATOMY", 106, 115], ["fibrosis", "OBSERVATION", 116, 124], ["pulmonary", "ANATOMY", 144, 153], ["lung", "ANATOMY", 175, 179]]], ["Moreover, taking into consideration the strong homologies existing among the various coronavirus strains, it was thought that vaccines acting on other coronaviruses, such the avian live IBV vaccine (strain H) directed towards the chicken CoV IBV, could be a valuable alternative therapeutic strategy [209] .VaccinesThe Coalition for Epidemic Preparedness Innovations (CEPI) recently announced that three programs aimed to develop COVID-19 vaccines, by utilizing established vaccine platforms, have started [210] .", [["coronavirus", "ORGANISM", 85, 96], ["coronaviruses", "ORGANISM", 151, 164], ["avian", "ORGANISM", 175, 180], ["live IBV", "ORGANISM", 181, 189], ["strain H", "ORGANISM", 199, 207], ["chicken", "ORGANISM", 230, 237], ["CoV IBV", "ORGANISM", 238, 245], ["avian live IBV", "SPECIES", 175, 189], ["chicken CoV IBV", "SPECIES", 230, 245], ["IBV", "SPECIES", 186, 189], ["chicken CoV IBV", "SPECIES", 230, 245], ["the various coronavirus strains", "PROBLEM", 73, 104], ["vaccines", "TREATMENT", 126, 134], ["other coronaviruses", "PROBLEM", 145, 164], ["IBV vaccine (strain H)", "TREATMENT", 186, 208], ["the chicken CoV IBV", "TREATMENT", 226, 245], ["Vaccines", "TREATMENT", 307, 315], ["COVID-19 vaccines", "TREATMENT", 430, 447], ["established vaccine platforms", "TREATMENT", 462, 491]]], ["In addition, CEPI already financed the company Moderna, Inc. to compare mRNA therapeutics and vaccines, allowing the release of the first batch of mRNA-1273 in February 2020, which is an mRNA vaccine against SARS-CoV-2 ready for phase I study in the United States.", [["mRNA-1273", "CHEMICAL", 147, 156], ["SARS-CoV", "SPECIES", 208, 216], ["mRNA therapeutics", "TREATMENT", 72, 89], ["vaccines", "TREATMENT", 94, 102], ["an mRNA vaccine", "TREATMENT", 184, 199], ["phase I study", "TEST", 229, 242]]], ["Available online: https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrnavaccine-against-novel-coronavirus-mrna-1273 (accessed on 24 February 2020).VaccinesMore recently, scientists from the University of Pittsburgh have announced a potential vaccine against SARS-CoV-2, delivered throughout a fingertip-sized patch, capable of producing SARS-CoV-2 specific IgG antibodies, sufficient for virus neutralization in mice.", [["SARS", "DISEASE", 289, 293], ["SARS-CoV-2", "ORGANISM", 289, 299], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 368, 378], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 388, 402], ["mice", "ORGANISM", 443, 447], ["SARS-CoV-2 specific IgG antibodies", "PROTEIN", 368, 402], ["mice", "SPECIES", 443, 447], ["SARS-CoV", "SPECIES", 289, 297], ["SARS-CoV", "SPECIES", 368, 376], ["mice", "SPECIES", 443, 447], ["Vaccines", "TREATMENT", 178, 186], ["a potential vaccine", "TREATMENT", 261, 280], ["SARS", "PROBLEM", 289, 293], ["CoV", "TEST", 294, 297], ["a fingertip-sized patch", "TREATMENT", 322, 345], ["producing SARS", "PROBLEM", 358, 372], ["CoV", "TEST", 373, 376], ["specific IgG antibodies", "TEST", 379, 402], ["virus neutralization", "TREATMENT", 419, 439]]], ["This vaccine, called PittCoVacc (acronym of Pittsburgh coronavirus vaccine), is a trimeric recombinant SARS-CoV-2-S1 subunit vaccine delivered intracutaneously by microneedle arrays (MNAs) [211] .", [["PittCoVacc", "CHEMICAL", 21, 31], ["Pittsburgh coronavirus", "ORGANISM", 44, 66], ["trimeric recombinant SARS-CoV-2-S1 subunit", "PROTEIN", 82, 124], ["Pittsburgh coronavirus vaccine", "SPECIES", 44, 74], ["Pittsburgh coronavirus", "SPECIES", 44, 66], ["This vaccine", "TREATMENT", 0, 12], ["Pittsburgh coronavirus vaccine", "TREATMENT", 44, 74], ["a trimeric recombinant SARS", "TREATMENT", 80, 107], ["CoV", "TEST", 108, 111], ["S1 subunit vaccine", "TREATMENT", 114, 132]]], ["Delivering vaccine components to a defined skin microenvironment improves safety by reducing systemic exposure, allowing to reach high vaccine concentrations with a relatively low dose of antigen [212, 213] .", [["skin", "ANATOMY", 43, 47], ["skin", "ORGAN", 43, 47], ["vaccine components", "TREATMENT", 11, 29], ["a defined skin microenvironment", "PROBLEM", 33, 64], ["high vaccine concentrations", "TREATMENT", 130, 157], ["skin", "ANATOMY", 43, 47]]], ["Furthermore, the skin delivery strategy promotes strong and long-lasting antigen-specific antibody responses due to both the high immunogenicity [214] [215] [216] [217] [218] and the redundant immunoregulatory circuits of the skin [217, 219, 220] .", [["skin", "ANATOMY", 17, 21], ["skin", "ANATOMY", 226, 230], ["skin", "ORGAN", 17, 21], ["skin", "ORGAN", 226, 230], ["the skin delivery strategy", "TREATMENT", 13, 39], ["specific antibody responses", "TEST", 81, 108], ["skin", "ANATOMY", 17, 21], ["immunoregulatory circuits", "OBSERVATION", 193, 218], ["skin", "ANATOMY", 226, 230]]], ["Given the urgent need for COVID-19 vaccines, MNAs strategy seems to be a promising immunization approach against coronavirus infection including SARS, MERS and other emerging infectious diseases.VaccinesOn April 24, the Oxford ChAdOx1 nCov-19 vaccine was the first in Europe to start human trial stage, with 1110 healthy volunteers enrolled for the tests.", [["coronavirus infection", "DISEASE", 113, 134], ["SARS", "DISEASE", 145, 149], ["infectious diseases", "DISEASE", 175, 194], ["MNAs", "SIMPLE_CHEMICAL", 45, 49], ["coronavirus", "ORGANISM", 113, 124], ["human", "ORGANISM", 284, 289], ["volunteers", "ORGANISM", 321, 331], ["coronavirus", "SPECIES", 113, 124], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 284, 289], ["COVID-19 vaccines", "TREATMENT", 26, 43], ["MNAs strategy", "TREATMENT", 45, 58], ["a promising immunization approach", "TREATMENT", 71, 104], ["coronavirus infection", "PROBLEM", 113, 134], ["SARS", "PROBLEM", 145, 149], ["MERS", "PROBLEM", 151, 155], ["other emerging infectious diseases", "PROBLEM", 160, 194], ["the Oxford ChAdOx1 nCov", "TREATMENT", 216, 239], ["the tests", "TEST", 345, 354], ["infectious", "OBSERVATION", 175, 185]]], ["Oxford scientists have already employed ChAdOx1 in the past to dispense vaccines against Ebola, Chikungunya, Rift Valley fever and, above all, MERS.", [["ChAdOx1", "CHEMICAL", 40, 47], ["Ebola", "DISEASE", 89, 94], ["Chikungunya", "DISEASE", 96, 107], ["Rift Valley fever", "DISEASE", 109, 126], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 40, 47], ["Ebola", "ORGANISM", 89, 94], ["Chikungunya", "ORGANISM", 96, 107], ["Rift Valley fever", "ORGANISM", 109, 126], ["ChAdOx1", "PROTEIN", 40, 47], ["Ebola", "SPECIES", 89, 94], ["Chikungunya", "SPECIES", 96, 107], ["Rift Valley fever", "SPECIES", 109, 126], ["vaccines", "TREATMENT", 72, 80], ["Ebola", "PROBLEM", 89, 94], ["Chikungunya", "PROBLEM", 96, 107], ["Rift Valley fever", "PROBLEM", 109, 126]]], ["ChAdOx1, a chimpanzee-derived adenovirus vector, has been employed to deliver the full-length MERS spike gene and shown to induce large amounts of neutralizing antibodies against MERS in a mouse model [221, 222] .", [["ChAdOx1", "CHEMICAL", 0, 7], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 0, 7], ["chimpanzee", "ORGANISM", 11, 21], ["adenovirus", "ORGANISM", 30, 40], ["MERS", "GENE_OR_GENE_PRODUCT", 94, 98], ["mouse", "ORGANISM", 189, 194], ["ChAdOx1", "DNA", 0, 7], ["MERS spike gene", "DNA", 94, 109], ["neutralizing antibodies", "PROTEIN", 147, 170], ["MERS", "PROTEIN", 179, 183], ["mouse", "SPECIES", 189, 194], ["mouse", "SPECIES", 189, 194], ["ChAdOx1", "TREATMENT", 0, 7], ["a chimpanzee-derived adenovirus vector", "TREATMENT", 9, 47], ["large amounts of neutralizing antibodies", "PROBLEM", 130, 170], ["large", "OBSERVATION_MODIFIER", 130, 135]]], ["Therefore, the modified ChAdOx1 vaccine, carrying the SARS-CoV-2 spike gene is under human trial stage.", [["ChAdOx1", "CHEMICAL", 24, 31], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 24, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["human", "ORGANISM", 85, 90], ["SARS-CoV-2 spike gene", "DNA", 54, 75], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["the modified ChAdOx1 vaccine", "TREATMENT", 11, 39], ["the SARS", "TEST", 50, 58], ["CoV", "TEST", 59, 62]]], ["On April 30, the University of Oxford has announced a collaboration with the UK-based global biopharmaceutical company AstraZeneca for further development, large-scale production and potential delivery of the COVID-19 vaccine candidate.", [["AstraZeneca", "CHEMICAL", 119, 130], ["UK", "GENE_OR_GENE_PRODUCT", 77, 79], ["AstraZeneca", "SIMPLE_CHEMICAL", 119, 130], ["AstraZeneca", "TREATMENT", 119, 130], ["large-scale production", "TREATMENT", 156, 178], ["the COVID", "TREATMENT", 205, 214], ["large", "OBSERVATION_MODIFIER", 156, 161]]], ["Since ChAdOx technology is already available and formerly tested in humans for other vaccines, Phase III will consist in administering vaccine to volunteers following them into their regular environments to ensure that these subjects actually become immune to the disease up to three years.", [["ChAdOx", "CHEMICAL", 6, 12], ["ChAdOx", "GENE_OR_GENE_PRODUCT", 6, 12], ["humans", "ORGANISM", 68, 74], ["volunteers", "ORGANISM", 146, 156], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["other vaccines", "TREATMENT", 79, 93], ["Phase III", "TREATMENT", 95, 104], ["administering vaccine", "TREATMENT", 121, 142], ["the disease", "PROBLEM", 260, 271]]], ["If trials succeed, Oxford researchers have proposed to complete testing throughout ring vaccination, namely delivering vaccine to members of the first circle of contacts of COVID-19 positive people and then to evaluate if the virus spreads to the second circle, as was previously done during the 2018 Ebola epidemic in the Democratic Republic of the Congo.Vaccinesto be a promising immunization approach against coronavirus infection including SARS, MERS and other emerging infectious diseases.VaccinesOn April 24, the Oxford ChAdOx1 nCov-19 vaccine was the first in Europe to start human trial stage, with 1110 healthy volunteers enrolled for the tests.", [["Ebola", "DISEASE", 301, 306], ["Vaccinesto", "CHEMICAL", 356, 366], ["coronavirus infection", "DISEASE", 412, 433], ["SARS", "DISEASE", 444, 448], ["infectious diseases", "DISEASE", 474, 493], ["COVID-19", "CELL", 173, 181], ["people", "ORGANISM", 191, 197], ["coronavirus", "ORGANISM", 412, 423], ["human", "ORGANISM", 583, 588], ["volunteers", "ORGANISM", 620, 630], ["people", "SPECIES", 191, 197], ["coronavirus", "SPECIES", 412, 423], ["human", "SPECIES", 583, 588], ["human", "SPECIES", 583, 588], ["complete testing", "TEST", 55, 71], ["throughout ring vaccination", "TREATMENT", 72, 99], ["COVID", "TEST", 173, 178], ["the virus", "PROBLEM", 222, 231], ["Vaccinesto", "TREATMENT", 356, 366], ["a promising immunization approach", "TREATMENT", 370, 403], ["coronavirus infection", "PROBLEM", 412, 433], ["SARS", "PROBLEM", 444, 448], ["other emerging infectious diseases", "PROBLEM", 459, 493], ["the Oxford ChAdOx1 nCov", "TREATMENT", 515, 538], ["the tests", "TEST", 644, 653], ["infectious", "OBSERVATION", 474, 484]]], ["Oxford scientists have already employed ChAdOx1 in the past to dispense vaccines against Ebola, Chikungunya, Rift Valley fever and, above all, MERS.", [["ChAdOx1", "CHEMICAL", 40, 47], ["Ebola", "DISEASE", 89, 94], ["Chikungunya", "DISEASE", 96, 107], ["Rift Valley fever", "DISEASE", 109, 126], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 40, 47], ["Ebola", "ORGANISM", 89, 94], ["Chikungunya", "ORGANISM", 96, 107], ["Rift Valley fever", "ORGANISM", 109, 126], ["ChAdOx1", "PROTEIN", 40, 47], ["Ebola", "SPECIES", 89, 94], ["Chikungunya", "SPECIES", 96, 107], ["Rift Valley fever", "SPECIES", 109, 126], ["vaccines", "TREATMENT", 72, 80], ["Ebola", "PROBLEM", 89, 94], ["Chikungunya", "PROBLEM", 96, 107], ["Rift Valley fever", "PROBLEM", 109, 126]]], ["ChAdOx1, a chimpanzee-derived adenovirus vector, has been employed to deliver the full-length MERS spike gene and shown to induce large amounts of neutralizing antibodies against MERS in a mouse model [221, 222] .", [["ChAdOx1", "CHEMICAL", 0, 7], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 0, 7], ["chimpanzee", "ORGANISM", 11, 21], ["adenovirus", "ORGANISM", 30, 40], ["MERS", "GENE_OR_GENE_PRODUCT", 94, 98], ["mouse", "ORGANISM", 189, 194], ["ChAdOx1", "DNA", 0, 7], ["MERS spike gene", "DNA", 94, 109], ["neutralizing antibodies", "PROTEIN", 147, 170], ["MERS", "PROTEIN", 179, 183], ["mouse", "SPECIES", 189, 194], ["mouse", "SPECIES", 189, 194], ["ChAdOx1", "TREATMENT", 0, 7], ["a chimpanzee-derived adenovirus vector", "TREATMENT", 9, 47], ["large amounts of neutralizing antibodies", "PROBLEM", 130, 170], ["large", "OBSERVATION_MODIFIER", 130, 135]]], ["Therefore, the modified ChAdOx1 vaccine, carrying the SARS-CoV-2 spike gene is under human trial stage.", [["ChAdOx1", "CHEMICAL", 24, 31], ["ChAdOx1", "GENE_OR_GENE_PRODUCT", 24, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["human", "ORGANISM", 85, 90], ["SARS-CoV-2 spike gene", "DNA", 54, 75], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["the modified ChAdOx1 vaccine", "TREATMENT", 11, 39], ["the SARS", "TEST", 50, 58], ["CoV", "TEST", 59, 62]]], ["On April 30, the University of Oxford has announced a collaboration with the UK-based global biopharmaceutical company AstraZeneca for further development, large-scale production and potential delivery of the COVID-19 vaccine candidate.", [["AstraZeneca", "CHEMICAL", 119, 130], ["UK", "GENE_OR_GENE_PRODUCT", 77, 79], ["AstraZeneca", "SIMPLE_CHEMICAL", 119, 130], ["AstraZeneca", "TREATMENT", 119, 130], ["large-scale production", "TREATMENT", 156, 178], ["the COVID", "TREATMENT", 205, 214], ["large", "OBSERVATION_MODIFIER", 156, 161]]], ["Since ChAdOx technology is already available and formerly tested in humans for other vaccines, Phase III will consist in administering vaccine to volunteers following them into their regular environments to ensure that these subjects actually become immune to the disease up to three years.", [["ChAdOx", "CHEMICAL", 6, 12], ["ChAdOx", "GENE_OR_GENE_PRODUCT", 6, 12], ["humans", "ORGANISM", 68, 74], ["volunteers", "ORGANISM", 146, 156], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["other vaccines", "TREATMENT", 79, 93], ["Phase III", "TREATMENT", 95, 104], ["administering vaccine", "TREATMENT", 121, 142], ["the disease", "PROBLEM", 260, 271]]], ["If trials succeed, Oxford researchers have proposed to complete testing throughout ring vaccination, namely delivering vaccine to members of the first circle of contacts of COVID-19 positive people and then to evaluate if the virus spreads to the second circle, as was previously done during the 2018 Ebola epidemic in the Democratic Republic of the Congo.", [["Ebola", "DISEASE", 301, 306], ["COVID-19", "CELL", 173, 181], ["people", "ORGANISM", 191, 197], ["people", "SPECIES", 191, 197], ["complete testing", "TEST", 55, 71], ["throughout ring vaccination", "TREATMENT", 72, 99], ["COVID", "TEST", 173, 178], ["the virus", "PROBLEM", 222, 231]]], ["Schematic representation of SARS-CoV-2 infection and virus-induced human immune system response.", [["immune system", "ANATOMY", 73, 86], ["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 39, 48], ["SARS-CoV-2", "ORGANISM", 28, 38], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["SARS-CoV", "SPECIES", 28, 36], ["human", "SPECIES", 67, 72], ["SARS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36], ["2 infection", "PROBLEM", 37, 48], ["virus", "PROBLEM", 53, 58], ["SARS", "OBSERVATION", 28, 32]]], ["Proposed drugs directed both towards specific SARS-CoV-2 molecular targets and biologic processes are highlighted: inhibitors of SARS-CoV-2 fusion/entry targeting ACE2 receptor, spike protein, TMPRSS2 or HR1 and HR2 epitopes and clathrin-mediated endocytosis (I); molecules against SARS-CoV-2 main protease (II); molecules against viral genome replication (III); CRISPR Figure 8 .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 129, 139], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 163, 176], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 193, 200], ["HR1", "GENE_OR_GENE_PRODUCT", 204, 207], ["HR2 epitopes", "GENE_OR_GENE_PRODUCT", 212, 224], ["clathrin", "GENE_OR_GENE_PRODUCT", 229, 237], ["ACE2 receptor", "PROTEIN", 163, 176], ["spike protein", "PROTEIN", 178, 191], ["TMPRSS2", "PROTEIN", 193, 200], ["HR1", "PROTEIN", 204, 207], ["HR2 epitopes", "PROTEIN", 212, 224], ["clathrin", "PROTEIN", 229, 237], ["SARS-CoV-2 main protease (II); molecules", "PROTEIN", 282, 322], ["CRISPR Figure 8", "DNA", 363, 378], ["Proposed drugs", "TREATMENT", 0, 14], ["specific SARS", "TEST", 37, 50], ["CoV", "TEST", 51, 54], ["SARS", "PROBLEM", 129, 133], ["CoV", "TEST", 134, 137], ["2 fusion", "TREATMENT", 138, 146], ["ACE2 receptor", "TEST", 163, 176], ["spike protein", "TEST", 178, 191], ["TMPRSS2", "TEST", 193, 200], ["HR1", "TEST", 204, 207], ["HR2 epitopes", "TEST", 212, 224], ["clathrin", "TEST", 229, 237], ["SARS", "PROBLEM", 282, 286], ["CoV", "TEST", 287, 290], ["protease (II)", "TREATMENT", 298, 311], ["viral genome replication", "TREATMENT", 331, 355], ["CRISPR Figure", "PROBLEM", 363, 376]]], ["Schematic representation of SARS-CoV-2 infection and virus-induced human immune system response.", [["immune system", "ANATOMY", 73, 86], ["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 39, 48], ["SARS-CoV-2", "ORGANISM", 28, 38], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["SARS-CoV", "SPECIES", 28, 36], ["human", "SPECIES", 67, 72], ["SARS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36], ["2 infection", "PROBLEM", 37, 48], ["virus", "PROBLEM", 53, 58], ["SARS", "OBSERVATION", 28, 32]]], ["Proposed drugs directed both towards specific SARS-CoV-2 molecular targets and biologic processes are highlighted: inhibitors of SARS-CoV-2 fusion/entry targeting ACE2 receptor, spike protein, TMPRSS2 or HR1 and HR2 epitopes and clathrin-mediated endocytosis (I); molecules against SARS-CoV-2 main protease (II); molecules against viral genome replication (III); CRISPR technologies targeting SARS-CoV-2 RNA genome (IV); modulators of SARS-CoV-2 induced inflammatory response (V) and human neutralizing antibodies (VI).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 129, 139], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 163, 176], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 193, 200], ["HR1", "GENE_OR_GENE_PRODUCT", 204, 207], ["HR2 epitopes", "GENE_OR_GENE_PRODUCT", 212, 224], ["clathrin", "GENE_OR_GENE_PRODUCT", 229, 237], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 282, 292], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 393, 403], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 435, 445], ["human", "ORGANISM", 484, 489], ["ACE2 receptor", "PROTEIN", 163, 176], ["spike protein", "PROTEIN", 178, 191], ["TMPRSS2", "PROTEIN", 193, 200], ["HR1", "PROTEIN", 204, 207], ["HR2 epitopes", "PROTEIN", 212, 224], ["clathrin", "PROTEIN", 229, 237], ["SARS-CoV-2 main protease (II); molecules", "PROTEIN", 282, 322], ["SARS-CoV-2 RNA genome", "DNA", 393, 414], ["human neutralizing antibodies", "PROTEIN", 484, 513], ["VI", "PROTEIN", 515, 517], ["human", "SPECIES", 484, 489], ["human", "SPECIES", 484, 489], ["Proposed drugs", "TREATMENT", 0, 14], ["specific SARS", "TEST", 37, 50], ["CoV", "TEST", 51, 54], ["SARS", "PROBLEM", 129, 133], ["CoV", "TEST", 134, 137], ["2 fusion", "TREATMENT", 138, 146], ["ACE2 receptor", "TEST", 163, 176], ["spike protein", "TEST", 178, 191], ["TMPRSS2", "TEST", 193, 200], ["HR1", "TEST", 204, 207], ["HR2 epitopes", "TEST", 212, 224], ["clathrin", "TEST", 229, 237], ["SARS", "PROBLEM", 282, 286], ["CoV", "TEST", 287, 290], ["protease (II)", "TREATMENT", 298, 311], ["viral genome replication", "TREATMENT", 331, 355], ["CRISPR technologies", "TEST", 363, 382], ["SARS", "TEST", 393, 397], ["CoV", "TEST", 398, 401], ["SARS", "PROBLEM", 435, 439], ["CoV", "TEST", 440, 443], ["inflammatory response", "PROBLEM", 454, 475], ["human neutralizing antibodies", "TEST", 484, 513], ["inflammatory", "OBSERVATION_MODIFIER", 454, 466]]], ["ACE2, angiotensin-converting enzyme 2; TMPRSS2, type 2 transmembrane serine proteases; RdRp, RNA-dependent RNA polymerase; HR1, heptad repeat 1; HR2, heptad repeat 2; HR2P, heptad repeat 2-derived peptides; EK1, a modified OC43-HR2P peptide.", [["angiotensin", "CHEMICAL", 6, 17], ["serine", "CHEMICAL", 69, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 6, 37], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 39, 46], ["RdRp", "GENE_OR_GENE_PRODUCT", 87, 91], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 93, 121], ["HR1", "GENE_OR_GENE_PRODUCT", 123, 126], ["heptad repeat 1", "GENE_OR_GENE_PRODUCT", 128, 143], ["HR2", "GENE_OR_GENE_PRODUCT", 145, 148], ["heptad repeat 2", "GENE_OR_GENE_PRODUCT", 150, 165], ["HR2P", "GENE_OR_GENE_PRODUCT", 167, 171], ["EK1", "GENE_OR_GENE_PRODUCT", 207, 210], ["OC43-HR2P peptide", "GENE_OR_GENE_PRODUCT", 223, 240], ["ACE2", "PROTEIN", 0, 4], ["angiotensin-converting enzyme 2", "PROTEIN", 6, 37], ["TMPRSS2", "PROTEIN", 39, 46], ["type 2 transmembrane serine proteases", "PROTEIN", 48, 85], ["RdRp", "PROTEIN", 87, 91], ["RNA-dependent RNA polymerase", "PROTEIN", 93, 121], ["HR1", "PROTEIN", 123, 126], ["heptad repeat 1", "PROTEIN", 128, 143], ["HR2", "PROTEIN", 145, 148], ["heptad repeat 2", "PROTEIN", 150, 165], ["HR2P", "PROTEIN", 167, 171], ["heptad repeat 2", "DNA", 173, 188], ["EK1", "PROTEIN", 207, 210], ["OC43", "PROTEIN", 223, 227], ["ACE2", "TEST", 0, 4], ["angiotensin", "TEST", 6, 17], ["enzyme", "TEST", 29, 35], ["TMPRSS2", "TEST", 39, 46], ["type 2 transmembrane serine proteases", "TREATMENT", 48, 85], ["RdRp", "TEST", 87, 91], ["RNA", "TEST", 93, 96], ["dependent RNA polymerase", "PROBLEM", 97, 121], ["heptad repeat", "TEST", 128, 141], ["HR2", "TEST", 145, 148], ["heptad repeat", "TEST", 150, 163], ["HR2P", "TEST", 167, 171], ["heptad repeat", "TEST", 173, 186], ["EK1", "TEST", 207, 210], ["a modified OC43-HR2P peptide", "TREATMENT", 212, 240]]], ["Adapted from [223] .VaccinesOverall, a joint effort headed to apply both already consolidate and innovative approaches, such as AI to facilitate drug discovery, will be required to develop a broad-spectrum antiviral drugs and vaccines towards existing and potential future coronavirus infections to prevent another highly pathogenic virus epidemic.", [["coronavirus infections", "DISEASE", 273, 295], ["coronavirus", "ORGANISM", 273, 284], ["coronavirus", "SPECIES", 273, 284], ["VaccinesOverall", "TREATMENT", 20, 35], ["innovative approaches", "TREATMENT", 97, 118], ["a broad-spectrum antiviral drugs", "TREATMENT", 189, 221], ["vaccines", "TREATMENT", 226, 234], ["coronavirus infections", "PROBLEM", 273, 295], ["another highly pathogenic virus epidemic", "PROBLEM", 307, 347], ["joint", "ANATOMY", 39, 44]]], ["Moreover, continuous collaboration in basic and clinical studies will improve the discovery of new antiviral drugs with therapeutic potentials, decrease the time for drug release on the market and make them affordable for all countries.", [["clinical studies", "TEST", 48, 64], ["new antiviral drugs", "TREATMENT", 95, 114], ["drug release on the market", "TREATMENT", 166, 192], ["new", "OBSERVATION_MODIFIER", 95, 98], ["antiviral drugs", "OBSERVATION", 99, 114]]], ["Furthermore, vaccine delivery strategies and cell-based therapies benefit from the significant progresses made by recombinant DNA technologies combined with emerging biotechnology and bioengineering methodologies.", [["cell", "ANATOMY", 45, 49], ["cell", "CELL", 45, 49], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["vaccine delivery strategies", "TREATMENT", 13, 40], ["cell-based therapies", "TREATMENT", 45, 65], ["recombinant DNA technologies", "TREATMENT", 114, 142], ["bioengineering methodologies", "TREATMENT", 184, 212]]], ["Thus, these approaches can speed up the development and set up of new vaccines and clinical therapies to fight against novel pathogens to protect public health all over the world.ConclusionsThis study represents a holistic picture of the current investigations in response to the outbreak of COVID-19.", [["new vaccines", "TREATMENT", 66, 78], ["clinical therapies", "TREATMENT", 83, 101], ["novel pathogens", "PROBLEM", 119, 134], ["This study", "TEST", 190, 200], ["the current investigations", "TEST", 234, 260], ["COVID", "TEST", 292, 297]]], ["The current pandemic is obviously an international public health problem and it remains a challenging task to fight the SARS-CoV-2 of unknown origin and mysterious biologic features.", [["SARS", "DISEASE", 120, 124], ["SARS-CoV-2", "ORGANISM", 120, 130], ["the SARS", "TEST", 116, 124], ["CoV", "TEST", 125, 128], ["mysterious biologic features", "PROBLEM", 153, 181], ["unknown origin", "OBSERVATION_MODIFIER", 134, 148], ["mysterious biologic", "OBSERVATION", 153, 172]]], ["Lesson from the previous two pandemics, MERS and SARS outbreaks, provide valuable insights about how to manage the current pandemic and provide a reference for future studies to combat disease progression.", [["SARS", "DISEASE", 49, 53], ["future studies", "TEST", 160, 174], ["disease progression", "PROBLEM", 185, 204]]], ["Despite SARS-CoV-2 rapid transmission, the scale up country readiness, speedy response teams and the capacity of all laboratories are reducing the spread of the virus as well as its mortality rate.", [["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["all laboratories", "TEST", 113, 129], ["the virus", "PROBLEM", 157, 166]]], ["As the pandemic is still ongoing and expanding, further studies on all aspects of the disease are needed to better understand the infection, beneficial treatments and development of vaccines.", [["infection", "DISEASE", 130, 139], ["further studies", "TEST", 48, 63], ["the disease", "PROBLEM", 82, 93], ["the infection", "PROBLEM", 126, 139], ["beneficial treatments", "TREATMENT", 141, 162], ["vaccines", "TREATMENT", 182, 190], ["disease", "OBSERVATION", 86, 93], ["infection", "OBSERVATION", 130, 139]]], ["Nevertheless, this pandemic, together with the previous ones, have taught us in the harshest possible way that the entire scientific community must be vigilant and ready to advice appropriate containment and screening measures to avoid the spread of any future emerging pathogen.Acknowledgments:We would like to acknowledge Majidi Nezhad for providing the meteorological data and climate analyses and Gaia Scoarughi and Adeleh Salehi for drawing figures.Conflicts of Interest:The authors declare no conflict of interest.AbbreviationsThe following abbreviations are used in this manuscript: 16 nonstructural polyproteins (nsps 1-16); 2019 novel coronavirus (2019-nCoV); 3-chymotrypsin-like protease (3CLpro); 3C-like protease (3CL); Acute respiratory distress syndrome (ARDS); adeno-associated virus (AAV); angiotensin receptor blockers (ARBs); angiotensin-converting enzyme 2 (ACE2); AP-2-associated protein kinase 1 (AAK1); artificial intelligence (AI); avian infectious bronchitis virus (IBV); basic reproduction number (R0); blood oxygen saturation (SpO2); bronchoalveolar lavage (BAL); centers for disease control and prevention (CDC); Chinese Center for Disease Control and Prevention (China CDC); chronic obstructive pulmonary disease (COPD); Coalition for Epidemic Preparedness Innovations (CEPI); computed tomography (CT); computer-aided design (CAD); convalescent plasma (CP); coronavirus (CoV); cytotoxic T lymphocyte (CTL); dendritic cell (DC); dipeptidyl peptidase 4 (DPP4, also known as CD26); envelope glycoprotein (E); enzyme-linked immunosorbent assay (ELISA); European Center for Medium-Range Weather Forecasts (ECMWF); European cities (ECs); feline infectious peritonitis (FIP); graft versus-host disease (GVHD); hemagglutinin-esterase glycoprotein (HE); heptad repeat 1 (HR1) and heptad repeat 2 (HR2); high-resolution CT (HRCT); HR2-derived peptides (HR2P); EK1 (a modified OC43-HR2P peptide); human coronaviruses (HCoVs); human CoVs (HCoVs); human single-chain antibody variable fragments (Hu-scFvs); humanized-nanobodies (single-domain antibodies, sdAb); intensive care unit (ICU); Istituto Superiore di Sanit\u00e0 (ISS); Janus kinase (JAK); membrane glycoprotein (M); mesenchymal stromal cells (MSCs); microneedle arrays (MNAs); Middle East Respiratory syndrome coronavirus (MERS-CoV); monoclonal antibodies (mAbs); naso-pharyngeal (NP); National Health Commission of the People's Republic of China (NHC); nonstructural protein 14 (nsp14); Northern Hemisphere (NH); nucleocapsid phosphoprotein (N); open reading frames (ORFs); oro-pharyngeal (OP); papain-like protease (PLpro); partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2); pathogen-associated molecules (PAMPs); Pittsburgh coronavirus vaccine (PittCoVacc); polypeptides (pps); porcine epidemic diarrhea virus (PEDV); real time quantitative polymerase chain reaction (RT-qPCR); receptor-binding domain (RBD); recombinant human ACE2 (rhACE2); replication-transcription complex (RTC); RNA-dependent RNA polymerase (RdRp); RNase P gene (RP); severe acute respiratory syndrome coronavirus (SARS-CoV); single-stranded positive-sense RNA (+ssRNA); Southern Hemisphere (SH); spike glycoprotein (S); subgenomic RNAs (sgRNAs); swine acute diarrhea syndrome coronavirus (SADS-CoV); swine enteric Alphacoronaviruses (SeACoVs); systemic lupus erythematosus (SLE); transmissible gastroenteritis virus (TGEV); virus-like particles (VLP); WHO's International Clinical Trials Registry Platform (WHO ICTRP); World Health Organization (WHO).", [["blood", "ANATOMY", 1028, 1033], ["BAL", "ANATOMY", 1084, 1087], ["pulmonary", "ANATOMY", 1223, 1232], ["plasma", "ANATOMY", 1373, 1379], ["cytotoxic T lymphocyte", "ANATOMY", 1405, 1427], ["CTL", "ANATOMY", 1429, 1432], ["dendritic cell", "ANATOMY", 1435, 1449], ["DC", "ANATOMY", 1451, 1453], ["ECs", "ANATOMY", 1654, 1657], ["graft", "ANATOMY", 1697, 1702], ["mesenchymal stromal cells", "ANATOMY", 2187, 2212], ["MSCs", "ANATOMY", 2214, 2218], ["arterial", "ANATOMY", 2617, 2625], ["Acute respiratory distress syndrome", "DISEASE", 732, 767], ["ARDS", "DISEASE", 769, 773], ["angiotensin", "CHEMICAL", 806, 817], ["angiotensin", "CHEMICAL", 844, 855], ["infectious bronchitis virus", "DISEASE", 961, 988], ["oxygen", "CHEMICAL", 1034, 1040], ["chronic obstructive pulmonary disease", "DISEASE", 1203, 1240], ["COPD", "DISEASE", 1242, 1246], ["feline infectious peritonitis", "DISEASE", 1660, 1689], ["FIP", "DISEASE", 1691, 1694], ["graft versus-host disease", "DISEASE", 1697, 1722], ["GVHD", "DISEASE", 1724, 1728], ["Respiratory syndrome coronavirus", "DISEASE", 2260, 2292], ["oxygen", "CHEMICAL", 2626, 2632], ["oxygen", "CHEMICAL", 2657, 2663], ["porcine epidemic diarrhea", "DISEASE", 2787, 2812], ["acute respiratory syndrome coronavirus", "DISEASE", 3055, 3093], ["SARS", "DISEASE", 3095, 3099], ["acute diarrhea syndrome coronavirus", "DISEASE", 3233, 3268], ["enteric Alphacoronaviruses", "DISEASE", 3287, 3313], ["systemic lupus erythematosus", "DISEASE", 3325, 3353], ["SLE", "DISEASE", 3355, 3358], ["transmissible gastroenteritis virus", "DISEASE", 3361, 3396], ["oxygen", "CHEMICAL", 1034, 1040], ["oxygen", "CHEMICAL", 2626, 2632], ["oxygen", "CHEMICAL", 2657, 2663], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 657, 666], ["3-chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 669, 697], ["3C-like protease", "GENE_OR_GENE_PRODUCT", 708, 724], ["AAV", "ORGANISM", 800, 803], ["angiotensin receptor blockers", "GENE_OR_GENE_PRODUCT", 806, 835], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 844, 875], ["ACE2", "GENE_OR_GENE_PRODUCT", 877, 881], ["AP-2-associated protein kinase 1", "GENE_OR_GENE_PRODUCT", 884, 916], ["AAK1", "GENE_OR_GENE_PRODUCT", 918, 922], ["avian infectious bronchitis virus", "ORGANISM", 955, 988], ["IBV", "ORGANISM", 990, 993], ["blood", "ORGANISM_SUBSTANCE", 1028, 1033], ["oxygen", "SIMPLE_CHEMICAL", 1034, 1040], ["pulmonary", "ORGAN", 1223, 1232], ["plasma", "ORGANISM_SUBSTANCE", 1373, 1379], ["coronavirus", "ORGANISM", 1386, 1397], ["CoV", "ORGANISM", 1399, 1402], ["cytotoxic T lymphocyte", "CELL", 1405, 1427], ["CTL", "CELL", 1429, 1432], ["dendritic cell", "CELL", 1435, 1449], ["DC", "CELL", 1451, 1453], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 1456, 1478], ["DPP4", "GENE_OR_GENE_PRODUCT", 1480, 1484], ["CD26", "GENE_OR_GENE_PRODUCT", 1500, 1504], ["ECs", "CELL", 1654, 1657], ["graft", "TISSUE", 1697, 1702], ["hemagglutinin-esterase glycoprotein (HE); heptad repeat 1", "GENE_OR_GENE_PRODUCT", 1731, 1788], ["HR1", "GENE_OR_GENE_PRODUCT", 1790, 1793], ["heptad repeat 2", "GENE_OR_GENE_PRODUCT", 1799, 1814], ["HR2", "GENE_OR_GENE_PRODUCT", 1816, 1819], ["HR2-derived peptides", "GENE_OR_GENE_PRODUCT", 1849, 1869], ["EK1", "GENE_OR_GENE_PRODUCT", 1878, 1881], ["OC43-HR2P peptide", "GENE_OR_GENE_PRODUCT", 1894, 1911], ["human", "ORGANISM", 1914, 1919], ["coronaviruses", "ORGANISM", 1920, 1933], ["HCoVs", "GENE_OR_GENE_PRODUCT", 1935, 1940], ["human", "ORGANISM", 1943, 1948], ["CoVs", "GENE_OR_GENE_PRODUCT", 1949, 1953], ["HCoVs", "GENE_OR_GENE_PRODUCT", 1955, 1960], ["human", "ORGANISM", 1963, 1968], ["Janus kinase (JAK); membrane glycoprotein", "GENE_OR_GENE_PRODUCT", 2140, 2181], ["mesenchymal stromal cells", "CELL", 2187, 2212], ["MSCs", "CELL", 2214, 2218], ["Middle East Respiratory syndrome coronavirus", "ORGANISM", 2248, 2292], ["MERS-CoV", "ORGANISM", 2294, 2302], ["nonstructural protein 14", "GENE_OR_GENE_PRODUCT", 2425, 2449], ["nucleocapsid phosphoprotein", "GENE_OR_GENE_PRODUCT", 2485, 2512], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 2567, 2587], ["arterial", "MULTI-TISSUE_STRUCTURE", 2617, 2625], ["oxygen", "SIMPLE_CHEMICAL", 2626, 2632], ["oxygen", "SIMPLE_CHEMICAL", 2657, 2663], ["pathogen-associated molecules", "GENE_OR_GENE_PRODUCT", 2683, 2712], ["Pittsburgh coronavirus", "ORGANISM", 2722, 2744], ["porcine epidemic diarrhea virus", "ORGANISM", 2787, 2818], ["human", "ORGANISM", 2930, 2935], ["ACE2", "GENE_OR_GENE_PRODUCT", 2936, 2940], ["rhACE2", "GENE_OR_GENE_PRODUCT", 2942, 2948], ["replication-transcription complex", "GENE_OR_GENE_PRODUCT", 2951, 2984], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 2992, 3020], ["RNase P", "GENE_OR_GENE_PRODUCT", 3029, 3036], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 3048, 3093], ["SARS-CoV", "ORGANISM", 3095, 3103], ["spike glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 3177, 3199], ["swine acute diarrhea syndrome coronavirus", "ORGANISM", 3227, 3268], ["SADS-CoV", "ORGANISM", 3270, 3278], ["transmissible gastroenteritis virus", "ORGANISM", 3361, 3396], ["TGEV", "ORGANISM", 3398, 3402], ["nonstructural polyproteins", "PROTEIN", 593, 619], ["chymotrypsin", "PROTEIN", 671, 683], ["protease", "PROTEIN", 689, 697], ["3CLpro", "PROTEIN", 699, 705], ["3C", "PROTEIN", 708, 710], ["protease", "PROTEIN", 716, 724], ["3CL", "PROTEIN", 726, 729], ["angiotensin-converting enzyme 2", "PROTEIN", 844, 875], ["ACE2", "PROTEIN", 877, 881], ["AP-2-associated protein kinase 1", "PROTEIN", 884, 916], ["AAK1", "PROTEIN", 918, 922], ["cytotoxic T lymphocyte", "CELL_TYPE", 1405, 1427], ["CTL", "CELL_TYPE", 1429, 1432], ["dendritic cell", "CELL_TYPE", 1435, 1449], ["DC", "CELL_TYPE", 1451, 1453], ["dipeptidyl peptidase 4", "PROTEIN", 1456, 1478], ["DPP4", "PROTEIN", 1480, 1484], ["CD26", "PROTEIN", 1500, 1504], ["envelope glycoprotein", "PROTEIN", 1507, 1528], ["E", "PROTEIN", 1530, 1531], ["hemagglutinin", "PROTEIN", 1731, 1744], ["esterase glycoprotein", "PROTEIN", 1745, 1766], ["HE", "PROTEIN", 1768, 1770], ["heptad repeat 1", "PROTEIN", 1773, 1788], ["HR1", "PROTEIN", 1790, 1793], ["heptad repeat 2", "PROTEIN", 1799, 1814], ["HR2", "PROTEIN", 1816, 1819], ["HR2", "PROTEIN", 1849, 1852], ["EK1", "PROTEIN", 1878, 1881], ["OC43", "PROTEIN", 1894, 1898], ["human coronaviruses", "PROTEIN", 1914, 1933], ["HCoVs", "PROTEIN", 1935, 1940], ["human CoVs", "PROTEIN", 1943, 1953], ["HCoVs", "PROTEIN", 1955, 1960], ["human single-chain antibody variable fragments", "PROTEIN", 1963, 2009], ["Hu-scFvs", "PROTEIN", 2011, 2019], ["humanized-nanobodies", "PROTEIN", 2022, 2042], ["single-domain antibodies", "PROTEIN", 2044, 2068], ["sdAb", "PROTEIN", 2070, 2074], ["Janus kinase", "PROTEIN", 2140, 2152], ["JAK", "PROTEIN", 2154, 2157], ["membrane glycoprotein", "PROTEIN", 2160, 2181], ["mesenchymal stromal cells", "CELL_TYPE", 2187, 2212], ["MSCs", "CELL_TYPE", 2214, 2218], ["monoclonal antibodies", "PROTEIN", 2305, 2326], ["mAbs", "PROTEIN", 2328, 2332], ["nonstructural protein 14", "PROTEIN", 2425, 2449], ["nsp14", "PROTEIN", 2451, 2456], ["Northern Hemisphere", "PROTEIN", 2459, 2478], ["NH", "PROTEIN", 2480, 2482], ["nucleocapsid phosphoprotein", "PROTEIN", 2485, 2512], ["N", "PROTEIN", 2514, 2515], ["open reading frames", "DNA", 2518, 2537], ["ORFs", "DNA", 2539, 2543], ["papain", "PROTEIN", 2567, 2573], ["protease", "PROTEIN", 2579, 2587], ["PLpro", "PROTEIN", 2589, 2594], ["pathogen-associated molecules", "PROTEIN", 2683, 2712], ["PAMPs", "PROTEIN", 2714, 2719], ["PittCoVacc", "PROTEIN", 2754, 2764], ["pps", "PROTEIN", 2781, 2784], ["receptor-binding domain", "PROTEIN", 2887, 2910], ["RBD", "PROTEIN", 2912, 2915], ["recombinant human ACE2", "PROTEIN", 2918, 2940], ["rhACE2", "PROTEIN", 2942, 2948], ["replication-transcription complex", "PROTEIN", 2951, 2984], ["RTC", "PROTEIN", 2986, 2989], ["RNA-dependent RNA polymerase", "PROTEIN", 2992, 3020], ["RdRp", "PROTEIN", 3022, 3026], ["RNase P gene", "DNA", 3029, 3041], ["RP", "DNA", 3043, 3045], ["spike glycoprotein", "PROTEIN", 3177, 3195], ["subgenomic RNAs", "RNA", 3201, 3216], ["avian infectious bronchitis virus", "SPECIES", 955, 988], ["coronavirus", "SPECIES", 1386, 1397], ["feline", "SPECIES", 1660, 1666], ["human", "SPECIES", 1914, 1919], ["human", "SPECIES", 1943, 1948], ["human", "SPECIES", 1963, 1968], ["People", "SPECIES", 2391, 2397], ["porcine epidemic diarrhea virus", "SPECIES", 2787, 2818], ["human", "SPECIES", 2930, 2935], ["swine", "SPECIES", 3227, 3232], ["diarrhea syndrome coronavirus", "SPECIES", 3239, 3268], ["swine", "SPECIES", 3281, 3286], ["transmissible gastroenteritis virus", "SPECIES", 3361, 3396], ["TGEV", "SPECIES", 3398, 3402], ["infectious bronchitis virus", "SPECIES", 961, 988], ["IBV", "SPECIES", 990, 993], ["CoV", "SPECIES", 1399, 1402], ["human coronaviruses", "SPECIES", 1914, 1933], ["human", "SPECIES", 1943, 1948], ["human", "SPECIES", 1963, 1968], ["Middle East Respiratory syndrome coronavirus", "SPECIES", 2248, 2292], ["MERS-CoV", "SPECIES", 2294, 2302], ["Pittsburgh coronavirus", "SPECIES", 2722, 2744], ["porcine epidemic diarrhea virus", "SPECIES", 2787, 2818], ["PEDV", "SPECIES", 2820, 2824], ["human", "SPECIES", 2930, 2935], ["severe acute respiratory syndrome coronavirus", "SPECIES", 3048, 3093], ["SARS-CoV", "SPECIES", 3095, 3103], ["swine acute diarrhea syndrome coronavirus", "SPECIES", 3227, 3268], ["SADS-CoV", "SPECIES", 3270, 3278], ["transmissible gastroenteritis virus", "SPECIES", 3361, 3396], ["TGEV", "SPECIES", 3398, 3402], ["appropriate containment", "TREATMENT", 180, 203], ["screening measures", "TREATMENT", 208, 226], ["the meteorological data", "TEST", 352, 375], ["climate analyses", "TEST", 380, 396], ["nonstructural polyproteins", "TEST", 593, 619], ["nsps", "TEST", 621, 625], ["novel coronavirus", "TEST", 638, 655], ["chymotrypsin", "TREATMENT", 671, 683], ["protease (3CLpro)", "TREATMENT", 689, 706], ["3C-like protease", "TREATMENT", 708, 724], ["Acute respiratory distress syndrome", "PROBLEM", 732, 767], ["ARDS)", "PROBLEM", 769, 774], ["adeno-associated virus", "PROBLEM", 776, 798], ["AAV)", "TREATMENT", 800, 804], ["angiotensin receptor blockers", "TREATMENT", 806, 835], ["ARBs", "TEST", 837, 841], ["angiotensin", "TEST", 844, 855], ["enzyme", "TEST", 867, 873], ["ACE2", "TEST", 877, 881], ["AP", "TEST", 884, 886], ["protein kinase", "TEST", 900, 914], ["artificial intelligence (AI)", "PROBLEM", 925, 953], ["avian infectious bronchitis virus", "PROBLEM", 955, 988], ["blood oxygen saturation", "TEST", 1028, 1051], ["SpO2", "TEST", 1053, 1057], ["bronchoalveolar lavage (BAL)", "TEST", 1060, 1088], ["disease control", "TREATMENT", 1102, 1117], ["Disease Control", "TREATMENT", 1159, 1174], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 1203, 1247], ["computed tomography (CT", "TEST", 1305, 1328], ["aided design (CAD)", "PROBLEM", 1340, 1358], ["convalescent plasma (CP)", "PROBLEM", 1360, 1384], ["coronavirus (CoV)", "TEST", 1386, 1403], ["cytotoxic T lymphocyte", "TEST", 1405, 1427], ["dendritic cell", "PROBLEM", 1435, 1449], ["dipeptidyl peptidase", "TEST", 1456, 1476], ["DPP4", "TEST", 1480, 1484], ["CD26", "TEST", 1500, 1504], ["envelope glycoprotein", "TEST", 1507, 1528], ["enzyme", "TEST", 1534, 1540], ["immunosorbent assay", "TEST", 1548, 1567], ["Medium", "TEST", 1597, 1603], ["feline infectious peritonitis", "PROBLEM", 1660, 1689], ["graft versus-host disease", "PROBLEM", 1697, 1722], ["GVHD", "PROBLEM", 1724, 1728], ["hemagglutinin-esterase glycoprotein", "TREATMENT", 1731, 1766], ["heptad repeat", "TEST", 1773, 1786], ["heptad repeat", "TEST", 1799, 1812], ["HR2", "TEST", 1816, 1819], ["high-resolution CT", "TEST", 1822, 1840], ["HRCT", "TEST", 1842, 1846], ["HR2", "TEST", 1849, 1852], ["EK1", "TEST", 1878, 1881], ["a modified OC43-HR2P peptide", "TREATMENT", 1883, 1911], ["human coronaviruses (HCoVs)", "PROBLEM", 1914, 1941], ["human CoVs (HCoVs)", "TREATMENT", 1943, 1961], ["human single-chain antibody variable fragments (Hu-scFvs", "TREATMENT", 1963, 2019], ["humanized-nanobodies", "TREATMENT", 2022, 2042], ["single-domain antibodies", "TREATMENT", 2044, 2068], ["Istituto Superiore di Sanit\u00e0 (ISS)", "TREATMENT", 2104, 2138], ["Janus kinase (JAK)", "TREATMENT", 2140, 2158], ["membrane glycoprotein (M); mesenchymal stromal cells (MSCs)", "TREATMENT", 2160, 2219], ["microneedle arrays (MNAs)", "TEST", 2221, 2246], ["Middle East Respiratory syndrome coronavirus", "PROBLEM", 2248, 2292], ["monoclonal antibodies (mAbs", "TEST", 2305, 2332], ["nonstructural protein", "TEST", 2425, 2446], ["nucleocapsid phosphoprotein (N)", "PROBLEM", 2485, 2516], ["open reading frames", "TEST", 2518, 2537], ["oro-pharyngeal (OP)", "TREATMENT", 2546, 2565], ["papain", "TREATMENT", 2567, 2573], ["protease (PLpro)", "TREATMENT", 2579, 2595], ["partial pressure of arterial oxygen", "TREATMENT", 2597, 2632], ["inspired oxygen ratio", "TEST", 2648, 2669], ["PaO2", "TEST", 2671, 2675], ["FiO2", "TEST", 2676, 2680], ["pathogen", "PROBLEM", 2683, 2691], ["associated molecules (PAMPs", "TREATMENT", 2692, 2719], ["Pittsburgh coronavirus vaccine (PittCoVacc)", "TREATMENT", 2722, 2765], ["polypeptides (pps", "TREATMENT", 2767, 2784], ["porcine epidemic diarrhea virus (PEDV", "PROBLEM", 2787, 2824], ["real time quantitative polymerase chain reaction", "PROBLEM", 2827, 2875], ["RT-qPCR", "TEST", 2877, 2884], ["receptor-binding domain (RBD)", "TREATMENT", 2887, 2916], ["recombinant human ACE2 (rhACE2)", "TREATMENT", 2918, 2949], ["replication-transcription complex (RTC)", "TREATMENT", 2951, 2990], ["RNA", "TEST", 2992, 2995], ["dependent RNA polymerase", "PROBLEM", 2996, 3020], ["RNase P gene (RP)", "TEST", 3029, 3046], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 3048, 3093], ["CoV", "TEST", 3100, 3103], ["single-stranded positive-sense RNA", "PROBLEM", 3106, 3140], ["spike glycoprotein (S)", "PROBLEM", 3177, 3199], ["subgenomic RNAs (sgRNAs)", "PROBLEM", 3201, 3225], ["swine acute diarrhea syndrome", "PROBLEM", 3227, 3256], ["coronavirus (SADS-CoV)", "PROBLEM", 3257, 3279], ["swine enteric Alphacoronaviruses (SeACoVs)", "TREATMENT", 3281, 3323], ["systemic lupus erythematosus", "PROBLEM", 3325, 3353], ["SLE)", "PROBLEM", 3355, 3359], ["transmissible gastroenteritis virus (TGEV)", "PROBLEM", 3361, 3403], ["virus", "PROBLEM", 3405, 3410], ["Acute", "OBSERVATION_MODIFIER", 732, 737], ["respiratory distress", "OBSERVATION", 738, 758], ["infectious", "OBSERVATION_MODIFIER", 961, 971], ["bronchitis", "OBSERVATION", 972, 982], ["bronchoalveolar lavage", "OBSERVATION", 1060, 1082], ["chronic", "OBSERVATION_MODIFIER", 1203, 1210], ["obstructive", "OBSERVATION_MODIFIER", 1211, 1222], ["pulmonary", "ANATOMY", 1223, 1232], ["disease", "OBSERVATION", 1233, 1240], ["COPD", "OBSERVATION", 1242, 1246], ["dendritic cell", "OBSERVATION", 1435, 1449], ["infectious", "OBSERVATION_MODIFIER", 1667, 1677], ["peritonitis", "OBSERVATION", 1678, 1689], ["graft", "OBSERVATION", 1697, 1702], ["host disease", "OBSERVATION", 1710, 1722], ["mesenchymal", "ANATOMY", 2187, 2198], ["stromal cells", "OBSERVATION", 2199, 2212], ["Middle", "ANATOMY_MODIFIER", 2248, 2254], ["Respiratory syndrome", "ANATOMY", 2260, 2280], ["pharyngeal", "ANATOMY", 2340, 2350], ["arterial", "ANATOMY", 2617, 2625], ["severe", "OBSERVATION_MODIFIER", 3048, 3054], ["acute", "OBSERVATION_MODIFIER", 3055, 3060], ["respiratory syndrome", "OBSERVATION", 3061, 3081], ["systemic", "ANATOMY", 3325, 3333], ["lupus erythematosus", "OBSERVATION", 3334, 3353]]]], "PMC7094370": [["INTRODUCTIONRespiratory tract infections (RTI), and their clinical presentation as bovine respiratory disease (BRD), are a major economic issue in all cattle operations worldwide and a leading indication for antimicrobial use (Pardon et al., 2012a,b; Reiten et al., 2018; Karle et al., 2019).", [["respiratory", "ANATOMY", 90, 101], ["INTRODUCTIONRespiratory tract infections", "DISEASE", 0, 40], ["RTI", "DISEASE", 42, 45], ["bovine respiratory disease", "DISEASE", 83, 109], ["BRD", "DISEASE", 111, 114], ["bovine", "ORGANISM", 83, 89], ["bovine", "SPECIES", 83, 89], ["BRD", "SPECIES", 111, 114], ["cattle", "SPECIES", 151, 157], ["INTRODUCTIONRespiratory tract infections (RTI)", "PROBLEM", 0, 46], ["bovine respiratory disease", "PROBLEM", 83, 109], ["BRD", "PROBLEM", 111, 114], ["tract", "OBSERVATION_MODIFIER", 24, 29], ["infections", "OBSERVATION", 30, 40], ["respiratory disease", "OBSERVATION", 90, 109]]], ["To reduce the selection pressure from antimicrobial use in the long run, better prevention and control of RTI is urgently needed (EMA/EFSA, 2017).", [["RTI", "DISEASE", 106, 109], ["the selection pressure", "TREATMENT", 10, 32], ["antimicrobial use", "TREATMENT", 38, 55], ["RTI", "PROBLEM", 106, 109], ["pressure", "OBSERVATION_MODIFIER", 24, 32], ["antimicrobial", "OBSERVATION_MODIFIER", 38, 51]]], ["Airway inflammation and bronchopneumonia result from a complex interplay between multiple viral and bacterial pathogens and environmental or host factors weakening defense mechanisms or stimulating pathogen spread (Griffin et al., 2010).", [["Airway", "ANATOMY", 0, 6], ["Airway inflammation", "DISEASE", 0, 19], ["bronchopneumonia", "DISEASE", 24, 40], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["Airway inflammation", "PROBLEM", 0, 19], ["bronchopneumonia", "PROBLEM", 24, 40], ["a complex interplay", "PROBLEM", 53, 72], ["multiple viral and bacterial pathogens", "PROBLEM", 81, 119], ["host factors weakening defense mechanisms", "PROBLEM", 141, 182], ["stimulating pathogen spread", "PROBLEM", 186, 213], ["inflammation", "OBSERVATION", 7, 19], ["bronchopneumonia", "OBSERVATION", 24, 40], ["complex", "OBSERVATION_MODIFIER", 55, 62], ["multiple", "OBSERVATION_MODIFIER", 81, 89], ["viral", "OBSERVATION", 90, 95], ["bacterial pathogens", "OBSERVATION", 100, 119]]], ["A long-lasting concept is that viruses are primary pathogens, paving the way for bacterial infections (Griffin et al., 2010).", [["bacterial infections", "DISEASE", 81, 101], ["viruses", "PROBLEM", 31, 38], ["primary pathogens", "PROBLEM", 43, 60], ["bacterial infections", "PROBLEM", 81, 101], ["viruses", "OBSERVATION", 31, 38], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["infections", "OBSERVATION", 91, 101]]], ["Also, Mycoplasma bovis is increasingly recognized as a primary pathogen, although this remains controversial in the scientific community (Calcutt et al., 2018).", [["Mycoplasma bovis", "DISEASE", 6, 22], ["Mycoplasma bovis", "ORGANISM", 6, 22], ["Mycoplasma bovis", "SPECIES", 6, 22], ["Mycoplasma bovis", "SPECIES", 6, 22], ["Mycoplasma bovis", "PROBLEM", 6, 22], ["a primary pathogen", "PROBLEM", 53, 71], ["Mycoplasma bovis", "OBSERVATION", 6, 22]]], ["Despite the importance of BRD, most available studies on pathogen identification in live animals are limited in number of herds and pathogens studied (Autio et al., 2007; Pardon et al., 2011; Murray et al., 2018).", [["BRD", "DISEASE", 26, 29], ["BRD", "PROBLEM", 26, 29], ["pathogen identification", "TEST", 57, 80]]], ["Also, most of them involve intensive systems such as feedlots or veal calves, which are confronted with respiratory disease year round at a predictable moment in the production cycle (Pardon et al., 2011; Timsit et al., 2017).", [["respiratory", "ANATOMY", 104, 115], ["respiratory disease", "DISEASE", 104, 123], ["calves", "ORGANISM", 70, 76], ["calves", "SPECIES", 70, 76], ["veal", "SPECIES", 65, 69], ["respiratory disease", "PROBLEM", 104, 123], ["veal calves", "ANATOMY", 65, 76], ["respiratory disease", "OBSERVATION", 104, 123]]], ["In contrast, pathogens involved in the classic epidemic respiratory disease outbreaks in winter in the most frequent European farming system of family-owned medium-sized dairy and beef farms are hardly documented (O'Neill et al., 2014).INTRODUCTIONTo justify antimicrobial use and customize prevention and control measures, sampling of the respiratory tract is recommended in more and more European countries (KNMVD, 2015; EMA/EFSA, 2017; AMCRA, 2019).", [["respiratory", "ANATOMY", 56, 67], ["respiratory tract", "ANATOMY", 340, 357], ["respiratory disease", "DISEASE", 56, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 340, 357], ["beef", "SPECIES", 180, 184], ["beef", "SPECIES", 180, 184], ["pathogens", "PROBLEM", 13, 22], ["the classic epidemic respiratory disease outbreaks", "PROBLEM", 35, 85], ["antimicrobial use", "TREATMENT", 259, 276], ["customize prevention", "TREATMENT", 281, 301], ["control measures", "TREATMENT", 306, 322], ["sampling of the respiratory tract", "TEST", 324, 357], ["epidemic", "OBSERVATION_MODIFIER", 47, 55], ["respiratory disease", "OBSERVATION", 56, 75], ["respiratory tract", "ANATOMY", 340, 357]]], ["Different sampling methods are available, of which deep nasopharyngeal swabs, transtracheal washes, and nonendoscopic broncho-alveolar lavage (nBAL) have found their way into practice (Doyle et al., 2017; Timsit et al., 2017; Van Driessche et al., 2017).", [["nasopharyngeal swabs", "ANATOMY", 56, 76], ["transtracheal", "ANATOMY", 78, 91], ["broncho-alveolar lavage", "ANATOMY", 118, 141], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 56, 76], ["alveolar lavage", "MULTI-TISSUE_STRUCTURE", 126, 141], ["Different sampling methods", "TEST", 0, 26], ["deep nasopharyngeal swabs", "TEST", 51, 76], ["transtracheal washes", "TREATMENT", 78, 98], ["nonendoscopic broncho-alveolar lavage", "TEST", 104, 141], ["deep", "ANATOMY_MODIFIER", 51, 55], ["nasopharyngeal", "ANATOMY", 56, 70], ["transtracheal", "ANATOMY", 78, 91], ["alveolar", "ANATOMY", 126, 134], ["lavage", "OBSERVATION", 135, 141]]], ["Next to classic bacterial culture and susceptibility testing, PCR is increasingly popular (O'Neill et al., 2014; DGZ, 2016).", [["classic bacterial culture", "TEST", 8, 33], ["susceptibility testing", "TEST", 38, 60], ["PCR", "TEST", 62, 65]]], ["According to practitioners, the main advantage is that many different pathogens, both viruses and bacteria, are tested and that the high sensitivity makes it possible to test pooled samples, which complies well with their desire to obtain a group diagnosis (O'Neill et al., 2014).", [["samples", "ANATOMY", 182, 189], ["many different pathogens", "PROBLEM", 55, 79], ["both viruses", "PROBLEM", 81, 93], ["bacteria", "PROBLEM", 98, 106], ["the high sensitivity", "PROBLEM", 128, 148]]], ["Also, contamination of the sample does not interfere with the test result as much as with culture.", [["sample", "ANATOMY", 27, 33], ["the test result", "TEST", 58, 73], ["culture", "TEST", 90, 97]]], ["Main disadvantages are the lack of antimicrobial susceptibility testing and difficulties in the interpretation of detection of opportunistic pathogens such as Pasteurellaceae (Fulton and Confer, 2012).INTRODUCTIONMany risk factors for RTI have been identified in multiple studies, but they all used a wide variety of case definitions, covered by the BRD concept.", [["RTI", "DISEASE", 235, 238], ["antimicrobial susceptibility testing", "TEST", 35, 71], ["opportunistic pathogens", "PROBLEM", 127, 150], ["Pasteurellaceae", "PROBLEM", 159, 174], ["RTI", "PROBLEM", 235, 238], ["multiple studies", "TEST", 263, 279]]], ["With the exception of M. bovis (Gille et al., 2018; Schibrowski et al., 2018), hardly any studies explored pathogen-specific risk factors for detection of the pathogen itself.", [["M. bovis", "ORGANISM", 22, 30], ["M. bovis", "SPECIES", 22, 30], ["M. bovis", "SPECIES", 22, 30], ["any studies", "TEST", 86, 97], ["pathogen", "PROBLEM", 107, 115], ["the pathogen itself", "PROBLEM", 155, 174], ["bovis", "OBSERVATION", 25, 30]]], ["In bovine mastitis, identification of pathogen-group-specific risk factors has led to targeted control and prevention, which is economically more efficient than a standard approach (Passchyn et al., 2014; Tolosa et al., 2015).", [["bovine mastitis", "DISEASE", 3, 18], ["bovine", "ORGANISM", 3, 9], ["bovine", "SPECIES", 3, 9], ["bovine", "SPECIES", 3, 9], ["bovine mastitis", "PROBLEM", 3, 18], ["pathogen", "PROBLEM", 38, 46], ["bovine mastitis", "OBSERVATION", 3, 18]]], ["Also, for respiratory pathogens, the eliciting risk factors might be different, enabling the possibility for customized advice instead of the current general approaches, conferring multiple and often expensive changes on farm.", [["respiratory pathogens", "DISEASE", 10, 31], ["respiratory pathogens", "PROBLEM", 10, 31], ["respiratory", "ANATOMY", 10, 21], ["pathogens", "OBSERVATION", 22, 31]]], ["Additionally, being able to predict the most likely pathogen (virus, M. bovis, or Pasteurellaceae) involved at the time of the first visit based on easily measurable environmental or circumstantial factors would be of great practical value to justify antimicrobial use.", [["M. bovis", "ORGANISM", 69, 77], ["M. bovis", "SPECIES", 69, 77], ["M. bovis", "SPECIES", 69, 77], ["pathogen (virus", "PROBLEM", 52, 67], ["Pasteurellaceae", "PROBLEM", 82, 97], ["most likely", "UNCERTAINTY", 40, 51]]], ["Therefore, the objective of the present study was to identify at the herd level pathogen-specific risk factors for respiratory viruses and bacteria involved in epidemic outbreaks of respiratory disease.Study Population, Design, and Sample Size Calculation ::: MATERIALS AND METHODSA cross-sectional study was conducted.", [["respiratory", "ANATOMY", 182, 193], ["respiratory viruses", "DISEASE", 115, 134], ["respiratory disease", "DISEASE", 182, 201], ["the present study", "TEST", 28, 45], ["the herd level pathogen", "PROBLEM", 65, 88], ["respiratory viruses", "PROBLEM", 115, 134], ["bacteria", "PROBLEM", 139, 147], ["respiratory disease", "PROBLEM", 182, 201], ["METHODSA cross-sectional study", "TEST", 274, 304], ["respiratory viruses", "OBSERVATION", 115, 134], ["respiratory disease", "OBSERVATION", 182, 201]]], ["The study period was set to include 2 winter seasons, and therefore took from September 2016 to January 2018.", [["The study", "TEST", 0, 9]]], ["This study used available data from the \u2018Griepbarometer' initiative of the Flemish Animal Health Service and Ghent University (DGZ, 2016).", [["This study", "TEST", 0, 10]]], ["This project aimed at developing an accessible monitoring tool for RTI in cattle, continuously available on a webpage to offer farmers and veterinarians a view on the prevalence and spread of respiratory pathogens in their surroundings.", [["RTI", "DISEASE", 67, 70], ["cattle", "ORGANISM", 74, 80], ["cattle", "SPECIES", 74, 80], ["cattle", "SPECIES", 74, 80], ["respiratory pathogens", "OBSERVATION", 192, 213]]], ["To stimulate sample submission, the PCR analysis of the samples was at the expense of the Flemish Animal Health Service.", [["sample", "ANATOMY", 13, 19], ["sample submission", "TEST", 13, 30], ["the PCR analysis", "TEST", 32, 48], ["the samples", "TEST", 52, 63]]], ["The target population was all cattle herds from the northern part of Belgium (Flanders).", [["cattle", "SPECIES", 30, 36], ["cattle", "SPECIES", 30, 36], ["target", "OBSERVATION_MODIFIER", 4, 10], ["population", "OBSERVATION_MODIFIER", 11, 21]]], ["The study population was conveniently selected based on willingness to participate at a first-come, first-serve basis until the budget was completed.", [["The study", "TEST", 0, 9]]], ["The aim was to sample epidemic outbreaks of respiratory disease.", [["respiratory", "ANATOMY", 44, 55], ["respiratory disease", "DISEASE", 44, 63], ["respiratory disease", "PROBLEM", 44, 63], ["respiratory disease", "OBSERVATION", 44, 63]]], ["Inclusion criteria were an acute outbreak of respiratory signs (cough, nasal discharge, increased breathing rate, fever, depression) affecting multiple animals (>5; minimum 15% ill animals) in multiple pens in the same barn/air space (compartment) of a farm in less than a week.", [["respiratory", "ANATOMY", 45, 56], ["nasal", "ANATOMY", 71, 76], ["respiratory signs", "DISEASE", 45, 62], ["cough", "DISEASE", 64, 69], ["fever", "DISEASE", 114, 119], ["depression", "DISEASE", 121, 131], ["nasal", "ORGANISM_SUBDIVISION", 71, 76], ["respiratory signs", "PROBLEM", 45, 62], ["cough", "PROBLEM", 64, 69], ["nasal discharge", "PROBLEM", 71, 86], ["increased breathing rate", "PROBLEM", 88, 112], ["fever", "PROBLEM", 114, 119], ["depression", "PROBLEM", 121, 131], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["outbreak", "OBSERVATION_MODIFIER", 33, 41], ["respiratory signs", "OBSERVATION", 45, 62], ["nasal", "ANATOMY", 71, 76], ["air space", "OBSERVATION", 224, 233]]], ["The advice was given to sample the outbreak within 7 d after the index case to optimize the odds for viral detection.", [["viral detection", "TEST", 101, 116]]], ["Financial support was only offered if the enquiry was filled in and returned.", [["Financial support", "TREATMENT", 0, 17]]], ["This was done through the different communication channels (email, website) of the Flemish Animal Health Service.Study Population, Design, and Sample Size Calculation ::: MATERIALS AND METHODSSample size was based on prevalence determination of respiratory pathogens in the study region.", [["respiratory pathogens", "DISEASE", 245, 266], ["METHODSSample size", "TREATMENT", 185, 203], ["respiratory pathogens in the study region", "PROBLEM", 245, 286], ["size", "OBSERVATION_MODIFIER", 199, 203], ["respiratory pathogens", "OBSERVATION", 245, 266]]], ["To determine the prevalence of the pathogens with 95% confidence, an expected prevalence of the pathogen of 50% (worst case scenario) and 10% accepted error, based on several herds in Flanders of 15,081 in 2016, 97 herds needed to be sampled (Winepiscope 2.0, Zaragoza, Spain; Thrusfield et al., 2001).", [["the pathogens", "PROBLEM", 31, 44], ["the pathogen", "TEST", 92, 104]]], ["The budget was set to sample 130 herds over 2 yr.Sampling and Risk Factor Data Collection ::: MATERIALS AND METHODSNonendoscopic broncho-alveolar lavage samples were taken as previously described using an instilled volume of saline of 0.5 to 1 mL/kg of BW (Van Driessche et al., 2017).", [["broncho-alveolar lavage samples", "ANATOMY", 129, 160], ["broncho-alveolar lavage samples", "CANCER", 129, 160], ["Sampling", "TEST", 49, 57], ["METHODSNonendoscopic broncho-alveolar lavage samples", "TREATMENT", 108, 160], ["an instilled volume of saline", "TREATMENT", 202, 231]]], ["Training sessions to perform the nBAL sampling had been organized for local practitioners by the Flemish Animal Health Service in collaboration with Ghent University all over the country in 2015 to 2017.", [["Training sessions", "TREATMENT", 0, 17], ["the nBAL sampling", "TEST", 29, 46]]], ["Only ill animals were sampled.", [["ill", "OBSERVATION_MODIFIER", 5, 8]]], ["The advice to sample acute cases, which were not treated with antimicrobials in the last 14 d, was given.", [["antimicrobials", "TREATMENT", 62, 76]]], ["Animal selection was left at their discretion and consisted of a combination of the following signs: fever (>39\u00b0C), nasal discharge, ocular discharge, (induced or spontaneous) cough, increased respiratory rate (>45 breaths/min), adventitious lung sounds, and depression.", [["nasal", "ANATOMY", 116, 121], ["ocular", "ANATOMY", 133, 139], ["respiratory", "ANATOMY", 193, 204], ["lung", "ANATOMY", 242, 246], ["fever", "DISEASE", 101, 106], ["cough", "DISEASE", 176, 181], ["adventitious lung sounds", "DISEASE", 229, 253], ["depression", "DISEASE", 259, 269], ["nasal", "ORGANISM_SUBDIVISION", 116, 121], ["lung", "ORGAN", 242, 246], ["fever", "PROBLEM", 101, 106], ["nasal discharge", "PROBLEM", 116, 131], ["ocular discharge", "PROBLEM", 133, 149], ["spontaneous) cough", "PROBLEM", 163, 181], ["increased respiratory rate", "PROBLEM", 183, 209], ["adventitious lung sounds", "PROBLEM", 229, 253], ["depression", "PROBLEM", 259, 269], ["fever", "OBSERVATION", 101, 106], ["nasal", "ANATOMY", 116, 121], ["ocular", "ANATOMY", 133, 139], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["respiratory rate", "OBSERVATION", 193, 209], ["adventitious", "OBSERVATION_MODIFIER", 229, 241], ["lung", "ANATOMY", 242, 246], ["sounds", "OBSERVATION", 247, 253], ["depression", "OBSERVATION", 259, 269]]], ["This sample size was based on the limitations of PCR to be used on pooled samples.", [["sample", "ANATOMY", 5, 11], ["samples", "ANATOMY", 74, 81], ["This sample size", "TEST", 0, 16], ["PCR", "TEST", 49, 52], ["pooled samples", "TEST", 67, 81], ["size", "OBSERVATION_MODIFIER", 12, 16]]], ["Diagnostic performance of the PCR was identical to individual samples when the pool was limited to 5 samples (in-house validation).", [["samples", "ANATOMY", 62, 69], ["the PCR", "TEST", 26, 33]]], ["A separate sterile nBAL catheter was used for each animal.", [["A separate sterile nBAL catheter", "TREATMENT", 0, 32], ["nBAL", "OBSERVATION_MODIFIER", 19, 23], ["catheter", "OBSERVATION", 24, 32]]], ["Lung lavage fluid was collected in sterile tubes and the 5 samples were sent to the laboratory as quickly as possible.", [["Lung lavage fluid", "ANATOMY", 0, 17], ["samples", "ANATOMY", 59, 66], ["Lung lavage fluid", "ORGANISM_SUBSTANCE", 0, 17], ["Lung lavage fluid", "TEST", 0, 17], ["sterile tubes", "TREATMENT", 35, 48], ["the 5 samples", "TEST", 53, 66], ["lavage fluid", "OBSERVATION", 5, 17], ["tubes", "OBSERVATION", 43, 48]]], ["All sampling techniques have been previously approved by the local ethical committee for use in routine sampling in practice (Ghent University EC 2014/189, EC 2016/20).Sampling and Risk Factor Data Collection ::: MATERIALS AND METHODSA questionnaire consisting of farm identification and 39 questions on management, housing, and clinical presentation was filled in by the practitioner using an oral interview of the farmer and local inspection of the environment.", [["oral", "ANATOMY", 394, 398], ["oral", "ORGANISM_SUBDIVISION", 394, 398], ["EC 2016/20", "CELL_LINE", 156, 166], ["All sampling techniques", "TREATMENT", 0, 23], ["Sampling", "TEST", 168, 176], ["management", "TREATMENT", 304, 314]]], ["Further data were collected from the national cattle identification, registration and movement database [SANITRACE, Animal Health Service Flanders (DGZ) and Federal Agency for the Safety of the Food Chain, Torhout/Brussels, Belgium].", [["cattle", "SPECIES", 46, 52], ["Further data", "TEST", 0, 12], ["the national cattle identification", "TEST", 33, 67]]], ["This consisted of herd size and animal age categories, breed, and purchase history.", [["size", "OBSERVATION_MODIFIER", 23, 27]]], ["All farmers gave informed consent for use of their data.Laboratory Analysis ::: MATERIALS AND METHODSA pool was made from the 5 separate samples by taking 5 mL from each sample.", [["samples", "ANATOMY", 137, 144], ["their data", "TEST", 45, 55], ["Laboratory Analysis", "TEST", 56, 75], ["METHODSA pool", "TREATMENT", 94, 107]]], ["A semiquantitative real-time PCR (Screening Pack Ruminant Respiratory Pathogens, Thermo Fisher Scientific, Waltham, MA) was conducted.", [["time PCR", "TEST", 24, 32]]], ["Seven individual PCR reactions per sample were performed, each targeting a single respiratory pathogen: bovine respiratory syncytial virus (bRSV; N gene), bovine parainfluenzavirus type 3 (P gene), bovine coronavirus (N gene), M. bovis (target gene = polC), Histophilus somni (RpoB), Pasteurella multocida (16S), and Mannheimia haemolytica (plpE).", [["respiratory syncytial virus", "DISEASE", 111, 138], ["bovine", "ORGANISM", 104, 110], ["respiratory syncytial virus", "ORGANISM", 111, 138], ["bRSV", "ORGANISM", 140, 144], ["bovine", "ORGANISM", 155, 161], ["parainfluenzavirus type 3", "GENE_OR_GENE_PRODUCT", 162, 187], ["bovine coronavirus", "ORGANISM", 198, 216], ["M. bovis", "ORGANISM", 227, 235], ["polC", "GENE_OR_GENE_PRODUCT", 251, 255], ["Histophilus somni", "ORGANISM", 258, 275], ["RpoB", "GENE_OR_GENE_PRODUCT", 277, 281], ["Pasteurella multocida", "ORGANISM", 284, 305], ["Mannheimia haemolytica", "ORGANISM", 317, 339], ["plpE", "GENE_OR_GENE_PRODUCT", 341, 345], ["bovine respiratory syncytial virus (bRSV; N gene", "DNA", 104, 152], ["bovine parainfluenzavirus type 3", "DNA", 155, 187], ["P gene", "DNA", 189, 195], ["bovine coronavirus (N gene", "DNA", 198, 224], ["polC", "DNA", 251, 255], ["Histophilus somni", "DNA", 258, 275], ["RpoB", "DNA", 277, 281], ["bovine", "SPECIES", 104, 110], ["respiratory syncytial virus", "SPECIES", 111, 138], ["bovine", "SPECIES", 155, 161], ["bovine", "SPECIES", 198, 204], ["coronavirus", "SPECIES", 205, 216], ["M. bovis", "SPECIES", 227, 235], ["Histophilus somni", "SPECIES", 258, 275], ["Pasteurella multocida", "SPECIES", 284, 305], ["Mannheimia haemolytica", "SPECIES", 317, 339], ["bovine respiratory syncytial virus", "SPECIES", 104, 138], ["bRSV", "SPECIES", 140, 144], ["bovine parainfluenzavirus type 3", "SPECIES", 155, 187], ["bovine coronavirus", "SPECIES", 198, 216], ["M. bovis", "SPECIES", 227, 235], ["Histophilus somni", "SPECIES", 258, 275], ["Pasteurella multocida", "SPECIES", 284, 305], ["Mannheimia haemolytica", "SPECIES", 317, 339], ["Seven individual PCR reactions", "PROBLEM", 0, 30], ["a single respiratory pathogen", "TEST", 73, 102], ["bovine respiratory syncytial virus", "PROBLEM", 104, 138], ["bRSV", "TEST", 140, 144], ["bovine parainfluenzavirus type", "TEST", 155, 185], ["bovine coronavirus", "PROBLEM", 198, 216], ["M. bovis", "TEST", 227, 235], ["Histophilus somni (RpoB)", "PROBLEM", 258, 282], ["Pasteurella multocida (16S)", "PROBLEM", 284, 311], ["Mannheimia haemolytica", "PROBLEM", 317, 339], ["respiratory syncytial virus", "OBSERVATION", 111, 138], ["Mannheimia haemolytica", "OBSERVATION", 317, 339]]], ["The DNA and RNA were extracted from bronchial alveolar lavage fluid samples using the MagVet Universal Kit (Thermo Fisher Scientific) according to the manufacturer's instructions and using 200 \u00b5L for extraction.", [["bronchial alveolar lavage fluid samples", "ANATOMY", 36, 75], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["bronchial alveolar lavage fluid samples", "ORGANISM_SUBSTANCE", 36, 75], ["The DNA and RNA", "PROBLEM", 0, 15], ["bronchial alveolar lavage fluid samples", "TEST", 36, 75], ["extraction", "TREATMENT", 200, 210], ["RNA", "OBSERVATION_MODIFIER", 12, 15], ["bronchial", "ANATOMY", 36, 45], ["alveolar", "ANATOMY_MODIFIER", 46, 54], ["lavage fluid", "OBSERVATION", 55, 67]]], ["The real-time PCR was performed on the ABI7500 detection system (Thermo Fisher Scientific) with the following cycling conditions: 10 min incubation at 45\u00b0C, 10 min incubation at 95\u00b0C, and 45 cycles of 95\u00b0C for 15 s and 60\u00b0C for 1 min.", [["The real-time PCR", "TEST", 0, 17]]], ["The fluorescence data were collected during the 60\u00b0C, 1 min stage.", [["The fluorescence data", "TEST", 0, 21]]], ["For each pathogen target, a duplex PCR was performed using a probe labeled with the FAM dye for the target gene and a probe labeled with the VIC dye for the internal positive control.", [["FAM", "CHEMICAL", 84, 87], ["FAM dye", "SIMPLE_CHEMICAL", 84, 91], ["VIC dye", "SIMPLE_CHEMICAL", 141, 148], ["target gene", "DNA", 100, 111], ["a duplex PCR", "TEST", 26, 38], ["the FAM dye", "TREATMENT", 80, 91], ["the VIC dye", "TREATMENT", 137, 148], ["the internal positive control", "TREATMENT", 153, 182], ["positive control", "OBSERVATION", 166, 182]]], ["This internal positive control is a bovine housekeeping gene whose detection is used to check for PCR inhibition and the presence of host genomic DNA.", [["bovine", "ORGANISM", 36, 42], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["bovine housekeeping gene", "DNA", 36, 60], ["host genomic DNA", "DNA", 133, 149], ["bovine", "SPECIES", 36, 42], ["PCR inhibition", "TEST", 98, 112], ["host genomic DNA", "PROBLEM", 133, 149], ["positive control", "OBSERVATION", 14, 30], ["host genomic DNA", "OBSERVATION", 133, 149]]], ["The PCR detection limits for all 7 pathogen targets range from 10 to 40 copies of nucleic acid per PCR reaction.", [["nucleic acid", "CHEMICAL", 82, 94], ["The PCR detection", "TEST", 0, 17], ["nucleic acid", "TEST", 82, 94], ["PCR reaction", "TEST", 99, 111]]], ["The efficiency of the PCR reactions for the 7 pathogen targets comprised between 89.3 and 108.2%.", [["the PCR reactions", "PROBLEM", 18, 35], ["the 7 pathogen targets", "TEST", 40, 62]]], ["The PCR results were classified according to the manufacturer's instructions as positive if the threshold cycle (Ct) value was <38.", [["The PCR", "TEST", 0, 7], ["the threshold cycle", "TEST", 92, 111], ["Ct) value", "TEST", 113, 122]]], ["If no Ct value was obtained, samples were considered negative.", [["samples", "ANATOMY", 29, 36], ["Ct value", "TEST", 6, 14], ["samples", "TEST", 29, 36]]], ["Values \u226538 were considered not interpretable and not included in the analysis for that pathogen.Statistical Analysis ::: MATERIALS AND METHODSData were analyzed with SAS 9.4 (SAS Institute Inc., Cary, NC).", [["Values", "TEST", 0, 6], ["the analysis", "TEST", 65, 77], ["pathogen", "PROBLEM", 87, 95], ["METHODSData", "TEST", 135, 146], ["SAS", "TEST", 166, 169]]], ["The unit of analysis was the herd.", [["analysis", "TEST", 12, 20]]], ["Outcomes of interest were the 7 pathogens, as detected by PCR.", [["the 7 pathogens", "PROBLEM", 26, 41]]], ["Noninterpretable results were not included in the analysis.", [["the analysis", "TEST", 46, 58]]], ["Risk factors for each of the 7 pathogens were identified using multivariable logistic regression.", [["Risk factors", "PROBLEM", 0, 12], ["the 7 pathogens", "PROBLEM", 25, 40], ["multivariable logistic regression", "PROBLEM", 63, 96]]], ["A generalized linear mixed model was used with binomial distribution and logit link function with Wald statistics for type 3 contrasts (PROC GLIMMIX).", [["A generalized linear mixed model", "PROBLEM", 0, 32], ["binomial distribution", "PROBLEM", 47, 68], ["type 3 contrasts (PROC GLIMMIX)", "TREATMENT", 118, 149], ["generalized", "OBSERVATION_MODIFIER", 2, 13], ["linear", "OBSERVATION_MODIFIER", 14, 20], ["mixed model", "OBSERVATION", 21, 32], ["binomial distribution", "OBSERVATION", 47, 68]]], ["A total of 45 predictors (Table 1) and the PCR results for the other 6 pathogens besides the outcome pathogen were considered for the analysis.", [["the PCR", "TEST", 39, 46], ["the other 6 pathogens", "PROBLEM", 59, 80], ["the outcome pathogen", "PROBLEM", 89, 109], ["the analysis", "TEST", 130, 142]]], ["Categorical predictors were regrouped if the number of observations within a group was lower than 8.", [["Categorical predictors", "TREATMENT", 0, 22]]], ["A variable was considered a confounder if it was not an intervening variable based on a causal diagram and induced changes >25% in the coefficient of another variable.", [["a causal diagram", "TEST", 86, 102]]], ["For the final models, pairwise comparisons for categorical predictors were made using Bonferroni adjustments.", [["Bonferroni adjustments", "TREATMENT", 86, 108]]], ["All biologically relevant 2-way interactions of significant fixed effects were tested.", [["significant fixed effects", "PROBLEM", 48, 73]]], ["Differences in management factors between dairy, dairy-mixed, and beef herds were determined by logistic regression (PROC GLIMMIX; as described above) for binary outcomes, and linear regression (PROC MIXED) for continuous outcomes.", [["dairy", "ORGANISM_SUBDIVISION", 42, 47], ["beef", "SPECIES", 66, 70], ["beef", "SPECIES", 66, 70]]], ["In the linear model, maximum likelihood was used, and Bonferroni corrections for multiple comparisons.Herd Characteristics ::: RESULTSBetween September 2016 and January 2018, samples from a total of 128 outbreaks arrived at the laboratory.", [["multiple comparisons", "TEST", 81, 101], ["samples", "TEST", 175, 182], ["maximum", "OBSERVATION_MODIFIER", 21, 28]]], ["Of the herds, 22.7% (29/128) were dairy (Holstein Friesian), 45.3% (58/128) were dairy type mixed farms, and 32.0% (41/128) were beef.", [["beef", "SPECIES", 129, 133], ["beef", "SPECIES", 129, 133]]], ["Dairy herds were generally medium sized (25th and 75th percentile: 89\u2013197 adult animals; range: 31\u2013689 animals), family-owned farms, representative for the mainstream dairy production in Western Europe.", [["dairy", "ORGANISM_SUBDIVISION", 167, 172], ["medium sized", "OBSERVATION_MODIFIER", 27, 39]]], ["Dairy-type mixed herds were herds with predominantly dairy cattle, but also a more limited number of beef cattle or dairy/beef crossbreds.", [["herds", "ORGANISM", 17, 22], ["dairy", "ORGANISM_SUBDIVISION", 116, 121], ["cattle", "SPECIES", 59, 65], ["cattle", "SPECIES", 106, 112], ["beef", "SPECIES", 122, 126], ["cattle", "SPECIES", 59, 65], ["beef", "SPECIES", 101, 105], ["cattle", "SPECIES", 106, 112], ["beef", "SPECIES", 122, 126]]], ["Beef breeds were mainly medium sized (25th and 75th percentile: 51\u2013142 adult animals; range: 15\u2013345) family-owned operations, of which 31.7% (13/41) were suckler herds and 68.3% (28/41) separated calves from the dam, shortly after birth, to raise them further in individual housing first and group housing afterward on either cow milk or milk replacer.", [["milk", "ANATOMY", 330, 334], ["calves", "ORGANISM", 196, 202], ["cow", "ORGANISM", 326, 329], ["milk", "ORGANISM_SUBSTANCE", 330, 334], ["milk", "ORGANISM_SUBSTANCE", 338, 342], ["calves", "SPECIES", 196, 202], ["cow", "SPECIES", 326, 329], ["cow", "SPECIES", 326, 329], ["milk replacer", "TREATMENT", 338, 351], ["medium sized", "OBSERVATION_MODIFIER", 24, 36]]], ["No specialized fattening units, such as veal facilities or feedlots, were included in the study.", [["the study", "TEST", 86, 95], ["specialized", "OBSERVATION_MODIFIER", 3, 14], ["fattening units", "OBSERVATION", 15, 30]]], ["The mean number of adult animals (139.9 \u00b1 118.8) in the study population was not significantly different from the target population (134; SANITRACE, national cattle registration databank; P = 0.58).", [["the study population", "TEST", 52, 72], ["SANITRACE", "TEST", 138, 147], ["P", "TEST", 188, 189], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["adult", "OBSERVATION_MODIFIER", 19, 24], ["animals", "OBSERVATION_MODIFIER", 25, 32], ["significantly different", "OBSERVATION_MODIFIER", 81, 104]]], ["Beef herds (85.8 \u00b1 18.2) were significantly smaller than dairy herds (197.6 \u00b1 20.8; P < 0.001) and dairy-mixed herds (146.6 \u00b1 14.8; P = 0.03).", [["Beef", "SPECIES", 0, 4], ["Beef herds", "TEST", 0, 10], ["P", "TEST", 84, 85], ["P", "TEST", 132, 133]]], ["In dairy herds, the second grouping of calves was done at a younger age than in beef herds (87.8 \u00b1 12.2 d vs. 136.0 \u00b1 11.4 d; P = 0.02).", [["calves", "ORGANISM", 39, 45], ["calves", "SPECIES", 39, 45], ["beef", "SPECIES", 80, 84], ["beef", "SPECIES", 80, 84], ["P", "TEST", 126, 127]]], ["Other significant differences in the predictor variables are shown in Table 2.Description of Outbreaks and Pathogen Detection Rates ::: RESULTSOf the study herds, 36.8% (46/125) reported epidemic respiratory disease only, whereas 63.2% (79/125) mentioned that the herd had suffered from endemic respiratory disease for a longer period as well.", [["respiratory", "ANATOMY", 196, 207], ["respiratory", "ANATOMY", 295, 306], ["respiratory disease", "DISEASE", 196, 215], ["respiratory disease", "DISEASE", 295, 314], ["the study herds", "TEST", 146, 161], ["epidemic respiratory disease", "PROBLEM", 187, 215], ["endemic respiratory disease", "PROBLEM", 287, 314], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["differences", "OBSERVATION_MODIFIER", 18, 29], ["respiratory disease", "OBSERVATION", 196, 215], ["endemic", "OBSERVATION_MODIFIER", 287, 294], ["respiratory disease", "OBSERVATION", 295, 314]]], ["The average number of days respiratory signs had been present on the farm before sampling was 5.9 \u00b1 4.4 (range = 0 \u221214) for the herds with only epidemic respiratory disease and 175.2 \u00b1 165 (range = 15\u2013600) for herds with also endemic respiratory disease.", [["respiratory", "ANATOMY", 27, 38], ["respiratory", "ANATOMY", 153, 164], ["respiratory", "ANATOMY", 234, 245], ["respiratory disease", "DISEASE", 153, 172], ["respiratory disease", "DISEASE", 234, 253], ["respiratory signs", "TEST", 27, 44], ["sampling", "TEST", 81, 89], ["epidemic respiratory disease", "PROBLEM", 144, 172], ["endemic respiratory disease", "PROBLEM", 226, 253], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["epidemic", "OBSERVATION_MODIFIER", 144, 152], ["respiratory disease", "OBSERVATION", 153, 172], ["endemic", "OBSERVATION_MODIFIER", 226, 233], ["respiratory disease", "OBSERVATION", 234, 253]]], ["At the time of sampling the average percentage of calves showing respiratory signs was 44.0 \u00b1 30.1%, ranging between 1 and 100%, and this did not differ between the epidemic only and endemic herds (P = 0.25).Description of Outbreaks and Pathogen Detection Rates ::: RESULTSThe vast majority of outbreaks occurred between October and March (Figure 1).", [["respiratory", "ANATOMY", 65, 76], ["calves", "ORGANISM", 50, 56], ["calves", "SPECIES", 50, 56], ["respiratory signs", "TEST", 65, 82], ["P", "TEST", 198, 199], ["outbreaks", "OBSERVATION", 294, 303]]], ["Univariable analysis showed a significant seasonal influence for bRSV (P < 0.001) only.", [["bRSV", "SPECIES", 65, 69], ["Univariable analysis", "TEST", 0, 20], ["a significant seasonal influence", "PROBLEM", 28, 60], ["bRSV", "PROBLEM", 65, 69], ["significant", "OBSERVATION_MODIFIER", 30, 41]]], ["Viruses were detected in 58.6% (75/128) of the outbreaks: bRSV, PI-3, and bovine coronavirus (BCV) in 29.4% (35/119), 8.1% (10/124), and 38.4% (48/125), respectively.", [["bovine coronavirus", "DISEASE", 74, 92], ["PI-3", "GENE_OR_GENE_PRODUCT", 64, 68], ["bovine coronavirus", "ORGANISM", 74, 92], ["BCV", "ORGANISM", 94, 97], ["bovine", "SPECIES", 74, 80], ["coronavirus", "SPECIES", 81, 92], ["bRSV", "SPECIES", 58, 62], ["PI-3", "SPECIES", 64, 68], ["bovine coronavirus", "SPECIES", 74, 92], ["BCV", "SPECIES", 94, 97], ["Viruses", "TEST", 0, 7], ["bRSV", "TEST", 58, 62], ["PI", "TEST", 64, 66], ["bovine coronavirus", "TEST", 74, 92], ["BCV", "TEST", 94, 97], ["bovine coronavirus", "ANATOMY", 74, 92]]], ["The prevalence of M. haemolytica, P. multocida, H. somni, and M. bovis was 41.2% (39/114), 89.1% (106/119), 36.4% (44/121), and 33.3% (41/123), respectively.", [["M. haemolytica", "ORGANISM", 18, 32], ["P. multocida", "ORGANISM", 34, 46], ["H. somni", "ORGANISM", 48, 56], ["M. bovis", "ORGANISM", 62, 70], ["M. haemolytica", "SPECIES", 18, 32], ["P. multocida", "SPECIES", 34, 46], ["H. somni", "SPECIES", 48, 56], ["M. bovis", "SPECIES", 62, 70], ["M. haemolytica", "SPECIES", 18, 32], ["P. multocida", "SPECIES", 34, 46], ["H. somni", "SPECIES", 48, 56], ["M. bovis", "SPECIES", 62, 70], ["M. haemolytica", "PROBLEM", 18, 32], ["H. somni", "TEST", 48, 56], ["M. bovis", "TEST", 62, 70], ["M. haemolytica", "OBSERVATION", 18, 32]]], ["In 13.3% (17/128) of the herds, multiple viruses were involved (Table 3).", [["multiple viruses", "PROBLEM", 32, 48], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["viruses", "OBSERVATION", 41, 48]]], ["In 95.9% (71/74) of the herds with viral infection, also bacterial DNA was retrieved.", [["viral infection", "DISEASE", 35, 50], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["viral infection", "PROBLEM", 35, 50], ["bacterial DNA", "PROBLEM", 57, 70], ["viral infection", "OBSERVATION", 35, 50], ["bacterial DNA", "OBSERVATION", 57, 70]]], ["Only in 4 herds was bRSV the single identified pathogen.", [["bRSV", "SPECIES", 20, 24], ["bRSV", "PROBLEM", 20, 24], ["pathogen", "OBSERVATION", 47, 55]]], ["Also, in 61.0% (25/41) of the M. bovis-positive outbreaks, a virus [72.0% (18/25) BCV, 16.0% (4/25) PI-3, and 12.0% (3/25) bRSV] was simultaneously detected.", [["M. bovis", "ORGANISM", 30, 38], ["M. bovis", "SPECIES", 30, 38], ["M. bovis", "SPECIES", 30, 38], ["the M. bovis", "TEST", 26, 38], ["positive outbreaks", "PROBLEM", 39, 57], ["a virus", "TEST", 59, 66], ["BCV", "TEST", 82, 85], ["PI", "TEST", 100, 102], ["bRSV", "PROBLEM", 123, 127], ["positive outbreaks", "OBSERVATION", 39, 57]]], ["In 4.7% (6/128) of the herds, not a single one of the studied pathogens could be retrieved, and in 10.9% (14/128) only P. multocida DNA was found.", [["P. multocida", "ORGANISM", 119, 131], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["P. multocida", "SPECIES", 119, 131], ["P. multocida", "SPECIES", 119, 131], ["P. multocida DNA", "PROBLEM", 119, 135]]], ["No significant differences in detection rates between dairy, beef, or dairy-mixed herds were found for any of the studied pathogens.", [["dairy", "ORGANISM_SUBDIVISION", 54, 59], ["beef", "ORGANISM_SUBDIVISION", 61, 65], ["beef", "SPECIES", 61, 65], ["beef", "SPECIES", 61, 65], ["the studied pathogens", "PROBLEM", 110, 131], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26]]], ["No differences were observed in pathogen detection rates between herds reporting endemic problems next to the epidemic and these with only epidemic disease, except for bRSV.Virus-Specific Risk Factors ::: RESULTSFactors univariably associated with a positive bRSV PCR on pooled broncho-alveolar lavage (BAL) fluid samples were days with clinical signs before sampling (P = 0.02), percentage of calves with respiratory signs (P = 0.03), endemic respiratory disease (P < 0.01), vaccination against bRSV (P = 0.14), use of fresh colostrum (P = 0.15), H. somni-positive BAL PCR (P = 0.15), BCV-positive BAL PCR (P = 0.18), M. bovis-positive BAL PCR (P = 0.11), PI-3-positive BAL PCR (P = 0.03), month (P < 0.01), and season (P < 0.001).", [["broncho-alveolar lavage (BAL) fluid samples", "ANATOMY", 278, 321], ["respiratory", "ANATOMY", 406, 417], ["respiratory", "ANATOMY", 444, 455], ["BAL", "ANATOMY", 599, 602], ["BAL", "ANATOMY", 637, 640], ["respiratory signs", "DISEASE", 406, 423], ["respiratory disease", "DISEASE", 444, 463], ["alveolar lavage", "ORGANISM_SUBSTANCE", 286, 301], ["calves", "ORGANISM", 394, 400], ["colostrum", "ORGANISM_SUBSTANCE", 526, 535], ["M. bovis", "ORGANISM", 619, 627], ["PI-3", "GENE_OR_GENE_PRODUCT", 657, 661], ["calves", "SPECIES", 394, 400], ["M. bovis", "SPECIES", 619, 627], ["bRSV", "SPECIES", 168, 172], ["bRSV", "SPECIES", 259, 263], ["bRSV", "SPECIES", 496, 500], ["M. bovis", "SPECIES", 619, 627], ["pathogen detection", "TEST", 32, 50], ["endemic problems", "PROBLEM", 81, 97], ["epidemic disease", "PROBLEM", 139, 155], ["bRSV", "PROBLEM", 168, 172], ["RESULTSFactors", "PROBLEM", 205, 219], ["a positive bRSV PCR", "PROBLEM", 248, 267], ["pooled broncho-alveolar lavage", "TEST", 271, 301], ["BAL) fluid samples", "TEST", 303, 321], ["clinical signs", "TEST", 337, 351], ["sampling", "TEST", 359, 367], ["P", "TEST", 369, 370], ["respiratory signs", "TEST", 406, 423], ["P", "TEST", 425, 426], ["endemic respiratory disease", "PROBLEM", 436, 463], ["vaccination", "TREATMENT", 476, 487], ["bRSV", "PROBLEM", 496, 500], ["fresh colostrum", "TREATMENT", 520, 535], ["P", "TEST", 537, 538], ["H. somni-positive BAL PCR", "TEST", 548, 573], ["P", "TEST", 575, 576], ["BCV", "TEST", 586, 589], ["BAL PCR", "TEST", 599, 606], ["P", "TEST", 608, 609], ["M. bovis", "TEST", 619, 627], ["BAL PCR", "TEST", 637, 644], ["P", "TEST", 646, 647], ["PI", "TEST", 657, 659], ["BAL PCR", "TEST", 671, 678], ["P", "TEST", 680, 681], ["alveolar", "ANATOMY", 286, 294], ["lavage", "OBSERVATION", 295, 301], ["respiratory", "ANATOMY", 406, 417], ["endemic", "OBSERVATION_MODIFIER", 436, 443], ["respiratory disease", "OBSERVATION", 444, 463], ["BCV", "ANATOMY", 586, 589]]], ["Month and season were associated, and therefore only season was added to the multivariable model building procedure.", [["the multivariable model building procedure", "TREATMENT", 73, 115]]], ["In winter (December to March), bRSV was significantly more frequent compared with summer/spring [odds ratio (OR) = 34.5 (95% CI = 3.0\u2013392.9; P < 0.01)] or autumn [OR = 10.3 (95% CI = 2.8\u201337.5; P < 0.001)].", [["bRSV", "SPECIES", 31, 35], ["bRSV", "PROBLEM", 31, 35], ["ratio", "TEST", 102, 107], ["CI", "TEST", 125, 127], ["P", "TEST", 141, 142], ["autumn", "TEST", 155, 161], ["CI", "TEST", 178, 180], ["P", "TEST", 193, 194]]], ["The final multivariable model consisted of PI-3-positive BAL PCR, season, number of days with signs, and prevalence of calves with respiratory disease (Table 4).Virus-Specific Risk Factors ::: RESULTSFor BCV, univariable associations were found for previous detection of coronavirus in diarrheic calves (P < 0.01), shaving calves for winter (P = 0.04), purchase of colostrum (P = 0.06), recent purchase of cattle (P = 0.05), detection of M. haemolytica (P = 0.02), herd size (P = 0.03), and year (P = 0.13).", [["respiratory", "ANATOMY", 131, 142], ["respiratory disease", "DISEASE", 131, 150], ["coronavirus", "DISEASE", 271, 282], ["diarrheic", "DISEASE", 286, 295], ["PI-3", "GENE_OR_GENE_PRODUCT", 43, 47], ["calves", "ORGANISM", 119, 125], ["BCV", "ORGANISM", 204, 207], ["coronavirus", "ORGANISM", 271, 282], ["calves", "ORGANISM_SUBDIVISION", 323, 329], ["colostrum", "ORGANISM_SUBSTANCE", 365, 374], ["M. haemolytica", "ORGANISM", 438, 452], ["calves", "SPECIES", 119, 125], ["calves", "SPECIES", 296, 302], ["calves", "SPECIES", 323, 329], ["cattle", "SPECIES", 406, 412], ["M. haemolytica", "SPECIES", 438, 452], ["calves", "SPECIES", 119, 125], ["colostrum", "SPECIES", 365, 374], ["cattle", "SPECIES", 406, 412], ["M. haemolytica", "SPECIES", 438, 452], ["PI", "TEST", 43, 45], ["positive BAL PCR", "PROBLEM", 48, 64], ["signs", "TEST", 94, 99], ["respiratory disease", "PROBLEM", 131, 150], ["coronavirus in diarrheic calves", "PROBLEM", 271, 302], ["shaving calves", "PROBLEM", 315, 329], ["colostrum", "TEST", 365, 374], ["M. haemolytica", "PROBLEM", 438, 452], ["P", "TEST", 454, 455], ["herd size", "TEST", 465, 474], ["P", "TEST", 476, 477], ["BAL PCR", "OBSERVATION", 57, 64], ["calves", "ANATOMY", 119, 125], ["respiratory disease", "OBSERVATION", 131, 150], ["coronavirus", "OBSERVATION", 271, 282], ["size", "OBSERVATION_MODIFIER", 470, 474]]], ["The following factors were univariably associated with a positive PI-3 PCR: ill animals recently purchased (P = 0.08), use of an automatic straw disperser (P = 0.07), M. bovis-positive PCR (P = 0.11), bRSV-positive PCR (P = 0.03), and herd size (P = 0.10).", [["PI-3", "GENE_OR_GENE_PRODUCT", 66, 70], ["M. bovis", "ORGANISM", 167, 175], ["M. bovis", "SPECIES", 167, 175], ["M. bovis", "SPECIES", 167, 175], ["a positive PI", "PROBLEM", 55, 68], ["ill animals", "PROBLEM", 76, 87], ["an automatic straw disperser", "TEST", 126, 154], ["M. bovis", "TEST", 167, 175], ["PCR", "TEST", 185, 188], ["P", "TEST", 190, 191], ["bRSV", "TEST", 201, 205], ["PCR", "TEST", 215, 218], ["P", "TEST", 220, 221], ["herd size", "TEST", 235, 244], ["P", "TEST", 246, 247], ["size", "OBSERVATION_MODIFIER", 240, 244]]], ["The final multivariable model consisted of bRSV-positive PCR (OR = 4.6; 95% CI = 1.2\u201317.4; P = 0.03).Bacteria-Specific Risk Factors ::: RESULTSFor bacteria, univariable analysis showed associations between a positive PCR result for M. haemolytica and group size of the sampled pen (P = 0.01), presence of neonatal diarrhea in the calves (P = 0.06), presence of a shared airspace between ill calves and cattle over 1 yr old, age at first grouping (P = 0.08), suckler herd (P = 0.14), bedding type (P = 0.03), >24 h with the dam (P = 0.08), ventilation type (P = 0.15), BCV-positive PCR result (P = 0.02), and M. bovis-positive PCR result (P = 0.15).", [["airspace", "ANATOMY", 370, 378], ["neonatal diarrhea", "DISEASE", 305, 322], ["M. haemolytica", "ORGANISM", 232, 246], ["calves", "ORGANISM", 330, 336], ["airspace", "PATHOLOGICAL_FORMATION", 370, 378], ["calves", "ORGANISM", 391, 397], ["M. bovis", "GENE_OR_GENE_PRODUCT", 608, 616], ["M. haemolytica", "SPECIES", 232, 246], ["calves", "SPECIES", 330, 336], ["calves", "SPECIES", 391, 397], ["cattle", "SPECIES", 402, 408], ["M. bovis", "SPECIES", 608, 616], ["M. haemolytica", "SPECIES", 232, 246], ["cattle", "SPECIES", 402, 408], ["M. bovis", "SPECIES", 608, 616], ["bRSV", "TEST", 43, 47], ["positive PCR", "PROBLEM", 48, 60], ["CI", "TEST", 76, 78], ["P", "TEST", 91, 92], ["Bacteria", "PROBLEM", 101, 109], ["RESULTSFor bacteria", "PROBLEM", 136, 155], ["univariable analysis", "TEST", 157, 177], ["a positive PCR result", "PROBLEM", 206, 227], ["M. haemolytica", "PROBLEM", 232, 246], ["group size", "TEST", 251, 261], ["P", "TEST", 282, 283], ["neonatal diarrhea in the calves", "PROBLEM", 305, 336], ["a shared airspace between ill calves", "PROBLEM", 361, 397], ["P", "TEST", 447, 448], ["P", "TEST", 472, 473], ["ventilation type", "TEST", 539, 555], ["BCV", "TEST", 568, 571], ["P", "TEST", 593, 594], ["M. bovis", "TEST", 608, 616], ["P", "TEST", 638, 639], ["size", "OBSERVATION_MODIFIER", 257, 261], ["neonatal", "OBSERVATION_MODIFIER", 305, 313], ["diarrhea", "OBSERVATION", 314, 322], ["calves", "ANATOMY", 330, 336], ["airspace", "ANATOMY_MODIFIER", 370, 378], ["ill calves", "ANATOMY", 387, 397]]], ["The final multivariable model consisted of number of animals per pen in the outbreak group, BCV-positive PCR result, and bedding type (Table 6).Bacteria-Specific Risk Factors ::: RESULTSUnivariable analysis for H. somni identified M. haemolytica vaccination (P = 0.04), bedding type (P = 0.06), herd size (P = 0.04), P. multocida PCR positive (P = 0.11), M. bovis PCR positive (P = 0.18), bRSV PCR positive (P = 0.15), ill animals recently purchased (P = 0.17), and season (P = 0.13) to be used in the multivariable analysis.", [["H. somni", "ORGANISM", 211, 219], ["M. haemolytica", "ORGANISM", 231, 245], ["P. multocida", "ORGANISM", 317, 329], ["H. somni", "SPECIES", 211, 219], ["M. haemolytica", "SPECIES", 231, 245], ["P. multocida", "SPECIES", 317, 329], ["M. bovis", "SPECIES", 355, 363], ["BCV", "SPECIES", 92, 95], ["H. somni", "SPECIES", 211, 219], ["M. haemolytica", "SPECIES", 231, 245], ["P. multocida", "SPECIES", 317, 329], ["M. bovis", "SPECIES", 355, 363], ["bRSV", "SPECIES", 389, 393], ["BCV", "TEST", 92, 95], ["positive PCR result", "PROBLEM", 96, 115], ["Bacteria", "PROBLEM", 144, 152], ["RESULTSUnivariable analysis", "TEST", 179, 206], ["H. somni", "TEST", 211, 219], ["haemolytica vaccination", "TEST", 234, 257], ["P", "TEST", 259, 260], ["bedding type", "TEST", 270, 282], ["P", "TEST", 284, 285], ["herd size", "TEST", 295, 304], ["P", "TEST", 306, 307], ["P. multocida PCR", "TEST", 317, 333], ["P", "TEST", 344, 345], ["M. bovis PCR", "TEST", 355, 367], ["P", "TEST", 378, 379], ["bRSV PCR", "TEST", 389, 397], ["P", "TEST", 408, 409], ["ill animals", "PROBLEM", 419, 430], ["P", "TEST", 451, 452], ["the multivariable analysis", "TEST", 498, 524]]], ["In the final model, herds using sawdust bedding and vaccinating for M. haemolytica had higher odds for H. somni detection (Table 7).", [["M. haemolytica", "ORGANISM", 68, 82], ["M. haemolytica", "SPECIES", 68, 82], ["H. somni", "SPECIES", 103, 111], ["M. haemolytica", "SPECIES", 68, 82], ["H. somni", "SPECIES", 103, 111], ["sawdust bedding", "TREATMENT", 32, 47], ["H. somni detection", "TEST", 103, 121]]], ["For P. multocida, a positive fecal ELISA result for enterotoxigenic Escherichia coli in the last year (P = 0.17), use of an automatic milk feeder (P = 0.02), purchase of colostrum (P = 0.15), availability of a quarantine stable (P = 0.16), H. somni positive PCR result (P = 0.10), and BCV-positive test result (P = 0.08) were selected for the multivariable model.", [["milk feeder", "ANATOMY", 134, 145], ["colostrum", "ANATOMY", 170, 179], ["P. multocida", "ORGANISM", 4, 16], ["fecal", "ORGANISM_SUBSTANCE", 29, 34], ["Escherichia coli", "ORGANISM", 68, 84], ["colostrum", "ORGANISM_SUBSTANCE", 170, 179], ["P. multocida", "SPECIES", 4, 16], ["Escherichia coli", "SPECIES", 68, 84], ["P. multocida", "SPECIES", 4, 16], ["Escherichia coli", "SPECIES", 68, 84], ["H. somni", "SPECIES", 240, 248], ["P. multocida", "PROBLEM", 4, 16], ["a positive fecal ELISA", "TEST", 18, 40], ["enterotoxigenic Escherichia coli", "PROBLEM", 52, 84], ["P", "TEST", 103, 104], ["an automatic milk feeder", "TREATMENT", 121, 145], ["P", "TEST", 270, 271], ["BCV", "TEST", 285, 288], ["P", "TEST", 311, 312], ["Escherichia coli", "OBSERVATION", 68, 84]]], ["In the final multivariable model herds with an automated milk feeder (compared with bucket or trough feeding) had lower odds of detecting P. multocida in BAL by PCR [69.2 vs. 92.0%; OR = 0.19 (0.05\u20130.75); P = 0.02].Bacteria-Specific Risk Factors ::: RESULTSFinally, for M. bovis the following factors were significant in the univariable analysis: respiratory signs in adults (P = 0.14), presence of a chronically ill animal in the pen (P = 0.14), age at first grouping (P = 0.06), recently purchased animals present in the same airspace (P < 0.01), H. somni-positive PCR (P = 0.17), M. haemolytica positive (P = 0.15), PI-3-positive PCR (P = 0.11), bRSV-positive PCR (P = 0.11), purchase of animals (P = 0.03), and herd size (P = 0.06).", [["milk feeder", "ANATOMY", 57, 68], ["BAL", "ANATOMY", 154, 157], ["respiratory", "ANATOMY", 347, 358], ["P. multocida", "DISEASE", 138, 150], ["respiratory signs", "DISEASE", 347, 364], ["chronically ill", "DISEASE", 401, 416], ["milk", "ORGANISM", 57, 61], ["P. multocida", "ORGANISM", 138, 150], ["BAL", "ORGANISM_SUBSTANCE", 154, 157], ["M. bovis", "ORGANISM", 270, 278], ["M. haemolytica", "ORGANISM", 583, 597], ["PI-3", "GENE_OR_GENE_PRODUCT", 619, 623], ["P. multocida", "SPECIES", 138, 150], ["M. bovis", "SPECIES", 270, 278], ["M. haemolytica", "SPECIES", 583, 597], ["P. multocida", "SPECIES", 138, 150], ["M. bovis", "SPECIES", 270, 278], ["M. haemolytica", "SPECIES", 583, 597], ["an automated milk feeder", "TREATMENT", 44, 68], ["P. multocida in BAL", "TEST", 138, 157], ["PCR", "TEST", 161, 164], ["OR", "TEST", 182, 184], ["P", "TEST", 205, 206], ["Bacteria", "PROBLEM", 215, 223], ["M. bovis", "PROBLEM", 270, 278], ["the univariable analysis", "TEST", 321, 345], ["respiratory signs", "TEST", 347, 364], ["P", "TEST", 376, 377], ["a chronically ill animal in the pen", "PROBLEM", 399, 434], ["H. somni-positive PCR", "TEST", 549, 570], ["P", "TEST", 572, 573], ["M. haemolytica", "TEST", 583, 597], ["P", "TEST", 608, 609], ["PI", "TEST", 619, 621], ["PCR", "TEST", 633, 636], ["P", "TEST", 638, 639], ["bRSV", "TEST", 649, 653], ["PCR", "TEST", 663, 666], ["P", "TEST", 668, 669], ["animals", "TEST", 691, 698], ["P", "TEST", 700, 701], ["herd size", "TEST", 715, 724], ["P", "TEST", 726, 727], ["chronically", "OBSERVATION_MODIFIER", 401, 412], ["ill", "OBSERVATION", 413, 416], ["airspace", "ANATOMY_MODIFIER", 528, 536], ["size", "OBSERVATION_MODIFIER", 720, 724]]], ["The final multivariable model consisted of purchase of animals and recently purchased animals in the same airspace (Table 8).", [["airspace", "MULTI-TISSUE_STRUCTURE", 106, 114], ["airspace", "ANATOMY_MODIFIER", 106, 114]]], ["For all viruses and bacteria detected, no significant effect of production type could be evidenced.DISCUSSIONThis study provides a prevalence estimate of pathogens involved or potentially involved in epidemic respiratory disease in calves, based on a convenience sample from a Western European country.", [["respiratory", "ANATOMY", 209, 220], ["respiratory disease", "DISEASE", 209, 228], ["calves", "ORGANISM", 232, 238], ["calves", "SPECIES", 232, 238], ["all viruses", "PROBLEM", 4, 15], ["bacteria", "PROBLEM", 20, 28], ["production type", "PROBLEM", 64, 79], ["pathogens", "PROBLEM", 154, 163], ["epidemic respiratory disease in calves", "PROBLEM", 200, 238], ["viruses", "OBSERVATION", 8, 15], ["bacteria", "OBSERVATION", 20, 28], ["no", "UNCERTAINTY", 39, 41], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["respiratory disease", "OBSERVATION", 209, 228]]], ["We used PCR, which is increasingly popular and accessible, but has important drawbacks for its interpretation at the herd level (Parker et al., 2018).", [["PCR", "TEST", 8, 11], ["increasingly", "OBSERVATION_MODIFIER", 22, 34], ["popular", "OBSERVATION", 35, 42]]], ["For what are considered primary pathogens (viruses and M. bovis), detection at the herd level likely represents involvement in the outbreak.", [["M. bovis", "ORGANISM", 55, 63], ["M. bovis", "SPECIES", 55, 63], ["M. bovis", "SPECIES", 55, 63], ["primary pathogens (viruses and M. bovis", "PROBLEM", 24, 63], ["likely represents", "UNCERTAINTY", 94, 111], ["involvement", "OBSERVATION", 112, 123]]], ["For opportunistic pathogens, in this case the Pasteurellaceae family, no such conclusions can be drawn, because these species can be isolated from healthy animals as well (Van Driessche et al., 2017; Timsit et al., 2018).", [["opportunistic pathogens", "DISEASE", 4, 27], ["Pasteurellaceae", "GENE_OR_GENE_PRODUCT", 46, 61], ["opportunistic pathogens", "PROBLEM", 4, 27], ["these species", "PROBLEM", 112, 125], ["opportunistic", "OBSERVATION_MODIFIER", 4, 17], ["pathogens", "OBSERVATION", 18, 27]]], ["Also, PCR detects the smallest amount of even dead bacteria, pointing toward the importance of sample contamination by nasal passage with the nBAL technique.", [["sample", "ANATOMY", 95, 101], ["nasal", "ANATOMY", 119, 124], ["nasal", "ORGANISM_SUBDIVISION", 119, 124], ["PCR", "TEST", 6, 9], ["dead bacteria", "PROBLEM", 46, 59], ["sample contamination", "PROBLEM", 95, 115], ["the nBAL technique", "TREATMENT", 138, 156], ["smallest", "OBSERVATION_MODIFIER", 22, 30], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["dead bacteria", "OBSERVATION", 46, 59]]], ["Therefore, in our opinion PCR results for Pasteurellaceae both at the herd and individual level can only be interpreted as presence of the pathogen in the herd/animal.", [["Pasteurellaceae", "GENE_OR_GENE_PRODUCT", 42, 57], ["herd", "ORGANISM_SUBDIVISION", 155, 159], ["our opinion PCR", "TEST", 14, 29], ["Pasteurellaceae", "PROBLEM", 42, 57], ["the pathogen", "PROBLEM", 135, 147]]], ["We opted for the nBAL, even though deep nasopharyngeal swabs are easier to perform, because it has a higher sensitivity to detect bRSV (Kimman et al., 1986; Doyle et al., 2017).", [["nasopharyngeal swabs", "ANATOMY", 40, 60], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 40, 60], ["bRSV", "SPECIES", 130, 134], ["the nBAL", "TEST", 13, 21], ["deep nasopharyngeal swabs", "PROBLEM", 35, 60], ["bRSV", "PROBLEM", 130, 134], ["deep", "ANATOMY_MODIFIER", 35, 39], ["nasopharyngeal", "ANATOMY", 40, 54]]], ["Many participating veterinarians also requested bacteriology to obtain an antibiogram, which is more straightforward to interpret on samples from the lower respiratory tract.", [["samples", "ANATOMY", 133, 140], ["lower respiratory tract", "ANATOMY", 150, 173], ["lower", "ORGANISM_SUBDIVISION", 150, 155], ["respiratory tract", "ORGANISM_SUBDIVISION", 156, 173], ["an antibiogram", "TEST", 71, 85], ["lower", "ANATOMY_MODIFIER", 150, 155], ["respiratory tract", "ANATOMY", 156, 173]]], ["The sample pooling procedure we used was evidenced in a previous study to increase the detection rate of respiratory viruses (O'Neill et al., 2014).", [["respiratory viruses", "DISEASE", 105, 124], ["The sample pooling procedure", "TREATMENT", 0, 28], ["a previous study", "TEST", 54, 70], ["respiratory viruses", "PROBLEM", 105, 124], ["respiratory viruses", "OBSERVATION", 105, 124]]], ["Unfortunately, in many occasions the PCR returned noninterpretable results for some of the pathogens, reducing the power of the study.", [["the PCR", "TEST", 33, 40], ["the pathogens", "PROBLEM", 87, 100], ["the study", "TEST", 124, 133], ["pathogens", "OBSERVATION", 91, 100]]], ["Most likely, noninterpretable results can be judged as negative, but we took the precaution not to include them in the analysis.", [["the precaution", "TREATMENT", 77, 91], ["the analysis", "TEST", 115, 127]]], ["Given the low number of positive and negative cases for PI-3 and P. multocida, respectively, results should be interpreted carefully.", [["PI-3", "GENE_OR_GENE_PRODUCT", 56, 60], ["P. multocida", "ORGANISM", 65, 77], ["P. multocida", "SPECIES", 65, 77], ["PI-3", "SPECIES", 56, 60], ["P. multocida", "SPECIES", 65, 77], ["PI", "TEST", 56, 58], ["P. multocida", "TEST", 65, 77], ["low number", "OBSERVATION_MODIFIER", 10, 20]]], ["Detection of P. multocida on almost every farm, makes it different to interpret its role in BRD, when using PCR for diagnosis.DISCUSSIONThe study was subject to several sources of potential bias, as with many cross-sectional studies.", [["BRD", "DISEASE", 92, 95], ["P. multocida", "ORGANISM", 13, 25], ["P. multocida", "SPECIES", 13, 25], ["P. multocida", "SPECIES", 13, 25], ["P. multocida", "PROBLEM", 13, 25], ["BRD", "PROBLEM", 92, 95], ["PCR", "TEST", 108, 111], ["The study", "TEST", 136, 145], ["potential bias", "PROBLEM", 180, 194], ["many cross-sectional studies", "TEST", 204, 232]]], ["First, using a convenience sampling holds the risk of selection bias.", [["a convenience sampling", "TREATMENT", 13, 35]]], ["We could not demonstrate any significant differences in herd size between the study and target population, which is favorable in this regard.", [["herd", "ORGANISM_SUBDIVISION", 56, 60], ["the study", "TEST", 74, 83], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["differences", "OBSERVATION_MODIFIER", 41, 52], ["size", "OBSERVATION_MODIFIER", 61, 65], ["target", "OBSERVATION_MODIFIER", 88, 94], ["population", "OBSERVATION", 95, 105], ["favorable", "OBSERVATION_MODIFIER", 116, 125]]], ["Also, working with many different veterinarians potentially having differing motivations (e.g., the attractiveness of a free analysis) holds the inherent risk that inclusion criteria were not respected to the same extent in every outbreak.", [["a free analysis", "TEST", 118, 133]]], ["We clearly targeted epidemic outbreaks using the inclusion criteria.", [["targeted", "OBSERVATION_MODIFIER", 11, 19], ["epidemic", "OBSERVATION_MODIFIER", 20, 28]]], ["However, in endemic BRD herds, a short-lived increase in disease prevalence can occur for various reasons (exposure to another risk factor or infection, increase in the amount of susceptible animals, and so on).", [["BRD", "DISEASE", 20, 23], ["infection", "DISEASE", 142, 151], ["BRD", "SPECIES", 20, 23], ["endemic BRD herds", "PROBLEM", 12, 29], ["disease prevalence", "PROBLEM", 57, 75], ["another risk factor", "PROBLEM", 119, 138], ["infection", "PROBLEM", 142, 151], ["disease", "OBSERVATION", 57, 64], ["infection", "OBSERVATION", 142, 151]]], ["It is important to realize that when using more sensitive techniques such as thoracic ultrasonography, lung lesions are found in more than 40% of the calves in herds not reporting any issues with respiratory disease (van Leenen et al., 2019).", [["lung lesions", "ANATOMY", 103, 115], ["respiratory", "ANATOMY", 196, 207], ["respiratory disease", "DISEASE", 196, 215], ["lung lesions", "CANCER", 103, 115], ["calves", "ORGANISM", 150, 156], ["calves", "SPECIES", 150, 156], ["thoracic ultrasonography", "TEST", 77, 101], ["lung lesions", "PROBLEM", 103, 115], ["respiratory disease", "PROBLEM", 196, 215], ["thoracic", "ANATOMY", 77, 85], ["lung", "ANATOMY", 103, 107], ["lesions", "OBSERVATION", 108, 115]]], ["Also, at the level of the calf, the use of clinical criteria for BRD diagnosis holds the risk of a substantial between-observer variation (Buczinski et al., 2016).", [["BRD", "DISEASE", 65, 68], ["calf", "ORGANISM_SUBDIVISION", 26, 30], ["calf", "SPECIES", 26, 30], ["calf", "ANATOMY", 26, 30]]], ["The use of thoracic ultrasonography, currently the most accurate field diagnostic tool for pneumonia (Buczinski et al., 2014), would have improved our study.", [["thoracic", "ANATOMY", 11, 19], ["pneumonia", "DISEASE", 91, 100], ["thoracic", "ORGAN", 11, 19], ["thoracic ultrasonography", "TEST", 11, 35], ["pneumonia", "PROBLEM", 91, 100], ["our study", "TEST", 147, 156], ["thoracic", "ANATOMY", 11, 19], ["pneumonia", "OBSERVATION", 91, 100]]], ["Also within the questionnaire, misclassification bias for the evaluated risk factors is possible because many different persons were interviewing.", [["persons", "ORGANISM", 120, 127], ["persons", "SPECIES", 120, 127], ["misclassification bias", "PROBLEM", 31, 53]]], ["We also faced information bias because in some questionnaires not every question was answered, and sometimes handwriting was not legible.DISCUSSIONThe study clearly shows that epidemic respiratory disease peaks in winter months and is primarily of viral origin.", [["respiratory", "ANATOMY", 185, 196], ["respiratory disease", "DISEASE", 185, 204], ["The study", "TEST", 147, 156], ["epidemic respiratory disease peaks", "PROBLEM", 176, 210], ["epidemic", "OBSERVATION_MODIFIER", 176, 184], ["respiratory disease", "OBSERVATION", 185, 204], ["viral origin", "OBSERVATION", 248, 260]]], ["We found a much higher prevalence of viruses than the only other PCR study so far, available from Ireland (O'Neill et al., 2014).", [["viruses", "PROBLEM", 37, 44], ["other PCR study", "TEST", 59, 74], ["viruses", "OBSERVATION", 37, 44]]], ["Possibly, more strict case definitions and sampling earlier in the disease course in our study explains these differences.", [["our study", "TEST", 85, 94]]], ["However, we still suspect an underestimation of the viral component, as viruses can only be detected for a limited number of days (Saif, 2010), and part of the samplings were later than a week after the start of the outbreak.", [["the viral component", "PROBLEM", 48, 67], ["viruses", "PROBLEM", 72, 79], ["underestimation", "OBSERVATION", 29, 44], ["viral component", "OBSERVATION", 52, 67]]], ["Also, not including bovine herpesvirus-1 and bovine viral diarrhea virus in our analysis might have contributed to an underestimation.", [["viral diarrhea", "DISEASE", 52, 66], ["bovine herpesvirus-1", "ORGANISM", 20, 40], ["bovine viral diarrhea virus", "ORGANISM", 45, 72], ["bovine", "SPECIES", 20, 26], ["herpesvirus-1", "SPECIES", 27, 40], ["bovine", "SPECIES", 45, 51], ["viral diarrhea virus", "SPECIES", 52, 72], ["bovine herpesvirus-1", "SPECIES", 20, 40], ["bovine viral diarrhea virus", "SPECIES", 45, 72], ["bovine herpesvirus", "PROBLEM", 20, 38], ["bovine viral diarrhea virus", "PROBLEM", 45, 72], ["an underestimation", "PROBLEM", 115, 133], ["underestimation", "OBSERVATION", 118, 133]]], ["However, Belgium has official eradication programs for both diseases and outbreaks of these viruses have become scarce.", [["official eradication programs", "TREATMENT", 21, 50], ["both diseases", "PROBLEM", 55, 68], ["these viruses", "PROBLEM", 86, 99]]], ["Also, not including bovine adenovirus type 3 can be considered a flaw, given the high seroconversion rates in earlier work in this region (Pardon et al., 2011).", [["bovine", "ORGANISM", 20, 26], ["adenovirus type 3", "ORGANISM", 27, 44], ["bovine", "SPECIES", 20, 26], ["bovine adenovirus type 3", "SPECIES", 20, 44], ["bovine adenovirus type 3", "PROBLEM", 20, 44], ["the high seroconversion rates", "PROBLEM", 77, 106]]], ["However, the role of adenoviruses in BRD is still not clear (Caldow et al., 1988; Giusti et al., 1998).", [["BRD", "DISEASE", 37, 40], ["adenoviruses", "ORGANISM", 21, 33], ["adenoviruses", "PROBLEM", 21, 33], ["BRD", "PROBLEM", 37, 40], ["adenoviruses", "OBSERVATION", 21, 33]]], ["As seen in Ireland, BCV was the most prevalent virus, followed by bRSV (O'Neill et al., 2014).", [["BCV", "ORGANISM", 20, 23], ["BCV", "SPECIES", 20, 23], ["bRSV", "SPECIES", 66, 70], ["BCV", "ANATOMY", 20, 23], ["most prevalent", "OBSERVATION_MODIFIER", 32, 46]]], ["In recent years, although still under debate, a primary role of BCV in BRD is more and more recognized (Ellis, 2019).", [["BRD", "DISEASE", 71, 74], ["BCV", "ORGANISM", 64, 67], ["BCV", "SPECIES", 64, 67], ["BRD", "SPECIES", 71, 74], ["BRD", "PROBLEM", 71, 74], ["BCV", "ANATOMY", 64, 67], ["BRD", "OBSERVATION", 71, 74]]], ["Bovine coronavirus has been linked as a single pathogen to lethal outbreaks of respiratory disease and diarrhea in adult dairy cattle (Decaro et al., 2008; Saif, 2010), but within the BRD complex this virus is basically still considered an initiator of secondary infections (Ellis, 2019).", [["respiratory", "ANATOMY", 79, 90], ["Bovine coronavirus", "DISEASE", 0, 18], ["respiratory disease", "DISEASE", 79, 98], ["diarrhea", "DISEASE", 103, 111], ["infections", "DISEASE", 263, 273], ["Bovine", "ORGANISM", 0, 6], ["coronavirus", "ORGANISM", 7, 18], ["Bovine", "SPECIES", 0, 6], ["coronavirus", "SPECIES", 7, 18], ["cattle", "SPECIES", 127, 133], ["Bovine coronavirus", "SPECIES", 0, 18], ["cattle", "SPECIES", 127, 133], ["Bovine coronavirus", "PROBLEM", 0, 18], ["respiratory disease", "PROBLEM", 79, 98], ["diarrhea", "PROBLEM", 103, 111], ["the BRD complex this virus", "PROBLEM", 180, 206], ["secondary infections", "PROBLEM", 253, 273], ["coronavirus", "OBSERVATION", 7, 18], ["respiratory disease", "OBSERVATION", 79, 98], ["secondary", "OBSERVATION_MODIFIER", 253, 262], ["infections", "OBSERVATION", 263, 273]]], ["The association between coronavirus and M. haemolytica in our study might be pointing in this direction, as was previously observed for H. somni as well (Workman et al., 2019).", [["coronavirus", "ORGANISM", 24, 35], ["M. haemolytica", "ORGANISM", 40, 54], ["H. somni", "ORGANISM", 136, 144], ["coronavirus", "SPECIES", 24, 35], ["M. haemolytica", "SPECIES", 40, 54], ["H. somni", "SPECIES", 136, 144], ["M. haemolytica", "SPECIES", 40, 54], ["H. somni", "SPECIES", 136, 144], ["coronavirus and M. haemolytica", "PROBLEM", 24, 54], ["our study", "TEST", 58, 67], ["haemolytica", "OBSERVATION", 43, 54]]], ["The question remains whether BCV or other viruses are a necessary initiator for these Pasteurellaceae to cause pneumonia.", [["pneumonia", "DISEASE", 111, 120], ["BCV", "ORGANISM", 29, 32], ["Pasteurellaceae", "ORGANISM", 86, 101], ["BCV", "SPECIES", 29, 32], ["BCV", "PROBLEM", 29, 32], ["other viruses", "PROBLEM", 36, 49], ["these Pasteurellaceae", "PROBLEM", 80, 101], ["pneumonia", "PROBLEM", 111, 120], ["viruses", "OBSERVATION", 42, 49], ["pneumonia", "OBSERVATION", 111, 120]]], ["Regardless, with this large prevalence of respiratory BCV in Western European countries (Ohlson et al., 2010; Pardon et al., 2011; Toftaker et al., 2016), it deserves better control and prevention.", [["respiratory BCV", "ANATOMY", 42, 57]]], ["In contrast to North America, to our knowledge no licensed respiratory coronavirus vaccines are available within the European Union, leaving only biosecurity options accessible.", [["respiratory coronavirus", "DISEASE", 59, 82], ["respiratory coronavirus", "ORGANISM", 59, 82], ["licensed respiratory coronavirus vaccines", "TREATMENT", 50, 91], ["respiratory coronavirus", "OBSERVATION", 59, 82]]], ["Indeed, biosecurity is the core of the recently initiated BCV and bRSV eradication campaign in Norway (Toftaker et al., 2018).", [["BCV", "ORGANISM", 58, 61], ["BCV", "SPECIES", 58, 61], ["bRSV", "SPECIES", 66, 70], ["BCV", "ANATOMY", 58, 61], ["bRSV eradication", "OBSERVATION", 66, 82]]], ["Larger herds were at increased risk for a BCV outbreak in our study, as was shown in a serological study in Norway before (Toftaker et al., 2016).", [["BCV", "SPECIES", 42, 45], ["Larger herds", "PROBLEM", 0, 12], ["a BCV outbreak", "PROBLEM", 40, 54], ["our study", "TEST", 58, 67], ["a serological study", "TEST", 85, 104], ["BCV", "ANATOMY", 42, 45], ["outbreak", "OBSERVATION", 46, 54]]], ["In contrast to that study, purchase of animals was only univariably associated with BCV detection in our study.", [["BCV", "SPECIES", 84, 87], ["that study", "TEST", 15, 25], ["BCV detection", "TEST", 84, 97], ["our study", "TEST", 101, 110]]], ["The routine use of antigen-ELISA in cases of neonatal diarrhea might be useful to identify herds at risk in time, as the pathogen is not seasonal and potentially persists on farm.DISCUSSIONDespite relatively high vaccination rates in the study population, bRSV was still frequently detected in outbreaks on these farms.", [["neonatal diarrhea", "DISEASE", 45, 62], ["bRSV", "ORGANISM", 256, 260], ["bRSV", "SPECIES", 256, 260], ["antigen-ELISA", "TREATMENT", 19, 32], ["neonatal diarrhea", "PROBLEM", 45, 62], ["the pathogen", "PROBLEM", 117, 129], ["relatively high vaccination rates", "PROBLEM", 197, 230], ["bRSV", "PROBLEM", 256, 260]]], ["Given the use of intranasal vaccines in Belgium, false positives cannot be totally excluded (Timsit et al., 2009).", [["intranasal vaccines", "TREATMENT", 17, 36], ["false positives", "PROBLEM", 49, 64], ["false positives", "OBSERVATION", 49, 64], ["cannot be totally excluded", "UNCERTAINTY", 65, 91]]], ["In contrast to BCV, bRSV showed a strictly seasonal distribution between November and April with a peak in December as is well known from human RSV, but sometimes neglected in veterinary medicine (Leecaster et al., 2011).", [["BCV", "ORGANISM", 15, 18], ["bRSV", "GENE_OR_GENE_PRODUCT", 20, 24], ["human", "ORGANISM", 138, 143], ["RSV", "ORGANISM", 144, 147], ["human", "SPECIES", 138, 143], ["BCV", "SPECIES", 15, 18], ["bRSV", "SPECIES", 20, 24], ["human", "SPECIES", 138, 143], ["RSV", "SPECIES", 144, 147], ["bRSV", "PROBLEM", 20, 24], ["human RSV", "PROBLEM", 138, 147], ["BCV", "ANATOMY", 15, 18], ["RSV", "OBSERVATION", 144, 147]]], ["The multivariable model only consisted of typical characteristics of an RSV outbreak such as seasonality, many diseased animals, and recent occurrence of disease.", [["RSV", "ORGANISM", 72, 75], ["RSV", "SPECIES", 72, 75], ["an RSV outbreak", "PROBLEM", 69, 84], ["many diseased animals", "PROBLEM", 106, 127], ["disease", "PROBLEM", 154, 161], ["RSV", "OBSERVATION", 72, 75], ["many", "OBSERVATION_MODIFIER", 106, 110], ["diseased", "OBSERVATION", 111, 119], ["disease", "OBSERVATION", 154, 161]]], ["These factors might be suitable for building predictive models for RSV outbreaks, distinguishing them from other pathogens.", [["RSV", "ORGANISM", 67, 70], ["RSV", "SPECIES", 67, 70], ["RSV outbreaks", "PROBLEM", 67, 80], ["other pathogens", "PROBLEM", 107, 122]]], ["The PI-3 was not frequently detected in the present study and almost always together with RSV.", [["RSV", "DISEASE", 90, 93], ["PI-3", "GENE_OR_GENE_PRODUCT", 4, 8], ["RSV", "ORGANISM", 90, 93], ["RSV", "SPECIES", 90, 93], ["The PI", "TEST", 0, 6], ["the present study", "TEST", 40, 57], ["RSV", "PROBLEM", 90, 93], ["RSV", "OBSERVATION", 90, 93]]], ["This might signify that PI-3 as a single agent only induces mild clinical signs instead of more severe outbreaks as studied here.DISCUSSIONAlso, M. bovis, mostly known as a chronic pathogen, was frequently detected in these acute outbreaks of respiratory disease.", [["respiratory", "ANATOMY", 243, 254], ["PI-3", "CHEMICAL", 24, 28], ["respiratory disease", "DISEASE", 243, 262], ["PI-3", "CHEMICAL", 24, 28], ["PI-3", "GENE_OR_GENE_PRODUCT", 24, 28], ["M. bovis", "ORGANISM", 145, 153], ["M. bovis", "SPECIES", 145, 153], ["M. bovis", "SPECIES", 145, 153], ["PI", "TEST", 24, 26], ["a single agent", "TREATMENT", 32, 46], ["mild clinical signs", "PROBLEM", 60, 79], ["more severe outbreaks", "PROBLEM", 91, 112], ["a chronic pathogen", "PROBLEM", 171, 189], ["respiratory disease", "PROBLEM", 243, 262], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["outbreaks", "OBSERVATION", 103, 112], ["bovis", "OBSERVATION", 148, 153], ["chronic", "OBSERVATION_MODIFIER", 173, 180], ["pathogen", "OBSERVATION", 181, 189], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["respiratory disease", "OBSERVATION", 243, 262]]], ["Its involvement in epidemic outbreaks is well known from the veal industry, where the incidence reaches 100% (Pardon et al., 2011; Soehnlen et al., 2012).", [["epidemic", "OBSERVATION_MODIFIER", 19, 27]]], ["Detection of M. bovis in one-third of the outbreaks on dairy and beef farms is very worrisome, but in line with a recent prevalence study on bulk tank milk in the studied region (Gille et al., 2018).", [["M. bovis", "ORGANISM", 13, 21], ["dairy", "ORGANISM_SUBDIVISION", 55, 60], ["milk", "ORGANISM_SUBSTANCE", 151, 155], ["M. bovis", "SPECIES", 13, 21], ["beef", "SPECIES", 65, 69], ["M. bovis", "SPECIES", 13, 21], ["dairy", "SPECIES", 55, 60], ["beef", "SPECIES", 65, 69], ["M. bovis", "PROBLEM", 13, 21], ["M. bovis", "OBSERVATION", 13, 21]]], ["The detection likely represents primary involvement in the outbreak, rather than persistent infection, as it was not detected more frequently on farms reporting endemic respiratory disease besides the outbreak.", [["respiratory", "ANATOMY", 169, 180], ["infection", "DISEASE", 92, 101], ["respiratory disease", "DISEASE", 169, 188], ["The detection", "TEST", 0, 13], ["primary involvement", "PROBLEM", 32, 51], ["the outbreak", "PROBLEM", 55, 67], ["persistent infection", "PROBLEM", 81, 101], ["endemic respiratory disease", "PROBLEM", 161, 188], ["likely represents", "UNCERTAINTY", 14, 31], ["primary", "OBSERVATION_MODIFIER", 32, 39], ["persistent", "OBSERVATION_MODIFIER", 81, 91], ["infection", "OBSERVATION", 92, 101], ["endemic", "OBSERVATION_MODIFIER", 161, 168], ["respiratory disease", "OBSERVATION", 169, 188]]], ["The M. bovis-specific risk factors identified in our model all relate to purchase activities, which are the major risk factors for this pathogen (Maunsell et al., 2011).DISCUSSION", [["M. bovis", "ORGANISM", 4, 12], ["M. bovis", "SPECIES", 4, 12], ["M. bovis", "SPECIES", 4, 12], ["The M. bovis", "TEST", 0, 12], ["specific risk factors", "PROBLEM", 13, 34], ["this pathogen", "PROBLEM", 131, 144], ["bovis", "OBSERVATION", 7, 12]]]]}